data_1exh_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1exh _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.448 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.969 0.414 . . . . 0.0 111.126 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -178.28 43.21 0.09 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.562 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 26.5 p -60.42 -160.79 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.779 -0.71 . . . . 0.0 110.94 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.64 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -165.3 157.55 15.39 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.192 179.859 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.444 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.0 m -139.63 130.6 32.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.151 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.452 HD22 ' N ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -95.79 157.09 16.05 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.718 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.541 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 2.6 t-105 -114.55 141.44 47.73 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.831 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.14 76.28 0.41 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.2 p -69.23 149.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 . . . . . 0 C--N 1.302 -1.491 0 CA-C-N 113.91 -1.496 . . . . 0.0 107.348 179.839 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.3 p90 . . . . . 0 CA--C 1.487 -1.448 0 CA-C-O 121.583 0.706 . . . . 0.0 111.192 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -97.11 114.34 26.0 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.541 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -93.74 120.62 34.24 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.367 -0.933 . . . . 0.0 113.422 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -99.08 95.83 7.38 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.45 HG11 ' N ' ' A' ' 26' ' ' THR . 29.8 t -91.81 152.46 3.39 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.45 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.0 OUTLIER -138.88 106.08 5.49 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.184 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.1 t -71.2 149.01 10.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.101 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.433 ' HD3' ' CG2' ' A' ' 81' ' ' THR . 6.5 tptm -141.03 102.81 4.34 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.12 -0.945 . . . . 0.0 110.186 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.799 HD21 ' N ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -96.76 136.93 36.61 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.948 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.799 ' N ' HD21 ' A' ' 29' ' ' ASN . 9.5 t -141.47 -4.31 1.12 Allowed 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.681 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.1 p -51.97 -81.27 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.118 -1.033 . . . . 0.0 110.339 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.465 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.52 73.55 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.373 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.518 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -169.49 149.28 3.67 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.22 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -72.27 97.37 0.85 Allowed 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 121.207 1.271 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -77.49 100.52 2.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.78 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -110.44 58.4 0.61 Allowed 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.06 152.39 21.39 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 107.909 -2.077 . . . . 0.0 107.909 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.644 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 37.3 p-90 -166.35 178.07 6.41 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 117.693 -1.603 . . . . 0.0 112.208 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.34 102.51 4.37 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.133 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.605 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -93.97 175.06 6.86 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.957 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.486 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -169.92 156.22 6.07 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 117.854 -1.539 . . . . 0.0 112.679 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.498 ' CD2' ' N ' ' A' ' 43' ' ' SER . 20.2 p90 -176.73 -132.81 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 113.565 -1.652 . . . . 0.0 107.8 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.498 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -162.29 148.23 13.0 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 117.726 -1.589 . . . . 0.0 111.951 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.486 ' CE2' HG23 ' A' ' 65' ' ' VAL . 2.2 m-85 -82.8 119.01 73.62 Favored Pre-proline 0 N--CA 1.486 1.36 0 C-N-CA 118.601 -1.24 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -55.23 -72.42 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 121.083 1.189 . . . . 0.0 111.764 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.594 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 5.6 t -69.58 -134.0 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 110.535 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.594 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -118.57 51.86 0.73 Allowed Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.343 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.689 ' C ' HE21 ' A' ' 49' ' ' GLN . 1.6 mp0 -67.96 88.35 0.27 Allowed 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.492 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.825 ' N ' HE21 ' A' ' 49' ' ' GLN . 1.2 mm-40 -76.99 85.75 3.51 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.473 HG22 ' CD2' ' A' ' 86' ' ' PHE . 7.3 p -74.64 144.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.839 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.486 HG22 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -143.38 -61.02 0.41 Allowed 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 119.033 -1.067 . . . . 0.0 111.932 -179.838 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.486 ' H ' HG22 ' A' ' 51' ' ' THR . 1.1 mt-30 -75.54 135.26 40.6 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.569 -1.252 . . . . 0.0 110.073 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -147.89 156.11 42.33 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 118.785 -1.166 . . . . 0.0 112.146 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 34.2 t-105 -151.91 142.16 22.38 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.6 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 t 62.31 27.43 16.39 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.583 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.58 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -171.36 125.34 0.62 Allowed 'General case' 0 C--N 1.303 -1.428 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.317 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -87.28 73.59 9.65 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.035 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.0 m -69.01 153.86 8.66 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 115.044 -0.98 . . . . 0.0 112.484 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 44.2 p -155.42 112.4 3.26 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.658 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.475 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 6.8 pt20 -91.02 113.42 25.68 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 4.7 p -87.68 86.07 7.14 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.774 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 73.71 -71.59 1.34 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -139.28 -15.98 1.08 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.029 -0.668 . . . . 0.0 109.716 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -87.9 -176.46 5.49 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.048 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.611 ' CG1' ' N ' ' A' ' 66' ' ' THR . 44.8 t -145.54 161.06 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 C-N-CA 118.596 -1.242 . . . . 0.0 113.888 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.611 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 44.9 m -157.52 143.79 17.76 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 113.627 -1.624 . . . . 0.0 108.284 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.4 ' CG1' ' HB3' ' A' ' 56' ' ' SER . 2.2 t -139.66 117.47 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.617 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -99.03 91.87 5.22 Favored 'General case' 0 C--N 1.288 -2.092 0 CA-C-N 114.291 -1.322 . . . . 0.0 108.132 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.644 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.8 p-10 -72.47 121.56 19.8 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.195 -1.002 . . . . 0.0 112.215 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.701 ' CB ' HD22 ' A' ' 73' ' ' ASN . . . -40.88 162.07 0.11 Allowed Pre-proline 0 N--CA 1.488 1.475 0 CA-C-N 113.563 -1.653 . . . . 0.0 112.47 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.86 -36.36 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 121.869 1.713 . . . . 0.0 111.939 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.575 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.67 -56.3 7.63 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 118.962 -1.095 . . . . 0.0 110.494 -179.895 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.701 HD22 ' CB ' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -74.33 2.73 8.64 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 118.818 -1.153 . . . . 0.0 109.492 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.508 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -122.43 37.12 2.94 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -104.71 56.53 0.7 Allowed 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.207 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.53 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -106.86 130.62 22.61 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.741 -0.783 . . . . 0.0 111.195 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 78' ' ' ALA . 8.7 Cg_endo -72.32 154.19 56.2 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 121.606 1.537 . . . . 0.0 113.381 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.518 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -21.84 -49.14 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.67 70.71 0.21 Allowed Glycine 0 N--CA 1.493 2.447 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -153.5 -165.56 13.71 Favored Glycine 0 C--N 1.285 -2.293 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.069 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.53 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.8 OUTLIER -140.9 164.05 31.29 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 119.271 -0.972 . . . . 0.0 112.528 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -132.78 -177.35 4.45 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 114.352 -1.294 . . . . 0.0 107.646 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.48 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.8 OUTLIER -167.6 143.5 4.06 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 116.875 -1.93 . . . . 0.0 113.54 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.58 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 8.7 p90 -159.22 176.12 12.59 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.664 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.69 170.28 41.12 Favored Glycine 0 N--CA 1.5 2.931 0 C-N-CA 117.897 -2.097 . . . . 0.0 112.137 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.547 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 5.6 p90 -159.32 168.88 25.28 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.703 -0.799 . . . . 0.0 111.022 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.531 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -121.93 114.21 20.68 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.896 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.443 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -126.07 150.29 17.57 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.3 p . . . . . 0 N--CA 1.483 1.204 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.852 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.419 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.492 1.666 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.476 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -66.58 -144.32 0.02 OUTLIER 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 121.454 1.436 . . . . 0.0 111.401 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.427 ' H ' ' HG1' ' A' ' 98' ' ' THR . 0.8 OUTLIER -108.45 -101.48 0.37 Allowed 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.002 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.6 106.08 18.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 118.807 -1.157 . . . . 0.0 112.402 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.567 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.3 m-30 -74.99 -148.19 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.397 -0.921 . . . . 0.0 108.714 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.469 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -159.84 114.85 2.36 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 117.145 -1.822 . . . . 0.0 113.457 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.602 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.1 mt -58.47 -175.84 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.06 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.468 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 2.0 p30 -64.89 76.49 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.071 -1.052 . . . . 0.0 111.764 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.49 11.46 33.26 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.57 -1.3 . . . . 0.0 112.374 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.602 ' O ' ' N ' ' A' ' 102' ' ' LEU . 6.5 p -151.92 145.81 18.05 Favored Pre-proline 0 N--CA 1.493 1.709 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.091 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -65.04 170.78 9.87 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.342 1.361 . . . . 0.0 111.713 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.64 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 3.1 t -163.79 106.53 0.96 Allowed 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.491 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.5 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 7.5 p -70.49 130.62 42.37 Favored 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.427 ' CG1' ' CZ ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -53.96 175.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.525 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.496 2.649 0 CA-C-O 116.368 -2.351 . . . . 0.0 110.274 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.633 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.48 1.048 0 CA-C-O 121.406 0.622 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.43 28.34 0.36 Allowed Glycine 0 N--CA 1.5 2.911 0 N-CA-C 106.939 -2.465 . . . . 0.0 106.939 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -52.83 -174.05 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 113.49 -1.355 . . . . 0.0 113.213 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -137.22 108.16 6.7 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.768 -1.56 . . . . 0.0 109.654 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.472 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 4.9 m -100.67 122.73 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.384 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.468 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -95.2 159.62 14.93 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.389 -0.924 . . . . 0.0 109.653 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.484 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 1.8 t-105 -121.22 139.76 52.94 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.748 -0.781 . . . . 0.0 112.013 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 73.38 0.4 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 107.279 -2.328 . . . . 0.0 107.279 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -72.84 152.27 7.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.445 ' CB ' HG21 ' A' ' 22' ' ' THR . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.288 0 CA-C-N 113.969 -1.469 . . . . 0.0 108.675 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.527 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 2.7 p90 . . . . . 0 CA--C 1.506 -0.745 0 CA-C-O 121.185 0.517 . . . . 0.0 112.256 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.445 HG21 ' CB ' ' A' ' 15' ' ' ASN . 8.2 t -73.48 172.86 10.52 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HB3' ' HE1' ' A' ' 12' ' ' TRP . . . -159.32 110.23 2.02 Favored 'General case' 0 C--N 1.289 -2.027 0 C-N-CA 117.289 -1.764 . . . . 0.0 112.919 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -93.02 103.92 16.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.455 HG11 ' N ' ' A' ' 26' ' ' THR . 24.6 t -99.64 140.43 18.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 119.451 -0.9 . . . . 0.0 113.124 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.46 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 3.5 m -131.14 113.11 13.49 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.783 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.8 t -84.7 143.04 12.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.618 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -124.9 99.92 6.36 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.933 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.629 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 0.1 OUTLIER -91.54 106.22 18.32 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.191 -1.004 . . . . 0.0 108.372 179.828 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 t -119.17 -1.11 10.92 Favored 'General case' 0 C--N 1.311 -1.107 0 O-C-N 124.174 0.921 . . . . 0.0 110.142 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.629 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -50.34 -81.85 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.399 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.597 ' HG ' ' C ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.69 37.49 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.305 -179.886 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.605 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -137.5 146.65 54.39 Favored Pre-proline 0 N--CA 1.485 1.301 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.187 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -70.22 107.4 1.94 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 121.212 1.275 . . . . 0.0 109.882 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -86.63 110.49 20.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.487 -1.285 . . . . 0.0 111.981 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -120.1 65.45 0.82 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.64 146.22 20.56 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 106.885 -2.486 . . . . 0.0 106.885 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 47.9 p-90 -163.51 175.54 10.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 117.419 -1.712 . . . . 0.0 112.095 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -141.06 112.39 7.4 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.777 179.92 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.603 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.44 175.35 5.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.395 179.896 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.47 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -159.35 152.48 22.18 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 117.919 -1.512 . . . . 0.0 112.289 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.533 ' CD2' ' N ' ' A' ' 43' ' ' SER . 23.6 p90 -175.1 -150.91 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.931 -1.486 . . . . 0.0 108.432 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.533 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 14.7 m -158.66 154.39 26.37 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.881 -1.528 . . . . 0.0 111.835 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.517 ' CD2' ' O ' ' A' ' 48' ' ' GLN . 8.2 m-85 -87.71 116.96 67.82 Favored Pre-proline 0 C--N 1.309 -1.153 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.901 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -56.99 -74.87 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 121.292 1.328 . . . . 0.0 112.619 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.26 -136.11 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.636 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -107.6 63.92 0.27 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.857 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.517 ' O ' ' CD2' ' A' ' 44' ' ' PHE . 21.5 mt-30 -110.97 112.14 23.75 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.802 -0.759 . . . . 0.0 110.667 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.522 HE21 ' C ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -121.34 118.62 29.93 Favored 'General case' 0 N--CA 1.499 2.007 0 C-N-CA 119.764 -0.774 . . . . 0.0 111.212 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.441 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.0 p -72.79 156.0 6.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.383 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.508 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 80.4 p -132.45 -69.67 0.58 Allowed 'General case' 0 N--CA 1.492 1.669 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.777 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.508 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.8 OUTLIER -88.02 141.88 28.23 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.292 -0.963 . . . . 0.0 109.801 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.429 ' CB ' HG23 ' A' ' 58' ' ' VAL . . . -151.99 166.99 29.84 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.859 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.638 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 42.5 t-105 -154.45 157.15 38.01 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.003 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.638 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 51.75 26.79 3.68 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.771 -179.839 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.4 m -172.98 127.58 0.47 Allowed 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.695 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.4 m -90.15 77.19 6.8 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.795 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.429 HG23 ' CB ' ' A' ' 53' ' ' ALA . 1.3 m -69.69 151.81 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-N 115.365 -0.834 . . . . 0.0 112.306 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -152.17 104.2 2.94 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.462 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -82.69 120.8 26.04 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 10.4 p -94.13 75.76 4.05 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.589 -0.844 . . . . 0.0 110.718 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.65 -65.59 2.82 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.041 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.41 -16.01 0.94 Allowed 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.294 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.473 ' HB3' ' HG ' ' A' ' 43' ' ' SER . . . -91.61 -171.15 2.81 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 119.268 -0.973 . . . . 0.0 110.215 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.49 HG23 ' CE2' ' A' ' 44' ' ' PHE . 72.7 t -147.3 154.55 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 118.744 -1.182 . . . . 0.0 113.262 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 17.1 m -155.75 119.82 4.53 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 114.396 -1.275 . . . . 0.0 108.441 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.418 ' CG2' HD23 ' A' ' 40' ' ' LEU . 1.9 t -114.32 149.38 16.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.938 0 C-N-CA 119.614 -0.835 . . . . 0.0 111.847 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -132.33 93.0 3.18 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.632 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 3.1 p-10 -72.88 122.16 21.18 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.055 -1.058 . . . . 0.0 112.329 -179.582 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.64 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -41.95 161.45 0.15 Allowed Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 113.549 -1.659 . . . . 0.0 112.05 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -65.54 -37.67 28.58 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 121.95 1.767 . . . . 0.0 112.273 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.544 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.46 -55.93 8.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.579 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.64 HD22 ' N ' ' A' ' 70' ' ' ALA . 1.8 p30 -74.69 11.83 0.95 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.738 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.526 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -133.44 22.95 3.88 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.747 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.8 m -93.93 57.08 2.39 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.331 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.491 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -110.52 128.72 24.88 Favored Pre-proline 0 N--CA 1.489 1.495 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.68 179.971 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.599 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.4 Cg_endo -69.8 154.52 67.47 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 121.448 1.432 . . . . 0.0 111.012 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.605 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -42.49 -12.53 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.745 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.08 55.82 0.5 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.98 -165.65 24.74 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 118.511 -1.804 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.491 ' N ' HG13 ' A' ' 76' ' ' ILE . 5.9 p -137.93 163.17 32.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.183 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -121.56 -176.95 3.42 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -169.91 144.71 2.81 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 116.906 -1.917 . . . . 0.0 113.246 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.579 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 4.4 p90 -159.31 169.11 24.75 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.045 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -155.99 163.58 31.9 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 118.052 -2.023 . . . . 0.0 112.023 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 5.5 p90 -161.16 161.52 31.04 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.242 -0.983 . . . . 0.0 112.287 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 25.8 m-20 -112.79 111.79 22.83 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.271 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.25 164.3 12.16 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.948 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.313 -0.986 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.878 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.484 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 111.187 0.069 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.414 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.2 Cg_endo -63.13 -121.82 0.0 OUTLIER 'Trans proline' 0 CA--C 1.557 1.658 0 C-N-CA 121.125 1.216 . . . . 0.0 111.935 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.414 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 27.4 p -136.4 -77.43 0.42 Allowed 'General case' 0 N--CA 1.505 2.278 0 C-N-CA 119.246 -0.982 . . . . 0.0 112.608 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -98.72 97.9 9.09 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.842 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 107' ' ' CYS . 45.2 m-85 -66.73 -170.12 0.1 Allowed 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.9 m -146.78 113.99 6.24 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 117.457 -1.697 . . . . 0.0 113.897 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -60.59 -178.19 0.09 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.629 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 102' ' ' LEU . 26.0 m-80 -30.38 -39.85 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -159.98 39.18 0.46 Allowed Glycine 0 N--CA 1.498 2.776 0 C-N-CA 118.583 -1.77 . . . . 0.0 111.598 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.633 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 9.7 m -162.23 137.61 5.5 Favored Pre-proline 0 N--CA 1.49 1.531 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -50.8 177.57 0.03 OUTLIER 'Trans proline' 0 C--O 1.211 -0.858 0 C-N-CA 121.473 1.448 . . . . 0.0 112.361 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.475 ' N ' ' O ' ' A' ' 100' ' ' PHE . 22.0 t -166.35 98.45 0.6 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.411 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 p -46.68 154.82 0.28 Allowed 'General case' 0 N--CA 1.502 2.129 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.678 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.741 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 2.8 p -68.92 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 118.787 -1.165 . . . . 0.0 109.4 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.741 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.137 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.435 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.63 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 121.358 0.599 . . . . 0.0 112.431 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.23 51.25 0.04 OUTLIER Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -51.56 177.84 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.027 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -133.01 99.84 4.7 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.332 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.587 ' CG1' ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -91.87 135.01 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 118.967 -1.093 . . . . 0.0 111.875 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.48 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -112.93 164.83 12.95 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.915 179.824 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.556 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.8 t-105 -125.32 143.95 50.72 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.653 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.83 75.8 0.42 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 15' ' ' ASN . 10.0 p -79.2 158.96 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.487 ' N ' ' CG2' ' A' ' 14' ' ' VAL . 3.6 t30 . . . . . 0 C--N 1.302 -1.482 0 CA-C-N 113.238 -1.801 . . . . 0.0 107.129 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.612 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 14.6 p90 . . . . . 0 C--O 1.215 -0.731 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.421 HG21 ' CB ' ' A' ' 15' ' ' ASN . 14.0 t -72.4 173.95 8.05 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.406 ' HB2' ' CE2' ' A' ' 12' ' ' TRP . . . -155.37 120.42 4.85 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 117.251 -1.779 . . . . 0.0 112.908 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -104.0 98.87 8.63 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.561 -1.2 . . . . 0.0 107.904 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.441 HG11 ' N ' ' A' ' 26' ' ' THR . 23.2 t -96.95 140.8 16.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.306 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.48 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 98.7 m -126.39 108.15 10.95 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.278 -0.874 . . . . 0.0 108.809 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.1 t -83.44 101.1 7.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 C-N-CA 119.727 -0.789 . . . . 0.0 111.959 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 11.5 tttp -87.82 109.51 19.8 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.512 -1.275 . . . . 0.0 109.992 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -95.56 112.38 24.11 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.504 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -111.68 -7.69 14.24 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.617 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.9 p -72.64 98.84 2.43 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-N 113.779 -1.555 . . . . 0.0 111.314 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.417 ' HA ' ' CB ' ' A' ' 78' ' ' ALA . 69.4 p -27.37 76.43 0.0 OUTLIER 'General case' 0 N--CA 1.512 2.646 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.797 ' H ' ' CB ' ' A' ' 78' ' ' ALA . . . -157.57 137.15 8.45 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.596 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -72.1 100.04 1.06 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.971 1.114 . . . . 0.0 109.463 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -85.03 106.87 15.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.461 -1.296 . . . . 0.0 111.836 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -124.21 80.07 1.8 Allowed 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.55 135.78 3.22 Favored Glycine 0 C--N 1.292 -1.902 0 N-CA-C 106.625 -2.59 . . . . 0.0 106.625 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 43.7 p-90 -159.43 176.68 11.82 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 117.327 -1.749 . . . . 0.0 112.303 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -138.04 113.19 9.26 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.047 179.781 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.591 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.05 172.13 6.99 Favored 'General case' 0 N--CA 1.5 2.026 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.839 -179.968 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.651 ' HG1' ' HG1' ' A' ' 66' ' ' THR . 1.2 m -156.29 146.7 21.59 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 118.017 -1.473 . . . . 0.0 112.605 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.63 ' CD2' ' N ' ' A' ' 43' ' ' SER . 11.7 p90 -172.29 -151.21 0.06 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 114.429 -1.259 . . . . 0.0 108.504 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.63 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.7 m -159.42 158.89 32.96 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.616 -1.633 . . . . 0.0 112.351 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.477 ' CE2' HG23 ' A' ' 65' ' ' VAL . 8.8 m-85 -86.28 121.13 72.62 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.88 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -58.75 -67.87 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.084 1.19 . . . . 0.0 112.225 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.483 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 29.8 t -69.54 -112.84 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 118.946 -1.102 . . . . 0.0 111.054 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.483 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -141.98 37.68 1.56 Allowed Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.685 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.459 ' HB3' ' CE1' ' A' ' 21' ' ' PHE . 6.7 mt-30 -75.46 115.59 15.28 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.828 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.483 ' HA ' HE22 ' A' ' 60' ' ' GLN . 0.0 OUTLIER -106.38 119.04 38.23 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.353 -0.939 . . . . 0.0 111.673 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.464 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.2 p -74.38 157.92 6.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.94 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 20.4 p -132.74 -63.89 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.615 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -88.59 170.51 10.79 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -166.03 151.72 8.85 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 118.521 -1.271 . . . . 0.0 112.194 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.671 ' C ' ' HG ' ' A' ' 55' ' ' SER . 36.3 t-105 -149.26 150.77 33.1 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.458 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.671 ' HG ' ' C ' ' A' ' 54' ' ' TRP . 1.4 p 46.77 32.11 1.65 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.617 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -173.64 118.08 0.27 Allowed 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.81 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 m -83.33 72.49 10.2 Favored 'General case' 0 C--N 1.279 -2.473 0 C-N-CA 119.161 -1.016 . . . . 0.0 109.377 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -70.91 166.57 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.832 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.443 ' O ' ' CG2' ' A' ' 59' ' ' THR . 6.1 t -164.68 130.54 2.83 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.557 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.483 HE22 ' HA ' ' A' ' 49' ' ' GLN . 5.0 tt0 -94.67 116.05 28.29 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.2 p -93.92 75.53 4.18 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.304 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.37 -67.38 2.82 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.351 -1.404 . . . . 0.0 109.69 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -143.7 -16.51 0.62 Allowed 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.979 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.43 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -89.9 -170.81 2.93 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.076 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.501 ' CG1' ' N ' ' A' ' 66' ' ' THR . 65.2 t -148.39 156.6 8.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 118.826 -1.15 . . . . 0.0 113.038 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.651 ' HG1' ' HG1' ' A' ' 41' ' ' THR . 2.1 m -154.71 141.2 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.312 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 39' ' ' THR . 2.4 t -134.84 153.51 34.92 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.078 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.426 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -133.39 90.84 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.6 p-10 -72.54 121.07 19.06 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.298 -179.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.794 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -42.68 163.61 0.14 Allowed Pre-proline 0 C--N 1.303 -1.45 0 CA-C-N 113.291 -1.777 . . . . 0.0 111.807 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -66.46 -35.88 28.81 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.901 1.734 . . . . 0.0 112.315 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.553 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.39 -54.28 15.2 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.749 -179.891 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.794 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.25 14.17 1.28 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 118.958 -1.097 . . . . 0.0 109.862 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -129.4 18.98 5.43 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.49 77.4 5.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.197 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.539 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -136.64 125.29 15.18 Favored Pre-proline 0 C--O 1.209 -1.063 0 C-N-CA 119.782 -0.767 . . . . 0.0 111.643 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.612 ' C ' ' H ' ' A' ' 79' ' ' GLY . 5.8 Cg_endo -71.63 162.86 40.84 Favored 'Trans proline' 0 C--O 1.213 -0.754 0 C-N-CA 120.91 1.073 . . . . 0.0 110.236 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.797 ' CB ' ' H ' ' A' ' 33' ' ' ALA . . . -46.98 -3.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.871 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.612 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -120.13 56.77 0.59 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.81 -159.99 15.77 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 117.905 -2.093 . . . . 0.0 111.12 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.539 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.2 p -139.85 155.06 47.43 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.939 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -130.1 100.65 5.5 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.45 ' HG2' ' CG2' ' A' ' 26' ' ' THR . 21.6 mt-30 -91.13 161.21 15.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 114.709 1.374 . . . . 0.0 114.709 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.414 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 2.1 p90 -166.0 165.17 18.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 113.286 -1.779 . . . . 0.0 109.224 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.98 170.83 37.75 Favored Glycine 0 N--CA 1.504 3.17 0 C-N-CA 117.547 -2.264 . . . . 0.0 112.611 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.556 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.2 p90 -156.62 -167.86 2.52 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.345 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.404 ' OD1' ' N ' ' A' ' 87' ' ' ASN . 1.2 m120 -140.53 112.21 7.48 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.821 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -120.14 158.21 15.45 Favored Glycine 0 N--CA 1.505 3.279 0 C-N-CA 119.784 -1.198 . . . . 0.0 111.426 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.486 1.345 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.154 179.926 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.556 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.507 2.418 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -64.57 -144.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 121.319 1.346 . . . . 0.0 110.965 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.644 ' HG1' ' N ' ' A' ' 99' ' ' ALA . 10.5 p -116.78 -63.51 1.44 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.495 -0.882 . . . . 0.0 112.376 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.644 ' N ' ' HG1' ' A' ' 98' ' ' THR . . . -107.87 111.09 23.04 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.764 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.4 m-85 -81.16 -163.72 0.65 Allowed 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.618 -0.833 . . . . 0.0 109.545 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -145.44 103.04 3.78 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -52.29 173.92 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.501 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 39' ' ' THR . 8.2 p30 -41.87 -20.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.484 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.83 45.0 0.22 Allowed Glycine 0 N--CA 1.487 2.039 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.171 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.63 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -175.01 149.07 1.16 Allowed Pre-proline 0 N--CA 1.494 1.734 0 C-N-CA 119.164 -1.014 . . . . 0.0 111.049 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -63.04 170.35 7.69 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 121.372 1.381 . . . . 0.0 111.956 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.587 ' SG ' ' CG1' ' A' ' 10' ' ' VAL . 6.5 t -161.88 90.95 0.79 Allowed 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.538 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 m -51.99 165.18 0.22 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.69 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 10' ' ' VAL . 0.1 OUTLIER -65.05 -156.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 119.176 -1.01 . . . . 0.0 109.588 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 CA-C-O 116.319 -2.378 . . . . 0.0 110.371 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 CA-C-O 121.235 0.54 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.18 59.91 0.04 OUTLIER Glycine 0 N--CA 1.49 2.237 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.674 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -56.32 -161.88 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.278 1.037 . . . . 0.0 112.54 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.674 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 37.0 mt-30 -150.97 89.02 1.5 Allowed 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 113.553 -1.658 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.467 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.9 m -90.32 128.71 42.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 118.972 -1.091 . . . . 0.0 111.83 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.454 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -102.27 171.27 7.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.149 179.831 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.477 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.5 t-105 -130.39 147.59 52.11 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.768 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.407 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.67 76.4 0.41 Allowed Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.026 -2.03 . . . . 0.0 108.026 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -72.51 142.9 14.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.452 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 8.4 t-20 . . . . . 0 N--CA 1.493 1.711 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.301 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.62 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 14.4 p90 . . . . . 0 C--O 1.215 -0.734 0 CA-C-O 121.515 0.674 . . . . 0.0 110.555 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.462 HG22 ' N ' ' A' ' 23' ' ' ALA . 1.0 OUTLIER -71.08 176.56 4.33 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 118.074 -1.451 . . . . 0.0 107.74 179.791 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.509 ' CB ' ' CZ ' ' A' ' 86' ' ' PHE . . . -148.76 103.08 3.35 Favored 'General case' 0 C--N 1.291 -1.937 0 C-N-CA 118.469 -1.293 . . . . 0.0 111.616 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -94.1 94.35 8.34 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.431 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 15.6 t -97.16 137.38 25.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.664 -0.815 . . . . 0.0 113.003 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.454 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 1.5 m -128.36 114.45 16.88 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.864 -1.062 . . . . 0.0 108.406 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -86.94 128.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 C-N-CA 119.81 -0.756 . . . . 0.0 112.783 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.4 tptt -114.23 100.93 8.73 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.426 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.573 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -89.87 117.46 28.71 Favored 'General case' 0 C--N 1.282 -2.353 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.452 179.742 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.62 -2.09 8.43 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 124.185 0.928 . . . . 0.0 109.754 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.573 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -49.87 -83.89 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.588 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.512 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 159.51 72.32 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 123.666 0.604 . . . . 0.0 111.504 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.582 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.52 149.9 3.17 Favored Pre-proline 0 C--N 1.304 -1.392 0 C-N-CA 119.148 -1.021 . . . . 0.0 111.016 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -70.45 102.45 1.14 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 121.012 1.142 . . . . 0.0 109.243 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.37 106.56 16.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.48 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -116.94 72.43 0.83 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.11 144.43 13.78 Favored Glycine 0 N--CA 1.484 1.853 0 N-CA-C 107.372 -2.291 . . . . 0.0 107.372 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.602 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 36.9 p-90 -161.05 176.9 10.85 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 117.592 -1.643 . . . . 0.0 112.014 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.853 ' H ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.59 103.32 4.66 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.957 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.613 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -91.56 174.2 7.49 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.258 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.471 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 97.8 m -156.59 146.31 20.87 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.278 -1.369 . . . . 0.0 112.143 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.595 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.1 p90 -172.5 -150.95 0.06 Allowed 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 114.589 -1.187 . . . . 0.0 108.999 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.595 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 20.1 m -156.2 153.42 29.19 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 117.807 -1.557 . . . . 0.0 112.09 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.501 ' CE2' HG23 ' A' ' 65' ' ' VAL . 4.1 m-85 -81.03 119.37 75.8 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 118.526 -1.27 . . . . 0.0 109.578 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -55.74 -71.71 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.443 1.429 . . . . 0.0 112.319 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.1 t -69.37 -113.91 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.715 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.02 48.02 0.75 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.436 -1.364 . . . . 0.0 110.334 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.674 ' C ' HE21 ' A' ' 49' ' ' GLN . 20.7 mp0 -71.56 112.86 8.02 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.416 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.674 HE21 ' C ' ' A' ' 48' ' ' GLN . 3.0 mm-40 -93.56 94.94 8.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.0 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.471 HG22 ' CD2' ' A' ' 86' ' ' PHE . 9.1 p -72.66 151.92 7.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.697 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 43.1 p -143.0 -63.27 0.41 Allowed 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.551 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.98 160.09 30.2 Favored 'General case' 0 C--N 1.301 -1.537 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.164 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -164.22 156.63 17.01 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 118.551 -1.26 . . . . 0.0 112.06 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 23.6 t-105 -155.52 137.04 14.13 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.847 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.477 ' C ' ' HG ' ' A' ' 56' ' ' SER . 0.5 OUTLIER 62.56 29.14 16.97 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.21 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.477 ' HG ' ' C ' ' A' ' 55' ' ' SER . 0.3 OUTLIER -170.43 122.39 0.64 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.613 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.3 m -84.54 69.39 10.58 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.948 -1.101 . . . . 0.0 108.845 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.407 ' H ' HG11 ' A' ' 58' ' ' VAL . 3.3 m -69.29 164.39 2.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 114.904 -1.044 . . . . 0.0 112.828 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 1.5 t -168.04 145.54 4.27 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.768 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -98.27 109.72 22.43 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.138 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.502 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 7.7 p -91.2 72.91 6.26 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.67 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.495 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 56.38 75.89 0.23 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.2 -1.476 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 74.94 -28.79 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.149 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.502 ' CB ' ' HG ' ' A' ' 61' ' ' SER . . . -88.49 -171.65 3.43 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 118.728 -1.189 . . . . 0.0 110.663 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.593 ' CG1' ' N ' ' A' ' 66' ' ' THR . 55.9 t -148.65 162.34 5.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.471 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.593 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 6.2 m -157.0 147.63 21.49 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 114.083 -1.417 . . . . 0.0 108.131 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.1 t -142.95 116.08 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 118.491 -1.284 . . . . 0.0 112.865 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -97.55 89.71 4.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.602 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.3 p-10 -70.27 120.43 15.94 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.075 -1.05 . . . . 0.0 112.063 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.571 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -38.27 158.33 0.09 OUTLIER Pre-proline 0 N--CA 1.486 1.36 0 CA-C-N 113.745 -1.571 . . . . 0.0 112.611 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -68.03 -35.49 20.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.897 1.731 . . . . 0.0 112.385 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.571 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -69.86 -56.53 6.84 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.862 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.602 HD21 ' N ' ' A' ' 74' ' ' GLY . 0.4 OUTLIER -74.07 -1.85 21.87 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.823 -1.151 . . . . 0.0 109.696 -179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.602 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -113.17 20.42 19.18 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 8.8 m -90.03 59.73 4.62 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.262 -0.975 . . . . 0.0 111.272 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.512 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -108.05 122.96 39.09 Favored Pre-proline 0 CA--C 1.566 1.566 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.564 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 78' ' ' ALA . 5.8 Cg_endo -70.25 156.38 62.2 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 121.565 1.51 . . . . 0.0 113.766 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.582 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -23.47 -46.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.885 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.74 65.88 0.24 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.089 -1.204 . . . . 0.0 110.089 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -151.98 -170.31 18.48 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.837 -1.649 . . . . 0.0 110.139 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.512 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.9 p -139.49 158.3 44.36 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.199 -1.001 . . . . 0.0 112.527 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -125.59 -176.18 3.53 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.409 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 6.3 tt0 -168.12 148.1 4.82 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.019 -1.872 . . . . 0.0 112.92 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.431 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 3.3 p90 -165.22 168.08 17.41 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.068 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.48 171.95 40.11 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 117.694 -2.193 . . . . 0.0 112.223 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.1 p90 -155.06 -172.75 4.3 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -136.21 112.32 9.71 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.967 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -125.57 153.76 18.34 Favored Glycine 0 N--CA 1.51 3.596 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.024 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.429 ' HG ' ' HB2' ' A' ' 49' ' ' GLN . 77.7 p . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.912 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.477 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.493 1.676 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -62.61 -143.11 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 121.588 1.525 . . . . 0.0 111.771 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 19.3 p -127.25 -58.35 1.28 Allowed 'General case' 0 N--CA 1.5 2.036 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.766 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.524 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.25 91.58 3.71 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.443 -0.903 . . . . 0.0 111.996 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.439 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 32.3 m-85 -65.53 -166.81 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.1 m -146.43 107.68 4.22 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 117.552 -1.659 . . . . 0.0 113.884 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.9 mt -58.94 168.19 1.36 Allowed 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.853 HD22 ' H ' ' A' ' 39' ' ' THR . 0.3 OUTLIER -41.24 92.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.053 179.861 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.6 45.88 93.59 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 119.495 -1.336 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.59 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -167.13 146.41 4.5 Favored Pre-proline 0 C--O 1.196 -1.743 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.157 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -64.22 166.16 17.67 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.31 1.34 . . . . 0.0 112.241 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -163.68 94.96 0.79 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 17.0 p -65.2 170.26 4.79 Favored 'General case' 0 N--CA 1.511 2.595 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.453 ' CG1' ' HA ' ' A' ' 98' ' ' THR . 17.0 m -60.53 -155.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.562 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.405 ' H ' ' HB ' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.194 0 CA-C-O 116.322 -2.377 . . . . 0.0 110.378 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.756 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.725 0.774 . . . . 0.0 113.064 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.99 43.3 0.06 OUTLIER Glycine 0 N--CA 1.497 2.703 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -52.41 -175.81 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 114.496 -0.852 . . . . 0.0 112.774 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.516 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 5.3 pt20 -142.25 126.48 17.53 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.907 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.457 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.3 m -115.1 128.41 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.163 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.465 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -97.12 171.93 8.15 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.313 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.542 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 2.7 t-105 -125.39 147.84 49.01 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.829 -0.748 . . . . 0.0 112.026 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.1 79.66 0.35 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 107.759 -2.137 . . . . 0.0 107.759 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -68.99 146.8 12.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 122.018 0.913 . . . . 0.0 113.112 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 C--N 1.296 -1.718 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.519 179.811 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.647 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.6 p90 . . . . . 0 CA--C 1.497 -1.08 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.67 114.32 28.26 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 179.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.542 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -91.53 115.83 28.36 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 119.19 -1.004 . . . . 0.0 113.52 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -98.53 96.85 8.26 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.47 HG11 ' N ' ' A' ' 26' ' ' THR . 33.5 t -92.64 144.54 9.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.47 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.5 m -131.27 103.43 6.46 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.771 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.2 t -74.12 151.57 7.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.731 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.516 ' NZ ' ' OE1' ' A' ' 9' ' ' GLN . 0.3 OUTLIER -148.16 111.29 4.88 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.643 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.513 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 2.1 t30 -96.85 129.73 44.24 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.962 -1.017 . . . . 0.0 108.397 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -132.06 -6.85 3.48 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 124.087 0.867 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.513 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 2.0 p -51.0 -80.87 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.732 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.0 37.16 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.194 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.556 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.598 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -136.45 147.78 61.33 Favored Pre-proline 0 N--CA 1.488 1.451 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.414 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -72.46 115.95 4.53 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 121.403 1.402 . . . . 0.0 110.406 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 t -98.34 95.83 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.236 -0.985 . . . . 0.0 112.109 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -105.76 63.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 99.99 154.14 27.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.626 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 39.9 p-90 -169.95 177.17 4.44 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.172 -1.811 . . . . 0.0 112.911 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.23 99.19 3.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.017 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.619 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -87.93 172.72 9.38 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 118.576 -1.25 . . . . 0.0 110.051 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.46 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -153.97 145.08 22.82 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 118.642 -1.223 . . . . 0.0 111.633 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.622 ' CD2' ' N ' ' A' ' 43' ' ' SER . 10.6 p90 -172.92 -156.36 0.09 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.407 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.622 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 56.5 m -158.55 157.52 32.2 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 117.53 -1.668 . . . . 0.0 112.075 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.473 ' CE2' HG23 ' A' ' 65' ' ' VAL . 10.9 m-85 -86.58 122.22 71.89 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 118.712 -1.195 . . . . 0.0 109.443 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.48 -62.1 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.244 1.296 . . . . 0.0 112.196 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.9 p -69.5 -58.81 3.5 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.793 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . 145.65 31.4 0.08 OUTLIER Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.418 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.647 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 49.6 mt-30 -43.69 131.93 5.14 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.394 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.585 HE21 ' CA ' ' A' ' 49' ' ' GLN . 0.1 OUTLIER -94.64 80.49 3.81 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.289 -0.964 . . . . 0.0 111.478 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.1 p -62.78 147.84 11.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.306 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.502 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 61.8 p -140.47 -71.18 0.37 Allowed 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.283 -0.967 . . . . 0.0 111.558 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.52 ' NE2' ' N ' ' A' ' 52' ' ' GLN . 0.0 OUTLIER -69.73 164.36 23.69 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.289 -179.951 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.2 5.51 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 118.645 -1.222 . . . . 0.0 112.056 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.425 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 30.8 t-105 -153.11 143.28 22.35 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.655 -0.818 . . . . 0.0 110.496 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 0.9 OUTLIER 57.71 30.24 18.59 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.663 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.423 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.4 OUTLIER -172.9 119.18 0.34 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.675 -179.884 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 m -82.81 74.37 9.78 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.975 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 10.3 m -69.41 156.83 6.93 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 CA-C-N 115.017 -0.992 . . . . 0.0 112.78 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 58.8 p -155.19 115.65 3.84 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.876 -1.056 . . . . 0.0 109.731 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.582 HE22 ' NE2' ' A' ' 49' ' ' GLN . 5.9 tt0 -89.86 113.44 25.04 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.18 -1.008 . . . . 0.0 110.532 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.6 p -92.19 80.44 5.04 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.923 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.44 -67.85 2.17 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.443 -1.36 . . . . 0.0 110.127 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.528 ' HG ' ' N ' ' A' ' 64' ' ' ALA . 10.3 p -141.94 -17.6 0.75 Allowed 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.223 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.543 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -88.93 -172.26 3.62 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.163 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.55 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.0 t -149.93 159.01 5.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 118.709 -1.197 . . . . 0.0 113.639 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.55 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 53.1 m -153.94 149.35 27.18 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.203 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.416 ' N ' HG21 ' A' ' 66' ' ' THR . 3.8 t -144.63 119.44 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 118.386 -1.326 . . . . 0.0 112.73 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.16 91.08 5.09 Favored 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.046 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.626 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.4 p-10 -71.23 120.95 17.54 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.879 -1.128 . . . . 0.0 111.625 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.547 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -43.14 167.39 0.08 OUTLIER Pre-proline 0 N--CA 1.487 1.377 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.452 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -70.34 -35.92 10.14 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.23 1.953 . . . . 0.0 112.373 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.549 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.47 -54.29 14.99 Favored 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.869 -179.834 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.526 ' ND2' ' O ' ' A' ' 55' ' ' SER . 4.8 p-10 -79.37 10.79 3.41 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.444 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.497 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -127.42 40.2 1.8 Allowed Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.186 -1.007 . . . . 0.0 110.673 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -109.93 62.82 0.6 Allowed 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.908 -0.717 . . . . 0.0 111.21 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.484 ' O ' ' CD1' ' A' ' 76' ' ' ILE . 0.0 OUTLIER -116.87 121.4 32.81 Favored Pre-proline 0 N--CA 1.483 1.187 0 C-N-CA 120.058 -0.657 . . . . 0.0 111.243 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.592 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.6 Cg_endo -67.38 156.35 66.55 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 C-N-CA 121.103 1.202 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.598 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -39.36 -18.75 0.01 OUTLIER 'General case' 0 C--O 1.205 -1.271 0 C-N-CA 119.895 -0.722 . . . . 0.0 112.676 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.592 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.24 62.52 0.43 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -163.67 -161.72 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 C-N-CA 118.979 -1.581 . . . . 0.0 110.635 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.467 ' N ' HG13 ' A' ' 76' ' ' ILE . 7.3 p -143.98 162.94 34.9 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.063 -1.055 . . . . 0.0 112.978 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -131.31 179.53 5.97 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.106 -1.407 . . . . 0.0 107.733 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.439 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 32.0 tt0 -164.03 144.55 8.36 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 117.226 -1.789 . . . . 0.0 113.187 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.439 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 3.2 p90 -157.7 170.28 22.74 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.779 -1.101 . . . . 0.0 109.857 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.79 164.8 37.18 Favored Glycine 0 N--CA 1.498 2.798 0 C-N-CA 117.704 -2.189 . . . . 0.0 112.557 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.639 ' C ' ' ND2' ' A' ' 87' ' ' ASN . 1.7 p90 -153.04 -177.77 6.5 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 114.889 -0.656 . . . . 0.0 110.608 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.826 ' N ' HD21 ' A' ' 87' ' ' ASN . 0.1 OUTLIER -138.39 111.4 7.83 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.693 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -109.96 169.38 13.58 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.288 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.484 1.268 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.866 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.533 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.509 2.515 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.496 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.5 Cg_endo -62.7 -101.11 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 120.962 1.108 . . . . 0.0 111.952 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.41 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 45.7 p -152.58 -69.2 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 118.829 -1.148 . . . . 0.0 111.946 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -106.54 94.98 5.43 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.56 -0.856 . . . . 0.0 111.255 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.496 ' CZ ' ' HD2' ' A' ' 97' ' ' PRO . 38.6 m-85 -65.03 -162.76 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.057 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -149.93 98.48 2.72 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 117.605 -1.638 . . . . 0.0 113.323 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.586 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.7 mt -52.17 171.59 0.05 OUTLIER 'General case' 0 C--O 1.21 -0.989 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.481 ' H ' HD21 ' A' ' 102' ' ' LEU . 2.7 p30 -55.54 82.41 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.755 -1.178 . . . . 0.0 110.783 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 87.51 41.85 6.34 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.756 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -174.44 130.36 0.47 Allowed Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.151 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.63 170.75 3.16 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 121.029 1.153 . . . . 0.0 111.22 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.4 ' SG ' HG12 ' A' ' 10' ' ' VAL . 8.2 t -166.73 101.95 0.57 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.179 -1.008 . . . . 0.0 111.117 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.47 169.48 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.844 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.712 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 9.8 p -80.25 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.876 -1.13 . . . . 0.0 109.876 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.712 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.402 0 CA-C-O 116.333 -2.371 . . . . 0.0 110.585 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.737 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.32 0.581 . . . . 0.0 111.355 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.15 43.94 0.06 OUTLIER Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.235 -1.946 . . . . 0.0 108.235 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.623 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 26.7 p -56.58 -168.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.87 -0.665 . . . . 0.0 110.955 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.486 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 1.8 pt20 -159.75 155.96 26.82 Favored 'General case' 0 C--N 1.287 -2.147 0 C-N-CA 118.754 -1.178 . . . . 0.0 110.407 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -141.35 138.88 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.002 -1.079 . . . . 0.0 111.67 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.457 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -100.44 171.61 7.64 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.157 179.95 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.461 ' NE1' ' HB3' ' A' ' 23' ' ' ALA . 1.3 t-105 -133.94 143.32 48.13 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.834 -0.746 . . . . 0.0 111.961 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.09 71.79 0.41 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.9 p -69.61 140.77 18.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.9 t30 . . . . . 0 N--CA 1.494 1.758 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.029 179.71 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.588 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 27.5 p90 . . . . . 0 CA--C 1.504 -0.81 0 CA-C-O 121.275 0.56 . . . . 0.0 111.984 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -65.13 173.82 2.28 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.461 ' HB3' ' NE1' ' A' ' 12' ' ' TRP . . . -152.52 98.25 2.35 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 117.651 -1.62 . . . . 0.0 112.755 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -92.12 97.95 11.24 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.475 HG11 ' N ' ' A' ' 26' ' ' THR . 19.4 t -95.55 145.56 8.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 C-N-CA 119.681 -0.807 . . . . 0.0 112.583 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.475 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.5 m -134.71 101.75 5.04 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.439 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.9 t -71.06 153.81 8.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.698 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.407 ' HZ3' ' HB ' ' A' ' 30' ' ' THR . 4.3 tttp -148.63 115.35 5.99 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.936 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.53 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.2 t30 -102.21 119.6 39.07 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.407 ' HB ' ' HZ3' ' A' ' 28' ' ' LYS . 11.2 t -122.19 1.42 9.71 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 124.169 0.918 . . . . 0.0 109.866 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.53 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -63.02 -79.49 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.951 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.491 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.4 OUTLIER 159.31 78.98 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 123.723 0.639 . . . . 0.0 111.498 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.554 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.54 141.24 1.55 Allowed Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.195 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -67.67 100.52 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.712 0 N-CA-C 108.972 -1.203 . . . . 0.0 108.972 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.84 112.29 23.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 118.244 -1.382 . . . . 0.0 111.442 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -124.22 76.76 1.5 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.23 136.76 6.01 Favored Glycine 0 N--CA 1.483 1.8 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.801 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 26.3 p-90 -154.54 -179.81 8.32 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 117.905 -1.518 . . . . 0.0 111.959 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.822 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -140.13 100.48 3.92 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.491 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.624 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -91.87 175.51 6.86 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.748 -1.181 . . . . 0.0 109.462 179.932 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.478 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -162.46 149.28 13.3 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 117.629 -1.629 . . . . 0.0 112.731 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.469 ' CD2' ' N ' ' A' ' 43' ' ' SER . 22.2 p90 -173.72 -140.93 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 113.571 -1.65 . . . . 0.0 107.558 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.584 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 31.0 m -163.39 -179.06 6.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.375 -1.73 . . . . 0.0 112.735 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CE1' ' OE1' ' A' ' 48' ' ' GLN . 8.1 m-85 -114.64 91.2 24.33 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -55.38 -36.97 94.99 Favored 'Trans proline' 0 CA--C 1.51 -0.72 0 C-N-CA 121.015 1.143 . . . . 0.0 110.065 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.43 ' HG ' ' HG2' ' A' ' 48' ' ' GLN . 22.2 p -79.44 165.26 23.25 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 119.322 -0.951 . . . . 0.0 108.973 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.12 48.27 3.31 Favored Glycine 0 C--N 1.29 -2.009 0 C-N-CA 118.663 -1.732 . . . . 0.0 109.968 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.533 ' OE1' ' CE1' ' A' ' 44' ' ' PHE . 3.2 pt20 -109.76 143.46 39.55 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.309 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.48 133.57 34.76 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.496 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.595 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.7 p -72.69 164.48 3.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.584 -0.846 . . . . 0.0 111.728 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.595 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 66.3 p -136.17 -63.24 0.65 Allowed 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.264 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.48 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.6 mt-30 -89.23 164.64 14.87 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.177 -1.009 . . . . 0.0 109.346 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -170.37 153.5 4.4 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.259 -1.376 . . . . 0.0 112.227 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.435 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 33.6 t-105 -156.1 144.84 20.26 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.881 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.435 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.8 OUTLIER 61.82 28.62 17.55 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 119.541 -0.863 . . . . 0.0 109.993 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.594 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.9 OUTLIER -172.58 124.54 0.47 Allowed 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.323 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.5 m -87.99 75.88 8.7 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -69.08 152.82 9.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.954 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 60.2 p -154.57 113.93 3.71 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.032 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.471 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.9 pt20 -90.51 117.71 29.41 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.924 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.0 p -94.09 85.49 4.71 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.999 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.93 -67.52 2.36 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.391 -1.385 . . . . 0.0 109.966 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -144.82 -12.72 0.56 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.293 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.584 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -93.28 -170.3 2.35 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.119 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.615 ' CG1' ' N ' ' A' ' 66' ' ' THR . 62.1 t -148.99 162.98 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.795 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.615 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 10.6 m -156.65 139.87 15.58 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 113.625 -1.625 . . . . 0.0 108.267 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.2 t -132.51 114.88 23.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.368 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -96.63 88.5 4.67 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.801 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.61 119.41 14.72 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.02 -1.072 . . . . 0.0 111.674 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.775 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -41.0 163.83 0.09 OUTLIER Pre-proline 0 N--CA 1.487 1.402 0 CA-C-N 113.741 -1.572 . . . . 0.0 112.417 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -64.57 -35.29 48.69 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 121.703 1.602 . . . . 0.0 112.195 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.538 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.33 -52.48 22.38 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 118.816 -1.154 . . . . 0.0 111.162 -179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.775 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.08 8.96 4.09 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.883 -1.127 . . . . 0.0 110.224 179.922 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.49 ' CA ' ' OD1' ' A' ' 69' ' ' ASN . . . -124.91 18.3 7.09 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 120.081 -1.057 . . . . 0.0 110.495 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.5 m -86.72 58.44 5.07 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.222 -0.991 . . . . 0.0 111.262 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.475 ' O ' ' CD1' ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.46 114.86 54.77 Favored Pre-proline 0 CA--C 1.564 1.496 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.245 179.934 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.3 Cg_endo -67.57 156.02 67.78 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.395 1.397 . . . . 0.0 113.663 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.554 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -18.45 -45.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 114.273 -1.33 . . . . 0.0 114.156 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.43 69.58 0.28 Allowed Glycine 0 N--CA 1.497 2.712 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -151.13 -164.11 11.84 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.62 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.467 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.2 p -143.38 154.72 44.02 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 118.997 -1.081 . . . . 0.0 112.592 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -124.34 175.48 7.06 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.505 ' C ' ' CD ' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -167.22 147.64 5.49 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 116.973 -1.891 . . . . 0.0 113.191 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.594 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 10.9 p90 -157.03 -179.13 7.91 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.609 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.29 161.42 34.82 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 117.471 -2.3 . . . . 0.0 112.705 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.584 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.7 p90 -157.16 175.24 14.32 Favored 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 114.806 -0.697 . . . . 0.0 111.008 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -125.52 115.73 20.67 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.906 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -127.27 158.02 20.96 Favored Glycine 0 N--CA 1.51 3.58 0 C-N-CA 119.38 -1.39 . . . . 0.0 112.638 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.7 p . . . . . 0 N--CA 1.481 1.092 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.789 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.26 0.076 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 3.8 Cg_endo -65.63 -143.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.217 -0.552 0 C-N-CA 121.048 1.166 . . . . 0.0 110.808 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.1 p -113.45 -92.91 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.6 -0.84 . . . . 0.0 112.112 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -89.1 99.11 12.17 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.625 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.573 ' C ' ' HG ' ' A' ' 101' ' ' SER . 6.6 m-30 -68.08 -149.41 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.573 ' HG ' ' C ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -160.0 112.04 2.03 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 116.712 -1.995 . . . . 0.0 114.521 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -64.77 172.76 2.58 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.822 ' ND2' ' H ' ' A' ' 39' ' ' THR . 69.0 m-80 -35.72 91.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.51 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 55.88 49.42 66.66 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.55 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.737 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 21.1 m -163.37 131.6 2.77 Favored Pre-proline 0 C--O 1.189 -2.119 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.92 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -61.06 158.86 32.32 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 121.263 1.309 . . . . 0.0 112.636 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.623 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.1 t -157.62 110.98 2.51 Favored 'General case' 0 N--CA 1.496 1.852 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.221 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -73.45 128.03 34.36 Favored 'General case' 0 N--CA 1.508 2.447 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -179.773 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.432 ' H ' HG21 ' A' ' 109' ' ' VAL . 2.5 m -56.53 -177.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.659 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 116.301 -2.388 . . . . 0.0 110.461 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.72 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 121.2 0.524 . . . . 0.0 111.366 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.76 43.25 0.1 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.631 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 2.3 p -53.55 -178.12 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 121.541 0.686 . . . . 0.0 112.077 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' NE2' ' HA2' ' A' ' 110' ' ' GLY . 0.1 OUTLIER -138.34 108.44 6.39 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.795 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' A' ' 109' ' ' VAL . 4.6 m -103.39 124.06 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.238 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.46 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.15 165.05 12.6 Favored 'General case' 0 C--N 1.294 -1.84 0 C-N-CA 119.291 -0.964 . . . . 0.0 109.321 179.88 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.486 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 3.4 t-105 -124.74 143.32 50.84 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.614 -0.835 . . . . 0.0 112.444 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 75.45 0.38 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.76 149.0 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.97 -0.692 . . . . 0.0 112.832 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.482 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.528 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.7 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.0 p90 . . . . . 0 CA--C 1.503 -0.844 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.456 ' CG2' ' N ' ' A' ' 23' ' ' ALA . 0.6 OUTLIER -80.85 163.97 23.01 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 179.407 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.456 ' N ' ' CG2' ' A' ' 22' ' ' THR . . . -145.65 110.11 5.03 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.894 -1.522 . . . . 0.0 112.89 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 31.2 t30 -99.09 101.15 12.41 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.456 ' CG1' ' CE1' ' A' ' 84' ' ' PHE . 13.4 t -99.5 140.91 17.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 119.645 -0.822 . . . . 0.0 112.341 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.46 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.3 m -133.49 114.83 14.05 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.276 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -85.31 150.38 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.264 -0.975 . . . . 0.0 111.651 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 28' ' ' LYS . 9.9 tttt -130.53 85.91 2.33 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.815 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.417 ' HB3' ' CD1' ' A' ' 76' ' ' ILE . 0.8 OUTLIER -68.8 104.94 2.17 Favored 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 118.565 -1.254 . . . . 0.0 109.807 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -105.8 -1.34 24.44 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.335 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.541 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.7 p -81.07 102.56 10.3 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.728 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 97.5 p -37.23 87.59 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 113.138 0.792 . . . . 0.0 113.138 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.583 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -166.06 146.81 5.58 Favored Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.536 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -70.76 100.92 0.99 Allowed 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 121.027 1.152 . . . . 0.0 109.166 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -86.76 108.52 18.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.149 -1.42 . . . . 0.0 111.817 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -122.63 63.32 0.97 Allowed 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.32 142.54 13.47 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 107.42 -2.272 . . . . 0.0 107.42 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.856 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.7 p-90 -159.37 176.1 12.54 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 117.707 -1.597 . . . . 0.0 111.796 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.794 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -140.01 111.93 7.5 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.982 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.604 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.61 178.47 4.62 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.794 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.505 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.26 152.06 16.28 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.245 -1.382 . . . . 0.0 112.413 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' ' N ' ' A' ' 43' ' ' SER . 17.3 p90 -177.12 -150.09 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 113.919 -1.491 . . . . 0.0 108.408 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.549 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 42.7 m -162.16 161.95 28.23 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 118.046 -1.462 . . . . 0.0 112.026 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.5 ' CD2' ' O ' ' A' ' 48' ' ' GLN . 16.5 m-85 -91.7 116.25 66.09 Favored Pre-proline 0 N--CA 1.484 1.275 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.005 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.08 -67.82 0.05 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 121.539 1.492 . . . . 0.0 112.938 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 19.7 m -68.74 -132.72 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.515 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -117.33 58.74 0.49 Allowed Glycine 0 N--CA 1.503 3.109 0 C-N-CA 119.631 -1.271 . . . . 0.0 111.715 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.7 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 tt0 -110.48 114.84 28.58 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.961 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.522 ' NE2' ' OE1' ' A' ' 60' ' ' GLN . 5.2 mm-40 -118.22 136.95 53.34 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 120.131 -0.628 . . . . 0.0 111.291 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.478 HG22 ' CD2' ' A' ' 86' ' ' PHE . 6.2 p -96.3 156.9 3.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.269 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.481 HG22 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -138.56 -59.53 0.62 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 119.598 -0.841 . . . . 0.0 111.059 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.481 ' H ' HG22 ' A' ' 51' ' ' THR . 0.8 OUTLIER -90.32 131.08 36.31 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.499 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.78 160.39 40.82 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.119 -1.032 . . . . 0.0 112.476 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.458 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 39.1 t-105 -155.33 149.46 25.78 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.676 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.458 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.3 t 66.07 20.07 11.2 Favored 'General case' 0 C--N 1.316 -0.877 0 C-N-CA 119.649 -0.82 . . . . 0.0 109.573 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.44 ' HB3' ' CB ' ' A' ' 84' ' ' PHE . 5.5 p -173.25 123.84 0.4 Allowed 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.921 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -80.33 77.88 7.06 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.321 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -72.6 152.62 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.538 -0.755 . . . . 0.0 112.277 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 40.7 p -150.06 109.15 3.91 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.883 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.522 ' OE1' ' NE2' ' A' ' 49' ' ' GLN . 33.0 tt0 -87.45 114.75 24.35 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.074 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.3 p -91.41 81.23 5.43 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.864 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.09 -69.74 1.88 Allowed Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.403 -1.379 . . . . 0.0 110.074 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.5 t -139.13 -19.06 0.99 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.858 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.522 ' CB ' ' HG ' ' A' ' 43' ' ' SER . . . -86.65 -173.81 4.68 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.815 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 66' ' ' THR . 49.7 t -145.13 160.66 13.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 C-N-CA 118.77 -1.172 . . . . 0.0 113.226 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.561 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 11.6 m -159.36 129.61 5.72 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.889 -1.505 . . . . 0.0 108.121 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.423 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.0 t -125.3 146.89 30.23 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.004 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.849 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -130.47 93.33 3.43 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.856 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.74 117.63 15.75 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.229 -0.988 . . . . 0.0 112.402 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.617 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -42.17 156.91 0.23 Allowed Pre-proline 0 N--CA 1.481 1.088 0 CA-C-N 113.537 -1.665 . . . . 0.0 111.876 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -59.99 -34.91 94.69 Favored 'Trans proline' 0 C--O 1.213 -0.736 0 C-N-CA 121.745 1.63 . . . . 0.0 112.065 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.617 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.92 -53.52 20.53 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.987 179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.666 ' C ' HD21 ' A' ' 73' ' ' ASN . 0.3 OUTLIER -79.67 12.78 2.39 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.496 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.444 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -133.6 20.71 4.1 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.516 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.4 m -94.53 60.57 2.62 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.395 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.52 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -113.49 131.81 22.8 Favored Pre-proline 0 N--CA 1.491 1.595 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.472 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.504 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -70.86 151.42 62.77 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.468 1.445 . . . . 0.0 114.19 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -18.03 -45.92 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.504 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -106.4 68.31 0.24 Allowed Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.883 -1.151 . . . . 0.0 111.084 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.19 23.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 118.398 -1.858 . . . . 0.0 111.384 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.52 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.2 p -132.39 162.15 31.83 Favored 'General case' 0 N--CA 1.482 1.172 0 CA-C-O 121.74 0.781 . . . . 0.0 112.686 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.03 174.21 9.05 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.43 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 26.6 tt0 -165.96 144.84 5.99 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 116.831 -1.948 . . . . 0.0 113.545 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 25' ' ' VAL . 18.3 p90 -156.28 178.01 10.79 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.625 -1.171 . . . . 0.0 110.181 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -159.32 169.2 35.42 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 117.761 -2.162 . . . . 0.0 112.107 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.478 ' CD2' HG22 ' A' ' 50' ' ' VAL . 14.4 p90 -166.85 156.89 11.43 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.371 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -108.7 114.79 28.89 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.198 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.6 166.56 12.17 Favored Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.863 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 C--N 1.316 -0.856 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.486 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.493 1.693 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.476 ' HD2' ' CE2' ' A' ' 100' ' ' PHE . 1.9 Cg_endo -64.91 -137.3 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 121.312 1.341 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.489 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 30.9 p -121.09 -59.74 1.7 Allowed 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.309 -0.956 . . . . 0.0 113.027 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.489 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.36 100.06 8.74 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.078 -1.049 . . . . 0.0 112.29 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.502 ' N ' ' O ' ' A' ' 107' ' ' CYS . 19.3 m-85 -72.64 -169.12 0.51 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.5 m -143.5 122.5 12.81 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 117.888 -1.525 . . . . 0.0 112.469 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.631 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -80.81 174.54 11.52 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.538 -0.865 . . . . 0.0 109.243 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.794 ' ND2' ' H ' ' A' ' 39' ' ' THR . 74.7 m-80 -34.61 89.18 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.324 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.073 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 60.45 57.7 17.71 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.466 -1.35 . . . . 0.0 110.744 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.72 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -178.24 148.61 0.64 Allowed Pre-proline 0 C--O 1.201 -1.454 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.244 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.41 176.55 3.27 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 121.647 1.565 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.502 ' O ' ' N ' ' A' ' 100' ' ' PHE . 10.3 t -173.57 99.06 0.11 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.099 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.431 ' HB ' ' NE2' ' A' ' 9' ' ' GLN . 0.2 OUTLIER -59.97 173.98 0.55 Allowed 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.037 -0.665 . . . . 0.0 112.29 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -71.24 -91.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.592 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.434 ' HA2' ' NE2' ' A' ' 9' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.218 0 CA-C-O 116.364 -2.353 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 121.228 0.537 . . . . 0.0 111.697 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.11 44.98 0.22 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 p -53.27 179.0 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.668 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.52 118.29 12.38 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.096 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.464 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.2 m -108.88 125.97 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.28 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.457 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -98.44 170.53 8.77 Favored 'General case' 0 C--N 1.292 -1.9 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.673 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.425 ' CE3' ' HB3' ' A' ' 96' ' ' ALA . 4.8 t-105 -125.44 143.01 51.19 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.769 -0.772 . . . . 0.0 111.785 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.14 72.48 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.62 151.61 9.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.916 0.865 . . . . 0.0 113.266 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.005 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 27.1 p90 . . . . . 0 CA--C 1.493 -1.25 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.2 t -70.53 168.92 15.24 Favored 'General case' 0 C--N 1.283 -2.317 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.09 118.74 10.43 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.157 -1.417 . . . . 0.0 112.626 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -104.28 90.93 3.71 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.467 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 11.5 t -92.73 133.03 35.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.703 -0.799 . . . . 0.0 112.275 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.454 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 1.6 m -119.17 107.2 13.17 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.522 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 82' ' ' ALA . 2.9 t -78.29 144.27 11.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 119.149 -1.021 . . . . 0.0 110.68 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.4 tptm -135.37 103.05 5.35 Favored 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.859 -0.736 . . . . 0.0 109.576 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.741 HD21 ' N ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -100.33 124.37 45.72 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.088 179.89 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.741 ' N ' HD21 ' A' ' 29' ' ' ASN . 8.6 t -135.78 -2.65 2.36 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.011 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.69 ' HG ' ' H ' ' A' ' 32' ' ' SER . 4.3 p -52.19 -80.96 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 119.291 -0.963 . . . . 0.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.69 ' H ' ' HG ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.08 61.04 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 123.657 0.598 . . . . 0.0 110.803 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.657 ' H ' ' CB ' ' A' ' 78' ' ' ALA . . . -152.72 134.43 8.52 Favored Pre-proline 0 C--N 1.306 -1.283 0 C-N-CA 119.044 -1.063 . . . . 0.0 110.45 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.64 106.7 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 120.922 1.081 . . . . 0.0 110.269 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.5 t -87.77 67.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 118.639 -1.224 . . . . 0.0 111.809 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -88.16 65.08 7.99 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 101.03 145.6 17.37 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 107.046 -2.421 . . . . 0.0 107.046 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.828 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 49.7 p-90 -162.31 174.61 12.59 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 116.976 -1.89 . . . . 0.0 112.666 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -142.87 99.21 3.42 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.862 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.594 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -87.05 173.34 9.34 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 118.328 -1.349 . . . . 0.0 109.439 179.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.467 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -158.12 147.78 19.81 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 117.907 -1.517 . . . . 0.0 112.441 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.594 ' CG ' ' N ' ' A' ' 43' ' ' SER . 10.8 p90 -173.79 -137.29 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.958 -1.474 . . . . 0.0 108.043 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.594 ' N ' ' CG ' ' A' ' 42' ' ' PHE . 41.8 m -161.06 174.33 13.89 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 117.563 -1.655 . . . . 0.0 112.455 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.505 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 1.9 m-85 -114.47 95.93 41.54 Favored Pre-proline 0 N--CA 1.496 1.873 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.189 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.46 ' C ' ' H ' ' A' ' 47' ' ' GLY . 5.0 Cg_exo -60.05 -40.9 57.11 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 121.261 1.307 . . . . 0.0 111.676 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.3 t -74.96 15.45 0.4 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.563 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 45' ' ' PRO . . . 55.79 29.38 54.62 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.233 -1.46 . . . . 0.0 110.133 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -61.07 116.47 4.55 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.609 ' CD ' HE22 ' A' ' 60' ' ' GLN . 0.0 OUTLIER -95.5 97.77 10.03 Favored 'General case' 0 N--CA 1.484 1.275 0 C-N-CA 119.359 -0.937 . . . . 0.0 110.621 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 51' ' ' THR . 0.9 OUTLIER -64.47 157.58 4.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.177 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 40.4 p -133.05 -64.45 0.74 Allowed 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.755 -0.778 . . . . 0.0 111.259 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.551 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.9 OUTLIER -90.58 173.98 7.76 Favored 'General case' 0 N--CA 1.494 1.74 0 C-N-CA 118.87 -1.132 . . . . 0.0 110.133 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -173.2 147.46 1.56 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.961 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.456 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 37.2 t-105 -151.2 143.7 24.26 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.713 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.456 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.3 OUTLIER 60.57 27.53 17.21 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.753 -179.944 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.432 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -174.85 122.62 0.24 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.566 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -84.84 77.63 10.05 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 118.987 -1.085 . . . . 0.0 109.462 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 m -69.23 152.57 9.34 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.296 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.418 ' HG1' ' HB ' ' A' ' 66' ' ' THR . 36.9 p -155.24 119.27 4.6 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.074 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.609 HE22 ' CD ' ' A' ' 49' ' ' GLN . 27.9 tt0 -91.53 116.92 29.26 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.906 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.439 ' H ' ' HG ' ' A' ' 61' ' ' SER . 3.2 p -90.52 77.35 6.48 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.685 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.36 -68.71 2.06 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.41 -1.376 . . . . 0.0 110.156 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -138.27 -17.16 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.903 -0.719 . . . . 0.0 110.291 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.423 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -91.68 -172.44 3.22 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.988 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.612 ' CG1' ' N ' ' A' ' 66' ' ' THR . 46.1 t -143.83 162.27 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.0 -1.08 . . . . 0.0 113.462 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.612 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 23.5 m -157.79 137.24 11.94 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.573 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.432 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.8 t -131.8 116.33 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 C-N-CA 119.1 -1.04 . . . . 0.0 112.192 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.407 ' CB ' HH11 ' A' ' 68' ' ' ARG . 0.3 OUTLIER -99.53 96.06 7.41 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.269 -1.332 . . . . 0.0 108.74 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.828 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -76.02 120.11 20.89 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.836 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.659 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -40.28 160.62 0.12 Allowed Pre-proline 0 N--CA 1.483 1.192 0 CA-C-N 113.44 -1.709 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -64.89 -38.6 28.83 Favored 'Trans proline' 0 C--O 1.211 -0.844 0 C-N-CA 122.106 1.87 . . . . 0.0 112.229 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.558 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.1 OUTLIER -69.11 -54.69 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.581 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.659 HD22 ' N ' ' A' ' 70' ' ' ALA . 2.5 p30 -76.13 5.84 6.23 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.032 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -128.4 50.25 0.9 Allowed Glycine 0 C--O 1.202 -1.901 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.1 m -118.98 61.66 0.8 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 119.78 -0.768 . . . . 0.0 111.303 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.455 ' O ' ' CD1' ' A' ' 76' ' ' ILE . 0.0 OUTLIER -120.46 109.02 36.97 Favored Pre-proline 0 CA--C 1.56 1.353 0 C-N-CA 119.963 -0.695 . . . . 0.0 111.312 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.633 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.3 Cg_endo -71.65 118.9 5.88 Favored 'Trans proline' 0 C--O 1.207 -1.063 0 C-N-CA 121.182 1.255 . . . . 0.0 111.389 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.657 ' CB ' ' H ' ' A' ' 33' ' ' ALA . . . -7.65 68.07 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.694 1.246 . . . . 0.0 113.257 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.633 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . 170.18 46.1 0.03 OUTLIER Glycine 0 C--N 1.277 -2.722 0 CA-C-N 114.148 -1.387 . . . . 0.0 110.124 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -174.98 -152.92 9.61 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.021 -1.561 . . . . 0.0 110.192 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 p -140.77 173.64 11.29 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.26 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 27' ' ' VAL . . . -148.94 90.79 1.79 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -85.04 146.44 27.18 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.467 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 12.0 p90 -155.03 175.56 13.67 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 113.997 -1.456 . . . . 0.0 108.851 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.7 176.82 41.12 Favored Glycine 0 N--CA 1.498 2.82 0 C-N-CA 117.489 -2.291 . . . . 0.0 112.532 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.489 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 6.8 p90 -163.68 -175.14 3.99 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.949 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -129.77 113.59 14.89 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 119.753 -0.779 . . . . 0.0 110.507 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.495 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.45 152.66 20.3 Favored Glycine 0 N--CA 1.504 3.199 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.472 ' H ' ' HG ' ' A' ' 89' ' ' SER . 1.9 p . . . . . 0 N--CA 1.481 1.099 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.165 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.425 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 111.283 0.105 . . . . 0.0 111.283 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.502 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -61.19 -95.72 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.909 1.073 . . . . 0.0 112.465 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.9 p -155.04 -81.73 0.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.177 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -102.59 94.34 5.6 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.329 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.562 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -67.65 -150.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.209 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 19.4 m -157.12 110.72 2.6 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 117.215 -1.794 . . . . 0.0 113.59 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.544 ' O ' ' N ' ' A' ' 104' ' ' GLY . 2.5 mt -55.89 177.43 0.06 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.599 ' ND2' ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.15 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.544 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -163.63 20.29 0.15 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 118.676 -1.726 . . . . 0.0 111.435 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.541 ' O ' ' N ' ' A' ' 102' ' ' LEU . 3.5 p -139.6 150.66 64.16 Favored Pre-proline 0 N--CA 1.501 2.087 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.561 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.83 163.82 17.98 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.437 1.425 . . . . 0.0 111.531 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 4.7 t -157.03 98.62 1.76 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 4.5 p -50.95 161.67 0.35 Allowed 'General case' 0 N--CA 1.498 1.957 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.828 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.764 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 10.8 p -75.52 -135.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.038 -1.065 . . . . 0.0 109.648 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.764 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.13 0 CA-C-O 116.267 -2.407 . . . . 0.0 110.393 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.528 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.488 1.453 0 CA-C-O 121.022 0.439 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 177.12 48.33 0.06 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' C ' ' NE2' ' A' ' 9' ' ' GLN . 4.0 p -52.79 178.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.495 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.438 ' NE2' ' C ' ' A' ' 8' ' ' CYS . 0.0 OUTLIER -129.73 124.39 33.39 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.88 179.948 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 110' ' ' GLY . 2.5 m -117.36 125.53 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.532 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.438 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.68 168.24 10.28 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.646 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.539 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.4 t-105 -134.31 143.44 47.72 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 119.43 -0.908 . . . . 0.0 112.601 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.66 73.73 0.45 Allowed Glycine 0 N--CA 1.496 2.677 0 N-CA-C 107.3 -2.32 . . . . 0.0 107.3 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -69.93 162.46 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 113.867 1.062 . . . . 0.0 113.867 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 2.0 t30 . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 113.686 -1.597 . . . . 0.0 108.689 179.798 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 37.7 p90 . . . . . 0 CA--C 1.495 -1.171 0 CA-C-O 121.65 0.738 . . . . 0.0 112.62 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.8 t -71.81 168.58 17.54 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.539 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -150.18 118.88 6.55 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 117.675 -1.61 . . . . 0.0 112.701 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -100.42 95.82 7.0 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.449 HG11 ' N ' ' A' ' 26' ' ' THR . 18.6 t -94.91 141.5 14.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 C-N-CA 119.584 -0.847 . . . . 0.0 112.423 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.449 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.1 m -127.28 120.75 29.36 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.685 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -90.55 148.34 4.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.719 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.9 tptp -136.15 103.83 5.46 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.028 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.71 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.2 OUTLIER -95.71 132.56 40.78 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.519 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.462 ' N ' ' ND2' ' A' ' 29' ' ' ASN . 13.7 t -139.48 -3.42 1.51 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.565 ' C ' ' HG ' ' A' ' 32' ' ' SER . 5.1 p -50.68 -82.15 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.505 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.565 ' HG ' ' C ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 161.54 69.7 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.478 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.515 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.02 154.13 4.99 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 118.518 -1.273 . . . . 0.0 111.499 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -73.18 99.51 1.12 Allowed 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 121.413 1.409 . . . . 0.0 109.598 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -78.32 81.94 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 118.381 -1.327 . . . . 0.0 111.902 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -95.03 54.73 1.72 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 107.38 152.95 18.39 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 107.506 -2.238 . . . . 0.0 107.506 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 41.9 p-90 -163.31 174.09 12.46 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 117.13 -1.828 . . . . 0.0 112.502 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.36 98.16 3.54 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.124 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.605 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -84.9 171.84 11.86 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 118.168 -1.413 . . . . 0.0 109.635 179.945 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.456 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -155.92 142.99 19.08 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 118.673 -1.211 . . . . 0.0 111.63 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.585 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.1 p90 -172.1 -148.92 0.05 Allowed 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.625 -1.171 . . . . 0.0 108.606 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.585 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 65.6 m -159.08 157.71 31.58 Favored 'General case' 0 C--N 1.29 -2.005 0 C-N-CA 117.782 -1.567 . . . . 0.0 111.485 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.476 ' CE2' HG23 ' A' ' 65' ' ' VAL . 4.4 m-85 -88.31 114.35 59.15 Favored Pre-proline 0 N--CA 1.491 1.578 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.94 -54.52 4.64 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 N-CA-C 108.654 -1.325 . . . . 0.0 108.654 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.452 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 2.4 t -72.61 163.13 28.55 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 118.777 -1.169 . . . . 0.0 108.063 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.452 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -78.07 59.98 3.89 Favored Glycine 0 C--N 1.277 -2.72 0 C-N-CA 118.338 -1.887 . . . . 0.0 108.72 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.567 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 mt-30 -90.96 176.53 6.57 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.627 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.52 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -162.02 111.92 1.54 Allowed 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.838 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -68.91 157.89 6.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.504 -0.878 . . . . 0.0 111.311 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.836 ' HG1' ' H ' ' A' ' 52' ' ' GLN . 62.2 p -134.71 -66.01 0.61 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.389 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.836 ' H ' ' HG1' ' A' ' 51' ' ' THR . 0.1 OUTLIER -83.96 168.98 15.49 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.414 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.33 152.72 7.4 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 118.327 -1.349 . . . . 0.0 112.272 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.428 ' CE2' ' HB2' ' A' ' 55' ' ' SER . 18.4 t-105 -146.72 132.21 18.69 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.626 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.428 ' HB2' ' CE2' ' A' ' 54' ' ' TRP . 2.2 t 58.57 33.18 22.89 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.095 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.5 114.79 0.47 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.376 -0.929 . . . . 0.0 110.672 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.8 m -80.91 74.85 7.88 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 118.87 -1.132 . . . . 0.0 108.929 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -69.07 168.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 114.966 -1.016 . . . . 0.0 112.843 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 10.0 t -170.18 123.57 0.71 Allowed 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.825 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -86.41 102.45 14.06 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.315 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.2 p -91.2 82.83 5.48 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.546 -0.862 . . . . 0.0 111.773 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.585 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 55.69 78.15 0.13 Allowed Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.481 -1.343 . . . . 0.0 110.861 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.546 ' HG ' ' N ' ' A' ' 64' ' ' ALA . 1.2 p 67.59 -23.93 0.12 Allowed 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.825 -0.75 . . . . 0.0 111.487 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.585 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -90.95 -176.07 4.53 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.876 -1.129 . . . . 0.0 110.852 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' A' ' 66' ' ' THR . 33.1 t -149.26 160.11 5.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 118.844 -1.143 . . . . 0.0 113.6 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.572 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.1 m -154.51 154.58 33.36 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.024 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.454 ' N ' HG21 ' A' ' 66' ' ' THR . 7.1 t -147.85 117.85 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 118.511 -1.276 . . . . 0.0 112.197 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.24 90.42 5.11 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.441 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.599 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.7 p-10 -70.57 119.01 14.1 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.805 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.626 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -38.3 158.14 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.482 0 CA-C-N 113.477 -1.692 . . . . 0.0 112.628 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -65.48 -36.74 32.95 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 121.875 1.717 . . . . 0.0 112.072 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.575 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.4 -56.56 7.1 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 118.928 -1.109 . . . . 0.0 110.226 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.626 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -70.22 -3.26 16.15 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.012 179.842 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -123.58 51.3 0.81 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 t -118.2 54.16 0.94 Allowed 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.677 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.508 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -110.69 135.58 20.73 Favored Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.297 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.3 Cg_endo -76.32 156.42 37.2 Favored 'Trans proline' 0 C--O 1.212 -0.793 0 C-N-CA 121.507 1.472 . . . . 0.0 112.306 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.515 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -28.5 -32.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.5 71.53 0.22 Allowed Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.984 -1.103 . . . . 0.0 110.771 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.401 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -164.54 -164.6 20.18 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 118.739 -1.696 . . . . 0.0 111.07 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.508 ' N ' HG13 ' A' ' 76' ' ' ILE . 11.6 p -139.99 167.78 21.33 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.99 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -132.66 -169.05 2.17 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.173 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.505 ' NE2' ' O ' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -169.8 141.82 2.34 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 117.628 -1.629 . . . . 0.0 112.617 -179.926 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.422 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 2.5 p90 -163.13 161.73 25.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -157.54 173.18 34.95 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 117.994 -2.051 . . . . 0.0 111.946 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 7.2 p90 -164.59 -174.63 3.5 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.506 -0.878 . . . . 0.0 111.328 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.446 HD21 ' HB3' ' A' ' 52' ' ' GLN . 70.8 m-80 -130.79 115.71 16.99 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.224 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.41 153.43 20.6 Favored Glycine 0 N--CA 1.511 3.639 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.834 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.64 179.883 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.483 ' HG2' ' CE2' ' A' ' 100' ' ' PHE . 2.3 Cg_endo -64.9 -144.9 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.764 0 C-N-CA 121.548 1.499 . . . . 0.0 111.514 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.622 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.8 p -134.67 -63.37 0.71 Allowed 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 119.696 -0.802 . . . . 0.0 111.873 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.622 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.2 106.98 16.62 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.622 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 12.4 m-85 -80.98 -168.83 1.95 Allowed 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.8 m -144.83 106.24 4.23 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 117.906 -1.517 . . . . 0.0 113.378 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -54.78 174.04 0.08 Allowed 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.236 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.492 HD21 ' HB2' ' A' ' 38' ' ' TRP . 3.1 p30 -57.84 79.95 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.205 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.22 9.02 40.14 Favored Glycine 0 N--CA 1.499 2.877 0 C-N-CA 119.625 -1.274 . . . . 0.0 112.447 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.606 ' O ' ' N ' ' A' ' 102' ' ' LEU . 3.2 p -152.5 153.48 30.63 Favored Pre-proline 0 C--O 1.194 -1.847 0 C-N-CA 118.482 -1.287 . . . . 0.0 111.449 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -66.79 -179.51 1.69 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 121.679 1.586 . . . . 0.0 112.037 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.428 ' SG ' HG12 ' A' ' 10' ' ' VAL . 5.4 t -173.2 100.5 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.843 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.31 165.38 4.62 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.791 -0.764 . . . . 0.0 111.879 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.672 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 0.2 OUTLIER -75.11 172.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.012 179.635 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.672 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.178 0 CA-C-O 116.341 -2.366 . . . . 0.0 110.357 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.44 ' CB ' HG22 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.488 1.448 0 CA-C-O 121.438 0.637 . . . . 0.0 111.848 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.46 55.25 0.06 OUTLIER Glycine 0 N--CA 1.502 3.078 0 N-CA-C 107.384 -2.286 . . . . 0.0 107.384 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -53.88 -165.46 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.503 1.144 . . . . 0.0 113.895 -179.747 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.572 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 13.5 mt-30 -145.03 89.84 1.99 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.455 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.538 ' CG1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 m -87.83 141.3 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.793 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.505 ' CD2' ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -116.12 172.8 6.94 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.778 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.52 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 8.8 t-105 -133.14 147.84 52.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.768 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.13 87.85 0.32 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.94 141.03 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.578 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.426 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 55.2 t30 . . . . . 0 C--N 1.303 -1.423 0 CA-C-N 115.105 -0.952 . . . . 0.0 109.327 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 21' ' ' PHE . 35.9 p90 . . . . . 0 CA--C 1.49 -1.327 0 CA-C-O 121.355 0.598 . . . . 0.0 112.607 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.457 HG22 ' N ' ' A' ' 23' ' ' ALA . 0.5 OUTLIER -68.95 171.28 8.3 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 179.559 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 22' ' ' THR . . . -151.11 103.34 3.03 Favored 'General case' 0 C--N 1.29 -2.011 0 C-N-CA 117.754 -1.578 . . . . 0.0 112.468 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -91.26 98.88 11.99 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.494 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 8.4 t -97.19 139.81 18.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 119.706 -0.797 . . . . 0.0 112.669 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -125.01 149.47 47.71 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.24 179.796 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.6 t -123.54 101.65 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.694 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.437 ' HD3' ' CG2' ' A' ' 81' ' ' THR . 35.3 tptt -87.85 101.95 14.22 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.014 -1.075 . . . . 0.0 110.054 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.702 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.2 OUTLIER -97.16 121.09 38.66 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.274 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -128.51 -1.02 5.57 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.708 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.9 p -47.04 -84.77 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.364 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.473 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 164.75 42.69 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.17 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.817 -179.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.576 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -147.71 153.17 42.64 Favored Pre-proline 0 N--CA 1.486 1.333 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.337 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -69.6 95.84 0.56 Allowed 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 121.36 1.373 . . . . 0.0 110.006 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 t -72.8 96.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.508 -1.277 . . . . 0.0 111.253 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -113.45 82.96 1.76 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.55 139.45 1.92 Allowed Glycine 0 C--N 1.292 -1.89 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.769 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 46.1 p-90 -159.87 176.18 12.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 117.895 -1.522 . . . . 0.0 111.935 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.626 ' HG1' ' C ' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -142.35 110.03 5.78 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.587 179.925 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.579 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.21 173.55 6.74 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.842 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.441 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -154.94 147.72 24.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.01 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.7 p90 -173.26 -144.96 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.451 -1.25 . . . . 0.0 108.904 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.54 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.1 m -159.42 153.3 23.16 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 117.801 -1.56 . . . . 0.0 112.364 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.8 m-85 -84.32 117.56 69.03 Favored Pre-proline 0 N--CA 1.484 1.27 0 C-N-CA 118.825 -1.15 . . . . 0.0 108.23 179.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -57.68 -62.59 0.2 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.628 0.885 . . . . 0.0 110.717 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.576 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 34.9 t -77.91 -174.79 3.7 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.967 -1.093 . . . . 0.0 110.177 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.576 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -79.81 54.33 4.41 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 118.983 -1.58 . . . . 0.0 109.782 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.552 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 1.9 mt-30 -88.27 139.85 30.08 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 119.106 -1.037 . . . . 0.0 110.79 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.504 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -139.89 112.26 7.75 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.961 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 1.6 p -69.43 149.12 11.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.691 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.593 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 26.5 p -126.07 -61.92 1.2 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.898 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.593 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -98.31 125.54 43.47 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.657 -0.817 . . . . 0.0 109.813 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -130.76 160.04 35.51 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 119.445 -0.902 . . . . 0.0 112.388 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 27.7 t-105 -151.86 143.93 23.87 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.428 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 p 54.74 31.93 16.43 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.686 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.503 ' HG ' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -172.89 113.32 0.25 Allowed 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.219 -0.901 . . . . 0.0 109.744 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 m -80.12 77.16 6.85 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.211 -0.995 . . . . 0.0 110.361 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 3.5 m -71.73 156.03 7.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.401 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 64.1 p -155.65 118.18 4.19 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.232 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -81.02 108.24 14.53 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.464 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.5 p -97.89 94.28 6.81 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.381 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.626 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 47.88 72.58 0.42 Allowed Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.043 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.408 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 68.26 -24.12 0.13 Allowed 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.964 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.626 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -84.93 -172.38 4.15 Favored 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 118.746 -1.182 . . . . 0.0 110.424 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.533 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 75.7 t -142.38 158.68 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.865 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.493 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 20.3 m -160.0 124.37 3.8 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.384 -1.28 . . . . 0.0 108.649 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.503 ' CG1' ' HG ' ' A' ' 56' ' ' SER . 1.9 t -121.66 148.21 25.23 Favored 'Isoleucine or valine' 0 C--O 1.194 -1.859 0 C-N-CA 119.569 -0.852 . . . . 0.0 111.885 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -130.13 92.91 3.37 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.769 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 13.1 p-10 -71.13 121.02 17.55 Favored 'General case' 0 C--N 1.299 -1.619 0 C-N-CA 119.354 -0.938 . . . . 0.0 111.669 -179.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.698 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -47.71 170.7 0.09 OUTLIER Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.611 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.416 ' HD2' ' CB ' ' A' ' 70' ' ' ALA . 3.7 Cg_endo -68.41 -38.98 10.46 Favored 'Trans proline' 0 C--N 1.322 -0.816 0 C-N-CA 122.163 1.908 . . . . 0.0 112.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.529 ' CE2' ' HB2' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -54.03 15.73 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.063 -1.055 . . . . 0.0 111.335 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.698 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.9 OUTLIER -75.7 14.73 0.59 Allowed 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.222 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -145.54 34.11 1.51 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 119.284 -1.436 . . . . 0.0 111.319 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.0 m -102.85 58.63 0.78 Allowed 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.584 -0.846 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -111.98 132.49 21.98 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 119.896 -0.721 . . . . 0.0 111.661 -179.915 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.584 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.9 Cg_endo -69.53 156.26 64.46 Favored 'Trans proline' 0 C--O 1.208 -0.978 0 C-N-CA 121.211 1.274 . . . . 0.0 110.14 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.576 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -41.52 -14.41 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.83 66.85 0.26 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -173.61 -161.51 23.92 Favored Glycine 0 N--CA 1.494 2.534 0 C-N-CA 118.361 -1.876 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.478 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.0 p -139.37 158.17 44.61 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 119.342 -0.943 . . . . 0.0 112.701 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -124.19 173.94 8.0 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.468 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 9.6 tt0 -169.08 145.79 3.52 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 116.881 -1.928 . . . . 0.0 113.207 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.494 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 11.2 p90 -154.98 175.83 13.3 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 114.671 -1.149 . . . . 0.0 109.469 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.18 164.65 37.69 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 116.935 -2.555 . . . . 0.0 112.593 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.571 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 3.4 p90 -157.03 -170.23 3.22 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.399 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.433 ' N ' HD21 ' A' ' 87' ' ' ASN . 1.7 m-80 -135.58 114.84 12.42 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.005 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -125.35 150.16 17.25 Favored Glycine 0 N--CA 1.508 3.475 0 C-N-CA 119.408 -1.377 . . . . 0.0 112.342 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 84.9 p . . . . . 0 N--CA 1.476 0.858 0 C-N-CA 120.072 -0.651 . . . . 0.0 109.902 179.788 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.52 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.509 2.485 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.496 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.0 OUTLIER -65.2 -101.4 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 121.14 1.226 . . . . 0.0 112.468 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.479 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 81.4 p -150.1 -66.07 0.21 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 118.897 -1.121 . . . . 0.0 112.265 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.479 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -109.93 103.57 12.36 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.594 -0.843 . . . . 0.0 110.662 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 14.4 m-85 -74.57 -169.67 0.89 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.253 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.4 m -136.57 93.61 2.9 Favored 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 118.667 -1.213 . . . . 0.0 112.726 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.574 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.4 mt -52.53 173.54 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.545 -0.862 . . . . 0.0 108.956 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.532 ' H ' HD21 ' A' ' 102' ' ' LEU . 1.4 p30 -45.14 90.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.014 -1.074 . . . . 0.0 110.608 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.06 58.22 12.67 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.443 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.562 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.8 OUTLIER 175.48 139.58 0.2 Allowed Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.869 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.9 167.13 4.52 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 121.551 1.501 . . . . 0.0 112.65 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -164.36 82.33 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 50.1 p -46.61 167.95 0.02 OUTLIER 'General case' 0 N--CA 1.517 2.88 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.448 ' C ' ' O ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -66.7 -160.08 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.113 -1.035 . . . . 0.0 109.69 179.562 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.099 0 CA-C-O 116.333 -2.37 . . . . 0.0 110.386 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.5 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 121.365 0.602 . . . . 0.0 111.911 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.79 49.35 0.05 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.5 p -53.23 -179.31 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.618 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.536 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 26.6 mt-30 -137.03 113.09 9.73 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.547 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.46 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.0 m -108.77 130.82 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.976 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.464 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -103.88 167.38 9.81 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.104 179.94 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.407 ' NE1' ' HB2' ' A' ' 23' ' ' ALA . 1.6 t-105 -130.59 145.45 51.89 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.031 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.18 73.14 0.47 Allowed Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -72.43 153.04 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.437 ' CB ' HG21 ' A' ' 22' ' ' THR . 1.2 t30 . . . . . 0 N--CA 1.485 1.281 0 CA-C-N 114.323 -1.308 . . . . 0.0 108.742 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.592 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 3.1 p90 . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 121.463 0.649 . . . . 0.0 111.629 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.437 HG21 ' CB ' ' A' ' 15' ' ' ASN . 7.0 t -75.33 173.84 10.35 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.407 ' HB2' ' NE1' ' A' ' 12' ' ' TRP . . . -158.1 117.01 3.14 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 117.22 -1.792 . . . . 0.0 113.358 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -99.89 101.54 12.69 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.503 ' C ' ' HG1' ' A' ' 26' ' ' THR . 17.8 t -99.63 147.05 7.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.58 -0.848 . . . . 0.0 112.802 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.503 ' HG1' ' C ' ' A' ' 25' ' ' VAL . 1.5 m -138.9 110.35 7.0 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.345 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.8 t -83.23 149.81 4.43 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 C-N-CA 119.724 -0.79 . . . . 0.0 112.201 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.536 ' NZ ' ' NE2' ' A' ' 9' ' ' GLN . 2.2 tttm -142.19 106.97 4.87 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.802 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.529 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 3.3 t30 -93.22 120.17 33.21 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 118.971 -1.092 . . . . 0.0 108.594 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -123.15 -2.77 8.58 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 124.219 0.95 . . . . 0.0 109.818 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.529 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -53.35 -81.4 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.801 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 160.52 73.53 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.383 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.567 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.26 143.32 1.93 Allowed Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.089 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -68.32 101.88 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.42 109.28 18.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 118.281 -1.367 . . . . 0.0 111.643 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -117.38 73.63 0.89 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.06 143.75 11.75 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.846 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.4 p-90 -162.48 177.31 9.6 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 117.761 -1.576 . . . . 0.0 112.098 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -138.45 112.97 8.86 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.379 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.61 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.72 173.29 6.37 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 119.285 -0.966 . . . . 0.0 109.326 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.528 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -167.18 159.2 12.68 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.762 -1.575 . . . . 0.0 112.638 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.528 ' N ' ' CG2' ' A' ' 41' ' ' THR . 23.5 p90 -176.71 -134.49 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.63 -1.623 . . . . 0.0 107.954 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.483 ' OG ' ' C ' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -163.0 139.12 7.11 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.685 -1.606 . . . . 0.0 112.237 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.748 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.7 m-85 -69.28 122.28 84.9 Favored Pre-proline 0 N--CA 1.486 1.344 0 C-N-CA 118.838 -1.145 . . . . 0.0 108.465 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -52.68 -68.76 0.07 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.343 1.362 . . . . 0.0 112.729 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 p -69.42 -68.58 0.4 Allowed 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 119.173 -1.011 . . . . 0.0 111.105 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.13 26.71 0.02 OUTLIER Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.222 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.508 ' OE1' ' N ' ' A' ' 48' ' ' GLN . 1.1 mp0 -43.73 144.6 0.8 Allowed 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.614 -0.834 . . . . 0.0 110.847 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.592 HE21 ' CA ' ' A' ' 49' ' ' GLN . 0.1 OUTLIER -110.54 82.95 1.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.508 -179.944 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.68 147.75 10.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.398 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.498 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 68.5 p -136.77 -71.91 0.44 Allowed 'General case' 0 N--CA 1.497 1.879 0 C-N-CA 119.181 -1.007 . . . . 0.0 112.157 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.498 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -76.6 145.72 38.74 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.935 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -156.19 153.86 29.9 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.733 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.443 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.2 t-105 -152.55 147.98 26.83 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.182 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 71.27 14.3 6.56 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.686 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.587 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 31.3 t -174.1 151.2 1.66 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.396 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.507 ' N ' ' HG ' ' A' ' 56' ' ' SER . 0.6 OUTLIER -102.66 84.58 2.43 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.699 -179.961 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -85.43 163.13 2.76 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.963 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.8 t -164.21 132.26 3.47 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.613 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.87 113.27 24.81 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.698 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.447 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 p -84.28 68.33 10.14 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.722 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.31 -63.74 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.5 m -142.19 -16.7 0.75 Allowed 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 120.062 -0.655 . . . . 0.0 109.269 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.447 ' CB ' ' OG ' ' A' ' 61' ' ' SER . . . -88.47 -172.89 3.95 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.252 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.748 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 94.6 t -146.15 153.1 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 118.79 -1.164 . . . . 0.0 112.587 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.453 ' OG1' ' OG1' ' A' ' 41' ' ' THR . 3.6 m -159.89 135.87 8.64 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 114.909 -1.042 . . . . 0.0 108.976 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.587 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 3.0 t -129.46 153.36 38.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.943 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.49 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -135.91 89.29 2.47 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.846 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.86 118.53 13.75 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.162 -1.015 . . . . 0.0 112.08 -179.582 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.613 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -38.07 154.83 0.12 Allowed Pre-proline 0 N--CA 1.484 1.237 0 CA-C-N 113.731 -1.577 . . . . 0.0 112.012 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -64.69 -35.14 48.14 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 121.942 1.762 . . . . 0.0 112.626 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.613 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.59 -57.36 5.28 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.775 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.601 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -69.83 -13.18 62.14 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.106 -1.038 . . . . 0.0 109.911 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.08 22.12 42.46 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.621 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 m -87.53 58.65 5.05 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.002 . . . . 0.0 111.271 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -108.96 115.39 57.18 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.171 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' GLY . 2.0 Cg_endo -67.96 159.45 52.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 121.317 1.345 . . . . 0.0 113.745 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.567 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -24.08 -38.55 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 114.332 -1.304 . . . . 0.0 114.058 179.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.07 68.56 0.33 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.35 -168.22 18.14 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 118.857 -1.639 . . . . 0.0 110.284 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.478 ' N ' HG13 ' A' ' 76' ' ' ILE . 22.0 p -141.96 164.37 30.36 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.085 -1.046 . . . . 0.0 112.819 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -130.68 -179.95 5.6 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.476 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.511 ' C ' ' CD ' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -170.24 151.53 3.89 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 116.883 -1.927 . . . . 0.0 113.101 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.465 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 5.6 p90 -167.64 171.49 10.16 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.32 160.89 30.5 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.729 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.604 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.4 p90 -150.1 160.42 43.67 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.308 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.4 m-20 -115.62 110.93 19.89 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.428 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -105.6 176.5 22.33 Favored Glycine 0 N--CA 1.501 3.012 0 C-N-CA 119.491 -1.338 . . . . 0.0 111.972 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.482 1.158 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.393 179.968 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -68.16 -145.02 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 121.244 1.296 . . . . 0.0 111.287 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.4 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 1.2 p -116.74 -87.91 0.6 Allowed 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 119.667 -0.813 . . . . 0.0 112.259 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.63 107.11 18.67 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.237 -0.985 . . . . 0.0 112.018 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.1 m-30 -78.6 -155.98 0.09 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.63 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.9 m -159.53 122.73 3.63 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 117.043 -1.863 . . . . 0.0 113.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.522 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.3 mt -60.65 -178.61 0.1 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.564 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.663 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.09 -41.24 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -155.69 27.7 0.59 Allowed Glycine 0 N--CA 1.495 2.604 0 C-N-CA 118.593 -1.765 . . . . 0.0 111.352 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 102' ' ' LEU . 21.3 p -145.07 151.6 49.02 Favored Pre-proline 0 N--CA 1.494 1.752 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.229 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -62.26 174.49 2.59 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 121.628 1.552 . . . . 0.0 112.451 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.44 ' SG ' HG12 ' A' ' 10' ' ' VAL . 3.0 t -168.19 106.38 0.49 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.471 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 41.4 p -72.63 146.08 46.86 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.971 -0.692 . . . . 0.0 112.403 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -59.32 -167.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.257 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 CA-C-O 116.339 -2.367 . . . . 0.0 110.296 179.986 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.604 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-O 121.454 0.645 . . . . 0.0 111.445 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.69 40.04 0.19 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.6 p -50.88 177.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 114.33 -0.935 . . . . 0.0 112.319 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -131.78 121.64 24.51 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.11 -1.404 . . . . 0.0 109.614 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 1.5 m -112.46 127.01 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.603 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.424 ' CG ' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.56 171.38 7.6 Favored 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.055 179.881 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.535 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 3.2 t-105 -132.25 149.28 52.41 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.706 -0.798 . . . . 0.0 112.042 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.29 83.55 0.32 Allowed Glycine 0 N--CA 1.497 2.726 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.78 144.75 12.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 54.0 t30 . . . . . 0 N--CA 1.488 1.468 0 CA-C-N 114.165 -1.38 . . . . 0.0 107.619 179.843 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.609 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 24.2 p90 . . . . . 0 CA--C 1.505 -0.78 0 CA-C-O 121.308 0.575 . . . . 0.0 111.324 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.46 HG22 ' N ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -83.87 165.37 18.8 Favored 'General case' 0 C--N 1.284 -2.256 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.623 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.46 ' N ' HG22 ' A' ' 22' ' ' THR . . . -145.56 106.34 4.12 Favored 'General case' 0 C--N 1.29 -2.014 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.899 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -93.35 96.84 10.2 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.464 HG11 ' N ' ' A' ' 26' ' ' THR . 17.9 t -93.46 147.39 5.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 115.383 -0.826 . . . . 0.0 113.007 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.464 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.3 m -133.36 127.12 32.8 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.5 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -97.73 145.95 8.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.989 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.429 ' HD3' ' CG2' ' A' ' 81' ' ' THR . 12.2 tptt -126.97 100.56 6.19 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.835 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.667 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.2 OUTLIER -93.7 119.72 33.06 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.561 179.852 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 t -130.53 -0.92 4.4 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.8 p -50.52 -83.01 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.29 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.38 67.78 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.64 -179.943 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.559 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -169.09 157.94 7.37 Favored Pre-proline 0 N--CA 1.482 1.127 0 C-N-CA 118.372 -1.331 . . . . 0.0 111.625 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.65 95.79 0.96 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.588 1.525 . . . . 0.0 109.052 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -74.47 87.54 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 118.47 -1.292 . . . . 0.0 111.744 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -100.06 56.52 0.95 Allowed 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 115.374 -0.83 . . . . 0.0 108.868 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.03 150.28 19.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.865 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 42.0 p-90 -164.14 176.68 9.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 117.652 -1.619 . . . . 0.0 112.059 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.577 ' HG1' ' C ' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -141.28 110.11 6.11 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.545 179.907 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.605 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -99.34 177.0 5.33 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.264 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.486 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.9 150.77 13.69 Favored 'General case' 0 C--N 1.289 -2.024 0 C-N-CA 117.867 -1.533 . . . . 0.0 112.361 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' ' N ' ' A' ' 43' ' ' SER . 14.4 p90 -174.55 -145.99 0.03 OUTLIER 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.753 -1.567 . . . . 0.0 107.952 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.556 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 41.7 m -161.12 154.12 21.15 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 117.804 -1.558 . . . . 0.0 111.758 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.504 ' CE2' HG23 ' A' ' 65' ' ' VAL . 8.4 m-85 -84.61 116.86 67.1 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.15 -53.89 4.3 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.16 1.24 . . . . 0.0 112.407 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.0 t -74.36 -82.77 0.06 Allowed 'General case' 0 C--N 1.294 -1.842 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.087 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 175.45 25.13 0.03 OUTLIER Glycine 0 N--CA 1.486 2.025 0 C-N-CA 119.289 -1.434 . . . . 0.0 110.193 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.419 ' HG3' ' CE1' ' A' ' 21' ' ' PHE . 0.8 OUTLIER -43.04 121.86 2.26 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.524 179.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.594 HE21 ' CA ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -93.81 84.78 4.64 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.959 -179.83 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.446 ' CG1' HE21 ' A' ' 60' ' ' GLN . 0.5 OUTLIER -64.63 148.57 11.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.554 179.786 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.493 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 76.0 p -137.78 -69.23 0.45 Allowed 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.37 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.493 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.5 mt-30 -73.36 161.51 30.38 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 118.842 -1.143 . . . . 0.0 110.024 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.62 142.16 3.05 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.323 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.432 ' CG ' ' N ' ' A' ' 55' ' ' SER . 38.8 t-105 -146.9 149.09 32.54 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.592 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.432 ' N ' ' CG ' ' A' ' 54' ' ' TRP . 6.3 t 57.11 27.82 14.01 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 119.326 -0.95 . . . . 0.0 109.07 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.588 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -174.66 125.42 0.29 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.135 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -87.57 72.34 9.62 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.596 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.585 ' CG1' ' HG ' ' A' ' 56' ' ' SER . 2.6 m -71.92 153.18 7.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.33 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.404 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.0 t -153.95 134.94 13.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.944 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.498 HE22 ' NE2' ' A' ' 49' ' ' GLN . 6.9 tt0 -100.51 120.2 39.65 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.285 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.0 p -100.58 80.48 2.21 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.706 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.56 2.53 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.468 -1.349 . . . . 0.0 109.956 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 41.8 t -146.77 -18.23 0.42 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.967 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.556 ' CB ' ' HG ' ' A' ' 43' ' ' SER . . . -87.8 -170.66 3.09 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.155 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.546 ' CG1' ' N ' ' A' ' 66' ' ' THR . 79.1 t -148.02 160.64 7.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.917 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.546 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 2.8 m -158.65 125.95 4.94 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 114.392 -1.276 . . . . 0.0 108.642 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.588 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.6 t -116.98 146.68 21.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.08 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.674 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -130.18 92.44 3.29 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.865 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.41 118.2 17.1 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.284 -0.966 . . . . 0.0 112.433 -179.709 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.55 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -42.73 165.65 0.1 OUTLIER Pre-proline 0 N--CA 1.487 1.406 0 CA-C-N 113.578 -1.646 . . . . 0.0 112.483 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -68.71 -33.03 22.34 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.058 1.839 . . . . 0.0 112.583 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.564 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.66 -57.7 4.84 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.477 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.43 HD22 ' N ' ' A' ' 70' ' ' ALA . 2.4 p30 -73.26 -4.43 33.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 119.12 -1.032 . . . . 0.0 109.652 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -119.77 50.25 0.83 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.5 t -120.54 57.07 0.97 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 120.029 -0.669 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.02 134.61 22.13 Favored Pre-proline 0 N--CA 1.486 1.356 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.551 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -71.52 158.71 53.22 Favored 'Trans proline' 0 C--O 1.214 -0.713 0 C-N-CA 121.464 1.443 . . . . 0.0 112.814 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.559 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -31.44 -29.51 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -115.5 72.9 0.25 Allowed Glycine 0 N--CA 1.497 2.706 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.899 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.33 -167.47 27.03 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.793 -1.67 . . . . 0.0 110.809 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.518 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.5 p -138.35 160.01 40.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.088 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -122.56 -176.45 3.38 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.468 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -169.37 142.07 2.6 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 117.068 -1.853 . . . . 0.0 113.361 -179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.468 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 7.5 p90 -159.12 174.14 15.34 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.054 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.0 168.33 39.7 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 117.638 -2.22 . . . . 0.0 112.521 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.591 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.9 p90 -152.94 -176.36 5.73 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.944 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.501 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 1.2 m120 -138.09 111.66 8.16 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.774 -0.771 . . . . 0.0 110.783 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -123.42 163.62 16.85 Favored Glycine 0 N--CA 1.507 3.379 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.892 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.502 ' H ' ' HG ' ' A' ' 89' ' ' SER . 1.6 p . . . . . 0 N--CA 1.481 1.105 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.796 179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.535 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.446 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -65.29 -142.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 121.21 1.274 . . . . 0.0 110.772 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.621 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.0 p -116.25 -64.63 1.28 Allowed 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 119.45 -0.9 . . . . 0.0 112.593 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.621 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.03 112.15 23.97 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.288 -0.965 . . . . 0.0 111.333 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 8.9 m-85 -84.32 -164.17 0.91 Allowed 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.035 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.2 m -144.52 117.6 8.89 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 118.421 -1.312 . . . . 0.0 112.009 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.548 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.3 mt -68.38 -178.67 1.14 Allowed 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.581 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.575 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -27.69 -37.46 0.01 OUTLIER 'General case' 0 N--CA 1.512 2.631 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.82 55.6 0.21 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.199 -1.477 . . . . 0.0 110.274 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.604 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 2.4 t -174.38 145.81 1.04 Allowed Pre-proline 0 C--O 1.196 -1.726 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.774 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -56.3 168.59 1.96 Allowed 'Trans proline' 0 C--N 1.324 -0.758 0 C-N-CA 121.511 1.474 . . . . 0.0 112.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.429 ' SG ' HG12 ' A' ' 10' ' ' VAL . 10.8 t -164.84 95.12 0.7 Allowed 'General case' 0 N--CA 1.494 1.74 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.118 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.463 ' OG1' ' N ' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -51.99 168.45 0.09 Allowed 'General case' 0 N--CA 1.501 2.075 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.203 -179.688 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.777 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 9.4 p -67.77 -151.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.442 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.777 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.871 0 CA-C-O 116.281 -2.4 . . . . 0.0 110.125 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.509 ' H ' HG23 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 122.205 1.002 . . . . 0.0 112.396 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.635 ' O ' ' SG ' ' A' ' 8' ' ' CYS . . . -176.55 -79.79 0.05 OUTLIER Glycine 0 C--O 1.189 -2.714 0 N-CA-C 107.023 -2.431 . . . . 0.0 107.023 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.722 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 6.6 p 63.62 176.97 0.16 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.541 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 55.3 mt-30 -151.27 158.98 44.56 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.482 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.46 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.7 m -141.19 126.54 18.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.954 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.478 HD22 ' N ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -98.44 170.65 8.69 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.023 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.495 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 4.0 t-105 -126.73 144.11 51.04 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 123.895 0.747 . . . . 0.0 112.471 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.31 74.7 0.43 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.538 -2.225 . . . . 0.0 107.538 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.42 ' CG2' ' N ' ' A' ' 15' ' ' ASN . 7.2 p -69.77 152.52 9.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.42 ' N ' ' CG2' ' A' ' 14' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.499 0 CA-C-N 113.81 -1.541 . . . . 0.0 107.857 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.563 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 32.5 p90 . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.124 0.488 . . . . 0.0 112.047 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.04 106.75 18.97 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.495 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -90.03 120.62 31.39 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -101.78 96.41 7.05 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 179.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 26' ' ' THR . 33.6 t -90.14 154.46 3.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.483 ' N ' ' CG1' ' A' ' 25' ' ' VAL . 1.9 m -142.05 101.19 3.88 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.57 -1.195 . . . . 0.0 109.698 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.4 t -75.06 147.81 8.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.184 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 5.8 tttp -136.95 105.43 5.78 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.558 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.81 118.72 29.62 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 118.736 -1.186 . . . . 0.0 108.349 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.0 t -118.21 2.15 11.95 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.185 0.928 . . . . 0.0 110.013 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.671 ' HG ' ' H ' ' A' ' 32' ' ' SER . 14.9 p -54.09 -84.01 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.671 ' H ' ' HG ' ' A' ' 31' ' ' SER . 0.6 OUTLIER 158.77 68.45 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.934 0 O-C-N 123.873 0.733 . . . . 0.0 111.29 -179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.572 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -168.16 154.04 6.92 Favored Pre-proline 0 N--CA 1.483 1.192 0 C-N-CA 118.629 -1.228 . . . . 0.0 111.428 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -70.95 93.18 0.63 Allowed 'Trans proline' 0 C--N 1.326 -0.639 0 C-N-CA 121.144 1.23 . . . . 0.0 109.051 179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -78.33 107.27 10.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.598 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -114.41 62.72 0.67 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.22 147.9 20.15 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.846 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 39.6 p-90 -164.45 -179.11 5.8 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.427 -1.309 . . . . 0.0 111.805 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.29 118.29 12.54 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.257 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.624 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -112.05 174.81 5.7 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 119.474 -0.891 . . . . 0.0 109.412 179.831 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.486 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -166.05 153.68 10.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.736 -1.586 . . . . 0.0 112.858 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.509 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.9 p90 -176.3 -139.67 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 113.809 -1.541 . . . . 0.0 108.22 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.509 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.6 m -160.15 172.0 18.23 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.798 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.503 ' CD2' HG23 ' A' ' 65' ' ' VAL . 3.0 m-85 -114.14 96.5 42.41 Favored Pre-proline 0 N--CA 1.497 1.881 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.57 -42.95 42.87 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 121.469 1.446 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.571 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.4 t -69.71 -115.7 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.91 -1.116 . . . . 0.0 110.632 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.571 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -145.85 21.22 1.8 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.476 ' HB2' ' CD1' ' A' ' 44' ' ' PHE . 16.4 mt-30 -61.85 89.96 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.689 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.415 ' NE2' ' HA ' ' A' ' 49' ' ' GLN . 2.9 mm100 -88.86 97.18 11.02 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.3 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 1.5 p -68.06 138.25 22.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.651 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 44.0 p -127.19 -65.77 0.93 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.814 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.531 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -81.4 153.34 27.0 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.453 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -162.1 155.05 20.21 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.277 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.4 t-105 -157.71 142.41 16.49 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.796 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.482 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.2 OUTLIER 75.27 14.31 3.02 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.515 179.931 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.478 ' HB2' ' CB ' ' A' ' 84' ' ' PHE . 1.4 t -174.32 115.43 0.2 Allowed 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.5 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -71.2 85.52 0.76 Allowed 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.898 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.4 m -86.2 167.36 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.821 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.434 ' O ' ' CG2' ' A' ' 59' ' ' THR . 4.0 t -163.55 133.9 4.4 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.21 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.515 ' NE2' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER -94.42 123.99 38.17 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.733 -179.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.618 ' O ' ' N ' ' A' ' 63' ' ' SER . 34.0 p -110.01 -151.34 0.47 Allowed 'General case' 0 C--O 1.2 -1.519 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.394 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.551 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -53.33 84.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.657 0 C-N-CA 118.645 -1.74 . . . . 0.0 109.178 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.618 ' N ' ' O ' ' A' ' 61' ' ' SER . 28.4 m 47.68 13.66 0.04 OUTLIER 'General case' 0 C--N 1.31 -1.118 0 C-N-CA 119.606 -0.837 . . . . 0.0 109.686 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.551 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -109.59 -167.55 1.22 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.427 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.503 HG23 ' CD2' ' A' ' 44' ' ' PHE . 99.3 t -148.71 154.55 9.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 118.664 -1.215 . . . . 0.0 112.586 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.466 ' OG1' ' OG1' ' A' ' 41' ' ' THR . 1.5 m -156.08 139.14 15.46 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.621 179.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.43 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.7 t -132.83 156.4 42.25 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.748 0 C-N-CA 119.05 -1.06 . . . . 0.0 112.442 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 6.2 mtm180 -139.85 90.21 2.37 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 113.888 -1.505 . . . . 0.0 106.993 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.846 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.21 121.87 21.92 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.854 -179.554 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.725 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -40.93 158.66 0.17 Allowed Pre-proline 0 N--CA 1.482 1.136 0 CA-C-N 113.618 -1.628 . . . . 0.0 112.049 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.62 -39.14 22.09 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.921 1.747 . . . . 0.0 111.865 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.57 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.54 -55.88 8.91 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.43 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.725 HD22 ' N ' ' A' ' 70' ' ' ALA . 1.8 p30 -66.41 -20.8 66.16 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 118.755 -1.178 . . . . 0.0 109.221 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.77 31.77 8.01 Favored Glycine 0 N--CA 1.483 1.802 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 t -92.12 55.77 2.68 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.515 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -104.76 133.9 19.93 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.646 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.46 ' O ' ' N ' ' A' ' 79' ' ' GLY . 11.9 Cg_endo -77.32 163.08 30.49 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 121.628 1.552 . . . . 0.0 114.07 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.572 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -27.29 -39.35 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 114.031 -1.441 . . . . 0.0 113.658 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -123.98 73.37 0.41 Allowed Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.426 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -152.59 -163.18 11.43 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.041 -1.552 . . . . 0.0 110.39 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.515 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.0 OUTLIER -141.8 163.23 33.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.626 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -146.91 99.32 3.17 Favored 'General case' 0 N--CA 1.485 1.278 0 CA-C-N 114.484 -1.235 . . . . 0.0 107.936 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.409 ' HB3' ' CG2' ' A' ' 26' ' ' THR . 0.0 OUTLIER -94.14 172.7 8.05 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -179.661 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.478 ' CB ' ' HB2' ' A' ' 56' ' ' SER . 34.9 p90 -168.62 -167.93 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 112.633 -2.076 . . . . 0.0 109.482 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 84' ' ' PHE . . . -172.98 158.93 29.14 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 117.483 -2.294 . . . . 0.0 112.555 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.601 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.5 p90 -149.69 166.62 28.81 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 114.962 -0.619 . . . . 0.0 110.369 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.0 OUTLIER -123.41 110.26 14.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.89 -0.724 . . . . 0.0 110.724 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.553 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -129.62 167.19 21.57 Favored Glycine 0 N--CA 1.505 3.251 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.711 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p . . . . . 0 N--CA 1.483 1.184 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.133 179.84 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.496 -0.187 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -59.79 -100.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 120.754 0.969 . . . . 0.0 112.445 -179.898 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.409 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 1.3 p -150.89 -98.86 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.454 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.71 95.75 9.75 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 118.492 -1.283 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -65.49 -157.33 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.339 -0.945 . . . . 0.0 108.995 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.473 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.58 128.5 5.86 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 116.679 -2.008 . . . . 0.0 113.982 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.8 mt -62.86 -173.27 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.398 179.668 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.582 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -32.15 -49.17 0.19 Allowed 'General case' 0 N--CA 1.505 2.3 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -147.95 28.46 1.42 Allowed Glycine 0 N--CA 1.494 2.511 0 C-N-CA 118.847 -1.644 . . . . 0.0 111.411 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.579 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -146.15 155.24 50.82 Favored Pre-proline 0 C--O 1.191 -2.026 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.239 -179.993 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -65.97 -178.14 0.97 Allowed 'Trans proline' 0 C--N 1.321 -0.87 0 C-N-CA 121.781 1.654 . . . . 0.0 112.571 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.722 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 9.7 t -174.45 111.76 0.15 Allowed 'General case' 0 N--CA 1.501 2.097 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.907 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.534 ' H ' ' HG1' ' A' ' 108' ' ' THR . 0.0 OUTLIER -71.12 132.36 44.94 Favored 'General case' 0 N--CA 1.515 2.814 0 N-CA-C 114.202 1.186 . . . . 0.0 114.202 -179.592 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -52.33 174.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 C-N-CA 118.824 -1.15 . . . . 0.0 110.54 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.161 0 CA-C-O 116.371 -2.35 . . . . 0.0 110.479 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.439 ' HB3' ' CB ' ' A' ' 31' ' ' SER . . . . . . . . 0 N--CA 1.485 1.289 0 CA-C-O 120.907 0.385 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.411 ' H ' ' HB2' ' A' ' 6' ' ' ALA . . . -168.73 55.23 0.21 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.445 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 2.9 p -51.44 177.39 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.187 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.42 116.36 15.94 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.592 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' A' ' 109' ' ' VAL . 3.5 m -110.51 124.16 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.256 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.465 HD22 ' N ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -95.11 166.86 11.72 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.582 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.533 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.5 t-105 -134.75 140.05 45.63 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.613 -0.835 . . . . 0.0 111.463 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -122.98 71.22 0.42 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -72.17 147.67 10.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 29.7 t30 . . . . . 0 C--N 1.3 -1.562 0 CA-C-N 113.989 -1.459 . . . . 0.0 107.513 179.807 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.598 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 20.2 p90 . . . . . 0 N--CA 1.478 0.928 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.46 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 2.4 t -72.61 171.87 11.67 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.533 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -156.81 113.54 3.06 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 117.385 -1.726 . . . . 0.0 113.19 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -98.82 101.17 12.48 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.477 HG11 ' N ' ' A' ' 26' ' ' THR . 27.2 t -99.43 143.24 13.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.918 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.477 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.8 m -132.54 110.77 10.71 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.93 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.1 t -82.0 150.42 4.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 C-N-CA 119.486 -0.885 . . . . 0.0 112.213 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.3 tttp -138.91 115.77 10.81 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.067 179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.404 ' HB2' ' CD1' ' A' ' 76' ' ' ILE . 1.4 t-20 -98.24 109.71 22.42 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.5 t -121.77 -2.08 9.37 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.147 0.905 . . . . 0.0 109.78 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.8 p -58.68 -79.46 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.261 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.34 43.21 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.522 -179.857 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.63 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -140.15 145.91 43.87 Favored Pre-proline 0 N--CA 1.487 1.388 0 C-N-CA 118.91 -1.116 . . . . 0.0 111.494 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -72.4 109.26 2.7 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 121.3 1.334 . . . . 0.0 109.596 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -97.5 112.97 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.001 -1.079 . . . . 0.0 112.211 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -122.35 70.01 0.97 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 141.77 12.1 Favored Glycine 0 C--N 1.294 -1.782 0 N-CA-C 106.657 -2.577 . . . . 0.0 106.657 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 31.0 p-90 -158.88 178.86 9.63 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 117.136 -1.825 . . . . 0.0 112.456 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.55 95.76 3.04 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.057 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.591 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -82.22 168.84 17.23 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.223 -1.391 . . . . 0.0 109.469 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.449 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.5 m -156.95 149.59 23.45 Favored 'General case' 0 C--N 1.287 -2.152 0 C-N-CA 118.122 -1.431 . . . . 0.0 112.012 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 25.5 p90 -174.03 -149.73 0.04 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.996 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.1 m -158.96 149.62 19.84 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 117.623 -1.631 . . . . 0.0 112.001 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.486 ' CE2' HG23 ' A' ' 65' ' ' VAL . 7.4 m-85 -78.79 123.55 85.26 Favored Pre-proline 0 C--N 1.307 -1.261 0 C-N-CA 118.326 -1.35 . . . . 0.0 107.712 179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -65.72 -63.26 0.07 OUTLIER 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 121.358 1.372 . . . . 0.0 112.226 -179.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.52 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 62.0 p -69.05 -120.68 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 118.613 -1.235 . . . . 0.0 110.464 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.52 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -132.91 42.68 1.35 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -84.92 133.07 34.3 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.762 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -131.56 117.07 18.24 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.801 179.976 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.422 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -69.38 155.06 7.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.974 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.554 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.7 p -128.6 -64.85 0.91 Allowed 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.894 -0.723 . . . . 0.0 110.92 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.554 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -95.28 140.46 30.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.601 -0.839 . . . . 0.0 109.446 179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.73 160.72 40.22 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 118.917 -1.113 . . . . 0.0 112.354 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 35.3 t-105 -153.15 143.07 22.16 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.649 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.3 t 60.97 26.56 16.49 Favored 'General case' 0 C--N 1.313 -0.978 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.466 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -170.97 124.07 0.63 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.717 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 m -87.01 75.09 9.58 Favored 'General case' 0 C--N 1.281 -2.384 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.354 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 16.7 m -69.21 151.1 10.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.256 -0.884 . . . . 0.0 112.462 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.9 p -155.32 115.31 3.74 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.104 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -90.74 124.44 35.11 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 119.11 -1.036 . . . . 0.0 110.612 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.455 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 5.7 p -91.71 75.31 5.77 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.5 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.511 ' C ' ' HG ' ' A' ' 63' ' ' SER . . . 76.18 -42.9 1.69 Allowed Glycine 0 N--CA 1.496 2.661 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.222 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.511 ' HG ' ' C ' ' A' ' 62' ' ' GLY . 0.8 OUTLIER -163.76 -19.01 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.087 -0.645 . . . . 0.0 109.563 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.455 ' CB ' ' OG ' ' A' ' 61' ' ' SER . . . -85.33 -169.18 2.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.17 -1.012 . . . . 0.0 109.754 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.499 ' CG1' ' N ' ' A' ' 66' ' ' THR . 98.3 t -150.33 157.97 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 118.007 -1.477 . . . . 0.0 114.152 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.499 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 13.4 m -157.86 143.6 17.18 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.67 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.2 t -139.12 114.74 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 C-N-CA 118.834 -1.147 . . . . 0.0 112.144 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -94.14 89.41 5.98 Favored 'General case' 0 C--N 1.281 -2.374 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.095 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.694 HD22 ' CA ' ' A' ' 74' ' ' GLY . 0.9 OUTLIER -71.75 117.28 13.13 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.021 -1.072 . . . . 0.0 111.909 -179.694 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.595 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -37.6 155.75 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.454 0 CA-C-N 113.622 -1.626 . . . . 0.0 112.297 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -62.47 -36.79 63.78 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.998 1.799 . . . . 0.0 112.312 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.595 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.07 -52.45 28.32 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.304 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.691 ' ND2' HD21 ' A' ' 69' ' ' ASN . 0.2 OUTLIER -75.56 0.59 16.84 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.686 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.694 ' CA ' HD22 ' A' ' 69' ' ' ASN . . . -118.94 25.41 7.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.6 p -92.73 73.25 4.97 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.75 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.519 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -133.89 126.07 18.58 Favored Pre-proline 0 N--CA 1.483 1.206 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.23 179.928 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.65 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.5 Cg_endo -72.41 167.59 26.57 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 120.953 1.102 . . . . 0.0 110.233 179.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.63 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -52.55 1.71 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.655 0 C-N-CA 119.609 -0.836 . . . . 0.0 112.399 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.65 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -128.8 67.29 0.56 Allowed Glycine 0 N--CA 1.496 2.663 0 C-N-CA 119.597 -1.287 . . . . 0.0 109.945 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 178.73 -162.06 28.92 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 118.831 -1.652 . . . . 0.0 110.376 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.519 ' N ' HG13 ' A' ' 76' ' ' ILE . 15.8 p -142.09 166.32 25.04 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.093 -1.043 . . . . 0.0 113.179 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.56 -177.31 4.13 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 113.896 -1.502 . . . . 0.0 107.113 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.412 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 13.0 tt0 -168.21 148.29 4.78 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 116.85 -1.94 . . . . 0.0 113.494 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.44 ' CE2' ' CE1' ' A' ' 86' ' ' PHE . 4.0 p90 -161.86 169.83 20.57 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.312 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.62 161.12 32.47 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 117.981 -2.057 . . . . 0.0 112.174 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.571 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.5 p90 -155.37 175.08 14.33 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.46 ' ND2' ' OG1' ' A' ' 22' ' ' THR . 10.5 m120 -124.07 109.42 13.47 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.284 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.81 174.83 15.63 Favored Glycine 0 N--CA 1.497 2.737 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.678 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 N--CA 1.485 1.285 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.705 179.908 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.487 ' HB3' ' CZ3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.43 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 9.2 Cg_endo -68.86 -151.14 0.03 OUTLIER 'Trans proline' 0 C--O 1.216 -0.585 0 C-N-CA 121.408 1.405 . . . . 0.0 111.594 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.433 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 9.3 p -120.06 -47.82 2.37 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.914 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.433 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.5 91.61 3.72 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.939 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 33.7 m-85 -64.18 -164.03 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.066 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.1 m -146.66 98.9 3.13 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 117.761 -1.576 . . . . 0.0 113.336 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -51.53 165.85 0.15 Allowed 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 119.304 -0.958 . . . . 0.0 108.655 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.488 ' H ' HD21 ' A' ' 102' ' ' LEU . 2.0 p30 -43.03 91.15 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.058 -1.057 . . . . 0.0 110.669 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 68.91 55.88 10.18 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.59 -1.291 . . . . 0.0 110.51 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.594 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.9 OUTLIER 175.97 135.57 0.18 Allowed Pre-proline 0 C--O 1.195 -1.797 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.739 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -58.97 166.86 6.27 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 121.568 1.512 . . . . 0.0 112.818 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 9.0 t -165.53 102.36 0.71 Allowed 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.94 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 p -58.68 173.37 0.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.211 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 10' ' ' VAL . 16.3 m -64.26 -143.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.66 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.002 0 CA-C-O 116.32 -2.378 . . . . 0.0 110.227 179.941 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.442 ' H ' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 121.213 0.53 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.44 45.42 0.04 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.643 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 4.3 p -50.94 175.12 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 69.0 mt-30 -138.27 118.64 13.73 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.714 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.1 m -109.57 124.47 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.861 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.458 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.72 163.3 12.69 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.966 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.475 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 6.1 t-105 -115.82 143.19 45.75 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.857 -0.737 . . . . 0.0 111.871 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 74.03 0.39 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.437 HG21 ' N ' ' A' ' 15' ' ' ASN . 8.2 p -68.73 141.71 17.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.826 -0.749 . . . . 0.0 112.597 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.437 ' N ' HG21 ' A' ' 14' ' ' VAL . 23.6 t-20 . . . . . 0 C--N 1.307 -1.242 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.006 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.517 ' CZ ' ' OE1' ' A' ' 48' ' ' GLN . 2.8 p90 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.96 118.93 27.84 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.484 ' HB1' ' CZ ' ' A' ' 86' ' ' PHE . . . -96.96 110.58 23.08 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 119.239 -0.984 . . . . 0.0 113.517 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -92.77 100.42 12.91 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.458 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 23.4 t -93.51 145.43 7.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 119.236 -0.985 . . . . 0.0 113.583 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.458 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 1.7 m -135.52 109.94 8.47 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.239 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -81.02 151.4 4.43 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 C-N-CA 119.501 -0.88 . . . . 0.0 111.816 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.92 98.23 3.71 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.535 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.48 101.22 13.71 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.216 -0.994 . . . . 0.0 108.369 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -114.19 1.85 14.66 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.349 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.1 p -61.7 -79.64 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.61 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.491 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 160.91 75.24 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.535 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.591 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -167.32 152.44 6.98 Favored Pre-proline 0 C--N 1.31 -1.152 0 C-N-CA 118.665 -1.214 . . . . 0.0 111.587 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -72.72 94.64 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.71 0 N-CA-C 108.672 -1.318 . . . . 0.0 108.672 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.23 102.5 5.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 118.31 -1.356 . . . . 0.0 111.698 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -119.92 57.36 0.93 Allowed 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.97 148.76 18.34 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.787 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.7 p-90 -167.08 175.89 7.24 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.637 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -139.34 109.81 6.59 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.699 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.593 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.54 174.94 6.01 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.324 -0.95 . . . . 0.0 109.656 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.464 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -161.65 150.09 15.46 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 117.874 -1.53 . . . . 0.0 112.719 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 43' ' ' SER . 12.9 p90 -175.6 -130.43 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.039 -1.437 . . . . 0.0 108.596 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.539 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 m -167.13 176.9 6.52 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 117.819 -1.553 . . . . 0.0 112.495 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.475 ' CE2' HG23 ' A' ' 65' ' ' VAL . 2.2 m-85 -117.14 87.81 24.74 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.605 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -59.03 -27.45 85.06 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 121.786 1.657 . . . . 0.0 112.499 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.476 ' OG ' ' CG ' ' A' ' 48' ' ' GLN . 0.9 OUTLIER -69.59 -13.37 62.29 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.731 179.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 78.99 19.78 71.85 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.742 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.517 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 21.7 mt-30 -73.85 177.12 5.76 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.631 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.717 HE22 ' CG2' ' A' ' 51' ' ' THR . 0.0 OUTLIER -141.77 111.26 6.5 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.452 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.401 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.4 p -76.07 155.13 5.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.861 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.717 ' CG2' HE22 ' A' ' 49' ' ' GLN . 64.8 p -138.66 -68.1 0.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.314 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.433 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -82.88 131.01 35.21 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.056 -1.058 . . . . 0.0 110.423 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.44 152.81 41.98 Favored 'General case' 0 N--CA 1.49 1.575 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.65 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 39.5 t-105 -154.73 144.48 21.57 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.004 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 69.0 18.81 8.33 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.071 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.623 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 3.3 m -172.23 111.12 0.26 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.115 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -69.93 79.79 0.47 Allowed 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.484 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 9.5 m -81.05 155.95 4.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.067 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.6 t -155.43 129.88 9.03 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.21 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -95.68 114.21 25.93 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.518 -0.873 . . . . 0.0 111.043 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.8 p -91.1 78.23 5.92 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.683 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.89 -68.28 2.26 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.095 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -142.08 -15.77 0.78 Allowed 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.188 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.539 ' CB ' ' HG ' ' A' ' 43' ' ' SER . . . -92.63 -170.81 2.57 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.567 ' CG1' ' N ' ' A' ' 66' ' ' THR . 54.1 t -145.78 160.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 C-N-CA 118.838 -1.145 . . . . 0.0 113.029 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.567 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.4 m -161.07 127.36 3.92 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.121 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 39' ' ' THR . 2.0 t -122.54 147.53 26.65 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.845 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 mtm-85 -129.38 92.73 3.41 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.787 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 8.6 p-10 -72.81 122.05 20.93 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.272 -0.971 . . . . 0.0 112.445 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.58 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -48.25 156.69 0.75 Allowed Pre-proline 0 C--N 1.305 -1.343 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.316 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.98 -36.81 81.08 Favored 'Trans proline' 0 C--N 1.325 -0.706 0 C-N-CA 121.895 1.73 . . . . 0.0 112.628 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.58 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -56.27 7.68 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 118.733 -1.187 . . . . 0.0 110.61 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.657 ' C ' HD21 ' A' ' 73' ' ' ASN . 0.3 OUTLIER -72.33 7.7 1.66 Allowed 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 109.714 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.524 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -137.05 33.82 2.27 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 27.9 t -99.94 59.72 1.06 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.846 -0.742 . . . . 0.0 111.298 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.01 135.86 22.12 Favored Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.808 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.2 Cg_endo -73.44 158.91 47.45 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.631 1.554 . . . . 0.0 114.027 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.591 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -27.37 -32.73 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 CA-C-N 113.888 -1.505 . . . . 0.0 114.758 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.52 68.82 0.29 Allowed Glycine 0 N--CA 1.503 3.125 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.968 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.15 23.19 Favored Glycine 0 C--N 1.29 -1.992 0 C-N-CA 118.637 -1.744 . . . . 0.0 110.695 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.518 ' N ' HG13 ' A' ' 76' ' ' ILE . 6.3 p -138.08 162.9 32.97 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 119.691 -0.804 . . . . 0.0 112.008 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.36 169.54 14.13 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.472 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.7 OUTLIER -160.45 142.08 12.44 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 117.016 -1.874 . . . . 0.0 113.486 -179.842 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.623 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 13.5 p90 -154.7 177.36 11.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 114.33 -1.305 . . . . 0.0 109.296 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.72 159.69 33.05 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 117.604 -2.236 . . . . 0.0 112.135 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.654 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 0.9 OUTLIER -145.17 -178.36 6.02 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.798 179.923 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.65 HD21 ' C ' ' A' ' 86' ' ' PHE . 1.0 OUTLIER -133.62 110.53 9.95 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.089 179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -113.91 173.43 14.96 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.899 -1.143 . . . . 0.0 111.278 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.0 p . . . . . 0 N--CA 1.485 1.287 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.828 179.882 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.609 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.466 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.3 Cg_endo -66.3 -142.85 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 121.169 1.246 . . . . 0.0 110.999 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.644 ' HG1' ' H ' ' A' ' 99' ' ' ALA . 42.5 p -111.73 -88.12 0.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.642 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.644 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -97.56 105.54 17.71 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.008 -1.077 . . . . 0.0 112.146 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.564 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -74.9 -146.26 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.528 -0.869 . . . . 0.0 108.995 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.72 98.87 1.96 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 117.369 -1.733 . . . . 0.0 113.775 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.643 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -53.17 172.15 0.06 Allowed 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.788 HD21 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.22 86.83 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.944 -1.102 . . . . 0.0 110.488 179.891 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 76.07 42.86 23.31 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.62 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.612 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -169.92 138.65 1.51 Allowed Pre-proline 0 C--O 1.196 -1.733 0 C-N-CA 119.493 -0.883 . . . . 0.0 110.818 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -64.72 154.8 70.64 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.137 1.225 . . . . 0.0 111.677 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.453 ' SG ' HG12 ' A' ' 10' ' ' VAL . 2.7 t -151.11 104.43 3.13 Favored 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 119.424 -0.91 . . . . 0.0 110.908 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.51 157.37 11.54 Favored 'General case' 0 N--CA 1.5 2.05 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.019 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.681 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 6.1 p -70.44 -140.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.234 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.681 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.278 0 CA-C-O 116.342 -2.366 . . . . 0.0 110.446 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 121.435 0.636 . . . . 0.0 111.604 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 175.03 41.55 0.05 OUTLIER Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.709 -2.157 . . . . 0.0 107.709 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.626 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 26.7 p -56.45 -167.94 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.252 -0.974 . . . . 0.0 111.469 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.587 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 2.0 pt20 -159.15 152.67 22.76 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 118.984 -1.086 . . . . 0.0 110.402 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -137.29 133.77 46.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.2 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.465 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.42 164.83 11.57 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.968 179.855 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 1.6 t-105 -118.9 142.86 47.37 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.927 -0.709 . . . . 0.0 112.072 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.76 76.58 0.38 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 107.804 -2.119 . . . . 0.0 107.804 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -69.16 150.97 10.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.622 -0.831 . . . . 0.0 113.0 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 . . . . . 0 C--N 1.305 -1.344 0 CA-C-N 114.321 -1.309 . . . . 0.0 108.534 179.956 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.563 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 23.7 p90 . . . . . 0 CA--C 1.494 -1.203 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.13 153.25 27.38 Favored 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 105.433 -2.062 . . . . 0.0 105.433 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.452 ' CB ' ' CZ ' ' A' ' 86' ' ' PHE . . . -128.79 108.9 10.83 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.378 -1.329 . . . . 0.0 112.657 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -95.74 94.91 7.96 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.465 HG11 ' N ' ' A' ' 26' ' ' THR . 36.9 t -91.92 154.14 3.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.296 -0.962 . . . . 0.0 112.452 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.465 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.2 m -139.36 104.11 4.89 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.222 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' A' ' 82' ' ' ALA . 1.5 t -74.8 148.81 7.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 C-N-CA 119.732 -0.787 . . . . 0.0 112.17 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.587 ' NZ ' ' NE2' ' A' ' 9' ' ' GLN . 0.3 OUTLIER -136.21 96.09 3.32 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.784 179.693 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.427 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.9 t30 -88.28 106.98 18.58 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.883 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 t -113.45 5.52 16.76 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.835 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.634 ' HG ' ' H ' ' A' ' 32' ' ' SER . 12.6 p -54.17 -84.9 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.894 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.634 ' H ' ' HG ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.01 65.39 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.752 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.555 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.44 160.2 6.17 Favored Pre-proline 0 N--CA 1.486 1.331 0 C-N-CA 118.804 -1.158 . . . . 0.0 111.413 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -71.72 95.07 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.484 1.456 . . . . 0.0 109.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.1 t -75.13 79.79 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 C-N-CA 118.87 -1.132 . . . . 0.0 112.301 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -91.46 57.41 3.31 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.431 -0.908 . . . . 0.0 108.714 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 106.62 157.83 21.5 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.777 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 48.0 p-90 -171.58 178.82 3.03 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 117.752 -1.579 . . . . 0.0 112.382 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.505 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -141.18 115.63 9.48 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.017 179.779 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.602 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -106.35 176.43 5.17 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.1 179.834 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.485 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -167.18 152.44 7.43 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 117.5 -1.68 . . . . 0.0 113.009 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.447 ' CD2' ' N ' ' A' ' 43' ' ' SER . 19.4 p90 -176.79 -137.48 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 113.756 -1.566 . . . . 0.0 108.161 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.566 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 6.8 m -165.71 168.55 16.06 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 117.665 -1.614 . . . . 0.0 112.604 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.487 ' CE2' HG23 ' A' ' 65' ' ' VAL . 8.4 m-85 -102.16 108.12 55.61 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.71 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -55.98 -66.79 0.08 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.051 1.168 . . . . 0.0 111.726 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.512 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 35.2 t -70.28 -171.91 0.52 Allowed 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.526 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.512 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -79.36 49.07 3.51 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.198 -1.477 . . . . 0.0 109.915 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.18 109.86 19.18 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.445 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.648 ' CD ' ' H ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -113.91 130.4 56.51 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.729 179.978 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.434 HG22 ' CD2' ' A' ' 86' ' ' PHE . 5.2 p -96.41 159.51 2.98 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.083 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.592 ' HG1' ' N ' ' A' ' 52' ' ' GLN . 30.4 p -133.09 -65.77 0.69 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.707 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.592 ' N ' ' HG1' ' A' ' 51' ' ' THR . 3.5 mt-30 -81.72 166.5 20.03 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.282 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -169.29 148.48 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.976 -1.09 . . . . 0.0 111.454 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.46 ' CD1' ' HB3' ' A' ' 55' ' ' SER . 36.8 t-105 -150.6 141.42 22.81 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.001 -1.079 . . . . 0.0 111.645 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.501 ' HG ' ' HB2' ' A' ' 84' ' ' PHE . 0.9 OUTLIER 63.8 20.92 12.45 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.311 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.491 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.2 m -165.06 109.31 0.89 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.422 -0.911 . . . . 0.0 110.381 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.458 ' H ' ' HG1' ' A' ' 57' ' ' THR . 1.7 m -70.57 78.36 0.58 Allowed 'General case' 0 C--N 1.285 -2.216 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.126 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -81.48 162.34 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.461 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.429 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.9 t -160.55 133.92 6.75 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.348 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.94 108.83 18.98 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.734 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.407 ' HG ' ' HB1' ' A' ' 64' ' ' ALA . 7.5 p -93.34 75.5 4.54 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.476 -0.889 . . . . 0.0 110.875 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 53.56 74.27 0.32 Allowed Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.357 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 0.3 OUTLIER 76.17 -35.91 0.26 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.491 -179.977 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.566 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -81.67 -171.06 3.13 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.666 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.511 ' CG1' ' N ' ' A' ' 66' ' ' THR . 77.4 t -149.71 157.62 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 118.725 -1.19 . . . . 0.0 113.05 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.511 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 35.9 m -156.69 131.9 9.18 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 114.234 -1.348 . . . . 0.0 107.96 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.426 ' CG2' HD23 ' A' ' 40' ' ' LEU . 2.0 t -126.07 146.98 30.95 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.07 0 C-N-CA 119.326 -0.95 . . . . 0.0 112.225 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -130.46 93.22 3.4 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.777 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -72.7 124.31 25.05 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.373 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.786 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -46.52 162.98 0.24 Allowed Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 113.719 -1.582 . . . . 0.0 111.593 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -67.12 -39.13 14.12 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.897 1.731 . . . . 0.0 111.933 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.539 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.38 -56.06 8.56 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.246 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.786 HD22 ' N ' ' A' ' 70' ' ' ALA . 2.0 p30 -70.63 -5.75 31.73 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.024 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.513 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -119.62 48.13 0.97 Allowed Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.532 ' H ' ' HG ' ' A' ' 75' ' ' SER . 2.4 p -112.67 74.33 0.86 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.099 -0.641 . . . . 0.0 110.971 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.577 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -130.69 132.28 23.84 Favored Pre-proline 0 CA--C 1.56 1.352 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.94 179.866 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.433 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.4 Cg_endo -71.18 159.24 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 122.023 1.815 . . . . 0.0 114.498 -179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.555 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -26.24 -40.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.679 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -114.76 68.84 0.26 Allowed Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.77 -1.205 . . . . 0.0 111.038 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -154.78 -168.83 18.68 Favored Glycine 0 C--N 1.29 -2.023 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.002 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.577 ' N ' HG13 ' A' ' 76' ' ' ILE . 7.6 p -137.1 166.39 23.82 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.818 0.818 . . . . 0.0 112.364 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.445 ' O ' ' N ' ' A' ' 27' ' ' VAL . . . -138.38 162.41 34.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -139.52 158.2 44.53 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 118.114 -1.434 . . . . 0.0 113.355 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.501 ' HB2' ' HG ' ' A' ' 55' ' ' SER . 1.6 p90 -171.03 161.86 6.99 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.103 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.57 169.81 37.15 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 117.438 -2.315 . . . . 0.0 112.741 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.1 p90 -150.97 -176.94 5.73 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.347 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.552 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 0.6 OUTLIER -128.82 104.68 7.76 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.622 179.842 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.34 175.51 15.74 Favored Glycine 0 N--CA 1.498 2.769 0 C-N-CA 120.058 -1.068 . . . . 0.0 111.41 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.516 ' O ' ' NE2' ' A' ' 49' ' ' GLN . 2.7 p . . . . . 0 N--CA 1.483 1.182 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.221 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 111.295 0.109 . . . . 0.0 111.295 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.455 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.6 Cg_endo -65.63 -143.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 121.093 1.195 . . . . 0.0 110.442 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.716 ' HG1' ' H ' ' A' ' 99' ' ' ALA . 27.0 p -104.39 -101.1 0.31 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.355 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.716 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -90.89 109.6 20.82 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 118.711 -1.196 . . . . 0.0 112.537 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.664 ' CZ ' ' CG1' ' A' ' 109' ' ' VAL . 4.1 m-30 -76.1 -149.76 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.45 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.87 116.27 2.8 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 117.107 -1.837 . . . . 0.0 113.696 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.626 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 2.1 mt -58.81 -172.53 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.114 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.505 ' N ' ' O ' ' A' ' 39' ' ' THR . 3.5 p30 -65.99 76.53 0.08 Allowed 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.919 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 102.22 10.7 38.5 Favored Glycine 0 N--CA 1.5 2.913 0 C-N-CA 119.521 -1.323 . . . . 0.0 112.374 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 102' ' ' LEU . 62.3 p -150.46 151.14 30.46 Favored Pre-proline 0 N--CA 1.495 1.796 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -66.51 171.53 10.51 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.583 1.522 . . . . 0.0 112.388 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.62 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.8 t -165.85 111.13 0.86 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.088 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 1.1 p -72.58 128.11 34.59 Favored 'General case' 0 N--CA 1.506 2.354 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.664 ' CG1' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -54.45 178.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 C-N-CA 118.793 -1.163 . . . . 0.0 110.531 179.796 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.287 0 CA-C-O 116.379 -2.345 . . . . 0.0 110.324 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 CA-C-O 121.256 0.55 . . . . 0.0 110.994 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.2 50.45 0.02 OUTLIER Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.546 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 2.7 p -52.31 178.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.771 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -137.72 110.67 7.72 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.467 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.5 m -101.75 125.79 55.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.2 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.44 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -104.81 133.96 48.75 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.28 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.465 ' CE3' ' HB1' ' A' ' 96' ' ' ALA . 1.4 t-105 -95.17 139.68 31.16 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.911 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.14 73.12 0.44 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.466 HG21 ' H ' ' A' ' 15' ' ' ASN . 0.6 OUTLIER -69.73 159.75 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.466 ' H ' HG21 ' A' ' 14' ' ' VAL . 1.3 t30 . . . . . 0 C--N 1.302 -1.461 0 CA-C-N 113.974 -1.466 . . . . 0.0 108.549 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.581 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 22.0 p90 . . . . . 0 CA--C 1.495 -1.172 0 CA-C-O 121.906 0.86 . . . . 0.0 113.264 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t -73.26 162.99 28.74 Favored 'General case' 0 C--N 1.283 -2.287 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.33 117.94 10.38 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.048 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.786 HD22 HE21 ' A' ' 83' ' ' GLN . 1.4 t-20 -100.86 99.17 9.63 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.316 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.515 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 6.1 t -99.39 136.1 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 119.726 -0.789 . . . . 0.0 112.25 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.44 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.7 m -130.03 108.88 10.42 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.738 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.7 t -78.03 149.87 5.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 3.6 tttt -133.17 96.06 3.67 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.831 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.39 96.75 7.45 Favored 'General case' 0 C--N 1.291 -1.964 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.038 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.5 t -111.65 6.11 19.71 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.334 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.505 ' H ' ' HG ' ' A' ' 31' ' ' SER . 1.7 p -71.93 -78.31 0.08 Allowed 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.332 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 158.27 78.18 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 123.906 0.754 . . . . 0.0 111.498 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.581 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -166.17 145.08 4.89 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 118.648 -1.221 . . . . 0.0 111.373 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -68.91 97.34 0.56 Allowed 'Trans proline' 0 N--CA 1.456 -0.719 0 N-CA-C 108.172 -1.511 . . . . 0.0 108.172 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.38 100.25 9.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 118.194 -1.402 . . . . 0.0 112.029 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -113.71 55.3 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.85 148.7 14.25 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.873 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 43.3 p-90 -163.55 176.68 9.47 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.964 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -140.54 109.53 6.08 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.805 179.901 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.564 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.61 173.22 7.02 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.537 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.464 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.3 m -155.49 148.09 24.08 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.023 -1.471 . . . . 0.0 112.882 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.3 p90 -174.51 -141.54 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 113.999 -1.455 . . . . 0.0 108.417 179.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.5 m -163.17 173.11 13.85 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 117.625 -1.63 . . . . 0.0 112.921 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.561 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 5.3 m-85 -111.12 98.46 39.29 Favored Pre-proline 0 N--CA 1.491 1.575 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.015 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -53.31 -55.15 3.9 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.007 1.138 . . . . 0.0 111.301 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.474 ' C ' ' H ' ' A' ' 48' ' ' GLN . 62.2 p -74.15 -179.83 4.05 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.101 -1.04 . . . . 0.0 109.794 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -77.71 41.79 1.95 Allowed Glycine 0 N--CA 1.484 1.864 0 C-N-CA 118.863 -1.637 . . . . 0.0 109.494 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.474 ' H ' ' C ' ' A' ' 46' ' ' SER . 8.7 mt-30 -78.05 108.53 11.4 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.539 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -116.55 109.85 17.79 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.207 179.91 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.602 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.1 p -68.45 164.54 2.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.089 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.853 ' HG1' ' H ' ' A' ' 52' ' ' GLN . 36.8 p -137.5 -63.92 0.57 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.626 -0.829 . . . . 0.0 110.986 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.853 ' H ' ' HG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -97.59 137.11 37.02 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.709 179.941 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.52 159.15 42.8 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.726 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 36.2 t-105 -155.02 141.73 18.96 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.988 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.445 ' HG ' ' CB ' ' A' ' 73' ' ' ASN . 1.0 OUTLIER 67.12 23.84 9.49 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.091 -179.999 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.471 ' HB3' ' CG ' ' A' ' 84' ' ' PHE . 2.1 p -172.8 110.4 0.21 Allowed 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.249 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.4 m -71.46 74.64 0.76 Allowed 'General case' 0 C--N 1.284 -2.239 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.07 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.4 m -69.6 155.05 7.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.953 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 65.5 p -152.6 112.5 3.97 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.196 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -78.57 104.91 9.49 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.001 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.1 p -85.72 -160.89 0.56 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.948 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.638 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -50.84 88.22 0.01 OUTLIER Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.139 -1.505 . . . . 0.0 109.655 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER 53.22 4.19 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.707 -179.828 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.638 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.51 -169.27 1.6 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.555 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 77.9 t -143.17 154.22 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 C-N-CA 119.119 -1.033 . . . . 0.0 112.691 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.423 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 15.6 m -158.01 127.83 6.01 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.551 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 39' ' ' THR . 1.9 t -126.35 142.55 42.63 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.958 0 C-N-CA 119.279 -0.968 . . . . 0.0 111.747 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.46 94.33 4.11 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 124.735 1.272 . . . . 0.0 107.938 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.873 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.22 119.78 18.89 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.045 -1.062 . . . . 0.0 111.937 -179.647 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.801 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -46.73 172.43 0.05 OUTLIER Pre-proline 0 N--CA 1.485 1.303 0 CA-C-N 113.751 -1.568 . . . . 0.0 112.308 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.411 ' HD2' ' CB ' ' A' ' 70' ' ' ALA . 1.4 Cg_endo -68.28 -35.8 17.89 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.185 1.924 . . . . 0.0 112.707 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.562 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -68.9 -52.49 28.88 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 118.743 -1.183 . . . . 0.0 110.529 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.801 HD22 ' N ' ' A' ' 70' ' ' ALA . 1.1 p-10 -80.75 5.07 16.87 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 118.998 -1.081 . . . . 0.0 109.576 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -127.06 26.01 5.12 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.538 ' H ' ' HG ' ' A' ' 75' ' ' SER . 4.5 p -99.09 67.53 1.62 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.733 -0.787 . . . . 0.0 111.487 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.552 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -129.17 127.44 23.25 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 119.858 -0.737 . . . . 0.0 110.615 179.859 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.7 Cg_endo -72.12 156.98 55.01 Favored 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 121.621 1.547 . . . . 0.0 113.846 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.581 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -23.84 -38.03 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 114.89 1.441 . . . . 0.0 114.89 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -107.0 67.97 0.23 Allowed Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.686 -1.245 . . . . 0.0 111.216 -179.697 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.74 -169.05 25.58 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 118.27 -1.919 . . . . 0.0 111.397 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.552 ' N ' HG13 ' A' ' 76' ' ' ILE . 2.6 p -137.46 163.95 29.87 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.549 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -126.07 177.34 6.42 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.01 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.786 HE21 HD22 ' A' ' 24' ' ' ASN . 30.5 tt0 -168.52 146.66 4.14 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 117.124 -1.83 . . . . 0.0 113.624 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.515 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 14.6 p90 -160.1 175.21 13.22 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.037 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.21 166.44 35.21 Favored Glycine 0 N--CA 1.497 2.75 0 C-N-CA 117.902 -2.094 . . . . 0.0 112.166 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 5.8 p90 -161.94 156.85 22.94 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.457 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.636 ' N ' HD21 ' A' ' 87' ' ' ASN . 0.6 OUTLIER -104.66 111.41 24.1 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.232 179.889 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.25 163.62 14.66 Favored Glycine 0 N--CA 1.503 3.14 0 C-N-CA 119.737 -1.221 . . . . 0.0 111.33 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 120.42 -0.512 . . . . 0.0 109.996 179.969 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.465 ' HB1' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.506 2.372 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.498 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.7 Cg_endo -62.44 -95.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 120.862 1.041 . . . . 0.0 112.34 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -151.65 -96.77 0.06 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 118.674 -1.211 . . . . 0.0 112.397 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.61 95.07 8.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.844 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.2 m-30 -65.9 -157.46 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.254 -0.979 . . . . 0.0 109.135 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.28 115.0 3.7 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 117.524 -1.67 . . . . 0.0 113.286 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.3 mt -59.62 177.67 0.2 Allowed 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.358 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.716 HD21 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -60.05 77.58 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.791 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 101.7 12.36 35.29 Favored Glycine 0 N--CA 1.503 3.112 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.275 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.614 ' O ' ' N ' ' A' ' 102' ' ' LEU . 70.5 p -152.47 152.58 29.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 C-N-CA 118.885 -1.126 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -67.0 173.04 8.93 Favored 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 121.534 1.489 . . . . 0.0 112.141 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.2 106.43 0.79 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.833 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.48 138.76 47.25 Favored 'General case' 0 N--CA 1.505 2.309 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.667 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 1.7 p -68.82 172.08 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.52 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.667 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.442 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.399 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.49 ' H ' HG22 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.284 0.564 . . . . 0.0 111.814 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.83 39.45 0.02 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 108.061 -2.016 . . . . 0.0 108.061 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.66 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 25.2 p -54.0 -178.0 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.707 -0.746 . . . . 0.0 111.823 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.16 138.1 27.91 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.694 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.465 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 1.3 m -128.61 130.14 68.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.574 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.484 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -92.74 169.87 10.15 Favored 'General case' 0 C--N 1.284 -2.278 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.862 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.539 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 2.1 t-105 -130.62 147.2 52.27 Favored 'General case' 0 C--N 1.309 -1.183 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.986 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.48 75.92 0.39 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -69.46 140.01 19.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.797 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 18.1 t-20 . . . . . 0 C--N 1.305 -1.339 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.049 179.814 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.797 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 19.7 p90 . . . . . 0 C--O 1.216 -0.66 0 CA-C-O 121.394 0.616 . . . . 0.0 112.418 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.17 127.08 33.7 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.539 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -104.64 110.87 23.35 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.245 -0.982 . . . . 0.0 113.464 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -95.78 98.58 10.55 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.577 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.452 HG11 ' N ' ' A' ' 26' ' ' THR . 38.5 t -96.08 147.01 6.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.465 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.9 m -136.97 101.72 4.65 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.419 -1.264 . . . . 0.0 108.484 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.5 t -72.94 151.97 7.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 C-N-CA 119.669 -0.813 . . . . 0.0 112.364 -179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.1 tttt -143.59 104.04 4.16 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.468 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.529 ' ND2' ' HG ' ' A' ' 31' ' ' SER . 3.5 t30 -90.61 116.57 28.6 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -120.11 1.5 10.86 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 124.105 0.878 . . . . 0.0 110.147 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.529 ' HG ' ' ND2' ' A' ' 29' ' ' ASN . 20.6 p -57.9 -81.62 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.58 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.512 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 159.54 72.52 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 123.726 0.641 . . . . 0.0 111.592 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.568 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.8 152.58 3.75 Favored Pre-proline 0 C--N 1.306 -1.29 0 C-N-CA 119.012 -1.075 . . . . 0.0 111.395 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.37 105.49 1.59 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 121.192 1.261 . . . . 0.0 109.342 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -90.7 92.25 3.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 118.46 -1.296 . . . . 0.0 111.779 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -103.47 67.22 0.9 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.95 148.62 24.01 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.6 -2.2 . . . . 0.0 107.6 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.852 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.0 p-90 -165.69 177.44 7.28 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.7 -1.6 . . . . 0.0 112.103 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.72 108.79 5.74 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.625 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.592 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.43 173.7 6.83 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.194 -1.002 . . . . 0.0 108.94 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.475 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 3.3 m -157.83 152.73 25.36 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 117.745 -1.582 . . . . 0.0 112.913 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' ' N ' ' A' ' 43' ' ' SER . 24.2 p90 -178.69 -142.88 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 113.773 -1.558 . . . . 0.0 108.179 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.6 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 20.2 m -163.24 173.71 13.02 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 117.626 -1.63 . . . . 0.0 112.663 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.492 ' CE2' HG23 ' A' ' 65' ' ' VAL . 6.9 m-85 -107.26 101.5 38.92 Favored Pre-proline 0 N--CA 1.486 1.341 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.843 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -55.53 -55.62 2.91 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 120.79 0.993 . . . . 0.0 110.531 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.64 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 8.7 t -69.48 -178.25 1.37 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 118.839 -1.144 . . . . 0.0 109.914 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.64 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -87.27 55.91 4.54 Favored Glycine 0 C--N 1.291 -1.969 0 C-N-CA 118.961 -1.59 . . . . 0.0 110.241 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.797 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 3.7 mt-30 -90.94 125.34 35.74 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.025 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.0 OUTLIER -115.58 101.8 9.19 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.96 -179.923 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.55 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.3 p -65.03 161.17 3.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.135 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 43.2 p -142.94 -65.8 0.39 Allowed 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.475 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.552 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -90.81 136.07 33.31 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.093 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.9 153.59 40.3 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.502 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . 0.401 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 44.5 t-105 -154.04 146.18 23.72 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.054 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.401 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.4 OUTLIER 65.88 23.87 11.31 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.776 -179.989 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.436 ' HB3' ' CB ' ' A' ' 84' ' ' PHE . 4.4 p -173.78 113.63 0.2 Allowed 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.17 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -72.64 73.36 1.06 Allowed 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.555 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.0 m -70.13 148.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.719 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.8 p -149.26 107.16 3.69 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.78 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 5.7 tt0 -78.59 104.29 9.1 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.594 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.567 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.3 p -82.84 -155.67 0.16 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.409 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.645 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -49.83 88.71 0.01 OUTLIER Glycine 0 N--CA 1.497 2.742 0 C-N-CA 118.967 -1.587 . . . . 0.0 110.098 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.567 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.4 OUTLIER 53.19 2.19 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.549 -0.861 . . . . 0.0 110.49 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.645 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.59 -173.59 2.34 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.315 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.492 HG23 ' CE2' ' A' ' 44' ' ' PHE . 50.0 t -140.82 152.92 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.299 -0.96 . . . . 0.0 112.531 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.421 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 94.5 m -153.94 115.53 4.19 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.308 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.428 ' CG2' HD23 ' A' ' 40' ' ' LEU . 1.7 t -109.35 145.75 15.69 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.949 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.661 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -131.18 92.91 3.27 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 114.172 -1.376 . . . . 0.0 107.324 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.852 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.14 118.43 17.09 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.032 -1.067 . . . . 0.0 112.167 -179.608 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.816 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -43.1 164.68 0.12 Allowed Pre-proline 0 N--CA 1.481 1.111 0 CA-C-N 113.37 -1.741 . . . . 0.0 112.003 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -65.03 -34.78 45.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.066 1.844 . . . . 0.0 112.416 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.596 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -70.92 -54.91 9.69 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.984 -179.892 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.816 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -75.91 -1.16 24.12 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 118.947 -1.101 . . . . 0.0 110.15 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.67 40.08 2.62 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.451 ' H ' ' HG ' ' A' ' 75' ' ' SER . 2.0 p -105.28 71.41 0.93 Allowed 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.868 -0.733 . . . . 0.0 110.971 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -127.69 119.8 21.58 Favored Pre-proline 0 CA--C 1.565 1.541 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.483 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.2 Cg_endo -69.85 158.57 56.4 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.594 1.529 . . . . 0.0 114.114 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.568 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -22.52 -41.23 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 CA-C-N 114.159 -1.382 . . . . 0.0 114.051 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -117.82 69.31 0.31 Allowed Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -154.59 -168.01 17.32 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.354 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.487 ' N ' HG13 ' A' ' 76' ' ' ILE . 16.6 p -139.72 162.56 34.83 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.967 -1.093 . . . . 0.0 113.307 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.51 178.72 5.91 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 113.724 -1.58 . . . . 0.0 107.578 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.472 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 7.0 tt0 -167.66 145.78 4.62 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 116.987 -1.885 . . . . 0.0 113.53 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.472 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 16.6 p90 -158.96 -178.91 7.59 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.819 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.21 162.51 36.29 Favored Glycine 0 N--CA 1.495 2.614 0 C-N-CA 117.581 -2.247 . . . . 0.0 112.198 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.559 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.6 p90 -155.18 174.19 15.55 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 119.763 -0.775 . . . . 0.0 111.04 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.424 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.6 m-20 -126.65 111.85 14.78 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.053 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.428 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -122.75 154.47 17.01 Favored Glycine 0 N--CA 1.5 2.961 0 C-N-CA 119.983 -1.104 . . . . 0.0 111.966 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.1 p . . . . . 0 N--CA 1.481 1.099 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.773 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.439 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.502 2.169 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.486 ' HD2' ' CE1' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -65.92 -140.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 121.413 1.409 . . . . 0.0 111.189 179.957 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.546 ' HG1' ' H ' ' A' ' 99' ' ' ALA . 76.3 p -112.29 -76.39 0.59 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.571 -0.851 . . . . 0.0 112.857 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.546 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -105.79 99.91 9.49 Favored 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 119.062 -1.055 . . . . 0.0 111.583 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.542 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.8 m-30 -68.73 -142.42 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 115.311 -0.859 . . . . 0.0 108.842 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.7 m -160.8 108.52 1.55 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 116.994 -1.883 . . . . 0.0 113.454 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.66 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 0.4 OUTLIER -73.2 154.44 40.26 Favored 'General case' 0 C--O 1.206 -1.232 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.651 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.511 ' H ' HD21 ' A' ' 102' ' ' LEU . 0.2 OUTLIER -52.26 81.84 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.624 -1.23 . . . . 0.0 110.793 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.636 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 140.23 -33.95 2.04 Favored Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.989 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.49 HG22 ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -154.23 163.87 22.65 Favored Pre-proline 0 N--CA 1.505 2.289 0 C-N-CA 118.25 -1.38 . . . . 0.0 113.083 -179.821 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . 0.404 ' HD2' ' CG2' ' A' ' 105' ' ' THR . 1.7 Cg_endo -66.24 118.79 5.8 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 122.654 2.236 . . . . 0.0 111.907 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.525 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.6 t -100.1 123.05 43.89 Favored 'General case' 0 N--CA 1.501 2.108 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.967 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.78 162.22 16.49 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.859 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.775 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 12.8 p -90.07 -130.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.874 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.775 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.494 2.535 0 CA-C-O 116.323 -2.376 . . . . 0.0 110.308 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.513 ' H ' HG23 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 121.696 0.76 . . . . 0.0 112.092 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.68 39.58 0.02 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 107.422 -2.271 . . . . 0.0 107.422 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.459 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 24.3 p -55.01 -171.1 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.271 -0.964 . . . . 0.0 111.876 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.11 131.8 6.88 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.982 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.453 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.6 m -113.79 130.51 67.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 C-N-CA 120.004 -0.679 . . . . 0.0 110.581 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.477 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.2 OUTLIER -97.81 161.03 13.94 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.514 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.484 ' CZ3' ' CB ' ' A' ' 96' ' ' ALA . 22.5 t-105 -112.04 149.41 32.09 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.59 0.71 . . . . 0.0 112.517 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.59 76.98 0.36 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -68.92 146.61 12.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.7 t30 . . . . . 0 C--N 1.303 -1.436 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.209 179.824 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.553 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 32.0 p90 . . . . . 0 CA--C 1.507 -0.685 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.421 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 0.8 OUTLIER -99.49 111.91 24.19 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.614 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 86' ' ' PHE . . . -93.75 117.17 29.74 Favored 'General case' 0 C--N 1.292 -1.896 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.727 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.8 102.25 14.03 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.435 HG11 ' N ' ' A' ' 26' ' ' THR . 53.2 t -99.71 147.3 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 N-CA-C 113.993 1.109 . . . . 0.0 113.993 -179.555 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.472 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 18.5 m -136.71 100.58 4.37 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.948 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.0 t -68.79 146.88 12.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.104 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HZ2' ' HB ' ' A' ' 30' ' ' THR . 9.2 tmtt? -138.48 102.91 4.74 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.567 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.693 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -95.58 136.06 36.45 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.516 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.464 ' HB ' ' HZ2' ' A' ' 28' ' ' LYS . 6.7 t -131.64 5.8 4.34 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.544 -1.207 . . . . 0.0 109.523 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.511 ' HG ' ' ND2' ' A' ' 29' ' ' ASN . 19.1 p -47.24 -86.58 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.026 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.04 34.51 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.505 -179.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.599 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -147.4 155.71 45.94 Favored Pre-proline 0 N--CA 1.481 1.11 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.886 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.35 96.77 0.49 Allowed 'Trans proline' 0 C--N 1.323 -0.763 0 C-N-CA 121.284 1.322 . . . . 0.0 110.14 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.3 t -71.08 117.38 14.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.593 -1.243 . . . . 0.0 111.269 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -123.03 75.01 1.25 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.368 -0.833 . . . . 0.0 108.765 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.44 140.19 7.7 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.431 -1.867 . . . . 0.0 108.431 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.851 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.8 p-90 -158.79 177.46 11.15 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.303 -1.359 . . . . 0.0 111.626 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -141.08 112.37 7.38 Favored 'General case' 0 C--O 1.202 -1.4 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.715 179.897 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.607 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.41 174.68 5.76 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.934 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.512 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -163.55 157.71 19.89 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 117.325 -1.75 . . . . 0.0 113.153 -179.88 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.512 ' N ' ' CG2' ' A' ' 41' ' ' THR . 31.1 p90 -178.18 -141.43 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 113.368 -1.742 . . . . 0.0 107.997 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.478 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 61.2 m -160.82 146.9 14.87 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 117.876 -1.53 . . . . 0.0 112.187 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.65 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 8.3 m-85 -77.55 119.3 76.88 Favored Pre-proline 0 N--CA 1.482 1.132 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.146 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -63.38 -66.67 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.148 1.232 . . . . 0.0 111.579 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.536 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.4 t -69.44 -122.44 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.536 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -130.96 38.48 1.93 Allowed Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.483 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 3.2 mt-30 -75.24 98.31 3.74 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.517 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.538 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -98.95 112.42 24.54 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.57 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.422 HG21 ' N ' ' A' ' 51' ' ' THR . 2.4 p -70.52 148.26 10.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.2 -1.0 . . . . 0.0 111.12 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.619 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 21.8 p -127.6 -63.24 1.04 Allowed 'General case' 0 N--CA 1.491 1.596 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.77 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.619 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -96.94 138.59 34.24 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.794 179.938 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -148.29 157.19 43.34 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.101 -1.039 . . . . 0.0 111.345 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 43.3 t-105 -153.32 146.12 24.36 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.228 -0.989 . . . . 0.0 111.266 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 66.97 22.28 10.1 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.584 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.605 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 13.1 t -175.95 125.8 0.21 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.405 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.1 79.67 9.3 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.608 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -81.81 152.28 4.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.635 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -155.34 131.45 10.16 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.476 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.473 HE22 ' HB2' ' A' ' 49' ' ' GLN . 6.8 pt20 -95.12 119.98 34.55 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.647 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.419 ' H ' ' HG ' ' A' ' 61' ' ' SER . 3.7 p -86.91 68.93 10.22 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.18 -56.98 4.03 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 -20.18 0.3 Allowed 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.404 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.415 ' CB ' ' OG ' ' A' ' 61' ' ' SER . . . -85.99 -168.46 2.24 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.942 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.65 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 84.2 t -147.35 155.2 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.757 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.572 ' HG1' ' C ' ' A' ' 65' ' ' VAL . 70.7 m -161.63 124.29 3.03 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.705 -1.134 . . . . 0.0 108.653 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.605 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.4 t -117.53 146.4 22.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.093 0 C-N-CA 119.548 -0.861 . . . . 0.0 111.857 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -132.16 90.51 2.82 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.851 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.53 122.52 22.33 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 118.948 -1.101 . . . . 0.0 112.445 -179.626 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.59 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -40.3 155.88 0.18 Allowed Pre-proline 0 N--CA 1.479 0.993 0 CA-C-N 113.592 -1.64 . . . . 0.0 112.186 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.96 -35.28 35.45 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 121.759 1.639 . . . . 0.0 112.297 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.59 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -70.55 -57.38 4.81 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 118.931 -1.108 . . . . 0.0 110.981 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.507 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -65.85 -21.34 66.46 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.994 -1.082 . . . . 0.0 110.171 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -96.61 27.87 15.8 Favored Glycine 0 N--CA 1.486 1.967 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.654 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 32.2 m -91.86 60.68 3.95 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.956 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -108.49 136.4 19.91 Favored Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.387 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' GLY . 7.2 Cg_endo -69.81 151.42 68.75 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 121.51 1.474 . . . . 0.0 111.181 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.599 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -40.41 -22.32 0.01 OUTLIER 'General case' 0 C--O 1.2 -1.525 0 C-N-CA 119.749 -0.78 . . . . 0.0 112.268 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.71 64.19 0.28 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.31 -162.83 18.68 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 118.11 -1.995 . . . . 0.0 111.485 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.483 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.6 p -139.5 162.41 35.12 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-O 121.867 0.841 . . . . 0.0 112.765 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -136.84 122.2 19.39 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -114.82 164.91 13.43 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.438 ' CD2' ' HB3' ' A' ' 56' ' ' SER . 8.3 p90 -163.89 -178.09 5.48 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 112.688 -2.051 . . . . 0.0 108.986 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.24 159.13 32.39 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 117.556 -2.259 . . . . 0.0 111.937 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.3 p90 -154.77 169.2 24.51 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.487 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.507 HD21 ' C ' ' A' ' 86' ' ' PHE . 1.4 m120 -125.57 112.52 16.28 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.53 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.03 150.23 17.25 Favored Glycine 0 N--CA 1.512 3.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.464 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.427 ' OG ' ' CG ' ' A' ' 49' ' ' GLN . 52.1 p . . . . . 0 N--CA 1.482 1.14 0 C-N-CA 120.121 -0.631 . . . . 0.0 109.715 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.484 ' CB ' ' CZ3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.502 2.146 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.452 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.8 -142.16 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 121.214 1.276 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' THR . . . . . 0.452 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 42.8 p -108.5 -100.57 0.37 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.472 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.423 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -90.27 104.22 16.82 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 118.503 -1.279 . . . . 0.0 112.196 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.3 m-30 -70.37 -141.84 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.363 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.5 m -162.39 109.81 1.32 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 117.022 -1.871 . . . . 0.0 113.869 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.5 mt -53.85 178.14 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.817 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.49 ' H ' HD21 ' A' ' 102' ' ' LEU . 1.8 p30 -39.66 -26.41 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.927 -0.709 . . . . 0.0 111.973 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -165.31 41.7 0.29 Allowed Glycine 0 N--CA 1.491 2.307 0 C-N-CA 118.653 -1.737 . . . . 0.0 111.499 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.2 OUTLIER -171.83 147.68 2.01 Favored Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.685 179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.17 156.64 44.03 Favored 'Trans proline' 0 C--O 1.212 -0.813 0 C-N-CA 121.566 1.51 . . . . 0.0 112.554 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.41 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.0 t -147.26 101.65 3.41 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.342 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.01 135.75 57.81 Favored 'General case' 0 N--CA 1.518 2.951 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -179.587 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.792 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 5.3 p -59.93 -163.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 118.795 -1.162 . . . . 0.0 110.926 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.792 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 116.35 -2.361 . . . . 0.0 110.386 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.485 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.484 0.659 . . . . 0.0 111.946 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.33 38.42 0.05 OUTLIER Glycine 0 N--CA 1.492 2.419 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 4.3 p -49.21 178.63 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 113.904 -1.148 . . . . 0.0 113.016 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -135.13 106.37 6.74 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.035 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.508 ' CG1' ' SG ' ' A' ' 107' ' ' CYS . 2.1 m -99.45 139.12 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 119.061 -1.056 . . . . 0.0 112.428 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.44 ' CD2' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -109.21 162.65 14.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.848 179.772 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' TRP . . . . . 0.506 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.2 t-105 -128.05 139.68 52.39 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.318 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -116.22 62.59 0.37 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.334 -2.307 . . . . 0.0 107.334 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.455 HG21 ' N ' ' A' ' 15' ' ' ASN . 14.6 p -69.3 140.84 18.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.467 ' CB ' ' CG2' ' A' ' 22' ' ' THR . 2.4 t30 . . . . . 0 N--CA 1.489 1.496 0 CA-C-N 114.616 -1.175 . . . . 0.0 108.762 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.564 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 2.8 p90 . . . . . 0 CA--C 1.51 -0.566 0 CA-C-O 121.464 0.649 . . . . 0.0 112.681 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.467 ' CG2' ' CB ' ' A' ' 15' ' ' ASN . 1.4 t -78.92 174.02 11.95 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 179.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.506 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -153.2 125.73 8.18 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 117.04 -1.864 . . . . 0.0 114.053 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -107.8 91.5 3.68 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 179.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.452 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 40.5 t -96.02 144.3 10.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 113.94 1.089 . . . . 0.0 113.94 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.449 ' N ' HG11 ' A' ' 25' ' ' VAL . 0.4 OUTLIER -126.35 129.72 49.39 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 114.489 -1.232 . . . . 0.0 107.95 179.687 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 23.7 t -101.2 103.81 15.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 C-N-CA 119.281 -0.968 . . . . 0.0 113.151 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 12.6 tmtt? -95.1 106.53 18.54 Favored 'General case' 0 C--N 1.291 -1.951 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.395 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.692 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -107.87 140.94 40.22 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.72 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -140.69 19.34 2.34 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 114.214 -1.357 . . . . 0.0 109.028 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.413 ' O ' ' CB ' ' A' ' 32' ' ' SER . 13.1 p -48.08 -88.47 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.176 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.466 ' CA ' ' HB3' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 170.41 31.55 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.822 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.591 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -154.47 170.98 7.66 Favored Pre-proline 0 N--CA 1.48 1.07 0 C-N-CA 118.085 -1.446 . . . . 0.0 111.443 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.83 97.34 1.06 Allowed 'Trans proline' 0 C--N 1.323 -0.784 0 C-N-CA 121.842 1.695 . . . . 0.0 109.963 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.4 t -75.43 94.31 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 118.249 -1.38 . . . . 0.0 111.591 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.19 50.25 1.37 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 112.1 167.49 17.84 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 107.826 -2.11 . . . . 0.0 107.826 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.756 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 37.8 p-90 -171.17 176.39 3.97 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 117.808 -1.557 . . . . 0.0 111.836 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.1 102.14 4.32 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.607 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -89.63 172.8 8.69 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.699 -1.201 . . . . 0.0 109.409 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.452 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 2.0 m -160.73 142.12 12.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.437 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.559 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.6 p90 -171.0 -140.1 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.249 -1.342 . . . . 0.0 108.351 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.559 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.2 m -161.03 168.2 24.94 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 117.419 -1.713 . . . . 0.0 112.782 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.495 ' CE2' HG23 ' A' ' 65' ' ' VAL . 2.9 m-85 -101.66 109.41 59.26 Favored Pre-proline 0 N--CA 1.489 1.483 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.31 -63.7 0.12 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.098 1.199 . . . . 0.0 111.367 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.8 t -69.59 -172.7 0.5 Allowed 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.575 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.484 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -84.9 57.9 4.99 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.072 -1.537 . . . . 0.0 109.886 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.534 ' OE1' ' CE1' ' A' ' 21' ' ' PHE . 11.6 mm-40 -94.41 108.91 20.81 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 119.213 -0.995 . . . . 0.0 111.014 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.9 OUTLIER -106.57 108.89 20.63 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.913 -179.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.1 p -76.47 157.04 5.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.187 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.505 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 72.6 p -138.47 -68.82 0.44 Allowed 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.531 -0.867 . . . . 0.0 111.1 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLN . . . . . 0.505 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.2 mt-30 -80.59 165.26 22.24 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.03 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.14 153.58 8.24 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 118.717 -1.193 . . . . 0.0 111.923 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 32.3 t-105 -147.32 136.88 22.79 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.354 -0.939 . . . . 0.0 110.899 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.7 p 60.23 26.6 16.06 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.196 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.14 117.26 1.65 Allowed 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.0 m -82.11 77.64 8.89 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.977 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.2 m -68.99 154.37 8.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.613 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.9 p -154.07 108.14 3.0 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.908 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 3.6 tt0 -88.09 116.01 25.97 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.036 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.441 ' H ' ' HG ' ' A' ' 61' ' ' SER . 4.7 p -94.39 89.38 5.85 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.636 -0.825 . . . . 0.0 110.777 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 71.16 -74.6 0.66 Allowed Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.388 -1.387 . . . . 0.0 109.963 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 -14.69 1.55 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.122 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.545 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -89.29 -173.91 4.2 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.033 -1.067 . . . . 0.0 110.063 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.589 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.2 t -147.27 160.11 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 118.735 -1.186 . . . . 0.0 113.637 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.589 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.3 m -155.53 145.93 21.91 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.899 -1.5 . . . . 0.0 108.563 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.8 t -141.07 119.4 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 118.727 -1.189 . . . . 0.0 112.469 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.83 91.43 4.83 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.97 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.756 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -70.77 122.8 20.53 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.194 -1.003 . . . . 0.0 111.344 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.732 ' CA ' HD22 ' A' ' 73' ' ' ASN . . . -43.91 166.65 0.1 Allowed Pre-proline 0 C--N 1.307 -1.276 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.452 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.04 -39.98 5.38 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 122.155 1.903 . . . . 0.0 112.392 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' TRP . . . . . 0.514 ' CE2' ' HB2' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -68.56 -55.72 10.68 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.024 -1.07 . . . . 0.0 110.514 -179.875 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.732 HD22 ' CA ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -76.71 11.02 1.84 Allowed 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.18 -1.008 . . . . 0.0 109.624 179.823 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -139.87 37.56 1.71 Allowed Glycine 0 N--CA 1.484 1.898 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.574 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.1 m -104.08 61.74 0.74 Allowed 'General case' 0 C--N 1.309 -1.162 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.956 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.461 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -109.49 136.68 20.22 Favored Pre-proline 0 N--CA 1.484 1.267 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.368 179.926 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.663 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.9 Cg_endo -71.3 171.16 16.63 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 121.396 1.397 . . . . 0.0 111.068 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.591 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -63.18 17.72 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.563 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.663 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -149.8 61.76 0.42 Allowed Glycine 0 C--N 1.291 -1.954 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.22 -155.12 9.57 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 118.641 -1.742 . . . . 0.0 110.733 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.461 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.9 OUTLIER -141.73 168.8 18.89 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.244 -0.983 . . . . 0.0 112.603 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -132.34 -173.3 3.12 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . 0.641 ' CD ' ' N ' ' A' ' 84' ' ' PHE . 12.4 tm0? -167.59 144.74 4.4 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 116.792 -1.963 . . . . 0.0 113.649 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.641 ' N ' ' CD ' ' A' ' 83' ' ' GLN . 3.9 p90 -164.13 164.73 22.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.604 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.51 178.47 32.96 Favored Glycine 0 N--CA 1.504 3.192 0 C-N-CA 118.068 -2.015 . . . . 0.0 111.855 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 4.4 p90 -164.17 -169.8 1.93 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.687 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -142.93 110.8 5.93 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.64 -0.824 . . . . 0.0 110.741 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.71 164.08 12.7 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.026 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.857 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . 0.463 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.496 1.839 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.51 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.8 Cg_endo -64.25 -95.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 120.834 1.022 . . . . 0.0 112.248 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -153.25 -90.41 0.05 OUTLIER 'General case' 0 N--CA 1.497 1.882 0 C-N-CA 118.919 -1.113 . . . . 0.0 112.279 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -96.78 94.51 7.31 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.595 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -66.23 -158.34 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 43.3 m -153.79 118.71 5.03 Favored 'General case' 0 C--N 1.309 -1.179 0 C-N-CA 116.956 -1.898 . . . . 0.0 114.015 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -63.72 176.4 0.91 Allowed 'General case' 0 N--CA 1.48 1.026 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.315 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.469 ' H ' HD21 ' A' ' 102' ' ' LEU . 0.8 OUTLIER -36.94 -32.94 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 C-N-CA 120.025 -0.67 . . . . 0.0 112.675 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' CG2' ' A' ' 105' ' ' THR . . . -155.72 47.03 0.51 Allowed Glycine 0 N--CA 1.499 2.898 0 C-N-CA 118.463 -1.827 . . . . 0.0 111.865 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.544 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER 179.85 160.26 0.83 Allowed Pre-proline 0 C--O 1.192 -1.965 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.97 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.94 179.79 1.69 Allowed 'Trans proline' 0 C--N 1.321 -0.891 0 C-N-CA 122.004 1.802 . . . . 0.0 112.87 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' CYS . . . . . 0.508 ' SG ' ' CG1' ' A' ' 10' ' ' VAL . 5.5 t -170.13 106.68 0.33 Allowed 'General case' 0 N--CA 1.497 1.898 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.305 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 70.6 p -72.06 149.86 44.47 Favored 'General case' 0 N--CA 1.506 2.358 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.725 ' CG1' ' H ' ' A' ' 110' ' ' GLY . 5.0 t -59.05 -167.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 C-N-CA 118.981 -1.088 . . . . 0.0 110.422 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.725 ' H ' ' CG1' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.482 0 CA-C-O 116.289 -2.395 . . . . 0.0 110.301 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.106 0 CA-C-O 120.828 0.347 . . . . 0.0 110.098 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 t -89.75 46.07 1.33 Allowed 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.291 -0.964 . . . . 0.0 110.781 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -152.8 -89.13 0.05 Allowed 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.932 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 164.61 69.34 0.02 OUTLIER Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.416 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.1 -154.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.028 1.819 . . . . 0.0 111.577 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.448 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -84.62 -157.5 0.29 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -178.28 43.21 0.09 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.562 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 26.5 p -60.42 -160.79 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.779 -0.71 . . . . 0.0 110.94 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.64 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -165.3 157.55 15.39 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.192 179.859 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.444 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.0 m -139.63 130.6 32.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.151 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.452 HD22 ' N ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -95.79 157.09 16.05 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.718 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.541 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 2.6 t-105 -114.55 141.44 47.73 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.831 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.14 76.28 0.41 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.2 p -69.23 149.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -152.14 85.47 1.28 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 113.91 -1.496 . . . . 0.0 107.348 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.809 ' NE2' ' N ' ' A' ' 17' ' ' TRP . 0.0 OUTLIER -92.03 121.05 33.23 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.809 ' N ' ' NE2' ' A' ' 16' ' ' GLN . 19.5 p90 -110.5 128.4 55.6 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 105.761 -1.94 . . . . 0.0 105.761 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.407 ' C ' ' OE1' ' A' ' 16' ' ' GLN . 0.3 OUTLIER 47.49 -88.51 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.524 0 C-N-CA 118.152 -1.419 . . . . 0.0 107.408 -179.572 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.7 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER -148.83 112.19 4.98 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 179.405 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.674 ' C ' HE21 ' A' ' 16' ' ' GLN . . . 147.86 87.89 0.07 OUTLIER Glycine 0 C--N 1.274 -2.893 0 N-CA-C 106.276 -2.73 . . . . 0.0 106.276 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.3 p90 -81.49 117.33 21.81 Favored 'General case' 0 CA--C 1.487 -1.448 0 C-N-CA 119.464 -0.895 . . . . 0.0 111.192 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.442 ' HB ' ' CZ3' ' A' ' 17' ' ' TRP . 0.4 OUTLIER -97.11 114.34 26.0 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.541 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -93.74 120.62 34.24 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.367 -0.933 . . . . 0.0 113.422 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -99.08 95.83 7.38 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.45 HG11 ' N ' ' A' ' 26' ' ' THR . 29.8 t -91.81 152.46 3.39 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.45 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.0 OUTLIER -138.88 106.08 5.49 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.184 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.1 t -71.2 149.01 10.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.101 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.433 ' HD3' ' CG2' ' A' ' 81' ' ' THR . 6.5 tptm -141.03 102.81 4.34 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.12 -0.945 . . . . 0.0 110.186 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.799 HD21 ' N ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -96.76 136.93 36.61 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.948 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.799 ' N ' HD21 ' A' ' 29' ' ' ASN . 9.5 t -141.47 -4.31 1.12 Allowed 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.681 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.1 p -51.97 -81.27 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.118 -1.033 . . . . 0.0 110.339 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.465 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.52 73.55 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.373 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.518 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -169.49 149.28 3.67 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.22 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -72.27 97.37 0.85 Allowed 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 121.207 1.271 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -77.49 100.52 2.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.78 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -110.44 58.4 0.61 Allowed 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.06 152.39 21.39 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 107.909 -2.077 . . . . 0.0 107.909 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.644 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 37.3 p-90 -166.35 178.07 6.41 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 117.693 -1.603 . . . . 0.0 112.208 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.34 102.51 4.37 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.133 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.605 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -93.97 175.06 6.86 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.957 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.486 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -169.92 156.22 6.07 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 117.854 -1.539 . . . . 0.0 112.679 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.498 ' CD2' ' N ' ' A' ' 43' ' ' SER . 20.2 p90 -176.73 -132.81 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 113.565 -1.652 . . . . 0.0 107.8 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.498 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -162.29 148.23 13.0 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 117.726 -1.589 . . . . 0.0 111.951 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.486 ' CE2' HG23 ' A' ' 65' ' ' VAL . 2.2 m-85 -82.8 119.01 73.62 Favored Pre-proline 0 N--CA 1.486 1.36 0 C-N-CA 118.601 -1.24 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -55.23 -72.42 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 121.083 1.189 . . . . 0.0 111.764 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.594 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 5.6 t -69.58 -134.0 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 110.535 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.594 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -118.57 51.86 0.73 Allowed Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.343 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.689 ' C ' HE21 ' A' ' 49' ' ' GLN . 1.6 mp0 -67.96 88.35 0.27 Allowed 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.492 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.825 ' N ' HE21 ' A' ' 49' ' ' GLN . 1.2 mm-40 -76.99 85.75 3.51 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.473 HG22 ' CD2' ' A' ' 86' ' ' PHE . 7.3 p -74.64 144.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.839 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.486 HG22 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -143.38 -61.02 0.41 Allowed 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 119.033 -1.067 . . . . 0.0 111.932 -179.838 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.486 ' H ' HG22 ' A' ' 51' ' ' THR . 1.1 mt-30 -75.54 135.26 40.6 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.569 -1.252 . . . . 0.0 110.073 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -147.89 156.11 42.33 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 118.785 -1.166 . . . . 0.0 112.146 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 34.2 t-105 -151.91 142.16 22.38 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.6 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 t 62.31 27.43 16.39 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.583 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.58 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -171.36 125.34 0.62 Allowed 'General case' 0 C--N 1.303 -1.428 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.317 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -87.28 73.59 9.65 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.035 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 33.0 m -69.01 153.86 8.66 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 115.044 -0.98 . . . . 0.0 112.484 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 44.2 p -155.42 112.4 3.26 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.658 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.475 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 6.8 pt20 -91.02 113.42 25.68 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 4.7 p -87.68 86.07 7.14 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.774 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 73.71 -71.59 1.34 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -139.28 -15.98 1.08 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.029 -0.668 . . . . 0.0 109.716 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -87.9 -176.46 5.49 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.048 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.611 ' CG1' ' N ' ' A' ' 66' ' ' THR . 44.8 t -145.54 161.06 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 C-N-CA 118.596 -1.242 . . . . 0.0 113.888 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.611 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 44.9 m -157.52 143.79 17.76 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 113.627 -1.624 . . . . 0.0 108.284 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.4 ' CG1' ' HB3' ' A' ' 56' ' ' SER . 2.2 t -139.66 117.47 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.617 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -99.03 91.87 5.22 Favored 'General case' 0 C--N 1.288 -2.092 0 CA-C-N 114.291 -1.322 . . . . 0.0 108.132 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.644 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.8 p-10 -72.47 121.56 19.8 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.195 -1.002 . . . . 0.0 112.215 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.701 ' CB ' HD22 ' A' ' 73' ' ' ASN . . . -40.88 162.07 0.11 Allowed Pre-proline 0 N--CA 1.488 1.475 0 CA-C-N 113.563 -1.653 . . . . 0.0 112.47 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.86 -36.36 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 121.869 1.713 . . . . 0.0 111.939 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.575 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.67 -56.3 7.63 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 118.962 -1.095 . . . . 0.0 110.494 -179.895 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.701 HD22 ' CB ' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -74.33 2.73 8.64 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 118.818 -1.153 . . . . 0.0 109.492 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.508 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -122.43 37.12 2.94 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -104.71 56.53 0.7 Allowed 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.207 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.53 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -106.86 130.62 22.61 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.741 -0.783 . . . . 0.0 111.195 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 78' ' ' ALA . 8.7 Cg_endo -72.32 154.19 56.2 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 121.606 1.537 . . . . 0.0 113.381 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.518 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -21.84 -49.14 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.67 70.71 0.21 Allowed Glycine 0 N--CA 1.493 2.447 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -153.5 -165.56 13.71 Favored Glycine 0 C--N 1.285 -2.293 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.069 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.53 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.8 OUTLIER -140.9 164.05 31.29 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 119.271 -0.972 . . . . 0.0 112.528 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -132.78 -177.35 4.45 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 114.352 -1.294 . . . . 0.0 107.646 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.48 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.8 OUTLIER -167.6 143.5 4.06 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 116.875 -1.93 . . . . 0.0 113.54 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.58 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 8.7 p90 -159.22 176.12 12.59 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.664 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.69 170.28 41.12 Favored Glycine 0 N--CA 1.5 2.931 0 C-N-CA 117.897 -2.097 . . . . 0.0 112.137 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.547 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 5.6 p90 -159.32 168.88 25.28 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.703 -0.799 . . . . 0.0 111.022 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.531 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -121.93 114.21 20.68 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.896 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.443 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -126.07 150.29 17.57 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.3 p -83.39 136.02 34.48 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.852 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.66 ' NE2' ' CG ' ' A' ' 16' ' ' GLN . 10.2 p80 -114.52 -158.53 0.67 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.76 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -153.69 -2.88 0.2 Allowed 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.789 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.78 67.74 0.86 Allowed Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.742 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.581 ' CG2' ' H ' ' A' ' 94' ' ' ASN . 10.9 m -162.07 -167.38 1.63 Allowed 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.301 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.581 ' H ' ' CG2' ' A' ' 93' ' ' THR . 0.0 OUTLIER -61.08 129.16 39.98 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.129 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.54 -55.12 2.51 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.959 -0.696 . . . . 0.0 112.335 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.419 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . -101.94 120.72 53.1 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 119.633 -0.827 . . . . 0.0 112.131 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.476 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -66.58 -144.32 0.02 OUTLIER 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 121.454 1.436 . . . . 0.0 111.401 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.427 ' H ' ' HG1' ' A' ' 98' ' ' THR . 0.8 OUTLIER -108.45 -101.48 0.37 Allowed 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.002 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.6 106.08 18.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 118.807 -1.157 . . . . 0.0 112.402 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.567 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.3 m-30 -74.99 -148.19 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.397 -0.921 . . . . 0.0 108.714 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.469 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -159.84 114.85 2.36 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 117.145 -1.822 . . . . 0.0 113.457 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.602 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.1 mt -58.47 -175.84 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.06 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.468 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 2.0 p30 -64.89 76.49 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.071 -1.052 . . . . 0.0 111.764 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.49 11.46 33.26 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.57 -1.3 . . . . 0.0 112.374 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.602 ' O ' ' N ' ' A' ' 102' ' ' LEU . 6.5 p -151.92 145.81 18.05 Favored Pre-proline 0 N--CA 1.493 1.709 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.091 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -65.04 170.78 9.87 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.342 1.361 . . . . 0.0 111.713 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.64 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 3.1 t -163.79 106.53 0.96 Allowed 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.491 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.5 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 7.5 p -70.49 130.62 42.37 Favored 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.427 ' CG1' ' CZ ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -53.96 175.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.525 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.496 2.649 0 CA-C-O 116.368 -2.351 . . . . 0.0 110.274 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.437 ' H1 ' ' H ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 120.92 0.39 . . . . 0.0 110.035 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.437 ' H ' ' H1 ' ' A' ' 1' ' ' ALA . 36.0 p -69.11 148.54 49.84 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.881 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m 59.19 45.0 14.94 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.035 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -87.01 174.67 45.98 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 119.302 -1.428 . . . . 0.0 110.046 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -66.6 159.04 52.75 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 121.898 1.732 . . . . 0.0 111.18 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.633 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -111.51 -123.94 0.28 Allowed 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.152 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.43 28.34 0.36 Allowed Glycine 0 N--CA 1.5 2.911 0 N-CA-C 106.939 -2.465 . . . . 0.0 106.939 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -52.83 -174.05 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 113.49 -1.355 . . . . 0.0 113.213 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -137.22 108.16 6.7 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.768 -1.56 . . . . 0.0 109.654 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.472 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 4.9 m -100.67 122.73 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.384 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.468 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -95.2 159.62 14.93 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.389 -0.924 . . . . 0.0 109.653 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.484 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 1.8 t-105 -121.22 139.76 52.94 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.748 -0.781 . . . . 0.0 112.013 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 73.38 0.4 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 107.279 -2.328 . . . . 0.0 107.279 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -72.84 152.27 7.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.445 ' CB ' HG21 ' A' ' 22' ' ' THR . 1.0 OUTLIER -158.88 94.46 1.23 Allowed 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 113.969 -1.469 . . . . 0.0 108.675 179.756 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.559 ' H ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -94.38 157.88 15.82 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-O 121.937 0.875 . . . . 0.0 112.675 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.454 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -124.61 -106.0 0.35 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 113.674 -1.603 . . . . 0.0 109.323 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -66.53 -30.88 71.3 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.121 -1.031 . . . . 0.0 109.688 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.664 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 1.4 t -174.55 -49.48 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.203 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.664 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -58.04 166.27 6.54 Favored Glycine 0 CA--C 1.49 -1.51 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.527 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 2.7 p90 -137.77 121.28 17.22 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.533 -0.867 . . . . 0.0 112.256 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.445 HG21 ' CB ' ' A' ' 15' ' ' ASN . 8.2 t -73.48 172.86 10.52 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HB3' ' HE1' ' A' ' 12' ' ' TRP . . . -159.32 110.23 2.02 Favored 'General case' 0 C--N 1.289 -2.027 0 C-N-CA 117.289 -1.764 . . . . 0.0 112.919 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -93.02 103.92 16.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.455 HG11 ' N ' ' A' ' 26' ' ' THR . 24.6 t -99.64 140.43 18.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 119.451 -0.9 . . . . 0.0 113.124 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.46 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 3.5 m -131.14 113.11 13.49 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.783 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.8 t -84.7 143.04 12.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.618 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -124.9 99.92 6.36 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.933 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.629 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 0.1 OUTLIER -91.54 106.22 18.32 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.191 -1.004 . . . . 0.0 108.372 179.828 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 t -119.17 -1.11 10.92 Favored 'General case' 0 C--N 1.311 -1.107 0 O-C-N 124.174 0.921 . . . . 0.0 110.142 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.629 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -50.34 -81.85 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.399 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.597 ' HG ' ' C ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.69 37.49 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.305 -179.886 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.605 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -137.5 146.65 54.39 Favored Pre-proline 0 N--CA 1.485 1.301 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.187 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -70.22 107.4 1.94 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 121.212 1.275 . . . . 0.0 109.882 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -86.63 110.49 20.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.487 -1.285 . . . . 0.0 111.981 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -120.1 65.45 0.82 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.64 146.22 20.56 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 106.885 -2.486 . . . . 0.0 106.885 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 47.9 p-90 -163.51 175.54 10.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 117.419 -1.712 . . . . 0.0 112.095 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -141.06 112.39 7.4 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.777 179.92 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.603 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.44 175.35 5.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.395 179.896 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.47 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -159.35 152.48 22.18 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 117.919 -1.512 . . . . 0.0 112.289 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.533 ' CD2' ' N ' ' A' ' 43' ' ' SER . 23.6 p90 -175.1 -150.91 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.931 -1.486 . . . . 0.0 108.432 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.533 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 14.7 m -158.66 154.39 26.37 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.881 -1.528 . . . . 0.0 111.835 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.517 ' CD2' ' O ' ' A' ' 48' ' ' GLN . 8.2 m-85 -87.71 116.96 67.82 Favored Pre-proline 0 C--N 1.309 -1.153 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.901 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -56.99 -74.87 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 121.292 1.328 . . . . 0.0 112.619 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.638 ' OG ' ' N ' ' A' ' 93' ' ' THR . 0.9 OUTLIER -69.26 -136.11 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.636 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -107.6 63.92 0.27 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.857 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.517 ' O ' ' CD2' ' A' ' 44' ' ' PHE . 21.5 mt-30 -110.97 112.14 23.75 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.802 -0.759 . . . . 0.0 110.667 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.522 HE21 ' C ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -121.34 118.62 29.93 Favored 'General case' 0 N--CA 1.499 2.007 0 C-N-CA 119.764 -0.774 . . . . 0.0 111.212 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.441 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.0 p -72.79 156.0 6.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.383 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.508 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 80.4 p -132.45 -69.67 0.58 Allowed 'General case' 0 N--CA 1.492 1.669 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.777 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.508 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.8 OUTLIER -88.02 141.88 28.23 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.292 -0.963 . . . . 0.0 109.801 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.429 ' CB ' HG23 ' A' ' 58' ' ' VAL . . . -151.99 166.99 29.84 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.859 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.638 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 42.5 t-105 -154.45 157.15 38.01 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.003 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.638 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 51.75 26.79 3.68 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.771 -179.839 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.4 m -172.98 127.58 0.47 Allowed 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.695 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.4 m -90.15 77.19 6.8 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.795 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.429 HG23 ' CB ' ' A' ' 53' ' ' ALA . 1.3 m -69.69 151.81 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-N 115.365 -0.834 . . . . 0.0 112.306 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -152.17 104.2 2.94 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.462 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -82.69 120.8 26.04 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 10.4 p -94.13 75.76 4.05 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.589 -0.844 . . . . 0.0 110.718 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.65 -65.59 2.82 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.041 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.41 -16.01 0.94 Allowed 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.294 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.473 ' HB3' ' HG ' ' A' ' 43' ' ' SER . . . -91.61 -171.15 2.81 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 119.268 -0.973 . . . . 0.0 110.215 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.49 HG23 ' CE2' ' A' ' 44' ' ' PHE . 72.7 t -147.3 154.55 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 118.744 -1.182 . . . . 0.0 113.262 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 17.1 m -155.75 119.82 4.53 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 114.396 -1.275 . . . . 0.0 108.441 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.418 ' CG2' HD23 ' A' ' 40' ' ' LEU . 1.9 t -114.32 149.38 16.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.938 0 C-N-CA 119.614 -0.835 . . . . 0.0 111.847 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -132.33 93.0 3.18 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.632 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 3.1 p-10 -72.88 122.16 21.18 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.055 -1.058 . . . . 0.0 112.329 -179.582 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.64 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -41.95 161.45 0.15 Allowed Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 113.549 -1.659 . . . . 0.0 112.05 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -65.54 -37.67 28.58 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 121.95 1.767 . . . . 0.0 112.273 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.544 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.46 -55.93 8.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.579 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.64 HD22 ' N ' ' A' ' 70' ' ' ALA . 1.8 p30 -74.69 11.83 0.95 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.738 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.526 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -133.44 22.95 3.88 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.747 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.8 m -93.93 57.08 2.39 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.331 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.491 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -110.52 128.72 24.88 Favored Pre-proline 0 N--CA 1.489 1.495 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.68 179.971 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.599 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.4 Cg_endo -69.8 154.52 67.47 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 121.448 1.432 . . . . 0.0 111.012 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.605 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -42.49 -12.53 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.745 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.08 55.82 0.5 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.98 -165.65 24.74 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 118.511 -1.804 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.491 ' N ' HG13 ' A' ' 76' ' ' ILE . 5.9 p -137.93 163.17 32.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.183 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -121.56 -176.95 3.42 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -169.91 144.71 2.81 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 116.906 -1.917 . . . . 0.0 113.246 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.579 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 4.4 p90 -159.31 169.11 24.75 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.045 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -155.99 163.58 31.9 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 118.052 -2.023 . . . . 0.0 112.023 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 5.5 p90 -161.16 161.52 31.04 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.242 -0.983 . . . . 0.0 112.287 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 25.8 m-20 -112.79 111.79 22.83 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.271 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.25 164.3 12.16 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.948 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 p -113.17 143.72 43.9 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.718 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.1 OUTLIER -154.32 174.63 14.57 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 117.235 -1.786 . . . . 0.0 113.31 -179.901 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.718 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.4 t -170.88 8.55 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.446 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.43 -99.94 1.4 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.814 -1.184 . . . . 0.0 111.24 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.735 ' CG2' ' H ' ' A' ' 94' ' ' ASN . 15.9 m -164.38 -113.06 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.986 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.735 ' H ' ' CG2' ' A' ' 93' ' ' THR . 60.0 m-20 -30.29 131.52 0.08 Allowed 'General case' 0 N--CA 1.5 2.053 0 CA-C-N 115.316 -0.857 . . . . 0.0 112.449 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.73 -121.33 0.28 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.013 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.484 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -53.08 120.15 18.96 Favored Pre-proline 0 N--CA 1.489 1.496 0 C-N-CA 119.742 -0.783 . . . . 0.0 111.187 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.414 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.2 Cg_endo -63.13 -121.82 0.0 OUTLIER 'Trans proline' 0 CA--C 1.557 1.658 0 C-N-CA 121.125 1.216 . . . . 0.0 111.935 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.414 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 27.4 p -136.4 -77.43 0.42 Allowed 'General case' 0 N--CA 1.505 2.278 0 C-N-CA 119.246 -0.982 . . . . 0.0 112.608 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -98.72 97.9 9.09 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.842 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 107' ' ' CYS . 45.2 m-85 -66.73 -170.12 0.1 Allowed 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.9 m -146.78 113.99 6.24 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 117.457 -1.697 . . . . 0.0 113.897 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -60.59 -178.19 0.09 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.629 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 102' ' ' LEU . 26.0 m-80 -30.38 -39.85 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -159.98 39.18 0.46 Allowed Glycine 0 N--CA 1.498 2.776 0 C-N-CA 118.583 -1.77 . . . . 0.0 111.598 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.633 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 9.7 m -162.23 137.61 5.5 Favored Pre-proline 0 N--CA 1.49 1.531 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -50.8 177.57 0.03 OUTLIER 'Trans proline' 0 C--O 1.211 -0.858 0 C-N-CA 121.473 1.448 . . . . 0.0 112.361 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.475 ' N ' ' O ' ' A' ' 100' ' ' PHE . 22.0 t -166.35 98.45 0.6 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.411 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 p -46.68 154.82 0.28 Allowed 'General case' 0 N--CA 1.502 2.129 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.678 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.741 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 2.8 p -68.92 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 118.787 -1.165 . . . . 0.0 109.4 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.741 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.137 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.435 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.112 0 CA-C-O 120.787 0.327 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.58 -168.02 1.87 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.787 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.71 13.61 0.14 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.641 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 175.91 36.45 Favored Glycine 0 N--CA 1.49 2.234 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.326 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -55.38 -66.84 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.427 2.084 . . . . 0.0 112.757 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.63 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . -106.2 -166.71 1.22 Allowed 'General case' 0 N--CA 1.492 1.668 0 C-N-CA 119.598 -0.841 . . . . 0.0 112.431 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.23 51.25 0.04 OUTLIER Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -51.56 177.84 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.027 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -133.01 99.84 4.7 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.332 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.587 ' CG1' ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -91.87 135.01 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 118.967 -1.093 . . . . 0.0 111.875 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.48 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -112.93 164.83 12.95 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.915 179.824 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.556 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.8 t-105 -125.32 143.95 50.72 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.653 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.83 75.8 0.42 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 15' ' ' ASN . 10.0 p -79.2 158.96 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.487 ' N ' ' CG2' ' A' ' 14' ' ' VAL . 3.6 t30 -152.65 105.14 2.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 113.238 -1.801 . . . . 0.0 107.129 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.753 ' NE2' ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -113.48 141.86 46.61 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -179.504 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.573 ' O ' ' CD1' ' A' ' 17' ' ' TRP . 34.8 p90 -122.75 95.69 4.73 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 113.175 -1.83 . . . . 0.0 106.49 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.519 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 1.6 t30 79.49 -38.21 0.19 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.781 ' HG1' ' H ' ' A' ' 90' ' ' HIS . 10.5 t -176.94 -64.0 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.897 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.715 ' H ' ' CG2' ' A' ' 19' ' ' THR . . . -33.39 97.0 0.01 OUTLIER Glycine 0 N--CA 1.51 3.569 0 N-CA-C 109.058 -1.617 . . . . 0.0 109.058 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.612 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 14.6 p90 -101.51 109.73 21.6 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.421 HG21 ' CB ' ' A' ' 15' ' ' ASN . 14.0 t -72.4 173.95 8.05 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.406 ' HB2' ' CE2' ' A' ' 12' ' ' TRP . . . -155.37 120.42 4.85 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 117.251 -1.779 . . . . 0.0 112.908 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -104.0 98.87 8.63 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.561 -1.2 . . . . 0.0 107.904 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.441 HG11 ' N ' ' A' ' 26' ' ' THR . 23.2 t -96.95 140.8 16.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.306 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.48 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 98.7 m -126.39 108.15 10.95 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.278 -0.874 . . . . 0.0 108.809 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.1 t -83.44 101.1 7.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 C-N-CA 119.727 -0.789 . . . . 0.0 111.959 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 11.5 tttp -87.82 109.51 19.8 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.512 -1.275 . . . . 0.0 109.992 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -95.56 112.38 24.11 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.504 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -111.68 -7.69 14.24 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.617 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.9 p -72.64 98.84 2.43 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-N 113.779 -1.555 . . . . 0.0 111.314 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.417 ' HA ' ' CB ' ' A' ' 78' ' ' ALA . 69.4 p -27.37 76.43 0.0 OUTLIER 'General case' 0 N--CA 1.512 2.646 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.797 ' H ' ' CB ' ' A' ' 78' ' ' ALA . . . -157.57 137.15 8.45 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.596 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -72.1 100.04 1.06 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.971 1.114 . . . . 0.0 109.463 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -85.03 106.87 15.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.461 -1.296 . . . . 0.0 111.836 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -124.21 80.07 1.8 Allowed 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.55 135.78 3.22 Favored Glycine 0 C--N 1.292 -1.902 0 N-CA-C 106.625 -2.59 . . . . 0.0 106.625 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 43.7 p-90 -159.43 176.68 11.82 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 117.327 -1.749 . . . . 0.0 112.303 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -138.04 113.19 9.26 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.047 179.781 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.591 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.05 172.13 6.99 Favored 'General case' 0 N--CA 1.5 2.026 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.839 -179.968 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.651 ' HG1' ' HG1' ' A' ' 66' ' ' THR . 1.2 m -156.29 146.7 21.59 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 118.017 -1.473 . . . . 0.0 112.605 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.63 ' CD2' ' N ' ' A' ' 43' ' ' SER . 11.7 p90 -172.29 -151.21 0.06 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 114.429 -1.259 . . . . 0.0 108.504 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.63 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.7 m -159.42 158.89 32.96 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.616 -1.633 . . . . 0.0 112.351 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.477 ' CE2' HG23 ' A' ' 65' ' ' VAL . 8.8 m-85 -86.28 121.13 72.62 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.88 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -58.75 -67.87 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.084 1.19 . . . . 0.0 112.225 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.483 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 29.8 t -69.54 -112.84 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 118.946 -1.102 . . . . 0.0 111.054 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.483 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -141.98 37.68 1.56 Allowed Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.685 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.459 ' HB3' ' CE1' ' A' ' 21' ' ' PHE . 6.7 mt-30 -75.46 115.59 15.28 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.828 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.483 ' HA ' HE22 ' A' ' 60' ' ' GLN . 0.0 OUTLIER -106.38 119.04 38.23 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.353 -0.939 . . . . 0.0 111.673 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.464 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.2 p -74.38 157.92 6.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.94 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 20.4 p -132.74 -63.89 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.615 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -88.59 170.51 10.79 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -166.03 151.72 8.85 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 118.521 -1.271 . . . . 0.0 112.194 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.671 ' C ' ' HG ' ' A' ' 55' ' ' SER . 36.3 t-105 -149.26 150.77 33.1 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.458 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.671 ' HG ' ' C ' ' A' ' 54' ' ' TRP . 1.4 p 46.77 32.11 1.65 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.617 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -173.64 118.08 0.27 Allowed 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.81 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 m -83.33 72.49 10.2 Favored 'General case' 0 C--N 1.279 -2.473 0 C-N-CA 119.161 -1.016 . . . . 0.0 109.377 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -70.91 166.57 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.832 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.443 ' O ' ' CG2' ' A' ' 59' ' ' THR . 6.1 t -164.68 130.54 2.83 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.557 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.483 HE22 ' HA ' ' A' ' 49' ' ' GLN . 5.0 tt0 -94.67 116.05 28.29 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.2 p -93.92 75.53 4.18 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.304 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.37 -67.38 2.82 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.351 -1.404 . . . . 0.0 109.69 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -143.7 -16.51 0.62 Allowed 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.979 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.43 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -89.9 -170.81 2.93 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.076 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.501 ' CG1' ' N ' ' A' ' 66' ' ' THR . 65.2 t -148.39 156.6 8.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 118.826 -1.15 . . . . 0.0 113.038 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.651 ' HG1' ' HG1' ' A' ' 41' ' ' THR . 2.1 m -154.71 141.2 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.312 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 39' ' ' THR . 2.4 t -134.84 153.51 34.92 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.078 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.426 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -133.39 90.84 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.6 p-10 -72.54 121.07 19.06 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.298 -179.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.794 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -42.68 163.61 0.14 Allowed Pre-proline 0 C--N 1.303 -1.45 0 CA-C-N 113.291 -1.777 . . . . 0.0 111.807 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -66.46 -35.88 28.81 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.901 1.734 . . . . 0.0 112.315 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.553 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.39 -54.28 15.2 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.749 -179.891 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.794 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.25 14.17 1.28 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 118.958 -1.097 . . . . 0.0 109.862 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.52 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -129.4 18.98 5.43 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.49 77.4 5.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.197 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.539 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -136.64 125.29 15.18 Favored Pre-proline 0 C--O 1.209 -1.063 0 C-N-CA 119.782 -0.767 . . . . 0.0 111.643 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.612 ' C ' ' H ' ' A' ' 79' ' ' GLY . 5.8 Cg_endo -71.63 162.86 40.84 Favored 'Trans proline' 0 C--O 1.213 -0.754 0 C-N-CA 120.91 1.073 . . . . 0.0 110.236 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.797 ' CB ' ' H ' ' A' ' 33' ' ' ALA . . . -46.98 -3.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.871 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.612 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -120.13 56.77 0.59 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.81 -159.99 15.77 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 117.905 -2.093 . . . . 0.0 111.12 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.539 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.2 p -139.85 155.06 47.43 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.939 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -130.1 100.65 5.5 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.45 ' HG2' ' CG2' ' A' ' 26' ' ' THR . 21.6 mt-30 -91.13 161.21 15.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 114.709 1.374 . . . . 0.0 114.709 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.414 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 2.1 p90 -166.0 165.17 18.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 113.286 -1.779 . . . . 0.0 109.224 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.98 170.83 37.75 Favored Glycine 0 N--CA 1.504 3.17 0 C-N-CA 117.547 -2.264 . . . . 0.0 112.611 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.556 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.2 p90 -156.62 -167.86 2.52 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.345 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.404 ' OD1' ' N ' ' A' ' 87' ' ' ASN . 1.2 m120 -140.53 112.21 7.48 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.821 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -120.14 158.21 15.45 Favored Glycine 0 N--CA 1.505 3.279 0 C-N-CA 119.784 -1.198 . . . . 0.0 111.426 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.2 p -112.94 151.15 30.88 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.154 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.862 ' HD1' ' N ' ' A' ' 91' ' ' THR . 4.2 p80 -154.45 -144.29 0.14 Allowed 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.779 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.862 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 17.0 p -144.86 -2.38 0.83 Allowed 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.641 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 100.25 93.76 2.12 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.706 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.487 ' CG2' ' H ' ' A' ' 94' ' ' ASN . 3.2 m -162.74 -145.8 0.1 Allowed 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.164 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.487 ' H ' ' CG2' ' A' ' 93' ' ' THR . 63.4 t-20 -78.7 125.64 29.64 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.98 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.487 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.38 -163.82 0.88 Allowed 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.776 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.556 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -13.78 121.03 0.04 OUTLIER Pre-proline 0 N--CA 1.507 2.418 0 CA-C-N 114.781 -1.1 . . . . 0.0 113.425 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -64.57 -144.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 121.319 1.346 . . . . 0.0 110.965 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.644 ' HG1' ' N ' ' A' ' 99' ' ' ALA . 10.5 p -116.78 -63.51 1.44 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.495 -0.882 . . . . 0.0 112.376 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.644 ' N ' ' HG1' ' A' ' 98' ' ' THR . . . -107.87 111.09 23.04 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.764 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.4 m-85 -81.16 -163.72 0.65 Allowed 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.618 -0.833 . . . . 0.0 109.545 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -145.44 103.04 3.78 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -52.29 173.92 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.501 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 39' ' ' THR . 8.2 p30 -41.87 -20.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.484 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.83 45.0 0.22 Allowed Glycine 0 N--CA 1.487 2.039 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.171 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.63 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -175.01 149.07 1.16 Allowed Pre-proline 0 N--CA 1.494 1.734 0 C-N-CA 119.164 -1.014 . . . . 0.0 111.049 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -63.04 170.35 7.69 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 121.372 1.381 . . . . 0.0 111.956 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.587 ' SG ' ' CG1' ' A' ' 10' ' ' VAL . 6.5 t -161.88 90.95 0.79 Allowed 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.538 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 m -51.99 165.18 0.22 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.69 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 10' ' ' VAL . 0.1 OUTLIER -65.05 -156.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 119.176 -1.01 . . . . 0.0 109.588 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 CA-C-O 116.319 -2.378 . . . . 0.0 110.371 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.468 ' OG ' ' N ' ' A' ' 3' ' ' SER . 9.8 p 47.11 -149.9 0.12 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.827 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.468 ' N ' ' OG ' ' A' ' 2' ' ' SER . 64.9 m -145.98 -172.0 3.83 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.752 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.403 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . 51.73 68.66 1.43 Allowed Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.17 -1.49 . . . . 0.0 110.222 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.403 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 2.9 Cg_endo -63.03 -147.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 121.892 1.728 . . . . 0.0 111.399 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -92.33 -163.97 1.12 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.647 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.18 59.91 0.04 OUTLIER Glycine 0 N--CA 1.49 2.237 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.674 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -56.32 -161.88 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.278 1.037 . . . . 0.0 112.54 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.674 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 37.0 mt-30 -150.97 89.02 1.5 Allowed 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 113.553 -1.658 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.467 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.9 m -90.32 128.71 42.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 118.972 -1.091 . . . . 0.0 111.83 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.454 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -102.27 171.27 7.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.149 179.831 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.477 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.5 t-105 -130.39 147.59 52.11 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.768 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.407 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.67 76.4 0.41 Allowed Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.026 -2.03 . . . . 0.0 108.026 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -72.51 142.9 14.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.452 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 8.4 t-20 -140.53 95.97 2.95 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.578 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -98.46 117.0 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.648 -0.821 . . . . 0.0 112.882 -179.757 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.62 ' C ' ' H ' ' A' ' 19' ' ' THR . 42.0 p90 -98.37 -142.54 0.31 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.844 -1.142 . . . . 0.0 108.177 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.642 ' ND2' ' H ' ' A' ' 18' ' ' ASN . 0.3 OUTLIER -47.82 -16.79 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.083 -1.447 . . . . 0.0 108.2 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.647 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.3 OUTLIER 170.42 -179.88 0.05 OUTLIER 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.126 -1.852 . . . . 0.0 107.054 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.647 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 69.4 111.44 0.03 OUTLIER Glycine 0 C--N 1.274 -2.905 0 C-N-CA 117.901 -2.095 . . . . 0.0 109.634 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.62 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 14.4 p90 -102.86 115.63 30.97 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.555 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.462 HG22 ' N ' ' A' ' 23' ' ' ALA . 1.0 OUTLIER -71.08 176.56 4.33 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 118.074 -1.451 . . . . 0.0 107.74 179.791 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.509 ' CB ' ' CZ ' ' A' ' 86' ' ' PHE . . . -148.76 103.08 3.35 Favored 'General case' 0 C--N 1.291 -1.937 0 C-N-CA 118.469 -1.293 . . . . 0.0 111.616 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -94.1 94.35 8.34 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.431 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 15.6 t -97.16 137.38 25.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.664 -0.815 . . . . 0.0 113.003 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.454 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 1.5 m -128.36 114.45 16.88 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.864 -1.062 . . . . 0.0 108.406 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -86.94 128.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 C-N-CA 119.81 -0.756 . . . . 0.0 112.783 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 1.4 tptt -114.23 100.93 8.73 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.426 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.573 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -89.87 117.46 28.71 Favored 'General case' 0 C--N 1.282 -2.353 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.452 179.742 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.62 -2.09 8.43 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 124.185 0.928 . . . . 0.0 109.754 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.573 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -49.87 -83.89 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.588 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.512 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 159.51 72.32 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 123.666 0.604 . . . . 0.0 111.504 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.582 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.52 149.9 3.17 Favored Pre-proline 0 C--N 1.304 -1.392 0 C-N-CA 119.148 -1.021 . . . . 0.0 111.016 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -70.45 102.45 1.14 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 121.012 1.142 . . . . 0.0 109.243 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.37 106.56 16.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.48 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -116.94 72.43 0.83 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.11 144.43 13.78 Favored Glycine 0 N--CA 1.484 1.853 0 N-CA-C 107.372 -2.291 . . . . 0.0 107.372 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.602 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 36.9 p-90 -161.05 176.9 10.85 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 117.592 -1.643 . . . . 0.0 112.014 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.853 ' H ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.59 103.32 4.66 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.957 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.613 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -91.56 174.2 7.49 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.258 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.471 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 97.8 m -156.59 146.31 20.87 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.278 -1.369 . . . . 0.0 112.143 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.595 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.1 p90 -172.5 -150.95 0.06 Allowed 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 114.589 -1.187 . . . . 0.0 108.999 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.595 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 20.1 m -156.2 153.42 29.19 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 117.807 -1.557 . . . . 0.0 112.09 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.501 ' CE2' HG23 ' A' ' 65' ' ' VAL . 4.1 m-85 -81.03 119.37 75.8 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 118.526 -1.27 . . . . 0.0 109.578 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.445 ' HB2' HD21 ' A' ' 94' ' ' ASN . 5.6 Cg_exo -55.74 -71.71 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.443 1.429 . . . . 0.0 112.319 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.1 t -69.37 -113.91 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.715 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.02 48.02 0.75 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.436 -1.364 . . . . 0.0 110.334 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.674 ' C ' HE21 ' A' ' 49' ' ' GLN . 20.7 mp0 -71.56 112.86 8.02 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.416 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.674 HE21 ' C ' ' A' ' 48' ' ' GLN . 3.0 mm-40 -93.56 94.94 8.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.0 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.471 HG22 ' CD2' ' A' ' 86' ' ' PHE . 9.1 p -72.66 151.92 7.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.697 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 43.1 p -143.0 -63.27 0.41 Allowed 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.551 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.98 160.09 30.2 Favored 'General case' 0 C--N 1.301 -1.537 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.164 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -164.22 156.63 17.01 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 118.551 -1.26 . . . . 0.0 112.06 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 23.6 t-105 -155.52 137.04 14.13 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.847 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.477 ' C ' ' HG ' ' A' ' 56' ' ' SER . 0.5 OUTLIER 62.56 29.14 16.97 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.21 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.477 ' HG ' ' C ' ' A' ' 55' ' ' SER . 0.3 OUTLIER -170.43 122.39 0.64 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.613 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.3 m -84.54 69.39 10.58 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.948 -1.101 . . . . 0.0 108.845 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.407 ' H ' HG11 ' A' ' 58' ' ' VAL . 3.3 m -69.29 164.39 2.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 114.904 -1.044 . . . . 0.0 112.828 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 1.5 t -168.04 145.54 4.27 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.768 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -98.27 109.72 22.43 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.138 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.502 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 7.7 p -91.2 72.91 6.26 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.67 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.495 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 56.38 75.89 0.23 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.2 -1.476 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 74.94 -28.79 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.149 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.502 ' CB ' ' HG ' ' A' ' 61' ' ' SER . . . -88.49 -171.65 3.43 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 118.728 -1.189 . . . . 0.0 110.663 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.593 ' CG1' ' N ' ' A' ' 66' ' ' THR . 55.9 t -148.65 162.34 5.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.471 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.593 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 6.2 m -157.0 147.63 21.49 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 114.083 -1.417 . . . . 0.0 108.131 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.1 t -142.95 116.08 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 118.491 -1.284 . . . . 0.0 112.865 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -97.55 89.71 4.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.602 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.3 p-10 -70.27 120.43 15.94 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.075 -1.05 . . . . 0.0 112.063 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.571 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -38.27 158.33 0.09 OUTLIER Pre-proline 0 N--CA 1.486 1.36 0 CA-C-N 113.745 -1.571 . . . . 0.0 112.611 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -68.03 -35.49 20.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.897 1.731 . . . . 0.0 112.385 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.571 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -69.86 -56.53 6.84 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.862 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.602 HD21 ' N ' ' A' ' 74' ' ' GLY . 0.4 OUTLIER -74.07 -1.85 21.87 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.823 -1.151 . . . . 0.0 109.696 -179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.602 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -113.17 20.42 19.18 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 8.8 m -90.03 59.73 4.62 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.262 -0.975 . . . . 0.0 111.272 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.512 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -108.05 122.96 39.09 Favored Pre-proline 0 CA--C 1.566 1.566 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.564 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 78' ' ' ALA . 5.8 Cg_endo -70.25 156.38 62.2 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 121.565 1.51 . . . . 0.0 113.766 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.582 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -23.47 -46.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.885 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.74 65.88 0.24 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.089 -1.204 . . . . 0.0 110.089 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -151.98 -170.31 18.48 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.837 -1.649 . . . . 0.0 110.139 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.512 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.9 p -139.49 158.3 44.36 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.199 -1.001 . . . . 0.0 112.527 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -125.59 -176.18 3.53 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.409 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 6.3 tt0 -168.12 148.1 4.82 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.019 -1.872 . . . . 0.0 112.92 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.431 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 3.3 p90 -165.22 168.08 17.41 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.068 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.48 171.95 40.11 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 117.694 -2.193 . . . . 0.0 112.223 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.1 p90 -155.06 -172.75 4.3 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -136.21 112.32 9.71 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.967 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -125.57 153.76 18.34 Favored Glycine 0 N--CA 1.51 3.596 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.024 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.429 ' HG ' ' HB2' ' A' ' 49' ' ' GLN . 77.7 p -78.78 156.52 28.77 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.912 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.593 ' NE2' ' N ' ' A' ' 20' ' ' GLY . 11.9 p80 -140.57 -161.54 1.22 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.556 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -159.03 -4.33 0.08 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.574 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 104.91 65.2 0.67 Allowed Glycine 0 N--CA 1.497 2.751 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.674 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.462 HG21 ' H ' ' A' ' 94' ' ' ASN . 4.0 m -162.67 170.75 17.94 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.922 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.462 ' H ' HG21 ' A' ' 93' ' ' THR . 0.0 OUTLIER -42.81 125.61 3.48 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.841 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -108.23 -50.97 2.96 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.141 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.477 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -110.06 125.63 30.69 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.897 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -62.61 -143.11 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 121.588 1.525 . . . . 0.0 111.771 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 19.3 p -127.25 -58.35 1.28 Allowed 'General case' 0 N--CA 1.5 2.036 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.766 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.524 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.25 91.58 3.71 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.443 -0.903 . . . . 0.0 111.996 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.439 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 32.3 m-85 -65.53 -166.81 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.1 m -146.43 107.68 4.22 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 117.552 -1.659 . . . . 0.0 113.884 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.9 mt -58.94 168.19 1.36 Allowed 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.853 HD22 ' H ' ' A' ' 39' ' ' THR . 0.3 OUTLIER -41.24 92.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.053 179.861 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.6 45.88 93.59 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 119.495 -1.336 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.59 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -167.13 146.41 4.5 Favored Pre-proline 0 C--O 1.196 -1.743 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.157 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -64.22 166.16 17.67 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.31 1.34 . . . . 0.0 112.241 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -163.68 94.96 0.79 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 17.0 p -65.2 170.26 4.79 Favored 'General case' 0 N--CA 1.511 2.595 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.453 ' CG1' ' HA ' ' A' ' 98' ' ' THR . 17.0 m -60.53 -155.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.562 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.405 ' H ' ' HB ' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.194 0 CA-C-O 116.322 -2.377 . . . . 0.0 110.378 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.91 0.386 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 171.13 2.42 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.57 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.3 p -151.51 157.93 42.94 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.601 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.547 ' N ' ' HD2' ' A' ' 5' ' ' PRO . . . 138.33 -55.65 0.67 Allowed Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.402 -1.38 . . . . 0.0 111.399 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 4' ' ' GLY . 9.2 Cg_exo -54.0 -77.31 0.02 OUTLIER 'Trans proline' 0 C--N 1.317 -1.104 0 C-N-CA 121.795 1.663 . . . . 0.0 112.735 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.756 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . -102.12 -171.84 2.04 Favored 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 119.633 -0.827 . . . . 0.0 113.064 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.99 43.3 0.06 OUTLIER Glycine 0 N--CA 1.497 2.703 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -52.41 -175.81 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 114.496 -0.852 . . . . 0.0 112.774 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.516 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 5.3 pt20 -142.25 126.48 17.53 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.907 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.457 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.3 m -115.1 128.41 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.163 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.465 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -97.12 171.93 8.15 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.313 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.542 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 2.7 t-105 -125.39 147.84 49.01 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.829 -0.748 . . . . 0.0 112.026 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.1 79.66 0.35 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 107.759 -2.137 . . . . 0.0 107.759 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.45 HG12 HE22 ' A' ' 16' ' ' GLN . 1.2 p -68.99 146.8 12.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 122.018 0.913 . . . . 0.0 113.112 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -154.85 89.7 1.25 Allowed 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.519 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.859 ' NE2' ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -116.1 150.84 36.71 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -179.602 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.526 ' O ' ' CD1' ' A' ' 17' ' ' TRP . 17.4 p90 -115.81 92.72 3.99 Favored 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 112.998 -1.91 . . . . 0.0 107.771 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.493 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 78.9 -30.63 0.15 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.095 -179.849 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.711 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.5 OUTLIER -175.84 -65.83 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 119.051 -1.06 . . . . 0.0 111.587 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.711 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -46.52 110.31 0.5 Allowed Glycine 0 C--O 1.201 -1.963 0 N-CA-C 108.382 -1.887 . . . . 0.0 108.382 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.647 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.6 p90 -103.9 137.26 42.14 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -179.465 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.67 114.32 28.26 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 179.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.542 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -91.53 115.83 28.36 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 119.19 -1.004 . . . . 0.0 113.52 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -98.53 96.85 8.26 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.47 HG11 ' N ' ' A' ' 26' ' ' THR . 33.5 t -92.64 144.54 9.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.47 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.5 m -131.27 103.43 6.46 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.771 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.2 t -74.12 151.57 7.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.731 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.516 ' NZ ' ' OE1' ' A' ' 9' ' ' GLN . 0.3 OUTLIER -148.16 111.29 4.88 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.643 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.513 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 2.1 t30 -96.85 129.73 44.24 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.962 -1.017 . . . . 0.0 108.397 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -132.06 -6.85 3.48 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 124.087 0.867 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.513 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 2.0 p -51.0 -80.87 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.732 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.0 37.16 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.194 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.556 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.598 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -136.45 147.78 61.33 Favored Pre-proline 0 N--CA 1.488 1.451 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.414 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -72.46 115.95 4.53 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 121.403 1.402 . . . . 0.0 110.406 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 t -98.34 95.83 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.236 -0.985 . . . . 0.0 112.109 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -105.76 63.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 99.99 154.14 27.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.626 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 39.9 p-90 -169.95 177.17 4.44 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.172 -1.811 . . . . 0.0 112.911 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.23 99.19 3.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.017 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.619 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -87.93 172.72 9.38 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 118.576 -1.25 . . . . 0.0 110.051 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.46 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -153.97 145.08 22.82 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 118.642 -1.223 . . . . 0.0 111.633 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.622 ' CD2' ' N ' ' A' ' 43' ' ' SER . 10.6 p90 -172.92 -156.36 0.09 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.407 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.622 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 56.5 m -158.55 157.52 32.2 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 117.53 -1.668 . . . . 0.0 112.075 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.473 ' CE2' HG23 ' A' ' 65' ' ' VAL . 10.9 m-85 -86.58 122.22 71.89 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 118.712 -1.195 . . . . 0.0 109.443 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HB2' ' ND2' ' A' ' 94' ' ' ASN . 4.9 Cg_exo -57.48 -62.1 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.244 1.296 . . . . 0.0 112.196 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.9 p -69.5 -58.81 3.5 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.793 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . 145.65 31.4 0.08 OUTLIER Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.418 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.647 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 49.6 mt-30 -43.69 131.93 5.14 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.394 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.585 HE21 ' CA ' ' A' ' 49' ' ' GLN . 0.1 OUTLIER -94.64 80.49 3.81 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.289 -0.964 . . . . 0.0 111.478 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.1 p -62.78 147.84 11.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.306 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.502 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 61.8 p -140.47 -71.18 0.37 Allowed 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.283 -0.967 . . . . 0.0 111.558 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.52 ' NE2' ' N ' ' A' ' 52' ' ' GLN . 0.0 OUTLIER -69.73 164.36 23.69 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.289 -179.951 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.2 5.51 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 118.645 -1.222 . . . . 0.0 112.056 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.425 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 30.8 t-105 -153.11 143.28 22.35 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.655 -0.818 . . . . 0.0 110.496 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 0.9 OUTLIER 57.71 30.24 18.59 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.663 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.423 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.4 OUTLIER -172.9 119.18 0.34 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.675 -179.884 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 m -82.81 74.37 9.78 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.975 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 10.3 m -69.41 156.83 6.93 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 CA-C-N 115.017 -0.992 . . . . 0.0 112.78 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 58.8 p -155.19 115.65 3.84 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.876 -1.056 . . . . 0.0 109.731 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.582 HE22 ' NE2' ' A' ' 49' ' ' GLN . 5.9 tt0 -89.86 113.44 25.04 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.18 -1.008 . . . . 0.0 110.532 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.6 p -92.19 80.44 5.04 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.923 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.44 -67.85 2.17 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.443 -1.36 . . . . 0.0 110.127 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.528 ' HG ' ' N ' ' A' ' 64' ' ' ALA . 10.3 p -141.94 -17.6 0.75 Allowed 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.223 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.543 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -88.93 -172.26 3.62 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.163 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.55 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.0 t -149.93 159.01 5.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 118.709 -1.197 . . . . 0.0 113.639 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.55 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 53.1 m -153.94 149.35 27.18 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.203 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.416 ' N ' HG21 ' A' ' 66' ' ' THR . 3.8 t -144.63 119.44 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 118.386 -1.326 . . . . 0.0 112.73 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.16 91.08 5.09 Favored 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.046 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.626 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.4 p-10 -71.23 120.95 17.54 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.879 -1.128 . . . . 0.0 111.625 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.547 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -43.14 167.39 0.08 OUTLIER Pre-proline 0 N--CA 1.487 1.377 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.452 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -70.34 -35.92 10.14 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.23 1.953 . . . . 0.0 112.373 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.549 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.47 -54.29 14.99 Favored 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.869 -179.834 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.526 ' ND2' ' O ' ' A' ' 55' ' ' SER . 4.8 p-10 -79.37 10.79 3.41 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.444 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.497 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -127.42 40.2 1.8 Allowed Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.186 -1.007 . . . . 0.0 110.673 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -109.93 62.82 0.6 Allowed 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.908 -0.717 . . . . 0.0 111.21 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.484 ' O ' ' CD1' ' A' ' 76' ' ' ILE . 0.0 OUTLIER -116.87 121.4 32.81 Favored Pre-proline 0 N--CA 1.483 1.187 0 C-N-CA 120.058 -0.657 . . . . 0.0 111.243 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.592 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.6 Cg_endo -67.38 156.35 66.55 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 C-N-CA 121.103 1.202 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.598 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -39.36 -18.75 0.01 OUTLIER 'General case' 0 C--O 1.205 -1.271 0 C-N-CA 119.895 -0.722 . . . . 0.0 112.676 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.592 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.24 62.52 0.43 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -163.67 -161.72 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 C-N-CA 118.979 -1.581 . . . . 0.0 110.635 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.467 ' N ' HG13 ' A' ' 76' ' ' ILE . 7.3 p -143.98 162.94 34.9 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.063 -1.055 . . . . 0.0 112.978 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -131.31 179.53 5.97 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.106 -1.407 . . . . 0.0 107.733 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.439 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 32.0 tt0 -164.03 144.55 8.36 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 117.226 -1.789 . . . . 0.0 113.187 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.439 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 3.2 p90 -157.7 170.28 22.74 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.779 -1.101 . . . . 0.0 109.857 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.79 164.8 37.18 Favored Glycine 0 N--CA 1.498 2.798 0 C-N-CA 117.704 -2.189 . . . . 0.0 112.557 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.639 ' C ' ' ND2' ' A' ' 87' ' ' ASN . 1.7 p90 -153.04 -177.77 6.5 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 114.889 -0.656 . . . . 0.0 110.608 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.826 ' N ' HD21 ' A' ' 87' ' ' ASN . 0.1 OUTLIER -138.39 111.4 7.83 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.693 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -109.96 169.38 13.58 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.288 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.5 p -110.29 135.83 50.43 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.861 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.8 OUTLIER -146.02 -169.85 3.34 Favored 'General case' 0 N--CA 1.502 2.171 0 C-N-CA 117.664 -1.614 . . . . 0.0 112.603 -179.919 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.861 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -135.55 2.74 2.98 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.285 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.465 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 99.43 106.87 2.75 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 119.677 -1.249 . . . . 0.0 110.482 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.465 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER -164.16 -84.63 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.43 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.542 ' N ' ' OD1' ' A' ' 94' ' ' ASN . 1.3 p-10 -173.87 124.99 0.36 Allowed 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.852 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.474 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.79 -134.91 0.35 Allowed 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.177 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.533 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -9.53 106.36 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.515 0 CA-C-N 114.537 -1.21 . . . . 0.0 113.567 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.496 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.5 Cg_endo -62.7 -101.11 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 120.962 1.108 . . . . 0.0 111.952 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.41 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 45.7 p -152.58 -69.2 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 118.829 -1.148 . . . . 0.0 111.946 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -106.54 94.98 5.43 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.56 -0.856 . . . . 0.0 111.255 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.496 ' CZ ' ' HD2' ' A' ' 97' ' ' PRO . 38.6 m-85 -65.03 -162.76 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.057 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -149.93 98.48 2.72 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 117.605 -1.638 . . . . 0.0 113.323 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.586 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.7 mt -52.17 171.59 0.05 OUTLIER 'General case' 0 C--O 1.21 -0.989 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.481 ' H ' HD21 ' A' ' 102' ' ' LEU . 2.7 p30 -55.54 82.41 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.755 -1.178 . . . . 0.0 110.783 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 87.51 41.85 6.34 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.756 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -174.44 130.36 0.47 Allowed Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.151 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.63 170.75 3.16 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 121.029 1.153 . . . . 0.0 111.22 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.4 ' SG ' HG12 ' A' ' 10' ' ' VAL . 8.2 t -166.73 101.95 0.57 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.179 -1.008 . . . . 0.0 111.117 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.47 169.48 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.844 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.712 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 9.8 p -80.25 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.876 -1.13 . . . . 0.0 109.876 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.712 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.402 0 CA-C-O 116.333 -2.371 . . . . 0.0 110.585 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.133 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.9 p -109.79 124.27 50.99 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.961 -0.695 . . . . 0.0 110.765 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.3 164.48 37.35 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.825 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.459 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . -146.24 64.83 0.44 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.38 -1.39 . . . . 0.0 110.476 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.459 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 3.2 Cg_exo -58.82 -77.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 121.989 1.792 . . . . 0.0 111.695 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.737 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . -110.15 -152.39 0.49 Allowed 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.355 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.15 43.94 0.06 OUTLIER Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.235 -1.946 . . . . 0.0 108.235 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.623 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 26.7 p -56.58 -168.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.87 -0.665 . . . . 0.0 110.955 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.486 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 1.8 pt20 -159.75 155.96 26.82 Favored 'General case' 0 C--N 1.287 -2.147 0 C-N-CA 118.754 -1.178 . . . . 0.0 110.407 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -141.35 138.88 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.002 -1.079 . . . . 0.0 111.67 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.457 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -100.44 171.61 7.64 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.157 179.95 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.461 ' NE1' ' HB3' ' A' ' 23' ' ' ALA . 1.3 t-105 -133.94 143.32 48.13 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.834 -0.746 . . . . 0.0 111.961 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.09 71.79 0.41 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.9 p -69.61 140.77 18.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.571 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 62.9 t30 -136.61 86.2 2.2 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.029 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.602 ' CG ' ' NE2' ' A' ' 90' ' ' HIS . 0.0 OUTLIER -88.53 130.18 35.29 Favored 'General case' 0 N--CA 1.498 1.927 0 N-CA-C 113.458 0.911 . . . . 0.0 113.458 -179.682 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.767 ' C ' ' H ' ' A' ' 19' ' ' THR . 21.6 p90 -121.78 82.55 1.96 Allowed 'General case' 0 N--CA 1.495 1.818 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.468 ' O ' ' CB ' ' A' ' 19' ' ' THR . 0.5 OUTLIER 67.39 -15.16 0.18 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.059 -1.056 . . . . 0.0 108.492 -179.587 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.767 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.8 OUTLIER 163.27 171.13 0.02 OUTLIER 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 113.424 -1.717 . . . . 0.0 107.015 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.613 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 68.18 101.75 0.03 OUTLIER Glycine 0 C--N 1.283 -2.366 0 C-N-CA 117.717 -2.183 . . . . 0.0 107.698 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.588 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 27.5 p90 -111.55 113.6 26.12 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.864 -0.734 . . . . 0.0 111.984 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -65.13 173.82 2.28 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.461 ' HB3' ' NE1' ' A' ' 12' ' ' TRP . . . -152.52 98.25 2.35 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 117.651 -1.62 . . . . 0.0 112.755 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -92.12 97.95 11.24 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.475 HG11 ' N ' ' A' ' 26' ' ' THR . 19.4 t -95.55 145.56 8.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 C-N-CA 119.681 -0.807 . . . . 0.0 112.583 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.475 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.5 m -134.71 101.75 5.04 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.439 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.9 t -71.06 153.81 8.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.698 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.407 ' HZ3' ' HB ' ' A' ' 30' ' ' THR . 4.3 tttp -148.63 115.35 5.99 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.936 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.53 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.2 t30 -102.21 119.6 39.07 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.407 ' HB ' ' HZ3' ' A' ' 28' ' ' LYS . 11.2 t -122.19 1.42 9.71 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 124.169 0.918 . . . . 0.0 109.866 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.53 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -63.02 -79.49 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.951 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.491 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.4 OUTLIER 159.31 78.98 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 123.723 0.639 . . . . 0.0 111.498 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.554 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.54 141.24 1.55 Allowed Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.195 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -67.67 100.52 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.712 0 N-CA-C 108.972 -1.203 . . . . 0.0 108.972 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.84 112.29 23.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 118.244 -1.382 . . . . 0.0 111.442 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -124.22 76.76 1.5 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.23 136.76 6.01 Favored Glycine 0 N--CA 1.483 1.8 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.801 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 26.3 p-90 -154.54 -179.81 8.32 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 117.905 -1.518 . . . . 0.0 111.959 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.822 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -140.13 100.48 3.92 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.491 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.624 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -91.87 175.51 6.86 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.748 -1.181 . . . . 0.0 109.462 179.932 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.478 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -162.46 149.28 13.3 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 117.629 -1.629 . . . . 0.0 112.731 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.469 ' CD2' ' N ' ' A' ' 43' ' ' SER . 22.2 p90 -173.72 -140.93 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 113.571 -1.65 . . . . 0.0 107.558 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.584 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 31.0 m -163.39 -179.06 6.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.375 -1.73 . . . . 0.0 112.735 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CE1' ' OE1' ' A' ' 48' ' ' GLN . 8.1 m-85 -114.64 91.2 24.33 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -55.38 -36.97 94.99 Favored 'Trans proline' 0 CA--C 1.51 -0.72 0 C-N-CA 121.015 1.143 . . . . 0.0 110.065 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.43 ' HG ' ' HG2' ' A' ' 48' ' ' GLN . 22.2 p -79.44 165.26 23.25 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 119.322 -0.951 . . . . 0.0 108.973 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.12 48.27 3.31 Favored Glycine 0 C--N 1.29 -2.009 0 C-N-CA 118.663 -1.732 . . . . 0.0 109.968 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.652 HE22 ' CB ' ' A' ' 95' ' ' ALA . 3.2 pt20 -109.76 143.46 39.55 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.309 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.48 133.57 34.76 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.496 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.595 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.7 p -72.69 164.48 3.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.584 -0.846 . . . . 0.0 111.728 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.595 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 66.3 p -136.17 -63.24 0.65 Allowed 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.264 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.48 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.6 mt-30 -89.23 164.64 14.87 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.177 -1.009 . . . . 0.0 109.346 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -170.37 153.5 4.4 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.259 -1.376 . . . . 0.0 112.227 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.435 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 33.6 t-105 -156.1 144.84 20.26 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.881 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.435 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.8 OUTLIER 61.82 28.62 17.55 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 119.541 -0.863 . . . . 0.0 109.993 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.594 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.9 OUTLIER -172.58 124.54 0.47 Allowed 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.323 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.5 m -87.99 75.88 8.7 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -69.08 152.82 9.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.954 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 60.2 p -154.57 113.93 3.71 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.032 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.471 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.9 pt20 -90.51 117.71 29.41 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.924 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.0 p -94.09 85.49 4.71 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.999 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.93 -67.52 2.36 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.391 -1.385 . . . . 0.0 109.966 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -144.82 -12.72 0.56 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.293 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.584 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -93.28 -170.3 2.35 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.119 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.615 ' CG1' ' N ' ' A' ' 66' ' ' THR . 62.1 t -148.99 162.98 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.795 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.615 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 10.6 m -156.65 139.87 15.58 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 113.625 -1.625 . . . . 0.0 108.267 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.2 t -132.51 114.88 23.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.368 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -96.63 88.5 4.67 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.801 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.61 119.41 14.72 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.02 -1.072 . . . . 0.0 111.674 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.775 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -41.0 163.83 0.09 OUTLIER Pre-proline 0 N--CA 1.487 1.402 0 CA-C-N 113.741 -1.572 . . . . 0.0 112.417 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -64.57 -35.29 48.69 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 121.703 1.602 . . . . 0.0 112.195 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.538 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.33 -52.48 22.38 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 118.816 -1.154 . . . . 0.0 111.162 -179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.775 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.08 8.96 4.09 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.883 -1.127 . . . . 0.0 110.224 179.922 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.49 ' CA ' ' OD1' ' A' ' 69' ' ' ASN . . . -124.91 18.3 7.09 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 120.081 -1.057 . . . . 0.0 110.495 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.5 m -86.72 58.44 5.07 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.222 -0.991 . . . . 0.0 111.262 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.475 ' O ' ' CD1' ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.46 114.86 54.77 Favored Pre-proline 0 CA--C 1.564 1.496 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.245 179.934 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.3 Cg_endo -67.57 156.02 67.78 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.395 1.397 . . . . 0.0 113.663 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.554 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -18.45 -45.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 114.273 -1.33 . . . . 0.0 114.156 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.43 69.58 0.28 Allowed Glycine 0 N--CA 1.497 2.712 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -151.13 -164.11 11.84 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.62 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.467 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.2 p -143.38 154.72 44.02 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 118.997 -1.081 . . . . 0.0 112.592 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -124.34 175.48 7.06 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.505 ' C ' ' CD ' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -167.22 147.64 5.49 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 116.973 -1.891 . . . . 0.0 113.191 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.594 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 10.9 p90 -157.03 -179.13 7.91 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.609 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.29 161.42 34.82 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 117.471 -2.3 . . . . 0.0 112.705 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.584 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.7 p90 -157.16 175.24 14.32 Favored 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 114.806 -0.697 . . . . 0.0 111.008 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -125.52 115.73 20.67 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.906 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -127.27 158.02 20.96 Favored Glycine 0 N--CA 1.51 3.58 0 C-N-CA 119.38 -1.39 . . . . 0.0 112.638 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.7 p -107.42 152.93 23.53 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.718 ' HD1' ' N ' ' A' ' 91' ' ' THR . 4.6 p80 -142.62 -153.45 0.46 Allowed 'General case' 0 N--CA 1.495 1.792 0 C-N-CA 119.127 -1.029 . . . . 0.0 111.9 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.718 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.3 p -145.52 -9.52 0.56 Allowed 'General case' 0 N--CA 1.482 1.151 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.501 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 105.63 81.15 1.42 Allowed Glycine 0 N--CA 1.499 2.863 0 C-N-CA 119.889 -1.148 . . . . 0.0 110.88 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.423 ' HB ' ' CB ' ' A' ' 46' ' ' SER . 2.1 m -163.12 -174.64 3.93 Favored 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.855 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -61.24 101.52 0.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.208 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.652 ' CB ' HE22 ' A' ' 48' ' ' GLN . . . -88.33 -118.57 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.441 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -39.24 115.92 1.0 Allowed Pre-proline 0 N--CA 1.486 1.33 0 C-N-CA 120.024 -0.671 . . . . 0.0 111.141 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 3.8 Cg_endo -65.63 -143.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.217 -0.552 0 C-N-CA 121.048 1.166 . . . . 0.0 110.808 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.1 p -113.45 -92.91 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.6 -0.84 . . . . 0.0 112.112 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -89.1 99.11 12.17 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.625 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.573 ' C ' ' HG ' ' A' ' 101' ' ' SER . 6.6 m-30 -68.08 -149.41 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.573 ' HG ' ' C ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -160.0 112.04 2.03 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 116.712 -1.995 . . . . 0.0 114.521 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -64.77 172.76 2.58 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.822 ' ND2' ' H ' ' A' ' 39' ' ' THR . 69.0 m-80 -35.72 91.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.51 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 55.88 49.42 66.66 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.55 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.737 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 21.1 m -163.37 131.6 2.77 Favored Pre-proline 0 C--O 1.189 -2.119 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.92 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -61.06 158.86 32.32 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 121.263 1.309 . . . . 0.0 112.636 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.623 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.1 t -157.62 110.98 2.51 Favored 'General case' 0 N--CA 1.496 1.852 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.221 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -73.45 128.03 34.36 Favored 'General case' 0 N--CA 1.508 2.447 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -179.773 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.432 ' H ' HG21 ' A' ' 109' ' ' VAL . 2.5 m -56.53 -177.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.659 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 116.301 -2.388 . . . . 0.0 110.461 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.167 0 CA-C-O 120.887 0.375 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -152.62 -10.61 0.17 Allowed 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.667 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -176.1 -162.11 0.09 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.873 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.402 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . -156.63 69.84 0.27 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.402 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 1.1 Cg_endo -66.85 -173.87 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.966 1.777 . . . . 0.0 111.303 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.72 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -104.36 -161.96 0.86 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.953 -0.699 . . . . 0.0 111.366 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.76 43.25 0.1 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.631 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 2.3 p -53.55 -178.12 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 121.541 0.686 . . . . 0.0 112.077 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' NE2' ' HA2' ' A' ' 110' ' ' GLY . 0.1 OUTLIER -138.34 108.44 6.39 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.795 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' A' ' 109' ' ' VAL . 4.6 m -103.39 124.06 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.238 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.46 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.15 165.05 12.6 Favored 'General case' 0 C--N 1.294 -1.84 0 C-N-CA 119.291 -0.964 . . . . 0.0 109.321 179.88 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.486 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 3.4 t-105 -124.74 143.32 50.84 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.614 -0.835 . . . . 0.0 112.444 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 75.45 0.38 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.76 149.0 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.97 -0.692 . . . . 0.0 112.832 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -152.99 91.39 1.53 Allowed 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.528 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.605 ' N ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -75.76 132.34 40.4 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.397 -179.961 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.49 ' CZ3' ' N ' ' A' ' 22' ' ' THR . 5.5 p90 -106.54 -35.71 6.98 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.872 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.432 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 17.5 t-20 -157.7 -20.08 0.08 Allowed 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 122.041 0.924 . . . . 0.0 108.793 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.706 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -178.09 -55.2 0.01 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.281 179.957 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.706 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -65.77 176.23 15.97 Favored Glycine 0 C--N 1.292 -1.887 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.7 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.0 p90 -149.11 140.72 23.46 Favored 'General case' 0 C--N 1.283 -2.292 0 C-N-CA 118.498 -1.281 . . . . 0.0 112.984 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.49 ' N ' ' CZ3' ' A' ' 17' ' ' TRP . 0.6 OUTLIER -80.85 163.97 23.01 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 179.407 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.456 ' N ' ' CG2' ' A' ' 22' ' ' THR . . . -145.65 110.11 5.03 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.894 -1.522 . . . . 0.0 112.89 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 31.2 t30 -99.09 101.15 12.41 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.456 ' CG1' ' CE1' ' A' ' 84' ' ' PHE . 13.4 t -99.5 140.91 17.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 119.645 -0.822 . . . . 0.0 112.341 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.46 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.3 m -133.49 114.83 14.05 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.276 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -85.31 150.38 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.264 -0.975 . . . . 0.0 111.651 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CG ' ' A' ' 28' ' ' LYS . 9.9 tttt -130.53 85.91 2.33 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.815 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.417 ' HB3' ' CD1' ' A' ' 76' ' ' ILE . 0.8 OUTLIER -68.8 104.94 2.17 Favored 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 118.565 -1.254 . . . . 0.0 109.807 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -105.8 -1.34 24.44 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.335 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.541 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.7 p -81.07 102.56 10.3 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.728 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 97.5 p -37.23 87.59 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 113.138 0.792 . . . . 0.0 113.138 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.583 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -166.06 146.81 5.58 Favored Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.536 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -70.76 100.92 0.99 Allowed 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 121.027 1.152 . . . . 0.0 109.166 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -86.76 108.52 18.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.149 -1.42 . . . . 0.0 111.817 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -122.63 63.32 0.97 Allowed 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.32 142.54 13.47 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 107.42 -2.272 . . . . 0.0 107.42 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.856 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.7 p-90 -159.37 176.1 12.54 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 117.707 -1.597 . . . . 0.0 111.796 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.794 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -140.01 111.93 7.5 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.982 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.604 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.61 178.47 4.62 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.794 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.505 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.26 152.06 16.28 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.245 -1.382 . . . . 0.0 112.413 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' ' N ' ' A' ' 43' ' ' SER . 17.3 p90 -177.12 -150.09 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 113.919 -1.491 . . . . 0.0 108.408 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.549 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 42.7 m -162.16 161.95 28.23 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 118.046 -1.462 . . . . 0.0 112.026 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.5 ' CD2' ' O ' ' A' ' 48' ' ' GLN . 16.5 m-85 -91.7 116.25 66.09 Favored Pre-proline 0 N--CA 1.484 1.275 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.005 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.08 -67.82 0.05 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 121.539 1.492 . . . . 0.0 112.938 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.478 ' HB3' ' H ' ' A' ' 93' ' ' THR . 19.7 m -68.74 -132.72 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.515 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -117.33 58.74 0.49 Allowed Glycine 0 N--CA 1.503 3.109 0 C-N-CA 119.631 -1.271 . . . . 0.0 111.715 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.7 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 tt0 -110.48 114.84 28.58 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.961 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.522 ' NE2' ' OE1' ' A' ' 60' ' ' GLN . 5.2 mm-40 -118.22 136.95 53.34 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 120.131 -0.628 . . . . 0.0 111.291 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.478 HG22 ' CD2' ' A' ' 86' ' ' PHE . 6.2 p -96.3 156.9 3.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.269 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.481 HG22 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -138.56 -59.53 0.62 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 119.598 -0.841 . . . . 0.0 111.059 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.481 ' H ' HG22 ' A' ' 51' ' ' THR . 0.8 OUTLIER -90.32 131.08 36.31 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.499 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.78 160.39 40.82 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.119 -1.032 . . . . 0.0 112.476 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.458 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 39.1 t-105 -155.33 149.46 25.78 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.676 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.458 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.3 t 66.07 20.07 11.2 Favored 'General case' 0 C--N 1.316 -0.877 0 C-N-CA 119.649 -0.82 . . . . 0.0 109.573 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.44 ' HB3' ' CB ' ' A' ' 84' ' ' PHE . 5.5 p -173.25 123.84 0.4 Allowed 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.921 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -80.33 77.88 7.06 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.321 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -72.6 152.62 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.538 -0.755 . . . . 0.0 112.277 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 40.7 p -150.06 109.15 3.91 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.883 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.522 ' OE1' ' NE2' ' A' ' 49' ' ' GLN . 33.0 tt0 -87.45 114.75 24.35 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.074 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.3 p -91.41 81.23 5.43 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.864 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.09 -69.74 1.88 Allowed Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.403 -1.379 . . . . 0.0 110.074 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.5 t -139.13 -19.06 0.99 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.858 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.522 ' CB ' ' HG ' ' A' ' 43' ' ' SER . . . -86.65 -173.81 4.68 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.815 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 66' ' ' THR . 49.7 t -145.13 160.66 13.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 C-N-CA 118.77 -1.172 . . . . 0.0 113.226 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.561 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 11.6 m -159.36 129.61 5.72 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.889 -1.505 . . . . 0.0 108.121 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.423 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.0 t -125.3 146.89 30.23 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.004 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.849 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -130.47 93.33 3.43 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.856 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.74 117.63 15.75 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.229 -0.988 . . . . 0.0 112.402 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.617 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -42.17 156.91 0.23 Allowed Pre-proline 0 N--CA 1.481 1.088 0 CA-C-N 113.537 -1.665 . . . . 0.0 111.876 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -59.99 -34.91 94.69 Favored 'Trans proline' 0 C--O 1.213 -0.736 0 C-N-CA 121.745 1.63 . . . . 0.0 112.065 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.617 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.92 -53.52 20.53 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.987 179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.666 ' C ' HD21 ' A' ' 73' ' ' ASN . 0.3 OUTLIER -79.67 12.78 2.39 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.496 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.444 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -133.6 20.71 4.1 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.516 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.4 m -94.53 60.57 2.62 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.395 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.52 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -113.49 131.81 22.8 Favored Pre-proline 0 N--CA 1.491 1.595 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.472 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.504 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -70.86 151.42 62.77 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.468 1.445 . . . . 0.0 114.19 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -18.03 -45.92 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.504 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -106.4 68.31 0.24 Allowed Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.883 -1.151 . . . . 0.0 111.084 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.19 23.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 118.398 -1.858 . . . . 0.0 111.384 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.52 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.2 p -132.39 162.15 31.83 Favored 'General case' 0 N--CA 1.482 1.172 0 CA-C-O 121.74 0.781 . . . . 0.0 112.686 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.03 174.21 9.05 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.43 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 26.6 tt0 -165.96 144.84 5.99 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 116.831 -1.948 . . . . 0.0 113.545 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 25' ' ' VAL . 18.3 p90 -156.28 178.01 10.79 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.625 -1.171 . . . . 0.0 110.181 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -159.32 169.2 35.42 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 117.761 -2.162 . . . . 0.0 112.107 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.478 ' CD2' HG22 ' A' ' 50' ' ' VAL . 14.4 p90 -166.85 156.89 11.43 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.371 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -108.7 114.79 28.89 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.198 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.6 166.56 12.17 Favored Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.863 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 p -115.29 139.54 49.88 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.696 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.1 OUTLIER -150.61 175.28 12.07 Favored 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 117.332 -1.747 . . . . 0.0 113.423 -179.872 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.696 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.7 t -170.8 13.46 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 114.356 -1.293 . . . . 0.0 109.208 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.76 -93.69 1.67 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.743 -1.218 . . . . 0.0 111.352 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.76 ' CG2' ' H ' ' A' ' 94' ' ' ASN . 47.7 m -161.15 -122.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 118.955 -1.098 . . . . 0.0 112.17 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.76 ' H ' ' CG2' ' A' ' 93' ' ' THR . 10.7 p-10 -69.53 137.9 52.86 Favored 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.81 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.48 ' HB2' ' NE2' ' A' ' 48' ' ' GLN . . . -110.97 -98.28 0.41 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.726 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.486 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -32.75 108.63 0.3 Allowed Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.109 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.476 ' HD2' ' CE2' ' A' ' 100' ' ' PHE . 1.9 Cg_endo -64.91 -137.3 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 121.312 1.341 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.489 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 30.9 p -121.09 -59.74 1.7 Allowed 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.309 -0.956 . . . . 0.0 113.027 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.489 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.36 100.06 8.74 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.078 -1.049 . . . . 0.0 112.29 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.502 ' N ' ' O ' ' A' ' 107' ' ' CYS . 19.3 m-85 -72.64 -169.12 0.51 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.5 m -143.5 122.5 12.81 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 117.888 -1.525 . . . . 0.0 112.469 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.631 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -80.81 174.54 11.52 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.538 -0.865 . . . . 0.0 109.243 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.794 ' ND2' ' H ' ' A' ' 39' ' ' THR . 74.7 m-80 -34.61 89.18 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.324 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.073 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 60.45 57.7 17.71 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.466 -1.35 . . . . 0.0 110.744 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.72 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -178.24 148.61 0.64 Allowed Pre-proline 0 C--O 1.201 -1.454 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.244 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.41 176.55 3.27 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 121.647 1.565 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.502 ' O ' ' N ' ' A' ' 100' ' ' PHE . 10.3 t -173.57 99.06 0.11 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.099 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.431 ' HB ' ' NE2' ' A' ' 9' ' ' GLN . 0.2 OUTLIER -59.97 173.98 0.55 Allowed 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.037 -0.665 . . . . 0.0 112.29 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -71.24 -91.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.592 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.434 ' HA2' ' NE2' ' A' ' 9' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.218 0 CA-C-O 116.364 -2.353 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.52 -60.95 1.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.658 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.5 t -76.42 -173.74 2.61 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.89 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -99.45 -178.11 31.28 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.468 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -54.08 -61.58 0.41 Allowed 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.238 1.959 . . . . 0.0 112.182 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -95.74 -173.97 3.01 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.697 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.11 44.98 0.22 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 p -53.27 179.0 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.668 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.52 118.29 12.38 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.096 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.464 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.2 m -108.88 125.97 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.28 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.457 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -98.44 170.53 8.77 Favored 'General case' 0 C--N 1.292 -1.9 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.673 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.425 ' CE3' ' HB3' ' A' ' 96' ' ' ALA . 4.8 t-105 -125.44 143.01 51.19 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.769 -0.772 . . . . 0.0 111.785 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.14 72.48 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.62 151.61 9.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.916 0.865 . . . . 0.0 113.266 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -162.1 101.42 1.11 Allowed 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.005 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.781 ' N ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -129.87 166.0 20.87 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 122.556 1.169 . . . . 0.0 113.773 -179.761 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.639 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 32.9 p90 -126.22 -126.67 0.24 Allowed 'General case' 0 C--N 1.287 -2.137 0 CA-C-N 112.646 -2.07 . . . . 0.0 108.85 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.639 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 43.3 m-80 -77.26 72.78 3.83 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.436 ' HA ' ' NE2' ' A' ' 90' ' ' HIS . 0.3 OUTLIER 70.42 117.73 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.694 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' ' CZ2' ' A' ' 17' ' ' TRP . . . 125.88 96.34 1.03 Allowed Glycine 0 C--N 1.284 -2.346 0 N-CA-C 105.672 -2.971 . . . . 0.0 105.672 -179.593 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 27.1 p90 -113.46 119.56 38.02 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 -179.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 6.2 t -70.53 168.92 15.24 Favored 'General case' 0 C--N 1.283 -2.317 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.09 118.74 10.43 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.157 -1.417 . . . . 0.0 112.626 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -104.28 90.93 3.71 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.467 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 11.5 t -92.73 133.03 35.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.703 -0.799 . . . . 0.0 112.275 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.454 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 1.6 m -119.17 107.2 13.17 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.522 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 82' ' ' ALA . 2.9 t -78.29 144.27 11.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 119.149 -1.021 . . . . 0.0 110.68 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.4 tptm -135.37 103.05 5.35 Favored 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.859 -0.736 . . . . 0.0 109.576 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.741 HD21 ' N ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -100.33 124.37 45.72 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.088 179.89 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.741 ' N ' HD21 ' A' ' 29' ' ' ASN . 8.6 t -135.78 -2.65 2.36 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.011 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.69 ' HG ' ' H ' ' A' ' 32' ' ' SER . 4.3 p -52.19 -80.96 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 119.291 -0.963 . . . . 0.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.69 ' H ' ' HG ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.08 61.04 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 123.657 0.598 . . . . 0.0 110.803 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.657 ' H ' ' CB ' ' A' ' 78' ' ' ALA . . . -152.72 134.43 8.52 Favored Pre-proline 0 C--N 1.306 -1.283 0 C-N-CA 119.044 -1.063 . . . . 0.0 110.45 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.64 106.7 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 120.922 1.081 . . . . 0.0 110.269 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.5 t -87.77 67.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 118.639 -1.224 . . . . 0.0 111.809 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -88.16 65.08 7.99 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 101.03 145.6 17.37 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 107.046 -2.421 . . . . 0.0 107.046 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.828 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 49.7 p-90 -162.31 174.61 12.59 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 116.976 -1.89 . . . . 0.0 112.666 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -142.87 99.21 3.42 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.862 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.594 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -87.05 173.34 9.34 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 118.328 -1.349 . . . . 0.0 109.439 179.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.467 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -158.12 147.78 19.81 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 117.907 -1.517 . . . . 0.0 112.441 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.594 ' CG ' ' N ' ' A' ' 43' ' ' SER . 10.8 p90 -173.79 -137.29 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.958 -1.474 . . . . 0.0 108.043 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.594 ' N ' ' CG ' ' A' ' 42' ' ' PHE . 41.8 m -161.06 174.33 13.89 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 117.563 -1.655 . . . . 0.0 112.455 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.505 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 1.9 m-85 -114.47 95.93 41.54 Favored Pre-proline 0 N--CA 1.496 1.873 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.189 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.466 ' HB2' ' ND2' ' A' ' 94' ' ' ASN . 5.0 Cg_exo -60.05 -40.9 57.11 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 121.261 1.307 . . . . 0.0 111.676 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.3 t -74.96 15.45 0.4 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.563 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.46 ' H ' ' C ' ' A' ' 45' ' ' PRO . . . 55.79 29.38 54.62 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.233 -1.46 . . . . 0.0 110.133 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.562 ' NE2' ' CB ' ' A' ' 95' ' ' ALA . 7.3 mt-30 -61.07 116.47 4.55 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.609 ' CD ' HE22 ' A' ' 60' ' ' GLN . 0.0 OUTLIER -95.5 97.77 10.03 Favored 'General case' 0 N--CA 1.484 1.275 0 C-N-CA 119.359 -0.937 . . . . 0.0 110.621 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 51' ' ' THR . 0.9 OUTLIER -64.47 157.58 4.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.177 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 40.4 p -133.05 -64.45 0.74 Allowed 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.755 -0.778 . . . . 0.0 111.259 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.551 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.9 OUTLIER -90.58 173.98 7.76 Favored 'General case' 0 N--CA 1.494 1.74 0 C-N-CA 118.87 -1.132 . . . . 0.0 110.133 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -173.2 147.46 1.56 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.961 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.456 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 37.2 t-105 -151.2 143.7 24.26 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.713 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.456 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.3 OUTLIER 60.57 27.53 17.21 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.753 -179.944 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.432 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -174.85 122.62 0.24 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.566 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -84.84 77.63 10.05 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 118.987 -1.085 . . . . 0.0 109.462 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 m -69.23 152.57 9.34 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.296 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.418 ' HG1' ' HB ' ' A' ' 66' ' ' THR . 36.9 p -155.24 119.27 4.6 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.074 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.609 HE22 ' CD ' ' A' ' 49' ' ' GLN . 27.9 tt0 -91.53 116.92 29.26 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.906 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.439 ' H ' ' HG ' ' A' ' 61' ' ' SER . 3.2 p -90.52 77.35 6.48 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.685 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.36 -68.71 2.06 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.41 -1.376 . . . . 0.0 110.156 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -138.27 -17.16 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.903 -0.719 . . . . 0.0 110.291 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.423 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -91.68 -172.44 3.22 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.988 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.612 ' CG1' ' N ' ' A' ' 66' ' ' THR . 46.1 t -143.83 162.27 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.0 -1.08 . . . . 0.0 113.462 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.612 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 23.5 m -157.79 137.24 11.94 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.573 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.432 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.8 t -131.8 116.33 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 C-N-CA 119.1 -1.04 . . . . 0.0 112.192 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.407 ' CB ' HH11 ' A' ' 68' ' ' ARG . 0.3 OUTLIER -99.53 96.06 7.41 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.269 -1.332 . . . . 0.0 108.74 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.828 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -76.02 120.11 20.89 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.836 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.659 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -40.28 160.62 0.12 Allowed Pre-proline 0 N--CA 1.483 1.192 0 CA-C-N 113.44 -1.709 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -64.89 -38.6 28.83 Favored 'Trans proline' 0 C--O 1.211 -0.844 0 C-N-CA 122.106 1.87 . . . . 0.0 112.229 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.558 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.1 OUTLIER -69.11 -54.69 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.581 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.659 HD22 ' N ' ' A' ' 70' ' ' ALA . 2.5 p30 -76.13 5.84 6.23 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.032 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -128.4 50.25 0.9 Allowed Glycine 0 C--O 1.202 -1.901 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.1 m -118.98 61.66 0.8 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 119.78 -0.768 . . . . 0.0 111.303 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.455 ' O ' ' CD1' ' A' ' 76' ' ' ILE . 0.0 OUTLIER -120.46 109.02 36.97 Favored Pre-proline 0 CA--C 1.56 1.353 0 C-N-CA 119.963 -0.695 . . . . 0.0 111.312 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.633 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.3 Cg_endo -71.65 118.9 5.88 Favored 'Trans proline' 0 C--O 1.207 -1.063 0 C-N-CA 121.182 1.255 . . . . 0.0 111.389 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.657 ' CB ' ' H ' ' A' ' 33' ' ' ALA . . . -7.65 68.07 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.694 1.246 . . . . 0.0 113.257 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.633 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . 170.18 46.1 0.03 OUTLIER Glycine 0 C--N 1.277 -2.722 0 CA-C-N 114.148 -1.387 . . . . 0.0 110.124 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -174.98 -152.92 9.61 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.021 -1.561 . . . . 0.0 110.192 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 p -140.77 173.64 11.29 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.26 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 27' ' ' VAL . . . -148.94 90.79 1.79 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -85.04 146.44 27.18 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.467 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 12.0 p90 -155.03 175.56 13.67 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 113.997 -1.456 . . . . 0.0 108.851 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.7 176.82 41.12 Favored Glycine 0 N--CA 1.498 2.82 0 C-N-CA 117.489 -2.291 . . . . 0.0 112.532 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.489 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 6.8 p90 -163.68 -175.14 3.99 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.949 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -129.77 113.59 14.89 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 119.753 -0.779 . . . . 0.0 110.507 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.495 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.45 152.66 20.3 Favored Glycine 0 N--CA 1.504 3.199 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.472 ' H ' ' HG ' ' A' ' 89' ' ' SER . 1.9 p -94.23 135.52 35.53 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.165 179.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.436 ' NE2' ' HA ' ' A' ' 19' ' ' THR . 17.2 p80 -97.87 -166.17 1.35 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.303 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 36.4 p -145.78 -5.31 0.63 Allowed 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.081 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.66 73.12 1.14 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.594 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.553 ' CG2' ' ND2' ' A' ' 94' ' ' ASN . 88.7 m -161.17 -118.89 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.202 -0.999 . . . . 0.0 111.518 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.744 ' ND2' ' H ' ' A' ' 94' ' ' ASN . 0.0 OUTLIER -129.9 121.1 25.98 Favored 'General case' 0 N--CA 1.497 1.875 0 C-N-CA 120.104 -0.639 . . . . 0.0 111.259 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.562 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . . . -92.08 -113.56 0.09 Allowed 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.732 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.425 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . -40.78 110.45 0.7 Allowed Pre-proline 0 N--CA 1.488 1.467 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.283 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.502 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -61.19 -95.72 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.909 1.073 . . . . 0.0 112.465 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.9 p -155.04 -81.73 0.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.177 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -102.59 94.34 5.6 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.329 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.562 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -67.65 -150.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.209 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 19.4 m -157.12 110.72 2.6 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 117.215 -1.794 . . . . 0.0 113.59 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.544 ' O ' ' N ' ' A' ' 104' ' ' GLY . 2.5 mt -55.89 177.43 0.06 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.599 ' ND2' ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.15 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.544 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -163.63 20.29 0.15 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 118.676 -1.726 . . . . 0.0 111.435 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.541 ' O ' ' N ' ' A' ' 102' ' ' LEU . 3.5 p -139.6 150.66 64.16 Favored Pre-proline 0 N--CA 1.501 2.087 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.561 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.83 163.82 17.98 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.437 1.425 . . . . 0.0 111.531 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 4.7 t -157.03 98.62 1.76 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 4.5 p -50.95 161.67 0.35 Allowed 'General case' 0 N--CA 1.498 1.957 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.828 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.764 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 10.8 p -75.52 -135.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.038 -1.065 . . . . 0.0 109.648 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.764 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.13 0 CA-C-O 116.267 -2.407 . . . . 0.0 110.393 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.95 0.405 . . . . 0.0 110.07 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.478 ' C ' ' OG ' ' A' ' 3' ' ' SER . 0.4 OUTLIER 166.43 -86.23 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.668 179.994 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.478 ' OG ' ' C ' ' A' ' 2' ' ' SER . 1.2 p 42.57 79.4 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 88.12 179.72 47.03 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.469 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -61.58 -81.25 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.167 1.912 . . . . 0.0 111.559 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.528 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -107.91 -162.88 0.85 Allowed 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.07 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 177.12 48.33 0.06 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' C ' ' NE2' ' A' ' 9' ' ' GLN . 4.0 p -52.79 178.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.495 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.438 ' NE2' ' C ' ' A' ' 8' ' ' CYS . 0.0 OUTLIER -129.73 124.39 33.39 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.88 179.948 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 110' ' ' GLY . 2.5 m -117.36 125.53 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.532 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.438 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.68 168.24 10.28 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.646 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.539 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.4 t-105 -134.31 143.44 47.72 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 119.43 -0.908 . . . . 0.0 112.601 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.66 73.73 0.45 Allowed Glycine 0 N--CA 1.496 2.677 0 N-CA-C 107.3 -2.32 . . . . 0.0 107.3 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -69.93 162.46 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 113.867 1.062 . . . . 0.0 113.867 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -170.13 101.32 0.28 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 113.686 -1.597 . . . . 0.0 108.689 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.782 ' N ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -121.47 164.56 16.97 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.97 -179.813 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.55 ' NE1' ' O ' ' A' ' 19' ' ' THR . 19.8 p90 -122.84 -137.07 0.3 Allowed 'General case' 0 N--CA 1.506 2.367 0 CA-C-N 113.593 -1.64 . . . . 0.0 110.532 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.402 ' C ' ' O ' ' A' ' 17' ' ' TRP . 15.7 t-20 -46.02 -33.22 3.25 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 118.735 -1.186 . . . . 0.0 108.806 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.55 ' O ' ' NE1' ' A' ' 17' ' ' TRP . 0.4 OUTLIER 178.16 135.0 0.08 Allowed 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.368 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.88 104.06 2.51 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 106.821 -2.512 . . . . 0.0 106.821 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 37.7 p90 -107.7 116.34 31.78 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 121.65 0.738 . . . . 0.0 112.62 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.8 t -71.81 168.58 17.54 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.539 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -150.18 118.88 6.55 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 117.675 -1.61 . . . . 0.0 112.701 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -100.42 95.82 7.0 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.449 HG11 ' N ' ' A' ' 26' ' ' THR . 18.6 t -94.91 141.5 14.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 C-N-CA 119.584 -0.847 . . . . 0.0 112.423 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.449 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.1 m -127.28 120.75 29.36 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.685 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -90.55 148.34 4.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.719 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.9 tptp -136.15 103.83 5.46 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.028 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.71 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.2 OUTLIER -95.71 132.56 40.78 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.519 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.462 ' N ' ' ND2' ' A' ' 29' ' ' ASN . 13.7 t -139.48 -3.42 1.51 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.565 ' C ' ' HG ' ' A' ' 32' ' ' SER . 5.1 p -50.68 -82.15 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.505 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.565 ' HG ' ' C ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 161.54 69.7 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.478 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.515 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.02 154.13 4.99 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 118.518 -1.273 . . . . 0.0 111.499 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -73.18 99.51 1.12 Allowed 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 121.413 1.409 . . . . 0.0 109.598 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -78.32 81.94 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 118.381 -1.327 . . . . 0.0 111.902 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -95.03 54.73 1.72 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 107.38 152.95 18.39 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 107.506 -2.238 . . . . 0.0 107.506 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 41.9 p-90 -163.31 174.09 12.46 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 117.13 -1.828 . . . . 0.0 112.502 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.36 98.16 3.54 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.124 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.605 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -84.9 171.84 11.86 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 118.168 -1.413 . . . . 0.0 109.635 179.945 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.456 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -155.92 142.99 19.08 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 118.673 -1.211 . . . . 0.0 111.63 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.585 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.1 p90 -172.1 -148.92 0.05 Allowed 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.625 -1.171 . . . . 0.0 108.606 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.585 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 65.6 m -159.08 157.71 31.58 Favored 'General case' 0 C--N 1.29 -2.005 0 C-N-CA 117.782 -1.567 . . . . 0.0 111.485 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.476 ' CE2' HG23 ' A' ' 65' ' ' VAL . 4.4 m-85 -88.31 114.35 59.15 Favored Pre-proline 0 N--CA 1.491 1.578 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.544 ' HG2' ' ND2' ' A' ' 94' ' ' ASN . 8.0 Cg_exo -53.94 -54.52 4.64 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 N-CA-C 108.654 -1.325 . . . . 0.0 108.654 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' ASN . 2.4 t -72.61 163.13 28.55 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 118.777 -1.169 . . . . 0.0 108.063 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.527 ' H ' ' HA3' ' A' ' 92' ' ' GLY . . . -78.07 59.98 3.89 Favored Glycine 0 C--N 1.277 -2.72 0 C-N-CA 118.338 -1.887 . . . . 0.0 108.72 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.567 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 mt-30 -90.96 176.53 6.57 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.627 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.52 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -162.02 111.92 1.54 Allowed 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.838 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -68.91 157.89 6.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.504 -0.878 . . . . 0.0 111.311 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.836 ' HG1' ' H ' ' A' ' 52' ' ' GLN . 62.2 p -134.71 -66.01 0.61 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.389 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.836 ' H ' ' HG1' ' A' ' 51' ' ' THR . 0.1 OUTLIER -83.96 168.98 15.49 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.414 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.33 152.72 7.4 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 118.327 -1.349 . . . . 0.0 112.272 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.428 ' CE2' ' HB2' ' A' ' 55' ' ' SER . 18.4 t-105 -146.72 132.21 18.69 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.626 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.428 ' HB2' ' CE2' ' A' ' 54' ' ' TRP . 2.2 t 58.57 33.18 22.89 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.095 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.5 114.79 0.47 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.376 -0.929 . . . . 0.0 110.672 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.8 m -80.91 74.85 7.88 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 118.87 -1.132 . . . . 0.0 108.929 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -69.07 168.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 114.966 -1.016 . . . . 0.0 112.843 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 10.0 t -170.18 123.57 0.71 Allowed 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.825 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -86.41 102.45 14.06 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.315 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.2 p -91.2 82.83 5.48 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.546 -0.862 . . . . 0.0 111.773 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.585 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 55.69 78.15 0.13 Allowed Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.481 -1.343 . . . . 0.0 110.861 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.546 ' HG ' ' N ' ' A' ' 64' ' ' ALA . 1.2 p 67.59 -23.93 0.12 Allowed 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.825 -0.75 . . . . 0.0 111.487 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.585 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -90.95 -176.07 4.53 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.876 -1.129 . . . . 0.0 110.852 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' A' ' 66' ' ' THR . 33.1 t -149.26 160.11 5.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 118.844 -1.143 . . . . 0.0 113.6 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.572 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.1 m -154.51 154.58 33.36 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.024 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.454 ' N ' HG21 ' A' ' 66' ' ' THR . 7.1 t -147.85 117.85 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 118.511 -1.276 . . . . 0.0 112.197 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.24 90.42 5.11 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.441 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.599 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.7 p-10 -70.57 119.01 14.1 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.805 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.626 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -38.3 158.14 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.482 0 CA-C-N 113.477 -1.692 . . . . 0.0 112.628 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -65.48 -36.74 32.95 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 121.875 1.717 . . . . 0.0 112.072 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.575 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.4 -56.56 7.1 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 118.928 -1.109 . . . . 0.0 110.226 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.626 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -70.22 -3.26 16.15 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.012 179.842 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -123.58 51.3 0.81 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 t -118.2 54.16 0.94 Allowed 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.677 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.508 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -110.69 135.58 20.73 Favored Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.297 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.3 Cg_endo -76.32 156.42 37.2 Favored 'Trans proline' 0 C--O 1.212 -0.793 0 C-N-CA 121.507 1.472 . . . . 0.0 112.306 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.515 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -28.5 -32.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.5 71.53 0.22 Allowed Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.984 -1.103 . . . . 0.0 110.771 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.401 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -164.54 -164.6 20.18 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 118.739 -1.696 . . . . 0.0 111.07 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.508 ' N ' HG13 ' A' ' 76' ' ' ILE . 11.6 p -139.99 167.78 21.33 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.99 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -132.66 -169.05 2.17 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.173 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.505 ' NE2' ' O ' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -169.8 141.82 2.34 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 117.628 -1.629 . . . . 0.0 112.617 -179.926 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.422 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 2.5 p90 -163.13 161.73 25.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -157.54 173.18 34.95 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 117.994 -2.051 . . . . 0.0 111.946 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 7.2 p90 -164.59 -174.63 3.5 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.506 -0.878 . . . . 0.0 111.328 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.446 HD21 ' HB3' ' A' ' 52' ' ' GLN . 70.8 m-80 -130.79 115.71 16.99 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.224 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.41 153.43 20.6 Favored Glycine 0 N--CA 1.511 3.639 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.834 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 9.0 p -84.63 144.22 28.74 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.64 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' A' ' 90' ' ' HIS . 18.9 p80 -111.94 119.66 39.29 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.334 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.411 ' CG2' ' O ' ' A' ' 90' ' ' HIS . 1.8 p -161.29 83.53 0.63 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.464 -0.895 . . . . 0.0 110.906 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.527 ' HA3' ' H ' ' A' ' 47' ' ' GLY . . . 175.72 -100.59 0.15 Allowed Glycine 0 N--CA 1.491 2.331 0 C-N-CA 118.199 -1.953 . . . . 0.0 112.411 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.506 ' H ' ' HA ' ' A' ' 46' ' ' SER . 19.6 m -153.53 112.85 3.79 Favored 'General case' 0 N--CA 1.491 1.625 0 C-N-CA 119.617 -0.833 . . . . 0.0 111.777 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.728 HD21 ' N ' ' A' ' 95' ' ' ALA . 0.0 OUTLIER 60.78 122.32 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.259 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.408 -179.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.728 ' N ' HD21 ' A' ' 94' ' ' ASN . . . -94.58 -50.64 5.1 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 114.406 1.262 . . . . 0.0 114.406 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -94.15 118.55 67.16 Favored Pre-proline 0 N--CA 1.492 1.672 0 C-N-CA 118.936 -1.105 . . . . 0.0 113.489 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.483 ' HG2' ' CE2' ' A' ' 100' ' ' PHE . 2.3 Cg_endo -64.9 -144.9 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.764 0 C-N-CA 121.548 1.499 . . . . 0.0 111.514 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.622 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.8 p -134.67 -63.37 0.71 Allowed 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 119.696 -0.802 . . . . 0.0 111.873 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.622 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.2 106.98 16.62 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.622 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 12.4 m-85 -80.98 -168.83 1.95 Allowed 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.8 m -144.83 106.24 4.23 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 117.906 -1.517 . . . . 0.0 113.378 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -54.78 174.04 0.08 Allowed 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.236 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.492 HD21 ' HB2' ' A' ' 38' ' ' TRP . 3.1 p30 -57.84 79.95 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.205 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.22 9.02 40.14 Favored Glycine 0 N--CA 1.499 2.877 0 C-N-CA 119.625 -1.274 . . . . 0.0 112.447 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.606 ' O ' ' N ' ' A' ' 102' ' ' LEU . 3.2 p -152.5 153.48 30.63 Favored Pre-proline 0 C--O 1.194 -1.847 0 C-N-CA 118.482 -1.287 . . . . 0.0 111.449 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -66.79 -179.51 1.69 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 121.679 1.586 . . . . 0.0 112.037 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.428 ' SG ' HG12 ' A' ' 10' ' ' VAL . 5.4 t -173.2 100.5 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.843 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.31 165.38 4.62 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.791 -0.764 . . . . 0.0 111.879 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.672 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 0.2 OUTLIER -75.11 172.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.012 179.635 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.672 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.178 0 CA-C-O 116.341 -2.366 . . . . 0.0 110.357 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.1 m -83.47 107.78 16.18 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.849 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.2 p -152.22 166.13 32.7 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.633 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.72 74.59 0.24 Allowed Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.101 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -66.83 -179.12 1.52 Allowed 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 121.819 1.679 . . . . 0.0 111.378 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.44 ' CB ' HG22 ' A' ' 105' ' ' THR . . . -110.9 -162.88 0.82 Allowed 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.848 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.46 55.25 0.06 OUTLIER Glycine 0 N--CA 1.502 3.078 0 N-CA-C 107.384 -2.286 . . . . 0.0 107.384 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -53.88 -165.46 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.503 1.144 . . . . 0.0 113.895 -179.747 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.572 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 13.5 mt-30 -145.03 89.84 1.99 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.455 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.538 ' CG1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 m -87.83 141.3 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.793 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.505 ' CD2' ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -116.12 172.8 6.94 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.778 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.52 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 8.8 t-105 -133.14 147.84 52.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.768 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.13 87.85 0.32 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.94 141.03 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.578 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 55.2 t30 -150.37 71.11 1.04 Allowed 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.105 -0.952 . . . . 0.0 109.327 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.739 ' NE2' ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -92.17 147.38 22.98 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.18 -1.008 . . . . 0.0 113.707 -179.748 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.76 ' C ' ' H ' ' A' ' 19' ' ' THR . 1.2 p90 -116.46 92.31 3.84 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 113.26 -1.791 . . . . 0.0 109.711 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.507 ' O ' ' CB ' ' A' ' 19' ' ' THR . 1.0 OUTLIER 63.79 -13.06 0.09 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 118.805 -1.158 . . . . 0.0 108.884 -179.746 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.76 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.8 OUTLIER 163.74 163.63 0.02 OUTLIER 'General case' 0 C--N 1.287 -2.114 0 CA-C-N 114.079 -1.419 . . . . 0.0 108.167 -179.791 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.514 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 73.53 89.6 0.16 Allowed Glycine 0 C--N 1.284 -2.353 0 N-CA-C 106.568 -2.613 . . . . 0.0 106.568 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.558 ' CD2' ' O ' ' A' ' 21' ' ' PHE . 35.9 p90 -95.38 117.31 30.11 Favored 'General case' 0 CA--C 1.49 -1.327 0 C-N-CA 119.791 -0.764 . . . . 0.0 112.607 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.457 HG22 ' N ' ' A' ' 23' ' ' ALA . 0.5 OUTLIER -68.95 171.28 8.3 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 179.559 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 22' ' ' THR . . . -151.11 103.34 3.03 Favored 'General case' 0 C--N 1.29 -2.011 0 C-N-CA 117.754 -1.578 . . . . 0.0 112.468 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -91.26 98.88 11.99 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.494 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 8.4 t -97.19 139.81 18.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 119.706 -0.797 . . . . 0.0 112.669 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -125.01 149.47 47.71 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.24 179.796 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.6 t -123.54 101.65 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.694 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.437 ' HD3' ' CG2' ' A' ' 81' ' ' THR . 35.3 tptt -87.85 101.95 14.22 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.014 -1.075 . . . . 0.0 110.054 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.702 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.2 OUTLIER -97.16 121.09 38.66 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.274 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -128.51 -1.02 5.57 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.708 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.9 p -47.04 -84.77 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.364 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.473 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 164.75 42.69 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.17 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.817 -179.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.576 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -147.71 153.17 42.64 Favored Pre-proline 0 N--CA 1.486 1.333 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.337 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -69.6 95.84 0.56 Allowed 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 121.36 1.373 . . . . 0.0 110.006 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 t -72.8 96.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.508 -1.277 . . . . 0.0 111.253 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -113.45 82.96 1.76 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.55 139.45 1.92 Allowed Glycine 0 C--N 1.292 -1.89 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.769 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 46.1 p-90 -159.87 176.18 12.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 117.895 -1.522 . . . . 0.0 111.935 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.626 ' HG1' ' C ' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -142.35 110.03 5.78 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.587 179.925 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.579 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.21 173.55 6.74 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.842 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.441 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -154.94 147.72 24.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.01 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.7 p90 -173.26 -144.96 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.451 -1.25 . . . . 0.0 108.904 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.54 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.1 m -159.42 153.3 23.16 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 117.801 -1.56 . . . . 0.0 112.364 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.8 m-85 -84.32 117.56 69.03 Favored Pre-proline 0 N--CA 1.484 1.27 0 C-N-CA 118.825 -1.15 . . . . 0.0 108.23 179.762 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -57.68 -62.59 0.2 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.628 0.885 . . . . 0.0 110.717 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.576 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 34.9 t -77.91 -174.79 3.7 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.967 -1.093 . . . . 0.0 110.177 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.576 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -79.81 54.33 4.41 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 118.983 -1.58 . . . . 0.0 109.782 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.552 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 1.9 mt-30 -88.27 139.85 30.08 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 119.106 -1.037 . . . . 0.0 110.79 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.504 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -139.89 112.26 7.75 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.961 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 1.6 p -69.43 149.12 11.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.691 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.593 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 26.5 p -126.07 -61.92 1.2 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.898 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.593 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -98.31 125.54 43.47 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.657 -0.817 . . . . 0.0 109.813 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -130.76 160.04 35.51 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 119.445 -0.902 . . . . 0.0 112.388 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 27.7 t-105 -151.86 143.93 23.87 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.428 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 p 54.74 31.93 16.43 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.686 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.503 ' HG ' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -172.89 113.32 0.25 Allowed 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.219 -0.901 . . . . 0.0 109.744 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 m -80.12 77.16 6.85 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.211 -0.995 . . . . 0.0 110.361 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 3.5 m -71.73 156.03 7.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.401 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 64.1 p -155.65 118.18 4.19 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.232 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -81.02 108.24 14.53 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.464 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.5 p -97.89 94.28 6.81 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.381 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.626 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 47.88 72.58 0.42 Allowed Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.043 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.408 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 68.26 -24.12 0.13 Allowed 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.964 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.626 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -84.93 -172.38 4.15 Favored 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 118.746 -1.182 . . . . 0.0 110.424 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.533 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 75.7 t -142.38 158.68 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.865 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.493 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 20.3 m -160.0 124.37 3.8 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.384 -1.28 . . . . 0.0 108.649 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.503 ' CG1' ' HG ' ' A' ' 56' ' ' SER . 1.9 t -121.66 148.21 25.23 Favored 'Isoleucine or valine' 0 C--O 1.194 -1.859 0 C-N-CA 119.569 -0.852 . . . . 0.0 111.885 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -130.13 92.91 3.37 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.769 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 13.1 p-10 -71.13 121.02 17.55 Favored 'General case' 0 C--N 1.299 -1.619 0 C-N-CA 119.354 -0.938 . . . . 0.0 111.669 -179.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.698 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -47.71 170.7 0.09 OUTLIER Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.611 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.416 ' HD2' ' CB ' ' A' ' 70' ' ' ALA . 3.7 Cg_endo -68.41 -38.98 10.46 Favored 'Trans proline' 0 C--N 1.322 -0.816 0 C-N-CA 122.163 1.908 . . . . 0.0 112.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.529 ' CE2' ' HB2' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -54.03 15.73 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.063 -1.055 . . . . 0.0 111.335 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.698 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.9 OUTLIER -75.7 14.73 0.59 Allowed 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.222 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -145.54 34.11 1.51 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 119.284 -1.436 . . . . 0.0 111.319 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.0 m -102.85 58.63 0.78 Allowed 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.584 -0.846 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -111.98 132.49 21.98 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 119.896 -0.721 . . . . 0.0 111.661 -179.915 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.584 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.9 Cg_endo -69.53 156.26 64.46 Favored 'Trans proline' 0 C--O 1.208 -0.978 0 C-N-CA 121.211 1.274 . . . . 0.0 110.14 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.576 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -41.52 -14.41 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.83 66.85 0.26 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -173.61 -161.51 23.92 Favored Glycine 0 N--CA 1.494 2.534 0 C-N-CA 118.361 -1.876 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.478 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.0 p -139.37 158.17 44.61 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 119.342 -0.943 . . . . 0.0 112.701 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -124.19 173.94 8.0 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.468 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 9.6 tt0 -169.08 145.79 3.52 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 116.881 -1.928 . . . . 0.0 113.207 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.494 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 11.2 p90 -154.98 175.83 13.3 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 114.671 -1.149 . . . . 0.0 109.469 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.18 164.65 37.69 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 116.935 -2.555 . . . . 0.0 112.593 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.571 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 3.4 p90 -157.03 -170.23 3.22 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.399 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.433 ' N ' HD21 ' A' ' 87' ' ' ASN . 1.7 m-80 -135.58 114.84 12.42 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.005 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -125.35 150.16 17.25 Favored Glycine 0 N--CA 1.508 3.475 0 C-N-CA 119.408 -1.377 . . . . 0.0 112.342 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 84.9 p -86.28 152.2 22.96 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.072 -0.651 . . . . 0.0 109.902 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.531 ' NE2' ' HA ' ' A' ' 19' ' ' THR . 24.7 p80 -137.27 156.51 48.18 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.516 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 15.3 t -171.13 36.95 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.591 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -156.75 -115.57 0.48 Allowed Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.629 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.496 ' N ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -86.75 -153.63 0.21 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 120.163 -0.615 . . . . 0.0 112.017 -179.763 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.757 ' ND2' ' H ' ' A' ' 94' ' ' ASN . 0.0 OUTLIER -88.45 -179.41 6.08 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.744 -0.782 . . . . 0.0 111.374 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.496 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.88 -132.14 0.32 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.006 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.52 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -8.73 108.31 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.485 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.417 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.496 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.0 OUTLIER -65.2 -101.4 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 121.14 1.226 . . . . 0.0 112.468 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.479 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 81.4 p -150.1 -66.07 0.21 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 118.897 -1.121 . . . . 0.0 112.265 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.479 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -109.93 103.57 12.36 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.594 -0.843 . . . . 0.0 110.662 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 14.4 m-85 -74.57 -169.67 0.89 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.253 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.4 m -136.57 93.61 2.9 Favored 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 118.667 -1.213 . . . . 0.0 112.726 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.574 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.4 mt -52.53 173.54 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.545 -0.862 . . . . 0.0 108.956 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.532 ' H ' HD21 ' A' ' 102' ' ' LEU . 1.4 p30 -45.14 90.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.014 -1.074 . . . . 0.0 110.608 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.06 58.22 12.67 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.443 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.562 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.8 OUTLIER 175.48 139.58 0.2 Allowed Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.869 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.9 167.13 4.52 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 121.551 1.501 . . . . 0.0 112.65 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -164.36 82.33 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 50.1 p -46.61 167.95 0.02 OUTLIER 'General case' 0 N--CA 1.517 2.88 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.448 ' C ' ' O ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -66.7 -160.08 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.113 -1.035 . . . . 0.0 109.69 179.562 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.099 0 CA-C-O 116.333 -2.37 . . . . 0.0 110.386 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.133 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 50.0 -142.1 0.66 Allowed 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.922 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 p -124.1 86.36 2.56 Favored 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.74 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.33 74.34 0.29 Allowed Glycine 0 N--CA 1.49 2.234 0 C-N-CA 119.388 -1.386 . . . . 0.0 110.402 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.19 -156.57 0.02 OUTLIER 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 121.661 1.574 . . . . 0.0 111.444 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.5 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -90.29 -154.57 0.34 Allowed 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.911 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.79 49.35 0.05 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.5 p -53.23 -179.31 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.618 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.536 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 26.6 mt-30 -137.03 113.09 9.73 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.547 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.46 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.0 m -108.77 130.82 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.976 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.464 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -103.88 167.38 9.81 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.104 179.94 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.407 ' NE1' ' HB2' ' A' ' 23' ' ' ALA . 1.6 t-105 -130.59 145.45 51.89 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.031 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.18 73.14 0.47 Allowed Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -72.43 153.04 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.437 ' CB ' HG21 ' A' ' 22' ' ' THR . 1.2 t30 -157.23 92.87 1.28 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 114.323 -1.308 . . . . 0.0 108.742 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.563 ' H ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -97.64 158.35 15.55 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 121.764 0.792 . . . . 0.0 112.336 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.453 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.9 OUTLIER -123.26 -107.88 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.136 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -67.44 -27.06 66.73 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.468 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.697 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -174.96 -55.2 0.01 OUTLIER 'General case' 0 C--O 1.203 -1.368 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.274 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.697 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -50.33 158.23 1.82 Allowed Glycine 0 CA--C 1.484 -1.852 0 C-N-CA 119.355 -1.402 . . . . 0.0 109.632 -179.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.592 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 3.1 p90 -134.52 117.25 16.0 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.629 -179.77 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.437 HG21 ' CB ' ' A' ' 15' ' ' ASN . 7.0 t -75.33 173.84 10.35 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.407 ' HB2' ' NE1' ' A' ' 12' ' ' TRP . . . -158.1 117.01 3.14 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 117.22 -1.792 . . . . 0.0 113.358 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -99.89 101.54 12.69 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.503 ' C ' ' HG1' ' A' ' 26' ' ' THR . 17.8 t -99.63 147.05 7.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.58 -0.848 . . . . 0.0 112.802 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.503 ' HG1' ' C ' ' A' ' 25' ' ' VAL . 1.5 m -138.9 110.35 7.0 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.345 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.8 t -83.23 149.81 4.43 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 C-N-CA 119.724 -0.79 . . . . 0.0 112.201 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.536 ' NZ ' ' NE2' ' A' ' 9' ' ' GLN . 2.2 tttm -142.19 106.97 4.87 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.802 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.529 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 3.3 t30 -93.22 120.17 33.21 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 118.971 -1.092 . . . . 0.0 108.594 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -123.15 -2.77 8.58 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 124.219 0.95 . . . . 0.0 109.818 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.529 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -53.35 -81.4 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.801 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 160.52 73.53 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.383 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.567 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.26 143.32 1.93 Allowed Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.089 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -68.32 101.88 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.42 109.28 18.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 118.281 -1.367 . . . . 0.0 111.643 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -117.38 73.63 0.89 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.06 143.75 11.75 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.846 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.4 p-90 -162.48 177.31 9.6 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 117.761 -1.576 . . . . 0.0 112.098 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -138.45 112.97 8.86 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.379 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.61 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.72 173.29 6.37 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 119.285 -0.966 . . . . 0.0 109.326 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.528 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -167.18 159.2 12.68 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.762 -1.575 . . . . 0.0 112.638 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.528 ' N ' ' CG2' ' A' ' 41' ' ' THR . 23.5 p90 -176.71 -134.49 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.63 -1.623 . . . . 0.0 107.954 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.483 ' OG ' ' C ' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -163.0 139.12 7.11 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.685 -1.606 . . . . 0.0 112.237 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.748 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.7 m-85 -69.28 122.28 84.9 Favored Pre-proline 0 N--CA 1.486 1.344 0 C-N-CA 118.838 -1.145 . . . . 0.0 108.465 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -52.68 -68.76 0.07 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.343 1.362 . . . . 0.0 112.729 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.428 ' CB ' ' HB ' ' A' ' 93' ' ' THR . 2.5 p -69.42 -68.58 0.4 Allowed 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 119.173 -1.011 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.13 26.71 0.02 OUTLIER Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.222 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.508 ' OE1' ' N ' ' A' ' 48' ' ' GLN . 1.1 mp0 -43.73 144.6 0.8 Allowed 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.614 -0.834 . . . . 0.0 110.847 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.592 HE21 ' CA ' ' A' ' 49' ' ' GLN . 0.1 OUTLIER -110.54 82.95 1.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.508 -179.944 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.68 147.75 10.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.398 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.498 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 68.5 p -136.77 -71.91 0.44 Allowed 'General case' 0 N--CA 1.497 1.879 0 C-N-CA 119.181 -1.007 . . . . 0.0 112.157 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.498 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -76.6 145.72 38.74 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.935 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -156.19 153.86 29.9 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.733 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.443 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.2 t-105 -152.55 147.98 26.83 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.182 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 71.27 14.3 6.56 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.686 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.587 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 31.3 t -174.1 151.2 1.66 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.396 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.507 ' N ' ' HG ' ' A' ' 56' ' ' SER . 0.6 OUTLIER -102.66 84.58 2.43 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.699 -179.961 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -85.43 163.13 2.76 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.963 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.8 t -164.21 132.26 3.47 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.613 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.87 113.27 24.81 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.698 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.447 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 p -84.28 68.33 10.14 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.722 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.31 -63.74 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.5 m -142.19 -16.7 0.75 Allowed 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 120.062 -0.655 . . . . 0.0 109.269 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.447 ' CB ' ' OG ' ' A' ' 61' ' ' SER . . . -88.47 -172.89 3.95 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.252 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.748 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 94.6 t -146.15 153.1 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 118.79 -1.164 . . . . 0.0 112.587 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.453 ' OG1' ' OG1' ' A' ' 41' ' ' THR . 3.6 m -159.89 135.87 8.64 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 114.909 -1.042 . . . . 0.0 108.976 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.587 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 3.0 t -129.46 153.36 38.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.943 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.49 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -135.91 89.29 2.47 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.846 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.86 118.53 13.75 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.162 -1.015 . . . . 0.0 112.08 -179.582 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.613 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -38.07 154.83 0.12 Allowed Pre-proline 0 N--CA 1.484 1.237 0 CA-C-N 113.731 -1.577 . . . . 0.0 112.012 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -64.69 -35.14 48.14 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 121.942 1.762 . . . . 0.0 112.626 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.613 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.59 -57.36 5.28 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.775 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.601 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -69.83 -13.18 62.14 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.106 -1.038 . . . . 0.0 109.911 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.08 22.12 42.46 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.621 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 m -87.53 58.65 5.05 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.002 . . . . 0.0 111.271 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -108.96 115.39 57.18 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.171 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' GLY . 2.0 Cg_endo -67.96 159.45 52.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 121.317 1.345 . . . . 0.0 113.745 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.567 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -24.08 -38.55 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 114.332 -1.304 . . . . 0.0 114.058 179.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.07 68.56 0.33 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.35 -168.22 18.14 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 118.857 -1.639 . . . . 0.0 110.284 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.478 ' N ' HG13 ' A' ' 76' ' ' ILE . 22.0 p -141.96 164.37 30.36 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.085 -1.046 . . . . 0.0 112.819 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -130.68 -179.95 5.6 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.476 179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.511 ' C ' ' CD ' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -170.24 151.53 3.89 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 116.883 -1.927 . . . . 0.0 113.101 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.465 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 5.6 p90 -167.64 171.49 10.16 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.32 160.89 30.5 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.729 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.604 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.4 p90 -150.1 160.42 43.67 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.308 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.4 m-20 -115.62 110.93 19.89 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.428 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -105.6 176.5 22.33 Favored Glycine 0 N--CA 1.501 3.012 0 C-N-CA 119.491 -1.338 . . . . 0.0 111.972 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -127.29 134.47 50.03 Favored 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.393 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.855 ' HD1' ' N ' ' A' ' 91' ' ' THR . 1.7 p80 -150.18 -159.7 1.07 Allowed 'General case' 0 N--CA 1.502 2.145 0 C-N-CA 117.754 -1.579 . . . . 0.0 112.627 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.855 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -127.62 -2.96 6.05 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.115 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.743 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 111.81 90.09 1.92 Allowed Glycine 0 N--CA 1.504 3.226 0 C-N-CA 119.882 -1.152 . . . . 0.0 110.905 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.475 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.6 OUTLIER -165.85 167.47 16.79 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.514 -0.875 . . . . 0.0 110.961 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -70.13 115.63 9.56 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.662 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.28 -3.63 15.26 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.998 -0.681 . . . . 0.0 112.177 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -110.1 107.11 58.68 Favored Pre-proline 0 N--CA 1.492 1.637 0 C-N-CA 119.556 -0.857 . . . . 0.0 111.901 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -68.16 -145.02 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 121.244 1.296 . . . . 0.0 111.287 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.4 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 1.2 p -116.74 -87.91 0.6 Allowed 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 119.667 -0.813 . . . . 0.0 112.259 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.63 107.11 18.67 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.237 -0.985 . . . . 0.0 112.018 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.1 m-30 -78.6 -155.98 0.09 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.63 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.9 m -159.53 122.73 3.63 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 117.043 -1.863 . . . . 0.0 113.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.522 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.3 mt -60.65 -178.61 0.1 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.564 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.663 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.09 -41.24 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -155.69 27.7 0.59 Allowed Glycine 0 N--CA 1.495 2.604 0 C-N-CA 118.593 -1.765 . . . . 0.0 111.352 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 102' ' ' LEU . 21.3 p -145.07 151.6 49.02 Favored Pre-proline 0 N--CA 1.494 1.752 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.229 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -62.26 174.49 2.59 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 121.628 1.552 . . . . 0.0 112.451 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.44 ' SG ' HG12 ' A' ' 10' ' ' VAL . 3.0 t -168.19 106.38 0.49 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.471 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 41.4 p -72.63 146.08 46.86 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.971 -0.692 . . . . 0.0 112.403 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -59.32 -167.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.257 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 CA-C-O 116.339 -2.367 . . . . 0.0 110.296 179.986 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.162 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.511 ' OG ' ' N ' ' A' ' 3' ' ' SER . 13.5 p 44.98 -142.6 0.22 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.813 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.511 ' N ' ' OG ' ' A' ' 2' ' ' SER . 2.5 m 53.35 77.84 0.16 Allowed 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.381 -0.928 . . . . 0.0 111.005 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.98 -172.97 0.47 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.372 -1.394 . . . . 0.0 110.078 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.443 ' HB2' ' HG1' ' A' ' 105' ' ' THR . 3.0 Cg_endo -67.28 173.98 7.81 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 121.799 1.666 . . . . 0.0 110.819 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.604 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -110.43 -162.49 0.8 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.445 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.69 40.04 0.19 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.6 p -50.88 177.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 114.33 -0.935 . . . . 0.0 112.319 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -131.78 121.64 24.51 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.11 -1.404 . . . . 0.0 109.614 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 1.5 m -112.46 127.01 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.603 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.424 ' CG ' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.56 171.38 7.6 Favored 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.055 179.881 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.535 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 3.2 t-105 -132.25 149.28 52.41 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.706 -0.798 . . . . 0.0 112.042 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.29 83.55 0.32 Allowed Glycine 0 N--CA 1.497 2.726 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.78 144.75 12.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 54.0 t30 -148.67 100.72 3.14 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 114.165 -1.38 . . . . 0.0 107.619 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.685 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -102.49 149.61 24.22 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 114.969 1.47 . . . . 0.0 114.969 -179.568 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.652 ' O ' ' N ' ' A' ' 19' ' ' THR . 30.0 p90 -142.54 117.05 9.69 Favored 'General case' 0 C--N 1.293 -1.876 0 CA-C-N 113.217 -1.81 . . . . 0.0 106.245 179.463 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 52.05 -89.46 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 118.214 -1.394 . . . . 0.0 107.341 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.4 OUTLIER -144.84 106.17 4.22 Favored 'General case' 0 C--N 1.281 -2.411 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 179.505 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.4 ' N ' ' NE2' ' A' ' 90' ' ' HIS . . . 156.22 101.36 0.18 Allowed Glycine 0 C--N 1.272 -2.98 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.685 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 24.2 p90 -95.05 118.17 31.41 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.324 -179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.46 HG22 ' N ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -83.87 165.37 18.8 Favored 'General case' 0 C--N 1.284 -2.256 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.623 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.46 ' N ' HG22 ' A' ' 22' ' ' THR . . . -145.56 106.34 4.12 Favored 'General case' 0 C--N 1.29 -2.014 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.899 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -93.35 96.84 10.2 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.464 HG11 ' N ' ' A' ' 26' ' ' THR . 17.9 t -93.46 147.39 5.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 115.383 -0.826 . . . . 0.0 113.007 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.464 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.3 m -133.36 127.12 32.8 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.5 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -97.73 145.95 8.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.989 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.429 ' HD3' ' CG2' ' A' ' 81' ' ' THR . 12.2 tptt -126.97 100.56 6.19 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.835 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.667 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.2 OUTLIER -93.7 119.72 33.06 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.561 179.852 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 t -130.53 -0.92 4.4 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.8 p -50.52 -83.01 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.29 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.38 67.78 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.64 -179.943 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.559 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -169.09 157.94 7.37 Favored Pre-proline 0 N--CA 1.482 1.127 0 C-N-CA 118.372 -1.331 . . . . 0.0 111.625 179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.65 95.79 0.96 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.588 1.525 . . . . 0.0 109.052 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -74.47 87.54 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 118.47 -1.292 . . . . 0.0 111.744 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -100.06 56.52 0.95 Allowed 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 115.374 -0.83 . . . . 0.0 108.868 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.03 150.28 19.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.865 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 42.0 p-90 -164.14 176.68 9.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 117.652 -1.619 . . . . 0.0 112.059 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.577 ' HG1' ' C ' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -141.28 110.11 6.11 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.545 179.907 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.605 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -99.34 177.0 5.33 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.264 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.486 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.9 150.77 13.69 Favored 'General case' 0 C--N 1.289 -2.024 0 C-N-CA 117.867 -1.533 . . . . 0.0 112.361 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' ' N ' ' A' ' 43' ' ' SER . 14.4 p90 -174.55 -145.99 0.03 OUTLIER 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.753 -1.567 . . . . 0.0 107.952 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.556 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 41.7 m -161.12 154.12 21.15 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 117.804 -1.558 . . . . 0.0 111.758 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.504 ' CE2' HG23 ' A' ' 65' ' ' VAL . 8.4 m-85 -84.61 116.86 67.1 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.15 -53.89 4.3 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.16 1.24 . . . . 0.0 112.407 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.0 t -74.36 -82.77 0.06 Allowed 'General case' 0 C--N 1.294 -1.842 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.087 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 175.45 25.13 0.03 OUTLIER Glycine 0 N--CA 1.486 2.025 0 C-N-CA 119.289 -1.434 . . . . 0.0 110.193 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.419 ' HG3' ' CE1' ' A' ' 21' ' ' PHE . 0.8 OUTLIER -43.04 121.86 2.26 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.524 179.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.594 HE21 ' CA ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -93.81 84.78 4.64 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.959 -179.83 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.446 ' CG1' HE21 ' A' ' 60' ' ' GLN . 0.5 OUTLIER -64.63 148.57 11.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.554 179.786 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.493 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 76.0 p -137.78 -69.23 0.45 Allowed 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.37 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.493 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.5 mt-30 -73.36 161.51 30.38 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 118.842 -1.143 . . . . 0.0 110.024 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.62 142.16 3.05 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.323 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.432 ' CG ' ' N ' ' A' ' 55' ' ' SER . 38.8 t-105 -146.9 149.09 32.54 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.592 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.432 ' N ' ' CG ' ' A' ' 54' ' ' TRP . 6.3 t 57.11 27.82 14.01 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 119.326 -0.95 . . . . 0.0 109.07 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.588 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -174.66 125.42 0.29 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.135 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -87.57 72.34 9.62 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.596 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.585 ' CG1' ' HG ' ' A' ' 56' ' ' SER . 2.6 m -71.92 153.18 7.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.33 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.404 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.0 t -153.95 134.94 13.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.944 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.498 HE22 ' NE2' ' A' ' 49' ' ' GLN . 6.9 tt0 -100.51 120.2 39.65 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.285 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.0 p -100.58 80.48 2.21 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.706 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.56 2.53 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.468 -1.349 . . . . 0.0 109.956 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 41.8 t -146.77 -18.23 0.42 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.967 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.556 ' CB ' ' HG ' ' A' ' 43' ' ' SER . . . -87.8 -170.66 3.09 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.155 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.546 ' CG1' ' N ' ' A' ' 66' ' ' THR . 79.1 t -148.02 160.64 7.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.917 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.546 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 2.8 m -158.65 125.95 4.94 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 114.392 -1.276 . . . . 0.0 108.642 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.588 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.6 t -116.98 146.68 21.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.08 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.674 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -130.18 92.44 3.29 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.865 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.41 118.2 17.1 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.284 -0.966 . . . . 0.0 112.433 -179.709 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.55 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -42.73 165.65 0.1 OUTLIER Pre-proline 0 N--CA 1.487 1.406 0 CA-C-N 113.578 -1.646 . . . . 0.0 112.483 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -68.71 -33.03 22.34 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.058 1.839 . . . . 0.0 112.583 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.564 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.66 -57.7 4.84 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.477 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.43 HD22 ' N ' ' A' ' 70' ' ' ALA . 2.4 p30 -73.26 -4.43 33.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 119.12 -1.032 . . . . 0.0 109.652 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -119.77 50.25 0.83 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.5 t -120.54 57.07 0.97 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 120.029 -0.669 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.02 134.61 22.13 Favored Pre-proline 0 N--CA 1.486 1.356 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.551 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -71.52 158.71 53.22 Favored 'Trans proline' 0 C--O 1.214 -0.713 0 C-N-CA 121.464 1.443 . . . . 0.0 112.814 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.559 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -31.44 -29.51 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -115.5 72.9 0.25 Allowed Glycine 0 N--CA 1.497 2.706 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.899 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.33 -167.47 27.03 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.793 -1.67 . . . . 0.0 110.809 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.518 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.5 p -138.35 160.01 40.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.088 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -122.56 -176.45 3.38 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.468 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -169.37 142.07 2.6 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 117.068 -1.853 . . . . 0.0 113.361 -179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.468 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 7.5 p90 -159.12 174.14 15.34 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.054 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.0 168.33 39.7 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 117.638 -2.22 . . . . 0.0 112.521 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.591 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.9 p90 -152.94 -176.36 5.73 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.944 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.501 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 1.2 m120 -138.09 111.66 8.16 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.774 -0.771 . . . . 0.0 110.783 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -123.42 163.62 16.85 Favored Glycine 0 N--CA 1.507 3.379 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.892 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.502 ' H ' ' HG ' ' A' ' 89' ' ' SER . 1.6 p -94.87 132.1 40.05 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.796 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.652 ' CD2' ' H ' ' A' ' 90' ' ' HIS . 6.7 p80 -100.22 -161.55 0.88 Allowed 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.686 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -166.27 0.92 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.436 179.933 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.451 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 98.71 75.34 1.2 Allowed Glycine 0 N--CA 1.496 2.634 0 C-N-CA 119.673 -1.251 . . . . 0.0 110.309 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.496 HG23 ' H ' ' A' ' 94' ' ' ASN . 1.7 m -163.91 -159.29 0.49 Allowed 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.063 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.496 ' H ' HG23 ' A' ' 93' ' ' THR . 0.0 OUTLIER -101.57 127.25 48.36 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.853 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.28 -108.12 0.35 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.935 -0.706 . . . . 0.0 111.585 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.535 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -38.72 109.23 0.5 Allowed Pre-proline 0 N--CA 1.488 1.445 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.961 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.446 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -65.29 -142.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 121.21 1.274 . . . . 0.0 110.772 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.621 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.0 p -116.25 -64.63 1.28 Allowed 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 119.45 -0.9 . . . . 0.0 112.593 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.621 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.03 112.15 23.97 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.288 -0.965 . . . . 0.0 111.333 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 8.9 m-85 -84.32 -164.17 0.91 Allowed 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.035 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.2 m -144.52 117.6 8.89 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 118.421 -1.312 . . . . 0.0 112.009 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.548 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.3 mt -68.38 -178.67 1.14 Allowed 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.581 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.575 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -27.69 -37.46 0.01 OUTLIER 'General case' 0 N--CA 1.512 2.631 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.82 55.6 0.21 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.199 -1.477 . . . . 0.0 110.274 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.604 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 2.4 t -174.38 145.81 1.04 Allowed Pre-proline 0 C--O 1.196 -1.726 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.774 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -56.3 168.59 1.96 Allowed 'Trans proline' 0 C--N 1.324 -0.758 0 C-N-CA 121.511 1.474 . . . . 0.0 112.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.429 ' SG ' HG12 ' A' ' 10' ' ' VAL . 10.8 t -164.84 95.12 0.7 Allowed 'General case' 0 N--CA 1.494 1.74 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.118 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.463 ' OG1' ' N ' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -51.99 168.45 0.09 Allowed 'General case' 0 N--CA 1.501 2.075 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.203 -179.688 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.777 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 9.4 p -67.77 -151.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.442 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.777 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.871 0 CA-C-O 116.281 -2.4 . . . . 0.0 110.125 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.191 0 CA-C-O 120.874 0.369 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.97 19.91 3.88 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.791 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.442 ' HG ' ' N ' ' A' ' 4' ' ' GLY . 2.3 t -78.54 -69.23 0.58 Allowed 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.41 -0.916 . . . . 0.0 111.103 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.442 ' N ' ' HG ' ' A' ' 3' ' ' SER . . . 146.66 72.13 0.02 OUTLIER Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.438 -1.363 . . . . 0.0 110.209 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.413 ' HG2' ' CG2' ' A' ' 105' ' ' THR . 4.9 Cg_exo -57.28 -80.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 121.841 1.694 . . . . 0.0 112.206 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.509 ' H ' HG23 ' A' ' 105' ' ' THR . . . -105.32 -160.78 0.77 Allowed 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 122.205 1.002 . . . . 0.0 112.396 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.635 ' O ' ' SG ' ' A' ' 8' ' ' CYS . . . -176.55 -79.79 0.05 OUTLIER Glycine 0 C--O 1.189 -2.714 0 N-CA-C 107.023 -2.431 . . . . 0.0 107.023 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.722 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 6.6 p 63.62 176.97 0.16 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.541 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 55.3 mt-30 -151.27 158.98 44.56 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.482 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.46 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.7 m -141.19 126.54 18.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.954 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.478 HD22 ' N ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -98.44 170.65 8.69 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.023 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.495 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 4.0 t-105 -126.73 144.11 51.04 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 123.895 0.747 . . . . 0.0 112.471 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.31 74.7 0.43 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.538 -2.225 . . . . 0.0 107.538 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.42 ' CG2' ' N ' ' A' ' 15' ' ' ASN . 7.2 p -69.77 152.52 9.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.42 ' N ' ' CG2' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -149.21 100.06 3.0 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 113.81 -1.541 . . . . 0.0 107.857 179.87 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.742 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -96.83 145.56 25.74 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 114.681 1.364 . . . . 0.0 114.681 -179.593 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.545 ' O ' ' N ' ' A' ' 19' ' ' THR . 16.6 p90 -129.58 -147.51 0.34 Allowed 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 105.777 -1.935 . . . . 0.0 105.777 179.439 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.477 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 74.4 m-20 -67.31 76.73 0.15 Allowed 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.717 -1.593 . . . . 0.0 106.783 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 65.56 114.07 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.529 ' H ' ' CD2' ' A' ' 90' ' ' HIS . . . 135.62 105.32 0.8 Allowed Glycine 0 C--N 1.275 -2.838 0 N-CA-C 107.089 -2.404 . . . . 0.0 107.089 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.742 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 32.5 p90 -96.56 124.52 40.58 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.654 -0.818 . . . . 0.0 112.047 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -96.04 106.75 18.97 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.495 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -90.03 120.62 31.39 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -101.78 96.41 7.05 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 179.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 26' ' ' THR . 33.6 t -90.14 154.46 3.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.483 ' N ' ' CG1' ' A' ' 25' ' ' VAL . 1.9 m -142.05 101.19 3.88 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.57 -1.195 . . . . 0.0 109.698 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.4 t -75.06 147.81 8.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.184 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 5.8 tttp -136.95 105.43 5.78 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.558 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.81 118.72 29.62 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 118.736 -1.186 . . . . 0.0 108.349 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.0 t -118.21 2.15 11.95 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.185 0.928 . . . . 0.0 110.013 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.671 ' HG ' ' H ' ' A' ' 32' ' ' SER . 14.9 p -54.09 -84.01 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.671 ' H ' ' HG ' ' A' ' 31' ' ' SER . 0.6 OUTLIER 158.77 68.45 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.934 0 O-C-N 123.873 0.733 . . . . 0.0 111.29 -179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.572 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -168.16 154.04 6.92 Favored Pre-proline 0 N--CA 1.483 1.192 0 C-N-CA 118.629 -1.228 . . . . 0.0 111.428 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -70.95 93.18 0.63 Allowed 'Trans proline' 0 C--N 1.326 -0.639 0 C-N-CA 121.144 1.23 . . . . 0.0 109.051 179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -78.33 107.27 10.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.598 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -114.41 62.72 0.67 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.22 147.9 20.15 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.846 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 39.6 p-90 -164.45 -179.11 5.8 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.427 -1.309 . . . . 0.0 111.805 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.29 118.29 12.54 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.257 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.624 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -112.05 174.81 5.7 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 119.474 -0.891 . . . . 0.0 109.412 179.831 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.486 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -166.05 153.68 10.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.736 -1.586 . . . . 0.0 112.858 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.509 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.9 p90 -176.3 -139.67 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 113.809 -1.541 . . . . 0.0 108.22 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.509 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.6 m -160.15 172.0 18.23 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.798 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.503 ' CD2' HG23 ' A' ' 65' ' ' VAL . 3.0 m-85 -114.14 96.5 42.41 Favored Pre-proline 0 N--CA 1.497 1.881 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.617 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 4.4 Cg_exo -59.57 -42.95 42.87 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 121.469 1.446 . . . . 0.0 112.209 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.571 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.4 t -69.71 -115.7 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.91 -1.116 . . . . 0.0 110.632 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.571 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -145.85 21.22 1.8 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.495 ' NE2' ' CB ' ' A' ' 95' ' ' ALA . 16.4 mt-30 -61.85 89.96 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.689 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.415 ' NE2' ' HA ' ' A' ' 49' ' ' GLN . 2.9 mm100 -88.86 97.18 11.02 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.3 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 1.5 p -68.06 138.25 22.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.651 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 44.0 p -127.19 -65.77 0.93 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.814 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.531 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -81.4 153.34 27.0 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.453 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -162.1 155.05 20.21 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.277 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.4 t-105 -157.71 142.41 16.49 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.796 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.482 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.2 OUTLIER 75.27 14.31 3.02 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.515 179.931 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.478 ' HB2' ' CB ' ' A' ' 84' ' ' PHE . 1.4 t -174.32 115.43 0.2 Allowed 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.5 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -71.2 85.52 0.76 Allowed 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.898 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.4 m -86.2 167.36 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.821 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.434 ' O ' ' CG2' ' A' ' 59' ' ' THR . 4.0 t -163.55 133.9 4.4 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.21 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.515 ' NE2' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER -94.42 123.99 38.17 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.733 -179.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.618 ' O ' ' N ' ' A' ' 63' ' ' SER . 34.0 p -110.01 -151.34 0.47 Allowed 'General case' 0 C--O 1.2 -1.519 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.394 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.551 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -53.33 84.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.657 0 C-N-CA 118.645 -1.74 . . . . 0.0 109.178 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.618 ' N ' ' O ' ' A' ' 61' ' ' SER . 28.4 m 47.68 13.66 0.04 OUTLIER 'General case' 0 C--N 1.31 -1.118 0 C-N-CA 119.606 -0.837 . . . . 0.0 109.686 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.551 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -109.59 -167.55 1.22 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.427 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.503 HG23 ' CD2' ' A' ' 44' ' ' PHE . 99.3 t -148.71 154.55 9.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 118.664 -1.215 . . . . 0.0 112.586 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.466 ' OG1' ' OG1' ' A' ' 41' ' ' THR . 1.5 m -156.08 139.14 15.46 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.621 179.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.43 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.7 t -132.83 156.4 42.25 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.748 0 C-N-CA 119.05 -1.06 . . . . 0.0 112.442 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 6.2 mtm180 -139.85 90.21 2.37 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 113.888 -1.505 . . . . 0.0 106.993 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.846 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.21 121.87 21.92 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.854 -179.554 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.725 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -40.93 158.66 0.17 Allowed Pre-proline 0 N--CA 1.482 1.136 0 CA-C-N 113.618 -1.628 . . . . 0.0 112.049 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.62 -39.14 22.09 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.921 1.747 . . . . 0.0 111.865 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.57 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.54 -55.88 8.91 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.43 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.725 HD22 ' N ' ' A' ' 70' ' ' ALA . 1.8 p30 -66.41 -20.8 66.16 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 118.755 -1.178 . . . . 0.0 109.221 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.77 31.77 8.01 Favored Glycine 0 N--CA 1.483 1.802 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 t -92.12 55.77 2.68 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.515 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -104.76 133.9 19.93 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.646 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.46 ' O ' ' N ' ' A' ' 79' ' ' GLY . 11.9 Cg_endo -77.32 163.08 30.49 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 121.628 1.552 . . . . 0.0 114.07 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.572 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -27.29 -39.35 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 114.031 -1.441 . . . . 0.0 113.658 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -123.98 73.37 0.41 Allowed Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.426 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -152.59 -163.18 11.43 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.041 -1.552 . . . . 0.0 110.39 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.515 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.0 OUTLIER -141.8 163.23 33.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.626 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -146.91 99.32 3.17 Favored 'General case' 0 N--CA 1.485 1.278 0 CA-C-N 114.484 -1.235 . . . . 0.0 107.936 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.409 ' HB3' ' CG2' ' A' ' 26' ' ' THR . 0.0 OUTLIER -94.14 172.7 8.05 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -179.661 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.478 ' CB ' ' HB2' ' A' ' 56' ' ' SER . 34.9 p90 -168.62 -167.93 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 112.633 -2.076 . . . . 0.0 109.482 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 84' ' ' PHE . . . -172.98 158.93 29.14 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 117.483 -2.294 . . . . 0.0 112.555 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.601 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.5 p90 -149.69 166.62 28.81 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 114.962 -0.619 . . . . 0.0 110.369 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.0 OUTLIER -123.41 110.26 14.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.89 -0.724 . . . . 0.0 110.724 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.553 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -129.62 167.19 21.57 Favored Glycine 0 N--CA 1.505 3.251 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.711 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p -89.96 141.58 28.52 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.133 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.558 ' CD2' ' OE1' ' A' ' 16' ' ' GLN . 13.1 p80 -112.66 -160.92 0.73 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -162.77 -7.65 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.219 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.469 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 86.55 76.26 1.25 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.723 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.469 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.4 OUTLIER -164.87 -175.45 3.77 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.05 179.966 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.617 ' ND2' ' CB ' ' A' ' 45' ' ' PRO . 9.9 t30 -51.84 101.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.112 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.495 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . . . -90.68 -119.24 0.07 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -42.85 113.77 1.39 Allowed Pre-proline 0 C--N 1.307 -1.263 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.496 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -59.79 -100.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 120.754 0.969 . . . . 0.0 112.445 -179.898 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.409 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 1.3 p -150.89 -98.86 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.454 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.71 95.75 9.75 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 118.492 -1.283 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -65.49 -157.33 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.339 -0.945 . . . . 0.0 108.995 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.473 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.58 128.5 5.86 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 116.679 -2.008 . . . . 0.0 113.982 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.8 mt -62.86 -173.27 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.398 179.668 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.582 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -32.15 -49.17 0.19 Allowed 'General case' 0 N--CA 1.505 2.3 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -147.95 28.46 1.42 Allowed Glycine 0 N--CA 1.494 2.511 0 C-N-CA 118.847 -1.644 . . . . 0.0 111.411 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.579 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -146.15 155.24 50.82 Favored Pre-proline 0 C--O 1.191 -2.026 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.239 -179.993 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -65.97 -178.14 0.97 Allowed 'Trans proline' 0 C--N 1.321 -0.87 0 C-N-CA 121.781 1.654 . . . . 0.0 112.571 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.722 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 9.7 t -174.45 111.76 0.15 Allowed 'General case' 0 N--CA 1.501 2.097 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.907 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.534 ' H ' ' HG1' ' A' ' 108' ' ' THR . 0.0 OUTLIER -71.12 132.36 44.94 Favored 'General case' 0 N--CA 1.515 2.814 0 N-CA-C 114.202 1.186 . . . . 0.0 114.202 -179.592 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -52.33 174.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 C-N-CA 118.824 -1.15 . . . . 0.0 110.54 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.161 0 CA-C-O 116.371 -2.35 . . . . 0.0 110.479 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.169 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.9 t -108.3 -72.71 0.71 Allowed 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.8 m 45.41 -122.66 1.04 Allowed 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.64 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.08 156.28 26.8 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 119.106 -1.521 . . . . 0.0 110.502 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -64.46 176.92 2.41 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.755 1.637 . . . . 0.0 111.366 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.439 ' HB3' ' CB ' ' A' ' 31' ' ' SER . . . -98.33 -160.03 0.78 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.484 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.411 ' H ' ' HB2' ' A' ' 6' ' ' ALA . . . -168.73 55.23 0.21 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.445 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 2.9 p -51.44 177.39 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.187 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.42 116.36 15.94 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.592 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.523 ' N ' ' O ' ' A' ' 109' ' ' VAL . 3.5 m -110.51 124.16 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.256 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.465 HD22 ' N ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -95.11 166.86 11.72 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.582 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.533 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.5 t-105 -134.75 140.05 45.63 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.613 -0.835 . . . . 0.0 111.463 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -122.98 71.22 0.42 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -72.17 147.67 10.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 29.7 t30 -150.1 92.55 1.9 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 113.989 -1.459 . . . . 0.0 107.513 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.793 ' NE2' ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -114.61 145.48 41.93 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 -179.583 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.541 ' CZ2' ' O ' ' A' ' 20' ' ' GLY . 2.3 p90 -104.47 -109.58 0.27 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 113.55 -1.659 . . . . 0.0 108.09 179.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -62.98 -29.9 71.17 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.044 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.799 ' HG1' ' H ' ' A' ' 90' ' ' HIS . 9.4 t -176.16 -53.52 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.148 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.612 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -38.4 108.22 0.07 OUTLIER Glycine 0 N--CA 1.493 2.461 0 N-CA-C 107.903 -2.079 . . . . 0.0 107.903 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.598 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 20.2 p90 -112.97 113.65 25.79 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 119.598 -0.841 . . . . 0.0 112.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.46 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 2.4 t -72.61 171.87 11.67 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.533 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -156.81 113.54 3.06 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 117.385 -1.726 . . . . 0.0 113.19 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -98.82 101.17 12.48 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.477 HG11 ' N ' ' A' ' 26' ' ' THR . 27.2 t -99.43 143.24 13.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.918 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.477 ' N ' HG11 ' A' ' 25' ' ' VAL . 1.8 m -132.54 110.77 10.71 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.93 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.1 t -82.0 150.42 4.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 C-N-CA 119.486 -0.885 . . . . 0.0 112.213 -179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 13.3 tttp -138.91 115.77 10.81 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.067 179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.404 ' HB2' ' CD1' ' A' ' 76' ' ' ILE . 1.4 t-20 -98.24 109.71 22.42 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.5 t -121.77 -2.08 9.37 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.147 0.905 . . . . 0.0 109.78 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.8 p -58.68 -79.46 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.261 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.34 43.21 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.522 -179.857 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.63 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -140.15 145.91 43.87 Favored Pre-proline 0 N--CA 1.487 1.388 0 C-N-CA 118.91 -1.116 . . . . 0.0 111.494 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -72.4 109.26 2.7 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 121.3 1.334 . . . . 0.0 109.596 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -97.5 112.97 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.001 -1.079 . . . . 0.0 112.211 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -122.35 70.01 0.97 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 141.77 12.1 Favored Glycine 0 C--N 1.294 -1.782 0 N-CA-C 106.657 -2.577 . . . . 0.0 106.657 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 31.0 p-90 -158.88 178.86 9.63 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 117.136 -1.825 . . . . 0.0 112.456 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.55 95.76 3.04 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.057 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.591 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -82.22 168.84 17.23 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.223 -1.391 . . . . 0.0 109.469 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.449 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.5 m -156.95 149.59 23.45 Favored 'General case' 0 C--N 1.287 -2.152 0 C-N-CA 118.122 -1.431 . . . . 0.0 112.012 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 25.5 p90 -174.03 -149.73 0.04 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.996 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.1 m -158.96 149.62 19.84 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 117.623 -1.631 . . . . 0.0 112.001 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.486 ' CE2' HG23 ' A' ' 65' ' ' VAL . 7.4 m-85 -78.79 123.55 85.26 Favored Pre-proline 0 C--N 1.307 -1.261 0 C-N-CA 118.326 -1.35 . . . . 0.0 107.712 179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.611 ' CG ' HD21 ' A' ' 94' ' ' ASN . 11.5 Cg_endo -65.72 -63.26 0.07 OUTLIER 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 121.358 1.372 . . . . 0.0 112.226 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.52 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 62.0 p -69.05 -120.68 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 118.613 -1.235 . . . . 0.0 110.464 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.52 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -132.91 42.68 1.35 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.486 HE22 ' HA ' ' A' ' 95' ' ' ALA . 9.1 mt-30 -84.92 133.07 34.3 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.762 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -131.56 117.07 18.24 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.801 179.976 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.422 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -69.38 155.06 7.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.974 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.554 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.7 p -128.6 -64.85 0.91 Allowed 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.894 -0.723 . . . . 0.0 110.92 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.554 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -95.28 140.46 30.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.601 -0.839 . . . . 0.0 109.446 179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.73 160.72 40.22 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 118.917 -1.113 . . . . 0.0 112.354 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 35.3 t-105 -153.15 143.07 22.16 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.649 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.3 t 60.97 26.56 16.49 Favored 'General case' 0 C--N 1.313 -0.978 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.466 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -170.97 124.07 0.63 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.717 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 m -87.01 75.09 9.58 Favored 'General case' 0 C--N 1.281 -2.384 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.354 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 16.7 m -69.21 151.1 10.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.256 -0.884 . . . . 0.0 112.462 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.9 p -155.32 115.31 3.74 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.104 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -90.74 124.44 35.11 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 119.11 -1.036 . . . . 0.0 110.612 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.455 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 5.7 p -91.71 75.31 5.77 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.5 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.511 ' C ' ' HG ' ' A' ' 63' ' ' SER . . . 76.18 -42.9 1.69 Allowed Glycine 0 N--CA 1.496 2.661 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.222 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.511 ' HG ' ' C ' ' A' ' 62' ' ' GLY . 0.8 OUTLIER -163.76 -19.01 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.087 -0.645 . . . . 0.0 109.563 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.455 ' CB ' ' OG ' ' A' ' 61' ' ' SER . . . -85.33 -169.18 2.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.17 -1.012 . . . . 0.0 109.754 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.499 ' CG1' ' N ' ' A' ' 66' ' ' THR . 98.3 t -150.33 157.97 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 118.007 -1.477 . . . . 0.0 114.152 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.499 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 13.4 m -157.86 143.6 17.18 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.67 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.2 t -139.12 114.74 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 C-N-CA 118.834 -1.147 . . . . 0.0 112.144 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -94.14 89.41 5.98 Favored 'General case' 0 C--N 1.281 -2.374 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.095 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.694 HD22 ' CA ' ' A' ' 74' ' ' GLY . 0.9 OUTLIER -71.75 117.28 13.13 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.021 -1.072 . . . . 0.0 111.909 -179.694 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.595 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -37.6 155.75 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.454 0 CA-C-N 113.622 -1.626 . . . . 0.0 112.297 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -62.47 -36.79 63.78 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.998 1.799 . . . . 0.0 112.312 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.595 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.07 -52.45 28.32 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.304 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.691 ' ND2' HD21 ' A' ' 69' ' ' ASN . 0.2 OUTLIER -75.56 0.59 16.84 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.686 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.694 ' CA ' HD22 ' A' ' 69' ' ' ASN . . . -118.94 25.41 7.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.6 p -92.73 73.25 4.97 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.75 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.519 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -133.89 126.07 18.58 Favored Pre-proline 0 N--CA 1.483 1.206 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.23 179.928 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.65 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.5 Cg_endo -72.41 167.59 26.57 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 120.953 1.102 . . . . 0.0 110.233 179.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.63 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -52.55 1.71 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.655 0 C-N-CA 119.609 -0.836 . . . . 0.0 112.399 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.65 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -128.8 67.29 0.56 Allowed Glycine 0 N--CA 1.496 2.663 0 C-N-CA 119.597 -1.287 . . . . 0.0 109.945 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 178.73 -162.06 28.92 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 118.831 -1.652 . . . . 0.0 110.376 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.519 ' N ' HG13 ' A' ' 76' ' ' ILE . 15.8 p -142.09 166.32 25.04 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.093 -1.043 . . . . 0.0 113.179 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.56 -177.31 4.13 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 113.896 -1.502 . . . . 0.0 107.113 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.412 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 13.0 tt0 -168.21 148.29 4.78 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 116.85 -1.94 . . . . 0.0 113.494 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.44 ' CE2' ' CE1' ' A' ' 86' ' ' PHE . 4.0 p90 -161.86 169.83 20.57 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.312 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.62 161.12 32.47 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 117.981 -2.057 . . . . 0.0 112.174 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.571 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.5 p90 -155.37 175.08 14.33 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.46 ' ND2' ' OG1' ' A' ' 22' ' ' THR . 10.5 m120 -124.07 109.42 13.47 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.284 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.81 174.83 15.63 Favored Glycine 0 N--CA 1.497 2.737 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.678 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.2 p -136.22 160.56 38.32 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.705 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.861 ' HD1' ' N ' ' A' ' 91' ' ' THR . 10.1 p80 -158.8 -137.01 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 117.516 -1.674 . . . . 0.0 112.928 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.861 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 3.2 p -146.05 -6.91 0.56 Allowed 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.43 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.491 ' N ' ' HD1' ' A' ' 90' ' ' HIS . . . 96.38 91.71 1.82 Allowed Glycine 0 N--CA 1.495 2.568 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.94 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.688 ' CG2' ' H ' ' A' ' 94' ' ' ASN . 99.4 m -162.99 -124.17 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.479 -0.889 . . . . 0.0 111.122 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.688 ' H ' ' CG2' ' A' ' 93' ' ' THR . 1.3 t30 -81.64 119.93 24.43 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.776 -0.77 . . . . 0.0 111.078 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.486 ' HA ' HE22 ' A' ' 48' ' ' GLN . . . -91.82 -178.39 5.02 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.222 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.487 ' HB3' ' CZ3' ' A' ' 12' ' ' TRP . . . -34.03 147.26 0.11 Allowed Pre-proline 0 N--CA 1.491 1.58 0 CA-C-N 115.135 -0.939 . . . . 0.0 112.196 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.43 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 9.2 Cg_endo -68.86 -151.14 0.03 OUTLIER 'Trans proline' 0 C--O 1.216 -0.585 0 C-N-CA 121.408 1.405 . . . . 0.0 111.594 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.433 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 9.3 p -120.06 -47.82 2.37 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.914 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.433 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.5 91.61 3.72 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.939 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 33.7 m-85 -64.18 -164.03 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.066 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.1 m -146.66 98.9 3.13 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 117.761 -1.576 . . . . 0.0 113.336 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -51.53 165.85 0.15 Allowed 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 119.304 -0.958 . . . . 0.0 108.655 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.488 ' H ' HD21 ' A' ' 102' ' ' LEU . 2.0 p30 -43.03 91.15 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.058 -1.057 . . . . 0.0 110.669 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 68.91 55.88 10.18 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.59 -1.291 . . . . 0.0 110.51 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.594 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.9 OUTLIER 175.97 135.57 0.18 Allowed Pre-proline 0 C--O 1.195 -1.797 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.739 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -58.97 166.86 6.27 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 121.568 1.512 . . . . 0.0 112.818 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 9.0 t -165.53 102.36 0.71 Allowed 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.94 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 p -58.68 173.37 0.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.211 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 10' ' ' VAL . 16.3 m -64.26 -143.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.66 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.002 0 CA-C-O 116.32 -2.378 . . . . 0.0 110.227 179.941 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.79 121.84 11.41 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.7 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.07 -40.25 95.18 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.046 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.24 -150.78 20.78 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.164 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.441 ' HB2' ' CG2' ' A' ' 105' ' ' THR . 3.3 Cg_exo -60.71 -79.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.322 -0.822 0 C-N-CA 121.375 1.383 . . . . 0.0 111.252 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.442 ' H ' HG21 ' A' ' 105' ' ' THR . . . -109.23 -156.33 0.58 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.971 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.44 45.42 0.04 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.643 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 4.3 p -50.94 175.12 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 69.0 mt-30 -138.27 118.64 13.73 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.714 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.474 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.1 m -109.57 124.47 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.861 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.458 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.72 163.3 12.69 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.966 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.475 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 6.1 t-105 -115.82 143.19 45.75 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.857 -0.737 . . . . 0.0 111.871 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 74.03 0.39 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.76 ' CG2' HE22 ' A' ' 16' ' ' GLN . 8.2 p -68.73 141.71 17.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.826 -0.749 . . . . 0.0 112.597 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.437 ' N ' HG21 ' A' ' 14' ' ' VAL . 23.6 t-20 -145.19 80.24 1.6 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.006 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.76 HE22 ' CG2' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -64.94 130.21 42.58 Favored 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.85 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.564 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 19.0 p90 -103.86 -43.65 5.26 Favored 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.344 -0.942 . . . . 0.0 110.137 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.564 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 46.5 t-20 -148.35 -19.71 0.33 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.713 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -177.16 -56.66 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.734 0 CA-C-N 114.034 -1.439 . . . . 0.0 108.006 179.919 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.713 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -63.31 168.47 20.82 Favored Glycine 0 C--N 1.295 -1.711 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.625 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 2.8 p90 -138.45 133.18 32.44 Favored 'General case' 0 C--N 1.29 -1.986 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.598 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.96 118.93 27.84 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.484 ' HB1' ' CZ ' ' A' ' 86' ' ' PHE . . . -96.96 110.58 23.08 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 119.239 -0.984 . . . . 0.0 113.517 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -92.77 100.42 12.91 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.458 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 23.4 t -93.51 145.43 7.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 119.236 -0.985 . . . . 0.0 113.583 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.458 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 1.7 m -135.52 109.94 8.47 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.239 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -81.02 151.4 4.43 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 C-N-CA 119.501 -0.88 . . . . 0.0 111.816 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.92 98.23 3.71 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.535 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.48 101.22 13.71 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.216 -0.994 . . . . 0.0 108.369 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -114.19 1.85 14.66 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.349 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.1 p -61.7 -79.64 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.61 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.491 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 160.91 75.24 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.535 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.591 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -167.32 152.44 6.98 Favored Pre-proline 0 C--N 1.31 -1.152 0 C-N-CA 118.665 -1.214 . . . . 0.0 111.587 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -72.72 94.64 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.71 0 N-CA-C 108.672 -1.318 . . . . 0.0 108.672 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.23 102.5 5.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 118.31 -1.356 . . . . 0.0 111.698 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -119.92 57.36 0.93 Allowed 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.97 148.76 18.34 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.787 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.7 p-90 -167.08 175.89 7.24 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.637 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -139.34 109.81 6.59 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.699 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.593 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.54 174.94 6.01 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.324 -0.95 . . . . 0.0 109.656 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.464 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -161.65 150.09 15.46 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 117.874 -1.53 . . . . 0.0 112.719 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 43' ' ' SER . 12.9 p90 -175.6 -130.43 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.039 -1.437 . . . . 0.0 108.596 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.539 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 m -167.13 176.9 6.52 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 117.819 -1.553 . . . . 0.0 112.495 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.475 ' CE2' HG23 ' A' ' 65' ' ' VAL . 2.2 m-85 -117.14 87.81 24.74 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.605 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -59.03 -27.45 85.06 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 121.786 1.657 . . . . 0.0 112.499 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' ASN . 0.9 OUTLIER -69.59 -13.37 62.29 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.731 179.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 78.99 19.78 71.85 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.742 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.517 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 21.7 mt-30 -73.85 177.12 5.76 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.631 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.717 HE22 ' CG2' ' A' ' 51' ' ' THR . 0.0 OUTLIER -141.77 111.26 6.5 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.452 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.401 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.4 p -76.07 155.13 5.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.861 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.717 ' CG2' HE22 ' A' ' 49' ' ' GLN . 64.8 p -138.66 -68.1 0.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.314 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.433 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -82.88 131.01 35.21 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.056 -1.058 . . . . 0.0 110.423 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.44 152.81 41.98 Favored 'General case' 0 N--CA 1.49 1.575 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.65 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 39.5 t-105 -154.73 144.48 21.57 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.004 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 69.0 18.81 8.33 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.071 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.623 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 3.3 m -172.23 111.12 0.26 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.115 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -69.93 79.79 0.47 Allowed 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.484 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 9.5 m -81.05 155.95 4.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.067 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.6 t -155.43 129.88 9.03 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.21 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -95.68 114.21 25.93 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.518 -0.873 . . . . 0.0 111.043 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.8 p -91.1 78.23 5.92 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.683 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.89 -68.28 2.26 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.095 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -142.08 -15.77 0.78 Allowed 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.188 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.539 ' CB ' ' HG ' ' A' ' 43' ' ' SER . . . -92.63 -170.81 2.57 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.567 ' CG1' ' N ' ' A' ' 66' ' ' THR . 54.1 t -145.78 160.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 C-N-CA 118.838 -1.145 . . . . 0.0 113.029 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.567 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.4 m -161.07 127.36 3.92 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.121 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 39' ' ' THR . 2.0 t -122.54 147.53 26.65 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.845 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 mtm-85 -129.38 92.73 3.41 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.787 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 8.6 p-10 -72.81 122.05 20.93 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.272 -0.971 . . . . 0.0 112.445 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.58 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -48.25 156.69 0.75 Allowed Pre-proline 0 C--N 1.305 -1.343 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.316 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.98 -36.81 81.08 Favored 'Trans proline' 0 C--N 1.325 -0.706 0 C-N-CA 121.895 1.73 . . . . 0.0 112.628 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.58 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -56.27 7.68 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 118.733 -1.187 . . . . 0.0 110.61 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.657 ' C ' HD21 ' A' ' 73' ' ' ASN . 0.3 OUTLIER -72.33 7.7 1.66 Allowed 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 109.714 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.524 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -137.05 33.82 2.27 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 27.9 t -99.94 59.72 1.06 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.846 -0.742 . . . . 0.0 111.298 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.518 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.01 135.86 22.12 Favored Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.808 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.2 Cg_endo -73.44 158.91 47.45 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.631 1.554 . . . . 0.0 114.027 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.591 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -27.37 -32.73 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 CA-C-N 113.888 -1.505 . . . . 0.0 114.758 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.52 68.82 0.29 Allowed Glycine 0 N--CA 1.503 3.125 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.968 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.15 23.19 Favored Glycine 0 C--N 1.29 -1.992 0 C-N-CA 118.637 -1.744 . . . . 0.0 110.695 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.518 ' N ' HG13 ' A' ' 76' ' ' ILE . 6.3 p -138.08 162.9 32.97 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 119.691 -0.804 . . . . 0.0 112.008 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.36 169.54 14.13 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.472 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.7 OUTLIER -160.45 142.08 12.44 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 117.016 -1.874 . . . . 0.0 113.486 -179.842 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.623 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 13.5 p90 -154.7 177.36 11.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 114.33 -1.305 . . . . 0.0 109.296 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.72 159.69 33.05 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 117.604 -2.236 . . . . 0.0 112.135 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.654 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 0.9 OUTLIER -145.17 -178.36 6.02 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.798 179.923 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.65 HD21 ' C ' ' A' ' 86' ' ' PHE . 1.0 OUTLIER -133.62 110.53 9.95 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.089 179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -113.91 173.43 14.96 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.899 -1.143 . . . . 0.0 111.278 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.0 p -115.51 140.04 49.51 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.828 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.857 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.1 OUTLIER -150.29 -175.8 5.22 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 118.241 -1.384 . . . . 0.0 112.28 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.857 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 26.1 p -123.68 -3.21 8.28 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.304 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.533 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 106.17 95.69 2.41 Favored Glycine 0 N--CA 1.499 2.836 0 C-N-CA 119.889 -1.148 . . . . 0.0 110.836 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.465 ' HB ' ' HG ' ' A' ' 46' ' ' SER . 2.0 m -163.78 175.93 10.02 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.076 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -71.21 112.73 7.59 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.895 -179.961 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -106.94 -99.47 0.35 Allowed 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.53 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.417 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -34.89 102.55 0.23 Allowed Pre-proline 0 N--CA 1.491 1.609 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.876 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.466 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.3 Cg_endo -66.3 -142.85 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 121.169 1.246 . . . . 0.0 110.999 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.644 ' HG1' ' H ' ' A' ' 99' ' ' ALA . 42.5 p -111.73 -88.12 0.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.642 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.644 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -97.56 105.54 17.71 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.008 -1.077 . . . . 0.0 112.146 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.564 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -74.9 -146.26 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.528 -0.869 . . . . 0.0 108.995 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.72 98.87 1.96 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 117.369 -1.733 . . . . 0.0 113.775 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.643 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -53.17 172.15 0.06 Allowed 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.788 HD21 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.22 86.83 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.944 -1.102 . . . . 0.0 110.488 179.891 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 76.07 42.86 23.31 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.62 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.612 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -169.92 138.65 1.51 Allowed Pre-proline 0 C--O 1.196 -1.733 0 C-N-CA 119.493 -0.883 . . . . 0.0 110.818 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -64.72 154.8 70.64 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.137 1.225 . . . . 0.0 111.677 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.453 ' SG ' HG12 ' A' ' 10' ' ' VAL . 2.7 t -151.11 104.43 3.13 Favored 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 119.424 -0.91 . . . . 0.0 110.908 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.51 157.37 11.54 Favored 'General case' 0 N--CA 1.5 2.05 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.019 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.681 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 6.1 p -70.44 -140.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.234 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.681 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.278 0 CA-C-O 116.342 -2.366 . . . . 0.0 110.446 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.166 0 CA-C-O 120.834 0.349 . . . . 0.0 110.082 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.2 m -153.82 -70.89 0.14 Allowed 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.822 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -175.2 -42.47 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.859 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.7 -178.51 21.7 Favored Glycine 0 N--CA 1.492 2.411 0 C-N-CA 119.455 -1.355 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -55.05 -80.87 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.042 1.828 . . . . 0.0 111.857 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.37 -169.0 1.38 Allowed 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.946 -0.702 . . . . 0.0 111.604 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 175.03 41.55 0.05 OUTLIER Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.709 -2.157 . . . . 0.0 107.709 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.626 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 26.7 p -56.45 -167.94 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.252 -0.974 . . . . 0.0 111.469 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.587 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 2.0 pt20 -159.15 152.67 22.76 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 118.984 -1.086 . . . . 0.0 110.402 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -137.29 133.77 46.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.2 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.465 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.42 164.83 11.57 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.968 179.855 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 1.6 t-105 -118.9 142.86 47.37 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.927 -0.709 . . . . 0.0 112.072 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.76 76.58 0.38 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 107.804 -2.119 . . . . 0.0 107.804 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -69.16 150.97 10.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.622 -0.831 . . . . 0.0 113.0 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -158.23 69.45 0.51 Allowed 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 114.321 -1.309 . . . . 0.0 108.534 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.803 ' NE2' ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -104.55 148.38 26.57 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.972 -179.719 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.658 ' C ' ' H ' ' A' ' 19' ' ' THR . 8.0 p90 -102.97 -136.11 0.33 Allowed 'General case' 0 N--CA 1.493 1.699 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.39 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -50.68 -13.88 0.16 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.679 179.745 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.696 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER 168.6 -179.59 0.03 OUTLIER 'General case' 0 C--N 1.282 -2.342 0 CA-C-N 112.97 -1.923 . . . . 0.0 107.309 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.696 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 74.39 97.0 0.1 Allowed Glycine 0 C--N 1.279 -2.638 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.563 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 23.7 p90 -108.85 123.6 49.31 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -81.13 153.25 27.38 Favored 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 105.433 -2.062 . . . . 0.0 105.433 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.452 ' CB ' ' CZ ' ' A' ' 86' ' ' PHE . . . -128.79 108.9 10.83 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.378 -1.329 . . . . 0.0 112.657 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -95.74 94.91 7.96 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.465 HG11 ' N ' ' A' ' 26' ' ' THR . 36.9 t -91.92 154.14 3.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.296 -0.962 . . . . 0.0 112.452 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.465 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.2 m -139.36 104.11 4.89 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.222 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' A' ' 82' ' ' ALA . 1.5 t -74.8 148.81 7.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 C-N-CA 119.732 -0.787 . . . . 0.0 112.17 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.587 ' NZ ' ' NE2' ' A' ' 9' ' ' GLN . 0.3 OUTLIER -136.21 96.09 3.32 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.784 179.693 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.427 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.9 t30 -88.28 106.98 18.58 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.883 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 t -113.45 5.52 16.76 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.835 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.634 ' HG ' ' H ' ' A' ' 32' ' ' SER . 12.6 p -54.17 -84.9 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.894 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.634 ' H ' ' HG ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.01 65.39 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.752 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.555 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.44 160.2 6.17 Favored Pre-proline 0 N--CA 1.486 1.331 0 C-N-CA 118.804 -1.158 . . . . 0.0 111.413 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -71.72 95.07 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.484 1.456 . . . . 0.0 109.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.1 t -75.13 79.79 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 C-N-CA 118.87 -1.132 . . . . 0.0 112.301 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -91.46 57.41 3.31 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.431 -0.908 . . . . 0.0 108.714 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 106.62 157.83 21.5 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.777 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 48.0 p-90 -171.58 178.82 3.03 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 117.752 -1.579 . . . . 0.0 112.382 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.505 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -141.18 115.63 9.48 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.017 179.779 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.602 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -106.35 176.43 5.17 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.1 179.834 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.485 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -167.18 152.44 7.43 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 117.5 -1.68 . . . . 0.0 113.009 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.447 ' CD2' ' N ' ' A' ' 43' ' ' SER . 19.4 p90 -176.79 -137.48 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 113.756 -1.566 . . . . 0.0 108.161 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.566 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 6.8 m -165.71 168.55 16.06 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 117.665 -1.614 . . . . 0.0 112.604 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.487 ' CE2' HG23 ' A' ' 65' ' ' VAL . 8.4 m-85 -102.16 108.12 55.61 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.71 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.513 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 2.9 Cg_exo -55.98 -66.79 0.08 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.051 1.168 . . . . 0.0 111.726 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.512 ' HG ' ' H ' ' A' ' 47' ' ' GLY . 35.2 t -70.28 -171.91 0.52 Allowed 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.526 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.512 ' H ' ' HG ' ' A' ' 46' ' ' SER . . . -79.36 49.07 3.51 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.198 -1.477 . . . . 0.0 109.915 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.451 HE22 ' HB3' ' A' ' 95' ' ' ALA . 0.2 OUTLIER -86.18 109.86 19.18 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.445 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.648 ' CD ' ' H ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -113.91 130.4 56.51 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.729 179.978 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.434 HG22 ' CD2' ' A' ' 86' ' ' PHE . 5.2 p -96.41 159.51 2.98 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.083 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.592 ' HG1' ' N ' ' A' ' 52' ' ' GLN . 30.4 p -133.09 -65.77 0.69 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.707 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.592 ' N ' ' HG1' ' A' ' 51' ' ' THR . 3.5 mt-30 -81.72 166.5 20.03 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.282 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -169.29 148.48 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.976 -1.09 . . . . 0.0 111.454 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.46 ' CD1' ' HB3' ' A' ' 55' ' ' SER . 36.8 t-105 -150.6 141.42 22.81 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.001 -1.079 . . . . 0.0 111.645 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.501 ' HG ' ' HB2' ' A' ' 84' ' ' PHE . 0.9 OUTLIER 63.8 20.92 12.45 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.311 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.491 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.2 m -165.06 109.31 0.89 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.422 -0.911 . . . . 0.0 110.381 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.458 ' H ' ' HG1' ' A' ' 57' ' ' THR . 1.7 m -70.57 78.36 0.58 Allowed 'General case' 0 C--N 1.285 -2.216 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.126 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -81.48 162.34 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.461 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.429 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.9 t -160.55 133.92 6.75 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.348 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.94 108.83 18.98 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.734 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.407 ' HG ' ' HB1' ' A' ' 64' ' ' ALA . 7.5 p -93.34 75.5 4.54 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.476 -0.889 . . . . 0.0 110.875 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 53.56 74.27 0.32 Allowed Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.357 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 0.3 OUTLIER 76.17 -35.91 0.26 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.491 -179.977 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.566 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -81.67 -171.06 3.13 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.666 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.511 ' CG1' ' N ' ' A' ' 66' ' ' THR . 77.4 t -149.71 157.62 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 118.725 -1.19 . . . . 0.0 113.05 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.511 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 35.9 m -156.69 131.9 9.18 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 114.234 -1.348 . . . . 0.0 107.96 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.426 ' CG2' HD23 ' A' ' 40' ' ' LEU . 2.0 t -126.07 146.98 30.95 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.07 0 C-N-CA 119.326 -0.95 . . . . 0.0 112.225 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -130.46 93.22 3.4 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.777 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -72.7 124.31 25.05 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.373 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.786 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -46.52 162.98 0.24 Allowed Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 113.719 -1.582 . . . . 0.0 111.593 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -67.12 -39.13 14.12 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.897 1.731 . . . . 0.0 111.933 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.539 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.38 -56.06 8.56 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.246 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.786 HD22 ' N ' ' A' ' 70' ' ' ALA . 2.0 p30 -70.63 -5.75 31.73 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.024 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.513 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -119.62 48.13 0.97 Allowed Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.532 ' H ' ' HG ' ' A' ' 75' ' ' SER . 2.4 p -112.67 74.33 0.86 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.099 -0.641 . . . . 0.0 110.971 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.577 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -130.69 132.28 23.84 Favored Pre-proline 0 CA--C 1.56 1.352 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.94 179.866 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.433 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.4 Cg_endo -71.18 159.24 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 122.023 1.815 . . . . 0.0 114.498 -179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.555 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -26.24 -40.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.679 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -114.76 68.84 0.26 Allowed Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.77 -1.205 . . . . 0.0 111.038 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -154.78 -168.83 18.68 Favored Glycine 0 C--N 1.29 -2.023 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.002 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.577 ' N ' HG13 ' A' ' 76' ' ' ILE . 7.6 p -137.1 166.39 23.82 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.818 0.818 . . . . 0.0 112.364 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.445 ' O ' ' N ' ' A' ' 27' ' ' VAL . . . -138.38 162.41 34.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -139.52 158.2 44.53 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 118.114 -1.434 . . . . 0.0 113.355 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.501 ' HB2' ' HG ' ' A' ' 55' ' ' SER . 1.6 p90 -171.03 161.86 6.99 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.103 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.57 169.81 37.15 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 117.438 -2.315 . . . . 0.0 112.741 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 1.1 p90 -150.97 -176.94 5.73 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.347 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.552 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 0.6 OUTLIER -128.82 104.68 7.76 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.622 179.842 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.34 175.51 15.74 Favored Glycine 0 N--CA 1.498 2.769 0 C-N-CA 120.058 -1.068 . . . . 0.0 111.41 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.516 ' O ' ' NE2' ' A' ' 49' ' ' GLN . 2.7 p -126.26 156.77 39.79 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.221 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.771 ' HD1' ' N ' ' A' ' 91' ' ' THR . 4.7 p80 -153.79 -150.73 0.34 Allowed 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.485 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.771 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 55.6 p -147.89 -2.6 0.54 Allowed 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 99.04 83.83 1.75 Allowed Glycine 0 N--CA 1.497 2.732 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.888 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.472 HG21 ' H ' ' A' ' 94' ' ' ASN . 2.0 m -163.87 -149.37 0.13 Allowed 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.527 -0.869 . . . . 0.0 110.869 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.513 ' ND2' ' CB ' ' A' ' 45' ' ' PRO . 40.3 t30 -73.16 120.91 19.43 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.896 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.451 ' HB3' HE22 ' A' ' 48' ' ' GLN . . . -110.3 -115.11 0.31 Allowed 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.994 -0.682 . . . . 0.0 111.96 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -50.19 118.07 8.64 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.295 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.455 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.6 Cg_endo -65.63 -143.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 121.093 1.195 . . . . 0.0 110.442 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.716 ' HG1' ' H ' ' A' ' 99' ' ' ALA . 27.0 p -104.39 -101.1 0.31 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.355 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.716 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -90.89 109.6 20.82 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 118.711 -1.196 . . . . 0.0 112.537 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.664 ' CZ ' ' CG1' ' A' ' 109' ' ' VAL . 4.1 m-30 -76.1 -149.76 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.45 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.87 116.27 2.8 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 117.107 -1.837 . . . . 0.0 113.696 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.626 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 2.1 mt -58.81 -172.53 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.114 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.505 ' N ' ' O ' ' A' ' 39' ' ' THR . 3.5 p30 -65.99 76.53 0.08 Allowed 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.919 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 102.22 10.7 38.5 Favored Glycine 0 N--CA 1.5 2.913 0 C-N-CA 119.521 -1.323 . . . . 0.0 112.374 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 102' ' ' LEU . 62.3 p -150.46 151.14 30.46 Favored Pre-proline 0 N--CA 1.495 1.796 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -66.51 171.53 10.51 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.583 1.522 . . . . 0.0 112.388 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.62 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.8 t -165.85 111.13 0.86 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.088 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 1.1 p -72.58 128.11 34.59 Favored 'General case' 0 N--CA 1.506 2.354 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.664 ' CG1' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -54.45 178.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 C-N-CA 118.793 -1.163 . . . . 0.0 110.531 179.796 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.287 0 CA-C-O 116.379 -2.345 . . . . 0.0 110.324 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 CA-C-O 120.853 0.359 . . . . 0.0 110.058 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.4 t 44.42 -105.69 0.09 Allowed 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.786 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 t 174.36 105.65 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.768 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.67 104.05 1.86 Allowed Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.414 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -62.23 -152.26 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.45 1.434 . . . . 0.0 111.606 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -66.35 -145.5 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.994 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.2 50.45 0.02 OUTLIER Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.546 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 2.7 p -52.31 178.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.771 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -137.72 110.67 7.72 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.467 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 3.5 m -101.75 125.79 55.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.2 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.44 ' CD1' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -104.81 133.96 48.75 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.28 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.465 ' CE3' ' HB1' ' A' ' 96' ' ' ALA . 1.4 t-105 -95.17 139.68 31.16 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.911 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.14 73.12 0.44 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.466 HG21 ' H ' ' A' ' 15' ' ' ASN . 0.6 OUTLIER -69.73 159.75 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.466 ' H ' HG21 ' A' ' 14' ' ' VAL . 1.3 t30 -170.05 97.43 0.28 Allowed 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.974 -1.466 . . . . 0.0 108.549 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.806 ' H ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -124.86 165.77 17.46 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 122.391 1.091 . . . . 0.0 113.58 -179.693 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.48 ' O ' ' CB ' ' A' ' 18' ' ' ASN . 7.0 p90 -124.32 75.34 1.38 Allowed 'General case' 0 C--N 1.29 -2.004 0 CA-C-N 112.875 -1.966 . . . . 0.0 108.938 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.505 ' N ' ' ND2' ' A' ' 18' ' ' ASN . 0.4 OUTLIER 78.19 -56.51 0.48 Allowed 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.438 ' HG1' ' C ' ' A' ' 18' ' ' ASN . 2.4 m -149.42 121.83 8.47 Favored 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.716 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.41 ' O ' ' CE2' ' A' ' 17' ' ' TRP . . . 113.53 90.41 1.83 Allowed Glycine 0 C--N 1.284 -2.312 0 N-CA-C 105.719 -2.952 . . . . 0.0 105.719 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.581 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 22.0 p90 -109.47 118.37 36.44 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 121.906 0.86 . . . . 0.0 113.264 -179.64 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t -73.26 162.99 28.74 Favored 'General case' 0 C--N 1.283 -2.287 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.33 117.94 10.38 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.048 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.786 HD22 HE21 ' A' ' 83' ' ' GLN . 1.4 t-20 -100.86 99.17 9.63 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.316 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.515 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 6.1 t -99.39 136.1 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 119.726 -0.789 . . . . 0.0 112.25 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.44 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.7 m -130.03 108.88 10.42 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.738 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.7 t -78.03 149.87 5.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 3.6 tttt -133.17 96.06 3.67 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.831 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.39 96.75 7.45 Favored 'General case' 0 C--N 1.291 -1.964 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.038 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.5 t -111.65 6.11 19.71 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.334 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.505 ' H ' ' HG ' ' A' ' 31' ' ' SER . 1.7 p -71.93 -78.31 0.08 Allowed 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.332 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 158.27 78.18 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 123.906 0.754 . . . . 0.0 111.498 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.581 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -166.17 145.08 4.89 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 118.648 -1.221 . . . . 0.0 111.373 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -68.91 97.34 0.56 Allowed 'Trans proline' 0 N--CA 1.456 -0.719 0 N-CA-C 108.172 -1.511 . . . . 0.0 108.172 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.38 100.25 9.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 118.194 -1.402 . . . . 0.0 112.029 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -113.71 55.3 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.85 148.7 14.25 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.873 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 43.3 p-90 -163.55 176.68 9.47 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.964 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -140.54 109.53 6.08 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.805 179.901 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.564 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.61 173.22 7.02 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.537 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.464 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.3 m -155.49 148.09 24.08 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.023 -1.471 . . . . 0.0 112.882 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.3 p90 -174.51 -141.54 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 113.999 -1.455 . . . . 0.0 108.417 179.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.5 m -163.17 173.11 13.85 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 117.625 -1.63 . . . . 0.0 112.921 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.561 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 5.3 m-85 -111.12 98.46 39.29 Favored Pre-proline 0 N--CA 1.491 1.575 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.015 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -53.31 -55.15 3.9 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.007 1.138 . . . . 0.0 111.301 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.537 ' N ' HD21 ' A' ' 94' ' ' ASN . 62.2 p -74.15 -179.83 4.05 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.101 -1.04 . . . . 0.0 109.794 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -77.71 41.79 1.95 Allowed Glycine 0 N--CA 1.484 1.864 0 C-N-CA 118.863 -1.637 . . . . 0.0 109.494 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.491 ' NE2' ' CB ' ' A' ' 95' ' ' ALA . 8.7 mt-30 -78.05 108.53 11.4 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.539 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -116.55 109.85 17.79 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.207 179.91 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.602 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.1 p -68.45 164.54 2.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.089 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.853 ' HG1' ' H ' ' A' ' 52' ' ' GLN . 36.8 p -137.5 -63.92 0.57 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.626 -0.829 . . . . 0.0 110.986 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.853 ' H ' ' HG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -97.59 137.11 37.02 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.709 179.941 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.52 159.15 42.8 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.726 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 36.2 t-105 -155.02 141.73 18.96 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.988 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.445 ' HG ' ' CB ' ' A' ' 73' ' ' ASN . 1.0 OUTLIER 67.12 23.84 9.49 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.091 -179.999 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.471 ' HB3' ' CG ' ' A' ' 84' ' ' PHE . 2.1 p -172.8 110.4 0.21 Allowed 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.249 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.4 m -71.46 74.64 0.76 Allowed 'General case' 0 C--N 1.284 -2.239 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.07 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.4 m -69.6 155.05 7.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.953 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 65.5 p -152.6 112.5 3.97 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.196 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -78.57 104.91 9.49 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.001 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.1 p -85.72 -160.89 0.56 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.948 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.638 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -50.84 88.22 0.01 OUTLIER Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.139 -1.505 . . . . 0.0 109.655 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER 53.22 4.19 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.707 -179.828 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.638 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.51 -169.27 1.6 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.555 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 77.9 t -143.17 154.22 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 C-N-CA 119.119 -1.033 . . . . 0.0 112.691 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.423 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 15.6 m -158.01 127.83 6.01 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.551 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 39' ' ' THR . 1.9 t -126.35 142.55 42.63 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.958 0 C-N-CA 119.279 -0.968 . . . . 0.0 111.747 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.46 94.33 4.11 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 124.735 1.272 . . . . 0.0 107.938 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.873 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.22 119.78 18.89 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.045 -1.062 . . . . 0.0 111.937 -179.647 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.801 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -46.73 172.43 0.05 OUTLIER Pre-proline 0 N--CA 1.485 1.303 0 CA-C-N 113.751 -1.568 . . . . 0.0 112.308 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.411 ' HD2' ' CB ' ' A' ' 70' ' ' ALA . 1.4 Cg_endo -68.28 -35.8 17.89 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.185 1.924 . . . . 0.0 112.707 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.562 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -68.9 -52.49 28.88 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 118.743 -1.183 . . . . 0.0 110.529 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.801 HD22 ' N ' ' A' ' 70' ' ' ALA . 1.1 p-10 -80.75 5.07 16.87 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 118.998 -1.081 . . . . 0.0 109.576 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -127.06 26.01 5.12 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.538 ' H ' ' HG ' ' A' ' 75' ' ' SER . 4.5 p -99.09 67.53 1.62 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.733 -0.787 . . . . 0.0 111.487 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.552 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -129.17 127.44 23.25 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 119.858 -0.737 . . . . 0.0 110.615 179.859 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.7 Cg_endo -72.12 156.98 55.01 Favored 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 121.621 1.547 . . . . 0.0 113.846 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.581 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -23.84 -38.03 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 114.89 1.441 . . . . 0.0 114.89 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -107.0 67.97 0.23 Allowed Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.686 -1.245 . . . . 0.0 111.216 -179.697 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.74 -169.05 25.58 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 118.27 -1.919 . . . . 0.0 111.397 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.552 ' N ' HG13 ' A' ' 76' ' ' ILE . 2.6 p -137.46 163.95 29.87 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.549 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -126.07 177.34 6.42 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.01 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.786 HE21 HD22 ' A' ' 24' ' ' ASN . 30.5 tt0 -168.52 146.66 4.14 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 117.124 -1.83 . . . . 0.0 113.624 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.515 ' CE2' ' CG1' ' A' ' 25' ' ' VAL . 14.6 p90 -160.1 175.21 13.22 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.037 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.21 166.44 35.21 Favored Glycine 0 N--CA 1.497 2.75 0 C-N-CA 117.902 -2.094 . . . . 0.0 112.166 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 5.8 p90 -161.94 156.85 22.94 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.457 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.636 ' N ' HD21 ' A' ' 87' ' ' ASN . 0.6 OUTLIER -104.66 111.41 24.1 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.232 179.889 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.25 163.62 14.66 Favored Glycine 0 N--CA 1.503 3.14 0 C-N-CA 119.737 -1.221 . . . . 0.0 111.33 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.2 p -112.97 148.87 34.14 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 120.42 -0.512 . . . . 0.0 109.996 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.822 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.7 OUTLIER -142.67 -168.97 2.89 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 119.096 -1.042 . . . . 0.0 111.938 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.822 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 30.0 p -134.76 -8.88 2.41 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.23 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.46 94.73 1.41 Allowed Glycine 0 N--CA 1.496 2.692 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.863 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.46 ' C ' ' CG ' ' A' ' 94' ' ' ASN . 56.0 m -160.9 -50.73 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.259 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.537 HD21 ' N ' ' A' ' 46' ' ' SER . 0.1 OUTLIER 172.46 110.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.863 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.491 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . . . -98.51 -133.93 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.683 -0.807 . . . . 0.0 111.998 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.484 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -21.45 109.55 0.12 Allowed Pre-proline 0 N--CA 1.506 2.372 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.4 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.498 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.7 Cg_endo -62.44 -95.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 120.862 1.041 . . . . 0.0 112.34 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -151.65 -96.77 0.06 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 118.674 -1.211 . . . . 0.0 112.397 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.61 95.07 8.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.844 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.2 m-30 -65.9 -157.46 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.254 -0.979 . . . . 0.0 109.135 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.28 115.0 3.7 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 117.524 -1.67 . . . . 0.0 113.286 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.614 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.3 mt -59.62 177.67 0.2 Allowed 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.358 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.716 HD21 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -60.05 77.58 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.791 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 101.7 12.36 35.29 Favored Glycine 0 N--CA 1.503 3.112 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.275 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.614 ' O ' ' N ' ' A' ' 102' ' ' LEU . 70.5 p -152.47 152.58 29.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 C-N-CA 118.885 -1.126 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -67.0 173.04 8.93 Favored 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 121.534 1.489 . . . . 0.0 112.141 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 1.8 t -165.2 106.43 0.79 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.833 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.48 138.76 47.25 Favored 'General case' 0 N--CA 1.505 2.309 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.667 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 1.7 p -68.82 172.08 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.52 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.667 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.442 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.399 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.537 ' H3 ' ' CG ' ' A' ' 5' ' ' PRO . . . . . . . . 0 N--CA 1.481 1.119 0 CA-C-O 120.893 0.377 . . . . 0.0 110.021 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.444 ' C ' ' OG ' ' A' ' 3' ' ' SER . 53.4 p -46.78 -53.9 10.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.319 -0.952 . . . . 0.0 110.661 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.444 ' OG ' ' C ' ' A' ' 2' ' ' SER . 0.3 OUTLIER -165.95 -13.57 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.463 -0.895 . . . . 0.0 110.776 179.983 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.479 ' H ' ' HD3' ' A' ' 5' ' ' PRO . . . 153.31 66.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.428 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.537 ' CG ' ' H3 ' ' A' ' 1' ' ' ALA . 5.1 Cg_exo -59.3 -89.45 0.0 OUTLIER 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 121.864 1.709 . . . . 0.0 111.795 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.49 ' H ' HG22 ' A' ' 105' ' ' THR . . . -110.96 -159.16 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.854 -0.738 . . . . 0.0 111.814 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.83 39.45 0.02 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 108.061 -2.016 . . . . 0.0 108.061 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.66 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 25.2 p -54.0 -178.0 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.707 -0.746 . . . . 0.0 111.823 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.16 138.1 27.91 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.694 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.465 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 1.3 m -128.61 130.14 68.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.574 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.484 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -92.74 169.87 10.15 Favored 'General case' 0 C--N 1.284 -2.278 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.862 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.539 ' NE1' ' CB ' ' A' ' 23' ' ' ALA . 2.1 t-105 -130.62 147.2 52.27 Favored 'General case' 0 C--N 1.309 -1.183 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.986 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.48 75.92 0.39 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.674 ' CG2' HE22 ' A' ' 16' ' ' GLN . 0.4 OUTLIER -69.46 140.01 19.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.797 -179.708 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.538 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 18.1 t-20 -142.5 89.65 2.16 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.049 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.689 ' N ' HE21 ' A' ' 16' ' ' GLN . 0.0 OUTLIER -94.34 130.57 40.59 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.612 0.967 . . . . 0.0 113.612 -179.74 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.736 ' C ' ' H ' ' A' ' 19' ' ' THR . 9.2 p90 -114.69 75.01 0.9 Allowed 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.471 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER 72.26 -12.87 0.67 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -179.549 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.736 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER 163.71 178.41 0.02 OUTLIER 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 112.766 -2.016 . . . . 0.0 106.477 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.681 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 66.18 96.96 0.03 OUTLIER Glycine 0 C--N 1.285 -2.302 0 C-N-CA 117.482 -2.294 . . . . 0.0 107.536 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.797 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 19.7 p90 -106.59 115.83 30.89 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.832 -0.747 . . . . 0.0 112.418 -179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.17 127.08 33.7 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.539 ' CB ' ' NE1' ' A' ' 12' ' ' TRP . . . -104.64 110.87 23.35 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.245 -0.982 . . . . 0.0 113.464 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -95.78 98.58 10.55 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.577 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.452 HG11 ' N ' ' A' ' 26' ' ' THR . 38.5 t -96.08 147.01 6.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.465 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 2.9 m -136.97 101.72 4.65 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.419 -1.264 . . . . 0.0 108.484 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 1.5 t -72.94 151.97 7.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 C-N-CA 119.669 -0.813 . . . . 0.0 112.364 -179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 9.1 tttt -143.59 104.04 4.16 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.468 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.529 ' ND2' ' HG ' ' A' ' 31' ' ' SER . 3.5 t30 -90.61 116.57 28.6 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -120.11 1.5 10.86 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 124.105 0.878 . . . . 0.0 110.147 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.529 ' HG ' ' ND2' ' A' ' 29' ' ' ASN . 20.6 p -57.9 -81.62 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.58 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.512 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 159.54 72.52 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 123.726 0.641 . . . . 0.0 111.592 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.568 ' N ' ' HB3' ' A' ' 78' ' ' ALA . . . -170.8 152.58 3.75 Favored Pre-proline 0 C--N 1.306 -1.29 0 C-N-CA 119.012 -1.075 . . . . 0.0 111.395 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.37 105.49 1.59 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 121.192 1.261 . . . . 0.0 109.342 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -90.7 92.25 3.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 118.46 -1.296 . . . . 0.0 111.779 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -103.47 67.22 0.9 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.95 148.62 24.01 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.6 -2.2 . . . . 0.0 107.6 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.852 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.0 p-90 -165.69 177.44 7.28 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.7 -1.6 . . . . 0.0 112.103 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.72 108.79 5.74 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.625 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.592 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.43 173.7 6.83 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.194 -1.002 . . . . 0.0 108.94 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.475 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 3.3 m -157.83 152.73 25.36 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 117.745 -1.582 . . . . 0.0 112.913 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' ' N ' ' A' ' 43' ' ' SER . 24.2 p90 -178.69 -142.88 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 113.773 -1.558 . . . . 0.0 108.179 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.6 ' HG ' ' CB ' ' A' ' 64' ' ' ALA . 20.2 m -163.24 173.71 13.02 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 117.626 -1.63 . . . . 0.0 112.663 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.492 ' CE2' HG23 ' A' ' 65' ' ' VAL . 6.9 m-85 -107.26 101.5 38.92 Favored Pre-proline 0 N--CA 1.486 1.341 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.843 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -55.53 -55.62 2.91 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 120.79 0.993 . . . . 0.0 110.531 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.794 ' HG ' ' H ' ' A' ' 93' ' ' THR . 8.7 t -69.48 -178.25 1.37 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 118.839 -1.144 . . . . 0.0 109.914 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.64 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -87.27 55.91 4.54 Favored Glycine 0 C--N 1.291 -1.969 0 C-N-CA 118.961 -1.59 . . . . 0.0 110.241 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.797 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 3.7 mt-30 -90.94 125.34 35.74 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.025 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.0 OUTLIER -115.58 101.8 9.19 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.96 -179.923 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.55 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.3 p -65.03 161.17 3.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.135 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 43.2 p -142.94 -65.8 0.39 Allowed 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.475 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.552 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -90.81 136.07 33.31 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.093 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.9 153.59 40.3 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.502 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . 0.401 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 44.5 t-105 -154.04 146.18 23.72 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.054 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.401 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.4 OUTLIER 65.88 23.87 11.31 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.776 -179.989 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.436 ' HB3' ' CB ' ' A' ' 84' ' ' PHE . 4.4 p -173.78 113.63 0.2 Allowed 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.17 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -72.64 73.36 1.06 Allowed 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.555 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.0 m -70.13 148.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.719 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.8 p -149.26 107.16 3.69 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.78 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 5.7 tt0 -78.59 104.29 9.1 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.594 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.567 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.3 p -82.84 -155.67 0.16 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.409 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.645 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -49.83 88.71 0.01 OUTLIER Glycine 0 N--CA 1.497 2.742 0 C-N-CA 118.967 -1.587 . . . . 0.0 110.098 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.567 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.4 OUTLIER 53.19 2.19 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.549 -0.861 . . . . 0.0 110.49 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.645 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.59 -173.59 2.34 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.315 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.492 HG23 ' CE2' ' A' ' 44' ' ' PHE . 50.0 t -140.82 152.92 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.299 -0.96 . . . . 0.0 112.531 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.421 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 94.5 m -153.94 115.53 4.19 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.308 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.428 ' CG2' HD23 ' A' ' 40' ' ' LEU . 1.7 t -109.35 145.75 15.69 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.949 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.661 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -131.18 92.91 3.27 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 114.172 -1.376 . . . . 0.0 107.324 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.852 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.14 118.43 17.09 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.032 -1.067 . . . . 0.0 112.167 -179.608 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.816 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -43.1 164.68 0.12 Allowed Pre-proline 0 N--CA 1.481 1.111 0 CA-C-N 113.37 -1.741 . . . . 0.0 112.003 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -65.03 -34.78 45.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.066 1.844 . . . . 0.0 112.416 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.596 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -70.92 -54.91 9.69 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.984 -179.892 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.816 HD22 ' N ' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -75.91 -1.16 24.12 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 118.947 -1.101 . . . . 0.0 110.15 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.67 40.08 2.62 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.451 ' H ' ' HG ' ' A' ' 75' ' ' SER . 2.0 p -105.28 71.41 0.93 Allowed 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.868 -0.733 . . . . 0.0 110.971 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -127.69 119.8 21.58 Favored Pre-proline 0 CA--C 1.565 1.541 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.483 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.2 Cg_endo -69.85 158.57 56.4 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.594 1.529 . . . . 0.0 114.114 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.568 ' HB3' ' N ' ' A' ' 33' ' ' ALA . . . -22.52 -41.23 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 CA-C-N 114.159 -1.382 . . . . 0.0 114.051 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -117.82 69.31 0.31 Allowed Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -154.59 -168.01 17.32 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.354 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.487 ' N ' HG13 ' A' ' 76' ' ' ILE . 16.6 p -139.72 162.56 34.83 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.967 -1.093 . . . . 0.0 113.307 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.51 178.72 5.91 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 113.724 -1.58 . . . . 0.0 107.578 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.472 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 7.0 tt0 -167.66 145.78 4.62 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 116.987 -1.885 . . . . 0.0 113.53 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.472 ' N ' ' HG2' ' A' ' 83' ' ' GLN . 16.6 p90 -158.96 -178.91 7.59 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.819 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.21 162.51 36.29 Favored Glycine 0 N--CA 1.495 2.614 0 C-N-CA 117.581 -2.247 . . . . 0.0 112.198 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.559 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.6 p90 -155.18 174.19 15.55 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 119.763 -0.775 . . . . 0.0 111.04 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.424 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.6 m-20 -126.65 111.85 14.78 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.053 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.428 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -122.75 154.47 17.01 Favored Glycine 0 N--CA 1.5 2.961 0 C-N-CA 119.983 -1.104 . . . . 0.0 111.966 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.1 p -104.75 145.69 30.01 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.645 ' C ' ' HD1' ' A' ' 90' ' ' HIS . 0.9 OUTLIER -139.26 169.83 17.05 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.638 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 3.2 t -171.12 55.44 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.514 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -166.22 -71.38 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 118.736 -1.697 . . . . 0.0 112.043 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.794 ' H ' ' HG ' ' A' ' 46' ' ' SER . 84.2 m -145.02 -163.35 1.69 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.57 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.783 ' H ' ' CG2' ' A' ' 93' ' ' THR . 0.5 OUTLIER -78.61 160.09 27.75 Favored 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.908 -179.908 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.565 ' CB ' ' NE2' ' A' ' 48' ' ' GLN . . . -107.56 -88.98 0.46 Allowed 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.173 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.471 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -23.78 100.0 0.08 OUTLIER Pre-proline 0 N--CA 1.502 2.169 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.971 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.486 ' HD2' ' CE1' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -65.92 -140.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 121.413 1.409 . . . . 0.0 111.189 179.957 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.546 ' HG1' ' H ' ' A' ' 99' ' ' ALA . 76.3 p -112.29 -76.39 0.59 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.571 -0.851 . . . . 0.0 112.857 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.546 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -105.79 99.91 9.49 Favored 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 119.062 -1.055 . . . . 0.0 111.583 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.542 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.8 m-30 -68.73 -142.42 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 115.311 -0.859 . . . . 0.0 108.842 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.7 m -160.8 108.52 1.55 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 116.994 -1.883 . . . . 0.0 113.454 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.66 ' CD1' ' SG ' ' A' ' 8' ' ' CYS . 0.4 OUTLIER -73.2 154.44 40.26 Favored 'General case' 0 C--O 1.206 -1.232 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.651 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.511 ' H ' HD21 ' A' ' 102' ' ' LEU . 0.2 OUTLIER -52.26 81.84 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.624 -1.23 . . . . 0.0 110.793 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.636 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 140.23 -33.95 2.04 Favored Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.989 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.49 HG22 ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -154.23 163.87 22.65 Favored Pre-proline 0 N--CA 1.505 2.289 0 C-N-CA 118.25 -1.38 . . . . 0.0 113.083 -179.821 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . 0.404 ' HD2' ' CG2' ' A' ' 105' ' ' THR . 1.7 Cg_endo -66.24 118.79 5.8 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 122.654 2.236 . . . . 0.0 111.907 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.525 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.6 t -100.1 123.05 43.89 Favored 'General case' 0 N--CA 1.501 2.108 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.967 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.78 162.22 16.49 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.859 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.775 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 12.8 p -90.07 -130.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.874 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.775 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.494 2.535 0 CA-C-O 116.323 -2.376 . . . . 0.0 110.308 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 3' ' ' SER . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 120.867 0.365 . . . . 0.0 110.185 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 46.72 14.4 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.863 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.521 ' N ' ' O ' ' A' ' 1' ' ' ALA . 50.6 m -91.6 -69.17 0.75 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.816 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.13 174.46 26.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.377 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.433 ' HG2' ' CG2' ' A' ' 105' ' ' THR . 3.0 Cg_exo -56.05 -79.4 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.083 1.855 . . . . 0.0 111.922 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.513 ' H ' HG23 ' A' ' 105' ' ' THR . . . -99.74 -151.91 0.41 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.092 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.68 39.58 0.02 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 107.422 -2.271 . . . . 0.0 107.422 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.459 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 24.3 p -55.01 -171.1 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.271 -0.964 . . . . 0.0 111.876 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.11 131.8 6.88 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.982 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.453 ' O ' ' CG2' ' A' ' 10' ' ' VAL . 2.6 m -113.79 130.51 67.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 C-N-CA 120.004 -0.679 . . . . 0.0 110.581 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.477 ' H ' HD22 ' A' ' 11' ' ' LEU . 0.2 OUTLIER -97.81 161.03 13.94 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.514 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.484 ' CZ3' ' CB ' ' A' ' 96' ' ' ALA . 22.5 t-105 -112.04 149.41 32.09 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.59 0.71 . . . . 0.0 112.517 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.59 76.98 0.36 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -68.92 146.61 12.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.7 t30 -153.94 97.12 2.04 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.209 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.694 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -88.43 132.08 34.61 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -179.645 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.674 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 44.4 p90 -112.82 -149.4 0.45 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 179.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.674 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 81.8 m-20 -65.48 82.31 0.06 Allowed 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.517 -1.673 . . . . 0.0 107.273 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.581 ' O ' ' NE1' ' A' ' 17' ' ' TRP . 0.3 OUTLIER 68.33 133.73 0.03 OUTLIER 'General case' 0 C--O 1.203 -1.366 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.195 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.516 ' HA3' ' CZ2' ' A' ' 17' ' ' TRP . . . 101.75 129.33 6.65 Favored Glycine 0 C--N 1.279 -2.611 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.694 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 32.0 p90 -102.93 133.05 48.68 Favored 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.17 -0.612 . . . . 0.0 112.437 -179.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.421 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 0.8 OUTLIER -99.49 111.91 24.19 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.614 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 86' ' ' PHE . . . -93.75 117.17 29.74 Favored 'General case' 0 C--N 1.292 -1.896 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.727 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.8 102.25 14.03 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.435 HG11 ' N ' ' A' ' 26' ' ' THR . 53.2 t -99.71 147.3 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 N-CA-C 113.993 1.109 . . . . 0.0 113.993 -179.555 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.472 ' HB ' ' CD1' ' A' ' 11' ' ' LEU . 18.5 m -136.71 100.58 4.37 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.948 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.0 t -68.79 146.88 12.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.104 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HZ2' ' HB ' ' A' ' 30' ' ' THR . 9.2 tmtt? -138.48 102.91 4.74 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.567 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.693 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -95.58 136.06 36.45 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.516 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.464 ' HB ' ' HZ2' ' A' ' 28' ' ' LYS . 6.7 t -131.64 5.8 4.34 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.544 -1.207 . . . . 0.0 109.523 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.511 ' HG ' ' ND2' ' A' ' 29' ' ' ASN . 19.1 p -47.24 -86.58 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.026 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.04 34.51 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.505 -179.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.599 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -147.4 155.71 45.94 Favored Pre-proline 0 N--CA 1.481 1.11 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.886 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.35 96.77 0.49 Allowed 'Trans proline' 0 C--N 1.323 -0.763 0 C-N-CA 121.284 1.322 . . . . 0.0 110.14 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.3 t -71.08 117.38 14.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.593 -1.243 . . . . 0.0 111.269 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -123.03 75.01 1.25 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.368 -0.833 . . . . 0.0 108.765 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.44 140.19 7.7 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.431 -1.867 . . . . 0.0 108.431 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.851 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.8 p-90 -158.79 177.46 11.15 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.303 -1.359 . . . . 0.0 111.626 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -141.08 112.37 7.38 Favored 'General case' 0 C--O 1.202 -1.4 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.715 179.897 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.607 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.41 174.68 5.76 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.934 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.512 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -163.55 157.71 19.89 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 117.325 -1.75 . . . . 0.0 113.153 -179.88 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.512 ' N ' ' CG2' ' A' ' 41' ' ' THR . 31.1 p90 -178.18 -141.43 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 113.368 -1.742 . . . . 0.0 107.997 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.478 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 61.2 m -160.82 146.9 14.87 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 117.876 -1.53 . . . . 0.0 112.187 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.65 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 8.3 m-85 -77.55 119.3 76.88 Favored Pre-proline 0 N--CA 1.482 1.132 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.146 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.544 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 3.7 Cg_endo -63.38 -66.67 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.148 1.232 . . . . 0.0 111.579 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.536 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.4 t -69.44 -122.44 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.536 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -130.96 38.48 1.93 Allowed Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.483 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 3.2 mt-30 -75.24 98.31 3.74 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.517 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.538 ' NE2' ' O ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -98.95 112.42 24.54 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.57 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.422 HG21 ' N ' ' A' ' 51' ' ' THR . 2.4 p -70.52 148.26 10.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.2 -1.0 . . . . 0.0 111.12 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.619 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 21.8 p -127.6 -63.24 1.04 Allowed 'General case' 0 N--CA 1.491 1.596 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.77 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.619 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -96.94 138.59 34.24 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.794 179.938 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -148.29 157.19 43.34 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.101 -1.039 . . . . 0.0 111.345 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 43.3 t-105 -153.32 146.12 24.36 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.228 -0.989 . . . . 0.0 111.266 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 66.97 22.28 10.1 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.584 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.605 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 13.1 t -175.95 125.8 0.21 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.405 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.1 79.67 9.3 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.608 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -81.81 152.28 4.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.635 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -155.34 131.45 10.16 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.476 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.473 HE22 ' HB2' ' A' ' 49' ' ' GLN . 6.8 pt20 -95.12 119.98 34.55 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.647 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.419 ' H ' ' HG ' ' A' ' 61' ' ' SER . 3.7 p -86.91 68.93 10.22 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.18 -56.98 4.03 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 -20.18 0.3 Allowed 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.404 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.415 ' CB ' ' OG ' ' A' ' 61' ' ' SER . . . -85.99 -168.46 2.24 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.942 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.65 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 84.2 t -147.35 155.2 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.757 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.572 ' HG1' ' C ' ' A' ' 65' ' ' VAL . 70.7 m -161.63 124.29 3.03 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.705 -1.134 . . . . 0.0 108.653 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.605 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.4 t -117.53 146.4 22.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.093 0 C-N-CA 119.548 -0.861 . . . . 0.0 111.857 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -132.16 90.51 2.82 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.851 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.53 122.52 22.33 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 118.948 -1.101 . . . . 0.0 112.445 -179.626 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.59 ' CB ' ' CE2' ' A' ' 72' ' ' TRP . . . -40.3 155.88 0.18 Allowed Pre-proline 0 N--CA 1.479 0.993 0 CA-C-N 113.592 -1.64 . . . . 0.0 112.186 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.96 -35.28 35.45 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 121.759 1.639 . . . . 0.0 112.297 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.59 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -70.55 -57.38 4.81 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 118.931 -1.108 . . . . 0.0 110.981 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.507 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -65.85 -21.34 66.46 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.994 -1.082 . . . . 0.0 110.171 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -96.61 27.87 15.8 Favored Glycine 0 N--CA 1.486 1.967 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.654 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 32.2 m -91.86 60.68 3.95 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.956 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -108.49 136.4 19.91 Favored Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.387 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' GLY . 7.2 Cg_endo -69.81 151.42 68.75 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 121.51 1.474 . . . . 0.0 111.181 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.599 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -40.41 -22.32 0.01 OUTLIER 'General case' 0 C--O 1.2 -1.525 0 C-N-CA 119.749 -0.78 . . . . 0.0 112.268 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.71 64.19 0.28 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.31 -162.83 18.68 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 118.11 -1.995 . . . . 0.0 111.485 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.483 ' N ' HG13 ' A' ' 76' ' ' ILE . 3.6 p -139.5 162.41 35.12 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-O 121.867 0.841 . . . . 0.0 112.765 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -136.84 122.2 19.39 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -114.82 164.91 13.43 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.438 ' CD2' ' HB3' ' A' ' 56' ' ' SER . 8.3 p90 -163.89 -178.09 5.48 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 112.688 -2.051 . . . . 0.0 108.986 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.24 159.13 32.39 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 117.556 -2.259 . . . . 0.0 111.937 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 2.3 p90 -154.77 169.2 24.51 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.487 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.507 HD21 ' C ' ' A' ' 86' ' ' PHE . 1.4 m120 -125.57 112.52 16.28 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.53 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.03 150.23 17.25 Favored Glycine 0 N--CA 1.512 3.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.464 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.427 ' OG ' ' CG ' ' A' ' 49' ' ' GLN . 52.1 p -77.16 155.26 32.42 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 120.121 -0.631 . . . . 0.0 109.715 179.742 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.578 ' HD1' ' N ' ' A' ' 91' ' ' THR . 9.6 p80 -147.99 -157.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 118.957 -1.097 . . . . 0.0 111.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.578 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.3 p -151.78 -8.46 0.22 Allowed 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.05 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.63 84.7 1.69 Allowed Glycine 0 N--CA 1.494 2.544 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.968 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.715 ' CG2' ' H ' ' A' ' 94' ' ' ASN . 96.3 m -161.58 -130.86 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.283 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.715 ' H ' ' CG2' ' A' ' 93' ' ' THR . 32.6 t-20 -87.73 131.34 34.52 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.609 -0.836 . . . . 0.0 111.273 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.454 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -109.46 -155.36 0.56 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.016 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.484 ' CB ' ' CZ3' ' A' ' 12' ' ' TRP . . . -25.26 122.29 0.21 Allowed Pre-proline 0 N--CA 1.502 2.146 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.705 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.452 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.8 -142.16 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 121.214 1.276 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' THR . . . . . 0.452 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 42.8 p -108.5 -100.57 0.37 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.472 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.423 ' H ' ' HG1' ' A' ' 98' ' ' THR . . . -90.27 104.22 16.82 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 118.503 -1.279 . . . . 0.0 112.196 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.3 m-30 -70.37 -141.84 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.363 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.5 m -162.39 109.81 1.32 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 117.022 -1.871 . . . . 0.0 113.869 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.5 mt -53.85 178.14 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.817 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.49 ' H ' HD21 ' A' ' 102' ' ' LEU . 1.8 p30 -39.66 -26.41 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.927 -0.709 . . . . 0.0 111.973 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -165.31 41.7 0.29 Allowed Glycine 0 N--CA 1.491 2.307 0 C-N-CA 118.653 -1.737 . . . . 0.0 111.499 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.2 OUTLIER -171.83 147.68 2.01 Favored Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.685 179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.17 156.64 44.03 Favored 'Trans proline' 0 C--O 1.212 -0.813 0 C-N-CA 121.566 1.51 . . . . 0.0 112.554 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.41 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.0 t -147.26 101.65 3.41 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.342 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.01 135.75 57.81 Favored 'General case' 0 N--CA 1.518 2.951 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -179.587 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.792 ' CG2' ' H ' ' A' ' 110' ' ' GLY . 5.3 p -59.93 -163.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 118.795 -1.162 . . . . 0.0 110.926 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.792 ' H ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 116.35 -2.361 . . . . 0.0 110.386 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.41 ' HB2' ' H ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.41 ' H ' ' HB2' ' A' ' 1' ' ' ALA . 23.8 t -153.34 69.72 0.83 Allowed 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.849 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.7 p -169.8 155.09 5.64 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.819 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.02 173.27 31.85 Favored Glycine 0 N--CA 1.488 2.164 0 C-N-CA 119.501 -1.333 . . . . 0.0 110.251 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -54.67 -55.24 3.46 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.036 1.824 . . . . 0.0 111.915 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.485 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . -106.21 -159.77 0.72 Allowed 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.946 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.33 38.42 0.05 OUTLIER Glycine 0 N--CA 1.492 2.419 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 4.3 p -49.21 178.63 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 113.904 -1.148 . . . . 0.0 113.016 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -135.13 106.37 6.74 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.035 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.508 ' CG1' ' SG ' ' A' ' 107' ' ' CYS . 2.1 m -99.45 139.12 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 119.061 -1.056 . . . . 0.0 112.428 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.44 ' CD2' ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -109.21 162.65 14.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.848 179.772 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.506 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.2 t-105 -128.05 139.68 52.39 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.318 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -116.22 62.59 0.37 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.334 -2.307 . . . . 0.0 107.334 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.455 HG21 ' N ' ' A' ' 15' ' ' ASN . 14.6 p -69.3 140.84 18.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.467 ' CB ' ' CG2' ' A' ' 22' ' ' THR . 2.4 t30 -140.06 100.92 4.04 Favored 'General case' 0 N--CA 1.489 1.496 0 CA-C-N 114.616 -1.175 . . . . 0.0 108.762 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.843 ' NE2' ' N ' ' A' ' 17' ' ' TRP . 0.0 OUTLIER -85.17 107.92 17.46 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.105 -1.038 . . . . 0.0 112.967 -179.782 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.843 ' N ' ' NE2' ' A' ' 16' ' ' GLN . 5.0 p90 -106.75 99.84 9.39 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.801 ' N ' HD21 ' A' ' 18' ' ' ASN . 0.0 OUTLIER 78.89 -47.41 0.41 Allowed 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.541 -179.657 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.769 ' N ' HE22 ' A' ' 16' ' ' GLN . 0.7 OUTLIER -170.34 -56.18 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.514 179.894 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.702 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -59.3 163.98 11.3 Favored Glycine 0 C--O 1.198 -2.106 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.564 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 2.8 p90 -136.28 120.87 18.3 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 119.13 -1.028 . . . . 0.0 112.681 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.467 ' CG2' ' CB ' ' A' ' 15' ' ' ASN . 1.4 t -78.92 174.02 11.95 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 179.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.506 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -153.2 125.73 8.18 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 117.04 -1.864 . . . . 0.0 114.053 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -107.8 91.5 3.68 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 179.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.452 ' CG1' ' CE2' ' A' ' 84' ' ' PHE . 40.5 t -96.02 144.3 10.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 113.94 1.089 . . . . 0.0 113.94 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.449 ' N ' HG11 ' A' ' 25' ' ' VAL . 0.4 OUTLIER -126.35 129.72 49.39 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 114.489 -1.232 . . . . 0.0 107.95 179.687 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 23.7 t -101.2 103.81 15.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 C-N-CA 119.281 -0.968 . . . . 0.0 113.151 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 12.6 tmtt? -95.1 106.53 18.54 Favored 'General case' 0 C--N 1.291 -1.951 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.395 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.692 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -107.87 140.94 40.22 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.72 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -140.69 19.34 2.34 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 114.214 -1.357 . . . . 0.0 109.028 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.413 ' O ' ' CB ' ' A' ' 32' ' ' SER . 13.1 p -48.08 -88.47 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.176 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.466 ' CA ' ' HB3' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 170.41 31.55 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.822 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.591 ' N ' ' CB ' ' A' ' 78' ' ' ALA . . . -154.47 170.98 7.66 Favored Pre-proline 0 N--CA 1.48 1.07 0 C-N-CA 118.085 -1.446 . . . . 0.0 111.443 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.83 97.34 1.06 Allowed 'Trans proline' 0 C--N 1.323 -0.784 0 C-N-CA 121.842 1.695 . . . . 0.0 109.963 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.4 t -75.43 94.31 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 118.249 -1.38 . . . . 0.0 111.591 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.19 50.25 1.37 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 112.1 167.49 17.84 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 107.826 -2.11 . . . . 0.0 107.826 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.756 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 37.8 p-90 -171.17 176.39 3.97 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 117.808 -1.557 . . . . 0.0 111.836 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.1 102.14 4.32 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.607 ' C ' ' CD2' ' A' ' 40' ' ' LEU . 0.2 OUTLIER -89.63 172.8 8.69 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.699 -1.201 . . . . 0.0 109.409 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.452 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 2.0 m -160.73 142.12 12.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.437 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.559 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.6 p90 -171.0 -140.1 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.249 -1.342 . . . . 0.0 108.351 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.559 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.2 m -161.03 168.2 24.94 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 117.419 -1.713 . . . . 0.0 112.782 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.495 ' CE2' HG23 ' A' ' 65' ' ' VAL . 2.9 m-85 -101.66 109.41 59.26 Favored Pre-proline 0 N--CA 1.489 1.483 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.31 -63.7 0.12 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.098 1.199 . . . . 0.0 111.367 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.667 ' HG ' ' H ' ' A' ' 93' ' ' THR . 38.8 t -69.59 -172.7 0.5 Allowed 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.575 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.484 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -84.9 57.9 4.99 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.072 -1.537 . . . . 0.0 109.886 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.791 HE22 ' CD2' ' A' ' 90' ' ' HIS . 11.6 mm-40 -94.41 108.91 20.81 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 119.213 -0.995 . . . . 0.0 111.014 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.9 OUTLIER -106.57 108.89 20.63 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.913 -179.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.1 p -76.47 157.04 5.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.187 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.505 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 72.6 p -138.47 -68.82 0.44 Allowed 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.531 -0.867 . . . . 0.0 111.1 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLN . . . . . 0.505 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.2 mt-30 -80.59 165.26 22.24 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.03 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.14 153.58 8.24 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 118.717 -1.193 . . . . 0.0 111.923 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 32.3 t-105 -147.32 136.88 22.79 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.354 -0.939 . . . . 0.0 110.899 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.7 p 60.23 26.6 16.06 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.196 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.14 117.26 1.65 Allowed 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.0 m -82.11 77.64 8.89 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.977 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.2 m -68.99 154.37 8.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.613 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.9 p -154.07 108.14 3.0 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.908 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 3.6 tt0 -88.09 116.01 25.97 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.036 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.441 ' H ' ' HG ' ' A' ' 61' ' ' SER . 4.7 p -94.39 89.38 5.85 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.636 -0.825 . . . . 0.0 110.777 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 71.16 -74.6 0.66 Allowed Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.388 -1.387 . . . . 0.0 109.963 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 -14.69 1.55 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.122 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.545 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -89.29 -173.91 4.2 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.033 -1.067 . . . . 0.0 110.063 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.589 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.2 t -147.27 160.11 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 118.735 -1.186 . . . . 0.0 113.637 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.589 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.3 m -155.53 145.93 21.91 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.899 -1.5 . . . . 0.0 108.563 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 2.8 t -141.07 119.4 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 118.727 -1.189 . . . . 0.0 112.469 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.83 91.43 4.83 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.97 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.756 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -70.77 122.8 20.53 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.194 -1.003 . . . . 0.0 111.344 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.732 ' CA ' HD22 ' A' ' 73' ' ' ASN . . . -43.91 166.65 0.1 Allowed Pre-proline 0 C--N 1.307 -1.276 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.452 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.04 -39.98 5.38 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 122.155 1.903 . . . . 0.0 112.392 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' TRP . . . . . 0.514 ' CE2' ' HB2' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -68.56 -55.72 10.68 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.024 -1.07 . . . . 0.0 110.514 -179.875 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.732 HD22 ' CA ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -76.71 11.02 1.84 Allowed 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.18 -1.008 . . . . 0.0 109.624 179.823 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -139.87 37.56 1.71 Allowed Glycine 0 N--CA 1.484 1.898 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.574 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.1 m -104.08 61.74 0.74 Allowed 'General case' 0 C--N 1.309 -1.162 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.956 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.461 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -109.49 136.68 20.22 Favored Pre-proline 0 N--CA 1.484 1.267 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.368 179.926 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.663 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.9 Cg_endo -71.3 171.16 16.63 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 121.396 1.397 . . . . 0.0 111.068 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.591 ' CB ' ' N ' ' A' ' 33' ' ' ALA . . . -63.18 17.72 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.563 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.663 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -149.8 61.76 0.42 Allowed Glycine 0 C--N 1.291 -1.954 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.22 -155.12 9.57 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 118.641 -1.742 . . . . 0.0 110.733 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.461 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.9 OUTLIER -141.73 168.8 18.89 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.244 -0.983 . . . . 0.0 112.603 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -132.34 -173.3 3.12 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . 0.641 ' CD ' ' N ' ' A' ' 84' ' ' PHE . 12.4 tm0? -167.59 144.74 4.4 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 116.792 -1.963 . . . . 0.0 113.649 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.641 ' N ' ' CD ' ' A' ' 83' ' ' GLN . 3.9 p90 -164.13 164.73 22.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.604 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.51 178.47 32.96 Favored Glycine 0 N--CA 1.504 3.192 0 C-N-CA 118.068 -2.015 . . . . 0.0 111.855 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 86' ' ' PHE . 4.4 p90 -164.17 -169.8 1.93 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.687 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -142.93 110.8 5.93 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.64 -0.824 . . . . 0.0 110.741 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.71 164.08 12.7 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.026 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 85.2 p -114.08 136.38 52.99 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.791 ' CD2' HE22 ' A' ' 48' ' ' GLN . 0.3 OUTLIER -151.03 -175.33 5.1 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 117.538 -1.665 . . . . 0.0 113.514 -179.892 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.782 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 2.3 t -171.17 48.85 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.675 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.44 -129.97 1.98 Allowed Glycine 0 N--CA 1.493 2.459 0 C-N-CA 118.919 -1.61 . . . . 0.0 112.167 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.667 ' H ' ' HG ' ' A' ' 46' ' ' SER . 0.2 OUTLIER -90.92 -155.65 0.4 Allowed 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -70.72 165.48 22.9 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.84 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.432 ' HB3' ' CE1' ' A' ' 44' ' ' PHE . . . -111.6 -8.38 14.23 Favored 'General case' 0 N--CA 1.486 1.375 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.342 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.463 ' HB3' ' CE3' ' A' ' 12' ' ' TRP . . . -106.61 106.44 57.73 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.441 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.51 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.8 Cg_endo -64.25 -95.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 120.834 1.022 . . . . 0.0 112.248 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -153.25 -90.41 0.05 OUTLIER 'General case' 0 N--CA 1.497 1.882 0 C-N-CA 118.919 -1.113 . . . . 0.0 112.279 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -96.78 94.51 7.31 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.595 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -66.23 -158.34 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 43.3 m -153.79 118.71 5.03 Favored 'General case' 0 C--N 1.309 -1.179 0 C-N-CA 116.956 -1.898 . . . . 0.0 114.015 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -63.72 176.4 0.91 Allowed 'General case' 0 N--CA 1.48 1.026 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.315 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.469 ' H ' HD21 ' A' ' 102' ' ' LEU . 0.8 OUTLIER -36.94 -32.94 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 C-N-CA 120.025 -0.67 . . . . 0.0 112.675 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' CG2' ' A' ' 105' ' ' THR . . . -155.72 47.03 0.51 Allowed Glycine 0 N--CA 1.499 2.898 0 C-N-CA 118.463 -1.827 . . . . 0.0 111.865 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.544 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER 179.85 160.26 0.83 Allowed Pre-proline 0 C--O 1.192 -1.965 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.97 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.94 179.79 1.69 Allowed 'Trans proline' 0 C--N 1.321 -0.891 0 C-N-CA 122.004 1.802 . . . . 0.0 112.87 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.508 ' SG ' ' CG1' ' A' ' 10' ' ' VAL . 5.5 t -170.13 106.68 0.33 Allowed 'General case' 0 N--CA 1.497 1.898 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.305 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 70.6 p -72.06 149.86 44.47 Favored 'General case' 0 N--CA 1.506 2.358 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.725 ' CG1' ' H ' ' A' ' 110' ' ' GLY . 5.0 t -59.05 -167.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 C-N-CA 118.981 -1.088 . . . . 0.0 110.422 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.725 ' H ' ' CG1' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.482 0 CA-C-O 116.289 -2.395 . . . . 0.0 110.301 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.969 0.414 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -178.28 43.21 0.09 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.871 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.5 p -60.42 -160.79 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.779 -0.71 . . . . 0.0 110.94 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.64 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -165.3 157.55 15.39 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.192 179.859 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.477 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.0 m -139.63 130.6 32.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.151 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.555 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.79 157.09 16.05 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.718 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.563 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.6 t-105 -114.55 141.44 47.73 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.831 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.14 76.28 0.41 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.2 p -69.23 149.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 . . . . . 0 C--N 1.302 -1.491 0 CA-C-N 113.91 -1.496 . . . . 0.0 107.348 179.839 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.584 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 8.3 p90 . . . . . 0 CA--C 1.487 -1.448 0 CA-C-O 121.583 0.706 . . . . 0.0 111.192 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.504 HG22 ' O ' ' A' ' 22' ' ' THR . 0.4 OUTLIER -97.11 114.34 26.0 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.563 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -93.74 120.62 34.24 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.367 -0.933 . . . . 0.0 113.422 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -99.08 95.83 7.38 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG11 ' CE1' ' A' ' 84' ' ' PHE . 29.8 t -91.81 152.46 3.39 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.555 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.0 OUTLIER -138.88 106.08 5.49 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.184 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.1 t -71.2 149.01 10.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.101 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.514 ' HA ' HG22 ' A' ' 81' ' ' THR . 6.5 tptm -141.03 102.81 4.34 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.12 -0.945 . . . . 0.0 110.186 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.629 ' HB3' HD11 ' A' ' 76' ' ' ILE . 38.5 t-20 -96.76 136.93 36.61 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.948 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.5 t -141.47 -4.31 1.12 Allowed 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.681 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.1 p -51.97 -81.27 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.118 -1.033 . . . . 0.0 110.339 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.51 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 163.52 73.55 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.373 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.49 149.28 3.67 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.22 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -72.27 97.37 0.85 Allowed 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 121.207 1.271 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.451 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.9 OUTLIER -77.49 100.52 2.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.78 -179.89 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -110.44 58.4 0.61 Allowed 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.06 152.39 21.39 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 107.909 -2.077 . . . . 0.0 107.909 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.644 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 37.3 p-90 -166.35 178.07 6.41 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 117.693 -1.603 . . . . 0.0 112.208 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.34 102.51 4.37 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.133 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.869 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -93.97 175.06 6.86 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.957 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.542 ' HG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -169.92 156.22 6.07 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 117.854 -1.539 . . . . 0.0 112.679 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.498 ' CD2' ' N ' ' A' ' 43' ' ' SER . 20.2 p90 -176.73 -132.81 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 113.565 -1.652 . . . . 0.0 107.8 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.498 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -162.29 148.23 13.0 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 117.726 -1.589 . . . . 0.0 111.951 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.654 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -82.8 119.01 73.62 Favored Pre-proline 0 N--CA 1.486 1.36 0 C-N-CA 118.601 -1.24 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -55.23 -72.42 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 121.083 1.189 . . . . 0.0 111.764 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.42 ' HB3' HE22 ' A' ' 48' ' ' GLN . 5.6 t -69.58 -134.0 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 110.535 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -118.57 51.86 0.73 Allowed Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.343 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.492 ' HB2' ' CG ' ' A' ' 44' ' ' PHE . 15.2 mp0 -67.96 88.35 0.27 Allowed 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.492 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.443 ' CA ' ' OE1' ' A' ' 49' ' ' GLN . 3.1 mm100 -76.99 85.75 3.51 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -74.64 144.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.839 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.633 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -143.38 -61.02 0.41 Allowed 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 119.033 -1.067 . . . . 0.0 111.932 -179.838 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.633 ' H ' HG23 ' A' ' 51' ' ' THR . 1.1 mt-30 -75.54 135.26 40.6 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.569 -1.252 . . . . 0.0 110.073 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.431 ' HB2' HG21 ' A' ' 58' ' ' VAL . . . -147.89 156.11 42.33 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 118.785 -1.166 . . . . 0.0 112.146 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 34.2 t-105 -151.91 142.16 22.38 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.6 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 t 62.31 27.43 16.39 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.583 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -171.36 125.34 0.62 Allowed 'General case' 0 C--N 1.303 -1.428 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.317 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -87.28 73.59 9.65 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.035 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.489 HG12 HG13 ' A' ' 67' ' ' VAL . 33.0 m -69.01 153.86 8.66 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 115.044 -0.98 . . . . 0.0 112.484 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.416 HG23 ' C ' ' A' ' 58' ' ' VAL . 44.2 p -155.42 112.4 3.26 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.658 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.475 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 4.7 pt20 -91.02 113.42 25.68 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.489 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 4.7 p -87.68 86.07 7.14 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.774 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 73.71 -71.59 1.34 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -139.28 -15.98 1.08 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.029 -0.668 . . . . 0.0 109.716 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.489 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -87.9 -176.46 5.49 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.048 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.654 HG21 ' CD2' ' A' ' 44' ' ' PHE . 44.8 t -145.54 161.06 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 C-N-CA 118.596 -1.242 . . . . 0.0 113.888 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.611 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 44.9 m -157.52 143.79 17.76 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 113.627 -1.624 . . . . 0.0 108.284 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.556 HG23 HD21 ' A' ' 40' ' ' LEU . 2.2 t -139.66 117.47 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.617 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -99.03 91.87 5.22 Favored 'General case' 0 C--N 1.288 -2.092 0 CA-C-N 114.291 -1.322 . . . . 0.0 108.132 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.644 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.8 p-10 -72.47 121.56 19.8 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.195 -1.002 . . . . 0.0 112.215 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.719 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.88 162.07 0.11 Allowed Pre-proline 0 N--CA 1.488 1.475 0 CA-C-N 113.563 -1.653 . . . . 0.0 112.47 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.7 Cg_endo -68.86 -36.36 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 121.869 1.713 . . . . 0.0 111.939 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.719 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.67 -56.3 7.63 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 118.962 -1.095 . . . . 0.0 110.494 -179.895 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.717 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 5.4 p30 -74.33 2.73 8.64 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 118.818 -1.153 . . . . 0.0 109.492 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.545 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -122.43 37.12 2.94 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -104.71 56.53 0.7 Allowed 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.207 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.681 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -106.86 130.62 22.61 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.741 -0.783 . . . . 0.0 111.195 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 78' ' ' ALA . 8.7 Cg_endo -72.32 154.19 56.2 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 121.606 1.537 . . . . 0.0 113.381 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.51 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -21.84 -49.14 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.67 70.71 0.21 Allowed Glycine 0 N--CA 1.493 2.447 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.417 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -153.5 -165.56 13.71 Favored Glycine 0 C--N 1.285 -2.293 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.069 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.572 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.8 OUTLIER -140.9 164.05 31.29 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 119.271 -0.972 . . . . 0.0 112.528 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.603 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -132.78 -177.35 4.45 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 114.352 -1.294 . . . . 0.0 107.646 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.8 OUTLIER -167.6 143.5 4.06 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 116.875 -1.93 . . . . 0.0 113.54 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.579 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 8.7 p90 -159.22 176.12 12.59 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.664 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.69 170.28 41.12 Favored Glycine 0 N--CA 1.5 2.931 0 C-N-CA 117.897 -2.097 . . . . 0.0 112.137 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.6 p90 -159.32 168.88 25.28 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.703 -0.799 . . . . 0.0 111.022 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.531 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -121.93 114.21 20.68 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.896 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.443 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -126.07 150.29 17.57 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.3 p . . . . . 0 N--CA 1.483 1.204 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.852 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.418 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.492 1.666 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.463 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -66.58 -144.32 0.02 OUTLIER 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 121.454 1.436 . . . . 0.0 111.401 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.82 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.8 OUTLIER -108.45 -101.48 0.37 Allowed 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.002 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.6 106.08 18.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 118.807 -1.157 . . . . 0.0 112.402 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.567 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.3 m-30 -74.99 -148.19 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.397 -0.921 . . . . 0.0 108.714 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.469 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -159.84 114.85 2.36 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 117.145 -1.822 . . . . 0.0 113.457 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.871 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -58.47 -175.84 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.06 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.506 ' OD1' HD22 ' A' ' 102' ' ' LEU . 6.1 p-10 -64.89 76.49 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.071 -1.052 . . . . 0.0 111.764 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.49 11.46 33.26 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.57 -1.3 . . . . 0.0 112.374 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.602 ' O ' ' N ' ' A' ' 102' ' ' LEU . 6.5 p -151.92 145.81 18.05 Favored Pre-proline 0 N--CA 1.493 1.709 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.091 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -65.04 170.78 9.87 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.342 1.361 . . . . 0.0 111.713 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.64 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 3.1 t -163.79 106.53 0.96 Allowed 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.491 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.5 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 7.5 p -70.49 130.62 42.37 Favored 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 98' ' ' THR . 0.7 OUTLIER -53.96 175.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.525 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.496 2.649 0 CA-C-O 116.368 -2.351 . . . . 0.0 110.274 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.522 ' N ' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.48 1.048 0 CA-C-O 121.406 0.622 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.43 28.34 0.36 Allowed Glycine 0 N--CA 1.5 2.911 0 N-CA-C 106.939 -2.465 . . . . 0.0 106.939 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -52.83 -174.05 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 113.49 -1.355 . . . . 0.0 113.213 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -137.22 108.16 6.7 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.768 -1.56 . . . . 0.0 109.654 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.836 HG13 ' SG ' ' A' ' 107' ' ' CYS . 4.9 m -100.67 122.73 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.384 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.2 159.62 14.93 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.389 -0.924 . . . . 0.0 109.653 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.562 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.8 t-105 -121.22 139.76 52.94 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.748 -0.781 . . . . 0.0 112.013 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 73.38 0.4 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 107.279 -2.328 . . . . 0.0 107.279 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -72.84 152.27 7.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.574 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.288 0 CA-C-N 113.969 -1.469 . . . . 0.0 108.675 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.527 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.7 p90 . . . . . 0 CA--C 1.506 -0.745 0 CA-C-O 121.185 0.517 . . . . 0.0 112.256 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.574 HG22 ' CB ' ' A' ' 15' ' ' ASN . 8.2 t -73.48 172.86 10.52 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.562 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -159.32 110.23 2.02 Favored 'General case' 0 C--N 1.289 -2.027 0 C-N-CA 117.289 -1.764 . . . . 0.0 112.919 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -93.02 103.92 16.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.618 HG11 ' CE1' ' A' ' 84' ' ' PHE . 24.6 t -99.64 140.43 18.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 119.451 -0.9 . . . . 0.0 113.124 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.569 ' HB ' HD11 ' A' ' 11' ' ' LEU . 3.5 m -131.14 113.11 13.49 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.783 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.699 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -84.7 143.04 12.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.618 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.83 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.2 tptp -124.9 99.92 6.36 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.933 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.658 ' HB3' HD11 ' A' ' 76' ' ' ILE . 6.2 t-20 -91.54 106.22 18.32 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.191 -1.004 . . . . 0.0 108.372 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 t -119.17 -1.11 10.92 Favored 'General case' 0 C--N 1.311 -1.107 0 O-C-N 124.174 0.921 . . . . 0.0 110.142 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.5 p -50.34 -81.85 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.399 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.69 37.49 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.305 -179.886 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.892 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -137.5 146.65 54.39 Favored Pre-proline 0 N--CA 1.485 1.301 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.187 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -70.22 107.4 1.94 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 121.212 1.275 . . . . 0.0 109.882 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.419 HG21 ' ND2' ' A' ' 29' ' ' ASN . 1.0 OUTLIER -86.63 110.49 20.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.487 -1.285 . . . . 0.0 111.981 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -120.1 65.45 0.82 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.64 146.22 20.56 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 106.885 -2.486 . . . . 0.0 106.885 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 47.9 p-90 -163.51 175.54 10.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 117.419 -1.712 . . . . 0.0 112.095 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.416 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -141.06 112.39 7.4 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.777 179.92 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.44 175.35 5.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.395 179.896 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.484 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -159.35 152.48 22.18 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 117.919 -1.512 . . . . 0.0 112.289 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.533 ' CD2' ' N ' ' A' ' 43' ' ' SER . 23.6 p90 -175.1 -150.91 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.931 -1.486 . . . . 0.0 108.432 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.533 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 14.7 m -158.66 154.39 26.37 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.881 -1.528 . . . . 0.0 111.835 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.518 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.2 m-85 -87.71 116.96 67.82 Favored Pre-proline 0 C--N 1.309 -1.153 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.901 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -56.99 -74.87 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 121.292 1.328 . . . . 0.0 112.619 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.26 -136.11 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.636 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -107.6 63.92 0.27 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.857 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.517 ' O ' ' CD2' ' A' ' 44' ' ' PHE . 21.5 mt-30 -110.97 112.14 23.75 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.802 -0.759 . . . . 0.0 110.667 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.428 ' HB2' HE22 ' A' ' 60' ' ' GLN . 1.2 pp0? -121.34 118.62 29.93 Favored 'General case' 0 N--CA 1.499 2.007 0 C-N-CA 119.764 -0.774 . . . . 0.0 111.212 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.448 ' H ' HG12 ' A' ' 50' ' ' VAL . 2.0 p -72.79 156.0 6.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.383 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.508 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 80.4 p -132.45 -69.67 0.58 Allowed 'General case' 0 N--CA 1.492 1.669 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.777 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.508 ' N ' ' OG1' ' A' ' 51' ' ' THR . 5.1 mt-30 -88.02 141.88 28.23 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.292 -0.963 . . . . 0.0 109.801 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.99 166.99 29.84 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.859 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.605 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 42.5 t-105 -154.45 157.15 38.01 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.003 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.605 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 51.75 26.79 3.68 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.771 -179.839 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.4 m -172.98 127.58 0.47 Allowed 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.695 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.4 m -90.15 77.19 6.8 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.795 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.499 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.3 m -69.69 151.81 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-N 115.365 -0.834 . . . . 0.0 112.306 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -152.17 104.2 2.94 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.462 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.428 HE22 ' HB2' ' A' ' 49' ' ' GLN . 11.6 tt0 -82.69 120.8 26.04 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.682 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 10.4 p -94.13 75.76 4.05 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.589 -0.844 . . . . 0.0 110.718 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.65 -65.59 2.82 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.041 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.41 -16.01 0.94 Allowed 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.294 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.682 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -91.61 -171.15 2.81 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 119.268 -0.973 . . . . 0.0 110.215 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.518 HG21 ' CE2' ' A' ' 44' ' ' PHE . 72.7 t -147.3 154.55 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 118.744 -1.182 . . . . 0.0 113.262 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.481 ' N ' HG12 ' A' ' 65' ' ' VAL . 17.1 m -155.75 119.82 4.53 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 114.396 -1.275 . . . . 0.0 108.441 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.662 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -114.32 149.38 16.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.938 0 C-N-CA 119.614 -0.835 . . . . 0.0 111.847 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -132.33 93.0 3.18 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.794 ' HB2' HD22 ' A' ' 73' ' ' ASN . 3.1 p-10 -72.88 122.16 21.18 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.055 -1.058 . . . . 0.0 112.329 -179.582 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.591 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -41.95 161.45 0.15 Allowed Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 113.549 -1.659 . . . . 0.0 112.05 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.0 Cg_endo -65.54 -37.67 28.58 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 121.95 1.767 . . . . 0.0 112.273 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.591 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.46 -55.93 8.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.579 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.794 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.5 OUTLIER -74.69 11.83 0.95 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.738 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.568 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -133.44 22.95 3.88 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.747 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.8 m -93.93 57.08 2.39 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.331 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.759 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.52 128.72 24.88 Favored Pre-proline 0 N--CA 1.489 1.495 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.68 179.971 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.599 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.4 Cg_endo -69.8 154.52 67.47 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 121.448 1.432 . . . . 0.0 111.012 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.892 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -42.49 -12.53 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.745 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.08 55.82 0.5 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.98 -165.65 24.74 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 118.511 -1.804 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.83 HG22 ' HA ' ' A' ' 28' ' ' LYS . 5.9 p -137.93 163.17 32.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.183 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.517 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -121.56 -176.95 3.42 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -169.91 144.71 2.81 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 116.906 -1.917 . . . . 0.0 113.246 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.4 p90 -159.31 169.11 24.75 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.045 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -155.99 163.58 31.9 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 118.052 -2.023 . . . . 0.0 112.023 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.5 p90 -161.16 161.52 31.04 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.242 -0.983 . . . . 0.0 112.287 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 25.8 m-20 -112.79 111.79 22.83 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.271 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.25 164.3 12.16 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.948 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.313 -0.986 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.878 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.507 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 111.187 0.069 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.2 Cg_endo -63.13 -121.82 0.0 OUTLIER 'Trans proline' 0 CA--C 1.557 1.658 0 C-N-CA 121.125 1.216 . . . . 0.0 111.935 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.462 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 27.4 p -136.4 -77.43 0.42 Allowed 'General case' 0 N--CA 1.505 2.278 0 C-N-CA 119.246 -0.982 . . . . 0.0 112.608 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -98.72 97.9 9.09 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.842 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 107' ' ' CYS . 45.2 m-85 -66.73 -170.12 0.1 Allowed 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.9 m -146.78 113.99 6.24 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 117.457 -1.697 . . . . 0.0 113.897 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -60.59 -178.19 0.09 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.629 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 102' ' ' LEU . 26.0 m-80 -30.38 -39.85 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -159.98 39.18 0.46 Allowed Glycine 0 N--CA 1.498 2.776 0 C-N-CA 118.583 -1.77 . . . . 0.0 111.598 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.522 HG21 ' N ' ' A' ' 6' ' ' ALA . 9.7 m -162.23 137.61 5.5 Favored Pre-proline 0 N--CA 1.49 1.531 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -50.8 177.57 0.03 OUTLIER 'Trans proline' 0 C--O 1.211 -0.858 0 C-N-CA 121.473 1.448 . . . . 0.0 112.361 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.836 ' SG ' HG13 ' A' ' 10' ' ' VAL . 22.0 t -166.35 98.45 0.6 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.411 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 p -46.68 154.82 0.28 Allowed 'General case' 0 N--CA 1.502 2.129 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.678 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.942 HG22 ' N ' ' A' ' 110' ' ' GLY . 2.8 p -68.92 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 118.787 -1.165 . . . . 0.0 109.4 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.942 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.137 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.435 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.579 ' N ' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 121.358 0.599 . . . . 0.0 112.431 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.23 51.25 0.04 OUTLIER Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -51.56 177.84 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.027 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -133.01 99.84 4.7 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.332 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.741 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -91.87 135.01 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 118.967 -1.093 . . . . 0.0 111.875 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.596 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -112.93 164.83 12.95 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.915 179.824 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.665 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.8 t-105 -125.32 143.95 50.72 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.653 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.83 75.8 0.42 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.592 HG22 ' N ' ' A' ' 15' ' ' ASN . 10.0 p -79.2 158.96 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.602 ' CB ' HG22 ' A' ' 22' ' ' THR . 3.6 t30 . . . . . 0 C--N 1.302 -1.482 0 CA-C-N 113.238 -1.801 . . . . 0.0 107.129 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.612 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.6 p90 . . . . . 0 C--O 1.215 -0.731 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.602 HG22 ' CB ' ' A' ' 15' ' ' ASN . 14.0 t -72.4 173.95 8.05 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.441 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -155.37 120.42 4.85 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 117.251 -1.779 . . . . 0.0 112.908 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -104.0 98.87 8.63 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.561 -1.2 . . . . 0.0 107.904 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.625 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.2 t -96.95 140.8 16.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.306 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.767 HG23 ' HG2' ' A' ' 83' ' ' GLN . 98.7 m -126.39 108.15 10.95 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.278 -0.874 . . . . 0.0 108.809 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.1 t -83.44 101.1 7.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 C-N-CA 119.727 -0.789 . . . . 0.0 111.959 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.772 ' HA ' HG22 ' A' ' 81' ' ' THR . 11.5 tttp -87.82 109.51 19.8 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.512 -1.275 . . . . 0.0 109.992 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.454 ' HB3' HD11 ' A' ' 76' ' ' ILE . 1.4 t-20 -95.56 112.38 24.11 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.504 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -111.68 -7.69 14.24 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.617 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.9 p -72.64 98.84 2.43 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-N 113.779 -1.555 . . . . 0.0 111.314 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.474 ' HA ' ' CB ' ' A' ' 78' ' ' ALA . 69.4 p -27.37 76.43 0.0 OUTLIER 'General case' 0 N--CA 1.512 2.646 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 1.006 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -157.57 137.15 8.45 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.596 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -72.1 100.04 1.06 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.971 1.114 . . . . 0.0 109.463 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -85.03 106.87 15.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.461 -1.296 . . . . 0.0 111.836 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -124.21 80.07 1.8 Allowed 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.55 135.78 3.22 Favored Glycine 0 C--N 1.292 -1.902 0 N-CA-C 106.625 -2.59 . . . . 0.0 106.625 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 43.7 p-90 -159.43 176.68 11.82 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 117.327 -1.749 . . . . 0.0 112.303 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -138.04 113.19 9.26 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.047 179.781 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.888 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.05 172.13 6.99 Favored 'General case' 0 N--CA 1.5 2.026 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.839 -179.968 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.467 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -156.29 146.7 21.59 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 118.017 -1.473 . . . . 0.0 112.605 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.63 ' CD2' ' N ' ' A' ' 43' ' ' SER . 11.7 p90 -172.29 -151.21 0.06 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 114.429 -1.259 . . . . 0.0 108.504 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.63 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.7 m -159.42 158.89 32.96 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.616 -1.633 . . . . 0.0 112.351 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.492 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.8 m-85 -86.28 121.13 72.62 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.88 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -58.75 -67.87 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.084 1.19 . . . . 0.0 112.225 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.483 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 29.8 t -69.54 -112.84 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 118.946 -1.102 . . . . 0.0 111.054 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.483 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -141.98 37.68 1.56 Allowed Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.685 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.47 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 6.7 mt-30 -75.46 115.59 15.28 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.828 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.405 ' H ' ' HG3' ' A' ' 49' ' ' GLN . 1.0 OUTLIER -106.38 119.04 38.23 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.353 -0.939 . . . . 0.0 111.673 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.464 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.2 p -74.38 157.92 6.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.94 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 20.4 p -132.74 -63.89 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.615 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.9 mt-30 -88.59 170.51 10.79 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -166.03 151.72 8.85 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 118.521 -1.271 . . . . 0.0 112.194 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.503 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 36.3 t-105 -149.26 150.77 33.1 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.458 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.503 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 1.4 p 46.77 32.11 1.65 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.617 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -173.64 118.08 0.27 Allowed 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.81 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 m -83.33 72.49 10.2 Favored 'General case' 0 C--N 1.279 -2.473 0 C-N-CA 119.161 -1.016 . . . . 0.0 109.377 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.469 HG12 HG13 ' A' ' 67' ' ' VAL . 4.1 m -70.91 166.57 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.832 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.443 ' O ' ' CG2' ' A' ' 59' ' ' THR . 6.1 t -164.68 130.54 2.83 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.557 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -94.67 116.05 28.29 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.436 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.477 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 6.2 p -93.92 75.53 4.18 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.304 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.37 -67.38 2.82 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.351 -1.404 . . . . 0.0 109.69 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -143.7 -16.51 0.62 Allowed 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.979 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.566 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.9 -170.81 2.93 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.076 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.521 HG12 ' N ' ' A' ' 66' ' ' THR . 65.2 t -148.39 156.6 8.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 118.826 -1.15 . . . . 0.0 113.038 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.521 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.1 m -154.71 141.2 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.312 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.586 HG23 HD21 ' A' ' 40' ' ' LEU . 2.4 t -134.84 153.51 34.92 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.078 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.426 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -133.39 90.84 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.6 p-10 -72.54 121.07 19.06 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.298 -179.534 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.879 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -42.68 163.61 0.14 Allowed Pre-proline 0 C--N 1.303 -1.45 0 CA-C-N 113.291 -1.777 . . . . 0.0 111.807 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.2 Cg_endo -66.46 -35.88 28.81 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.901 1.734 . . . . 0.0 112.315 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.39 -54.28 15.2 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.749 -179.891 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.879 HD22 ' HB3' ' A' ' 70' ' ' ALA . 6.4 p30 -78.25 14.17 1.28 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 118.958 -1.097 . . . . 0.0 109.862 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -129.4 18.98 5.43 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.49 77.4 5.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.197 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.862 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -136.64 125.29 15.18 Favored Pre-proline 0 C--O 1.209 -1.063 0 C-N-CA 119.782 -0.767 . . . . 0.0 111.643 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.589 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.8 Cg_endo -71.63 162.86 40.84 Favored 'Trans proline' 0 C--O 1.213 -0.754 0 C-N-CA 120.91 1.073 . . . . 0.0 110.236 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 1.006 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -46.98 -3.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.871 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -120.13 56.77 0.59 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.81 -159.99 15.77 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 117.905 -2.093 . . . . 0.0 111.12 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.772 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.2 p -139.85 155.06 47.43 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.939 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.862 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.1 100.65 5.5 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.767 ' HG2' HG23 ' A' ' 26' ' ' THR . 21.6 mt-30 -91.13 161.21 15.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 114.709 1.374 . . . . 0.0 114.709 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.625 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.1 p90 -166.0 165.17 18.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 113.286 -1.779 . . . . 0.0 109.224 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.98 170.83 37.75 Favored Glycine 0 N--CA 1.504 3.17 0 C-N-CA 117.547 -2.264 . . . . 0.0 112.611 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.2 p90 -156.62 -167.86 2.52 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.345 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.404 ' OD1' ' N ' ' A' ' 87' ' ' ASN . 1.2 m120 -140.53 112.21 7.48 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.821 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -120.14 158.21 15.45 Favored Glycine 0 N--CA 1.505 3.279 0 C-N-CA 119.784 -1.198 . . . . 0.0 111.426 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.486 1.345 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.154 179.926 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.665 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.507 2.418 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.57 -144.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 121.319 1.346 . . . . 0.0 110.965 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 10.5 p -116.78 -63.51 1.44 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.495 -0.882 . . . . 0.0 112.376 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.615 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -107.87 111.09 23.04 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.764 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.4 m-85 -81.16 -163.72 0.65 Allowed 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.618 -0.833 . . . . 0.0 109.545 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -145.44 103.04 3.78 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -52.29 173.92 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.501 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 39' ' ' THR . 8.2 p30 -41.87 -20.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.484 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.83 45.0 0.22 Allowed Glycine 0 N--CA 1.487 2.039 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.171 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.579 HG21 ' N ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -175.01 149.07 1.16 Allowed Pre-proline 0 N--CA 1.494 1.734 0 C-N-CA 119.164 -1.014 . . . . 0.0 111.049 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -63.04 170.35 7.69 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 121.372 1.381 . . . . 0.0 111.956 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.741 ' SG ' HG13 ' A' ' 10' ' ' VAL . 6.5 t -161.88 90.95 0.79 Allowed 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.538 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 m -51.99 165.18 0.22 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.69 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -65.05 -156.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 119.176 -1.01 . . . . 0.0 109.588 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 CA-C-O 116.319 -2.378 . . . . 0.0 110.371 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 CA-C-O 121.235 0.54 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.18 59.91 0.04 OUTLIER Glycine 0 N--CA 1.49 2.237 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.699 ' SG ' HG13 ' A' ' 10' ' ' VAL . 0.6 OUTLIER -56.32 -161.88 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.278 1.037 . . . . 0.0 112.54 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.674 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 37.0 mt-30 -150.97 89.02 1.5 Allowed 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 113.553 -1.658 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.699 HG13 ' SG ' ' A' ' 8' ' ' CYS . 2.9 m -90.32 128.71 42.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 118.972 -1.091 . . . . 0.0 111.83 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.572 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -102.27 171.27 7.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.149 179.831 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.477 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.5 t-105 -130.39 147.59 52.11 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.768 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.407 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.67 76.4 0.41 Allowed Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.026 -2.03 . . . . 0.0 108.026 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.473 HG23 ' HD2' ' A' ' 21' ' ' PHE . 2.5 p -72.51 142.9 14.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.562 ' CB ' HG22 ' A' ' 22' ' ' THR . 8.4 t-20 . . . . . 0 N--CA 1.493 1.711 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.301 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.62 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.4 p90 . . . . . 0 C--O 1.215 -0.734 0 CA-C-O 121.515 0.674 . . . . 0.0 110.555 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.579 HG23 ' N ' ' A' ' 23' ' ' ALA . 1.0 OUTLIER -71.08 176.56 4.33 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 118.074 -1.451 . . . . 0.0 107.74 179.791 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.579 ' N ' HG23 ' A' ' 22' ' ' THR . . . -148.76 103.08 3.35 Favored 'General case' 0 C--N 1.291 -1.937 0 C-N-CA 118.469 -1.293 . . . . 0.0 111.616 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -94.1 94.35 8.34 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.632 HG11 ' CE2' ' A' ' 84' ' ' PHE . 15.6 t -97.16 137.38 25.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.664 -0.815 . . . . 0.0 113.003 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.572 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -128.36 114.45 16.88 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.864 -1.062 . . . . 0.0 108.406 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.523 HG13 HG12 ' A' ' 10' ' ' VAL . 3.6 t -86.94 128.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 C-N-CA 119.81 -0.756 . . . . 0.0 112.783 -179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.819 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.4 tptt -114.23 100.93 8.73 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.426 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.76 ' HB3' HD11 ' A' ' 76' ' ' ILE . 15.1 t-20 -89.87 117.46 28.71 Favored 'General case' 0 C--N 1.282 -2.353 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.452 179.742 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.62 -2.09 8.43 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 124.185 0.928 . . . . 0.0 109.754 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.4 p -49.87 -83.89 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.588 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.545 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.51 72.32 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 123.666 0.604 . . . . 0.0 111.504 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.52 149.9 3.17 Favored Pre-proline 0 C--N 1.304 -1.392 0 C-N-CA 119.148 -1.021 . . . . 0.0 111.016 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -70.45 102.45 1.14 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 121.012 1.142 . . . . 0.0 109.243 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.37 106.56 16.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.48 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -116.94 72.43 0.83 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.11 144.43 13.78 Favored Glycine 0 N--CA 1.484 1.853 0 N-CA-C 107.372 -2.291 . . . . 0.0 107.372 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.602 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 36.9 p-90 -161.05 176.9 10.85 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 117.592 -1.643 . . . . 0.0 112.014 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . 1.006 ' N ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.59 103.32 4.66 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.957 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.852 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -91.56 174.2 7.49 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.258 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.605 ' HG1' HG23 ' A' ' 66' ' ' THR . 97.8 m -156.59 146.31 20.87 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.278 -1.369 . . . . 0.0 112.143 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.595 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.1 p90 -172.5 -150.95 0.06 Allowed 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 114.589 -1.187 . . . . 0.0 108.999 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.595 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 20.1 m -156.2 153.42 29.19 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 117.807 -1.557 . . . . 0.0 112.09 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.512 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.1 m-85 -81.03 119.37 75.8 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 118.526 -1.27 . . . . 0.0 109.578 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -55.74 -71.71 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.443 1.429 . . . . 0.0 112.319 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.1 t -69.37 -113.91 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.715 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.02 48.02 0.75 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.436 -1.364 . . . . 0.0 110.334 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.424 ' CG ' ' CE1' ' A' ' 21' ' ' PHE . 20.7 mp0 -71.56 112.86 8.02 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.416 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.411 ' OE1' ' HA ' ' A' ' 49' ' ' GLN . 7.0 mm100 -93.56 94.94 8.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.0 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.1 p -72.66 151.92 7.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.697 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 43.1 p -143.0 -63.27 0.41 Allowed 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.551 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.98 160.09 30.2 Favored 'General case' 0 C--N 1.301 -1.537 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.164 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -164.22 156.63 17.01 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 118.551 -1.26 . . . . 0.0 112.06 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 23.6 t-105 -155.52 137.04 14.13 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.847 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 62.56 29.14 16.97 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.21 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.43 122.39 0.64 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.613 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.3 m -84.54 69.39 10.58 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.948 -1.101 . . . . 0.0 108.845 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 HG13 ' A' ' 67' ' ' VAL . 3.3 m -69.29 164.39 2.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 114.904 -1.044 . . . . 0.0 112.828 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 1.5 t -168.04 145.54 4.27 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.768 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -98.27 109.72 22.43 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.138 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.543 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 7.7 p -91.2 72.91 6.26 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.67 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 56.38 75.89 0.23 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.2 -1.476 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 74.94 -28.79 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.149 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.543 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.49 -171.65 3.43 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 118.728 -1.189 . . . . 0.0 110.663 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.615 HG12 ' N ' ' A' ' 66' ' ' THR . 55.9 t -148.65 162.34 5.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.471 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.615 ' N ' HG12 ' A' ' 65' ' ' VAL . 6.2 m -157.0 147.63 21.49 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 114.083 -1.417 . . . . 0.0 108.131 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 58' ' ' VAL . 3.1 t -142.95 116.08 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 118.491 -1.284 . . . . 0.0 112.865 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -97.55 89.71 4.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.602 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.3 p-10 -70.27 120.43 15.94 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.075 -1.05 . . . . 0.0 112.063 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.805 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.27 158.33 0.09 OUTLIER Pre-proline 0 N--CA 1.486 1.36 0 CA-C-N 113.745 -1.571 . . . . 0.0 112.611 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.408 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.3 Cg_endo -68.03 -35.49 20.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.897 1.731 . . . . 0.0 112.385 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.805 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -69.86 -56.53 6.84 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.862 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.784 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 10.9 p30 -74.07 -1.85 21.87 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.823 -1.151 . . . . 0.0 109.696 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.565 ' HA3' HD21 ' A' ' 69' ' ' ASN . . . -113.17 20.42 19.18 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 8.8 m -90.03 59.73 4.62 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.262 -0.975 . . . . 0.0 111.272 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.782 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.05 122.96 39.09 Favored Pre-proline 0 CA--C 1.566 1.566 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.564 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 78' ' ' ALA . 5.8 Cg_endo -70.25 156.38 62.2 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 121.565 1.51 . . . . 0.0 113.766 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.545 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.47 -46.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.885 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.74 65.88 0.24 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.089 -1.204 . . . . 0.0 110.089 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.427 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.98 -170.31 18.48 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.837 -1.649 . . . . 0.0 110.139 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.819 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.9 p -139.49 158.3 44.36 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.199 -1.001 . . . . 0.0 112.527 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.782 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -125.59 -176.18 3.53 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.429 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 49.9 tt0 -168.12 148.1 4.82 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.019 -1.872 . . . . 0.0 112.92 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.632 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.3 p90 -165.22 168.08 17.41 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.068 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.48 171.95 40.11 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 117.694 -2.193 . . . . 0.0 112.223 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.1 p90 -155.06 -172.75 4.3 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -136.21 112.32 9.71 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.967 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -125.57 153.76 18.34 Favored Glycine 0 N--CA 1.51 3.596 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.024 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.912 179.691 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.477 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.493 1.676 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -62.61 -143.11 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 121.588 1.525 . . . . 0.0 111.771 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.626 ' O ' HG13 ' A' ' 109' ' ' VAL . 19.3 p -127.25 -58.35 1.28 Allowed 'General case' 0 N--CA 1.5 2.036 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.766 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.524 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.25 91.58 3.71 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.443 -0.903 . . . . 0.0 111.996 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.449 ' HD1' ' H ' ' A' ' 100' ' ' PHE . 32.3 m-85 -65.53 -166.81 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.1 m -146.43 107.68 4.22 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 117.552 -1.659 . . . . 0.0 113.884 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.9 mt -58.94 168.19 1.36 Allowed 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 1.006 HD22 ' N ' ' A' ' 39' ' ' THR . 2.4 m120 -41.24 92.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.053 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.729 ' O ' HG23 ' A' ' 105' ' ' THR . . . 63.6 45.88 93.59 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 119.495 -1.336 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.729 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.6 OUTLIER -167.13 146.41 4.5 Favored Pre-proline 0 C--O 1.196 -1.743 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.157 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -64.22 166.16 17.67 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.31 1.34 . . . . 0.0 112.241 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -163.68 94.96 0.79 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 17.0 p -65.2 170.26 4.79 Favored 'General case' 0 N--CA 1.511 2.595 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 98' ' ' THR . 17.0 m -60.53 -155.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.562 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 CA-C-O 116.322 -2.377 . . . . 0.0 110.378 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.692 ' HB3' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.725 0.774 . . . . 0.0 113.064 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.99 43.3 0.06 OUTLIER Glycine 0 N--CA 1.497 2.703 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -52.41 -175.81 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 114.496 -0.852 . . . . 0.0 112.774 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.516 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 5.3 pt20 -142.25 126.48 17.53 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.907 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.649 HG12 HG13 ' A' ' 27' ' ' VAL . 3.3 m -115.1 128.41 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.163 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.554 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -97.12 171.93 8.15 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.313 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.893 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.7 t-105 -125.39 147.84 49.01 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.829 -0.748 . . . . 0.0 112.026 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.1 79.66 0.35 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 107.759 -2.137 . . . . 0.0 107.759 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -68.99 146.8 12.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 122.018 0.913 . . . . 0.0 113.112 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 C--N 1.296 -1.718 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.519 179.811 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.647 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.6 p90 . . . . . 0 CA--C 1.497 -1.08 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.516 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 0.7 OUTLIER -101.67 114.32 28.26 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 179.579 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.679 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -91.53 115.83 28.36 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 119.19 -1.004 . . . . 0.0 113.52 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -98.53 96.85 8.26 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.545 HG11 ' CE2' ' A' ' 84' ' ' PHE . 33.5 t -92.64 144.54 9.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.554 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -131.27 103.43 6.46 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.771 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.649 HG13 HG12 ' A' ' 10' ' ' VAL . 2.2 t -74.12 151.57 7.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.731 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.59 ' HB2' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -148.16 111.29 4.88 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.643 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.707 ' HB3' HD11 ' A' ' 76' ' ' ILE . 14.6 t-20 -96.85 129.73 44.24 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.962 -1.017 . . . . 0.0 108.397 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -132.06 -6.85 3.48 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 124.087 0.867 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 32' ' ' SER . 2.0 p -51.0 -80.87 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.732 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.0 37.16 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.194 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.556 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.853 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -136.45 147.78 61.33 Favored Pre-proline 0 N--CA 1.488 1.451 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.414 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -72.46 115.95 4.53 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 121.403 1.402 . . . . 0.0 110.406 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 t -98.34 95.83 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.236 -0.985 . . . . 0.0 112.109 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -105.76 63.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 99.99 154.14 27.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.626 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 39.9 p-90 -169.95 177.17 4.44 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.172 -1.811 . . . . 0.0 112.911 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.23 99.19 3.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.017 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.883 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -87.93 172.72 9.38 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 118.576 -1.25 . . . . 0.0 110.051 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.472 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -153.97 145.08 22.82 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 118.642 -1.223 . . . . 0.0 111.633 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.622 ' CD2' ' N ' ' A' ' 43' ' ' SER . 10.6 p90 -172.92 -156.36 0.09 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.407 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.622 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 56.5 m -158.55 157.52 32.2 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 117.53 -1.668 . . . . 0.0 112.075 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' A' ' 65' ' ' VAL . 10.9 m-85 -86.58 122.22 71.89 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 118.712 -1.195 . . . . 0.0 109.443 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.48 -62.1 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.244 1.296 . . . . 0.0 112.196 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.9 p -69.5 -58.81 3.5 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.793 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . 145.65 31.4 0.08 OUTLIER Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.418 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.647 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 17.3 mt-30 -43.69 131.93 5.14 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.394 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 6.1 mm-40 -94.64 80.49 3.81 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.289 -0.964 . . . . 0.0 111.478 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.1 p -62.78 147.84 11.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.306 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.502 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 61.8 p -140.47 -71.18 0.37 Allowed 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.283 -0.967 . . . . 0.0 111.558 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.502 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -69.73 164.36 23.69 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.289 -179.951 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.2 5.51 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 118.645 -1.222 . . . . 0.0 112.056 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.445 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 30.8 t-105 -153.11 143.28 22.35 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.655 -0.818 . . . . 0.0 110.496 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 0.9 OUTLIER 57.71 30.24 18.59 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.663 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.423 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.4 OUTLIER -172.9 119.18 0.34 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.675 -179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 m -82.81 74.37 9.78 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.975 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.404 ' C ' HG23 ' A' ' 59' ' ' THR . 10.3 m -69.41 156.83 6.93 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 CA-C-N 115.017 -0.992 . . . . 0.0 112.78 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.404 HG23 ' C ' ' A' ' 58' ' ' VAL . 58.8 p -155.19 115.65 3.84 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.876 -1.056 . . . . 0.0 109.731 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -89.86 113.44 25.04 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.18 -1.008 . . . . 0.0 110.532 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.413 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.6 p -92.19 80.44 5.04 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.923 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.44 -67.85 2.17 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.443 -1.36 . . . . 0.0 110.127 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 10.3 p -141.94 -17.6 0.75 Allowed 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.223 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -88.93 -172.26 3.62 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.163 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.55 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.0 t -149.93 159.01 5.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 118.709 -1.197 . . . . 0.0 113.639 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.55 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 53.1 m -153.94 149.35 27.18 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.203 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.443 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.8 t -144.63 119.44 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 118.386 -1.326 . . . . 0.0 112.73 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.16 91.08 5.09 Favored 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.046 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.626 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.4 p-10 -71.23 120.95 17.54 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.879 -1.128 . . . . 0.0 111.625 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.723 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -43.14 167.39 0.08 OUTLIER Pre-proline 0 N--CA 1.487 1.377 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.452 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.723 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.8 Cg_endo -70.34 -35.92 10.14 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.23 1.953 . . . . 0.0 112.373 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.683 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.47 -54.29 14.99 Favored 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.869 -179.834 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 4.8 p-10 -79.37 10.79 3.41 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.444 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.536 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -127.42 40.2 1.8 Allowed Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.186 -1.007 . . . . 0.0 110.673 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -109.93 62.82 0.6 Allowed 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.908 -0.717 . . . . 0.0 111.21 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.913 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -116.87 121.4 32.81 Favored Pre-proline 0 N--CA 1.483 1.187 0 C-N-CA 120.058 -0.657 . . . . 0.0 111.243 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.592 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.6 Cg_endo -67.38 156.35 66.55 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 C-N-CA 121.103 1.202 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.853 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -39.36 -18.75 0.01 OUTLIER 'General case' 0 C--O 1.205 -1.271 0 C-N-CA 119.895 -0.722 . . . . 0.0 112.676 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.592 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.24 62.52 0.43 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -163.67 -161.72 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 C-N-CA 118.979 -1.581 . . . . 0.0 110.635 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.59 HG22 ' HB2' ' A' ' 28' ' ' LYS . 7.3 p -143.98 162.94 34.9 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.063 -1.055 . . . . 0.0 112.978 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.707 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -131.31 179.53 5.97 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.106 -1.407 . . . . 0.0 107.733 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.451 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 32.0 tt0 -164.03 144.55 8.36 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 117.226 -1.789 . . . . 0.0 113.187 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.545 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.2 p90 -157.7 170.28 22.74 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.779 -1.101 . . . . 0.0 109.857 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.79 164.8 37.18 Favored Glycine 0 N--CA 1.498 2.798 0 C-N-CA 117.704 -2.189 . . . . 0.0 112.557 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.602 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.7 p90 -153.04 -177.77 6.5 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 114.889 -0.656 . . . . 0.0 110.608 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.555 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -138.39 111.4 7.83 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.693 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -109.96 169.38 13.58 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.288 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.484 1.268 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.866 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.893 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.509 2.515 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.504 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.5 Cg_endo -62.7 -101.11 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 120.962 1.108 . . . . 0.0 111.952 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.404 ' O ' ' N ' ' A' ' 109' ' ' VAL . 45.7 p -152.58 -69.2 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 118.829 -1.148 . . . . 0.0 111.946 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -106.54 94.98 5.43 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.56 -0.856 . . . . 0.0 111.255 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.504 ' CZ ' ' HD2' ' A' ' 97' ' ' PRO . 38.6 m-85 -65.03 -162.76 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.057 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -149.93 98.48 2.72 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 117.605 -1.638 . . . . 0.0 113.323 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.586 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.7 mt -52.17 171.59 0.05 OUTLIER 'General case' 0 C--O 1.21 -0.989 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.412 ' O ' ' ND2' ' A' ' 103' ' ' ASN . 5.4 p-10 -55.54 82.41 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.755 -1.178 . . . . 0.0 110.783 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 87.51 41.85 6.34 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.692 HG21 ' HB3' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -174.44 130.36 0.47 Allowed Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.151 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.63 170.75 3.16 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 121.029 1.153 . . . . 0.0 111.22 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.469 ' SG ' HG13 ' A' ' 10' ' ' VAL . 8.2 t -166.73 101.95 0.57 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.179 -1.008 . . . . 0.0 111.117 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.47 169.48 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.844 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.96 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.8 p -80.25 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.876 -1.13 . . . . 0.0 109.876 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.96 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.402 0 CA-C-O 116.333 -2.371 . . . . 0.0 110.585 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.831 ' HB3' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.32 0.581 . . . . 0.0 111.355 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.15 43.94 0.06 OUTLIER Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.235 -1.946 . . . . 0.0 108.235 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.738 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.58 -168.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.87 -0.665 . . . . 0.0 110.955 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.486 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 1.8 pt20 -159.75 155.96 26.82 Favored 'General case' 0 C--N 1.287 -2.147 0 C-N-CA 118.754 -1.178 . . . . 0.0 110.407 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.595 HG12 HG13 ' A' ' 27' ' ' VAL . 1.1 m -141.35 138.88 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.002 -1.079 . . . . 0.0 111.67 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -100.44 171.61 7.64 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.157 179.95 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -133.94 143.32 48.13 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.834 -0.746 . . . . 0.0 111.961 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.09 71.79 0.41 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.9 p -69.61 140.77 18.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.537 ' CB ' HG22 ' A' ' 22' ' ' THR . 62.9 t30 . . . . . 0 N--CA 1.494 1.758 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.029 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.588 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.5 p90 . . . . . 0 CA--C 1.504 -0.81 0 CA-C-O 121.275 0.56 . . . . 0.0 111.984 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.537 HG22 ' CB ' ' A' ' 15' ' ' ASN . 1.0 OUTLIER -65.13 173.82 2.28 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.487 ' N ' HG23 ' A' ' 22' ' ' THR . . . -152.52 98.25 2.35 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 117.651 -1.62 . . . . 0.0 112.755 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -92.12 97.95 11.24 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.515 HG11 ' CE1' ' A' ' 84' ' ' PHE . 19.4 t -95.55 145.56 8.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 C-N-CA 119.681 -0.807 . . . . 0.0 112.583 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.624 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -134.71 101.75 5.04 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.439 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.595 HG13 HG12 ' A' ' 10' ' ' VAL . 1.9 t -71.06 153.81 8.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.698 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.611 ' HB2' HG22 ' A' ' 81' ' ' THR . 4.3 tttp -148.63 115.35 5.99 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.936 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.702 ' HB3' HD11 ' A' ' 76' ' ' ILE . 15.6 t-20 -102.21 119.6 39.07 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.2 t -122.19 1.42 9.71 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 124.169 0.918 . . . . 0.0 109.866 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.5 p -63.02 -79.49 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.951 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.603 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.4 OUTLIER 159.31 78.98 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 123.723 0.639 . . . . 0.0 111.498 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.54 141.24 1.55 Allowed Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.195 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -67.67 100.52 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.712 0 N-CA-C 108.972 -1.203 . . . . 0.0 108.972 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.84 112.29 23.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 118.244 -1.382 . . . . 0.0 111.442 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -124.22 76.76 1.5 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.23 136.76 6.01 Favored Glycine 0 N--CA 1.483 1.8 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.449 ' CZ2' HG21 ' A' ' 27' ' ' VAL . 26.3 p-90 -154.54 -179.81 8.32 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 117.905 -1.518 . . . . 0.0 111.959 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.521 ' CB ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -140.13 100.48 3.92 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.491 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -91.87 175.51 6.86 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.748 -1.181 . . . . 0.0 109.462 179.932 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.496 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -162.46 149.28 13.3 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 117.629 -1.629 . . . . 0.0 112.731 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.469 ' CD2' ' N ' ' A' ' 43' ' ' SER . 22.2 p90 -173.72 -140.93 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 113.571 -1.65 . . . . 0.0 107.558 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.584 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 31.0 m -163.39 -179.06 6.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.375 -1.73 . . . . 0.0 112.735 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.683 ' CE1' ' NE2' ' A' ' 48' ' ' GLN . 8.1 m-85 -114.64 91.2 24.33 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -55.38 -36.97 94.99 Favored 'Trans proline' 0 CA--C 1.51 -0.72 0 C-N-CA 121.015 1.143 . . . . 0.0 110.065 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.2 p -79.44 165.26 23.25 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 119.322 -0.951 . . . . 0.0 108.973 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.12 48.27 3.31 Favored Glycine 0 C--N 1.29 -2.009 0 C-N-CA 118.663 -1.732 . . . . 0.0 109.968 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.683 ' NE2' ' CE1' ' A' ' 44' ' ' PHE . 15.4 pt20 -109.76 143.46 39.55 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.309 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -137.48 133.57 34.76 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.496 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.595 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.7 p -72.69 164.48 3.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.584 -0.846 . . . . 0.0 111.728 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.595 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 66.3 p -136.17 -63.24 0.65 Allowed 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.264 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.49 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.6 mt-30 -89.23 164.64 14.87 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.177 -1.009 . . . . 0.0 109.346 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -170.37 153.5 4.4 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.259 -1.376 . . . . 0.0 112.227 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.454 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 33.6 t-105 -156.1 144.84 20.26 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.881 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.454 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.8 OUTLIER 61.82 28.62 17.55 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 119.541 -0.863 . . . . 0.0 109.993 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.594 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.9 OUTLIER -172.58 124.54 0.47 Allowed 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.323 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.5 m -87.99 75.88 8.7 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.43 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.4 m -69.08 152.82 9.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.954 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.403 HG23 ' C ' ' A' ' 58' ' ' VAL . 60.2 p -154.57 113.93 3.71 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.032 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.471 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.9 pt20 -90.51 117.71 29.41 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.924 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.0 p -94.09 85.49 4.71 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.999 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.93 -67.52 2.36 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.391 -1.385 . . . . 0.0 109.966 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -144.82 -12.72 0.56 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.293 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.584 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -93.28 -170.3 2.35 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.119 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.654 HG12 ' N ' ' A' ' 66' ' ' THR . 62.1 t -148.99 162.98 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.795 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.654 ' N ' HG12 ' A' ' 65' ' ' VAL . 10.6 m -156.65 139.87 15.58 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 113.625 -1.625 . . . . 0.0 108.267 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.457 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -132.51 114.88 23.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.368 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -96.63 88.5 4.67 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.993 HD22 ' CA ' ' A' ' 74' ' ' GLY . 0.3 OUTLIER -70.61 119.41 14.72 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.02 -1.072 . . . . 0.0 111.674 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.642 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -41.0 163.83 0.09 OUTLIER Pre-proline 0 N--CA 1.487 1.402 0 CA-C-N 113.741 -1.572 . . . . 0.0 112.417 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.587 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -64.57 -35.29 48.69 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 121.703 1.602 . . . . 0.0 112.195 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.538 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.33 -52.48 22.38 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 118.816 -1.154 . . . . 0.0 111.162 -179.926 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.642 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 16.9 p30 -78.08 8.96 4.09 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.883 -1.127 . . . . 0.0 110.224 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.993 ' CA ' HD22 ' A' ' 69' ' ' ASN . . . -124.91 18.3 7.09 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 120.081 -1.057 . . . . 0.0 110.495 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.5 m -86.72 58.44 5.07 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.222 -0.991 . . . . 0.0 111.262 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.921 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.46 114.86 54.77 Favored Pre-proline 0 CA--C 1.564 1.496 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.245 179.934 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.3 Cg_endo -67.57 156.02 67.78 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.395 1.397 . . . . 0.0 113.663 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.45 -45.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 114.273 -1.33 . . . . 0.0 114.156 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.43 69.58 0.28 Allowed Glycine 0 N--CA 1.497 2.712 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.402 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.13 -164.11 11.84 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.62 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.611 HG22 ' HB2' ' A' ' 28' ' ' LYS . 1.2 p -143.38 154.72 44.02 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 118.997 -1.081 . . . . 0.0 112.592 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.768 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -124.34 175.48 7.06 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.624 ' HB2' HG23 ' A' ' 26' ' ' THR . 2.9 tm0? -167.22 147.64 5.49 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 116.973 -1.891 . . . . 0.0 113.191 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.594 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 10.9 p90 -157.03 -179.13 7.91 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.609 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.29 161.42 34.82 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 117.471 -2.3 . . . . 0.0 112.705 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.584 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.7 p90 -157.16 175.24 14.32 Favored 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 114.806 -0.697 . . . . 0.0 111.008 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -125.52 115.73 20.67 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.906 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -127.27 158.02 20.96 Favored Glycine 0 N--CA 1.51 3.58 0 C-N-CA 119.38 -1.39 . . . . 0.0 112.638 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.7 p . . . . . 0 N--CA 1.481 1.092 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.789 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.26 0.076 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 3.8 Cg_endo -65.63 -143.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.217 -0.552 0 C-N-CA 121.048 1.166 . . . . 0.0 110.808 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.775 ' O ' HG13 ' A' ' 109' ' ' VAL . 11.1 p -113.45 -92.91 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.6 -0.84 . . . . 0.0 112.112 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -89.1 99.11 12.17 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.625 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.6 m-30 -68.08 -149.41 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.487 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -160.0 112.04 2.03 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 116.712 -1.995 . . . . 0.0 114.521 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.738 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.5 mt -64.77 172.76 2.58 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.532 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.521 HD22 ' CB ' ' A' ' 39' ' ' THR . 28.6 m120 -35.72 91.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.51 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 55.88 49.42 66.66 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.55 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.831 HG21 ' HB3' ' A' ' 6' ' ' ALA . 21.1 m -163.37 131.6 2.77 Favored Pre-proline 0 C--O 1.189 -2.119 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.92 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -61.06 158.86 32.32 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 121.263 1.309 . . . . 0.0 112.636 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.623 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.1 t -157.62 110.98 2.51 Favored 'General case' 0 N--CA 1.496 1.852 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.221 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -73.45 128.03 34.36 Favored 'General case' 0 N--CA 1.508 2.447 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -179.773 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 98' ' ' THR . 2.5 m -56.53 -177.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.659 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 116.301 -2.388 . . . . 0.0 110.461 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.852 ' N ' ' HG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 121.2 0.524 . . . . 0.0 111.366 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.76 43.25 0.1 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.949 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.3 p -53.55 -178.12 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 121.541 0.686 . . . . 0.0 112.077 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -138.34 108.44 6.39 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.795 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.886 HG12 HG13 ' A' ' 27' ' ' VAL . 4.6 m -103.39 124.06 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.238 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.576 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.15 165.05 12.6 Favored 'General case' 0 C--N 1.294 -1.84 0 C-N-CA 119.291 -0.964 . . . . 0.0 109.321 179.88 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.594 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.4 t-105 -124.74 143.32 50.84 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.614 -0.835 . . . . 0.0 112.444 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 75.45 0.38 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.76 149.0 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.97 -0.692 . . . . 0.0 112.832 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.482 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.528 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.7 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.0 p90 . . . . . 0 CA--C 1.503 -0.844 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.456 ' CG2' ' N ' ' A' ' 23' ' ' ALA . 0.6 OUTLIER -80.85 163.97 23.01 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 179.407 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.456 ' N ' ' CG2' ' A' ' 22' ' ' THR . . . -145.65 110.11 5.03 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.894 -1.522 . . . . 0.0 112.89 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -99.09 101.15 12.41 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.646 HG11 ' CE1' ' A' ' 84' ' ' PHE . 13.4 t -99.5 140.91 17.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 119.645 -0.822 . . . . 0.0 112.341 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.576 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.3 m -133.49 114.83 14.05 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.276 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.886 HG13 HG12 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -85.31 150.38 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.264 -0.975 . . . . 0.0 111.651 -179.849 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.835 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tttt -130.53 85.91 2.33 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.815 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.447 ' HB3' ' CD1' ' A' ' 76' ' ' ILE . 21.0 t-20 -68.8 104.94 2.17 Favored 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 118.565 -1.254 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -105.8 -1.34 24.44 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.335 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.541 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.7 p -81.07 102.56 10.3 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.728 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.711 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 97.5 p -37.23 87.59 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 113.138 0.792 . . . . 0.0 113.138 -179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.541 ' N ' ' O ' ' A' ' 31' ' ' SER . . . -166.06 146.81 5.58 Favored Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.536 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -70.76 100.92 0.99 Allowed 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 121.027 1.152 . . . . 0.0 109.166 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -86.76 108.52 18.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.149 -1.42 . . . . 0.0 111.817 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -122.63 63.32 0.97 Allowed 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.32 142.54 13.47 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 107.42 -2.272 . . . . 0.0 107.42 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.683 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 40.7 p-90 -159.37 176.1 12.54 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 117.707 -1.597 . . . . 0.0 111.796 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.62 ' N ' HD22 ' A' ' 103' ' ' ASN . 0.3 OUTLIER -140.01 111.93 7.5 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.982 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.843 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.61 178.47 4.62 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.794 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.523 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.26 152.06 16.28 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.245 -1.382 . . . . 0.0 112.413 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' ' N ' ' A' ' 43' ' ' SER . 17.3 p90 -177.12 -150.09 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 113.919 -1.491 . . . . 0.0 108.408 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.549 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 42.7 m -162.16 161.95 28.23 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 118.046 -1.462 . . . . 0.0 112.026 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.613 ' CE2' HG21 ' A' ' 65' ' ' VAL . 16.5 m-85 -91.7 116.25 66.09 Favored Pre-proline 0 N--CA 1.484 1.275 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.005 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.08 -67.82 0.05 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 121.539 1.492 . . . . 0.0 112.938 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 19.7 m -68.74 -132.72 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.515 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -117.33 58.74 0.49 Allowed Glycine 0 N--CA 1.503 3.109 0 C-N-CA 119.631 -1.271 . . . . 0.0 111.715 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.7 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 tt0 -110.48 114.84 28.58 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.961 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.539 HE21 ' HA ' ' A' ' 49' ' ' GLN . 5.2 mm-40 -118.22 136.95 53.34 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 120.131 -0.628 . . . . 0.0 111.291 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 51' ' ' THR . 6.2 p -96.3 156.9 3.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.269 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.587 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -138.56 -59.53 0.62 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 119.598 -0.841 . . . . 0.0 111.059 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.587 ' H ' HG23 ' A' ' 51' ' ' THR . 0.8 OUTLIER -90.32 131.08 36.31 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.499 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.78 160.39 40.82 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.119 -1.032 . . . . 0.0 112.476 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.466 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 39.1 t-105 -155.33 149.46 25.78 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.676 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.466 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.3 t 66.07 20.07 11.2 Favored 'General case' 0 C--N 1.316 -0.877 0 C-N-CA 119.649 -0.82 . . . . 0.0 109.573 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.449 ' HG ' ' HD2' ' A' ' 84' ' ' PHE . 5.5 p -173.25 123.84 0.4 Allowed 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.921 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -80.33 77.88 7.06 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.321 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.447 HG12 HG13 ' A' ' 67' ' ' VAL . 2.2 m -72.6 152.62 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.538 -0.755 . . . . 0.0 112.277 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 40.7 p -150.06 109.15 3.91 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.883 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.522 ' OE1' ' NE2' ' A' ' 49' ' ' GLN . 33.0 tt0 -87.45 114.75 24.35 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.074 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.453 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.3 p -91.41 81.23 5.43 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.864 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.09 -69.74 1.88 Allowed Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.403 -1.379 . . . . 0.0 110.074 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.5 t -139.13 -19.06 0.99 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.858 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -86.65 -173.81 4.68 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.815 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.613 HG21 ' CE2' ' A' ' 44' ' ' PHE . 49.7 t -145.13 160.66 13.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 C-N-CA 118.77 -1.172 . . . . 0.0 113.226 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.571 ' N ' HG12 ' A' ' 65' ' ' VAL . 11.6 m -159.36 129.61 5.72 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.889 -1.505 . . . . 0.0 108.121 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.64 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -125.3 146.89 30.23 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.004 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.849 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -130.47 93.33 3.43 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.683 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 2.2 p-10 -73.74 117.63 15.75 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.229 -0.988 . . . . 0.0 112.402 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.866 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -42.17 156.91 0.23 Allowed Pre-proline 0 N--CA 1.481 1.088 0 CA-C-N 113.537 -1.665 . . . . 0.0 111.876 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -59.99 -34.91 94.69 Favored 'Trans proline' 0 C--O 1.213 -0.736 0 C-N-CA 121.745 1.63 . . . . 0.0 112.065 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.726 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.92 -53.52 20.53 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.987 179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.866 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 25.1 p30 -79.67 12.78 2.39 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.496 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.467 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -133.6 20.71 4.1 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.516 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.4 m -94.53 60.57 2.62 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.395 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.538 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -113.49 131.81 22.8 Favored Pre-proline 0 N--CA 1.491 1.595 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.472 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.504 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -70.86 151.42 62.77 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.468 1.445 . . . . 0.0 114.19 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.711 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.03 -45.92 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.504 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -106.4 68.31 0.24 Allowed Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.883 -1.151 . . . . 0.0 111.084 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.19 23.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 118.398 -1.858 . . . . 0.0 111.384 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.835 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.2 p -132.39 162.15 31.83 Favored 'General case' 0 N--CA 1.482 1.172 0 CA-C-O 121.74 0.781 . . . . 0.0 112.686 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.03 174.21 9.05 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.439 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 26.6 tt0 -165.96 144.84 5.99 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 116.831 -1.948 . . . . 0.0 113.545 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.646 ' CE1' HG11 ' A' ' 25' ' ' VAL . 18.3 p90 -156.28 178.01 10.79 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.625 -1.171 . . . . 0.0 110.181 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -159.32 169.2 35.42 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 117.761 -2.162 . . . . 0.0 112.107 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 14.4 p90 -166.85 156.89 11.43 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.371 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -108.7 114.79 28.89 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.198 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.6 166.56 12.17 Favored Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.863 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 C--N 1.316 -0.856 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.594 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.493 1.693 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.483 ' HD2' ' CE2' ' A' ' 100' ' ' PHE . 1.9 Cg_endo -64.91 -137.3 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 121.312 1.341 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.489 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 30.9 p -121.09 -59.74 1.7 Allowed 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.309 -0.956 . . . . 0.0 113.027 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.489 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.36 100.06 8.74 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.078 -1.049 . . . . 0.0 112.29 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.502 ' N ' ' O ' ' A' ' 107' ' ' CYS . 19.3 m-85 -72.64 -169.12 0.51 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.5 m -143.5 122.5 12.81 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 117.888 -1.525 . . . . 0.0 112.469 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.949 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -80.81 174.54 11.52 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.538 -0.865 . . . . 0.0 109.243 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.62 HD22 ' N ' ' A' ' 39' ' ' THR . 34.1 m120 -34.61 89.18 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.324 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.073 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 60.45 57.7 17.71 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.466 -1.35 . . . . 0.0 110.744 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.852 ' HG1' ' N ' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -178.24 148.61 0.64 Allowed Pre-proline 0 C--O 1.201 -1.454 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.244 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.41 176.55 3.27 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 121.647 1.565 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.538 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.3 t -173.57 99.06 0.11 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.099 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.97 173.98 0.55 Allowed 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.037 -0.665 . . . . 0.0 112.29 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -71.24 -91.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.592 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 CA-C-O 116.364 -2.353 . . . . 0.0 110.287 -179.985 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 121.228 0.537 . . . . 0.0 111.697 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.11 44.98 0.22 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 p -53.27 179.0 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.668 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.52 118.29 12.38 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.096 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.568 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.2 m -108.88 125.97 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.28 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.547 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.53 8.77 Favored 'General case' 0 C--N 1.292 -1.9 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.673 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.71 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 4.8 t-105 -125.44 143.01 51.19 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.769 -0.772 . . . . 0.0 111.785 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.14 72.48 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.62 151.61 9.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.916 0.865 . . . . 0.0 113.266 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.544 ' CB ' HG22 ' A' ' 22' ' ' THR . 0.7 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.005 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.1 p90 . . . . . 0 CA--C 1.493 -1.25 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.544 HG22 ' CB ' ' A' ' 15' ' ' ASN . 6.2 t -70.53 168.92 15.24 Favored 'General case' 0 C--N 1.283 -2.317 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.09 118.74 10.43 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.157 -1.417 . . . . 0.0 112.626 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -104.28 90.93 3.71 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 84' ' ' PHE . 11.5 t -92.73 133.03 35.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.703 -0.799 . . . . 0.0 112.275 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.6 m -119.17 107.2 13.17 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.522 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 82' ' ' ALA . 2.9 t -78.29 144.27 11.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 119.149 -1.021 . . . . 0.0 110.68 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.567 ' HA ' HG22 ' A' ' 81' ' ' THR . 13.4 tptm -135.37 103.05 5.35 Favored 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.859 -0.736 . . . . 0.0 109.576 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.606 ' HB3' HD11 ' A' ' 76' ' ' ILE . 44.7 t-20 -100.33 124.37 45.72 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.088 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.6 t -135.78 -2.65 2.36 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.011 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.525 ' H ' ' HG ' ' A' ' 31' ' ' SER . 4.3 p -52.19 -80.96 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 119.291 -0.963 . . . . 0.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.08 61.04 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 123.657 0.598 . . . . 0.0 110.803 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 1.027 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -152.72 134.43 8.52 Favored Pre-proline 0 C--N 1.306 -1.283 0 C-N-CA 119.044 -1.063 . . . . 0.0 110.45 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.64 106.7 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 120.922 1.081 . . . . 0.0 110.269 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.552 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.5 t -87.77 67.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 118.639 -1.224 . . . . 0.0 111.809 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -88.16 65.08 7.99 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 101.03 145.6 17.37 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 107.046 -2.421 . . . . 0.0 107.046 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.695 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 49.7 p-90 -162.31 174.61 12.59 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 116.976 -1.89 . . . . 0.0 112.666 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -142.87 99.21 3.42 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.862 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.878 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -87.05 173.34 9.34 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 118.328 -1.349 . . . . 0.0 109.439 179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.477 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -158.12 147.78 19.81 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 117.907 -1.517 . . . . 0.0 112.441 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.594 ' CG ' ' N ' ' A' ' 43' ' ' SER . 10.8 p90 -173.79 -137.29 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.958 -1.474 . . . . 0.0 108.043 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.594 ' N ' ' CG ' ' A' ' 42' ' ' PHE . 41.8 m -161.06 174.33 13.89 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 117.563 -1.655 . . . . 0.0 112.455 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.758 ' CD2' HG21 ' A' ' 65' ' ' VAL . 1.9 m-85 -114.47 95.93 41.54 Favored Pre-proline 0 N--CA 1.496 1.873 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.189 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.451 ' C ' ' H ' ' A' ' 47' ' ' GLY . 5.0 Cg_exo -60.05 -40.9 57.11 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 121.261 1.307 . . . . 0.0 111.676 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.3 t -74.96 15.45 0.4 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.563 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 45' ' ' PRO . . . 55.79 29.38 54.62 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.233 -1.46 . . . . 0.0 110.133 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -61.07 116.47 4.55 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.8 mm-40 -95.5 97.77 10.03 Favored 'General case' 0 N--CA 1.484 1.275 0 C-N-CA 119.359 -0.937 . . . . 0.0 110.621 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 51' ' ' THR . 0.9 OUTLIER -64.47 157.58 4.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.177 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 40.4 p -133.05 -64.45 0.74 Allowed 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.755 -0.778 . . . . 0.0 111.259 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.551 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.7 mt-30 -90.58 173.98 7.76 Favored 'General case' 0 N--CA 1.494 1.74 0 C-N-CA 118.87 -1.132 . . . . 0.0 110.133 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -173.2 147.46 1.56 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.961 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.474 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 37.2 t-105 -151.2 143.7 24.26 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.713 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.474 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.3 OUTLIER 60.57 27.53 17.21 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.753 -179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.468 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -174.85 122.62 0.24 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.566 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -84.84 77.63 10.05 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 118.987 -1.085 . . . . 0.0 109.462 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.417 ' C ' HG23 ' A' ' 59' ' ' THR . 13.6 m -69.23 152.57 9.34 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.296 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 58' ' ' VAL . 36.9 p -155.24 119.27 4.6 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.074 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -91.53 116.92 29.26 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.906 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.456 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.2 p -90.52 77.35 6.48 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.685 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.36 -68.71 2.06 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.41 -1.376 . . . . 0.0 110.156 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -138.27 -17.16 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.903 -0.719 . . . . 0.0 110.291 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.52 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -91.68 -172.44 3.22 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.988 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.758 HG21 ' CD2' ' A' ' 44' ' ' PHE . 46.1 t -143.83 162.27 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.0 -1.08 . . . . 0.0 113.462 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.612 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 23.5 m -157.79 137.24 11.94 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.573 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.468 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.8 t -131.8 116.33 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 C-N-CA 119.1 -1.04 . . . . 0.0 112.192 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.422 HH11 ' CB ' ' A' ' 68' ' ' ARG . 0.3 OUTLIER -99.53 96.06 7.41 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.269 -1.332 . . . . 0.0 108.74 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.793 ' HB2' HD22 ' A' ' 73' ' ' ASN . 1.6 p-10 -76.02 120.11 20.89 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.836 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.706 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.28 160.62 0.12 Allowed Pre-proline 0 N--CA 1.483 1.192 0 CA-C-N 113.44 -1.709 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -64.89 -38.6 28.83 Favored 'Trans proline' 0 C--O 1.211 -0.844 0 C-N-CA 122.106 1.87 . . . . 0.0 112.229 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.11 -54.69 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.581 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.793 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.5 OUTLIER -76.13 5.84 6.23 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.032 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -128.4 50.25 0.9 Allowed Glycine 0 C--O 1.202 -1.901 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.1 m -118.98 61.66 0.8 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 119.78 -0.768 . . . . 0.0 111.303 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.831 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -120.46 109.02 36.97 Favored Pre-proline 0 CA--C 1.56 1.353 0 C-N-CA 119.963 -0.695 . . . . 0.0 111.312 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.633 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.3 Cg_endo -71.65 118.9 5.88 Favored 'Trans proline' 0 C--O 1.207 -1.063 0 C-N-CA 121.182 1.255 . . . . 0.0 111.389 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 1.027 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -7.65 68.07 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.694 1.246 . . . . 0.0 113.257 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.633 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . 170.18 46.1 0.03 OUTLIER Glycine 0 C--N 1.277 -2.722 0 CA-C-N 114.148 -1.387 . . . . 0.0 110.124 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -174.98 -152.92 9.61 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.021 -1.561 . . . . 0.0 110.192 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.567 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.9 p -140.77 173.64 11.29 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.26 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.666 ' O ' HG23 ' A' ' 27' ' ' VAL . . . -148.94 90.79 1.79 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.679 ' HB2' HG23 ' A' ' 26' ' ' THR . 8.5 tt0 -85.04 146.44 27.18 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 25' ' ' VAL . 12.0 p90 -155.03 175.56 13.67 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 113.997 -1.456 . . . . 0.0 108.851 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.7 176.82 41.12 Favored Glycine 0 N--CA 1.498 2.82 0 C-N-CA 117.489 -2.291 . . . . 0.0 112.532 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.489 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 6.8 p90 -163.68 -175.14 3.99 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.949 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -129.77 113.59 14.89 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 119.753 -0.779 . . . . 0.0 110.507 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.495 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.45 152.66 20.3 Favored Glycine 0 N--CA 1.504 3.199 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.481 1.099 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.165 179.79 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.71 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 111.283 0.105 . . . . 0.0 111.283 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.507 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -61.19 -95.72 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.909 1.073 . . . . 0.0 112.465 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 97' ' ' PRO . 6.9 p -155.04 -81.73 0.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.177 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -102.59 94.34 5.6 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.329 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.562 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -67.65 -150.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.209 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 19.4 m -157.12 110.72 2.6 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 117.215 -1.794 . . . . 0.0 113.59 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.575 HD22 HD21 ' A' ' 103' ' ' ASN . 2.5 mt -55.89 177.43 0.06 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.64 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.15 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.544 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -163.63 20.29 0.15 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 118.676 -1.726 . . . . 0.0 111.435 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.605 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 3.5 p -139.6 150.66 64.16 Favored Pre-proline 0 N--CA 1.501 2.087 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.561 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.83 163.82 17.98 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.437 1.425 . . . . 0.0 111.531 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.54 ' SG ' HG13 ' A' ' 10' ' ' VAL . 4.7 t -157.03 98.62 1.76 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.986 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 4.5 p -50.95 161.67 0.35 Allowed 'General case' 0 N--CA 1.498 1.957 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.828 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.946 HG22 ' H ' ' A' ' 110' ' ' GLY . 10.8 p -75.52 -135.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.038 -1.065 . . . . 0.0 109.648 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.946 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.13 0 CA-C-O 116.267 -2.407 . . . . 0.0 110.393 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.49 ' HB1' ' HB3' ' A' ' 31' ' ' SER . . . . . . . . 0 N--CA 1.488 1.453 0 CA-C-O 121.022 0.439 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 177.12 48.33 0.06 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -52.79 178.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.495 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.73 124.39 33.39 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.88 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.558 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.5 m -117.36 125.53 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.532 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.68 168.24 10.28 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.646 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.655 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.4 t-105 -134.31 143.44 47.72 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 119.43 -0.908 . . . . 0.0 112.601 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.66 73.73 0.45 Allowed Glycine 0 N--CA 1.496 2.677 0 N-CA-C 107.3 -2.32 . . . . 0.0 107.3 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.7 OUTLIER -69.93 162.46 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 113.867 1.062 . . . . 0.0 113.867 -179.621 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.466 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.0 t30 . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 113.686 -1.597 . . . . 0.0 108.689 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.557 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 37.7 p90 . . . . . 0 CA--C 1.495 -1.171 0 CA-C-O 121.65 0.738 . . . . 0.0 112.62 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.466 HG22 ' HB3' ' A' ' 15' ' ' ASN . 14.8 t -71.81 168.58 17.54 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.655 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -150.18 118.88 6.55 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 117.675 -1.61 . . . . 0.0 112.701 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -100.42 95.82 7.0 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.662 HG11 ' CE2' ' A' ' 84' ' ' PHE . 18.6 t -94.91 141.5 14.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 C-N-CA 119.584 -0.847 . . . . 0.0 112.423 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.541 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.1 m -127.28 120.75 29.36 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.685 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 1.0 OUTLIER -90.55 148.34 4.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.719 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tptp -136.15 103.83 5.46 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.028 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.543 ' HB3' HD11 ' A' ' 76' ' ' ILE . 14.9 t-20 -95.71 132.56 40.78 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.519 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.7 t -139.48 -3.42 1.51 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.427 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 32' ' ' SER . 5.1 p -50.68 -82.15 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.505 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 161.54 69.7 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.478 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.02 154.13 4.99 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 118.518 -1.273 . . . . 0.0 111.499 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -73.18 99.51 1.12 Allowed 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 121.413 1.409 . . . . 0.0 109.598 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.418 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -78.32 81.94 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 118.381 -1.327 . . . . 0.0 111.902 -179.758 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -95.03 54.73 1.72 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 107.38 152.95 18.39 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 107.506 -2.238 . . . . 0.0 107.506 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 41.9 p-90 -163.31 174.09 12.46 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 117.13 -1.828 . . . . 0.0 112.502 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.36 98.16 3.54 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.124 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.867 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -84.9 171.84 11.86 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 118.168 -1.413 . . . . 0.0 109.635 179.945 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.469 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -155.92 142.99 19.08 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 118.673 -1.211 . . . . 0.0 111.63 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.585 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.1 p90 -172.1 -148.92 0.05 Allowed 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.625 -1.171 . . . . 0.0 108.606 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.585 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 65.6 m -159.08 157.71 31.58 Favored 'General case' 0 C--N 1.29 -2.005 0 C-N-CA 117.782 -1.567 . . . . 0.0 111.485 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.564 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.4 m-85 -88.31 114.35 59.15 Favored Pre-proline 0 N--CA 1.491 1.578 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.94 -54.52 4.64 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 N-CA-C 108.654 -1.325 . . . . 0.0 108.654 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.452 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 2.4 t -72.61 163.13 28.55 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 118.777 -1.169 . . . . 0.0 108.063 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.452 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -78.07 59.98 3.89 Favored Glycine 0 C--N 1.277 -2.72 0 C-N-CA 118.338 -1.887 . . . . 0.0 108.72 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.413 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 mt-30 -90.96 176.53 6.57 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.627 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -162.02 111.92 1.54 Allowed 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.838 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -68.91 157.89 6.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.504 -0.878 . . . . 0.0 111.311 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.509 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 62.2 p -134.71 -66.01 0.61 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.389 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.509 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.1 OUTLIER -83.96 168.98 15.49 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.414 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.33 152.72 7.4 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 118.327 -1.349 . . . . 0.0 112.272 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.43 ' CE2' ' HB2' ' A' ' 55' ' ' SER . 18.4 t-105 -146.72 132.21 18.69 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.626 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.43 ' HB2' ' CE2' ' A' ' 54' ' ' TRP . 2.2 t 58.57 33.18 22.89 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.095 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.5 114.79 0.47 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.376 -0.929 . . . . 0.0 110.672 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.8 m -80.91 74.85 7.88 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 118.87 -1.132 . . . . 0.0 108.929 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.428 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.6 m -69.07 168.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 114.966 -1.016 . . . . 0.0 112.843 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 59' ' ' THR . 10.0 t -170.18 123.57 0.71 Allowed 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.825 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -86.41 102.45 14.06 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.315 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.2 p -91.2 82.83 5.48 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.546 -0.862 . . . . 0.0 111.773 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.554 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 55.69 78.15 0.13 Allowed Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.481 -1.343 . . . . 0.0 110.861 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.2 p 67.59 -23.93 0.12 Allowed 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.825 -0.75 . . . . 0.0 111.487 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.554 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -90.95 -176.07 4.53 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.876 -1.129 . . . . 0.0 110.852 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' A' ' 66' ' ' THR . 33.1 t -149.26 160.11 5.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 118.844 -1.143 . . . . 0.0 113.6 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.572 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.1 m -154.51 154.58 33.36 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.024 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.467 ' HB ' HD22 ' A' ' 40' ' ' LEU . 7.1 t -147.85 117.85 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 118.511 -1.276 . . . . 0.0 112.197 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.24 90.42 5.11 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.441 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.695 ' HB2' HD22 ' A' ' 73' ' ' ASN . 1.7 p-10 -70.57 119.01 14.1 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.805 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.811 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.3 158.14 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.482 0 CA-C-N 113.477 -1.692 . . . . 0.0 112.628 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -65.48 -36.74 32.95 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 121.875 1.717 . . . . 0.0 112.072 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.811 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.4 -56.56 7.1 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 118.928 -1.109 . . . . 0.0 110.226 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.695 HD22 ' HB2' ' A' ' 69' ' ' ASN . 1.2 p-10 -70.22 -3.26 16.15 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.012 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -123.58 51.3 0.81 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 t -118.2 54.16 0.94 Allowed 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.677 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.69 135.58 20.73 Favored Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.297 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.3 Cg_endo -76.32 156.42 37.2 Favored 'Trans proline' 0 C--O 1.212 -0.793 0 C-N-CA 121.507 1.472 . . . . 0.0 112.306 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.407 ' C ' ' O ' ' A' ' 77' ' ' PRO . . . -28.5 -32.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.5 71.53 0.22 Allowed Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.984 -1.103 . . . . 0.0 110.771 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.442 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -164.54 -164.6 20.18 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 118.739 -1.696 . . . . 0.0 111.07 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 28' ' ' LYS . 11.6 p -139.99 167.78 21.33 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.99 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.437 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.66 -169.05 2.17 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.173 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -169.8 141.82 2.34 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 117.628 -1.629 . . . . 0.0 112.617 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.662 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.5 p90 -163.13 161.73 25.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -157.54 173.18 34.95 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 117.994 -2.051 . . . . 0.0 111.946 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.504 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 7.2 p90 -164.59 -174.63 3.5 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.506 -0.878 . . . . 0.0 111.328 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.497 HD22 ' HB3' ' A' ' 52' ' ' GLN . 70.8 m-80 -130.79 115.71 16.99 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.224 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.41 153.43 20.6 Favored Glycine 0 N--CA 1.511 3.639 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.834 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.64 179.883 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.494 ' HG2' ' CE2' ' A' ' 100' ' ' PHE . 2.3 Cg_endo -64.9 -144.9 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.764 0 C-N-CA 121.548 1.499 . . . . 0.0 111.514 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.622 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.8 p -134.67 -63.37 0.71 Allowed 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 119.696 -0.802 . . . . 0.0 111.873 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.622 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.2 106.98 16.62 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.622 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 12.4 m-85 -80.98 -168.83 1.95 Allowed 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.8 m -144.83 106.24 4.23 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 117.906 -1.517 . . . . 0.0 113.378 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -54.78 174.04 0.08 Allowed 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.236 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.408 ' ND2' ' O ' ' A' ' 103' ' ' ASN . 4.4 p-10 -57.84 79.95 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.205 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.22 9.02 40.14 Favored Glycine 0 N--CA 1.499 2.877 0 C-N-CA 119.625 -1.274 . . . . 0.0 112.447 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.606 ' O ' ' N ' ' A' ' 102' ' ' LEU . 3.2 p -152.5 153.48 30.63 Favored Pre-proline 0 C--O 1.194 -1.847 0 C-N-CA 118.482 -1.287 . . . . 0.0 111.449 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -66.79 -179.51 1.69 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 121.679 1.586 . . . . 0.0 112.037 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.558 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.4 t -173.2 100.5 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.843 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.31 165.38 4.62 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.791 -0.764 . . . . 0.0 111.879 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.672 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 0.2 OUTLIER -75.11 172.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.012 179.635 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.672 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.178 0 CA-C-O 116.341 -2.366 . . . . 0.0 110.357 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.8 ' HB3' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.488 1.448 0 CA-C-O 121.438 0.637 . . . . 0.0 111.848 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.46 55.25 0.06 OUTLIER Glycine 0 N--CA 1.502 3.078 0 N-CA-C 107.384 -2.286 . . . . 0.0 107.384 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -53.88 -165.46 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.503 1.144 . . . . 0.0 113.895 -179.747 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.572 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 13.5 mt-30 -145.03 89.84 1.99 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.455 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.538 ' CG1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 m -87.83 141.3 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.793 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.716 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -116.12 172.8 6.94 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.778 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.896 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 8.8 t-105 -133.14 147.84 52.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.768 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.13 87.85 0.32 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.94 141.03 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.578 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.454 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 55.2 t30 . . . . . 0 C--N 1.303 -1.423 0 CA-C-N 115.105 -0.952 . . . . 0.0 109.327 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.558 ' O ' ' CD2' ' A' ' 21' ' ' PHE . 35.9 p90 . . . . . 0 CA--C 1.49 -1.327 0 CA-C-O 121.355 0.598 . . . . 0.0 112.607 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.555 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.5 OUTLIER -68.95 171.28 8.3 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 179.559 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.555 ' N ' HG23 ' A' ' 22' ' ' THR . . . -151.11 103.34 3.03 Favored 'General case' 0 C--N 1.29 -2.011 0 C-N-CA 117.754 -1.578 . . . . 0.0 112.468 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -91.26 98.88 11.99 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.675 HG11 ' CE2' ' A' ' 84' ' ' PHE . 8.4 t -97.19 139.81 18.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 119.706 -0.797 . . . . 0.0 112.669 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.716 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.2 OUTLIER -125.01 149.47 47.71 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.24 179.796 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.593 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.6 t -123.54 101.65 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.694 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.729 ' HA ' HG22 ' A' ' 81' ' ' THR . 35.3 tptt -87.85 101.95 14.22 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.014 -1.075 . . . . 0.0 110.054 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.504 ' HB3' HD11 ' A' ' 76' ' ' ILE . 14.4 t-20 -97.16 121.09 38.66 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.274 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -128.51 -1.02 5.57 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.708 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.9 p -47.04 -84.77 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.364 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.473 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 164.75 42.69 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.17 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.817 -179.949 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.929 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.71 153.17 42.64 Favored Pre-proline 0 N--CA 1.486 1.333 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.337 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -69.6 95.84 0.56 Allowed 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 121.36 1.373 . . . . 0.0 110.006 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.9 t -72.8 96.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.508 -1.277 . . . . 0.0 111.253 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -113.45 82.96 1.76 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.55 139.45 1.92 Allowed Glycine 0 C--N 1.292 -1.89 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.769 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 46.1 p-90 -159.87 176.18 12.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 117.895 -1.522 . . . . 0.0 111.935 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.417 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -142.35 110.03 5.78 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.587 179.925 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.21 173.55 6.74 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.842 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.452 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -154.94 147.72 24.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.01 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.7 p90 -173.26 -144.96 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.451 -1.25 . . . . 0.0 108.904 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.54 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.1 m -159.42 153.3 23.16 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 117.801 -1.56 . . . . 0.0 112.364 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.8 m-85 -84.32 117.56 69.03 Favored Pre-proline 0 N--CA 1.484 1.27 0 C-N-CA 118.825 -1.15 . . . . 0.0 108.23 179.762 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -57.68 -62.59 0.2 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.628 0.885 . . . . 0.0 110.717 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.444 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 34.9 t -77.91 -174.79 3.7 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.967 -1.093 . . . . 0.0 110.177 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.444 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.81 54.33 4.41 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 118.983 -1.58 . . . . 0.0 109.782 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.552 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 1.9 mt-30 -88.27 139.85 30.08 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 119.106 -1.037 . . . . 0.0 110.79 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 49' ' ' GLN . 1.7 pp0? -139.89 112.26 7.75 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.961 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.472 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.43 149.12 11.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.691 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.593 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 26.5 p -126.07 -61.92 1.2 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.898 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.593 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.0 tt0 -98.31 125.54 43.47 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.657 -0.817 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -130.76 160.04 35.51 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 119.445 -0.902 . . . . 0.0 112.388 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.4 ' NE1' ' HB3' ' A' ' 55' ' ' SER . 27.7 t-105 -151.86 143.93 23.87 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.428 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.424 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 4.7 p 54.74 31.93 16.43 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.686 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.501 ' HB2' ' CG ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -172.89 113.32 0.25 Allowed 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.219 -0.901 . . . . 0.0 109.744 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 m -80.12 77.16 6.85 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.211 -0.995 . . . . 0.0 110.361 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.423 HG12 HG13 ' A' ' 67' ' ' VAL . 3.5 m -71.73 156.03 7.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.401 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.405 HG23 ' C ' ' A' ' 58' ' ' VAL . 64.1 p -155.65 118.18 4.19 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.232 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -81.02 108.24 14.53 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.464 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 p -97.89 94.28 6.81 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.381 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.581 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 47.88 72.58 0.42 Allowed Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.043 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.408 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 68.26 -24.12 0.13 Allowed 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.964 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.581 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -84.93 -172.38 4.15 Favored 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 118.746 -1.182 . . . . 0.0 110.424 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 66' ' ' THR . 75.7 t -142.38 158.68 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.865 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.548 ' N ' HG12 ' A' ' 65' ' ' VAL . 20.3 m -160.0 124.37 3.8 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.384 -1.28 . . . . 0.0 108.649 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.622 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -121.66 148.21 25.23 Favored 'Isoleucine or valine' 0 C--O 1.194 -1.859 0 C-N-CA 119.569 -0.852 . . . . 0.0 111.885 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -130.13 92.91 3.37 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.769 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 13.1 p-10 -71.13 121.02 17.55 Favored 'General case' 0 C--N 1.299 -1.619 0 C-N-CA 119.354 -0.938 . . . . 0.0 111.669 -179.712 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.824 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -47.71 170.7 0.09 OUTLIER Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.611 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.824 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.7 Cg_endo -68.41 -38.98 10.46 Favored 'Trans proline' 0 C--N 1.322 -0.816 0 C-N-CA 122.163 1.908 . . . . 0.0 112.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.522 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.71 -54.03 15.73 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.063 -1.055 . . . . 0.0 111.335 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.658 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.7 OUTLIER -75.7 14.73 0.59 Allowed 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.222 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -145.54 34.11 1.51 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 119.284 -1.436 . . . . 0.0 111.319 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.0 m -102.85 58.63 0.78 Allowed 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.584 -0.846 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.523 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -111.98 132.49 21.98 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 119.896 -0.721 . . . . 0.0 111.661 -179.915 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.584 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.9 Cg_endo -69.53 156.26 64.46 Favored 'Trans proline' 0 C--O 1.208 -0.978 0 C-N-CA 121.211 1.274 . . . . 0.0 110.14 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.929 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -41.52 -14.41 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.83 66.85 0.26 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -173.61 -161.51 23.92 Favored Glycine 0 N--CA 1.494 2.534 0 C-N-CA 118.361 -1.876 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.729 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.0 p -139.37 158.17 44.61 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 119.342 -0.943 . . . . 0.0 112.701 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.593 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -124.19 173.94 8.0 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.481 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 9.6 tt0 -169.08 145.79 3.52 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 116.881 -1.928 . . . . 0.0 113.207 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.675 ' CE2' HG11 ' A' ' 25' ' ' VAL . 11.2 p90 -154.98 175.83 13.3 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 114.671 -1.149 . . . . 0.0 109.469 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.18 164.65 37.69 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 116.935 -2.555 . . . . 0.0 112.593 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 3.4 p90 -157.03 -170.23 3.22 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.399 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -135.58 114.84 12.42 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.005 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -125.35 150.16 17.25 Favored Glycine 0 N--CA 1.508 3.475 0 C-N-CA 119.408 -1.377 . . . . 0.0 112.342 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 84.9 p . . . . . 0 N--CA 1.476 0.858 0 C-N-CA 120.072 -0.651 . . . . 0.0 109.902 179.788 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.896 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.509 2.485 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.498 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.0 OUTLIER -65.2 -101.4 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 121.14 1.226 . . . . 0.0 112.468 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.52 ' HA ' HG13 ' A' ' 109' ' ' VAL . 81.4 p -150.1 -66.07 0.21 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 118.897 -1.121 . . . . 0.0 112.265 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.479 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -109.93 103.57 12.36 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.594 -0.843 . . . . 0.0 110.662 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 14.4 m-85 -74.57 -169.67 0.89 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.253 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.4 m -136.57 93.61 2.9 Favored 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 118.667 -1.213 . . . . 0.0 112.726 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.574 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.4 mt -52.53 173.54 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.545 -0.862 . . . . 0.0 108.956 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.486 ' OD1' HD22 ' A' ' 102' ' ' LEU . 2.5 p-10 -45.14 90.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.014 -1.074 . . . . 0.0 110.608 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.06 58.22 12.67 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.443 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.8 HG21 ' HB3' ' A' ' 6' ' ' ALA . 0.8 OUTLIER 175.48 139.58 0.2 Allowed Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.869 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.9 167.13 4.52 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 121.551 1.501 . . . . 0.0 112.65 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -164.36 82.33 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.438 HG23 ' H ' ' A' ' 108' ' ' THR . 50.1 p -46.61 167.95 0.02 OUTLIER 'General case' 0 N--CA 1.517 2.88 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.52 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.0 OUTLIER -66.7 -160.08 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.113 -1.035 . . . . 0.0 109.69 179.562 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.099 0 CA-C-O 116.333 -2.37 . . . . 0.0 110.386 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.551 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 121.365 0.602 . . . . 0.0 111.911 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.79 49.35 0.05 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.5 p -53.23 -179.31 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.618 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.402 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 81.8 mt-30 -137.03 113.09 9.73 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.547 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.644 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -108.77 130.82 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.976 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.578 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -103.88 167.38 9.81 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.104 179.94 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.472 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.6 t-105 -130.59 145.45 51.89 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.031 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.18 73.14 0.47 Allowed Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -72.43 153.04 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.564 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.2 t30 . . . . . 0 N--CA 1.485 1.281 0 CA-C-N 114.323 -1.308 . . . . 0.0 108.742 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.592 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 3.1 p90 . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 121.463 0.649 . . . . 0.0 111.629 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.564 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.0 t -75.33 173.84 10.35 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.472 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -158.1 117.01 3.14 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 117.22 -1.792 . . . . 0.0 113.358 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -99.89 101.54 12.69 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.457 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.8 t -99.63 147.05 7.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.58 -0.848 . . . . 0.0 112.802 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.599 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -138.9 110.35 7.0 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.345 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.615 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -83.23 149.81 4.43 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 C-N-CA 119.724 -0.79 . . . . 0.0 112.201 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.417 ' HB2' HG22 ' A' ' 81' ' ' THR . 2.2 tttm -142.19 106.97 4.87 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.802 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.698 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.3 t30 -93.22 120.17 33.21 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 118.971 -1.092 . . . . 0.0 108.594 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -123.15 -2.77 8.58 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 124.219 0.95 . . . . 0.0 109.818 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.529 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -53.35 -81.4 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.801 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.509 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.52 73.53 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.383 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.26 143.32 1.93 Allowed Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.089 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -68.32 101.88 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.42 109.28 18.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 118.281 -1.367 . . . . 0.0 111.643 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -117.38 73.63 0.89 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.06 143.75 11.75 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.671 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 41.4 p-90 -162.48 177.31 9.6 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 117.761 -1.576 . . . . 0.0 112.098 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -138.45 112.97 8.86 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.379 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.72 173.29 6.37 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 119.285 -0.966 . . . . 0.0 109.326 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.528 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -167.18 159.2 12.68 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.762 -1.575 . . . . 0.0 112.638 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.528 ' N ' ' CG2' ' A' ' 41' ' ' THR . 23.5 p90 -176.71 -134.49 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.63 -1.623 . . . . 0.0 107.954 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.483 ' OG ' ' C ' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -163.0 139.12 7.11 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.685 -1.606 . . . . 0.0 112.237 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.748 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.7 m-85 -69.28 122.28 84.9 Favored Pre-proline 0 N--CA 1.486 1.344 0 C-N-CA 118.838 -1.145 . . . . 0.0 108.465 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -52.68 -68.76 0.07 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.343 1.362 . . . . 0.0 112.729 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 p -69.42 -68.58 0.4 Allowed 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 119.173 -1.011 . . . . 0.0 111.105 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.13 26.71 0.02 OUTLIER Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.222 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.508 ' N ' ' OE1' ' A' ' 48' ' ' GLN . 1.1 mp0 -43.73 144.6 0.8 Allowed 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.614 -0.834 . . . . 0.0 110.847 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -110.54 82.95 1.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.508 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.7 p -61.68 147.75 10.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.398 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.498 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 68.5 p -136.77 -71.91 0.44 Allowed 'General case' 0 N--CA 1.497 1.879 0 C-N-CA 119.181 -1.007 . . . . 0.0 112.157 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.498 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -76.6 145.72 38.74 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.935 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -156.19 153.86 29.9 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.733 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.443 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.2 t-105 -152.55 147.98 26.83 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.182 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 71.27 14.3 6.56 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.686 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.587 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 31.3 t -174.1 151.2 1.66 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.396 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -102.66 84.58 2.43 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.699 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -85.43 163.13 2.76 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.963 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.8 t -164.21 132.26 3.47 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.613 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.87 113.27 24.81 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.698 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.894 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.5 p -84.28 68.33 10.14 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.722 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.31 -63.74 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.5 m -142.19 -16.7 0.75 Allowed 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 120.062 -0.655 . . . . 0.0 109.269 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.47 -172.89 3.95 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.252 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.748 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 94.6 t -146.15 153.1 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 118.79 -1.164 . . . . 0.0 112.587 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.451 ' N ' HG12 ' A' ' 65' ' ' VAL . 3.6 m -159.89 135.87 8.64 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 114.909 -1.042 . . . . 0.0 108.976 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.631 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.0 t -129.46 153.36 38.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.943 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.49 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -135.91 89.29 2.47 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.671 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 3.9 p-10 -70.86 118.53 13.75 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.162 -1.015 . . . . 0.0 112.08 -179.582 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.774 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.07 154.83 0.12 Allowed Pre-proline 0 N--CA 1.484 1.237 0 CA-C-N 113.731 -1.577 . . . . 0.0 112.012 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -64.69 -35.14 48.14 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 121.942 1.762 . . . . 0.0 112.626 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.774 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.59 -57.36 5.28 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.775 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.601 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -69.83 -13.18 62.14 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.106 -1.038 . . . . 0.0 109.911 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.424 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -99.08 22.12 42.46 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.621 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 m -87.53 58.65 5.05 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.002 . . . . 0.0 111.271 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.916 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -108.96 115.39 57.18 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.171 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' GLY . 2.0 Cg_endo -67.96 159.45 52.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 121.317 1.345 . . . . 0.0 113.745 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.509 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -24.08 -38.55 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 114.332 -1.304 . . . . 0.0 114.058 179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.07 68.56 0.33 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -155.35 -168.22 18.14 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 118.857 -1.639 . . . . 0.0 110.284 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.516 ' N ' HG13 ' A' ' 76' ' ' ILE . 22.0 p -141.96 164.37 30.36 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.085 -1.046 . . . . 0.0 112.819 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.578 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.68 -179.95 5.6 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.476 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.599 ' HB2' HG23 ' A' ' 26' ' ' THR . 2.8 tm0? -170.24 151.53 3.89 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 116.883 -1.927 . . . . 0.0 113.101 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.457 ' CE1' HG11 ' A' ' 25' ' ' VAL . 5.6 p90 -167.64 171.49 10.16 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.32 160.89 30.5 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.729 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.604 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.4 p90 -150.1 160.42 43.67 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.308 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.4 m-20 -115.62 110.93 19.89 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.428 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -105.6 176.5 22.33 Favored Glycine 0 N--CA 1.501 3.012 0 C-N-CA 119.491 -1.338 . . . . 0.0 111.972 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.482 1.158 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.393 179.968 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.447 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -68.16 -145.02 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 121.244 1.296 . . . . 0.0 111.287 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.879 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.2 p -116.74 -87.91 0.6 Allowed 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 119.667 -0.813 . . . . 0.0 112.259 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.63 107.11 18.67 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.237 -0.985 . . . . 0.0 112.018 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.1 m-30 -78.6 -155.98 0.09 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.63 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.9 m -159.53 122.73 3.63 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 117.043 -1.863 . . . . 0.0 113.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.591 HD22 HD21 ' A' ' 103' ' ' ASN . 3.3 mt -60.65 -178.61 0.1 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.564 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.718 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.09 -41.24 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -155.69 27.7 0.59 Allowed Glycine 0 N--CA 1.495 2.604 0 C-N-CA 118.593 -1.765 . . . . 0.0 111.352 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.551 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 21.3 p -145.07 151.6 49.02 Favored Pre-proline 0 N--CA 1.494 1.752 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.229 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -62.26 174.49 2.59 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 121.628 1.552 . . . . 0.0 112.451 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.644 ' SG ' HG13 ' A' ' 10' ' ' VAL . 3.0 t -168.19 106.38 0.49 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.471 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 41.4 p -72.63 146.08 46.86 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.971 -0.692 . . . . 0.0 112.403 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.879 HG13 ' O ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -59.32 -167.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.257 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 CA-C-O 116.339 -2.367 . . . . 0.0 110.296 179.986 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.855 ' N ' ' HG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-O 121.454 0.645 . . . . 0.0 111.445 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.69 40.04 0.19 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.6 p -50.88 177.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 114.33 -0.935 . . . . 0.0 112.319 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -131.78 121.64 24.51 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.11 -1.404 . . . . 0.0 109.614 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.491 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 m -112.46 127.01 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.603 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.524 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.56 171.38 7.6 Favored 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.055 179.881 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.695 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.2 t-105 -132.25 149.28 52.41 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.706 -0.798 . . . . 0.0 112.042 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.29 83.55 0.32 Allowed Glycine 0 N--CA 1.497 2.726 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.78 144.75 12.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.421 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 54.0 t30 . . . . . 0 N--CA 1.488 1.468 0 CA-C-N 114.165 -1.38 . . . . 0.0 107.619 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.609 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 24.2 p90 . . . . . 0 CA--C 1.505 -0.78 0 CA-C-O 121.308 0.575 . . . . 0.0 111.324 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -83.87 165.37 18.8 Favored 'General case' 0 C--N 1.284 -2.256 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.623 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.691 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -145.56 106.34 4.12 Favored 'General case' 0 C--N 1.29 -2.014 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.899 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -93.35 96.84 10.2 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.567 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.9 t -93.46 147.39 5.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 115.383 -0.826 . . . . 0.0 113.007 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.524 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.3 m -133.36 127.12 32.8 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.5 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -97.73 145.95 8.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.989 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.655 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.2 tptt -126.97 100.56 6.19 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.835 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.473 ' OD1' ' C ' ' A' ' 29' ' ' ASN . 5.7 t-20 -93.7 119.72 33.06 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.561 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 t -130.53 -0.92 4.4 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.8 p -50.52 -83.01 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.29 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.38 67.78 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.64 -179.943 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.09 157.94 7.37 Favored Pre-proline 0 N--CA 1.482 1.127 0 C-N-CA 118.372 -1.331 . . . . 0.0 111.625 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.65 95.79 0.96 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.588 1.525 . . . . 0.0 109.052 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -74.47 87.54 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 118.47 -1.292 . . . . 0.0 111.744 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -100.06 56.52 0.95 Allowed 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 115.374 -0.83 . . . . 0.0 108.868 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.03 150.28 19.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.689 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 42.0 p-90 -164.14 176.68 9.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 117.652 -1.619 . . . . 0.0 112.059 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.5 OUTLIER -141.28 110.11 6.11 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.545 179.907 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.865 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -99.34 177.0 5.33 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.264 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.505 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.9 150.77 13.69 Favored 'General case' 0 C--N 1.289 -2.024 0 C-N-CA 117.867 -1.533 . . . . 0.0 112.361 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' ' N ' ' A' ' 43' ' ' SER . 14.4 p90 -174.55 -145.99 0.03 OUTLIER 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.753 -1.567 . . . . 0.0 107.952 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.52 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 41.7 m -161.12 154.12 21.15 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 117.804 -1.558 . . . . 0.0 111.758 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.502 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -84.61 116.86 67.1 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.15 -53.89 4.3 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.16 1.24 . . . . 0.0 112.407 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.0 t -74.36 -82.77 0.06 Allowed 'General case' 0 C--N 1.294 -1.842 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.087 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 175.45 25.13 0.03 OUTLIER Glycine 0 N--CA 1.486 2.025 0 C-N-CA 119.289 -1.434 . . . . 0.0 110.193 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.442 ' HG3' ' CE1' ' A' ' 21' ' ' PHE . 6.0 mp0 -43.04 121.86 2.26 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.524 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 4.5 mm-40 -93.81 84.78 4.64 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.959 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.451 ' H ' HG12 ' A' ' 50' ' ' VAL . 0.5 OUTLIER -64.63 148.57 11.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.554 179.786 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.493 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 76.0 p -137.78 -69.23 0.45 Allowed 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.37 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.493 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.5 mt-30 -73.36 161.51 30.38 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 118.842 -1.143 . . . . 0.0 110.024 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.62 142.16 3.05 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.323 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.432 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 38.8 t-105 -146.9 149.09 32.54 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.592 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.432 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 6.3 t 57.11 27.82 14.01 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 119.326 -0.95 . . . . 0.0 109.07 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.588 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -174.66 125.42 0.29 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.135 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -87.57 72.34 9.62 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.596 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 67' ' ' VAL . 2.6 m -71.92 153.18 7.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.33 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.404 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.0 t -153.95 134.94 13.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.944 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -100.51 120.2 39.65 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.285 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.0 p -100.58 80.48 2.21 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.706 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.56 2.53 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.468 -1.349 . . . . 0.0 109.956 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 41.8 t -146.77 -18.23 0.42 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.967 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -87.8 -170.66 3.09 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.155 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 66' ' ' THR . 79.1 t -148.02 160.64 7.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.917 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.8 m -158.65 125.95 4.94 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 114.392 -1.276 . . . . 0.0 108.642 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.589 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.6 t -116.98 146.68 21.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.08 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.674 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -130.18 92.44 3.29 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.689 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 2.0 p-10 -74.41 118.2 17.1 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.284 -0.966 . . . . 0.0 112.433 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.655 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -42.73 165.65 0.1 OUTLIER Pre-proline 0 N--CA 1.487 1.406 0 CA-C-N 113.578 -1.646 . . . . 0.0 112.483 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.619 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 4.9 Cg_endo -68.71 -33.03 22.34 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.058 1.839 . . . . 0.0 112.583 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.614 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.66 -57.7 4.84 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.477 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.655 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.4 p30 -73.26 -4.43 33.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 119.12 -1.032 . . . . 0.0 109.652 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -119.77 50.25 0.83 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.5 t -120.54 57.07 0.97 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 120.029 -0.669 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.543 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.02 134.61 22.13 Favored Pre-proline 0 N--CA 1.486 1.356 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.551 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -71.52 158.71 53.22 Favored 'Trans proline' 0 C--O 1.214 -0.713 0 C-N-CA 121.464 1.443 . . . . 0.0 112.814 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.449 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -31.44 -29.51 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -115.5 72.9 0.25 Allowed Glycine 0 N--CA 1.497 2.706 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.899 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.33 -167.47 27.03 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.793 -1.67 . . . . 0.0 110.809 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.655 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.5 p -138.35 160.01 40.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.088 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -122.56 -176.45 3.38 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.459 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -169.37 142.07 2.6 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 117.068 -1.853 . . . . 0.0 113.361 -179.946 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.567 ' CE1' HG11 ' A' ' 25' ' ' VAL . 7.5 p90 -159.12 174.14 15.34 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.054 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.0 168.33 39.7 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 117.638 -2.22 . . . . 0.0 112.521 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.9 p90 -152.94 -176.36 5.73 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.944 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.501 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 1.2 m120 -138.09 111.66 8.16 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.774 -0.771 . . . . 0.0 110.783 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -123.42 163.62 16.85 Favored Glycine 0 N--CA 1.507 3.379 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.892 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.6 p . . . . . 0 N--CA 1.481 1.105 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.796 179.74 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.695 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -65.29 -142.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 121.21 1.274 . . . . 0.0 110.772 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.621 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.0 p -116.25 -64.63 1.28 Allowed 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 119.45 -0.9 . . . . 0.0 112.593 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.621 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.03 112.15 23.97 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.288 -0.965 . . . . 0.0 111.333 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 8.9 m-85 -84.32 -164.17 0.91 Allowed 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.035 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.2 m -144.52 117.6 8.89 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 118.421 -1.312 . . . . 0.0 112.009 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.788 HD22 ' ND2' ' A' ' 103' ' ' ASN . 1.3 mt -68.38 -178.67 1.14 Allowed 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.581 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.788 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.5 OUTLIER -27.69 -37.46 0.01 OUTLIER 'General case' 0 N--CA 1.512 2.631 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.82 55.6 0.21 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.199 -1.477 . . . . 0.0 110.274 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.855 ' HG1' ' N ' ' A' ' 6' ' ' ALA . 2.4 t -174.38 145.81 1.04 Allowed Pre-proline 0 C--O 1.196 -1.726 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.774 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -56.3 168.59 1.96 Allowed 'Trans proline' 0 C--N 1.324 -0.758 0 C-N-CA 121.511 1.474 . . . . 0.0 112.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.455 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.8 t -164.84 95.12 0.7 Allowed 'General case' 0 N--CA 1.494 1.74 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.118 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.463 ' OG1' ' N ' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -51.99 168.45 0.09 Allowed 'General case' 0 N--CA 1.501 2.075 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.203 -179.688 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 1.095 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.4 p -67.77 -151.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.442 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.871 0 CA-C-O 116.281 -2.4 . . . . 0.0 110.125 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 122.205 1.002 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.635 ' O ' ' SG ' ' A' ' 8' ' ' CYS . . . -176.55 -79.79 0.05 OUTLIER Glycine 0 C--O 1.189 -2.714 0 N-CA-C 107.023 -2.431 . . . . 0.0 107.023 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.722 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 6.6 p 63.62 176.97 0.16 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.541 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 55.3 mt-30 -151.27 158.98 44.56 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.482 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.53 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.7 m -141.19 126.54 18.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.954 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.579 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.65 8.69 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.023 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.616 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 4.0 t-105 -126.73 144.11 51.04 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 123.895 0.747 . . . . 0.0 112.471 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.31 74.7 0.43 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.538 -2.225 . . . . 0.0 107.538 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 15' ' ' ASN . 7.2 p -69.77 152.52 9.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.472 ' N ' HG22 ' A' ' 14' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.499 0 CA-C-N 113.81 -1.541 . . . . 0.0 107.857 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.563 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 32.5 p90 . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.124 0.488 . . . . 0.0 112.047 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 22' ' ' THR . 0.9 OUTLIER -96.04 106.75 18.97 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.563 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.616 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -90.03 120.62 31.39 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -101.78 96.41 7.05 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 179.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 26' ' ' THR . 33.6 t -90.14 154.46 3.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.836 HG23 ' HB3' ' A' ' 83' ' ' GLN . 1.9 m -142.05 101.19 3.88 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.57 -1.195 . . . . 0.0 109.698 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.431 HG13 HG12 ' A' ' 10' ' ' VAL . 3.4 t -75.06 147.81 8.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.184 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.413 ' HA ' HG22 ' A' ' 81' ' ' THR . 5.8 tttp -136.95 105.43 5.78 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.558 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.81 118.72 29.62 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 118.736 -1.186 . . . . 0.0 108.349 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.0 t -118.21 2.15 11.95 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.185 0.928 . . . . 0.0 110.013 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 32' ' ' SER . 14.9 p -54.09 -84.01 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.646 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.6 OUTLIER 158.77 68.45 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.934 0 O-C-N 123.873 0.733 . . . . 0.0 111.29 -179.953 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.462 ' H ' ' HA ' ' A' ' 78' ' ' ALA . . . -168.16 154.04 6.92 Favored Pre-proline 0 N--CA 1.483 1.192 0 C-N-CA 118.629 -1.228 . . . . 0.0 111.428 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -70.95 93.18 0.63 Allowed 'Trans proline' 0 C--N 1.326 -0.639 0 C-N-CA 121.144 1.23 . . . . 0.0 109.051 179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.456 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -78.33 107.27 10.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.598 -179.852 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -114.41 62.72 0.67 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.22 147.9 20.15 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.691 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 39.6 p-90 -164.45 -179.11 5.8 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.427 -1.309 . . . . 0.0 111.805 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.29 118.29 12.54 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.257 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -112.05 174.81 5.7 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 119.474 -0.891 . . . . 0.0 109.412 179.831 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.503 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -166.05 153.68 10.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.736 -1.586 . . . . 0.0 112.858 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.509 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.9 p90 -176.3 -139.67 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 113.809 -1.541 . . . . 0.0 108.22 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.509 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.6 m -160.15 172.0 18.23 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.798 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.55 ' CD2' HG21 ' A' ' 65' ' ' VAL . 3.0 m-85 -114.14 96.5 42.41 Favored Pre-proline 0 N--CA 1.497 1.881 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.57 -42.95 42.87 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 121.469 1.446 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.571 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.4 t -69.71 -115.7 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.91 -1.116 . . . . 0.0 110.632 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.571 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -145.85 21.22 1.8 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.498 ' HB2' ' CD1' ' A' ' 44' ' ' PHE . 57.5 mt-30 -61.85 89.96 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.689 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -88.86 97.18 11.02 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.3 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.583 HG23 ' HB2' ' A' ' 86' ' ' PHE . 1.5 p -68.06 138.25 22.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.651 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 44.0 p -127.19 -65.77 0.93 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.814 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.531 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.4 OUTLIER -81.4 153.34 27.0 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.453 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.412 ' N ' ' HG3' ' A' ' 52' ' ' GLN . . . -162.1 155.05 20.21 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.277 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.4 t-105 -157.71 142.41 16.49 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.796 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.482 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.2 OUTLIER 75.27 14.31 3.02 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.515 179.931 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.574 ' OG ' HG11 ' A' ' 67' ' ' VAL . 1.4 t -174.32 115.43 0.2 Allowed 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.5 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -71.2 85.52 0.76 Allowed 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.898 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 56' ' ' SER . 1.4 m -86.2 167.36 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.821 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.434 ' O ' ' CG2' ' A' ' 59' ' ' THR . 4.0 t -163.55 133.9 4.4 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.21 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.515 ' NE2' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER -94.42 123.99 38.17 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.733 -179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.629 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 34.0 p -110.01 -151.34 0.47 Allowed 'General case' 0 C--O 1.2 -1.519 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.394 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.529 ' C ' ' N ' ' A' ' 64' ' ' ALA . . . -53.33 84.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.657 0 C-N-CA 118.645 -1.74 . . . . 0.0 109.178 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.618 ' N ' ' O ' ' A' ' 61' ' ' SER . 28.4 m 47.68 13.66 0.04 OUTLIER 'General case' 0 C--N 1.31 -1.118 0 C-N-CA 119.606 -0.837 . . . . 0.0 109.686 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.629 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -109.59 -167.55 1.22 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.427 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.55 HG21 ' CD2' ' A' ' 44' ' ' PHE . 99.3 t -148.71 154.55 9.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 118.664 -1.215 . . . . 0.0 112.586 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.508 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.5 m -156.08 139.14 15.46 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.621 179.746 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.612 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.7 t -132.83 156.4 42.25 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.748 0 C-N-CA 119.05 -1.06 . . . . 0.0 112.442 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.421 ' N ' HG12 ' A' ' 67' ' ' VAL . 6.2 mtm180 -139.85 90.21 2.37 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 113.888 -1.505 . . . . 0.0 106.993 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.852 ' HB2' HD22 ' A' ' 73' ' ' ASN . 6.9 p-10 -74.21 121.87 21.92 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.854 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.722 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.93 158.66 0.17 Allowed Pre-proline 0 N--CA 1.482 1.136 0 CA-C-N 113.618 -1.628 . . . . 0.0 112.049 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.42 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.8 Cg_endo -65.62 -39.14 22.09 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.921 1.747 . . . . 0.0 111.865 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.722 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.54 -55.88 8.91 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.43 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.852 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.2 OUTLIER -66.41 -20.8 66.16 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 118.755 -1.178 . . . . 0.0 109.221 179.879 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -99.77 31.77 8.01 Favored Glycine 0 N--CA 1.483 1.802 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 t -92.12 55.77 2.68 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.616 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -104.76 133.9 19.93 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.646 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.46 ' O ' ' N ' ' A' ' 79' ' ' GLY . 11.9 Cg_endo -77.32 163.08 30.49 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 121.628 1.552 . . . . 0.0 114.07 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.29 -39.35 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 114.031 -1.441 . . . . 0.0 113.658 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -123.98 73.37 0.41 Allowed Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.479 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -152.59 -163.18 11.43 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.041 -1.552 . . . . 0.0 110.39 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.563 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.0 OUTLIER -141.8 163.23 33.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.626 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -146.91 99.32 3.17 Favored 'General case' 0 N--CA 1.485 1.278 0 CA-C-N 114.484 -1.235 . . . . 0.0 107.936 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.836 ' HB3' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -94.14 172.7 8.05 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -179.661 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.519 ' CB ' ' HB2' ' A' ' 56' ' ' SER . 34.9 p90 -168.62 -167.93 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 112.633 -2.076 . . . . 0.0 109.482 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 84' ' ' PHE . . . -172.98 158.93 29.14 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 117.483 -2.294 . . . . 0.0 112.555 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.5 p90 -149.69 166.62 28.81 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 114.962 -0.619 . . . . 0.0 110.369 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.0 OUTLIER -123.41 110.26 14.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.89 -0.724 . . . . 0.0 110.724 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.553 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -129.62 167.19 21.57 Favored Glycine 0 N--CA 1.505 3.251 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.711 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p . . . . . 0 N--CA 1.483 1.184 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.133 179.84 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.496 -0.187 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.491 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -59.79 -100.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 120.754 0.969 . . . . 0.0 112.445 -179.898 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.849 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.3 p -150.89 -98.86 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.454 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.71 95.75 9.75 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 118.492 -1.283 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -65.49 -157.33 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.339 -0.945 . . . . 0.0 108.995 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.473 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.58 128.5 5.86 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 116.679 -2.008 . . . . 0.0 113.982 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.8 mt -62.86 -173.27 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.398 179.668 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.66 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -32.15 -49.17 0.19 Allowed 'General case' 0 N--CA 1.505 2.3 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -147.95 28.46 1.42 Allowed Glycine 0 N--CA 1.494 2.511 0 C-N-CA 118.847 -1.644 . . . . 0.0 111.411 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.579 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -146.15 155.24 50.82 Favored Pre-proline 0 C--O 1.191 -2.026 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.239 -179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -65.97 -178.14 0.97 Allowed 'Trans proline' 0 C--N 1.321 -0.87 0 C-N-CA 121.781 1.654 . . . . 0.0 112.571 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.722 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 9.7 t -174.45 111.76 0.15 Allowed 'General case' 0 N--CA 1.501 2.097 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.907 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.12 132.36 44.94 Favored 'General case' 0 N--CA 1.515 2.814 0 N-CA-C 114.202 1.186 . . . . 0.0 114.202 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 98' ' ' THR . 0.2 OUTLIER -52.33 174.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 C-N-CA 118.824 -1.15 . . . . 0.0 110.54 179.742 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.161 0 CA-C-O 116.371 -2.35 . . . . 0.0 110.479 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.595 ' HB1' ' CB ' ' A' ' 31' ' ' SER . . . . . . . . 0 N--CA 1.485 1.289 0 CA-C-O 120.907 0.385 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.73 55.23 0.21 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.445 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 2.9 p -51.44 177.39 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.187 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.42 116.36 15.94 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.592 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.662 HG12 HG13 ' A' ' 27' ' ' VAL . 3.5 m -110.51 124.16 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.256 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.11 166.86 11.72 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.582 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.626 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.5 t-105 -134.75 140.05 45.63 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.613 -0.835 . . . . 0.0 111.463 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -122.98 71.22 0.42 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -72.17 147.67 10.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.487 ' HB3' HG22 ' A' ' 22' ' ' THR . 29.7 t30 . . . . . 0 C--N 1.3 -1.562 0 CA-C-N 113.989 -1.459 . . . . 0.0 107.513 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.598 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 20.2 p90 . . . . . 0 N--CA 1.478 0.928 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.487 HG22 ' HB3' ' A' ' 15' ' ' ASN . 2.4 t -72.61 171.87 11.67 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.626 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -156.81 113.54 3.06 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 117.385 -1.726 . . . . 0.0 113.19 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -98.82 101.17 12.48 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.592 HG11 ' CE1' ' A' ' 84' ' ' PHE . 27.2 t -99.43 143.24 13.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.918 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.562 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.8 m -132.54 110.77 10.71 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.93 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.662 HG13 HG12 ' A' ' 10' ' ' VAL . 2.1 t -82.0 150.42 4.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 C-N-CA 119.486 -0.885 . . . . 0.0 112.213 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.419 ' HB2' HG22 ' A' ' 81' ' ' THR . 13.3 tttp -138.91 115.77 10.81 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.067 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.433 ' HB2' ' CD1' ' A' ' 76' ' ' ILE . 1.4 t-20 -98.24 109.71 22.42 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.5 t -121.77 -2.08 9.37 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.147 0.905 . . . . 0.0 109.78 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.595 ' CB ' ' HB1' ' A' ' 6' ' ' ALA . 1.8 p -58.68 -79.46 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.261 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.34 43.21 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.522 -179.857 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.955 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -140.15 145.91 43.87 Favored Pre-proline 0 N--CA 1.487 1.388 0 C-N-CA 118.91 -1.116 . . . . 0.0 111.494 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -72.4 109.26 2.7 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 121.3 1.334 . . . . 0.0 109.596 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -97.5 112.97 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.001 -1.079 . . . . 0.0 112.211 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -122.35 70.01 0.97 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 141.77 12.1 Favored Glycine 0 C--N 1.294 -1.782 0 N-CA-C 106.657 -2.577 . . . . 0.0 106.657 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 31.0 p-90 -158.88 178.86 9.63 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 117.136 -1.825 . . . . 0.0 112.456 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.55 95.76 3.04 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.057 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.893 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -82.22 168.84 17.23 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.223 -1.391 . . . . 0.0 109.469 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.5 m -156.95 149.59 23.45 Favored 'General case' 0 C--N 1.287 -2.152 0 C-N-CA 118.122 -1.431 . . . . 0.0 112.012 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 25.5 p90 -174.03 -149.73 0.04 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.996 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.1 m -158.96 149.62 19.84 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 117.623 -1.631 . . . . 0.0 112.001 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.456 ' CE2' HG21 ' A' ' 65' ' ' VAL . 7.4 m-85 -78.79 123.55 85.26 Favored Pre-proline 0 C--N 1.307 -1.261 0 C-N-CA 118.326 -1.35 . . . . 0.0 107.712 179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -65.72 -63.26 0.07 OUTLIER 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 121.358 1.372 . . . . 0.0 112.226 -179.579 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 p -69.05 -120.68 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 118.613 -1.235 . . . . 0.0 110.464 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -132.91 42.68 1.35 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -84.92 133.07 34.3 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.762 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.6 pp0? -131.56 117.07 18.24 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.801 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.464 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.38 155.06 7.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.974 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.554 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.7 p -128.6 -64.85 0.91 Allowed 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.894 -0.723 . . . . 0.0 110.92 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.554 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -95.28 140.46 30.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.601 -0.839 . . . . 0.0 109.446 179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.73 160.72 40.22 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 118.917 -1.113 . . . . 0.0 112.354 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 35.3 t-105 -153.15 143.07 22.16 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.649 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.3 t 60.97 26.56 16.49 Favored 'General case' 0 C--N 1.313 -0.978 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.466 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.419 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -170.97 124.07 0.63 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.717 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 m -87.01 75.09 9.58 Favored 'General case' 0 C--N 1.281 -2.384 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.354 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.414 ' C ' HG23 ' A' ' 59' ' ' THR . 16.7 m -69.21 151.1 10.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.256 -0.884 . . . . 0.0 112.462 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.414 HG23 ' C ' ' A' ' 58' ' ' VAL . 37.9 p -155.32 115.31 3.74 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -90.74 124.44 35.11 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 119.11 -1.036 . . . . 0.0 110.612 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.96 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.7 p -91.71 75.31 5.77 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.5 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.471 ' C ' ' OG ' ' A' ' 63' ' ' SER . . . 76.18 -42.9 1.69 Allowed Glycine 0 N--CA 1.496 2.661 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.222 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.471 ' OG ' ' C ' ' A' ' 62' ' ' GLY . 0.8 OUTLIER -163.76 -19.01 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.087 -0.645 . . . . 0.0 109.563 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.96 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.33 -169.18 2.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.17 -1.012 . . . . 0.0 109.754 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 66' ' ' THR . 98.3 t -150.33 157.97 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 118.007 -1.477 . . . . 0.0 114.152 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.587 ' N ' HG12 ' A' ' 65' ' ' VAL . 13.4 m -157.86 143.6 17.18 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.67 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.569 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -139.12 114.74 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 C-N-CA 118.834 -1.147 . . . . 0.0 112.144 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -94.14 89.41 5.98 Favored 'General case' 0 C--N 1.281 -2.374 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.095 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.727 HD21 ' CA ' ' A' ' 74' ' ' GLY . 0.9 OUTLIER -71.75 117.28 13.13 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.021 -1.072 . . . . 0.0 111.909 -179.694 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.928 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -37.6 155.75 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.454 0 CA-C-N 113.622 -1.626 . . . . 0.0 112.297 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -62.47 -36.79 63.78 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.998 1.799 . . . . 0.0 112.312 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.754 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.07 -52.45 28.32 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.304 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.928 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 12.9 p30 -75.56 0.59 16.84 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.686 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.727 ' CA ' HD21 ' A' ' 69' ' ' ASN . . . -118.94 25.41 7.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.6 p -92.73 73.25 4.97 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.75 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.549 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -133.89 126.07 18.58 Favored Pre-proline 0 N--CA 1.483 1.206 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.23 179.928 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.615 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.5 Cg_endo -72.41 167.59 26.57 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 120.953 1.102 . . . . 0.0 110.233 179.707 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.955 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -52.55 1.71 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.655 0 C-N-CA 119.609 -0.836 . . . . 0.0 112.399 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.615 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -128.8 67.29 0.56 Allowed Glycine 0 N--CA 1.496 2.663 0 C-N-CA 119.597 -1.287 . . . . 0.0 109.945 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 178.73 -162.06 28.92 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 118.831 -1.652 . . . . 0.0 110.376 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.549 ' N ' HG13 ' A' ' 76' ' ' ILE . 15.8 p -142.09 166.32 25.04 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.093 -1.043 . . . . 0.0 113.179 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.473 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -128.56 -177.31 4.13 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 113.896 -1.502 . . . . 0.0 107.113 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.421 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 13.0 tt0 -168.21 148.29 4.78 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 116.85 -1.94 . . . . 0.0 113.494 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.0 p90 -161.86 169.83 20.57 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.312 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.62 161.12 32.47 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 117.981 -2.057 . . . . 0.0 112.174 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.5 p90 -155.37 175.08 14.33 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -124.07 109.42 13.47 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.284 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.81 174.83 15.63 Favored Glycine 0 N--CA 1.497 2.737 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.678 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 N--CA 1.485 1.285 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.705 179.908 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.652 ' HB1' ' HZ ' ' A' ' 100' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 9.2 Cg_endo -68.86 -151.14 0.03 OUTLIER 'Trans proline' 0 C--O 1.216 -0.585 0 C-N-CA 121.408 1.405 . . . . 0.0 111.594 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.633 ' O ' HG13 ' A' ' 109' ' ' VAL . 9.3 p -120.06 -47.82 2.37 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.914 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.433 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.5 91.61 3.72 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.939 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.652 ' HZ ' ' HB1' ' A' ' 96' ' ' ALA . 33.7 m-85 -64.18 -164.03 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.066 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.1 m -146.66 98.9 3.13 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 117.761 -1.576 . . . . 0.0 113.336 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -51.53 165.85 0.15 Allowed 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 119.304 -0.958 . . . . 0.0 108.655 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -43.03 91.15 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.058 -1.057 . . . . 0.0 110.669 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 68.91 55.88 10.18 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.59 -1.291 . . . . 0.0 110.51 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.594 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.9 OUTLIER 175.97 135.57 0.18 Allowed Pre-proline 0 C--O 1.195 -1.797 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.739 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -58.97 166.86 6.27 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 121.568 1.512 . . . . 0.0 112.818 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.511 ' SG ' HG13 ' A' ' 10' ' ' VAL . 9.0 t -165.53 102.36 0.71 Allowed 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.94 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 p -58.68 173.37 0.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.211 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.633 HG13 ' O ' ' A' ' 98' ' ' THR . 16.3 m -64.26 -143.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.66 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.486 2.002 0 CA-C-O 116.32 -2.378 . . . . 0.0 110.227 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 121.213 0.53 . . . . 0.0 110.971 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.44 45.42 0.04 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.917 ' SG ' HD12 ' A' ' 102' ' ' LEU . 4.3 p -50.94 175.12 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 69.0 mt-30 -138.27 118.64 13.73 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.714 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.673 HG12 HG13 ' A' ' 27' ' ' VAL . 3.1 m -109.57 124.47 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.861 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.558 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.72 163.3 12.69 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.966 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.591 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 6.1 t-105 -115.82 143.19 45.75 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.857 -0.737 . . . . 0.0 111.871 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 74.03 0.39 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 21' ' ' PHE . 8.2 p -68.73 141.71 17.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.826 -0.749 . . . . 0.0 112.597 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.307 -1.242 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.006 179.851 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.517 ' CZ ' ' OE1' ' A' ' 48' ' ' GLN . 2.8 p90 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.509 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -87.96 118.93 27.84 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 179.577 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.591 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -96.96 110.58 23.08 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 119.239 -0.984 . . . . 0.0 113.517 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -92.77 100.42 12.91 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.599 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.4 t -93.51 145.43 7.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 119.236 -0.985 . . . . 0.0 113.583 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.595 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.7 m -135.52 109.94 8.47 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.239 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.673 HG13 HG12 ' A' ' 10' ' ' VAL . 0.3 OUTLIER -81.02 151.4 4.43 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 C-N-CA 119.501 -0.88 . . . . 0.0 111.816 -179.855 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.648 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.1 OUTLIER -136.92 98.23 3.71 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.535 179.729 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -88.48 101.22 13.71 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.216 -0.994 . . . . 0.0 108.369 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -114.19 1.85 14.66 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.349 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.1 p -61.7 -79.64 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.61 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.634 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.91 75.24 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.535 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -167.32 152.44 6.98 Favored Pre-proline 0 C--N 1.31 -1.152 0 C-N-CA 118.665 -1.214 . . . . 0.0 111.587 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -72.72 94.64 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.71 0 N-CA-C 108.672 -1.318 . . . . 0.0 108.672 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.23 102.5 5.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 118.31 -1.356 . . . . 0.0 111.698 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -119.92 57.36 0.93 Allowed 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.97 148.76 18.34 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.787 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.7 p-90 -167.08 175.89 7.24 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.637 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.34 109.81 6.59 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.699 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.54 174.94 6.01 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.324 -0.95 . . . . 0.0 109.656 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.479 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -161.65 150.09 15.46 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 117.874 -1.53 . . . . 0.0 112.719 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 43' ' ' SER . 12.9 p90 -175.6 -130.43 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.039 -1.437 . . . . 0.0 108.596 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.498 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 m -167.13 176.9 6.52 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 117.819 -1.553 . . . . 0.0 112.495 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.662 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -117.14 87.81 24.74 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.605 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -59.03 -27.45 85.06 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 121.786 1.657 . . . . 0.0 112.499 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.476 ' OG ' ' CG ' ' A' ' 48' ' ' GLN . 0.9 OUTLIER -69.59 -13.37 62.29 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.731 179.962 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 78.99 19.78 71.85 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.742 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.517 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 21.7 mt-30 -73.85 177.12 5.76 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.631 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -141.77 111.26 6.5 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 50' ' ' VAL . 2.4 p -76.07 155.13 5.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.861 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.433 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 64.8 p -138.66 -68.1 0.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.314 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.433 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -82.88 131.01 35.21 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.056 -1.058 . . . . 0.0 110.423 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.44 152.81 41.98 Favored 'General case' 0 N--CA 1.49 1.575 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.65 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 39.5 t-105 -154.73 144.48 21.57 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.004 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 69.0 18.81 8.33 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.071 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.615 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 3.3 m -172.23 111.12 0.26 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.115 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -69.93 79.79 0.47 Allowed 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.484 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.657 HG12 HG13 ' A' ' 67' ' ' VAL . 9.5 m -81.05 155.95 4.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.067 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.6 t -155.43 129.88 9.03 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.21 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 22.4 tt0 -95.68 114.21 25.93 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.518 -0.873 . . . . 0.0 111.043 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.8 p -91.1 78.23 5.92 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.683 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.89 -68.28 2.26 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.095 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -142.08 -15.77 0.78 Allowed 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.188 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.498 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -92.63 -170.81 2.57 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.662 HG21 ' CD2' ' A' ' 44' ' ' PHE . 54.1 t -145.78 160.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 C-N-CA 118.838 -1.145 . . . . 0.0 113.029 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.4 m -161.07 127.36 3.92 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.121 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 58' ' ' VAL . 2.0 t -122.54 147.53 26.65 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.845 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 mtm-85 -129.38 92.73 3.41 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.787 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 8.6 p-10 -72.81 122.05 20.93 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.272 -0.971 . . . . 0.0 112.445 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.766 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -48.25 156.69 0.75 Allowed Pre-proline 0 C--N 1.305 -1.343 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.316 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.98 -36.81 81.08 Favored 'Trans proline' 0 C--N 1.325 -0.706 0 C-N-CA 121.895 1.73 . . . . 0.0 112.628 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.654 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -56.27 7.68 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 118.733 -1.187 . . . . 0.0 110.61 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.766 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -72.33 7.7 1.66 Allowed 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 109.714 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -137.05 33.82 2.27 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 27.9 t -99.94 59.72 1.06 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.846 -0.742 . . . . 0.0 111.298 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.542 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.01 135.86 22.12 Favored Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.808 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.2 Cg_endo -73.44 158.91 47.45 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.631 1.554 . . . . 0.0 114.027 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.634 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.37 -32.73 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 CA-C-N 113.888 -1.505 . . . . 0.0 114.758 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.52 68.82 0.29 Allowed Glycine 0 N--CA 1.503 3.125 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.968 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.15 23.19 Favored Glycine 0 C--N 1.29 -1.992 0 C-N-CA 118.637 -1.744 . . . . 0.0 110.695 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 28' ' ' LYS . 6.3 p -138.08 162.9 32.97 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 119.691 -0.804 . . . . 0.0 112.008 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.36 169.54 14.13 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.595 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.7 OUTLIER -160.45 142.08 12.44 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 117.016 -1.874 . . . . 0.0 113.486 -179.842 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.615 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 13.5 p90 -154.7 177.36 11.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 114.33 -1.305 . . . . 0.0 109.296 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.72 159.69 33.05 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 117.604 -2.236 . . . . 0.0 112.135 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.654 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 0.9 OUTLIER -145.17 -178.36 6.02 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.798 179.923 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.509 ' ND2' ' OG1' ' A' ' 22' ' ' THR . 3.2 m120 -133.62 110.53 9.95 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.089 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -113.91 173.43 14.96 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.899 -1.143 . . . . 0.0 111.278 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.0 p . . . . . 0 N--CA 1.485 1.287 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.828 179.882 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.609 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.453 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.3 Cg_endo -66.3 -142.85 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 121.169 1.246 . . . . 0.0 110.999 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.404 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 42.5 p -111.73 -88.12 0.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.642 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.404 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -97.56 105.54 17.71 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.008 -1.077 . . . . 0.0 112.146 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.564 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -74.9 -146.26 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.528 -0.869 . . . . 0.0 108.995 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.72 98.87 1.96 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 117.369 -1.733 . . . . 0.0 113.775 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.917 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -53.17 172.15 0.06 Allowed 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.457 ' HB3' ' H ' ' A' ' 39' ' ' THR . 34.1 p-10 -52.22 86.83 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.944 -1.102 . . . . 0.0 110.488 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 76.07 42.86 23.31 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.62 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.612 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -169.92 138.65 1.51 Allowed Pre-proline 0 C--O 1.196 -1.733 0 C-N-CA 119.493 -0.883 . . . . 0.0 110.818 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -64.72 154.8 70.64 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.137 1.225 . . . . 0.0 111.677 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.459 ' SG ' HG13 ' A' ' 10' ' ' VAL . 2.7 t -151.11 104.43 3.13 Favored 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 119.424 -0.91 . . . . 0.0 110.908 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.51 157.37 11.54 Favored 'General case' 0 N--CA 1.5 2.05 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.019 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.896 HG13 ' N ' ' A' ' 110' ' ' GLY . 6.1 p -70.44 -140.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.234 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.896 ' N ' HG13 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.278 0 CA-C-O 116.342 -2.366 . . . . 0.0 110.446 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 121.435 0.636 . . . . 0.0 111.604 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 175.03 41.55 0.05 OUTLIER Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.709 -2.157 . . . . 0.0 107.709 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.664 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.45 -167.94 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.252 -0.974 . . . . 0.0 111.469 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.499 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.9 OUTLIER -159.15 152.67 22.76 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 118.984 -1.086 . . . . 0.0 110.402 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -137.29 133.77 46.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.2 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.56 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.42 164.83 11.57 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.968 179.855 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.609 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.6 t-105 -118.9 142.86 47.37 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.927 -0.709 . . . . 0.0 112.072 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.76 76.58 0.38 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 107.804 -2.119 . . . . 0.0 107.804 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -69.16 150.97 10.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.622 -0.831 . . . . 0.0 113.0 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.418 ' CB ' HG22 ' A' ' 22' ' ' THR . 10.9 t-20 . . . . . 0 C--N 1.305 -1.344 0 CA-C-N 114.321 -1.309 . . . . 0.0 108.534 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.563 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 23.7 p90 . . . . . 0 CA--C 1.494 -1.203 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' CB ' ' A' ' 15' ' ' ASN . 0.6 OUTLIER -81.13 153.25 27.38 Favored 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 105.433 -2.062 . . . . 0.0 105.433 179.447 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -128.79 108.9 10.83 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.378 -1.329 . . . . 0.0 112.657 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -95.74 94.91 7.96 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 84' ' ' PHE . 36.9 t -91.92 154.14 3.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.296 -0.962 . . . . 0.0 112.452 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.56 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.2 m -139.36 104.11 4.89 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.222 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 27' ' ' VAL . 1.5 t -74.8 148.81 7.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 C-N-CA 119.732 -0.787 . . . . 0.0 112.17 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.632 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -136.21 96.09 3.32 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.784 179.693 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.427 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.9 t30 -88.28 106.98 18.58 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.883 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 t -113.45 5.52 16.76 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.835 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.5 ' O ' ' CB ' ' A' ' 32' ' ' SER . 12.6 p -54.17 -84.9 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.894 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.59 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 162.01 65.39 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.752 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB1' ' HD2' ' A' ' 34' ' ' PRO . . . -170.44 160.2 6.17 Favored Pre-proline 0 N--CA 1.486 1.331 0 C-N-CA 118.804 -1.158 . . . . 0.0 111.413 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.44 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 7.1 Cg_endo -71.72 95.07 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.484 1.456 . . . . 0.0 109.571 179.571 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.1 t -75.13 79.79 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 C-N-CA 118.87 -1.132 . . . . 0.0 112.301 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -91.46 57.41 3.31 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.431 -0.908 . . . . 0.0 108.714 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 106.62 157.83 21.5 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.777 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 48.0 p-90 -171.58 178.82 3.03 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 117.752 -1.579 . . . . 0.0 112.382 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.505 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -141.18 115.63 9.48 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.017 179.779 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.844 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -106.35 176.43 5.17 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.1 179.834 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.624 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.1 m -167.18 152.44 7.43 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 117.5 -1.68 . . . . 0.0 113.009 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.447 ' CD2' ' N ' ' A' ' 43' ' ' SER . 19.4 p90 -176.79 -137.48 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 113.756 -1.566 . . . . 0.0 108.161 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.566 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 6.8 m -165.71 168.55 16.06 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 117.665 -1.614 . . . . 0.0 112.604 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.513 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -102.16 108.12 55.61 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.71 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -55.98 -66.79 0.08 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.051 1.168 . . . . 0.0 111.726 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.478 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 35.2 t -70.28 -171.91 0.52 Allowed 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.526 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.478 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.36 49.07 3.51 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.198 -1.477 . . . . 0.0 109.915 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -86.18 109.86 19.18 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.445 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.726 ' CD ' ' H ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -113.91 130.4 56.51 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.729 179.978 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 51' ' ' THR . 5.2 p -96.41 159.51 2.98 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.083 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.4 p -133.09 -65.77 0.69 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.707 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.581 ' N ' ' OG1' ' A' ' 51' ' ' THR . 3.5 mt-30 -81.72 166.5 20.03 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.282 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -169.29 148.48 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.976 -1.09 . . . . 0.0 111.454 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.462 ' CD1' ' HB3' ' A' ' 55' ' ' SER . 36.8 t-105 -150.6 141.42 22.81 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.001 -1.079 . . . . 0.0 111.645 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.462 ' HB3' ' CD1' ' A' ' 54' ' ' TRP . 0.9 OUTLIER 63.8 20.92 12.45 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.311 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.642 ' O ' HG13 ' A' ' 58' ' ' VAL . 1.2 m -165.06 109.31 0.89 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.422 -0.911 . . . . 0.0 110.381 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -70.57 78.36 0.58 Allowed 'General case' 0 C--N 1.285 -2.216 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.126 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.642 HG13 ' O ' ' A' ' 56' ' ' SER . 1.0 OUTLIER -81.48 162.34 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.461 -179.899 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.429 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.9 t -160.55 133.92 6.75 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.348 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.94 108.83 18.98 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.734 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.5 p -93.34 75.5 4.54 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.476 -0.889 . . . . 0.0 110.875 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 53.56 74.27 0.32 Allowed Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.357 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 0.3 OUTLIER 76.17 -35.91 0.26 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.491 -179.977 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.566 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -81.67 -171.06 3.13 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.666 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 66' ' ' THR . 77.4 t -149.71 157.62 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 118.725 -1.19 . . . . 0.0 113.05 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.624 HG23 ' OG1' ' A' ' 41' ' ' THR . 35.9 m -156.69 131.9 9.18 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 114.234 -1.348 . . . . 0.0 107.96 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.607 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -126.07 146.98 30.95 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.07 0 C-N-CA 119.326 -0.95 . . . . 0.0 112.225 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -130.46 93.22 3.4 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.78 ' HB2' HD22 ' A' ' 73' ' ' ASN . 10.4 p-10 -72.7 124.31 25.05 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.373 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.698 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -46.52 162.98 0.24 Allowed Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 113.719 -1.582 . . . . 0.0 111.593 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -67.12 -39.13 14.12 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.897 1.731 . . . . 0.0 111.933 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.698 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.38 -56.06 8.56 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.246 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.78 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.5 OUTLIER -70.63 -5.75 31.73 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.024 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -119.62 48.13 0.97 Allowed Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -112.67 74.33 0.86 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.099 -0.641 . . . . 0.0 110.971 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.623 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -130.69 132.28 23.84 Favored Pre-proline 0 CA--C 1.56 1.352 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.94 179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.433 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.4 Cg_endo -71.18 159.24 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 122.023 1.815 . . . . 0.0 114.498 -179.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.59 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -26.24 -40.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.679 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -114.76 68.84 0.26 Allowed Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.77 -1.205 . . . . 0.0 111.038 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.78 -168.83 18.68 Favored Glycine 0 C--N 1.29 -2.023 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.002 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 28' ' ' LYS . 7.6 p -137.1 166.39 23.82 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.818 0.818 . . . . 0.0 112.364 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.556 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -138.38 162.41 34.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.541 ' HG3' HG23 ' A' ' 26' ' ' THR . 1.4 mp0 -139.52 158.2 44.53 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 118.114 -1.434 . . . . 0.0 113.355 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 25' ' ' VAL . 1.6 p90 -171.03 161.86 6.99 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.103 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.57 169.81 37.15 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 117.438 -2.315 . . . . 0.0 112.741 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.1 p90 -150.97 -176.94 5.73 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.347 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.561 HD22 ' C ' ' A' ' 86' ' ' PHE . 0.6 OUTLIER -128.82 104.68 7.76 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.622 179.842 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.34 175.51 15.74 Favored Glycine 0 N--CA 1.498 2.769 0 C-N-CA 120.058 -1.068 . . . . 0.0 111.41 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . 0.418 ' O ' ' NE2' ' A' ' 49' ' ' GLN . 2.7 p . . . . . 0 N--CA 1.483 1.182 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.221 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.609 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 111.295 0.109 . . . . 0.0 111.295 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.6 Cg_endo -65.63 -143.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 121.093 1.195 . . . . 0.0 110.442 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.758 ' O ' HG13 ' A' ' 109' ' ' VAL . 27.0 p -104.39 -101.1 0.31 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.355 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.89 109.6 20.82 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 118.711 -1.196 . . . . 0.0 112.537 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.664 ' CZ ' ' CG1' ' A' ' 109' ' ' VAL . 4.1 m-30 -76.1 -149.76 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.45 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.87 116.27 2.8 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 117.107 -1.837 . . . . 0.0 113.696 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.664 HD12 ' SG ' ' A' ' 8' ' ' CYS . 2.1 mt -58.81 -172.53 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.114 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.505 ' N ' ' O ' ' A' ' 39' ' ' THR . 1.6 p-10 -65.99 76.53 0.08 Allowed 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.919 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 102.22 10.7 38.5 Favored Glycine 0 N--CA 1.5 2.913 0 C-N-CA 119.521 -1.323 . . . . 0.0 112.374 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 102' ' ' LEU . 62.3 p -150.46 151.14 30.46 Favored Pre-proline 0 N--CA 1.495 1.796 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -66.51 171.53 10.51 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.583 1.522 . . . . 0.0 112.388 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.62 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.8 t -165.85 111.13 0.86 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.088 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 1.1 p -72.58 128.11 34.59 Favored 'General case' 0 N--CA 1.506 2.354 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.758 HG13 ' O ' ' A' ' 98' ' ' THR . 0.9 OUTLIER -54.45 178.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 C-N-CA 118.793 -1.163 . . . . 0.0 110.531 179.796 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.287 0 CA-C-O 116.379 -2.345 . . . . 0.0 110.324 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.418 ' HB3' ' HB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.481 1.087 0 CA-C-O 121.256 0.55 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.2 50.45 0.02 OUTLIER Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.722 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.7 p -52.31 178.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.771 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.72 110.67 7.72 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.58 HG13 ' SG ' ' A' ' 107' ' ' CYS . 3.5 m -101.75 125.79 55.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.2 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.549 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -104.81 133.96 48.75 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.28 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.528 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.4 t-105 -95.17 139.68 31.16 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.911 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.14 73.12 0.44 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.6 OUTLIER -69.73 159.75 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.526 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.3 t30 . . . . . 0 C--N 1.302 -1.461 0 CA-C-N 113.974 -1.466 . . . . 0.0 108.549 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 22.0 p90 . . . . . 0 CA--C 1.495 -1.172 0 CA-C-O 121.906 0.86 . . . . 0.0 113.264 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.5 t -73.26 162.99 28.74 Favored 'General case' 0 C--N 1.283 -2.287 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.33 117.94 10.38 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.048 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -100.86 99.17 9.63 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.316 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.748 HG11 ' CE2' ' A' ' 84' ' ' PHE . 6.1 t -99.39 136.1 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 119.726 -0.789 . . . . 0.0 112.25 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.549 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.7 m -130.03 108.88 10.42 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.738 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.574 HG13 HG12 ' A' ' 10' ' ' VAL . 1.7 t -78.03 149.87 5.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.903 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.845 ' HA ' HG22 ' A' ' 81' ' ' THR . 3.6 tttt -133.17 96.06 3.67 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.831 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.39 96.75 7.45 Favored 'General case' 0 C--N 1.291 -1.964 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.038 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.5 t -111.65 6.11 19.71 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.334 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.495 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.7 p -71.93 -78.31 0.08 Allowed 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.332 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.62 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 158.27 78.18 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 123.906 0.754 . . . . 0.0 111.498 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -166.17 145.08 4.89 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 118.648 -1.221 . . . . 0.0 111.373 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -68.91 97.34 0.56 Allowed 'Trans proline' 0 N--CA 1.456 -0.719 0 N-CA-C 108.172 -1.511 . . . . 0.0 108.172 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -86.38 100.25 9.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 118.194 -1.402 . . . . 0.0 112.029 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -113.71 55.3 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.85 148.7 14.25 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.703 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.3 p-90 -163.55 176.68 9.47 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.964 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -140.54 109.53 6.08 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.805 179.901 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.61 173.22 7.02 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.537 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.474 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.3 m -155.49 148.09 24.08 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.023 -1.471 . . . . 0.0 112.882 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.3 p90 -174.51 -141.54 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 113.999 -1.455 . . . . 0.0 108.417 179.72 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.5 m -163.17 173.11 13.85 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 117.625 -1.63 . . . . 0.0 112.921 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.561 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 5.3 m-85 -111.12 98.46 39.29 Favored Pre-proline 0 N--CA 1.491 1.575 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.015 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -53.31 -55.15 3.9 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.007 1.138 . . . . 0.0 111.301 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.434 ' C ' ' H ' ' A' ' 48' ' ' GLN . 62.2 p -74.15 -179.83 4.05 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.101 -1.04 . . . . 0.0 109.794 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -77.71 41.79 1.95 Allowed Glycine 0 N--CA 1.484 1.864 0 C-N-CA 118.863 -1.637 . . . . 0.0 109.494 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.434 ' H ' ' C ' ' A' ' 46' ' ' SER . 8.7 mt-30 -78.05 108.53 11.4 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.404 ' O ' ' CG ' ' A' ' 49' ' ' GLN . 1.7 pp0? -116.55 109.85 17.79 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.207 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.602 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.1 p -68.45 164.54 2.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.089 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.602 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 36.8 p -137.5 -63.92 0.57 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.626 -0.829 . . . . 0.0 110.986 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.523 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -97.59 137.11 37.02 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.709 179.941 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.52 159.15 42.8 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.726 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.402 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 36.2 t-105 -155.02 141.73 18.96 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.988 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.402 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.0 OUTLIER 67.12 23.84 9.49 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.091 -179.999 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.478 ' HB3' ' CG ' ' A' ' 84' ' ' PHE . 2.1 p -172.8 110.4 0.21 Allowed 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.249 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.4 m -71.46 74.64 0.76 Allowed 'General case' 0 C--N 1.284 -2.239 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.07 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.541 HG12 HG13 ' A' ' 67' ' ' VAL . 13.4 m -69.6 155.05 7.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.953 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 65.5 p -152.6 112.5 3.97 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.196 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -78.57 104.91 9.49 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.001 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.584 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.1 p -85.72 -160.89 0.56 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.948 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.628 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -50.84 88.22 0.01 OUTLIER Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.139 -1.505 . . . . 0.0 109.655 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER 53.22 4.19 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.707 -179.828 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.628 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.51 -169.27 1.6 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.555 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 77.9 t -143.17 154.22 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 C-N-CA 119.119 -1.033 . . . . 0.0 112.691 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.477 ' N ' HG12 ' A' ' 65' ' ' VAL . 15.6 m -158.01 127.83 6.01 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.551 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.594 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -126.35 142.55 42.63 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.958 0 C-N-CA 119.279 -0.968 . . . . 0.0 111.747 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.46 94.33 4.11 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 124.735 1.272 . . . . 0.0 107.938 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.703 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 2.6 p-10 -74.22 119.78 18.89 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.045 -1.062 . . . . 0.0 111.937 -179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.05 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -46.73 172.43 0.05 OUTLIER Pre-proline 0 N--CA 1.485 1.303 0 CA-C-N 113.751 -1.568 . . . . 0.0 112.308 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.825 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.4 Cg_endo -68.28 -35.8 17.89 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.185 1.924 . . . . 0.0 112.707 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.685 ' CE3' ' ND2' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -68.9 -52.49 28.88 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 118.743 -1.183 . . . . 0.0 110.529 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.05 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.9 p30 -80.75 5.07 16.87 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 118.998 -1.081 . . . . 0.0 109.576 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.5 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -127.06 26.01 5.12 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -99.09 67.53 1.62 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.733 -0.787 . . . . 0.0 111.487 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.572 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -129.17 127.44 23.25 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 119.858 -0.737 . . . . 0.0 110.615 179.859 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.7 Cg_endo -72.12 156.98 55.01 Favored 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 121.621 1.547 . . . . 0.0 113.846 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.62 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.84 -38.03 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 114.89 1.441 . . . . 0.0 114.89 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -107.0 67.97 0.23 Allowed Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.686 -1.245 . . . . 0.0 111.216 -179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.74 -169.05 25.58 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 118.27 -1.919 . . . . 0.0 111.397 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.845 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.6 p -137.46 163.95 29.87 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.549 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -126.07 177.34 6.42 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.01 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.465 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 30.5 tt0 -168.52 146.66 4.14 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 117.124 -1.83 . . . . 0.0 113.624 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.748 ' CE2' HG11 ' A' ' 25' ' ' VAL . 14.6 p90 -160.1 175.21 13.22 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.037 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.21 166.44 35.21 Favored Glycine 0 N--CA 1.497 2.75 0 C-N-CA 117.902 -2.094 . . . . 0.0 112.166 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.522 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.8 p90 -161.94 156.85 22.94 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.457 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.411 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 2.8 m120 -104.66 111.41 24.1 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.232 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.25 163.62 14.66 Favored Glycine 0 N--CA 1.503 3.14 0 C-N-CA 119.737 -1.221 . . . . 0.0 111.33 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 120.42 -0.512 . . . . 0.0 109.996 179.969 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.528 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.506 2.372 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.506 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.7 Cg_endo -62.44 -95.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 120.862 1.041 . . . . 0.0 112.34 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -151.65 -96.77 0.06 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 118.674 -1.211 . . . . 0.0 112.397 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.61 95.07 8.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.844 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.2 m-30 -65.9 -157.46 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.254 -0.979 . . . . 0.0 109.135 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.28 115.0 3.7 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 117.524 -1.67 . . . . 0.0 113.286 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.722 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.3 mt -59.62 177.67 0.2 Allowed 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.358 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.492 ' N ' ' OD1' ' A' ' 103' ' ' ASN . 9.5 p30 -60.05 77.58 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.791 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 101.7 12.36 35.29 Favored Glycine 0 N--CA 1.503 3.112 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.275 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.614 ' O ' ' N ' ' A' ' 102' ' ' LEU . 70.5 p -152.47 152.58 29.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 C-N-CA 118.885 -1.126 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -67.0 173.04 8.93 Favored 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 121.534 1.489 . . . . 0.0 112.141 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.58 ' SG ' HG13 ' A' ' 10' ' ' VAL . 1.8 t -165.2 106.43 0.79 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.833 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.48 138.76 47.25 Favored 'General case' 0 N--CA 1.505 2.309 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.674 HG22 ' N ' ' A' ' 110' ' ' GLY . 1.7 p -68.82 172.08 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.52 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.674 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.442 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.399 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.854 ' N ' ' HG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.284 0.564 . . . . 0.0 111.814 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.83 39.45 0.02 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 108.061 -2.016 . . . . 0.0 108.061 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.933 ' SG ' HD12 ' A' ' 102' ' ' LEU . 25.2 p -54.0 -178.0 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.707 -0.746 . . . . 0.0 111.823 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.16 138.1 27.91 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.694 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.586 HG12 HG13 ' A' ' 27' ' ' VAL . 1.3 m -128.61 130.14 68.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.574 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.585 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -92.74 169.87 10.15 Favored 'General case' 0 C--N 1.284 -2.278 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.862 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.625 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.1 t-105 -130.62 147.2 52.27 Favored 'General case' 0 C--N 1.309 -1.183 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.986 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.48 75.92 0.39 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -69.46 140.01 19.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.797 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 18.1 t-20 . . . . . 0 C--N 1.305 -1.339 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.049 179.814 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.634 ' CZ ' ' OE1' ' A' ' 48' ' ' GLN . 19.7 p90 . . . . . 0 C--O 1.216 -0.66 0 CA-C-O 121.394 0.616 . . . . 0.0 112.418 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.17 127.08 33.7 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.625 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -104.64 110.87 23.35 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.245 -0.982 . . . . 0.0 113.464 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -95.78 98.58 10.55 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.577 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.558 HG11 ' CE1' ' A' ' 84' ' ' PHE . 38.5 t -96.08 147.01 6.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.585 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.9 m -136.97 101.72 4.65 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.419 -1.264 . . . . 0.0 108.484 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.586 HG13 HG12 ' A' ' 10' ' ' VAL . 1.5 t -72.94 151.97 7.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 C-N-CA 119.669 -0.813 . . . . 0.0 112.364 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.402 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.1 tttt -143.59 104.04 4.16 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.468 179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.661 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.5 t30 -90.61 116.57 28.6 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -120.11 1.5 10.86 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 124.105 0.878 . . . . 0.0 110.147 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' SER . 20.6 p -57.9 -81.62 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.58 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.583 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.54 72.52 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 123.726 0.641 . . . . 0.0 111.592 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.8 152.58 3.75 Favored Pre-proline 0 C--N 1.306 -1.29 0 C-N-CA 119.012 -1.075 . . . . 0.0 111.395 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.37 105.49 1.59 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 121.192 1.261 . . . . 0.0 109.342 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -90.7 92.25 3.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 118.46 -1.296 . . . . 0.0 111.779 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -103.47 67.22 0.9 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.95 148.62 24.01 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.6 -2.2 . . . . 0.0 107.6 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.673 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 41.0 p-90 -165.69 177.44 7.28 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.7 -1.6 . . . . 0.0 112.103 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.412 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.6 OUTLIER -140.72 108.79 5.74 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.625 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.881 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.43 173.7 6.83 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.194 -1.002 . . . . 0.0 108.94 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.495 ' OG1' HG23 ' A' ' 66' ' ' THR . 3.3 m -157.83 152.73 25.36 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 117.745 -1.582 . . . . 0.0 112.913 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' ' N ' ' A' ' 43' ' ' SER . 24.2 p90 -178.69 -142.88 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 113.773 -1.558 . . . . 0.0 108.179 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.574 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 20.2 m -163.24 173.71 13.02 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 117.626 -1.63 . . . . 0.0 112.663 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.579 ' CE2' HG21 ' A' ' 65' ' ' VAL . 6.9 m-85 -107.26 101.5 38.92 Favored Pre-proline 0 N--CA 1.486 1.341 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.843 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -55.53 -55.62 2.91 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 120.79 0.993 . . . . 0.0 110.531 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.64 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 8.7 t -69.48 -178.25 1.37 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 118.839 -1.144 . . . . 0.0 109.914 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.64 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -87.27 55.91 4.54 Favored Glycine 0 C--N 1.291 -1.969 0 C-N-CA 118.961 -1.59 . . . . 0.0 110.241 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.634 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 10.4 mt-30 -90.94 125.34 35.74 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.025 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.462 ' OE1' ' OE1' ' A' ' 60' ' ' GLN . 10.2 mm-40 -115.58 101.8 9.19 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.96 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.55 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.3 p -65.03 161.17 3.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.135 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 43.2 p -142.94 -65.8 0.39 Allowed 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.475 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.552 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -90.81 136.07 33.31 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.093 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.9 153.59 40.3 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.502 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.408 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 44.5 t-105 -154.04 146.18 23.72 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.054 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.408 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.4 OUTLIER 65.88 23.87 11.31 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.776 -179.989 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 58' ' ' VAL . 4.4 p -173.78 113.63 0.2 Allowed 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.17 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -72.64 73.36 1.06 Allowed 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.555 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 56' ' ' SER . 2.0 m -70.13 148.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.719 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.8 p -149.26 107.16 3.69 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.78 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.462 ' OE1' ' OE1' ' A' ' 49' ' ' GLN . 31.1 tt0 -78.59 104.29 9.1 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.594 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.567 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.3 p -82.84 -155.67 0.16 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.409 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.625 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -49.83 88.71 0.01 OUTLIER Glycine 0 N--CA 1.497 2.742 0 C-N-CA 118.967 -1.587 . . . . 0.0 110.098 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.567 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.4 OUTLIER 53.19 2.19 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.549 -0.861 . . . . 0.0 110.49 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.625 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.59 -173.59 2.34 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.315 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.579 HG21 ' CE2' ' A' ' 44' ' ' PHE . 50.0 t -140.82 152.92 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.299 -0.96 . . . . 0.0 112.531 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 41' ' ' THR . 94.5 m -153.94 115.53 4.19 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.308 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.667 HG23 HD21 ' A' ' 40' ' ' LEU . 1.7 t -109.35 145.75 15.69 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.949 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.661 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -131.18 92.91 3.27 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 114.172 -1.376 . . . . 0.0 107.324 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.673 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 4.6 p-10 -74.14 118.43 17.09 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.032 -1.067 . . . . 0.0 112.167 -179.608 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.121 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -43.1 164.68 0.12 Allowed Pre-proline 0 N--CA 1.481 1.111 0 CA-C-N 113.37 -1.741 . . . . 0.0 112.003 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -65.03 -34.78 45.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.066 1.844 . . . . 0.0 112.416 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.667 ' CE3' ' ND2' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -70.92 -54.91 9.69 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.984 -179.892 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.121 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.5 p30 -75.91 -1.16 24.12 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 118.947 -1.101 . . . . 0.0 110.15 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.475 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -113.67 40.08 2.62 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.0 p -105.28 71.41 0.93 Allowed 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.868 -0.733 . . . . 0.0 110.971 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.826 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -127.69 119.8 21.58 Favored Pre-proline 0 CA--C 1.565 1.541 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.483 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.2 Cg_endo -69.85 158.57 56.4 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.594 1.529 . . . . 0.0 114.114 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -22.52 -41.23 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 CA-C-N 114.159 -1.382 . . . . 0.0 114.051 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -117.82 69.31 0.31 Allowed Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.414 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.59 -168.01 17.32 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.354 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.525 ' N ' HG13 ' A' ' 76' ' ' ILE . 16.6 p -139.72 162.56 34.83 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.967 -1.093 . . . . 0.0 113.307 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.635 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -127.51 178.72 5.91 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 113.724 -1.58 . . . . 0.0 107.578 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.483 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 7.0 tt0 -167.66 145.78 4.62 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 116.987 -1.885 . . . . 0.0 113.53 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.558 ' CE1' HG11 ' A' ' 25' ' ' VAL . 16.6 p90 -158.96 -178.91 7.59 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.819 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.21 162.51 36.29 Favored Glycine 0 N--CA 1.495 2.614 0 C-N-CA 117.581 -2.247 . . . . 0.0 112.198 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.6 p90 -155.18 174.19 15.55 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 119.763 -0.775 . . . . 0.0 111.04 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.424 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.6 m-20 -126.65 111.85 14.78 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.053 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.428 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -122.75 154.47 17.01 Favored Glycine 0 N--CA 1.5 2.961 0 C-N-CA 119.983 -1.104 . . . . 0.0 111.966 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.1 p . . . . . 0 N--CA 1.481 1.099 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.773 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.169 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.461 ' HD2' ' CE1' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -65.92 -140.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 121.413 1.409 . . . . 0.0 111.189 179.957 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.461 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 76.3 p -112.29 -76.39 0.59 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.571 -0.851 . . . . 0.0 112.857 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.461 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -105.79 99.91 9.49 Favored 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 119.062 -1.055 . . . . 0.0 111.583 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.542 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.8 m-30 -68.73 -142.42 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 115.311 -0.859 . . . . 0.0 108.842 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.7 m -160.8 108.52 1.55 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 116.994 -1.883 . . . . 0.0 113.454 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.933 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.4 OUTLIER -73.2 154.44 40.26 Favored 'General case' 0 C--O 1.206 -1.232 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.651 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.55 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.2 OUTLIER -52.26 81.84 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.624 -1.23 . . . . 0.0 110.793 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.636 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 140.23 -33.95 2.04 Favored Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.989 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.854 ' HG1' ' N ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -154.23 163.87 22.65 Favored Pre-proline 0 N--CA 1.505 2.289 0 C-N-CA 118.25 -1.38 . . . . 0.0 113.083 -179.821 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 106' ' ' PRO . . . . . 0.695 ' HD2' HG22 ' A' ' 105' ' ' THR . 1.7 Cg_endo -66.24 118.79 5.8 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 122.654 2.236 . . . . 0.0 111.907 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.525 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.6 t -100.1 123.05 43.89 Favored 'General case' 0 N--CA 1.501 2.108 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.967 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.78 162.22 16.49 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.859 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.984 HG22 ' H ' ' A' ' 110' ' ' GLY . 12.8 p -90.07 -130.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.874 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.984 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.494 2.535 0 CA-C-O 116.323 -2.376 . . . . 0.0 110.308 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 121.696 0.76 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.68 39.58 0.02 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 107.422 -2.271 . . . . 0.0 107.422 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.459 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 24.3 p -55.01 -171.1 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.271 -0.964 . . . . 0.0 111.876 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.11 131.8 6.88 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.982 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.507 HG12 HG13 ' A' ' 27' ' ' VAL . 2.6 m -113.79 130.51 67.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 C-N-CA 120.004 -0.679 . . . . 0.0 110.581 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.613 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -97.81 161.03 13.94 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.514 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.895 ' CZ3' ' HB2' ' A' ' 96' ' ' ALA . 22.5 t-105 -112.04 149.41 32.09 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.59 0.71 . . . . 0.0 112.517 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.59 76.98 0.36 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -68.92 146.61 12.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.7 t30 . . . . . 0 C--N 1.303 -1.436 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.209 179.824 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.553 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 32.0 p90 . . . . . 0 CA--C 1.507 -0.685 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 22' ' ' THR . 0.8 OUTLIER -99.49 111.91 24.19 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.614 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.492 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -93.75 117.17 29.74 Favored 'General case' 0 C--N 1.292 -1.896 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.727 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.8 102.25 14.03 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.483 HG11 ' HE1' ' A' ' 84' ' ' PHE . 53.2 t -99.71 147.3 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 N-CA-C 113.993 1.109 . . . . 0.0 113.993 -179.555 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.613 ' HB ' HD11 ' A' ' 11' ' ' LEU . 18.5 m -136.71 100.58 4.37 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.948 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.512 HG21 ' CZ2' ' A' ' 38' ' ' TRP . 3.0 t -68.79 146.88 12.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.104 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.637 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.2 tmtt? -138.48 102.91 4.74 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.567 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.693 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -95.58 136.06 36.45 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.516 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -131.64 5.8 4.34 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.544 -1.207 . . . . 0.0 109.523 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' SER . 19.1 p -47.24 -86.58 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.026 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.04 34.51 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.505 -179.951 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.937 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.4 155.71 45.94 Favored Pre-proline 0 N--CA 1.481 1.11 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.886 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.35 96.77 0.49 Allowed 'Trans proline' 0 C--N 1.323 -0.763 0 C-N-CA 121.284 1.322 . . . . 0.0 110.14 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.449 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.3 t -71.08 117.38 14.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.593 -1.243 . . . . 0.0 111.269 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -123.03 75.01 1.25 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.368 -0.833 . . . . 0.0 108.765 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.44 140.19 7.7 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.431 -1.867 . . . . 0.0 108.431 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.706 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 40.8 p-90 -158.79 177.46 11.15 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.303 -1.359 . . . . 0.0 111.626 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -141.08 112.37 7.38 Favored 'General case' 0 C--O 1.202 -1.4 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.715 179.897 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.86 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.41 174.68 5.76 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.934 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.788 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -163.55 157.71 19.89 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 117.325 -1.75 . . . . 0.0 113.153 -179.88 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.512 ' N ' ' CG2' ' A' ' 41' ' ' THR . 31.1 p90 -178.18 -141.43 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 113.368 -1.742 . . . . 0.0 107.997 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.478 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 61.2 m -160.82 146.9 14.87 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 117.876 -1.53 . . . . 0.0 112.187 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.65 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 8.3 m-85 -77.55 119.3 76.88 Favored Pre-proline 0 N--CA 1.482 1.132 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.146 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -63.38 -66.67 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.148 1.232 . . . . 0.0 111.579 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.536 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.4 t -69.44 -122.44 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.536 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -130.96 38.48 1.93 Allowed Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.494 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 3.2 mt-30 -75.24 98.31 3.74 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.517 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.485 ' OE1' HG22 ' A' ' 51' ' ' THR . 1.5 pp0? -98.95 112.42 24.54 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.57 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 58' ' ' VAL . 2.4 p -70.52 148.26 10.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.2 -1.0 . . . . 0.0 111.12 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.619 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 21.8 p -127.6 -63.24 1.04 Allowed 'General case' 0 N--CA 1.491 1.596 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.77 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.619 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -96.94 138.59 34.24 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.794 179.938 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -148.29 157.19 43.34 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.101 -1.039 . . . . 0.0 111.345 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' TRP . . . . . 0.406 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 43.3 t-105 -153.32 146.12 24.36 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.228 -0.989 . . . . 0.0 111.266 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.5 OUTLIER 66.97 22.28 10.1 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.584 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.605 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 13.1 t -175.95 125.8 0.21 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.405 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.1 79.67 9.3 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.608 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 50' ' ' VAL . 1.0 OUTLIER -81.81 152.28 4.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.635 -179.971 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -155.34 131.45 10.16 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.476 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.468 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.6 pt20 -95.12 119.98 34.55 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.647 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.866 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.7 p -86.91 68.93 10.22 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.18 -56.98 4.03 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.404 ' H ' ' H ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -148.91 -20.18 0.3 Allowed 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.404 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.866 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.99 -168.46 2.24 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.942 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.65 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 84.2 t -147.35 155.2 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.757 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.788 HG23 ' OG1' ' A' ' 41' ' ' THR . 70.7 m -161.63 124.29 3.03 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.705 -1.134 . . . . 0.0 108.653 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.605 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.4 t -117.53 146.4 22.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.093 0 C-N-CA 119.548 -0.861 . . . . 0.0 111.857 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -132.16 90.51 2.82 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.706 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 6.8 p-10 -73.53 122.52 22.33 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 118.948 -1.101 . . . . 0.0 112.445 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.772 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.3 155.88 0.18 Allowed Pre-proline 0 N--CA 1.479 0.993 0 CA-C-N 113.592 -1.64 . . . . 0.0 112.186 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.96 -35.28 35.45 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 121.759 1.639 . . . . 0.0 112.297 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.772 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -70.55 -57.38 4.81 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 118.931 -1.108 . . . . 0.0 110.981 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.538 HD21 ' HB2' ' A' ' 69' ' ' ASN . 0.1 OUTLIER -65.85 -21.34 66.46 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.994 -1.082 . . . . 0.0 110.171 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.451 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -96.61 27.87 15.8 Favored Glycine 0 N--CA 1.486 1.967 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.654 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 32.2 m -91.86 60.68 3.95 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.956 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.734 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.49 136.4 19.91 Favored Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.387 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' GLY . 7.2 Cg_endo -69.81 151.42 68.75 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 121.51 1.474 . . . . 0.0 111.181 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.937 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -40.41 -22.32 0.01 OUTLIER 'General case' 0 C--O 1.2 -1.525 0 C-N-CA 119.749 -0.78 . . . . 0.0 112.268 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.71 64.19 0.28 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.31 -162.83 18.68 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 118.11 -1.995 . . . . 0.0 111.485 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.637 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.6 p -139.5 162.41 35.12 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-O 121.867 0.841 . . . . 0.0 112.765 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.734 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -136.84 122.2 19.39 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.592 ' CG ' HG23 ' A' ' 26' ' ' THR . 3.5 mp0 -114.82 164.91 13.43 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.483 ' HE1' HG11 ' A' ' 25' ' ' VAL . 8.3 p90 -163.89 -178.09 5.48 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 112.688 -2.051 . . . . 0.0 108.986 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.24 159.13 32.39 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 117.556 -2.259 . . . . 0.0 111.937 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.3 p90 -154.77 169.2 24.51 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.487 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.416 ' ND2' ' OE1' ' A' ' 52' ' ' GLN . 3.6 m-20 -125.57 112.52 16.28 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.53 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA2' HG23 ' A' ' 51' ' ' THR . . . -121.03 150.23 17.25 Favored Glycine 0 N--CA 1.512 3.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.464 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . 0.427 ' OG ' ' CG ' ' A' ' 49' ' ' GLN . 52.1 p . . . . . 0 N--CA 1.482 1.14 0 C-N-CA 120.121 -0.631 . . . . 0.0 109.715 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.895 ' HB2' ' CZ3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.502 2.146 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.8 -142.16 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 121.214 1.276 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.407 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 42.8 p -108.5 -100.57 0.37 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.472 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.27 104.22 16.82 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 118.503 -1.279 . . . . 0.0 112.196 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.3 m-30 -70.37 -141.84 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.363 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.5 m -162.39 109.81 1.32 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 117.022 -1.871 . . . . 0.0 113.869 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.5 mt -53.85 178.14 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.817 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -39.66 -26.41 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.927 -0.709 . . . . 0.0 111.973 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.804 ' O ' HG23 ' A' ' 105' ' ' THR . . . -165.31 41.7 0.29 Allowed Glycine 0 N--CA 1.491 2.307 0 C-N-CA 118.653 -1.737 . . . . 0.0 111.499 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.2 OUTLIER -171.83 147.68 2.01 Favored Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.685 179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.17 156.64 44.03 Favored 'Trans proline' 0 C--O 1.212 -0.813 0 C-N-CA 121.566 1.51 . . . . 0.0 112.554 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.41 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.0 t -147.26 101.65 3.41 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.342 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.01 135.75 57.81 Favored 'General case' 0 N--CA 1.518 2.951 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -179.587 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 1.056 HG22 ' H ' ' A' ' 110' ' ' GLY . 5.3 p -59.93 -163.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 118.795 -1.162 . . . . 0.0 110.926 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 1.056 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 116.35 -2.361 . . . . 0.0 110.386 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.719 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.484 0.659 . . . . 0.0 111.946 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.33 38.42 0.05 OUTLIER Glycine 0 N--CA 1.492 2.419 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.446 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 4.3 p -49.21 178.63 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 113.904 -1.148 . . . . 0.0 113.016 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -135.13 106.37 6.74 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.035 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.748 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.1 m -99.45 139.12 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 119.061 -1.056 . . . . 0.0 112.428 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.619 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -109.21 162.65 14.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.848 179.772 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 12' ' ' TRP . . . . . 0.533 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.2 t-105 -128.05 139.68 52.39 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.318 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -116.22 62.59 0.37 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.334 -2.307 . . . . 0.0 107.334 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 21' ' ' PHE . 14.6 p -69.3 140.84 18.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.485 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.4 t30 . . . . . 0 N--CA 1.489 1.496 0 CA-C-N 114.616 -1.175 . . . . 0.0 108.762 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.564 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.8 p90 . . . . . 0 CA--C 1.51 -0.566 0 CA-C-O 121.464 0.649 . . . . 0.0 112.681 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 15' ' ' ASN . 1.4 t -78.92 174.02 11.95 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 179.443 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.533 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -153.2 125.73 8.18 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 117.04 -1.864 . . . . 0.0 114.053 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -107.8 91.5 3.68 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 179.558 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.626 HG11 ' CE2' ' A' ' 84' ' ' PHE . 40.5 t -96.02 144.3 10.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 113.94 1.089 . . . . 0.0 113.94 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.619 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.4 OUTLIER -126.35 129.72 49.39 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 114.489 -1.232 . . . . 0.0 107.95 179.687 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.823 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 23.7 t -101.2 103.81 15.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 C-N-CA 119.281 -0.968 . . . . 0.0 113.151 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.76 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.6 tmtt? -95.1 106.53 18.54 Favored 'General case' 0 C--N 1.291 -1.951 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.395 179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.531 ' OD1' ' C ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -107.87 140.94 40.22 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.72 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -140.69 19.34 2.34 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 114.214 -1.357 . . . . 0.0 109.028 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.413 ' O ' ' CB ' ' A' ' 32' ' ' SER . 13.1 p -48.08 -88.47 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.176 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 170.41 31.55 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.822 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.998 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -154.47 170.98 7.66 Favored Pre-proline 0 N--CA 1.48 1.07 0 C-N-CA 118.085 -1.446 . . . . 0.0 111.443 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.796 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 9.2 Cg_endo -74.83 97.34 1.06 Allowed 'Trans proline' 0 C--N 1.323 -0.784 0 C-N-CA 121.842 1.695 . . . . 0.0 109.963 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.4 t -75.43 94.31 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 118.249 -1.38 . . . . 0.0 111.591 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.19 50.25 1.37 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 112.1 167.49 17.84 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 107.826 -2.11 . . . . 0.0 107.826 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.756 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 37.8 p-90 -171.17 176.39 3.97 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 117.808 -1.557 . . . . 0.0 111.836 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.1 102.14 4.32 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.887 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -89.63 172.8 8.69 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.699 -1.201 . . . . 0.0 109.409 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 2.0 m -160.73 142.12 12.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.437 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.559 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.6 p90 -171.0 -140.1 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.249 -1.342 . . . . 0.0 108.351 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.562 ' HG ' ' HB1' ' A' ' 64' ' ' ALA . 34.2 m -161.03 168.2 24.94 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 117.419 -1.713 . . . . 0.0 112.782 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.64 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.9 m-85 -101.66 109.41 59.26 Favored Pre-proline 0 N--CA 1.489 1.483 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.31 -63.7 0.12 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.098 1.199 . . . . 0.0 111.367 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.8 t -69.59 -172.7 0.5 Allowed 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.575 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.484 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -84.9 57.9 4.99 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.072 -1.537 . . . . 0.0 109.886 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.534 ' OE1' ' CE1' ' A' ' 21' ' ' PHE . 11.6 mm-40 -94.41 108.91 20.81 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 119.213 -0.995 . . . . 0.0 111.014 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.616 ' OE1' ' NE2' ' A' ' 60' ' ' GLN . 30.6 mm-40 -106.57 108.89 20.63 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.913 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.1 p -76.47 157.04 5.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.187 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.505 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 72.6 p -138.47 -68.82 0.44 Allowed 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.531 -0.867 . . . . 0.0 111.1 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLN . . . . . 0.505 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.2 mt-30 -80.59 165.26 22.24 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.03 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.14 153.58 8.24 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 118.717 -1.193 . . . . 0.0 111.923 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 32.3 t-105 -147.32 136.88 22.79 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.354 -0.939 . . . . 0.0 110.899 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.731 ' HA ' HD21 ' A' ' 73' ' ' ASN . 1.7 p 60.23 26.6 16.06 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.196 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.14 117.26 1.65 Allowed 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.0 m -82.11 77.64 8.89 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.977 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.2 m -68.99 154.37 8.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.613 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.9 p -154.07 108.14 3.0 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.908 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.616 ' NE2' ' OE1' ' A' ' 49' ' ' GLN . 3.6 tt0 -88.09 116.01 25.97 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.036 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 4.7 p -94.39 89.38 5.85 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.636 -0.825 . . . . 0.0 110.777 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 71.16 -74.6 0.66 Allowed Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.388 -1.387 . . . . 0.0 109.963 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 -14.69 1.55 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.122 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.562 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.29 -173.91 4.2 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.033 -1.067 . . . . 0.0 110.063 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 44' ' ' PHE . 51.2 t -147.27 160.11 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 118.735 -1.186 . . . . 0.0 113.637 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.3 m -155.53 145.93 21.91 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.899 -1.5 . . . . 0.0 108.563 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.416 HG23 HD21 ' A' ' 40' ' ' LEU . 2.8 t -141.07 119.4 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 118.727 -1.189 . . . . 0.0 112.469 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.83 91.43 4.83 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.97 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.756 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -70.77 122.8 20.53 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.194 -1.003 . . . . 0.0 111.344 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.713 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -43.91 166.65 0.1 Allowed Pre-proline 0 C--N 1.307 -1.276 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.452 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.0 Cg_endo -70.04 -39.98 5.38 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 122.155 1.903 . . . . 0.0 112.392 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' TRP . . . . . 0.605 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -68.56 -55.72 10.68 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.024 -1.07 . . . . 0.0 110.514 -179.875 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.731 HD21 ' HA ' ' A' ' 55' ' ' SER . 21.6 p30 -76.71 11.02 1.84 Allowed 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.18 -1.008 . . . . 0.0 109.624 179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.554 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -139.87 37.56 1.71 Allowed Glycine 0 N--CA 1.484 1.898 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.574 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.1 m -104.08 61.74 0.74 Allowed 'General case' 0 C--N 1.309 -1.162 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.956 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.484 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -109.49 136.68 20.22 Favored Pre-proline 0 N--CA 1.484 1.267 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.368 179.926 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.626 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.9 Cg_endo -71.3 171.16 16.63 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 121.396 1.397 . . . . 0.0 111.068 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.998 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -63.18 17.72 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.563 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.626 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -149.8 61.76 0.42 Allowed Glycine 0 C--N 1.291 -1.954 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.22 -155.12 9.57 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 118.641 -1.742 . . . . 0.0 110.733 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.76 HG22 ' HA ' ' A' ' 28' ' ' LYS . 0.9 OUTLIER -141.73 168.8 18.89 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.244 -0.983 . . . . 0.0 112.603 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.823 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.34 -173.3 3.12 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLN . . . . . 0.641 ' CD ' ' N ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -167.59 144.74 4.4 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 116.792 -1.963 . . . . 0.0 113.649 -179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.641 ' N ' ' CD ' ' A' ' 83' ' ' GLN . 3.9 p90 -164.13 164.73 22.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.604 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.51 178.47 32.96 Favored Glycine 0 N--CA 1.504 3.192 0 C-N-CA 118.068 -2.015 . . . . 0.0 111.855 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 4.4 p90 -164.17 -169.8 1.93 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.687 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -142.93 110.8 5.93 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.64 -0.824 . . . . 0.0 110.741 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.71 164.08 12.7 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.026 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.857 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.839 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.522 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.8 Cg_endo -64.25 -95.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 120.834 1.022 . . . . 0.0 112.248 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 109' ' ' VAL . 1.1 p -153.25 -90.41 0.05 OUTLIER 'General case' 0 N--CA 1.497 1.882 0 C-N-CA 118.919 -1.113 . . . . 0.0 112.279 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -96.78 94.51 7.31 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.595 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -66.23 -158.34 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 43.3 m -153.79 118.71 5.03 Favored 'General case' 0 C--N 1.309 -1.179 0 C-N-CA 116.956 -1.898 . . . . 0.0 114.015 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -63.72 176.4 0.91 Allowed 'General case' 0 N--CA 1.48 1.026 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.315 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -36.94 -32.94 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 C-N-CA 120.025 -0.67 . . . . 0.0 112.675 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.856 ' O ' HG23 ' A' ' 105' ' ' THR . . . -155.72 47.03 0.51 Allowed Glycine 0 N--CA 1.499 2.898 0 C-N-CA 118.463 -1.827 . . . . 0.0 111.865 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.856 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.0 OUTLIER 179.85 160.26 0.83 Allowed Pre-proline 0 C--O 1.192 -1.965 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.97 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.94 179.79 1.69 Allowed 'Trans proline' 0 C--N 1.321 -0.891 0 C-N-CA 122.004 1.802 . . . . 0.0 112.87 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' CYS . . . . . 0.748 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.5 t -170.13 106.68 0.33 Allowed 'General case' 0 N--CA 1.497 1.898 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.305 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 70.6 p -72.06 149.86 44.47 Favored 'General case' 0 N--CA 1.506 2.358 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 1.095 HG12 ' H ' ' A' ' 110' ' ' GLY . 5.0 t -59.05 -167.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 C-N-CA 118.981 -1.088 . . . . 0.0 110.422 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG12 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.482 0 CA-C-O 116.289 -2.395 . . . . 0.0 110.301 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.106 0 CA-C-O 120.828 0.347 . . . . 0.0 110.098 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 t -89.75 46.07 1.33 Allowed 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.291 -0.964 . . . . 0.0 110.781 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -152.8 -89.13 0.05 Allowed 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.932 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 164.61 69.34 0.02 OUTLIER Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.416 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.1 -154.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.028 1.819 . . . . 0.0 111.577 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.542 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -84.62 -157.5 0.29 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -178.28 43.21 0.09 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.871 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.5 p -60.42 -160.79 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.779 -0.71 . . . . 0.0 110.94 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.64 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -165.3 157.55 15.39 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.192 179.859 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.477 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.0 m -139.63 130.6 32.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.151 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.555 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.79 157.09 16.05 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.718 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.563 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.6 t-105 -114.55 141.44 47.73 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.831 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.14 76.28 0.41 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.2 p -69.23 149.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -152.14 85.47 1.28 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 113.91 -1.496 . . . . 0.0 107.348 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.832 HE22 ' C ' ' A' ' 17' ' ' TRP . 0.2 OUTLIER -92.03 121.05 33.23 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.832 ' C ' HE22 ' A' ' 16' ' ' GLN . 19.5 p90 -110.5 128.4 55.6 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 105.761 -1.94 . . . . 0.0 105.761 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.62 ' C ' HE22 ' A' ' 16' ' ' GLN . 0.3 OUTLIER 47.49 -88.51 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.524 0 C-N-CA 118.152 -1.419 . . . . 0.0 107.408 -179.572 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.7 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER -148.83 112.19 4.98 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 179.405 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.477 ' C ' ' OE1' ' A' ' 16' ' ' GLN . . . 147.86 87.89 0.07 OUTLIER Glycine 0 C--N 1.274 -2.893 0 N-CA-C 106.276 -2.73 . . . . 0.0 106.276 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.584 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 8.3 p90 -81.49 117.33 21.81 Favored 'General case' 0 CA--C 1.487 -1.448 0 C-N-CA 119.464 -0.895 . . . . 0.0 111.192 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.504 HG22 ' O ' ' A' ' 22' ' ' THR . 0.4 OUTLIER -97.11 114.34 26.0 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.563 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -93.74 120.62 34.24 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.367 -0.933 . . . . 0.0 113.422 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -99.08 95.83 7.38 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG11 ' CE1' ' A' ' 84' ' ' PHE . 29.8 t -91.81 152.46 3.39 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.555 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.0 OUTLIER -138.88 106.08 5.49 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.184 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.1 t -71.2 149.01 10.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.101 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.514 ' HA ' HG22 ' A' ' 81' ' ' THR . 6.5 tptm -141.03 102.81 4.34 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.12 -0.945 . . . . 0.0 110.186 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.629 ' HB3' HD11 ' A' ' 76' ' ' ILE . 38.5 t-20 -96.76 136.93 36.61 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.948 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.5 t -141.47 -4.31 1.12 Allowed 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.681 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.1 p -51.97 -81.27 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.118 -1.033 . . . . 0.0 110.339 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.51 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 163.52 73.55 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.373 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.49 149.28 3.67 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.22 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -72.27 97.37 0.85 Allowed 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 121.207 1.271 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.451 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.9 OUTLIER -77.49 100.52 2.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.78 -179.89 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -110.44 58.4 0.61 Allowed 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.06 152.39 21.39 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 107.909 -2.077 . . . . 0.0 107.909 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.644 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 37.3 p-90 -166.35 178.07 6.41 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 117.693 -1.603 . . . . 0.0 112.208 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.34 102.51 4.37 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.133 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.869 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -93.97 175.06 6.86 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.957 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.542 ' HG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -169.92 156.22 6.07 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 117.854 -1.539 . . . . 0.0 112.679 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.498 ' CD2' ' N ' ' A' ' 43' ' ' SER . 20.2 p90 -176.73 -132.81 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 113.565 -1.652 . . . . 0.0 107.8 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.498 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -162.29 148.23 13.0 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 117.726 -1.589 . . . . 0.0 111.951 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.654 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -82.8 119.01 73.62 Favored Pre-proline 0 N--CA 1.486 1.36 0 C-N-CA 118.601 -1.24 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -55.23 -72.42 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 121.083 1.189 . . . . 0.0 111.764 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.42 ' HB3' HE22 ' A' ' 48' ' ' GLN . 5.6 t -69.58 -134.0 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 110.535 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -118.57 51.86 0.73 Allowed Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.343 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.492 ' HB2' ' CG ' ' A' ' 44' ' ' PHE . 15.2 mp0 -67.96 88.35 0.27 Allowed 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.492 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.443 ' CA ' ' OE1' ' A' ' 49' ' ' GLN . 3.1 mm100 -76.99 85.75 3.51 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -74.64 144.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.839 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.633 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -143.38 -61.02 0.41 Allowed 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 119.033 -1.067 . . . . 0.0 111.932 -179.838 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.633 ' H ' HG23 ' A' ' 51' ' ' THR . 1.1 mt-30 -75.54 135.26 40.6 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.569 -1.252 . . . . 0.0 110.073 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.431 ' HB2' HG21 ' A' ' 58' ' ' VAL . . . -147.89 156.11 42.33 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 118.785 -1.166 . . . . 0.0 112.146 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 34.2 t-105 -151.91 142.16 22.38 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.6 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 t 62.31 27.43 16.39 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.583 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -171.36 125.34 0.62 Allowed 'General case' 0 C--N 1.303 -1.428 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.317 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -87.28 73.59 9.65 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.035 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.489 HG12 HG13 ' A' ' 67' ' ' VAL . 33.0 m -69.01 153.86 8.66 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 115.044 -0.98 . . . . 0.0 112.484 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.416 HG23 ' C ' ' A' ' 58' ' ' VAL . 44.2 p -155.42 112.4 3.26 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.658 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.475 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 4.7 pt20 -91.02 113.42 25.68 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.489 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 4.7 p -87.68 86.07 7.14 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.774 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 73.71 -71.59 1.34 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -139.28 -15.98 1.08 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.029 -0.668 . . . . 0.0 109.716 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.489 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -87.9 -176.46 5.49 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.048 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.654 HG21 ' CD2' ' A' ' 44' ' ' PHE . 44.8 t -145.54 161.06 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 C-N-CA 118.596 -1.242 . . . . 0.0 113.888 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.611 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 44.9 m -157.52 143.79 17.76 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 113.627 -1.624 . . . . 0.0 108.284 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.556 HG23 HD21 ' A' ' 40' ' ' LEU . 2.2 t -139.66 117.47 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.617 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -99.03 91.87 5.22 Favored 'General case' 0 C--N 1.288 -2.092 0 CA-C-N 114.291 -1.322 . . . . 0.0 108.132 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.644 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.8 p-10 -72.47 121.56 19.8 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.195 -1.002 . . . . 0.0 112.215 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.719 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.88 162.07 0.11 Allowed Pre-proline 0 N--CA 1.488 1.475 0 CA-C-N 113.563 -1.653 . . . . 0.0 112.47 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.7 Cg_endo -68.86 -36.36 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 121.869 1.713 . . . . 0.0 111.939 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.719 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.67 -56.3 7.63 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 118.962 -1.095 . . . . 0.0 110.494 -179.895 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.717 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 5.4 p30 -74.33 2.73 8.64 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 118.818 -1.153 . . . . 0.0 109.492 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.545 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -122.43 37.12 2.94 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -104.71 56.53 0.7 Allowed 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.207 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.681 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -106.86 130.62 22.61 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.741 -0.783 . . . . 0.0 111.195 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 78' ' ' ALA . 8.7 Cg_endo -72.32 154.19 56.2 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 121.606 1.537 . . . . 0.0 113.381 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.51 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -21.84 -49.14 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.67 70.71 0.21 Allowed Glycine 0 N--CA 1.493 2.447 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.417 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -153.5 -165.56 13.71 Favored Glycine 0 C--N 1.285 -2.293 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.069 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.572 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.8 OUTLIER -140.9 164.05 31.29 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 119.271 -0.972 . . . . 0.0 112.528 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.603 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -132.78 -177.35 4.45 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 114.352 -1.294 . . . . 0.0 107.646 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.8 OUTLIER -167.6 143.5 4.06 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 116.875 -1.93 . . . . 0.0 113.54 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.579 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 8.7 p90 -159.22 176.12 12.59 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.664 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.69 170.28 41.12 Favored Glycine 0 N--CA 1.5 2.931 0 C-N-CA 117.897 -2.097 . . . . 0.0 112.137 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.6 p90 -159.32 168.88 25.28 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.703 -0.799 . . . . 0.0 111.022 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.531 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -121.93 114.21 20.68 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.896 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.443 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -126.07 150.29 17.57 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.3 p -83.39 136.02 34.48 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.852 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.66 ' NE2' ' CG ' ' A' ' 16' ' ' GLN . 10.2 p80 -114.52 -158.53 0.67 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.76 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -153.69 -2.88 0.2 Allowed 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.789 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.78 67.74 0.86 Allowed Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.742 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.945 HG22 ' H ' ' A' ' 94' ' ' ASN . 10.9 m -162.07 -167.38 1.63 Allowed 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.301 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.945 ' H ' HG22 ' A' ' 93' ' ' THR . 0.0 OUTLIER -61.08 129.16 39.98 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.129 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.54 -55.12 2.51 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.959 -0.696 . . . . 0.0 112.335 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.418 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -101.94 120.72 53.1 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 119.633 -0.827 . . . . 0.0 112.131 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.463 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -66.58 -144.32 0.02 OUTLIER 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 121.454 1.436 . . . . 0.0 111.401 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.82 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.8 OUTLIER -108.45 -101.48 0.37 Allowed 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.002 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.6 106.08 18.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 118.807 -1.157 . . . . 0.0 112.402 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.567 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.3 m-30 -74.99 -148.19 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.397 -0.921 . . . . 0.0 108.714 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.469 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -159.84 114.85 2.36 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 117.145 -1.822 . . . . 0.0 113.457 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.871 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -58.47 -175.84 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.06 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.506 ' OD1' HD22 ' A' ' 102' ' ' LEU . 6.1 p-10 -64.89 76.49 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.071 -1.052 . . . . 0.0 111.764 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.49 11.46 33.26 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.57 -1.3 . . . . 0.0 112.374 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.602 ' O ' ' N ' ' A' ' 102' ' ' LEU . 6.5 p -151.92 145.81 18.05 Favored Pre-proline 0 N--CA 1.493 1.709 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.091 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -65.04 170.78 9.87 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.342 1.361 . . . . 0.0 111.713 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.64 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 3.1 t -163.79 106.53 0.96 Allowed 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.491 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.5 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 7.5 p -70.49 130.62 42.37 Favored 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 98' ' ' THR . 0.7 OUTLIER -53.96 175.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.525 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.496 2.649 0 CA-C-O 116.368 -2.351 . . . . 0.0 110.274 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 120.92 0.39 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.0 p -69.11 148.54 49.84 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m 59.19 45.0 14.94 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.035 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -87.01 174.67 45.98 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 119.302 -1.428 . . . . 0.0 110.046 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -66.6 159.04 52.75 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 121.898 1.732 . . . . 0.0 111.18 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.675 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -111.51 -123.94 0.28 Allowed 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.152 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.43 28.34 0.36 Allowed Glycine 0 N--CA 1.5 2.911 0 N-CA-C 106.939 -2.465 . . . . 0.0 106.939 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -52.83 -174.05 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 113.49 -1.355 . . . . 0.0 113.213 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -137.22 108.16 6.7 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.768 -1.56 . . . . 0.0 109.654 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.836 HG13 ' SG ' ' A' ' 107' ' ' CYS . 4.9 m -100.67 122.73 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.384 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.2 159.62 14.93 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.389 -0.924 . . . . 0.0 109.653 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.562 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.8 t-105 -121.22 139.76 52.94 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.748 -0.781 . . . . 0.0 112.013 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 73.38 0.4 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 107.279 -2.328 . . . . 0.0 107.279 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -72.84 152.27 7.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.574 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.0 OUTLIER -158.88 94.46 1.23 Allowed 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 113.969 -1.469 . . . . 0.0 108.675 179.756 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.493 ' C ' ' CD ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -94.38 157.88 15.82 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-O 121.937 0.875 . . . . 0.0 112.675 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.445 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -124.61 -106.0 0.35 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 113.674 -1.603 . . . . 0.0 109.323 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -66.53 -30.88 71.3 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.121 -1.031 . . . . 0.0 109.688 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.664 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 1.4 t -174.55 -49.48 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.203 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.664 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -58.04 166.27 6.54 Favored Glycine 0 CA--C 1.49 -1.51 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.527 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.7 p90 -137.77 121.28 17.22 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.533 -0.867 . . . . 0.0 112.256 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.574 HG22 ' CB ' ' A' ' 15' ' ' ASN . 8.2 t -73.48 172.86 10.52 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.562 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -159.32 110.23 2.02 Favored 'General case' 0 C--N 1.289 -2.027 0 C-N-CA 117.289 -1.764 . . . . 0.0 112.919 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -93.02 103.92 16.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.618 HG11 ' CE1' ' A' ' 84' ' ' PHE . 24.6 t -99.64 140.43 18.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 119.451 -0.9 . . . . 0.0 113.124 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.569 ' HB ' HD11 ' A' ' 11' ' ' LEU . 3.5 m -131.14 113.11 13.49 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.783 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.699 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -84.7 143.04 12.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.618 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.83 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.2 tptp -124.9 99.92 6.36 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.933 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.658 ' HB3' HD11 ' A' ' 76' ' ' ILE . 6.2 t-20 -91.54 106.22 18.32 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.191 -1.004 . . . . 0.0 108.372 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 t -119.17 -1.11 10.92 Favored 'General case' 0 C--N 1.311 -1.107 0 O-C-N 124.174 0.921 . . . . 0.0 110.142 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.5 p -50.34 -81.85 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.399 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.69 37.49 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.305 -179.886 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.892 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -137.5 146.65 54.39 Favored Pre-proline 0 N--CA 1.485 1.301 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.187 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -70.22 107.4 1.94 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 121.212 1.275 . . . . 0.0 109.882 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.419 HG21 ' ND2' ' A' ' 29' ' ' ASN . 1.0 OUTLIER -86.63 110.49 20.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.487 -1.285 . . . . 0.0 111.981 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -120.1 65.45 0.82 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.64 146.22 20.56 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 106.885 -2.486 . . . . 0.0 106.885 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 47.9 p-90 -163.51 175.54 10.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 117.419 -1.712 . . . . 0.0 112.095 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.416 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -141.06 112.39 7.4 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.777 179.92 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.44 175.35 5.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.395 179.896 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.484 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -159.35 152.48 22.18 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 117.919 -1.512 . . . . 0.0 112.289 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.533 ' CD2' ' N ' ' A' ' 43' ' ' SER . 23.6 p90 -175.1 -150.91 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.931 -1.486 . . . . 0.0 108.432 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.533 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 14.7 m -158.66 154.39 26.37 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.881 -1.528 . . . . 0.0 111.835 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.518 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.2 m-85 -87.71 116.96 67.82 Favored Pre-proline 0 C--N 1.309 -1.153 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.901 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -56.99 -74.87 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 121.292 1.328 . . . . 0.0 112.619 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.658 ' CB ' ' H ' ' A' ' 93' ' ' THR . 0.9 OUTLIER -69.26 -136.11 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.636 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -107.6 63.92 0.27 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.857 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.517 ' O ' ' CD2' ' A' ' 44' ' ' PHE . 21.5 mt-30 -110.97 112.14 23.75 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.802 -0.759 . . . . 0.0 110.667 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.428 ' HB2' HE22 ' A' ' 60' ' ' GLN . 1.2 pp0? -121.34 118.62 29.93 Favored 'General case' 0 N--CA 1.499 2.007 0 C-N-CA 119.764 -0.774 . . . . 0.0 111.212 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.448 ' H ' HG12 ' A' ' 50' ' ' VAL . 2.0 p -72.79 156.0 6.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.383 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.508 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 80.4 p -132.45 -69.67 0.58 Allowed 'General case' 0 N--CA 1.492 1.669 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.777 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.508 ' N ' ' OG1' ' A' ' 51' ' ' THR . 5.1 mt-30 -88.02 141.88 28.23 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.292 -0.963 . . . . 0.0 109.801 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.99 166.99 29.84 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.859 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.605 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 42.5 t-105 -154.45 157.15 38.01 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.003 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.605 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 51.75 26.79 3.68 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.771 -179.839 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.4 m -172.98 127.58 0.47 Allowed 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.695 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.4 m -90.15 77.19 6.8 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.795 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.499 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.3 m -69.69 151.81 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-N 115.365 -0.834 . . . . 0.0 112.306 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -152.17 104.2 2.94 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.462 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.428 HE22 ' HB2' ' A' ' 49' ' ' GLN . 11.6 tt0 -82.69 120.8 26.04 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.682 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 10.4 p -94.13 75.76 4.05 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.589 -0.844 . . . . 0.0 110.718 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.65 -65.59 2.82 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.041 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.41 -16.01 0.94 Allowed 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.294 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.682 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -91.61 -171.15 2.81 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 119.268 -0.973 . . . . 0.0 110.215 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.518 HG21 ' CE2' ' A' ' 44' ' ' PHE . 72.7 t -147.3 154.55 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 118.744 -1.182 . . . . 0.0 113.262 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.481 ' N ' HG12 ' A' ' 65' ' ' VAL . 17.1 m -155.75 119.82 4.53 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 114.396 -1.275 . . . . 0.0 108.441 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.662 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -114.32 149.38 16.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.938 0 C-N-CA 119.614 -0.835 . . . . 0.0 111.847 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -132.33 93.0 3.18 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.794 ' HB2' HD22 ' A' ' 73' ' ' ASN . 3.1 p-10 -72.88 122.16 21.18 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.055 -1.058 . . . . 0.0 112.329 -179.582 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.591 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -41.95 161.45 0.15 Allowed Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 113.549 -1.659 . . . . 0.0 112.05 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.0 Cg_endo -65.54 -37.67 28.58 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 121.95 1.767 . . . . 0.0 112.273 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.591 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.46 -55.93 8.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.579 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.794 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.5 OUTLIER -74.69 11.83 0.95 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.738 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.568 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -133.44 22.95 3.88 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.747 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.8 m -93.93 57.08 2.39 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.331 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.759 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.52 128.72 24.88 Favored Pre-proline 0 N--CA 1.489 1.495 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.68 179.971 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.599 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.4 Cg_endo -69.8 154.52 67.47 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 121.448 1.432 . . . . 0.0 111.012 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.892 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -42.49 -12.53 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.745 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.08 55.82 0.5 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.98 -165.65 24.74 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 118.511 -1.804 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.83 HG22 ' HA ' ' A' ' 28' ' ' LYS . 5.9 p -137.93 163.17 32.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.183 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.517 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -121.56 -176.95 3.42 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -169.91 144.71 2.81 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 116.906 -1.917 . . . . 0.0 113.246 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.4 p90 -159.31 169.11 24.75 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.045 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -155.99 163.58 31.9 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 118.052 -2.023 . . . . 0.0 112.023 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.5 p90 -161.16 161.52 31.04 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.242 -0.983 . . . . 0.0 112.287 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 25.8 m-20 -112.79 111.79 22.83 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.271 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.25 164.3 12.16 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.948 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 p -113.17 143.72 43.9 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.659 ' C ' ' ND1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -154.32 174.63 14.57 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 117.235 -1.786 . . . . 0.0 113.31 -179.901 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.426 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 1.4 t -170.88 8.55 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.446 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.43 -99.94 1.4 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.814 -1.184 . . . . 0.0 111.24 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.931 HG22 ' N ' ' A' ' 94' ' ' ASN . 15.9 m -164.38 -113.06 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.986 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.931 ' N ' HG22 ' A' ' 93' ' ' THR . 60.0 m-20 -30.29 131.52 0.08 Allowed 'General case' 0 N--CA 1.5 2.053 0 CA-C-N 115.316 -0.857 . . . . 0.0 112.449 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.73 -121.33 0.28 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.013 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.507 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -53.08 120.15 18.96 Favored Pre-proline 0 N--CA 1.489 1.496 0 C-N-CA 119.742 -0.783 . . . . 0.0 111.187 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.2 Cg_endo -63.13 -121.82 0.0 OUTLIER 'Trans proline' 0 CA--C 1.557 1.658 0 C-N-CA 121.125 1.216 . . . . 0.0 111.935 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.462 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 27.4 p -136.4 -77.43 0.42 Allowed 'General case' 0 N--CA 1.505 2.278 0 C-N-CA 119.246 -0.982 . . . . 0.0 112.608 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -98.72 97.9 9.09 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.842 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 107' ' ' CYS . 45.2 m-85 -66.73 -170.12 0.1 Allowed 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.9 m -146.78 113.99 6.24 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 117.457 -1.697 . . . . 0.0 113.897 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -60.59 -178.19 0.09 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.629 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 102' ' ' LEU . 26.0 m-80 -30.38 -39.85 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -159.98 39.18 0.46 Allowed Glycine 0 N--CA 1.498 2.776 0 C-N-CA 118.583 -1.77 . . . . 0.0 111.598 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.675 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 9.7 m -162.23 137.61 5.5 Favored Pre-proline 0 N--CA 1.49 1.531 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -50.8 177.57 0.03 OUTLIER 'Trans proline' 0 C--O 1.211 -0.858 0 C-N-CA 121.473 1.448 . . . . 0.0 112.361 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.836 ' SG ' HG13 ' A' ' 10' ' ' VAL . 22.0 t -166.35 98.45 0.6 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.411 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 p -46.68 154.82 0.28 Allowed 'General case' 0 N--CA 1.502 2.129 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.678 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.942 HG22 ' N ' ' A' ' 110' ' ' GLY . 2.8 p -68.92 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 118.787 -1.165 . . . . 0.0 109.4 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.942 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.137 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.435 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.112 0 CA-C-O 120.787 0.327 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.58 -168.02 1.87 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.787 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.71 13.61 0.14 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.641 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 175.91 36.45 Favored Glycine 0 N--CA 1.49 2.234 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.326 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.479 ' HG2' HG23 ' A' ' 105' ' ' THR . 6.2 Cg_exo -55.38 -66.84 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.427 2.084 . . . . 0.0 112.757 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 1.021 ' H ' HG21 ' A' ' 105' ' ' THR . . . -106.2 -166.71 1.22 Allowed 'General case' 0 N--CA 1.492 1.668 0 C-N-CA 119.598 -0.841 . . . . 0.0 112.431 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.23 51.25 0.04 OUTLIER Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -51.56 177.84 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.027 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -133.01 99.84 4.7 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.332 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.741 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -91.87 135.01 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 118.967 -1.093 . . . . 0.0 111.875 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.596 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -112.93 164.83 12.95 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.915 179.824 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.665 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.8 t-105 -125.32 143.95 50.72 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.653 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.83 75.8 0.42 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.592 HG22 ' N ' ' A' ' 15' ' ' ASN . 10.0 p -79.2 158.96 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.602 ' CB ' HG22 ' A' ' 22' ' ' THR . 3.6 t30 -152.65 105.14 2.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 113.238 -1.801 . . . . 0.0 107.129 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.413 ' CD ' ' O ' ' A' ' 16' ' ' GLN . 1.4 pm0 -113.48 141.86 46.61 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.573 ' CD1' ' O ' ' A' ' 17' ' ' TRP . 34.8 p90 -122.75 95.69 4.73 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 113.175 -1.83 . . . . 0.0 106.49 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.519 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 1.6 t30 79.49 -38.21 0.19 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.764 HG23 ' N ' ' A' ' 20' ' ' GLY . 10.5 t -176.94 -64.0 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.897 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.764 ' N ' HG23 ' A' ' 19' ' ' THR . . . -33.39 97.0 0.01 OUTLIER Glycine 0 N--CA 1.51 3.569 0 N-CA-C 109.058 -1.617 . . . . 0.0 109.058 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.612 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.6 p90 -101.51 109.73 21.6 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.602 HG22 ' CB ' ' A' ' 15' ' ' ASN . 14.0 t -72.4 173.95 8.05 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.441 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -155.37 120.42 4.85 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 117.251 -1.779 . . . . 0.0 112.908 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -104.0 98.87 8.63 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.561 -1.2 . . . . 0.0 107.904 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.625 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.2 t -96.95 140.8 16.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.306 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.767 HG23 ' HG2' ' A' ' 83' ' ' GLN . 98.7 m -126.39 108.15 10.95 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.278 -0.874 . . . . 0.0 108.809 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.1 t -83.44 101.1 7.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 C-N-CA 119.727 -0.789 . . . . 0.0 111.959 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.772 ' HA ' HG22 ' A' ' 81' ' ' THR . 11.5 tttp -87.82 109.51 19.8 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.512 -1.275 . . . . 0.0 109.992 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.454 ' HB3' HD11 ' A' ' 76' ' ' ILE . 1.4 t-20 -95.56 112.38 24.11 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.504 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -111.68 -7.69 14.24 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.617 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.9 p -72.64 98.84 2.43 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-N 113.779 -1.555 . . . . 0.0 111.314 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.474 ' HA ' ' CB ' ' A' ' 78' ' ' ALA . 69.4 p -27.37 76.43 0.0 OUTLIER 'General case' 0 N--CA 1.512 2.646 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 1.006 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -157.57 137.15 8.45 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.596 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -72.1 100.04 1.06 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.971 1.114 . . . . 0.0 109.463 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -85.03 106.87 15.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.461 -1.296 . . . . 0.0 111.836 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -124.21 80.07 1.8 Allowed 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.55 135.78 3.22 Favored Glycine 0 C--N 1.292 -1.902 0 N-CA-C 106.625 -2.59 . . . . 0.0 106.625 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 43.7 p-90 -159.43 176.68 11.82 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 117.327 -1.749 . . . . 0.0 112.303 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -138.04 113.19 9.26 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.047 179.781 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.888 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.05 172.13 6.99 Favored 'General case' 0 N--CA 1.5 2.026 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.839 -179.968 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.467 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -156.29 146.7 21.59 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 118.017 -1.473 . . . . 0.0 112.605 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.63 ' CD2' ' N ' ' A' ' 43' ' ' SER . 11.7 p90 -172.29 -151.21 0.06 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 114.429 -1.259 . . . . 0.0 108.504 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.63 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.7 m -159.42 158.89 32.96 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.616 -1.633 . . . . 0.0 112.351 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.492 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.8 m-85 -86.28 121.13 72.62 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.88 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -58.75 -67.87 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.084 1.19 . . . . 0.0 112.225 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.483 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 29.8 t -69.54 -112.84 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 118.946 -1.102 . . . . 0.0 111.054 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.483 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -141.98 37.68 1.56 Allowed Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.685 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.47 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 6.7 mt-30 -75.46 115.59 15.28 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.828 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.405 ' H ' ' HG3' ' A' ' 49' ' ' GLN . 1.0 OUTLIER -106.38 119.04 38.23 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.353 -0.939 . . . . 0.0 111.673 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.464 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.2 p -74.38 157.92 6.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.94 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 20.4 p -132.74 -63.89 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.615 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.9 mt-30 -88.59 170.51 10.79 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -166.03 151.72 8.85 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 118.521 -1.271 . . . . 0.0 112.194 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.503 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 36.3 t-105 -149.26 150.77 33.1 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.458 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.503 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 1.4 p 46.77 32.11 1.65 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.617 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -173.64 118.08 0.27 Allowed 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.81 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 m -83.33 72.49 10.2 Favored 'General case' 0 C--N 1.279 -2.473 0 C-N-CA 119.161 -1.016 . . . . 0.0 109.377 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.469 HG12 HG13 ' A' ' 67' ' ' VAL . 4.1 m -70.91 166.57 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.832 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.443 ' O ' ' CG2' ' A' ' 59' ' ' THR . 6.1 t -164.68 130.54 2.83 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.557 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -94.67 116.05 28.29 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.436 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.477 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 6.2 p -93.92 75.53 4.18 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.304 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.37 -67.38 2.82 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.351 -1.404 . . . . 0.0 109.69 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -143.7 -16.51 0.62 Allowed 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.979 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.566 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.9 -170.81 2.93 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.076 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.521 HG12 ' N ' ' A' ' 66' ' ' THR . 65.2 t -148.39 156.6 8.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 118.826 -1.15 . . . . 0.0 113.038 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.521 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.1 m -154.71 141.2 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.312 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.586 HG23 HD21 ' A' ' 40' ' ' LEU . 2.4 t -134.84 153.51 34.92 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.078 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.426 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -133.39 90.84 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.6 p-10 -72.54 121.07 19.06 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.298 -179.534 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.879 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -42.68 163.61 0.14 Allowed Pre-proline 0 C--N 1.303 -1.45 0 CA-C-N 113.291 -1.777 . . . . 0.0 111.807 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.2 Cg_endo -66.46 -35.88 28.81 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.901 1.734 . . . . 0.0 112.315 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.39 -54.28 15.2 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.749 -179.891 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.879 HD22 ' HB3' ' A' ' 70' ' ' ALA . 6.4 p30 -78.25 14.17 1.28 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 118.958 -1.097 . . . . 0.0 109.862 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -129.4 18.98 5.43 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.49 77.4 5.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.197 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.862 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -136.64 125.29 15.18 Favored Pre-proline 0 C--O 1.209 -1.063 0 C-N-CA 119.782 -0.767 . . . . 0.0 111.643 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.589 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.8 Cg_endo -71.63 162.86 40.84 Favored 'Trans proline' 0 C--O 1.213 -0.754 0 C-N-CA 120.91 1.073 . . . . 0.0 110.236 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 1.006 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -46.98 -3.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.871 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -120.13 56.77 0.59 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.81 -159.99 15.77 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 117.905 -2.093 . . . . 0.0 111.12 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.772 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.2 p -139.85 155.06 47.43 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.939 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.862 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.1 100.65 5.5 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.767 ' HG2' HG23 ' A' ' 26' ' ' THR . 21.6 mt-30 -91.13 161.21 15.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 114.709 1.374 . . . . 0.0 114.709 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.625 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.1 p90 -166.0 165.17 18.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 113.286 -1.779 . . . . 0.0 109.224 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.98 170.83 37.75 Favored Glycine 0 N--CA 1.504 3.17 0 C-N-CA 117.547 -2.264 . . . . 0.0 112.611 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.2 p90 -156.62 -167.86 2.52 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.345 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.404 ' OD1' ' N ' ' A' ' 87' ' ' ASN . 1.2 m120 -140.53 112.21 7.48 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.821 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -120.14 158.21 15.45 Favored Glycine 0 N--CA 1.505 3.279 0 C-N-CA 119.784 -1.198 . . . . 0.0 111.426 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.2 p -112.94 151.15 30.88 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.154 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.63 ' ND1' ' N ' ' A' ' 91' ' ' THR . 4.2 p80 -154.45 -144.29 0.14 Allowed 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.779 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.63 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 17.0 p -144.86 -2.38 0.83 Allowed 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.641 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 100.25 93.76 2.12 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.706 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 94' ' ' ASN . 3.2 m -162.74 -145.8 0.1 Allowed 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.164 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.611 ' H ' HG22 ' A' ' 93' ' ' THR . 63.4 t-20 -78.7 125.64 29.64 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.98 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.487 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.38 -163.82 0.88 Allowed 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.776 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.665 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -13.78 121.03 0.04 OUTLIER Pre-proline 0 N--CA 1.507 2.418 0 CA-C-N 114.781 -1.1 . . . . 0.0 113.425 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.57 -144.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 121.319 1.346 . . . . 0.0 110.965 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 10.5 p -116.78 -63.51 1.44 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.495 -0.882 . . . . 0.0 112.376 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.615 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -107.87 111.09 23.04 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.764 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.4 m-85 -81.16 -163.72 0.65 Allowed 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.618 -0.833 . . . . 0.0 109.545 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -145.44 103.04 3.78 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -52.29 173.92 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.501 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 39' ' ' THR . 8.2 p30 -41.87 -20.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.484 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.83 45.0 0.22 Allowed Glycine 0 N--CA 1.487 2.039 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.171 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' THR . . . . . 1.021 HG21 ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -175.01 149.07 1.16 Allowed Pre-proline 0 N--CA 1.494 1.734 0 C-N-CA 119.164 -1.014 . . . . 0.0 111.049 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -63.04 170.35 7.69 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 121.372 1.381 . . . . 0.0 111.956 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.741 ' SG ' HG13 ' A' ' 10' ' ' VAL . 6.5 t -161.88 90.95 0.79 Allowed 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.538 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 m -51.99 165.18 0.22 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.69 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -65.05 -156.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 119.176 -1.01 . . . . 0.0 109.588 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 CA-C-O 116.319 -2.378 . . . . 0.0 110.371 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.468 ' OG ' ' N ' ' A' ' 3' ' ' SER . 9.8 p 47.11 -149.9 0.12 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.827 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.468 ' N ' ' OG ' ' A' ' 2' ' ' SER . 64.9 m -145.98 -172.0 3.83 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.752 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.411 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . 51.73 68.66 1.43 Allowed Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.17 -1.49 . . . . 0.0 110.222 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.481 ' CB ' HG22 ' A' ' 105' ' ' THR . 2.9 Cg_endo -63.03 -147.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 121.892 1.728 . . . . 0.0 111.399 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -92.33 -163.97 1.12 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.647 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.18 59.91 0.04 OUTLIER Glycine 0 N--CA 1.49 2.237 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.699 ' SG ' HG13 ' A' ' 10' ' ' VAL . 0.6 OUTLIER -56.32 -161.88 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.278 1.037 . . . . 0.0 112.54 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.674 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 37.0 mt-30 -150.97 89.02 1.5 Allowed 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 113.553 -1.658 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.699 HG13 ' SG ' ' A' ' 8' ' ' CYS . 2.9 m -90.32 128.71 42.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 118.972 -1.091 . . . . 0.0 111.83 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.572 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -102.27 171.27 7.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.149 179.831 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.477 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.5 t-105 -130.39 147.59 52.11 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.768 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.407 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.67 76.4 0.41 Allowed Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.026 -2.03 . . . . 0.0 108.026 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.473 HG23 ' HD2' ' A' ' 21' ' ' PHE . 2.5 p -72.51 142.9 14.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.562 ' CB ' HG22 ' A' ' 22' ' ' THR . 8.4 t-20 -140.53 95.97 2.95 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.578 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -98.46 117.0 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.648 -0.821 . . . . 0.0 112.882 -179.757 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.58 ' C ' ' H ' ' A' ' 19' ' ' THR . 42.0 p90 -98.37 -142.54 0.31 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.844 -1.142 . . . . 0.0 108.177 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.521 ' OD1' ' N ' ' A' ' 18' ' ' ASN . 0.7 OUTLIER -47.82 -16.79 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.083 -1.447 . . . . 0.0 108.2 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.647 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.3 OUTLIER 170.42 -179.88 0.05 OUTLIER 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.126 -1.852 . . . . 0.0 107.054 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.647 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 69.4 111.44 0.03 OUTLIER Glycine 0 C--N 1.274 -2.905 0 C-N-CA 117.901 -2.095 . . . . 0.0 109.634 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.62 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.4 p90 -102.86 115.63 30.97 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.555 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.579 HG23 ' N ' ' A' ' 23' ' ' ALA . 1.0 OUTLIER -71.08 176.56 4.33 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 118.074 -1.451 . . . . 0.0 107.74 179.791 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.579 ' N ' HG23 ' A' ' 22' ' ' THR . . . -148.76 103.08 3.35 Favored 'General case' 0 C--N 1.291 -1.937 0 C-N-CA 118.469 -1.293 . . . . 0.0 111.616 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -94.1 94.35 8.34 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.632 HG11 ' CE2' ' A' ' 84' ' ' PHE . 15.6 t -97.16 137.38 25.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.664 -0.815 . . . . 0.0 113.003 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.572 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -128.36 114.45 16.88 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.864 -1.062 . . . . 0.0 108.406 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.523 HG13 HG12 ' A' ' 10' ' ' VAL . 3.6 t -86.94 128.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 C-N-CA 119.81 -0.756 . . . . 0.0 112.783 -179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.819 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.4 tptt -114.23 100.93 8.73 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.426 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.76 ' HB3' HD11 ' A' ' 76' ' ' ILE . 15.1 t-20 -89.87 117.46 28.71 Favored 'General case' 0 C--N 1.282 -2.353 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.452 179.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.62 -2.09 8.43 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 124.185 0.928 . . . . 0.0 109.754 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.4 p -49.87 -83.89 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.588 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.545 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.51 72.32 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 123.666 0.604 . . . . 0.0 111.504 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.52 149.9 3.17 Favored Pre-proline 0 C--N 1.304 -1.392 0 C-N-CA 119.148 -1.021 . . . . 0.0 111.016 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -70.45 102.45 1.14 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 121.012 1.142 . . . . 0.0 109.243 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.37 106.56 16.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.48 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -116.94 72.43 0.83 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.11 144.43 13.78 Favored Glycine 0 N--CA 1.484 1.853 0 N-CA-C 107.372 -2.291 . . . . 0.0 107.372 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.602 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 36.9 p-90 -161.05 176.9 10.85 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 117.592 -1.643 . . . . 0.0 112.014 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . 1.006 ' N ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.59 103.32 4.66 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.957 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.852 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -91.56 174.2 7.49 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.258 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.605 ' HG1' HG23 ' A' ' 66' ' ' THR . 97.8 m -156.59 146.31 20.87 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.278 -1.369 . . . . 0.0 112.143 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.595 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.1 p90 -172.5 -150.95 0.06 Allowed 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 114.589 -1.187 . . . . 0.0 108.999 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.595 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 20.1 m -156.2 153.42 29.19 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 117.807 -1.557 . . . . 0.0 112.09 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.512 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.1 m-85 -81.03 119.37 75.8 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 118.526 -1.27 . . . . 0.0 109.578 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -55.74 -71.71 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.443 1.429 . . . . 0.0 112.319 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.1 t -69.37 -113.91 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.715 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.02 48.02 0.75 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.436 -1.364 . . . . 0.0 110.334 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.424 ' CG ' ' CE1' ' A' ' 21' ' ' PHE . 20.7 mp0 -71.56 112.86 8.02 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.416 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.411 ' OE1' ' HA ' ' A' ' 49' ' ' GLN . 7.0 mm100 -93.56 94.94 8.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.0 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.1 p -72.66 151.92 7.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.697 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 43.1 p -143.0 -63.27 0.41 Allowed 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.551 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.98 160.09 30.2 Favored 'General case' 0 C--N 1.301 -1.537 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.164 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -164.22 156.63 17.01 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 118.551 -1.26 . . . . 0.0 112.06 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 23.6 t-105 -155.52 137.04 14.13 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.847 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 62.56 29.14 16.97 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.21 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.43 122.39 0.64 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.613 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.3 m -84.54 69.39 10.58 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.948 -1.101 . . . . 0.0 108.845 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 HG13 ' A' ' 67' ' ' VAL . 3.3 m -69.29 164.39 2.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 114.904 -1.044 . . . . 0.0 112.828 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 1.5 t -168.04 145.54 4.27 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.768 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -98.27 109.72 22.43 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.138 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.543 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 7.7 p -91.2 72.91 6.26 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.67 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 56.38 75.89 0.23 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.2 -1.476 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 74.94 -28.79 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.149 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.543 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.49 -171.65 3.43 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 118.728 -1.189 . . . . 0.0 110.663 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.615 HG12 ' N ' ' A' ' 66' ' ' THR . 55.9 t -148.65 162.34 5.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.471 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.615 ' N ' HG12 ' A' ' 65' ' ' VAL . 6.2 m -157.0 147.63 21.49 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 114.083 -1.417 . . . . 0.0 108.131 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 58' ' ' VAL . 3.1 t -142.95 116.08 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 118.491 -1.284 . . . . 0.0 112.865 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -97.55 89.71 4.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.602 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.3 p-10 -70.27 120.43 15.94 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.075 -1.05 . . . . 0.0 112.063 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.805 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.27 158.33 0.09 OUTLIER Pre-proline 0 N--CA 1.486 1.36 0 CA-C-N 113.745 -1.571 . . . . 0.0 112.611 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.408 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.3 Cg_endo -68.03 -35.49 20.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.897 1.731 . . . . 0.0 112.385 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.805 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -69.86 -56.53 6.84 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.862 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.784 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 10.9 p30 -74.07 -1.85 21.87 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.823 -1.151 . . . . 0.0 109.696 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.565 ' HA3' HD21 ' A' ' 69' ' ' ASN . . . -113.17 20.42 19.18 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 8.8 m -90.03 59.73 4.62 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.262 -0.975 . . . . 0.0 111.272 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.782 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.05 122.96 39.09 Favored Pre-proline 0 CA--C 1.566 1.566 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.564 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 78' ' ' ALA . 5.8 Cg_endo -70.25 156.38 62.2 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 121.565 1.51 . . . . 0.0 113.766 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.545 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.47 -46.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.885 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.74 65.88 0.24 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.089 -1.204 . . . . 0.0 110.089 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.427 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.98 -170.31 18.48 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.837 -1.649 . . . . 0.0 110.139 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.819 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.9 p -139.49 158.3 44.36 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.199 -1.001 . . . . 0.0 112.527 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.782 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -125.59 -176.18 3.53 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.429 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 49.9 tt0 -168.12 148.1 4.82 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.019 -1.872 . . . . 0.0 112.92 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.632 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.3 p90 -165.22 168.08 17.41 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.068 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.48 171.95 40.11 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 117.694 -2.193 . . . . 0.0 112.223 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.1 p90 -155.06 -172.75 4.3 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -136.21 112.32 9.71 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.967 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -125.57 153.76 18.34 Favored Glycine 0 N--CA 1.51 3.596 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.024 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p -78.78 156.52 28.77 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.912 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.593 ' NE2' ' N ' ' A' ' 20' ' ' GLY . 11.9 p80 -140.57 -161.54 1.22 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.556 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 90' ' ' HIS . 0.8 OUTLIER -159.03 -4.33 0.08 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.574 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 104.91 65.2 0.67 Allowed Glycine 0 N--CA 1.497 2.751 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.674 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 94' ' ' ASN . 4.0 m -162.67 170.75 17.94 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.922 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.411 ' ND2' ' H ' ' A' ' 94' ' ' ASN . 0.0 OUTLIER -42.81 125.61 3.48 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.841 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -108.23 -50.97 2.96 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.141 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.477 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -110.06 125.63 30.69 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.897 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -62.61 -143.11 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 121.588 1.525 . . . . 0.0 111.771 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.626 ' O ' HG13 ' A' ' 109' ' ' VAL . 19.3 p -127.25 -58.35 1.28 Allowed 'General case' 0 N--CA 1.5 2.036 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.766 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.524 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.25 91.58 3.71 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.443 -0.903 . . . . 0.0 111.996 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.449 ' HD1' ' H ' ' A' ' 100' ' ' PHE . 32.3 m-85 -65.53 -166.81 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.1 m -146.43 107.68 4.22 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 117.552 -1.659 . . . . 0.0 113.884 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.9 mt -58.94 168.19 1.36 Allowed 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 1.006 HD22 ' N ' ' A' ' 39' ' ' THR . 2.4 m120 -41.24 92.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.053 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.729 ' O ' HG23 ' A' ' 105' ' ' THR . . . 63.6 45.88 93.59 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 119.495 -1.336 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.729 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.6 OUTLIER -167.13 146.41 4.5 Favored Pre-proline 0 C--O 1.196 -1.743 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.157 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -64.22 166.16 17.67 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.31 1.34 . . . . 0.0 112.241 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -163.68 94.96 0.79 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 17.0 p -65.2 170.26 4.79 Favored 'General case' 0 N--CA 1.511 2.595 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 98' ' ' THR . 17.0 m -60.53 -155.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.562 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 CA-C-O 116.322 -2.377 . . . . 0.0 110.378 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.91 0.386 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.445 ' H ' ' H ' ' A' ' 3' ' ' SER . 0.3 OUTLIER 171.13 2.42 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.57 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.445 ' H ' ' H ' ' A' ' 2' ' ' SER . 6.3 p -151.51 157.93 42.94 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.601 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.57 ' N ' ' HD2' ' A' ' 5' ' ' PRO . . . 138.33 -55.65 0.67 Allowed Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.402 -1.38 . . . . 0.0 111.399 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 4' ' ' GLY . 9.2 Cg_exo -54.0 -77.31 0.02 OUTLIER 'Trans proline' 0 C--N 1.317 -1.104 0 C-N-CA 121.795 1.663 . . . . 0.0 112.735 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.848 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . -102.12 -171.84 2.04 Favored 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 119.633 -0.827 . . . . 0.0 113.064 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.99 43.3 0.06 OUTLIER Glycine 0 N--CA 1.497 2.703 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -52.41 -175.81 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 114.496 -0.852 . . . . 0.0 112.774 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.516 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 5.3 pt20 -142.25 126.48 17.53 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.907 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.649 HG12 HG13 ' A' ' 27' ' ' VAL . 3.3 m -115.1 128.41 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.163 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.554 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -97.12 171.93 8.15 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.313 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.893 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.7 t-105 -125.39 147.84 49.01 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.829 -0.748 . . . . 0.0 112.026 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.1 79.66 0.35 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 107.759 -2.137 . . . . 0.0 107.759 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -68.99 146.8 12.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 122.018 0.913 . . . . 0.0 113.112 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -154.85 89.7 1.25 Allowed 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.519 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.628 ' OE1' ' N ' ' A' ' 16' ' ' GLN . 6.2 pm0 -116.1 150.84 36.71 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.526 ' CD1' ' O ' ' A' ' 17' ' ' TRP . 17.4 p90 -115.81 92.72 3.99 Favored 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 112.998 -1.91 . . . . 0.0 107.771 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.493 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 78.9 -30.63 0.15 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.095 -179.849 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.755 HG22 ' H ' ' A' ' 20' ' ' GLY . 0.5 OUTLIER -175.84 -65.83 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 119.051 -1.06 . . . . 0.0 111.587 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.755 ' H ' HG22 ' A' ' 19' ' ' THR . . . -46.52 110.31 0.5 Allowed Glycine 0 C--O 1.201 -1.963 0 N-CA-C 108.382 -1.887 . . . . 0.0 108.382 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.647 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.6 p90 -103.9 137.26 42.14 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -179.465 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.516 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 0.7 OUTLIER -101.67 114.32 28.26 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 179.579 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.679 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -91.53 115.83 28.36 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 119.19 -1.004 . . . . 0.0 113.52 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -98.53 96.85 8.26 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.545 HG11 ' CE2' ' A' ' 84' ' ' PHE . 33.5 t -92.64 144.54 9.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.554 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -131.27 103.43 6.46 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.771 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.649 HG13 HG12 ' A' ' 10' ' ' VAL . 2.2 t -74.12 151.57 7.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.731 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.59 ' HB2' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -148.16 111.29 4.88 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.643 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.707 ' HB3' HD11 ' A' ' 76' ' ' ILE . 14.6 t-20 -96.85 129.73 44.24 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.962 -1.017 . . . . 0.0 108.397 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -132.06 -6.85 3.48 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 124.087 0.867 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 32' ' ' SER . 2.0 p -51.0 -80.87 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.732 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.0 37.16 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.194 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.556 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.853 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -136.45 147.78 61.33 Favored Pre-proline 0 N--CA 1.488 1.451 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.414 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -72.46 115.95 4.53 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 121.403 1.402 . . . . 0.0 110.406 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 t -98.34 95.83 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.236 -0.985 . . . . 0.0 112.109 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -105.76 63.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 99.99 154.14 27.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.626 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 39.9 p-90 -169.95 177.17 4.44 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.172 -1.811 . . . . 0.0 112.911 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.23 99.19 3.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.017 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.883 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -87.93 172.72 9.38 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 118.576 -1.25 . . . . 0.0 110.051 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.472 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -153.97 145.08 22.82 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 118.642 -1.223 . . . . 0.0 111.633 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.622 ' CD2' ' N ' ' A' ' 43' ' ' SER . 10.6 p90 -172.92 -156.36 0.09 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.407 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.622 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 56.5 m -158.55 157.52 32.2 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 117.53 -1.668 . . . . 0.0 112.075 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' A' ' 65' ' ' VAL . 10.9 m-85 -86.58 122.22 71.89 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 118.712 -1.195 . . . . 0.0 109.443 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.465 ' HB2' ' ND2' ' A' ' 94' ' ' ASN . 4.9 Cg_exo -57.48 -62.1 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.244 1.296 . . . . 0.0 112.196 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.9 p -69.5 -58.81 3.5 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.793 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . 145.65 31.4 0.08 OUTLIER Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.418 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.647 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 17.3 mt-30 -43.69 131.93 5.14 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.394 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 6.1 mm-40 -94.64 80.49 3.81 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.289 -0.964 . . . . 0.0 111.478 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.1 p -62.78 147.84 11.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.306 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.502 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 61.8 p -140.47 -71.18 0.37 Allowed 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.283 -0.967 . . . . 0.0 111.558 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.502 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -69.73 164.36 23.69 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.289 -179.951 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.2 5.51 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 118.645 -1.222 . . . . 0.0 112.056 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.445 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 30.8 t-105 -153.11 143.28 22.35 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.655 -0.818 . . . . 0.0 110.496 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 0.9 OUTLIER 57.71 30.24 18.59 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.663 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.423 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.4 OUTLIER -172.9 119.18 0.34 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.675 -179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 m -82.81 74.37 9.78 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.975 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.404 ' C ' HG23 ' A' ' 59' ' ' THR . 10.3 m -69.41 156.83 6.93 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 CA-C-N 115.017 -0.992 . . . . 0.0 112.78 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.404 HG23 ' C ' ' A' ' 58' ' ' VAL . 58.8 p -155.19 115.65 3.84 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.876 -1.056 . . . . 0.0 109.731 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -89.86 113.44 25.04 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.18 -1.008 . . . . 0.0 110.532 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.413 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.6 p -92.19 80.44 5.04 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.923 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.44 -67.85 2.17 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.443 -1.36 . . . . 0.0 110.127 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 10.3 p -141.94 -17.6 0.75 Allowed 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.223 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -88.93 -172.26 3.62 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.163 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.55 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.0 t -149.93 159.01 5.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 118.709 -1.197 . . . . 0.0 113.639 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.55 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 53.1 m -153.94 149.35 27.18 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.203 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.443 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.8 t -144.63 119.44 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 118.386 -1.326 . . . . 0.0 112.73 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.16 91.08 5.09 Favored 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.046 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.626 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.4 p-10 -71.23 120.95 17.54 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.879 -1.128 . . . . 0.0 111.625 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.723 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -43.14 167.39 0.08 OUTLIER Pre-proline 0 N--CA 1.487 1.377 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.452 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.723 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.8 Cg_endo -70.34 -35.92 10.14 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.23 1.953 . . . . 0.0 112.373 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.683 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.47 -54.29 14.99 Favored 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.869 -179.834 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 4.8 p-10 -79.37 10.79 3.41 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.444 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.536 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -127.42 40.2 1.8 Allowed Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.186 -1.007 . . . . 0.0 110.673 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -109.93 62.82 0.6 Allowed 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.908 -0.717 . . . . 0.0 111.21 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.913 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -116.87 121.4 32.81 Favored Pre-proline 0 N--CA 1.483 1.187 0 C-N-CA 120.058 -0.657 . . . . 0.0 111.243 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.592 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.6 Cg_endo -67.38 156.35 66.55 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 C-N-CA 121.103 1.202 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.853 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -39.36 -18.75 0.01 OUTLIER 'General case' 0 C--O 1.205 -1.271 0 C-N-CA 119.895 -0.722 . . . . 0.0 112.676 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.592 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.24 62.52 0.43 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -163.67 -161.72 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 C-N-CA 118.979 -1.581 . . . . 0.0 110.635 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.59 HG22 ' HB2' ' A' ' 28' ' ' LYS . 7.3 p -143.98 162.94 34.9 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.063 -1.055 . . . . 0.0 112.978 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.707 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -131.31 179.53 5.97 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.106 -1.407 . . . . 0.0 107.733 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.451 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 32.0 tt0 -164.03 144.55 8.36 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 117.226 -1.789 . . . . 0.0 113.187 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.545 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.2 p90 -157.7 170.28 22.74 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.779 -1.101 . . . . 0.0 109.857 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.79 164.8 37.18 Favored Glycine 0 N--CA 1.498 2.798 0 C-N-CA 117.704 -2.189 . . . . 0.0 112.557 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.602 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.7 p90 -153.04 -177.77 6.5 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 114.889 -0.656 . . . . 0.0 110.608 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.555 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -138.39 111.4 7.83 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.693 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -109.96 169.38 13.58 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.288 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.5 p -110.29 135.83 50.43 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' A' ' 91' ' ' THR . 0.8 OUTLIER -146.02 -169.85 3.34 Favored 'General case' 0 N--CA 1.502 2.171 0 C-N-CA 117.664 -1.614 . . . . 0.0 112.603 -179.919 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.581 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -135.55 2.74 2.98 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.285 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.465 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 99.43 106.87 2.75 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 119.677 -1.249 . . . . 0.0 110.482 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.465 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER -164.16 -84.63 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.43 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.542 ' OD1' ' N ' ' A' ' 94' ' ' ASN . 1.3 p-10 -173.87 124.99 0.36 Allowed 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.852 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.474 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.79 -134.91 0.35 Allowed 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.177 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.893 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -9.53 106.36 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.515 0 CA-C-N 114.537 -1.21 . . . . 0.0 113.567 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.504 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.5 Cg_endo -62.7 -101.11 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 120.962 1.108 . . . . 0.0 111.952 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.404 ' O ' ' N ' ' A' ' 109' ' ' VAL . 45.7 p -152.58 -69.2 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 118.829 -1.148 . . . . 0.0 111.946 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -106.54 94.98 5.43 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.56 -0.856 . . . . 0.0 111.255 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.504 ' CZ ' ' HD2' ' A' ' 97' ' ' PRO . 38.6 m-85 -65.03 -162.76 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.057 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -149.93 98.48 2.72 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 117.605 -1.638 . . . . 0.0 113.323 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.586 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.7 mt -52.17 171.59 0.05 OUTLIER 'General case' 0 C--O 1.21 -0.989 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.412 ' O ' ' ND2' ' A' ' 103' ' ' ASN . 5.4 p-10 -55.54 82.41 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.755 -1.178 . . . . 0.0 110.783 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 87.51 41.85 6.34 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.848 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -174.44 130.36 0.47 Allowed Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.151 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.63 170.75 3.16 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 121.029 1.153 . . . . 0.0 111.22 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.469 ' SG ' HG13 ' A' ' 10' ' ' VAL . 8.2 t -166.73 101.95 0.57 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.179 -1.008 . . . . 0.0 111.117 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.47 169.48 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.844 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.96 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.8 p -80.25 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.876 -1.13 . . . . 0.0 109.876 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.96 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.402 0 CA-C-O 116.333 -2.371 . . . . 0.0 110.585 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.133 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.9 p -109.79 124.27 50.99 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.961 -0.695 . . . . 0.0 110.765 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.3 164.48 37.35 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.825 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.466 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . -146.24 64.83 0.44 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.38 -1.39 . . . . 0.0 110.476 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.466 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 3.2 Cg_exo -58.82 -77.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 121.989 1.792 . . . . 0.0 111.695 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.831 ' HB3' HG21 ' A' ' 105' ' ' THR . . . -110.15 -152.39 0.49 Allowed 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.355 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.15 43.94 0.06 OUTLIER Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.235 -1.946 . . . . 0.0 108.235 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.738 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.58 -168.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.87 -0.665 . . . . 0.0 110.955 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.486 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 1.8 pt20 -159.75 155.96 26.82 Favored 'General case' 0 C--N 1.287 -2.147 0 C-N-CA 118.754 -1.178 . . . . 0.0 110.407 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.595 HG12 HG13 ' A' ' 27' ' ' VAL . 1.1 m -141.35 138.88 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.002 -1.079 . . . . 0.0 111.67 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -100.44 171.61 7.64 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.157 179.95 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -133.94 143.32 48.13 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.834 -0.746 . . . . 0.0 111.961 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.09 71.79 0.41 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.9 p -69.61 140.77 18.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.571 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 62.9 t30 -136.61 86.2 2.2 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.029 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.69 ' NE2' ' NE2' ' A' ' 90' ' ' HIS . 0.0 OUTLIER -88.53 130.18 35.29 Favored 'General case' 0 N--CA 1.498 1.927 0 N-CA-C 113.458 0.911 . . . . 0.0 113.458 -179.682 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.777 ' C ' ' H ' ' A' ' 19' ' ' THR . 21.6 p90 -121.78 82.55 1.96 Allowed 'General case' 0 N--CA 1.495 1.818 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.468 ' O ' ' CB ' ' A' ' 19' ' ' THR . 0.5 OUTLIER 67.39 -15.16 0.18 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.059 -1.056 . . . . 0.0 108.492 -179.587 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.777 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.8 OUTLIER 163.27 171.13 0.02 OUTLIER 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 113.424 -1.717 . . . . 0.0 107.015 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.613 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 68.18 101.75 0.03 OUTLIER Glycine 0 C--N 1.283 -2.366 0 C-N-CA 117.717 -2.183 . . . . 0.0 107.698 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.588 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.5 p90 -111.55 113.6 26.12 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.864 -0.734 . . . . 0.0 111.984 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.537 HG22 ' CB ' ' A' ' 15' ' ' ASN . 1.0 OUTLIER -65.13 173.82 2.28 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.487 ' N ' HG23 ' A' ' 22' ' ' THR . . . -152.52 98.25 2.35 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 117.651 -1.62 . . . . 0.0 112.755 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -92.12 97.95 11.24 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.515 HG11 ' CE1' ' A' ' 84' ' ' PHE . 19.4 t -95.55 145.56 8.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 C-N-CA 119.681 -0.807 . . . . 0.0 112.583 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.624 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -134.71 101.75 5.04 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.439 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.595 HG13 HG12 ' A' ' 10' ' ' VAL . 1.9 t -71.06 153.81 8.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.698 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.611 ' HB2' HG22 ' A' ' 81' ' ' THR . 4.3 tttp -148.63 115.35 5.99 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.936 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.702 ' HB3' HD11 ' A' ' 76' ' ' ILE . 15.6 t-20 -102.21 119.6 39.07 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.2 t -122.19 1.42 9.71 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 124.169 0.918 . . . . 0.0 109.866 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.5 p -63.02 -79.49 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.951 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.603 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.4 OUTLIER 159.31 78.98 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 123.723 0.639 . . . . 0.0 111.498 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.54 141.24 1.55 Allowed Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.195 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -67.67 100.52 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.712 0 N-CA-C 108.972 -1.203 . . . . 0.0 108.972 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.84 112.29 23.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 118.244 -1.382 . . . . 0.0 111.442 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -124.22 76.76 1.5 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.23 136.76 6.01 Favored Glycine 0 N--CA 1.483 1.8 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.449 ' CZ2' HG21 ' A' ' 27' ' ' VAL . 26.3 p-90 -154.54 -179.81 8.32 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 117.905 -1.518 . . . . 0.0 111.959 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.521 ' CB ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -140.13 100.48 3.92 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.491 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -91.87 175.51 6.86 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.748 -1.181 . . . . 0.0 109.462 179.932 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.496 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -162.46 149.28 13.3 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 117.629 -1.629 . . . . 0.0 112.731 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.469 ' CD2' ' N ' ' A' ' 43' ' ' SER . 22.2 p90 -173.72 -140.93 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 113.571 -1.65 . . . . 0.0 107.558 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.584 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 31.0 m -163.39 -179.06 6.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.375 -1.73 . . . . 0.0 112.735 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.683 ' CE1' ' NE2' ' A' ' 48' ' ' GLN . 8.1 m-85 -114.64 91.2 24.33 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -55.38 -36.97 94.99 Favored 'Trans proline' 0 CA--C 1.51 -0.72 0 C-N-CA 121.015 1.143 . . . . 0.0 110.065 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.439 ' CB ' ' HB ' ' A' ' 93' ' ' THR . 22.2 p -79.44 165.26 23.25 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 119.322 -0.951 . . . . 0.0 108.973 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.12 48.27 3.31 Favored Glycine 0 C--N 1.29 -2.009 0 C-N-CA 118.663 -1.732 . . . . 0.0 109.968 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.683 ' NE2' ' CE1' ' A' ' 44' ' ' PHE . 15.4 pt20 -109.76 143.46 39.55 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.309 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -137.48 133.57 34.76 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.496 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.595 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.7 p -72.69 164.48 3.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.584 -0.846 . . . . 0.0 111.728 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.595 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 66.3 p -136.17 -63.24 0.65 Allowed 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.264 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.49 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.6 mt-30 -89.23 164.64 14.87 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.177 -1.009 . . . . 0.0 109.346 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -170.37 153.5 4.4 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.259 -1.376 . . . . 0.0 112.227 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.454 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 33.6 t-105 -156.1 144.84 20.26 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.881 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.454 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.8 OUTLIER 61.82 28.62 17.55 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 119.541 -0.863 . . . . 0.0 109.993 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.594 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.9 OUTLIER -172.58 124.54 0.47 Allowed 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.323 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.5 m -87.99 75.88 8.7 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.43 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.4 m -69.08 152.82 9.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.954 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.403 HG23 ' C ' ' A' ' 58' ' ' VAL . 60.2 p -154.57 113.93 3.71 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.032 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.471 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.9 pt20 -90.51 117.71 29.41 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.924 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.0 p -94.09 85.49 4.71 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.999 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.93 -67.52 2.36 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.391 -1.385 . . . . 0.0 109.966 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -144.82 -12.72 0.56 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.293 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.584 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -93.28 -170.3 2.35 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.119 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.654 HG12 ' N ' ' A' ' 66' ' ' THR . 62.1 t -148.99 162.98 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.795 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.654 ' N ' HG12 ' A' ' 65' ' ' VAL . 10.6 m -156.65 139.87 15.58 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 113.625 -1.625 . . . . 0.0 108.267 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.457 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -132.51 114.88 23.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.368 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -96.63 88.5 4.67 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.993 HD22 ' CA ' ' A' ' 74' ' ' GLY . 0.3 OUTLIER -70.61 119.41 14.72 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.02 -1.072 . . . . 0.0 111.674 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.642 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -41.0 163.83 0.09 OUTLIER Pre-proline 0 N--CA 1.487 1.402 0 CA-C-N 113.741 -1.572 . . . . 0.0 112.417 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.587 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -64.57 -35.29 48.69 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 121.703 1.602 . . . . 0.0 112.195 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.538 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.33 -52.48 22.38 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 118.816 -1.154 . . . . 0.0 111.162 -179.926 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.642 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 16.9 p30 -78.08 8.96 4.09 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.883 -1.127 . . . . 0.0 110.224 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.993 ' CA ' HD22 ' A' ' 69' ' ' ASN . . . -124.91 18.3 7.09 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 120.081 -1.057 . . . . 0.0 110.495 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.5 m -86.72 58.44 5.07 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.222 -0.991 . . . . 0.0 111.262 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.921 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.46 114.86 54.77 Favored Pre-proline 0 CA--C 1.564 1.496 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.245 179.934 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.3 Cg_endo -67.57 156.02 67.78 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.395 1.397 . . . . 0.0 113.663 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.45 -45.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 114.273 -1.33 . . . . 0.0 114.156 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.43 69.58 0.28 Allowed Glycine 0 N--CA 1.497 2.712 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.402 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.13 -164.11 11.84 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.62 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.611 HG22 ' HB2' ' A' ' 28' ' ' LYS . 1.2 p -143.38 154.72 44.02 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 118.997 -1.081 . . . . 0.0 112.592 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.768 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -124.34 175.48 7.06 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.624 ' HB2' HG23 ' A' ' 26' ' ' THR . 2.9 tm0? -167.22 147.64 5.49 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 116.973 -1.891 . . . . 0.0 113.191 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.594 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 10.9 p90 -157.03 -179.13 7.91 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.609 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.29 161.42 34.82 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 117.471 -2.3 . . . . 0.0 112.705 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.584 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.7 p90 -157.16 175.24 14.32 Favored 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 114.806 -0.697 . . . . 0.0 111.008 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -125.52 115.73 20.67 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.906 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -127.27 158.02 20.96 Favored Glycine 0 N--CA 1.51 3.58 0 C-N-CA 119.38 -1.39 . . . . 0.0 112.638 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.7 p -107.42 152.93 23.53 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.745 ' HD1' ' N ' ' A' ' 91' ' ' THR . 4.6 p80 -142.62 -153.45 0.46 Allowed 'General case' 0 N--CA 1.495 1.792 0 C-N-CA 119.127 -1.029 . . . . 0.0 111.9 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.745 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.3 p -145.52 -9.52 0.56 Allowed 'General case' 0 N--CA 1.482 1.151 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.501 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 105.63 81.15 1.42 Allowed Glycine 0 N--CA 1.499 2.863 0 C-N-CA 119.889 -1.148 . . . . 0.0 110.88 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.632 HG22 ' H ' ' A' ' 94' ' ' ASN . 2.1 m -163.12 -174.64 3.93 Favored 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.855 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.632 ' H ' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -61.24 101.52 0.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.208 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.447 ' HB1' HE22 ' A' ' 48' ' ' GLN . . . -88.33 -118.57 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.441 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -39.24 115.92 1.0 Allowed Pre-proline 0 N--CA 1.486 1.33 0 C-N-CA 120.024 -0.671 . . . . 0.0 111.141 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 3.8 Cg_endo -65.63 -143.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.217 -0.552 0 C-N-CA 121.048 1.166 . . . . 0.0 110.808 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.775 ' O ' HG13 ' A' ' 109' ' ' VAL . 11.1 p -113.45 -92.91 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.6 -0.84 . . . . 0.0 112.112 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -89.1 99.11 12.17 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.625 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.6 m-30 -68.08 -149.41 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.487 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -160.0 112.04 2.03 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 116.712 -1.995 . . . . 0.0 114.521 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.738 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.5 mt -64.77 172.76 2.58 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.532 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.521 HD22 ' CB ' ' A' ' 39' ' ' THR . 28.6 m120 -35.72 91.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.51 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 55.88 49.42 66.66 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.55 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.831 HG21 ' HB3' ' A' ' 6' ' ' ALA . 21.1 m -163.37 131.6 2.77 Favored Pre-proline 0 C--O 1.189 -2.119 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.92 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -61.06 158.86 32.32 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 121.263 1.309 . . . . 0.0 112.636 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.623 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.1 t -157.62 110.98 2.51 Favored 'General case' 0 N--CA 1.496 1.852 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.221 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -73.45 128.03 34.36 Favored 'General case' 0 N--CA 1.508 2.447 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -179.773 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 98' ' ' THR . 2.5 m -56.53 -177.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.659 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 116.301 -2.388 . . . . 0.0 110.461 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.167 0 CA-C-O 120.887 0.375 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -152.62 -10.61 0.17 Allowed 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.667 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -176.1 -162.11 0.09 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.873 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.406 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . -156.63 69.84 0.27 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.406 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 1.1 Cg_endo -66.85 -173.87 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.966 1.777 . . . . 0.0 111.303 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.776 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -104.36 -161.96 0.86 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.953 -0.699 . . . . 0.0 111.366 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.76 43.25 0.1 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.949 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.3 p -53.55 -178.12 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 121.541 0.686 . . . . 0.0 112.077 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -138.34 108.44 6.39 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.795 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.886 HG12 HG13 ' A' ' 27' ' ' VAL . 4.6 m -103.39 124.06 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.238 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.576 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.15 165.05 12.6 Favored 'General case' 0 C--N 1.294 -1.84 0 C-N-CA 119.291 -0.964 . . . . 0.0 109.321 179.88 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.594 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.4 t-105 -124.74 143.32 50.84 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.614 -0.835 . . . . 0.0 112.444 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 75.45 0.38 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.76 149.0 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.97 -0.692 . . . . 0.0 112.832 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -152.99 91.39 1.53 Allowed 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.528 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.678 ' NE2' ' NE2' ' A' ' 90' ' ' HIS . 0.0 OUTLIER -75.76 132.34 40.4 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.397 -179.961 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.49 ' CZ3' ' N ' ' A' ' 22' ' ' THR . 5.5 p90 -106.54 -35.71 6.98 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.872 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.432 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 0.1 OUTLIER -157.7 -20.08 0.08 Allowed 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 122.041 0.924 . . . . 0.0 108.793 179.938 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.706 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -178.09 -55.2 0.01 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.281 179.957 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.706 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -65.77 176.23 15.97 Favored Glycine 0 C--N 1.292 -1.887 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.7 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.0 p90 -149.11 140.72 23.46 Favored 'General case' 0 C--N 1.283 -2.292 0 C-N-CA 118.498 -1.281 . . . . 0.0 112.984 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.49 ' N ' ' CZ3' ' A' ' 17' ' ' TRP . 0.6 OUTLIER -80.85 163.97 23.01 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 179.407 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.456 ' N ' ' CG2' ' A' ' 22' ' ' THR . . . -145.65 110.11 5.03 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.894 -1.522 . . . . 0.0 112.89 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -99.09 101.15 12.41 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.646 HG11 ' CE1' ' A' ' 84' ' ' PHE . 13.4 t -99.5 140.91 17.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 119.645 -0.822 . . . . 0.0 112.341 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.576 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.3 m -133.49 114.83 14.05 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.276 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.886 HG13 HG12 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -85.31 150.38 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.264 -0.975 . . . . 0.0 111.651 -179.849 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.835 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tttt -130.53 85.91 2.33 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.815 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.447 ' HB3' ' CD1' ' A' ' 76' ' ' ILE . 21.0 t-20 -68.8 104.94 2.17 Favored 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 118.565 -1.254 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -105.8 -1.34 24.44 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.335 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.541 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.7 p -81.07 102.56 10.3 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.728 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.711 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 97.5 p -37.23 87.59 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 113.138 0.792 . . . . 0.0 113.138 -179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.541 ' N ' ' O ' ' A' ' 31' ' ' SER . . . -166.06 146.81 5.58 Favored Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.536 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -70.76 100.92 0.99 Allowed 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 121.027 1.152 . . . . 0.0 109.166 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -86.76 108.52 18.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.149 -1.42 . . . . 0.0 111.817 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -122.63 63.32 0.97 Allowed 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.32 142.54 13.47 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 107.42 -2.272 . . . . 0.0 107.42 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.683 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 40.7 p-90 -159.37 176.1 12.54 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 117.707 -1.597 . . . . 0.0 111.796 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.62 ' N ' HD22 ' A' ' 103' ' ' ASN . 0.3 OUTLIER -140.01 111.93 7.5 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.982 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.843 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.61 178.47 4.62 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.794 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.523 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.26 152.06 16.28 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.245 -1.382 . . . . 0.0 112.413 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' ' N ' ' A' ' 43' ' ' SER . 17.3 p90 -177.12 -150.09 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 113.919 -1.491 . . . . 0.0 108.408 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.549 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 42.7 m -162.16 161.95 28.23 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 118.046 -1.462 . . . . 0.0 112.026 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.613 ' CE2' HG21 ' A' ' 65' ' ' VAL . 16.5 m-85 -91.7 116.25 66.09 Favored Pre-proline 0 N--CA 1.484 1.275 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.005 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.08 -67.82 0.05 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 121.539 1.492 . . . . 0.0 112.938 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.52 ' HB3' ' H ' ' A' ' 93' ' ' THR . 19.7 m -68.74 -132.72 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.515 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -117.33 58.74 0.49 Allowed Glycine 0 N--CA 1.503 3.109 0 C-N-CA 119.631 -1.271 . . . . 0.0 111.715 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.7 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 tt0 -110.48 114.84 28.58 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.961 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.539 HE21 ' HA ' ' A' ' 49' ' ' GLN . 5.2 mm-40 -118.22 136.95 53.34 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 120.131 -0.628 . . . . 0.0 111.291 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 51' ' ' THR . 6.2 p -96.3 156.9 3.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.269 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.587 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -138.56 -59.53 0.62 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 119.598 -0.841 . . . . 0.0 111.059 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.587 ' H ' HG23 ' A' ' 51' ' ' THR . 0.8 OUTLIER -90.32 131.08 36.31 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.499 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.78 160.39 40.82 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.119 -1.032 . . . . 0.0 112.476 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.466 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 39.1 t-105 -155.33 149.46 25.78 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.676 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.466 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.3 t 66.07 20.07 11.2 Favored 'General case' 0 C--N 1.316 -0.877 0 C-N-CA 119.649 -0.82 . . . . 0.0 109.573 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.449 ' HG ' ' HD2' ' A' ' 84' ' ' PHE . 5.5 p -173.25 123.84 0.4 Allowed 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.921 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -80.33 77.88 7.06 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.321 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.447 HG12 HG13 ' A' ' 67' ' ' VAL . 2.2 m -72.6 152.62 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.538 -0.755 . . . . 0.0 112.277 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 40.7 p -150.06 109.15 3.91 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.883 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.522 ' OE1' ' NE2' ' A' ' 49' ' ' GLN . 33.0 tt0 -87.45 114.75 24.35 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.074 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.453 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.3 p -91.41 81.23 5.43 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.864 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.09 -69.74 1.88 Allowed Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.403 -1.379 . . . . 0.0 110.074 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.5 t -139.13 -19.06 0.99 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.858 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -86.65 -173.81 4.68 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.815 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.613 HG21 ' CE2' ' A' ' 44' ' ' PHE . 49.7 t -145.13 160.66 13.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 C-N-CA 118.77 -1.172 . . . . 0.0 113.226 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.571 ' N ' HG12 ' A' ' 65' ' ' VAL . 11.6 m -159.36 129.61 5.72 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.889 -1.505 . . . . 0.0 108.121 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.64 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -125.3 146.89 30.23 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.004 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.849 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -130.47 93.33 3.43 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.683 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 2.2 p-10 -73.74 117.63 15.75 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.229 -0.988 . . . . 0.0 112.402 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.866 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -42.17 156.91 0.23 Allowed Pre-proline 0 N--CA 1.481 1.088 0 CA-C-N 113.537 -1.665 . . . . 0.0 111.876 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -59.99 -34.91 94.69 Favored 'Trans proline' 0 C--O 1.213 -0.736 0 C-N-CA 121.745 1.63 . . . . 0.0 112.065 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.726 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.92 -53.52 20.53 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.987 179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.866 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 25.1 p30 -79.67 12.78 2.39 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.496 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.467 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -133.6 20.71 4.1 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.516 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.4 m -94.53 60.57 2.62 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.395 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.538 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -113.49 131.81 22.8 Favored Pre-proline 0 N--CA 1.491 1.595 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.472 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.504 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -70.86 151.42 62.77 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.468 1.445 . . . . 0.0 114.19 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.711 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.03 -45.92 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.504 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -106.4 68.31 0.24 Allowed Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.883 -1.151 . . . . 0.0 111.084 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.19 23.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 118.398 -1.858 . . . . 0.0 111.384 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.835 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.2 p -132.39 162.15 31.83 Favored 'General case' 0 N--CA 1.482 1.172 0 CA-C-O 121.74 0.781 . . . . 0.0 112.686 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.03 174.21 9.05 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.439 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 26.6 tt0 -165.96 144.84 5.99 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 116.831 -1.948 . . . . 0.0 113.545 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.646 ' CE1' HG11 ' A' ' 25' ' ' VAL . 18.3 p90 -156.28 178.01 10.79 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.625 -1.171 . . . . 0.0 110.181 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -159.32 169.2 35.42 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 117.761 -2.162 . . . . 0.0 112.107 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 14.4 p90 -166.85 156.89 11.43 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.371 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -108.7 114.79 28.89 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.198 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.6 166.56 12.17 Favored Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.863 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 p -115.29 139.54 49.88 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.728 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.1 OUTLIER -150.61 175.28 12.07 Favored 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 117.332 -1.747 . . . . 0.0 113.423 -179.872 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.728 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.7 t -170.8 13.46 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 114.356 -1.293 . . . . 0.0 109.208 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.76 -93.69 1.67 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.743 -1.218 . . . . 0.0 111.352 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.94 HG22 ' H ' ' A' ' 94' ' ' ASN . 47.7 m -161.15 -122.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 118.955 -1.098 . . . . 0.0 112.17 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.94 ' H ' HG22 ' A' ' 93' ' ' THR . 10.7 p-10 -69.53 137.9 52.86 Favored 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.81 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.466 ' CB ' ' CD ' ' A' ' 48' ' ' GLN . . . -110.97 -98.28 0.41 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.726 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.594 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -32.75 108.63 0.3 Allowed Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.109 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.483 ' HD2' ' CE2' ' A' ' 100' ' ' PHE . 1.9 Cg_endo -64.91 -137.3 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 121.312 1.341 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.489 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 30.9 p -121.09 -59.74 1.7 Allowed 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.309 -0.956 . . . . 0.0 113.027 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.489 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.36 100.06 8.74 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.078 -1.049 . . . . 0.0 112.29 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.502 ' N ' ' O ' ' A' ' 107' ' ' CYS . 19.3 m-85 -72.64 -169.12 0.51 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.5 m -143.5 122.5 12.81 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 117.888 -1.525 . . . . 0.0 112.469 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.949 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -80.81 174.54 11.52 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.538 -0.865 . . . . 0.0 109.243 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.62 HD22 ' N ' ' A' ' 39' ' ' THR . 34.1 m120 -34.61 89.18 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.324 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.073 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 60.45 57.7 17.71 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.466 -1.35 . . . . 0.0 110.744 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.776 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -178.24 148.61 0.64 Allowed Pre-proline 0 C--O 1.201 -1.454 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.244 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.41 176.55 3.27 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 121.647 1.565 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.538 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.3 t -173.57 99.06 0.11 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.099 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.97 173.98 0.55 Allowed 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.037 -0.665 . . . . 0.0 112.29 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -71.24 -91.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.592 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 CA-C-O 116.364 -2.353 . . . . 0.0 110.287 -179.985 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.52 -60.95 1.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.658 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.5 t -76.42 -173.74 2.61 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.89 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -99.45 -178.11 31.28 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.468 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HG2' HG22 ' A' ' 105' ' ' THR . 12.0 Cg_exo -54.08 -61.58 0.41 Allowed 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.238 1.959 . . . . 0.0 112.182 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . -95.74 -173.97 3.01 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.697 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.11 44.98 0.22 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 p -53.27 179.0 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.668 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.52 118.29 12.38 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.096 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.568 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.2 m -108.88 125.97 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.28 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.547 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.53 8.77 Favored 'General case' 0 C--N 1.292 -1.9 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.673 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.71 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 4.8 t-105 -125.44 143.01 51.19 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.769 -0.772 . . . . 0.0 111.785 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.14 72.48 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.62 151.61 9.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.916 0.865 . . . . 0.0 113.266 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.544 ' CB ' HG22 ' A' ' 22' ' ' THR . 0.7 OUTLIER -162.1 101.42 1.11 Allowed 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.005 179.787 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.517 ' C ' ' CD ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -129.87 166.0 20.87 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 122.556 1.169 . . . . 0.0 113.773 -179.761 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.639 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 32.9 p90 -126.22 -126.67 0.24 Allowed 'General case' 0 C--N 1.287 -2.137 0 CA-C-N 112.646 -2.07 . . . . 0.0 108.85 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.639 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 43.3 m-80 -77.26 72.78 3.83 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 19' ' ' THR . 0.3 OUTLIER 70.42 117.73 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.694 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' ' CZ2' ' A' ' 17' ' ' TRP . . . 125.88 96.34 1.03 Allowed Glycine 0 C--N 1.284 -2.346 0 N-CA-C 105.672 -2.971 . . . . 0.0 105.672 -179.593 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.1 p90 -113.46 119.56 38.02 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 -179.551 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.544 HG22 ' CB ' ' A' ' 15' ' ' ASN . 6.2 t -70.53 168.92 15.24 Favored 'General case' 0 C--N 1.283 -2.317 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.09 118.74 10.43 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.157 -1.417 . . . . 0.0 112.626 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -104.28 90.93 3.71 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 84' ' ' PHE . 11.5 t -92.73 133.03 35.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.703 -0.799 . . . . 0.0 112.275 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.6 m -119.17 107.2 13.17 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.522 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 82' ' ' ALA . 2.9 t -78.29 144.27 11.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 119.149 -1.021 . . . . 0.0 110.68 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.567 ' HA ' HG22 ' A' ' 81' ' ' THR . 13.4 tptm -135.37 103.05 5.35 Favored 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.859 -0.736 . . . . 0.0 109.576 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.606 ' HB3' HD11 ' A' ' 76' ' ' ILE . 44.7 t-20 -100.33 124.37 45.72 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.088 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.6 t -135.78 -2.65 2.36 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.011 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.525 ' H ' ' HG ' ' A' ' 31' ' ' SER . 4.3 p -52.19 -80.96 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 119.291 -0.963 . . . . 0.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.08 61.04 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 123.657 0.598 . . . . 0.0 110.803 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 1.027 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -152.72 134.43 8.52 Favored Pre-proline 0 C--N 1.306 -1.283 0 C-N-CA 119.044 -1.063 . . . . 0.0 110.45 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.64 106.7 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 120.922 1.081 . . . . 0.0 110.269 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.552 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.5 t -87.77 67.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 118.639 -1.224 . . . . 0.0 111.809 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -88.16 65.08 7.99 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 101.03 145.6 17.37 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 107.046 -2.421 . . . . 0.0 107.046 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.695 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 49.7 p-90 -162.31 174.61 12.59 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 116.976 -1.89 . . . . 0.0 112.666 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -142.87 99.21 3.42 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.862 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.878 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -87.05 173.34 9.34 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 118.328 -1.349 . . . . 0.0 109.439 179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.477 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -158.12 147.78 19.81 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 117.907 -1.517 . . . . 0.0 112.441 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.594 ' CG ' ' N ' ' A' ' 43' ' ' SER . 10.8 p90 -173.79 -137.29 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.958 -1.474 . . . . 0.0 108.043 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.594 ' N ' ' CG ' ' A' ' 42' ' ' PHE . 41.8 m -161.06 174.33 13.89 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 117.563 -1.655 . . . . 0.0 112.455 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.758 ' CD2' HG21 ' A' ' 65' ' ' VAL . 1.9 m-85 -114.47 95.93 41.54 Favored Pre-proline 0 N--CA 1.496 1.873 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.189 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.451 ' C ' ' H ' ' A' ' 47' ' ' GLY . 5.0 Cg_exo -60.05 -40.9 57.11 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 121.261 1.307 . . . . 0.0 111.676 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.3 t -74.96 15.45 0.4 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.563 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 45' ' ' PRO . . . 55.79 29.38 54.62 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.233 -1.46 . . . . 0.0 110.133 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.692 ' NE2' ' HB1' ' A' ' 95' ' ' ALA . 7.3 mt-30 -61.07 116.47 4.55 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.8 mm-40 -95.5 97.77 10.03 Favored 'General case' 0 N--CA 1.484 1.275 0 C-N-CA 119.359 -0.937 . . . . 0.0 110.621 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 51' ' ' THR . 0.9 OUTLIER -64.47 157.58 4.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.177 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 40.4 p -133.05 -64.45 0.74 Allowed 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.755 -0.778 . . . . 0.0 111.259 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.551 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.7 mt-30 -90.58 173.98 7.76 Favored 'General case' 0 N--CA 1.494 1.74 0 C-N-CA 118.87 -1.132 . . . . 0.0 110.133 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -173.2 147.46 1.56 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.961 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.474 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 37.2 t-105 -151.2 143.7 24.26 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.713 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.474 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.3 OUTLIER 60.57 27.53 17.21 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.753 -179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.468 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -174.85 122.62 0.24 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.566 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -84.84 77.63 10.05 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 118.987 -1.085 . . . . 0.0 109.462 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.417 ' C ' HG23 ' A' ' 59' ' ' THR . 13.6 m -69.23 152.57 9.34 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.296 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 58' ' ' VAL . 36.9 p -155.24 119.27 4.6 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.074 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -91.53 116.92 29.26 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.906 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.456 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.2 p -90.52 77.35 6.48 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.685 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.36 -68.71 2.06 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.41 -1.376 . . . . 0.0 110.156 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -138.27 -17.16 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.903 -0.719 . . . . 0.0 110.291 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.52 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -91.68 -172.44 3.22 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.988 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.758 HG21 ' CD2' ' A' ' 44' ' ' PHE . 46.1 t -143.83 162.27 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.0 -1.08 . . . . 0.0 113.462 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.612 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 23.5 m -157.79 137.24 11.94 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.573 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.468 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.8 t -131.8 116.33 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 C-N-CA 119.1 -1.04 . . . . 0.0 112.192 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.422 HH11 ' CB ' ' A' ' 68' ' ' ARG . 0.3 OUTLIER -99.53 96.06 7.41 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.269 -1.332 . . . . 0.0 108.74 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.793 ' HB2' HD22 ' A' ' 73' ' ' ASN . 1.6 p-10 -76.02 120.11 20.89 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.836 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.706 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.28 160.62 0.12 Allowed Pre-proline 0 N--CA 1.483 1.192 0 CA-C-N 113.44 -1.709 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -64.89 -38.6 28.83 Favored 'Trans proline' 0 C--O 1.211 -0.844 0 C-N-CA 122.106 1.87 . . . . 0.0 112.229 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.11 -54.69 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.581 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.793 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.5 OUTLIER -76.13 5.84 6.23 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.032 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -128.4 50.25 0.9 Allowed Glycine 0 C--O 1.202 -1.901 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.1 m -118.98 61.66 0.8 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 119.78 -0.768 . . . . 0.0 111.303 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.831 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -120.46 109.02 36.97 Favored Pre-proline 0 CA--C 1.56 1.353 0 C-N-CA 119.963 -0.695 . . . . 0.0 111.312 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.633 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.3 Cg_endo -71.65 118.9 5.88 Favored 'Trans proline' 0 C--O 1.207 -1.063 0 C-N-CA 121.182 1.255 . . . . 0.0 111.389 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 1.027 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -7.65 68.07 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.694 1.246 . . . . 0.0 113.257 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.633 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . 170.18 46.1 0.03 OUTLIER Glycine 0 C--N 1.277 -2.722 0 CA-C-N 114.148 -1.387 . . . . 0.0 110.124 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -174.98 -152.92 9.61 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.021 -1.561 . . . . 0.0 110.192 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.567 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.9 p -140.77 173.64 11.29 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.26 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.666 ' O ' HG23 ' A' ' 27' ' ' VAL . . . -148.94 90.79 1.79 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.679 ' HB2' HG23 ' A' ' 26' ' ' THR . 8.5 tt0 -85.04 146.44 27.18 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 25' ' ' VAL . 12.0 p90 -155.03 175.56 13.67 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 113.997 -1.456 . . . . 0.0 108.851 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.7 176.82 41.12 Favored Glycine 0 N--CA 1.498 2.82 0 C-N-CA 117.489 -2.291 . . . . 0.0 112.532 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.489 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 6.8 p90 -163.68 -175.14 3.99 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.949 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -129.77 113.59 14.89 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 119.753 -0.779 . . . . 0.0 110.507 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.495 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.45 152.66 20.3 Favored Glycine 0 N--CA 1.504 3.199 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 p -94.23 135.52 35.53 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.165 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.427 ' NE2' ' HA ' ' A' ' 19' ' ' THR . 17.2 p80 -97.87 -166.17 1.35 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.303 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 36.4 p -145.78 -5.31 0.63 Allowed 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.081 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.66 73.12 1.14 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.594 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.687 HG22 ' OD1' ' A' ' 94' ' ' ASN . 88.7 m -161.17 -118.89 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.202 -0.999 . . . . 0.0 111.518 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.687 ' OD1' HG22 ' A' ' 93' ' ' THR . 1.6 p30 -129.9 121.1 25.98 Favored 'General case' 0 N--CA 1.497 1.875 0 C-N-CA 120.104 -0.639 . . . . 0.0 111.259 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.692 ' HB1' ' NE2' ' A' ' 48' ' ' GLN . . . -92.08 -113.56 0.09 Allowed 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.732 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.71 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -40.78 110.45 0.7 Allowed Pre-proline 0 N--CA 1.488 1.467 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.283 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.507 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -61.19 -95.72 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.909 1.073 . . . . 0.0 112.465 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 97' ' ' PRO . 6.9 p -155.04 -81.73 0.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.177 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -102.59 94.34 5.6 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.329 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.562 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -67.65 -150.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.209 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 19.4 m -157.12 110.72 2.6 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 117.215 -1.794 . . . . 0.0 113.59 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.575 HD22 HD21 ' A' ' 103' ' ' ASN . 2.5 mt -55.89 177.43 0.06 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.64 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.15 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.544 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -163.63 20.29 0.15 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 118.676 -1.726 . . . . 0.0 111.435 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.605 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 3.5 p -139.6 150.66 64.16 Favored Pre-proline 0 N--CA 1.501 2.087 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.561 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.83 163.82 17.98 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.437 1.425 . . . . 0.0 111.531 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.54 ' SG ' HG13 ' A' ' 10' ' ' VAL . 4.7 t -157.03 98.62 1.76 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.986 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 4.5 p -50.95 161.67 0.35 Allowed 'General case' 0 N--CA 1.498 1.957 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.828 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.946 HG22 ' H ' ' A' ' 110' ' ' GLY . 10.8 p -75.52 -135.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.038 -1.065 . . . . 0.0 109.648 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.946 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.13 0 CA-C-O 116.267 -2.407 . . . . 0.0 110.393 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.95 0.405 . . . . 0.0 110.07 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.478 ' C ' ' OG ' ' A' ' 3' ' ' SER . 0.4 OUTLIER 166.43 -86.23 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.668 179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.478 ' OG ' ' C ' ' A' ' 2' ' ' SER . 1.2 p 42.57 79.4 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 88.12 179.72 47.03 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.469 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -61.58 -81.25 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.167 1.912 . . . . 0.0 111.559 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.627 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -107.91 -162.88 0.85 Allowed 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.07 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 177.12 48.33 0.06 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -52.79 178.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.495 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.73 124.39 33.39 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.88 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.558 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.5 m -117.36 125.53 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.532 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.68 168.24 10.28 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.646 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.655 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.4 t-105 -134.31 143.44 47.72 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 119.43 -0.908 . . . . 0.0 112.601 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.66 73.73 0.45 Allowed Glycine 0 N--CA 1.496 2.677 0 N-CA-C 107.3 -2.32 . . . . 0.0 107.3 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.7 OUTLIER -69.93 162.46 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 113.867 1.062 . . . . 0.0 113.867 -179.621 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.466 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.0 t30 -170.13 101.32 0.28 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 113.686 -1.597 . . . . 0.0 108.689 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.476 ' C ' ' CD ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -121.47 164.56 16.97 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.97 -179.813 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.55 ' NE1' ' O ' ' A' ' 19' ' ' THR . 19.8 p90 -122.84 -137.07 0.3 Allowed 'General case' 0 N--CA 1.506 2.367 0 CA-C-N 113.593 -1.64 . . . . 0.0 110.532 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.435 ' H ' ' HB2' ' A' ' 17' ' ' TRP . 15.7 t-20 -46.02 -33.22 3.25 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 118.735 -1.186 . . . . 0.0 108.806 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.55 ' O ' ' NE1' ' A' ' 17' ' ' TRP . 0.4 OUTLIER 178.16 135.0 0.08 Allowed 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.368 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.423 ' H ' ' CD2' ' A' ' 90' ' ' HIS . . . 114.88 104.06 2.51 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 106.821 -2.512 . . . . 0.0 106.821 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.557 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 37.7 p90 -107.7 116.34 31.78 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 121.65 0.738 . . . . 0.0 112.62 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.466 HG22 ' HB3' ' A' ' 15' ' ' ASN . 14.8 t -71.81 168.58 17.54 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.655 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -150.18 118.88 6.55 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 117.675 -1.61 . . . . 0.0 112.701 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -100.42 95.82 7.0 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.662 HG11 ' CE2' ' A' ' 84' ' ' PHE . 18.6 t -94.91 141.5 14.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 C-N-CA 119.584 -0.847 . . . . 0.0 112.423 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.541 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.1 m -127.28 120.75 29.36 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.685 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 1.0 OUTLIER -90.55 148.34 4.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.719 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tptp -136.15 103.83 5.46 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.028 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.543 ' HB3' HD11 ' A' ' 76' ' ' ILE . 14.9 t-20 -95.71 132.56 40.78 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.519 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.7 t -139.48 -3.42 1.51 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.427 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 32' ' ' SER . 5.1 p -50.68 -82.15 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.505 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 161.54 69.7 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.478 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.02 154.13 4.99 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 118.518 -1.273 . . . . 0.0 111.499 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -73.18 99.51 1.12 Allowed 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 121.413 1.409 . . . . 0.0 109.598 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.418 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -78.32 81.94 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 118.381 -1.327 . . . . 0.0 111.902 -179.758 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -95.03 54.73 1.72 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 107.38 152.95 18.39 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 107.506 -2.238 . . . . 0.0 107.506 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 41.9 p-90 -163.31 174.09 12.46 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 117.13 -1.828 . . . . 0.0 112.502 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.36 98.16 3.54 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.124 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.867 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -84.9 171.84 11.86 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 118.168 -1.413 . . . . 0.0 109.635 179.945 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.469 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -155.92 142.99 19.08 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 118.673 -1.211 . . . . 0.0 111.63 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.585 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.1 p90 -172.1 -148.92 0.05 Allowed 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.625 -1.171 . . . . 0.0 108.606 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.585 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 65.6 m -159.08 157.71 31.58 Favored 'General case' 0 C--N 1.29 -2.005 0 C-N-CA 117.782 -1.567 . . . . 0.0 111.485 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.564 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.4 m-85 -88.31 114.35 59.15 Favored Pre-proline 0 N--CA 1.491 1.578 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.613 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 8.0 Cg_exo -53.94 -54.52 4.64 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 N-CA-C 108.654 -1.325 . . . . 0.0 108.654 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.608 ' HA ' ' H ' ' A' ' 93' ' ' THR . 2.4 t -72.61 163.13 28.55 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 118.777 -1.169 . . . . 0.0 108.063 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.582 ' H ' ' HA3' ' A' ' 92' ' ' GLY . . . -78.07 59.98 3.89 Favored Glycine 0 C--N 1.277 -2.72 0 C-N-CA 118.338 -1.887 . . . . 0.0 108.72 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.443 ' NE2' ' CB ' ' A' ' 90' ' ' HIS . 1.5 mt-30 -90.96 176.53 6.57 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.627 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -162.02 111.92 1.54 Allowed 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.838 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -68.91 157.89 6.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.504 -0.878 . . . . 0.0 111.311 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.509 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 62.2 p -134.71 -66.01 0.61 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.389 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.509 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.1 OUTLIER -83.96 168.98 15.49 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.414 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.33 152.72 7.4 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 118.327 -1.349 . . . . 0.0 112.272 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.43 ' CE2' ' HB2' ' A' ' 55' ' ' SER . 18.4 t-105 -146.72 132.21 18.69 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.626 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.43 ' HB2' ' CE2' ' A' ' 54' ' ' TRP . 2.2 t 58.57 33.18 22.89 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.095 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.5 114.79 0.47 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.376 -0.929 . . . . 0.0 110.672 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.8 m -80.91 74.85 7.88 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 118.87 -1.132 . . . . 0.0 108.929 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.428 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.6 m -69.07 168.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 114.966 -1.016 . . . . 0.0 112.843 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 59' ' ' THR . 10.0 t -170.18 123.57 0.71 Allowed 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.825 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -86.41 102.45 14.06 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.315 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.2 p -91.2 82.83 5.48 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.546 -0.862 . . . . 0.0 111.773 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.554 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 55.69 78.15 0.13 Allowed Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.481 -1.343 . . . . 0.0 110.861 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.2 p 67.59 -23.93 0.12 Allowed 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.825 -0.75 . . . . 0.0 111.487 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.554 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -90.95 -176.07 4.53 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.876 -1.129 . . . . 0.0 110.852 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' A' ' 66' ' ' THR . 33.1 t -149.26 160.11 5.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 118.844 -1.143 . . . . 0.0 113.6 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.572 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.1 m -154.51 154.58 33.36 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.024 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.467 ' HB ' HD22 ' A' ' 40' ' ' LEU . 7.1 t -147.85 117.85 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 118.511 -1.276 . . . . 0.0 112.197 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.24 90.42 5.11 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.441 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.695 ' HB2' HD22 ' A' ' 73' ' ' ASN . 1.7 p-10 -70.57 119.01 14.1 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.805 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.811 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.3 158.14 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.482 0 CA-C-N 113.477 -1.692 . . . . 0.0 112.628 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -65.48 -36.74 32.95 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 121.875 1.717 . . . . 0.0 112.072 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.811 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.4 -56.56 7.1 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 118.928 -1.109 . . . . 0.0 110.226 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.695 HD22 ' HB2' ' A' ' 69' ' ' ASN . 1.2 p-10 -70.22 -3.26 16.15 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.012 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -123.58 51.3 0.81 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 t -118.2 54.16 0.94 Allowed 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.677 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.69 135.58 20.73 Favored Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.297 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.3 Cg_endo -76.32 156.42 37.2 Favored 'Trans proline' 0 C--O 1.212 -0.793 0 C-N-CA 121.507 1.472 . . . . 0.0 112.306 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.407 ' C ' ' O ' ' A' ' 77' ' ' PRO . . . -28.5 -32.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.5 71.53 0.22 Allowed Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.984 -1.103 . . . . 0.0 110.771 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.442 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -164.54 -164.6 20.18 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 118.739 -1.696 . . . . 0.0 111.07 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 28' ' ' LYS . 11.6 p -139.99 167.78 21.33 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.99 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.437 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.66 -169.05 2.17 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.173 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -169.8 141.82 2.34 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 117.628 -1.629 . . . . 0.0 112.617 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.662 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.5 p90 -163.13 161.73 25.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -157.54 173.18 34.95 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 117.994 -2.051 . . . . 0.0 111.946 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.504 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 7.2 p90 -164.59 -174.63 3.5 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.506 -0.878 . . . . 0.0 111.328 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.497 HD22 ' HB3' ' A' ' 52' ' ' GLN . 70.8 m-80 -130.79 115.71 16.99 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.224 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.41 153.43 20.6 Favored Glycine 0 N--CA 1.511 3.639 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.834 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 9.0 p -84.63 144.22 28.74 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.64 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.582 ' O ' HG23 ' A' ' 91' ' ' THR . 18.9 p80 -111.94 119.66 39.29 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.334 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.582 HG23 ' O ' ' A' ' 90' ' ' HIS . 1.8 p -161.29 83.53 0.63 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.464 -0.895 . . . . 0.0 110.906 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.582 ' HA3' ' H ' ' A' ' 47' ' ' GLY . . . 175.72 -100.59 0.15 Allowed Glycine 0 N--CA 1.491 2.331 0 C-N-CA 118.199 -1.953 . . . . 0.0 112.411 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.608 ' H ' ' HA ' ' A' ' 46' ' ' SER . 19.6 m -153.53 112.85 3.79 Favored 'General case' 0 N--CA 1.491 1.625 0 C-N-CA 119.617 -0.833 . . . . 0.0 111.777 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.613 ' ND2' ' CB ' ' A' ' 45' ' ' PRO . 0.4 OUTLIER 60.78 122.32 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.259 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.408 -179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.58 -50.64 5.1 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 114.406 1.262 . . . . 0.0 114.406 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -94.15 118.55 67.16 Favored Pre-proline 0 N--CA 1.492 1.672 0 C-N-CA 118.936 -1.105 . . . . 0.0 113.489 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.494 ' HG2' ' CE2' ' A' ' 100' ' ' PHE . 2.3 Cg_endo -64.9 -144.9 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.764 0 C-N-CA 121.548 1.499 . . . . 0.0 111.514 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.622 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.8 p -134.67 -63.37 0.71 Allowed 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 119.696 -0.802 . . . . 0.0 111.873 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.622 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.2 106.98 16.62 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.622 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 12.4 m-85 -80.98 -168.83 1.95 Allowed 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.8 m -144.83 106.24 4.23 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 117.906 -1.517 . . . . 0.0 113.378 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -54.78 174.04 0.08 Allowed 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.236 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.408 ' ND2' ' O ' ' A' ' 103' ' ' ASN . 4.4 p-10 -57.84 79.95 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.205 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.22 9.02 40.14 Favored Glycine 0 N--CA 1.499 2.877 0 C-N-CA 119.625 -1.274 . . . . 0.0 112.447 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.627 ' HB ' ' H ' ' A' ' 6' ' ' ALA . 3.2 p -152.5 153.48 30.63 Favored Pre-proline 0 C--O 1.194 -1.847 0 C-N-CA 118.482 -1.287 . . . . 0.0 111.449 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -66.79 -179.51 1.69 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 121.679 1.586 . . . . 0.0 112.037 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.558 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.4 t -173.2 100.5 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.843 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.31 165.38 4.62 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.791 -0.764 . . . . 0.0 111.879 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.672 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 0.2 OUTLIER -75.11 172.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.012 179.635 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.672 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.178 0 CA-C-O 116.341 -2.366 . . . . 0.0 110.357 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.1 m -83.47 107.78 16.18 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.849 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.2 p -152.22 166.13 32.7 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.633 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.72 74.59 0.24 Allowed Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.101 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -66.83 -179.12 1.52 Allowed 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 121.819 1.679 . . . . 0.0 111.378 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.8 ' HB3' HG21 ' A' ' 105' ' ' THR . . . -110.9 -162.88 0.82 Allowed 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.848 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.46 55.25 0.06 OUTLIER Glycine 0 N--CA 1.502 3.078 0 N-CA-C 107.384 -2.286 . . . . 0.0 107.384 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -53.88 -165.46 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.503 1.144 . . . . 0.0 113.895 -179.747 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.572 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 13.5 mt-30 -145.03 89.84 1.99 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.455 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.538 ' CG1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 m -87.83 141.3 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.793 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.716 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -116.12 172.8 6.94 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.778 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.896 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 8.8 t-105 -133.14 147.84 52.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.768 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.13 87.85 0.32 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.94 141.03 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.578 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 55.2 t30 -150.37 71.11 1.04 Allowed 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.105 -0.952 . . . . 0.0 109.327 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.411 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 1.5 pm0 -92.17 147.38 22.98 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.18 -1.008 . . . . 0.0 113.707 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.765 ' C ' ' H ' ' A' ' 19' ' ' THR . 1.2 p90 -116.46 92.31 3.84 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 113.26 -1.791 . . . . 0.0 109.711 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.507 ' O ' ' CB ' ' A' ' 19' ' ' THR . 1.0 OUTLIER 63.79 -13.06 0.09 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 118.805 -1.158 . . . . 0.0 108.884 -179.746 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.765 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.8 OUTLIER 163.74 163.63 0.02 OUTLIER 'General case' 0 C--N 1.287 -2.114 0 CA-C-N 114.079 -1.419 . . . . 0.0 108.167 -179.791 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.514 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 73.53 89.6 0.16 Allowed Glycine 0 C--N 1.284 -2.353 0 N-CA-C 106.568 -2.613 . . . . 0.0 106.568 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.558 ' O ' ' CD2' ' A' ' 21' ' ' PHE . 35.9 p90 -95.38 117.31 30.11 Favored 'General case' 0 CA--C 1.49 -1.327 0 C-N-CA 119.791 -0.764 . . . . 0.0 112.607 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.555 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.5 OUTLIER -68.95 171.28 8.3 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 179.559 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.555 ' N ' HG23 ' A' ' 22' ' ' THR . . . -151.11 103.34 3.03 Favored 'General case' 0 C--N 1.29 -2.011 0 C-N-CA 117.754 -1.578 . . . . 0.0 112.468 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -91.26 98.88 11.99 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.675 HG11 ' CE2' ' A' ' 84' ' ' PHE . 8.4 t -97.19 139.81 18.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 119.706 -0.797 . . . . 0.0 112.669 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.716 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.2 OUTLIER -125.01 149.47 47.71 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.24 179.796 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.593 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.6 t -123.54 101.65 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.694 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.729 ' HA ' HG22 ' A' ' 81' ' ' THR . 35.3 tptt -87.85 101.95 14.22 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.014 -1.075 . . . . 0.0 110.054 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.504 ' HB3' HD11 ' A' ' 76' ' ' ILE . 14.4 t-20 -97.16 121.09 38.66 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.274 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -128.51 -1.02 5.57 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.708 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.9 p -47.04 -84.77 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.364 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.473 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 164.75 42.69 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.17 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.817 -179.949 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.929 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.71 153.17 42.64 Favored Pre-proline 0 N--CA 1.486 1.333 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.337 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -69.6 95.84 0.56 Allowed 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 121.36 1.373 . . . . 0.0 110.006 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.9 t -72.8 96.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.508 -1.277 . . . . 0.0 111.253 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -113.45 82.96 1.76 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.55 139.45 1.92 Allowed Glycine 0 C--N 1.292 -1.89 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.769 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 46.1 p-90 -159.87 176.18 12.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 117.895 -1.522 . . . . 0.0 111.935 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.417 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -142.35 110.03 5.78 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.587 179.925 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.21 173.55 6.74 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.842 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.452 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -154.94 147.72 24.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.01 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.7 p90 -173.26 -144.96 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.451 -1.25 . . . . 0.0 108.904 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.54 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.1 m -159.42 153.3 23.16 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 117.801 -1.56 . . . . 0.0 112.364 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.8 m-85 -84.32 117.56 69.03 Favored Pre-proline 0 N--CA 1.484 1.27 0 C-N-CA 118.825 -1.15 . . . . 0.0 108.23 179.762 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -57.68 -62.59 0.2 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.628 0.885 . . . . 0.0 110.717 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.496 ' OG ' ' N ' ' A' ' 93' ' ' THR . 34.9 t -77.91 -174.79 3.7 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.967 -1.093 . . . . 0.0 110.177 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.444 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.81 54.33 4.41 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 118.983 -1.58 . . . . 0.0 109.782 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.615 ' OE1' ' HB2' ' A' ' 95' ' ' ALA . 1.9 mt-30 -88.27 139.85 30.08 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 119.106 -1.037 . . . . 0.0 110.79 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.4 ' O ' ' CG ' ' A' ' 49' ' ' GLN . 1.7 pp0? -139.89 112.26 7.75 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.961 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.472 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.43 149.12 11.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.691 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.593 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 26.5 p -126.07 -61.92 1.2 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.898 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.593 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.0 tt0 -98.31 125.54 43.47 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.657 -0.817 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -130.76 160.04 35.51 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 119.445 -0.902 . . . . 0.0 112.388 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.4 ' NE1' ' HB3' ' A' ' 55' ' ' SER . 27.7 t-105 -151.86 143.93 23.87 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.428 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.424 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 4.7 p 54.74 31.93 16.43 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.686 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.501 ' HB2' ' CG ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -172.89 113.32 0.25 Allowed 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.219 -0.901 . . . . 0.0 109.744 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 m -80.12 77.16 6.85 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.211 -0.995 . . . . 0.0 110.361 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.423 HG12 HG13 ' A' ' 67' ' ' VAL . 3.5 m -71.73 156.03 7.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.401 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.405 HG23 ' C ' ' A' ' 58' ' ' VAL . 64.1 p -155.65 118.18 4.19 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.232 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -81.02 108.24 14.53 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.464 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 p -97.89 94.28 6.81 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.381 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.581 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 47.88 72.58 0.42 Allowed Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.043 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.408 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 68.26 -24.12 0.13 Allowed 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.964 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.581 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -84.93 -172.38 4.15 Favored 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 118.746 -1.182 . . . . 0.0 110.424 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 66' ' ' THR . 75.7 t -142.38 158.68 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.865 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.548 ' N ' HG12 ' A' ' 65' ' ' VAL . 20.3 m -160.0 124.37 3.8 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.384 -1.28 . . . . 0.0 108.649 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.622 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -121.66 148.21 25.23 Favored 'Isoleucine or valine' 0 C--O 1.194 -1.859 0 C-N-CA 119.569 -0.852 . . . . 0.0 111.885 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -130.13 92.91 3.37 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.769 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 13.1 p-10 -71.13 121.02 17.55 Favored 'General case' 0 C--N 1.299 -1.619 0 C-N-CA 119.354 -0.938 . . . . 0.0 111.669 -179.712 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.824 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -47.71 170.7 0.09 OUTLIER Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.611 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.824 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.7 Cg_endo -68.41 -38.98 10.46 Favored 'Trans proline' 0 C--N 1.322 -0.816 0 C-N-CA 122.163 1.908 . . . . 0.0 112.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.522 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.71 -54.03 15.73 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.063 -1.055 . . . . 0.0 111.335 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.658 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.7 OUTLIER -75.7 14.73 0.59 Allowed 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.222 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -145.54 34.11 1.51 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 119.284 -1.436 . . . . 0.0 111.319 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.0 m -102.85 58.63 0.78 Allowed 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.584 -0.846 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.523 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -111.98 132.49 21.98 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 119.896 -0.721 . . . . 0.0 111.661 -179.915 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.584 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.9 Cg_endo -69.53 156.26 64.46 Favored 'Trans proline' 0 C--O 1.208 -0.978 0 C-N-CA 121.211 1.274 . . . . 0.0 110.14 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.929 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -41.52 -14.41 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.83 66.85 0.26 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -173.61 -161.51 23.92 Favored Glycine 0 N--CA 1.494 2.534 0 C-N-CA 118.361 -1.876 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.729 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.0 p -139.37 158.17 44.61 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 119.342 -0.943 . . . . 0.0 112.701 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.593 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -124.19 173.94 8.0 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.481 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 9.6 tt0 -169.08 145.79 3.52 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 116.881 -1.928 . . . . 0.0 113.207 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.675 ' CE2' HG11 ' A' ' 25' ' ' VAL . 11.2 p90 -154.98 175.83 13.3 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 114.671 -1.149 . . . . 0.0 109.469 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.18 164.65 37.69 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 116.935 -2.555 . . . . 0.0 112.593 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 3.4 p90 -157.03 -170.23 3.22 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.399 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -135.58 114.84 12.42 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.005 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -125.35 150.16 17.25 Favored Glycine 0 N--CA 1.508 3.475 0 C-N-CA 119.408 -1.377 . . . . 0.0 112.342 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 84.9 p -86.28 152.2 22.96 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.072 -0.651 . . . . 0.0 109.902 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.548 ' NE2' ' HA ' ' A' ' 19' ' ' THR . 24.7 p80 -137.27 156.51 48.18 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.516 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 91' ' ' THR . 15.3 t -171.13 36.95 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.591 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -156.75 -115.57 0.48 Allowed Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.629 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.496 ' N ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -86.75 -153.63 0.21 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 120.163 -0.615 . . . . 0.0 112.017 -179.763 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.413 ' H ' ' HB ' ' A' ' 93' ' ' THR . 0.0 OUTLIER -88.45 -179.41 6.08 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.744 -0.782 . . . . 0.0 111.374 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.615 ' HB2' ' OE1' ' A' ' 48' ' ' GLN . . . -110.88 -132.14 0.32 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.006 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.896 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -8.73 108.31 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.485 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.417 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.498 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.0 OUTLIER -65.2 -101.4 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 121.14 1.226 . . . . 0.0 112.468 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.52 ' HA ' HG13 ' A' ' 109' ' ' VAL . 81.4 p -150.1 -66.07 0.21 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 118.897 -1.121 . . . . 0.0 112.265 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.479 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -109.93 103.57 12.36 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.594 -0.843 . . . . 0.0 110.662 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 14.4 m-85 -74.57 -169.67 0.89 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.253 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.4 m -136.57 93.61 2.9 Favored 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 118.667 -1.213 . . . . 0.0 112.726 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.574 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.4 mt -52.53 173.54 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.545 -0.862 . . . . 0.0 108.956 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.486 ' OD1' HD22 ' A' ' 102' ' ' LEU . 2.5 p-10 -45.14 90.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.014 -1.074 . . . . 0.0 110.608 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.06 58.22 12.67 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.443 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.8 HG21 ' HB3' ' A' ' 6' ' ' ALA . 0.8 OUTLIER 175.48 139.58 0.2 Allowed Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.869 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.9 167.13 4.52 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 121.551 1.501 . . . . 0.0 112.65 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -164.36 82.33 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.438 HG23 ' H ' ' A' ' 108' ' ' THR . 50.1 p -46.61 167.95 0.02 OUTLIER 'General case' 0 N--CA 1.517 2.88 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.52 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.0 OUTLIER -66.7 -160.08 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.113 -1.035 . . . . 0.0 109.69 179.562 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.099 0 CA-C-O 116.333 -2.37 . . . . 0.0 110.386 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.133 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 50.0 -142.1 0.66 Allowed 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.922 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 p -124.1 86.36 2.56 Favored 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.74 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.33 74.34 0.29 Allowed Glycine 0 N--CA 1.49 2.234 0 C-N-CA 119.388 -1.386 . . . . 0.0 110.402 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.19 -156.57 0.02 OUTLIER 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 121.661 1.574 . . . . 0.0 111.444 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.618 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -90.29 -154.57 0.34 Allowed 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.911 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.79 49.35 0.05 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.5 p -53.23 -179.31 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.618 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.402 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 81.8 mt-30 -137.03 113.09 9.73 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.547 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.644 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -108.77 130.82 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.976 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.578 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -103.88 167.38 9.81 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.104 179.94 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.472 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.6 t-105 -130.59 145.45 51.89 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.031 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.18 73.14 0.47 Allowed Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -72.43 153.04 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.564 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.2 t30 -157.23 92.87 1.28 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 114.323 -1.308 . . . . 0.0 108.742 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.502 ' C ' ' CD ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -97.64 158.35 15.55 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 121.764 0.792 . . . . 0.0 112.336 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.444 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.9 OUTLIER -123.26 -107.88 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.136 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -67.44 -27.06 66.73 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.468 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.697 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -174.96 -55.2 0.01 OUTLIER 'General case' 0 C--O 1.203 -1.368 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.274 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.697 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -50.33 158.23 1.82 Allowed Glycine 0 CA--C 1.484 -1.852 0 C-N-CA 119.355 -1.402 . . . . 0.0 109.632 -179.753 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.592 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 3.1 p90 -134.52 117.25 16.0 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.629 -179.77 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.564 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.0 t -75.33 173.84 10.35 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.472 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -158.1 117.01 3.14 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 117.22 -1.792 . . . . 0.0 113.358 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -99.89 101.54 12.69 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.457 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.8 t -99.63 147.05 7.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.58 -0.848 . . . . 0.0 112.802 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.599 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -138.9 110.35 7.0 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.345 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.615 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -83.23 149.81 4.43 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 C-N-CA 119.724 -0.79 . . . . 0.0 112.201 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.417 ' HB2' HG22 ' A' ' 81' ' ' THR . 2.2 tttm -142.19 106.97 4.87 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.802 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.698 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.3 t30 -93.22 120.17 33.21 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 118.971 -1.092 . . . . 0.0 108.594 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -123.15 -2.77 8.58 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 124.219 0.95 . . . . 0.0 109.818 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.529 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -53.35 -81.4 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.801 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.509 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.52 73.53 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.383 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.26 143.32 1.93 Allowed Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.089 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -68.32 101.88 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.42 109.28 18.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 118.281 -1.367 . . . . 0.0 111.643 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -117.38 73.63 0.89 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.06 143.75 11.75 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.671 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 41.4 p-90 -162.48 177.31 9.6 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 117.761 -1.576 . . . . 0.0 112.098 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -138.45 112.97 8.86 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.379 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.72 173.29 6.37 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 119.285 -0.966 . . . . 0.0 109.326 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.528 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -167.18 159.2 12.68 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.762 -1.575 . . . . 0.0 112.638 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.528 ' N ' ' CG2' ' A' ' 41' ' ' THR . 23.5 p90 -176.71 -134.49 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.63 -1.623 . . . . 0.0 107.954 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.483 ' OG ' ' C ' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -163.0 139.12 7.11 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.685 -1.606 . . . . 0.0 112.237 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.748 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.7 m-85 -69.28 122.28 84.9 Favored Pre-proline 0 N--CA 1.486 1.344 0 C-N-CA 118.838 -1.145 . . . . 0.0 108.465 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -52.68 -68.76 0.07 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.343 1.362 . . . . 0.0 112.729 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.455 ' HB3' ' CG2' ' A' ' 93' ' ' THR . 2.5 p -69.42 -68.58 0.4 Allowed 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 119.173 -1.011 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.13 26.71 0.02 OUTLIER Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.222 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.637 ' CD ' ' HB2' ' A' ' 95' ' ' ALA . 1.1 mp0 -43.73 144.6 0.8 Allowed 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.614 -0.834 . . . . 0.0 110.847 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -110.54 82.95 1.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.508 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.7 p -61.68 147.75 10.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.398 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.498 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 68.5 p -136.77 -71.91 0.44 Allowed 'General case' 0 N--CA 1.497 1.879 0 C-N-CA 119.181 -1.007 . . . . 0.0 112.157 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.498 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -76.6 145.72 38.74 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.935 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -156.19 153.86 29.9 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.733 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.443 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.2 t-105 -152.55 147.98 26.83 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.182 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 71.27 14.3 6.56 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.686 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.587 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 31.3 t -174.1 151.2 1.66 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.396 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -102.66 84.58 2.43 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.699 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -85.43 163.13 2.76 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.963 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.8 t -164.21 132.26 3.47 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.613 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.87 113.27 24.81 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.698 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.894 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.5 p -84.28 68.33 10.14 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.722 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.31 -63.74 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.5 m -142.19 -16.7 0.75 Allowed 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 120.062 -0.655 . . . . 0.0 109.269 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.47 -172.89 3.95 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.252 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.748 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 94.6 t -146.15 153.1 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 118.79 -1.164 . . . . 0.0 112.587 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.451 ' N ' HG12 ' A' ' 65' ' ' VAL . 3.6 m -159.89 135.87 8.64 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 114.909 -1.042 . . . . 0.0 108.976 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.631 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.0 t -129.46 153.36 38.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.943 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.49 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -135.91 89.29 2.47 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.671 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 3.9 p-10 -70.86 118.53 13.75 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.162 -1.015 . . . . 0.0 112.08 -179.582 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.774 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.07 154.83 0.12 Allowed Pre-proline 0 N--CA 1.484 1.237 0 CA-C-N 113.731 -1.577 . . . . 0.0 112.012 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -64.69 -35.14 48.14 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 121.942 1.762 . . . . 0.0 112.626 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.774 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.59 -57.36 5.28 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.775 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.601 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -69.83 -13.18 62.14 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.106 -1.038 . . . . 0.0 109.911 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.424 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -99.08 22.12 42.46 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.621 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 m -87.53 58.65 5.05 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.002 . . . . 0.0 111.271 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.916 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -108.96 115.39 57.18 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.171 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' GLY . 2.0 Cg_endo -67.96 159.45 52.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 121.317 1.345 . . . . 0.0 113.745 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.509 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -24.08 -38.55 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 114.332 -1.304 . . . . 0.0 114.058 179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.07 68.56 0.33 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -155.35 -168.22 18.14 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 118.857 -1.639 . . . . 0.0 110.284 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.516 ' N ' HG13 ' A' ' 76' ' ' ILE . 22.0 p -141.96 164.37 30.36 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.085 -1.046 . . . . 0.0 112.819 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.578 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.68 -179.95 5.6 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.476 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.599 ' HB2' HG23 ' A' ' 26' ' ' THR . 2.8 tm0? -170.24 151.53 3.89 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 116.883 -1.927 . . . . 0.0 113.101 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.457 ' CE1' HG11 ' A' ' 25' ' ' VAL . 5.6 p90 -167.64 171.49 10.16 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.32 160.89 30.5 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.729 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.604 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.4 p90 -150.1 160.42 43.67 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.308 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.4 m-20 -115.62 110.93 19.89 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.428 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -105.6 176.5 22.33 Favored Glycine 0 N--CA 1.501 3.012 0 C-N-CA 119.491 -1.338 . . . . 0.0 111.972 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -127.29 134.47 50.03 Favored 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.393 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.743 ' ND1' ' N ' ' A' ' 92' ' ' GLY . 1.7 p80 -150.18 -159.7 1.07 Allowed 'General case' 0 N--CA 1.502 2.145 0 C-N-CA 117.754 -1.579 . . . . 0.0 112.627 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.612 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -127.62 -2.96 6.05 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.115 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.743 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 111.81 90.09 1.92 Allowed Glycine 0 N--CA 1.504 3.226 0 C-N-CA 119.882 -1.152 . . . . 0.0 110.905 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.475 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.6 OUTLIER -165.85 167.47 16.79 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.514 -0.875 . . . . 0.0 110.961 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -70.13 115.63 9.56 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.662 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.637 ' HB2' ' CD ' ' A' ' 48' ' ' GLN . . . -111.28 -3.63 15.26 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.998 -0.681 . . . . 0.0 112.177 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -110.1 107.11 58.68 Favored Pre-proline 0 N--CA 1.492 1.637 0 C-N-CA 119.556 -0.857 . . . . 0.0 111.901 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.447 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -68.16 -145.02 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 121.244 1.296 . . . . 0.0 111.287 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.879 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.2 p -116.74 -87.91 0.6 Allowed 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 119.667 -0.813 . . . . 0.0 112.259 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.63 107.11 18.67 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.237 -0.985 . . . . 0.0 112.018 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.1 m-30 -78.6 -155.98 0.09 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.63 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.9 m -159.53 122.73 3.63 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 117.043 -1.863 . . . . 0.0 113.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.591 HD22 HD21 ' A' ' 103' ' ' ASN . 3.3 mt -60.65 -178.61 0.1 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.564 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.718 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.09 -41.24 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -155.69 27.7 0.59 Allowed Glycine 0 N--CA 1.495 2.604 0 C-N-CA 118.593 -1.765 . . . . 0.0 111.352 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.618 ' HB ' ' H ' ' A' ' 6' ' ' ALA . 21.3 p -145.07 151.6 49.02 Favored Pre-proline 0 N--CA 1.494 1.752 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.229 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -62.26 174.49 2.59 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 121.628 1.552 . . . . 0.0 112.451 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.644 ' SG ' HG13 ' A' ' 10' ' ' VAL . 3.0 t -168.19 106.38 0.49 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.471 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 41.4 p -72.63 146.08 46.86 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.971 -0.692 . . . . 0.0 112.403 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.879 HG13 ' O ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -59.32 -167.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.257 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 CA-C-O 116.339 -2.367 . . . . 0.0 110.296 179.986 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.162 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.511 ' OG ' ' N ' ' A' ' 3' ' ' SER . 13.5 p 44.98 -142.6 0.22 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.813 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.511 ' N ' ' OG ' ' A' ' 2' ' ' SER . 2.5 m 53.35 77.84 0.16 Allowed 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.381 -0.928 . . . . 0.0 111.005 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.98 -172.97 0.47 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.372 -1.394 . . . . 0.0 110.078 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -67.28 173.98 7.81 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 121.799 1.666 . . . . 0.0 110.819 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.631 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -110.43 -162.49 0.8 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.445 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.69 40.04 0.19 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.6 p -50.88 177.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 114.33 -0.935 . . . . 0.0 112.319 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -131.78 121.64 24.51 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.11 -1.404 . . . . 0.0 109.614 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.491 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 m -112.46 127.01 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.603 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.524 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.56 171.38 7.6 Favored 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.055 179.881 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.695 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.2 t-105 -132.25 149.28 52.41 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.706 -0.798 . . . . 0.0 112.042 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.29 83.55 0.32 Allowed Glycine 0 N--CA 1.497 2.726 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.78 144.75 12.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.421 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 10.5 t-20 -148.67 100.72 3.14 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 114.165 -1.38 . . . . 0.0 107.619 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.685 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -102.49 149.61 24.22 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 114.969 1.47 . . . . 0.0 114.969 -179.568 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.652 ' O ' ' N ' ' A' ' 19' ' ' THR . 30.0 p90 -142.54 117.05 9.69 Favored 'General case' 0 C--N 1.293 -1.876 0 CA-C-N 113.217 -1.81 . . . . 0.0 106.245 179.463 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 52.05 -89.46 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 118.214 -1.394 . . . . 0.0 107.341 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.4 OUTLIER -144.84 106.17 4.22 Favored 'General case' 0 C--N 1.281 -2.411 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 179.505 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.4 ' N ' ' NE2' ' A' ' 90' ' ' HIS . . . 156.22 101.36 0.18 Allowed Glycine 0 C--N 1.272 -2.98 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.685 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 24.2 p90 -95.05 118.17 31.41 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.324 -179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -83.87 165.37 18.8 Favored 'General case' 0 C--N 1.284 -2.256 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.623 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.691 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -145.56 106.34 4.12 Favored 'General case' 0 C--N 1.29 -2.014 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.899 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -93.35 96.84 10.2 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.567 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.9 t -93.46 147.39 5.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 115.383 -0.826 . . . . 0.0 113.007 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.524 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.3 m -133.36 127.12 32.8 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.5 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -97.73 145.95 8.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.989 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.655 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.2 tptt -126.97 100.56 6.19 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.835 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.473 ' OD1' ' C ' ' A' ' 29' ' ' ASN . 5.7 t-20 -93.7 119.72 33.06 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.561 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 t -130.53 -0.92 4.4 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.8 p -50.52 -83.01 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.29 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.38 67.78 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.64 -179.943 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.09 157.94 7.37 Favored Pre-proline 0 N--CA 1.482 1.127 0 C-N-CA 118.372 -1.331 . . . . 0.0 111.625 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.65 95.79 0.96 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.588 1.525 . . . . 0.0 109.052 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -74.47 87.54 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 118.47 -1.292 . . . . 0.0 111.744 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -100.06 56.52 0.95 Allowed 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 115.374 -0.83 . . . . 0.0 108.868 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.03 150.28 19.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.689 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 42.0 p-90 -164.14 176.68 9.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 117.652 -1.619 . . . . 0.0 112.059 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.5 OUTLIER -141.28 110.11 6.11 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.545 179.907 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.865 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -99.34 177.0 5.33 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.264 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.505 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.9 150.77 13.69 Favored 'General case' 0 C--N 1.289 -2.024 0 C-N-CA 117.867 -1.533 . . . . 0.0 112.361 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' ' N ' ' A' ' 43' ' ' SER . 14.4 p90 -174.55 -145.99 0.03 OUTLIER 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.753 -1.567 . . . . 0.0 107.952 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.52 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 41.7 m -161.12 154.12 21.15 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 117.804 -1.558 . . . . 0.0 111.758 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.502 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -84.61 116.86 67.1 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.15 -53.89 4.3 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.16 1.24 . . . . 0.0 112.407 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.531 ' OG ' HG21 ' A' ' 93' ' ' THR . 14.0 t -74.36 -82.77 0.06 Allowed 'General case' 0 C--N 1.294 -1.842 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.087 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 175.45 25.13 0.03 OUTLIER Glycine 0 N--CA 1.486 2.025 0 C-N-CA 119.289 -1.434 . . . . 0.0 110.193 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.442 ' HG3' ' CE1' ' A' ' 21' ' ' PHE . 6.0 mp0 -43.04 121.86 2.26 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.524 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 4.5 mm-40 -93.81 84.78 4.64 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.959 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.451 ' H ' HG12 ' A' ' 50' ' ' VAL . 0.5 OUTLIER -64.63 148.57 11.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.554 179.786 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.493 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 76.0 p -137.78 -69.23 0.45 Allowed 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.37 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.493 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.5 mt-30 -73.36 161.51 30.38 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 118.842 -1.143 . . . . 0.0 110.024 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.62 142.16 3.05 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.323 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.432 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 38.8 t-105 -146.9 149.09 32.54 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.592 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.432 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 6.3 t 57.11 27.82 14.01 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 119.326 -0.95 . . . . 0.0 109.07 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.588 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -174.66 125.42 0.29 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.135 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -87.57 72.34 9.62 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.596 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 67' ' ' VAL . 2.6 m -71.92 153.18 7.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.33 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.404 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.0 t -153.95 134.94 13.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.944 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -100.51 120.2 39.65 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.285 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.0 p -100.58 80.48 2.21 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.706 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.56 2.53 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.468 -1.349 . . . . 0.0 109.956 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 41.8 t -146.77 -18.23 0.42 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.967 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -87.8 -170.66 3.09 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.155 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 66' ' ' THR . 79.1 t -148.02 160.64 7.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.917 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.8 m -158.65 125.95 4.94 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 114.392 -1.276 . . . . 0.0 108.642 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.589 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.6 t -116.98 146.68 21.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.08 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.674 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -130.18 92.44 3.29 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.689 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 2.0 p-10 -74.41 118.2 17.1 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.284 -0.966 . . . . 0.0 112.433 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.655 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -42.73 165.65 0.1 OUTLIER Pre-proline 0 N--CA 1.487 1.406 0 CA-C-N 113.578 -1.646 . . . . 0.0 112.483 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.619 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 4.9 Cg_endo -68.71 -33.03 22.34 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.058 1.839 . . . . 0.0 112.583 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.614 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.66 -57.7 4.84 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.477 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.655 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.4 p30 -73.26 -4.43 33.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 119.12 -1.032 . . . . 0.0 109.652 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -119.77 50.25 0.83 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.5 t -120.54 57.07 0.97 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 120.029 -0.669 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.543 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.02 134.61 22.13 Favored Pre-proline 0 N--CA 1.486 1.356 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.551 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -71.52 158.71 53.22 Favored 'Trans proline' 0 C--O 1.214 -0.713 0 C-N-CA 121.464 1.443 . . . . 0.0 112.814 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.449 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -31.44 -29.51 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -115.5 72.9 0.25 Allowed Glycine 0 N--CA 1.497 2.706 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.899 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.33 -167.47 27.03 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.793 -1.67 . . . . 0.0 110.809 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.655 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.5 p -138.35 160.01 40.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.088 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -122.56 -176.45 3.38 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.459 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -169.37 142.07 2.6 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 117.068 -1.853 . . . . 0.0 113.361 -179.946 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.567 ' CE1' HG11 ' A' ' 25' ' ' VAL . 7.5 p90 -159.12 174.14 15.34 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.054 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.0 168.33 39.7 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 117.638 -2.22 . . . . 0.0 112.521 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.9 p90 -152.94 -176.36 5.73 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.944 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.501 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 1.2 m120 -138.09 111.66 8.16 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.774 -0.771 . . . . 0.0 110.783 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -123.42 163.62 16.85 Favored Glycine 0 N--CA 1.507 3.379 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.892 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.6 p -94.87 132.1 40.05 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.796 179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.732 ' O ' HG23 ' A' ' 91' ' ' THR . 6.7 p80 -100.22 -161.55 0.88 Allowed 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.686 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.732 HG23 ' O ' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -166.27 0.92 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.436 179.933 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.451 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 98.71 75.34 1.2 Allowed Glycine 0 N--CA 1.496 2.634 0 C-N-CA 119.673 -1.251 . . . . 0.0 110.309 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.648 HG22 ' H ' ' A' ' 94' ' ' ASN . 1.7 m -163.91 -159.29 0.49 Allowed 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.063 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.648 ' H ' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -101.57 127.25 48.36 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.853 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.28 -108.12 0.35 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.935 -0.706 . . . . 0.0 111.585 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.695 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -38.72 109.23 0.5 Allowed Pre-proline 0 N--CA 1.488 1.445 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.961 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -65.29 -142.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 121.21 1.274 . . . . 0.0 110.772 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.621 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.0 p -116.25 -64.63 1.28 Allowed 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 119.45 -0.9 . . . . 0.0 112.593 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.621 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.03 112.15 23.97 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.288 -0.965 . . . . 0.0 111.333 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 8.9 m-85 -84.32 -164.17 0.91 Allowed 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.035 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.2 m -144.52 117.6 8.89 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 118.421 -1.312 . . . . 0.0 112.009 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.788 HD22 ' ND2' ' A' ' 103' ' ' ASN . 1.3 mt -68.38 -178.67 1.14 Allowed 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.581 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.788 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.5 OUTLIER -27.69 -37.46 0.01 OUTLIER 'General case' 0 N--CA 1.512 2.631 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.82 55.6 0.21 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.199 -1.477 . . . . 0.0 110.274 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.631 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 2.4 t -174.38 145.81 1.04 Allowed Pre-proline 0 C--O 1.196 -1.726 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.774 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -56.3 168.59 1.96 Allowed 'Trans proline' 0 C--N 1.324 -0.758 0 C-N-CA 121.511 1.474 . . . . 0.0 112.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.455 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.8 t -164.84 95.12 0.7 Allowed 'General case' 0 N--CA 1.494 1.74 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.118 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.463 ' OG1' ' N ' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -51.99 168.45 0.09 Allowed 'General case' 0 N--CA 1.501 2.075 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.203 -179.688 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 1.095 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.4 p -67.77 -151.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.442 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.871 0 CA-C-O 116.281 -2.4 . . . . 0.0 110.125 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.191 0 CA-C-O 120.874 0.369 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.97 19.91 3.88 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.791 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 t -78.54 -69.23 0.58 Allowed 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.41 -0.916 . . . . 0.0 111.103 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.66 72.13 0.02 OUTLIER Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.438 -1.363 . . . . 0.0 110.209 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.484 ' HB2' HG21 ' A' ' 105' ' ' THR . 4.9 Cg_exo -57.28 -80.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 121.841 1.694 . . . . 0.0 112.206 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.836 ' H ' HG21 ' A' ' 105' ' ' THR . . . -105.32 -160.78 0.77 Allowed 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 122.205 1.002 . . . . 0.0 112.396 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.635 ' O ' ' SG ' ' A' ' 8' ' ' CYS . . . -176.55 -79.79 0.05 OUTLIER Glycine 0 C--O 1.189 -2.714 0 N-CA-C 107.023 -2.431 . . . . 0.0 107.023 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.722 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 6.6 p 63.62 176.97 0.16 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.541 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 55.3 mt-30 -151.27 158.98 44.56 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.482 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.53 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.7 m -141.19 126.54 18.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.954 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.579 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.65 8.69 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.023 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.616 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 4.0 t-105 -126.73 144.11 51.04 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 123.895 0.747 . . . . 0.0 112.471 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.31 74.7 0.43 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.538 -2.225 . . . . 0.0 107.538 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 15' ' ' ASN . 7.2 p -69.77 152.52 9.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.472 ' N ' HG22 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -149.21 100.06 3.0 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 113.81 -1.541 . . . . 0.0 107.857 179.87 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.742 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -96.83 145.56 25.74 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 114.681 1.364 . . . . 0.0 114.681 -179.593 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.545 ' O ' ' N ' ' A' ' 19' ' ' THR . 16.6 p90 -129.58 -147.51 0.34 Allowed 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 105.777 -1.935 . . . . 0.0 105.777 179.439 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.477 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 74.4 m-20 -67.31 76.73 0.15 Allowed 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.717 -1.593 . . . . 0.0 106.783 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 65.56 114.07 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.606 ' H ' ' CD2' ' A' ' 90' ' ' HIS . . . 135.62 105.32 0.8 Allowed Glycine 0 C--N 1.275 -2.838 0 N-CA-C 107.089 -2.404 . . . . 0.0 107.089 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.742 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 32.5 p90 -96.56 124.52 40.58 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.654 -0.818 . . . . 0.0 112.047 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 22' ' ' THR . 0.9 OUTLIER -96.04 106.75 18.97 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.563 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.616 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -90.03 120.62 31.39 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -101.78 96.41 7.05 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 179.537 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 26' ' ' THR . 33.6 t -90.14 154.46 3.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.836 HG23 ' HB3' ' A' ' 83' ' ' GLN . 1.9 m -142.05 101.19 3.88 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.57 -1.195 . . . . 0.0 109.698 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.431 HG13 HG12 ' A' ' 10' ' ' VAL . 3.4 t -75.06 147.81 8.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.184 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.413 ' HA ' HG22 ' A' ' 81' ' ' THR . 5.8 tttp -136.95 105.43 5.78 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.558 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.81 118.72 29.62 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 118.736 -1.186 . . . . 0.0 108.349 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.0 t -118.21 2.15 11.95 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.185 0.928 . . . . 0.0 110.013 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 32' ' ' SER . 14.9 p -54.09 -84.01 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.646 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.6 OUTLIER 158.77 68.45 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.934 0 O-C-N 123.873 0.733 . . . . 0.0 111.29 -179.953 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.462 ' H ' ' HA ' ' A' ' 78' ' ' ALA . . . -168.16 154.04 6.92 Favored Pre-proline 0 N--CA 1.483 1.192 0 C-N-CA 118.629 -1.228 . . . . 0.0 111.428 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -70.95 93.18 0.63 Allowed 'Trans proline' 0 C--N 1.326 -0.639 0 C-N-CA 121.144 1.23 . . . . 0.0 109.051 179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.456 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -78.33 107.27 10.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.598 -179.852 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -114.41 62.72 0.67 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.22 147.9 20.15 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.691 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 39.6 p-90 -164.45 -179.11 5.8 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.427 -1.309 . . . . 0.0 111.805 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.29 118.29 12.54 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.257 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -112.05 174.81 5.7 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 119.474 -0.891 . . . . 0.0 109.412 179.831 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.503 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -166.05 153.68 10.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.736 -1.586 . . . . 0.0 112.858 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.509 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.9 p90 -176.3 -139.67 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 113.809 -1.541 . . . . 0.0 108.22 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.509 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.6 m -160.15 172.0 18.23 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.798 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.55 ' CD2' HG21 ' A' ' 65' ' ' VAL . 3.0 m-85 -114.14 96.5 42.41 Favored Pre-proline 0 N--CA 1.497 1.881 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' CB ' ' OD1' ' A' ' 94' ' ' ASN . 4.4 Cg_exo -59.57 -42.95 42.87 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 121.469 1.446 . . . . 0.0 112.209 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.571 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.4 t -69.71 -115.7 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.91 -1.116 . . . . 0.0 110.632 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.571 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -145.85 21.22 1.8 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.498 ' HB2' ' CD1' ' A' ' 44' ' ' PHE . 57.5 mt-30 -61.85 89.96 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.689 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 23.7 mm-40 -88.86 97.18 11.02 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.3 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.583 HG23 ' HB2' ' A' ' 86' ' ' PHE . 1.5 p -68.06 138.25 22.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.651 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 44.0 p -127.19 -65.77 0.93 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.814 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.531 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.4 OUTLIER -81.4 153.34 27.0 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.453 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.412 ' N ' ' HG3' ' A' ' 52' ' ' GLN . . . -162.1 155.05 20.21 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.277 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.4 t-105 -157.71 142.41 16.49 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.796 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.482 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.2 OUTLIER 75.27 14.31 3.02 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.515 179.931 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.574 ' OG ' HG11 ' A' ' 67' ' ' VAL . 1.4 t -174.32 115.43 0.2 Allowed 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.5 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -71.2 85.52 0.76 Allowed 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.898 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 56' ' ' SER . 1.4 m -86.2 167.36 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.821 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.434 ' O ' ' CG2' ' A' ' 59' ' ' THR . 4.0 t -163.55 133.9 4.4 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.21 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.515 ' NE2' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER -94.42 123.99 38.17 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.733 -179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.629 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 34.0 p -110.01 -151.34 0.47 Allowed 'General case' 0 C--O 1.2 -1.519 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.394 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.529 ' C ' ' N ' ' A' ' 64' ' ' ALA . . . -53.33 84.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.657 0 C-N-CA 118.645 -1.74 . . . . 0.0 109.178 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.618 ' N ' ' O ' ' A' ' 61' ' ' SER . 28.4 m 47.68 13.66 0.04 OUTLIER 'General case' 0 C--N 1.31 -1.118 0 C-N-CA 119.606 -0.837 . . . . 0.0 109.686 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.629 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -109.59 -167.55 1.22 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.427 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.55 HG21 ' CD2' ' A' ' 44' ' ' PHE . 99.3 t -148.71 154.55 9.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 118.664 -1.215 . . . . 0.0 112.586 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.508 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.5 m -156.08 139.14 15.46 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.621 179.746 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.612 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.7 t -132.83 156.4 42.25 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.748 0 C-N-CA 119.05 -1.06 . . . . 0.0 112.442 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.421 ' N ' HG12 ' A' ' 67' ' ' VAL . 6.2 mtm180 -139.85 90.21 2.37 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 113.888 -1.505 . . . . 0.0 106.993 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.852 ' HB2' HD22 ' A' ' 73' ' ' ASN . 6.9 p-10 -74.21 121.87 21.92 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.854 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.722 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.93 158.66 0.17 Allowed Pre-proline 0 N--CA 1.482 1.136 0 CA-C-N 113.618 -1.628 . . . . 0.0 112.049 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.42 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.8 Cg_endo -65.62 -39.14 22.09 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.921 1.747 . . . . 0.0 111.865 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.722 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.54 -55.88 8.91 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.43 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.852 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.2 OUTLIER -66.41 -20.8 66.16 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 118.755 -1.178 . . . . 0.0 109.221 179.879 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -99.77 31.77 8.01 Favored Glycine 0 N--CA 1.483 1.802 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 t -92.12 55.77 2.68 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.616 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -104.76 133.9 19.93 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.646 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.46 ' O ' ' N ' ' A' ' 79' ' ' GLY . 11.9 Cg_endo -77.32 163.08 30.49 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 121.628 1.552 . . . . 0.0 114.07 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.29 -39.35 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 114.031 -1.441 . . . . 0.0 113.658 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -123.98 73.37 0.41 Allowed Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.479 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -152.59 -163.18 11.43 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.041 -1.552 . . . . 0.0 110.39 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.563 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.0 OUTLIER -141.8 163.23 33.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.626 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -146.91 99.32 3.17 Favored 'General case' 0 N--CA 1.485 1.278 0 CA-C-N 114.484 -1.235 . . . . 0.0 107.936 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.836 ' HB3' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -94.14 172.7 8.05 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -179.661 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.519 ' CB ' ' HB2' ' A' ' 56' ' ' SER . 34.9 p90 -168.62 -167.93 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 112.633 -2.076 . . . . 0.0 109.482 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 84' ' ' PHE . . . -172.98 158.93 29.14 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 117.483 -2.294 . . . . 0.0 112.555 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.5 p90 -149.69 166.62 28.81 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 114.962 -0.619 . . . . 0.0 110.369 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.0 OUTLIER -123.41 110.26 14.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.89 -0.724 . . . . 0.0 110.724 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.553 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -129.62 167.19 21.57 Favored Glycine 0 N--CA 1.505 3.251 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.711 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p -89.96 141.58 28.52 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.133 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.606 ' CD2' ' H ' ' A' ' 20' ' ' GLY . 13.1 p80 -112.66 -160.92 0.73 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.497 HG22 ' C ' ' A' ' 90' ' ' HIS . 0.2 OUTLIER -162.77 -7.65 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.219 179.928 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.469 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 86.55 76.26 1.25 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.723 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.469 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.4 OUTLIER -164.87 -175.45 3.77 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.05 179.966 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.487 ' C ' ' ND2' ' A' ' 94' ' ' ASN . 1.0 OUTLIER -51.84 101.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.112 179.995 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.481 ' HB1' ' NE2' ' A' ' 48' ' ' GLN . . . -90.68 -119.24 0.07 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -42.85 113.77 1.39 Allowed Pre-proline 0 C--N 1.307 -1.263 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.496 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.491 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -59.79 -100.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 120.754 0.969 . . . . 0.0 112.445 -179.898 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.849 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.3 p -150.89 -98.86 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.454 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.71 95.75 9.75 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 118.492 -1.283 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -65.49 -157.33 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.339 -0.945 . . . . 0.0 108.995 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.473 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.58 128.5 5.86 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 116.679 -2.008 . . . . 0.0 113.982 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.8 mt -62.86 -173.27 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.398 179.668 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.66 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -32.15 -49.17 0.19 Allowed 'General case' 0 N--CA 1.505 2.3 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -147.95 28.46 1.42 Allowed Glycine 0 N--CA 1.494 2.511 0 C-N-CA 118.847 -1.644 . . . . 0.0 111.411 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.836 HG21 ' H ' ' A' ' 6' ' ' ALA . 0.6 OUTLIER -146.15 155.24 50.82 Favored Pre-proline 0 C--O 1.191 -2.026 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.239 -179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -65.97 -178.14 0.97 Allowed 'Trans proline' 0 C--N 1.321 -0.87 0 C-N-CA 121.781 1.654 . . . . 0.0 112.571 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.722 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 9.7 t -174.45 111.76 0.15 Allowed 'General case' 0 N--CA 1.501 2.097 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.907 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.12 132.36 44.94 Favored 'General case' 0 N--CA 1.515 2.814 0 N-CA-C 114.202 1.186 . . . . 0.0 114.202 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 98' ' ' THR . 0.2 OUTLIER -52.33 174.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 C-N-CA 118.824 -1.15 . . . . 0.0 110.54 179.742 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.161 0 CA-C-O 116.371 -2.35 . . . . 0.0 110.479 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.169 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.9 t -108.3 -72.71 0.71 Allowed 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.8 m 45.41 -122.66 1.04 Allowed 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.64 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.08 156.28 26.8 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 119.106 -1.521 . . . . 0.0 110.502 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -64.46 176.92 2.41 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.755 1.637 . . . . 0.0 111.366 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.595 ' HB1' ' CB ' ' A' ' 31' ' ' SER . . . -98.33 -160.03 0.78 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.484 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.73 55.23 0.21 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.445 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 2.9 p -51.44 177.39 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.187 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.42 116.36 15.94 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.592 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.662 HG12 HG13 ' A' ' 27' ' ' VAL . 3.5 m -110.51 124.16 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.256 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.11 166.86 11.72 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.582 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.626 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.5 t-105 -134.75 140.05 45.63 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.613 -0.835 . . . . 0.0 111.463 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -122.98 71.22 0.42 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -72.17 147.67 10.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.487 ' HB3' HG22 ' A' ' 22' ' ' THR . 29.7 t30 -150.1 92.55 1.9 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 113.989 -1.459 . . . . 0.0 107.513 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.415 ' CD ' ' O ' ' A' ' 16' ' ' GLN . 1.4 pm0 -114.61 145.48 41.93 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.541 ' CZ2' ' O ' ' A' ' 20' ' ' GLY . 2.3 p90 -104.47 -109.58 0.27 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 113.55 -1.659 . . . . 0.0 108.09 179.677 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -62.98 -29.9 71.17 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.044 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.711 HG23 ' N ' ' A' ' 20' ' ' GLY . 9.4 t -176.16 -53.52 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.148 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.711 ' N ' HG23 ' A' ' 19' ' ' THR . . . -38.4 108.22 0.07 OUTLIER Glycine 0 N--CA 1.493 2.461 0 N-CA-C 107.903 -2.079 . . . . 0.0 107.903 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.598 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 20.2 p90 -112.97 113.65 25.79 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 119.598 -0.841 . . . . 0.0 112.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.487 HG22 ' HB3' ' A' ' 15' ' ' ASN . 2.4 t -72.61 171.87 11.67 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.626 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -156.81 113.54 3.06 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 117.385 -1.726 . . . . 0.0 113.19 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -98.82 101.17 12.48 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.592 HG11 ' CE1' ' A' ' 84' ' ' PHE . 27.2 t -99.43 143.24 13.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.918 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.562 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.8 m -132.54 110.77 10.71 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.93 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.662 HG13 HG12 ' A' ' 10' ' ' VAL . 2.1 t -82.0 150.42 4.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 C-N-CA 119.486 -0.885 . . . . 0.0 112.213 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.419 ' HB2' HG22 ' A' ' 81' ' ' THR . 13.3 tttp -138.91 115.77 10.81 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.067 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.433 ' HB2' ' CD1' ' A' ' 76' ' ' ILE . 1.4 t-20 -98.24 109.71 22.42 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.5 t -121.77 -2.08 9.37 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.147 0.905 . . . . 0.0 109.78 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.595 ' CB ' ' HB1' ' A' ' 6' ' ' ALA . 1.8 p -58.68 -79.46 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.261 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.34 43.21 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.522 -179.857 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.955 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -140.15 145.91 43.87 Favored Pre-proline 0 N--CA 1.487 1.388 0 C-N-CA 118.91 -1.116 . . . . 0.0 111.494 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -72.4 109.26 2.7 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 121.3 1.334 . . . . 0.0 109.596 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -97.5 112.97 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.001 -1.079 . . . . 0.0 112.211 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -122.35 70.01 0.97 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 141.77 12.1 Favored Glycine 0 C--N 1.294 -1.782 0 N-CA-C 106.657 -2.577 . . . . 0.0 106.657 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 31.0 p-90 -158.88 178.86 9.63 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 117.136 -1.825 . . . . 0.0 112.456 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.55 95.76 3.04 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.057 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.893 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -82.22 168.84 17.23 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.223 -1.391 . . . . 0.0 109.469 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.5 m -156.95 149.59 23.45 Favored 'General case' 0 C--N 1.287 -2.152 0 C-N-CA 118.122 -1.431 . . . . 0.0 112.012 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 25.5 p90 -174.03 -149.73 0.04 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.996 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.1 m -158.96 149.62 19.84 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 117.623 -1.631 . . . . 0.0 112.001 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.456 ' CE2' HG21 ' A' ' 65' ' ' VAL . 7.4 m-85 -78.79 123.55 85.26 Favored Pre-proline 0 C--N 1.307 -1.261 0 C-N-CA 118.326 -1.35 . . . . 0.0 107.712 179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -65.72 -63.26 0.07 OUTLIER 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 121.358 1.372 . . . . 0.0 112.226 -179.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.461 ' HB3' ' H ' ' A' ' 94' ' ' ASN . 62.0 p -69.05 -120.68 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 118.613 -1.235 . . . . 0.0 110.464 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -132.91 42.68 1.35 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.574 HE22 ' HA ' ' A' ' 95' ' ' ALA . 3.5 mt-30 -84.92 133.07 34.3 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.762 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.6 pp0? -131.56 117.07 18.24 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.801 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.464 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.38 155.06 7.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.974 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.554 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.7 p -128.6 -64.85 0.91 Allowed 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.894 -0.723 . . . . 0.0 110.92 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.554 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -95.28 140.46 30.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.601 -0.839 . . . . 0.0 109.446 179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.73 160.72 40.22 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 118.917 -1.113 . . . . 0.0 112.354 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 35.3 t-105 -153.15 143.07 22.16 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.649 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.3 t 60.97 26.56 16.49 Favored 'General case' 0 C--N 1.313 -0.978 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.466 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.419 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -170.97 124.07 0.63 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.717 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 m -87.01 75.09 9.58 Favored 'General case' 0 C--N 1.281 -2.384 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.354 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.414 ' C ' HG23 ' A' ' 59' ' ' THR . 16.7 m -69.21 151.1 10.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.256 -0.884 . . . . 0.0 112.462 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.414 HG23 ' C ' ' A' ' 58' ' ' VAL . 37.9 p -155.32 115.31 3.74 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -90.74 124.44 35.11 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 119.11 -1.036 . . . . 0.0 110.612 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.96 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.7 p -91.71 75.31 5.77 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.5 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.471 ' C ' ' OG ' ' A' ' 63' ' ' SER . . . 76.18 -42.9 1.69 Allowed Glycine 0 N--CA 1.496 2.661 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.222 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.471 ' OG ' ' C ' ' A' ' 62' ' ' GLY . 0.8 OUTLIER -163.76 -19.01 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.087 -0.645 . . . . 0.0 109.563 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.96 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.33 -169.18 2.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.17 -1.012 . . . . 0.0 109.754 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 66' ' ' THR . 98.3 t -150.33 157.97 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 118.007 -1.477 . . . . 0.0 114.152 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.587 ' N ' HG12 ' A' ' 65' ' ' VAL . 13.4 m -157.86 143.6 17.18 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.67 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.569 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -139.12 114.74 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 C-N-CA 118.834 -1.147 . . . . 0.0 112.144 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -94.14 89.41 5.98 Favored 'General case' 0 C--N 1.281 -2.374 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.095 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.727 HD21 ' CA ' ' A' ' 74' ' ' GLY . 0.9 OUTLIER -71.75 117.28 13.13 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.021 -1.072 . . . . 0.0 111.909 -179.694 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.928 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -37.6 155.75 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.454 0 CA-C-N 113.622 -1.626 . . . . 0.0 112.297 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -62.47 -36.79 63.78 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.998 1.799 . . . . 0.0 112.312 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.754 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.07 -52.45 28.32 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.304 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.928 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 12.9 p30 -75.56 0.59 16.84 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.686 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.727 ' CA ' HD21 ' A' ' 69' ' ' ASN . . . -118.94 25.41 7.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.6 p -92.73 73.25 4.97 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.75 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.549 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -133.89 126.07 18.58 Favored Pre-proline 0 N--CA 1.483 1.206 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.23 179.928 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.615 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.5 Cg_endo -72.41 167.59 26.57 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 120.953 1.102 . . . . 0.0 110.233 179.707 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.955 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -52.55 1.71 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.655 0 C-N-CA 119.609 -0.836 . . . . 0.0 112.399 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.615 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -128.8 67.29 0.56 Allowed Glycine 0 N--CA 1.496 2.663 0 C-N-CA 119.597 -1.287 . . . . 0.0 109.945 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 178.73 -162.06 28.92 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 118.831 -1.652 . . . . 0.0 110.376 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.549 ' N ' HG13 ' A' ' 76' ' ' ILE . 15.8 p -142.09 166.32 25.04 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.093 -1.043 . . . . 0.0 113.179 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.473 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -128.56 -177.31 4.13 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 113.896 -1.502 . . . . 0.0 107.113 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.421 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 13.0 tt0 -168.21 148.29 4.78 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 116.85 -1.94 . . . . 0.0 113.494 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.0 p90 -161.86 169.83 20.57 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.312 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.62 161.12 32.47 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 117.981 -2.057 . . . . 0.0 112.174 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.5 p90 -155.37 175.08 14.33 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -124.07 109.42 13.47 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.284 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.81 174.83 15.63 Favored Glycine 0 N--CA 1.497 2.737 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.678 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . 0.412 ' HA ' ' HA2' ' A' ' 20' ' ' GLY . 29.2 p -136.22 160.56 38.32 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.705 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 91' ' ' THR . 10.1 p80 -158.8 -137.01 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 117.516 -1.674 . . . . 0.0 112.928 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.624 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 3.2 p -146.05 -6.91 0.56 Allowed 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.43 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.465 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 96.38 91.71 1.82 Allowed Glycine 0 N--CA 1.495 2.568 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.94 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.802 HG22 ' H ' ' A' ' 94' ' ' ASN . 99.4 m -162.99 -124.17 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.479 -0.889 . . . . 0.0 111.122 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.802 ' H ' HG22 ' A' ' 93' ' ' THR . 4.7 t-20 -81.64 119.93 24.43 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.776 -0.77 . . . . 0.0 111.078 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.574 ' HA ' HE22 ' A' ' 48' ' ' GLN . . . -91.82 -178.39 5.02 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.222 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.652 ' HB1' ' HZ ' ' A' ' 100' ' ' PHE . . . -34.03 147.26 0.11 Allowed Pre-proline 0 N--CA 1.491 1.58 0 CA-C-N 115.135 -0.939 . . . . 0.0 112.196 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 9.2 Cg_endo -68.86 -151.14 0.03 OUTLIER 'Trans proline' 0 C--O 1.216 -0.585 0 C-N-CA 121.408 1.405 . . . . 0.0 111.594 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.633 ' O ' HG13 ' A' ' 109' ' ' VAL . 9.3 p -120.06 -47.82 2.37 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.914 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.433 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.5 91.61 3.72 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.939 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.652 ' HZ ' ' HB1' ' A' ' 96' ' ' ALA . 33.7 m-85 -64.18 -164.03 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.066 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.1 m -146.66 98.9 3.13 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 117.761 -1.576 . . . . 0.0 113.336 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -51.53 165.85 0.15 Allowed 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 119.304 -0.958 . . . . 0.0 108.655 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -43.03 91.15 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.058 -1.057 . . . . 0.0 110.669 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 68.91 55.88 10.18 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.59 -1.291 . . . . 0.0 110.51 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.594 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.9 OUTLIER 175.97 135.57 0.18 Allowed Pre-proline 0 C--O 1.195 -1.797 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.739 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -58.97 166.86 6.27 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 121.568 1.512 . . . . 0.0 112.818 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.511 ' SG ' HG13 ' A' ' 10' ' ' VAL . 9.0 t -165.53 102.36 0.71 Allowed 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.94 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 p -58.68 173.37 0.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.211 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.633 HG13 ' O ' ' A' ' 98' ' ' THR . 16.3 m -64.26 -143.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.66 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.486 2.002 0 CA-C-O 116.32 -2.378 . . . . 0.0 110.227 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.79 121.84 11.41 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.7 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.07 -40.25 95.18 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.046 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.24 -150.78 20.78 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.164 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.44 ' HB2' ' CG2' ' A' ' 105' ' ' THR . 3.3 Cg_exo -60.71 -79.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.322 -0.822 0 C-N-CA 121.375 1.383 . . . . 0.0 111.252 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.601 ' H ' HG22 ' A' ' 105' ' ' THR . . . -109.23 -156.33 0.58 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.971 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.44 45.42 0.04 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.917 ' SG ' HD12 ' A' ' 102' ' ' LEU . 4.3 p -50.94 175.12 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 69.0 mt-30 -138.27 118.64 13.73 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.714 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.673 HG12 HG13 ' A' ' 27' ' ' VAL . 3.1 m -109.57 124.47 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.861 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.558 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.72 163.3 12.69 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.966 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.591 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 6.1 t-105 -115.82 143.19 45.75 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.857 -0.737 . . . . 0.0 111.871 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 74.03 0.39 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 21' ' ' PHE . 8.2 p -68.73 141.71 17.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.826 -0.749 . . . . 0.0 112.597 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -145.19 80.24 1.6 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.006 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.683 ' NE2' ' NE2' ' A' ' 90' ' ' HIS . 0.0 OUTLIER -64.94 130.21 42.58 Favored 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.85 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.564 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 19.0 p90 -103.86 -43.65 5.26 Favored 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.344 -0.942 . . . . 0.0 110.137 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.564 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 46.5 t-20 -148.35 -19.71 0.33 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.713 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -177.16 -56.66 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.734 0 CA-C-N 114.034 -1.439 . . . . 0.0 108.006 179.919 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.713 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -63.31 168.47 20.82 Favored Glycine 0 C--N 1.295 -1.711 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.517 ' CZ ' ' OE1' ' A' ' 48' ' ' GLN . 2.8 p90 -138.45 133.18 32.44 Favored 'General case' 0 C--N 1.29 -1.986 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.598 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.509 ' OG1' ' ND2' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -87.96 118.93 27.84 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 179.577 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.591 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -96.96 110.58 23.08 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 119.239 -0.984 . . . . 0.0 113.517 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -92.77 100.42 12.91 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.599 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.4 t -93.51 145.43 7.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 119.236 -0.985 . . . . 0.0 113.583 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.595 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.7 m -135.52 109.94 8.47 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.239 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.673 HG13 HG12 ' A' ' 10' ' ' VAL . 0.3 OUTLIER -81.02 151.4 4.43 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 C-N-CA 119.501 -0.88 . . . . 0.0 111.816 -179.855 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.648 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.1 OUTLIER -136.92 98.23 3.71 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.535 179.729 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -88.48 101.22 13.71 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.216 -0.994 . . . . 0.0 108.369 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -114.19 1.85 14.66 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.349 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.1 p -61.7 -79.64 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.61 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.634 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.91 75.24 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.535 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -167.32 152.44 6.98 Favored Pre-proline 0 C--N 1.31 -1.152 0 C-N-CA 118.665 -1.214 . . . . 0.0 111.587 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -72.72 94.64 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.71 0 N-CA-C 108.672 -1.318 . . . . 0.0 108.672 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.23 102.5 5.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 118.31 -1.356 . . . . 0.0 111.698 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -119.92 57.36 0.93 Allowed 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.97 148.76 18.34 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.787 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.7 p-90 -167.08 175.89 7.24 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.637 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.34 109.81 6.59 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.699 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.54 174.94 6.01 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.324 -0.95 . . . . 0.0 109.656 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.479 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -161.65 150.09 15.46 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 117.874 -1.53 . . . . 0.0 112.719 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 43' ' ' SER . 12.9 p90 -175.6 -130.43 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.039 -1.437 . . . . 0.0 108.596 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.498 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 m -167.13 176.9 6.52 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 117.819 -1.553 . . . . 0.0 112.495 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.662 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -117.14 87.81 24.74 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.605 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -59.03 -27.45 85.06 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 121.786 1.657 . . . . 0.0 112.499 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' ASN . 0.9 OUTLIER -69.59 -13.37 62.29 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.731 179.962 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 78.99 19.78 71.85 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.742 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.517 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 21.7 mt-30 -73.85 177.12 5.76 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.631 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -141.77 111.26 6.5 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.452 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 50' ' ' VAL . 2.4 p -76.07 155.13 5.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.861 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.433 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 64.8 p -138.66 -68.1 0.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.314 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.433 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -82.88 131.01 35.21 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.056 -1.058 . . . . 0.0 110.423 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.44 152.81 41.98 Favored 'General case' 0 N--CA 1.49 1.575 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.65 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 39.5 t-105 -154.73 144.48 21.57 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.004 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 69.0 18.81 8.33 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.071 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.615 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 3.3 m -172.23 111.12 0.26 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.115 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -69.93 79.79 0.47 Allowed 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.484 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.657 HG12 HG13 ' A' ' 67' ' ' VAL . 9.5 m -81.05 155.95 4.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.067 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.6 t -155.43 129.88 9.03 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.21 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 22.4 tt0 -95.68 114.21 25.93 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.518 -0.873 . . . . 0.0 111.043 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.8 p -91.1 78.23 5.92 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.683 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.89 -68.28 2.26 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.095 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -142.08 -15.77 0.78 Allowed 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.188 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.498 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -92.63 -170.81 2.57 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.662 HG21 ' CD2' ' A' ' 44' ' ' PHE . 54.1 t -145.78 160.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 C-N-CA 118.838 -1.145 . . . . 0.0 113.029 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.4 m -161.07 127.36 3.92 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.121 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 58' ' ' VAL . 2.0 t -122.54 147.53 26.65 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.845 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 mtm-85 -129.38 92.73 3.41 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.787 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 8.6 p-10 -72.81 122.05 20.93 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.272 -0.971 . . . . 0.0 112.445 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.766 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -48.25 156.69 0.75 Allowed Pre-proline 0 C--N 1.305 -1.343 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.316 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.98 -36.81 81.08 Favored 'Trans proline' 0 C--N 1.325 -0.706 0 C-N-CA 121.895 1.73 . . . . 0.0 112.628 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.654 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -56.27 7.68 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 118.733 -1.187 . . . . 0.0 110.61 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.766 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -72.33 7.7 1.66 Allowed 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 109.714 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -137.05 33.82 2.27 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 27.9 t -99.94 59.72 1.06 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.846 -0.742 . . . . 0.0 111.298 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.542 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.01 135.86 22.12 Favored Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.808 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.2 Cg_endo -73.44 158.91 47.45 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.631 1.554 . . . . 0.0 114.027 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.634 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.37 -32.73 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 CA-C-N 113.888 -1.505 . . . . 0.0 114.758 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.52 68.82 0.29 Allowed Glycine 0 N--CA 1.503 3.125 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.968 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.15 23.19 Favored Glycine 0 C--N 1.29 -1.992 0 C-N-CA 118.637 -1.744 . . . . 0.0 110.695 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 28' ' ' LYS . 6.3 p -138.08 162.9 32.97 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 119.691 -0.804 . . . . 0.0 112.008 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.36 169.54 14.13 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.595 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.7 OUTLIER -160.45 142.08 12.44 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 117.016 -1.874 . . . . 0.0 113.486 -179.842 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.615 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 13.5 p90 -154.7 177.36 11.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 114.33 -1.305 . . . . 0.0 109.296 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.72 159.69 33.05 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 117.604 -2.236 . . . . 0.0 112.135 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.654 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 0.9 OUTLIER -145.17 -178.36 6.02 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.798 179.923 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.509 ' ND2' ' OG1' ' A' ' 22' ' ' THR . 3.2 m120 -133.62 110.53 9.95 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.089 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -113.91 173.43 14.96 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.899 -1.143 . . . . 0.0 111.278 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.0 p -115.51 140.04 49.51 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.828 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.894 ' HD1' ' N ' ' A' ' 91' ' ' THR . 0.1 OUTLIER -150.29 -175.8 5.22 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 118.241 -1.384 . . . . 0.0 112.28 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.894 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 26.1 p -123.68 -3.21 8.28 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.304 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.533 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 106.17 95.69 2.41 Favored Glycine 0 N--CA 1.499 2.836 0 C-N-CA 119.889 -1.148 . . . . 0.0 110.836 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.474 HG22 ' H ' ' A' ' 94' ' ' ASN . 2.0 m -163.78 175.93 10.02 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.076 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -71.21 112.73 7.59 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.895 -179.961 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -106.94 -99.47 0.35 Allowed 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.53 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.417 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -34.89 102.55 0.23 Allowed Pre-proline 0 N--CA 1.491 1.609 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.876 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.453 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.3 Cg_endo -66.3 -142.85 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 121.169 1.246 . . . . 0.0 110.999 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.404 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 42.5 p -111.73 -88.12 0.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.642 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.404 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -97.56 105.54 17.71 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.008 -1.077 . . . . 0.0 112.146 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.564 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -74.9 -146.26 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.528 -0.869 . . . . 0.0 108.995 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.72 98.87 1.96 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 117.369 -1.733 . . . . 0.0 113.775 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.917 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -53.17 172.15 0.06 Allowed 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.457 ' HB3' ' H ' ' A' ' 39' ' ' THR . 34.1 p-10 -52.22 86.83 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.944 -1.102 . . . . 0.0 110.488 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 76.07 42.86 23.31 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.62 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.612 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -169.92 138.65 1.51 Allowed Pre-proline 0 C--O 1.196 -1.733 0 C-N-CA 119.493 -0.883 . . . . 0.0 110.818 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -64.72 154.8 70.64 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.137 1.225 . . . . 0.0 111.677 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.459 ' SG ' HG13 ' A' ' 10' ' ' VAL . 2.7 t -151.11 104.43 3.13 Favored 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 119.424 -0.91 . . . . 0.0 110.908 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.51 157.37 11.54 Favored 'General case' 0 N--CA 1.5 2.05 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.019 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.896 HG13 ' N ' ' A' ' 110' ' ' GLY . 6.1 p -70.44 -140.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.234 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.896 ' N ' HG13 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.278 0 CA-C-O 116.342 -2.366 . . . . 0.0 110.446 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.166 0 CA-C-O 120.834 0.349 . . . . 0.0 110.082 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.2 m -153.82 -70.89 0.14 Allowed 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.822 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -175.2 -42.47 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.859 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.7 -178.51 21.7 Favored Glycine 0 N--CA 1.492 2.411 0 C-N-CA 119.455 -1.355 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -55.05 -80.87 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.042 1.828 . . . . 0.0 111.857 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.37 -169.0 1.38 Allowed 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.946 -0.702 . . . . 0.0 111.604 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 175.03 41.55 0.05 OUTLIER Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.709 -2.157 . . . . 0.0 107.709 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.664 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.45 -167.94 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.252 -0.974 . . . . 0.0 111.469 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.499 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.9 OUTLIER -159.15 152.67 22.76 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 118.984 -1.086 . . . . 0.0 110.402 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -137.29 133.77 46.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.2 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.56 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.42 164.83 11.57 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.968 179.855 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.609 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.6 t-105 -118.9 142.86 47.37 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.927 -0.709 . . . . 0.0 112.072 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.76 76.58 0.38 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 107.804 -2.119 . . . . 0.0 107.804 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -69.16 150.97 10.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.622 -0.831 . . . . 0.0 113.0 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.418 ' CB ' HG22 ' A' ' 22' ' ' THR . 10.9 t-20 -158.23 69.45 0.51 Allowed 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 114.321 -1.309 . . . . 0.0 108.534 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.731 ' HG3' ' HE2' ' A' ' 90' ' ' HIS . 1.1 pm0 -104.55 148.38 26.57 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.972 -179.719 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.634 ' C ' ' H ' ' A' ' 19' ' ' THR . 8.0 p90 -102.97 -136.11 0.33 Allowed 'General case' 0 N--CA 1.493 1.699 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.39 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -50.68 -13.88 0.16 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.679 179.745 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.696 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER 168.6 -179.59 0.03 OUTLIER 'General case' 0 C--N 1.282 -2.342 0 CA-C-N 112.97 -1.923 . . . . 0.0 107.309 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.696 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 74.39 97.0 0.1 Allowed Glycine 0 C--N 1.279 -2.638 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.563 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 23.7 p90 -108.85 123.6 49.31 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' CB ' ' A' ' 15' ' ' ASN . 0.6 OUTLIER -81.13 153.25 27.38 Favored 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 105.433 -2.062 . . . . 0.0 105.433 179.447 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -128.79 108.9 10.83 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.378 -1.329 . . . . 0.0 112.657 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -95.74 94.91 7.96 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 84' ' ' PHE . 36.9 t -91.92 154.14 3.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.296 -0.962 . . . . 0.0 112.452 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.56 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.2 m -139.36 104.11 4.89 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.222 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 27' ' ' VAL . 1.5 t -74.8 148.81 7.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 C-N-CA 119.732 -0.787 . . . . 0.0 112.17 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.632 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -136.21 96.09 3.32 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.784 179.693 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.427 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.9 t30 -88.28 106.98 18.58 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.883 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 t -113.45 5.52 16.76 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.835 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.5 ' O ' ' CB ' ' A' ' 32' ' ' SER . 12.6 p -54.17 -84.9 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.894 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.59 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 162.01 65.39 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.752 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB1' ' HD2' ' A' ' 34' ' ' PRO . . . -170.44 160.2 6.17 Favored Pre-proline 0 N--CA 1.486 1.331 0 C-N-CA 118.804 -1.158 . . . . 0.0 111.413 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.44 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 7.1 Cg_endo -71.72 95.07 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.484 1.456 . . . . 0.0 109.571 179.571 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.1 t -75.13 79.79 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 C-N-CA 118.87 -1.132 . . . . 0.0 112.301 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -91.46 57.41 3.31 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.431 -0.908 . . . . 0.0 108.714 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 106.62 157.83 21.5 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.777 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 48.0 p-90 -171.58 178.82 3.03 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 117.752 -1.579 . . . . 0.0 112.382 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.505 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -141.18 115.63 9.48 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.017 179.779 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.844 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -106.35 176.43 5.17 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.1 179.834 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.624 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.1 m -167.18 152.44 7.43 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 117.5 -1.68 . . . . 0.0 113.009 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.447 ' CD2' ' N ' ' A' ' 43' ' ' SER . 19.4 p90 -176.79 -137.48 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 113.756 -1.566 . . . . 0.0 108.161 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.566 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 6.8 m -165.71 168.55 16.06 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 117.665 -1.614 . . . . 0.0 112.604 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.513 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -102.16 108.12 55.61 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.71 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.513 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 2.9 Cg_exo -55.98 -66.79 0.08 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.051 1.168 . . . . 0.0 111.726 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.478 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 35.2 t -70.28 -171.91 0.52 Allowed 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.526 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.478 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.36 49.07 3.51 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.198 -1.477 . . . . 0.0 109.915 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.18 109.86 19.18 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.445 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.726 ' CD ' ' H ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -113.91 130.4 56.51 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.729 179.978 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 51' ' ' THR . 5.2 p -96.41 159.51 2.98 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.083 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.4 p -133.09 -65.77 0.69 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.707 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.581 ' N ' ' OG1' ' A' ' 51' ' ' THR . 3.5 mt-30 -81.72 166.5 20.03 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.282 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -169.29 148.48 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.976 -1.09 . . . . 0.0 111.454 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.462 ' CD1' ' HB3' ' A' ' 55' ' ' SER . 36.8 t-105 -150.6 141.42 22.81 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.001 -1.079 . . . . 0.0 111.645 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.462 ' HB3' ' CD1' ' A' ' 54' ' ' TRP . 0.9 OUTLIER 63.8 20.92 12.45 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.311 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.642 ' O ' HG13 ' A' ' 58' ' ' VAL . 1.2 m -165.06 109.31 0.89 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.422 -0.911 . . . . 0.0 110.381 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -70.57 78.36 0.58 Allowed 'General case' 0 C--N 1.285 -2.216 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.126 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.642 HG13 ' O ' ' A' ' 56' ' ' SER . 1.0 OUTLIER -81.48 162.34 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.461 -179.899 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.429 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.9 t -160.55 133.92 6.75 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.348 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.94 108.83 18.98 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.734 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.5 p -93.34 75.5 4.54 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.476 -0.889 . . . . 0.0 110.875 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 53.56 74.27 0.32 Allowed Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.357 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 0.3 OUTLIER 76.17 -35.91 0.26 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.491 -179.977 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.566 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -81.67 -171.06 3.13 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.666 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 66' ' ' THR . 77.4 t -149.71 157.62 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 118.725 -1.19 . . . . 0.0 113.05 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.624 HG23 ' OG1' ' A' ' 41' ' ' THR . 35.9 m -156.69 131.9 9.18 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 114.234 -1.348 . . . . 0.0 107.96 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.607 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -126.07 146.98 30.95 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.07 0 C-N-CA 119.326 -0.95 . . . . 0.0 112.225 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -130.46 93.22 3.4 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.78 ' HB2' HD22 ' A' ' 73' ' ' ASN . 10.4 p-10 -72.7 124.31 25.05 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.373 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.698 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -46.52 162.98 0.24 Allowed Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 113.719 -1.582 . . . . 0.0 111.593 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -67.12 -39.13 14.12 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.897 1.731 . . . . 0.0 111.933 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.698 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.38 -56.06 8.56 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.246 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.78 HD22 ' HB2' ' A' ' 69' ' ' ASN . 0.5 OUTLIER -70.63 -5.75 31.73 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.024 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -119.62 48.13 0.97 Allowed Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -112.67 74.33 0.86 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.099 -0.641 . . . . 0.0 110.971 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.623 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -130.69 132.28 23.84 Favored Pre-proline 0 CA--C 1.56 1.352 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.94 179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.433 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.4 Cg_endo -71.18 159.24 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 122.023 1.815 . . . . 0.0 114.498 -179.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.59 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -26.24 -40.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.679 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -114.76 68.84 0.26 Allowed Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.77 -1.205 . . . . 0.0 111.038 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.78 -168.83 18.68 Favored Glycine 0 C--N 1.29 -2.023 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.002 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 28' ' ' LYS . 7.6 p -137.1 166.39 23.82 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.818 0.818 . . . . 0.0 112.364 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.556 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -138.38 162.41 34.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.541 ' HG3' HG23 ' A' ' 26' ' ' THR . 1.4 mp0 -139.52 158.2 44.53 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 118.114 -1.434 . . . . 0.0 113.355 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 25' ' ' VAL . 1.6 p90 -171.03 161.86 6.99 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.103 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.57 169.81 37.15 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 117.438 -2.315 . . . . 0.0 112.741 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.1 p90 -150.97 -176.94 5.73 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.347 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.561 HD22 ' C ' ' A' ' 86' ' ' PHE . 0.6 OUTLIER -128.82 104.68 7.76 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.622 179.842 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.34 175.51 15.74 Favored Glycine 0 N--CA 1.498 2.769 0 C-N-CA 120.058 -1.068 . . . . 0.0 111.41 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . 0.418 ' O ' ' NE2' ' A' ' 49' ' ' GLN . 2.7 p -126.26 156.77 39.79 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.221 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.731 ' HE2' ' HG3' ' A' ' 16' ' ' GLN . 4.7 p80 -153.79 -150.73 0.34 Allowed 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.485 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.545 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 55.6 p -147.89 -2.6 0.54 Allowed 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 99.04 83.83 1.75 Allowed Glycine 0 N--CA 1.497 2.732 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.888 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.568 HG22 ' H ' ' A' ' 94' ' ' ASN . 2.0 m -163.87 -149.37 0.13 Allowed 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.527 -0.869 . . . . 0.0 110.869 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.568 ' H ' HG22 ' A' ' 93' ' ' THR . 40.3 t30 -73.16 120.91 19.43 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.896 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.3 -115.11 0.31 Allowed 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.994 -0.682 . . . . 0.0 111.96 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.609 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -50.19 118.07 8.64 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.295 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.6 Cg_endo -65.63 -143.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 121.093 1.195 . . . . 0.0 110.442 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.758 ' O ' HG13 ' A' ' 109' ' ' VAL . 27.0 p -104.39 -101.1 0.31 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.355 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.89 109.6 20.82 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 118.711 -1.196 . . . . 0.0 112.537 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.664 ' CZ ' ' CG1' ' A' ' 109' ' ' VAL . 4.1 m-30 -76.1 -149.76 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.45 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.87 116.27 2.8 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 117.107 -1.837 . . . . 0.0 113.696 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.664 HD12 ' SG ' ' A' ' 8' ' ' CYS . 2.1 mt -58.81 -172.53 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.114 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.505 ' N ' ' O ' ' A' ' 39' ' ' THR . 1.6 p-10 -65.99 76.53 0.08 Allowed 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.919 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 102.22 10.7 38.5 Favored Glycine 0 N--CA 1.5 2.913 0 C-N-CA 119.521 -1.323 . . . . 0.0 112.374 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 102' ' ' LEU . 62.3 p -150.46 151.14 30.46 Favored Pre-proline 0 N--CA 1.495 1.796 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -66.51 171.53 10.51 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.583 1.522 . . . . 0.0 112.388 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.62 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.8 t -165.85 111.13 0.86 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.088 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 1.1 p -72.58 128.11 34.59 Favored 'General case' 0 N--CA 1.506 2.354 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.758 HG13 ' O ' ' A' ' 98' ' ' THR . 0.9 OUTLIER -54.45 178.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 C-N-CA 118.793 -1.163 . . . . 0.0 110.531 179.796 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.287 0 CA-C-O 116.379 -2.345 . . . . 0.0 110.324 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 CA-C-O 120.853 0.359 . . . . 0.0 110.058 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.4 t 44.42 -105.69 0.09 Allowed 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.786 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 t 174.36 105.65 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.768 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.67 104.05 1.86 Allowed Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.414 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -62.23 -152.26 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.45 1.434 . . . . 0.0 111.606 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.418 ' HB3' ' HB ' ' A' ' 105' ' ' THR . . . -66.35 -145.5 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.994 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.2 50.45 0.02 OUTLIER Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.722 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.7 p -52.31 178.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.771 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.72 110.67 7.72 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.58 HG13 ' SG ' ' A' ' 107' ' ' CYS . 3.5 m -101.75 125.79 55.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.2 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.549 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -104.81 133.96 48.75 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.28 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.528 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.4 t-105 -95.17 139.68 31.16 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.911 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.14 73.12 0.44 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.6 OUTLIER -69.73 159.75 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.526 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.3 t30 -170.05 97.43 0.28 Allowed 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.974 -1.466 . . . . 0.0 108.549 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.708 ' HG3' ' HE2' ' A' ' 90' ' ' HIS . 0.0 OUTLIER -124.86 165.77 17.46 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 122.391 1.091 . . . . 0.0 113.58 -179.693 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.48 ' O ' ' CB ' ' A' ' 18' ' ' ASN . 7.0 p90 -124.32 75.34 1.38 Allowed 'General case' 0 C--N 1.29 -2.004 0 CA-C-N 112.875 -1.966 . . . . 0.0 108.938 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.48 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 78.19 -56.51 0.48 Allowed 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 m -149.42 121.83 8.47 Favored 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.716 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.41 ' O ' ' CE2' ' A' ' 17' ' ' TRP . . . 113.53 90.41 1.83 Allowed Glycine 0 C--N 1.284 -2.312 0 N-CA-C 105.719 -2.952 . . . . 0.0 105.719 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 22.0 p90 -109.47 118.37 36.44 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 121.906 0.86 . . . . 0.0 113.264 -179.64 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.5 t -73.26 162.99 28.74 Favored 'General case' 0 C--N 1.283 -2.287 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.33 117.94 10.38 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.048 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -100.86 99.17 9.63 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.316 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.748 HG11 ' CE2' ' A' ' 84' ' ' PHE . 6.1 t -99.39 136.1 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 119.726 -0.789 . . . . 0.0 112.25 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.549 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.7 m -130.03 108.88 10.42 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.738 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.574 HG13 HG12 ' A' ' 10' ' ' VAL . 1.7 t -78.03 149.87 5.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.903 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.845 ' HA ' HG22 ' A' ' 81' ' ' THR . 3.6 tttt -133.17 96.06 3.67 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.831 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.39 96.75 7.45 Favored 'General case' 0 C--N 1.291 -1.964 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.038 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.5 t -111.65 6.11 19.71 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.334 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.495 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.7 p -71.93 -78.31 0.08 Allowed 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.332 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.62 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 158.27 78.18 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 123.906 0.754 . . . . 0.0 111.498 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -166.17 145.08 4.89 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 118.648 -1.221 . . . . 0.0 111.373 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -68.91 97.34 0.56 Allowed 'Trans proline' 0 N--CA 1.456 -0.719 0 N-CA-C 108.172 -1.511 . . . . 0.0 108.172 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -86.38 100.25 9.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 118.194 -1.402 . . . . 0.0 112.029 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -113.71 55.3 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.85 148.7 14.25 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.703 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.3 p-90 -163.55 176.68 9.47 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.964 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -140.54 109.53 6.08 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.805 179.901 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.61 173.22 7.02 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.537 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.474 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.3 m -155.49 148.09 24.08 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.023 -1.471 . . . . 0.0 112.882 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.3 p90 -174.51 -141.54 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 113.999 -1.455 . . . . 0.0 108.417 179.72 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.5 m -163.17 173.11 13.85 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 117.625 -1.63 . . . . 0.0 112.921 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.588 ' CE1' ' NE2' ' A' ' 48' ' ' GLN . 5.3 m-85 -111.12 98.46 39.29 Favored Pre-proline 0 N--CA 1.491 1.575 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.015 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -53.31 -55.15 3.9 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.007 1.138 . . . . 0.0 111.301 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.508 ' HB3' ' H ' ' A' ' 94' ' ' ASN . 62.2 p -74.15 -179.83 4.05 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.101 -1.04 . . . . 0.0 109.794 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -77.71 41.79 1.95 Allowed Glycine 0 N--CA 1.484 1.864 0 C-N-CA 118.863 -1.637 . . . . 0.0 109.494 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.588 ' NE2' ' CE1' ' A' ' 44' ' ' PHE . 3.6 mt-30 -78.05 108.53 11.4 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.404 ' O ' ' CG ' ' A' ' 49' ' ' GLN . 1.7 pp0? -116.55 109.85 17.79 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.207 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.602 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.1 p -68.45 164.54 2.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.089 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.602 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 36.8 p -137.5 -63.92 0.57 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.626 -0.829 . . . . 0.0 110.986 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.523 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -97.59 137.11 37.02 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.709 179.941 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.52 159.15 42.8 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.726 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.402 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 36.2 t-105 -155.02 141.73 18.96 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.988 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.402 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.0 OUTLIER 67.12 23.84 9.49 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.091 -179.999 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.478 ' HB3' ' CG ' ' A' ' 84' ' ' PHE . 2.1 p -172.8 110.4 0.21 Allowed 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.249 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.4 m -71.46 74.64 0.76 Allowed 'General case' 0 C--N 1.284 -2.239 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.07 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.541 HG12 HG13 ' A' ' 67' ' ' VAL . 13.4 m -69.6 155.05 7.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.953 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 65.5 p -152.6 112.5 3.97 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.196 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -78.57 104.91 9.49 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.001 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.584 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.1 p -85.72 -160.89 0.56 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.948 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.628 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -50.84 88.22 0.01 OUTLIER Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.139 -1.505 . . . . 0.0 109.655 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER 53.22 4.19 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.707 -179.828 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.628 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.51 -169.27 1.6 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.555 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 77.9 t -143.17 154.22 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 C-N-CA 119.119 -1.033 . . . . 0.0 112.691 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.477 ' N ' HG12 ' A' ' 65' ' ' VAL . 15.6 m -158.01 127.83 6.01 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.551 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.594 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -126.35 142.55 42.63 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.958 0 C-N-CA 119.279 -0.968 . . . . 0.0 111.747 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.46 94.33 4.11 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 124.735 1.272 . . . . 0.0 107.938 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.703 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 2.6 p-10 -74.22 119.78 18.89 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.045 -1.062 . . . . 0.0 111.937 -179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.05 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -46.73 172.43 0.05 OUTLIER Pre-proline 0 N--CA 1.485 1.303 0 CA-C-N 113.751 -1.568 . . . . 0.0 112.308 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.825 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.4 Cg_endo -68.28 -35.8 17.89 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.185 1.924 . . . . 0.0 112.707 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.685 ' CE3' ' ND2' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -68.9 -52.49 28.88 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 118.743 -1.183 . . . . 0.0 110.529 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.05 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.9 p30 -80.75 5.07 16.87 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 118.998 -1.081 . . . . 0.0 109.576 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.5 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -127.06 26.01 5.12 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -99.09 67.53 1.62 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.733 -0.787 . . . . 0.0 111.487 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.572 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -129.17 127.44 23.25 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 119.858 -0.737 . . . . 0.0 110.615 179.859 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.7 Cg_endo -72.12 156.98 55.01 Favored 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 121.621 1.547 . . . . 0.0 113.846 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.62 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.84 -38.03 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 114.89 1.441 . . . . 0.0 114.89 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -107.0 67.97 0.23 Allowed Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.686 -1.245 . . . . 0.0 111.216 -179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.74 -169.05 25.58 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 118.27 -1.919 . . . . 0.0 111.397 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.845 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.6 p -137.46 163.95 29.87 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.549 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -126.07 177.34 6.42 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.01 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.465 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 30.5 tt0 -168.52 146.66 4.14 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 117.124 -1.83 . . . . 0.0 113.624 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.748 ' CE2' HG11 ' A' ' 25' ' ' VAL . 14.6 p90 -160.1 175.21 13.22 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.037 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.21 166.44 35.21 Favored Glycine 0 N--CA 1.497 2.75 0 C-N-CA 117.902 -2.094 . . . . 0.0 112.166 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.522 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.8 p90 -161.94 156.85 22.94 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.457 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.411 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 2.8 m120 -104.66 111.41 24.1 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.232 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.25 163.62 14.66 Favored Glycine 0 N--CA 1.503 3.14 0 C-N-CA 119.737 -1.221 . . . . 0.0 111.33 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.2 p -112.97 148.87 34.14 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 120.42 -0.512 . . . . 0.0 109.996 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.708 ' HE2' ' HG3' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -142.67 -168.97 2.89 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 119.096 -1.042 . . . . 0.0 111.938 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.542 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 30.0 p -134.76 -8.88 2.41 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.23 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.46 94.73 1.41 Allowed Glycine 0 N--CA 1.496 2.692 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.863 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' THR . . . . . 1.002 HG22 ' ND2' ' A' ' 94' ' ' ASN . 56.0 m -160.9 -50.73 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.259 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 1.002 ' ND2' HG22 ' A' ' 93' ' ' THR . 0.3 OUTLIER 172.46 110.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.863 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.54 ' HB2' ' OE1' ' A' ' 48' ' ' GLN . . . -98.51 -133.93 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.683 -0.807 . . . . 0.0 111.998 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.528 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -21.45 109.55 0.12 Allowed Pre-proline 0 N--CA 1.506 2.372 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.4 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.506 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.7 Cg_endo -62.44 -95.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 120.862 1.041 . . . . 0.0 112.34 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -151.65 -96.77 0.06 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 118.674 -1.211 . . . . 0.0 112.397 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.61 95.07 8.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.844 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.2 m-30 -65.9 -157.46 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.254 -0.979 . . . . 0.0 109.135 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.28 115.0 3.7 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 117.524 -1.67 . . . . 0.0 113.286 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.722 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.3 mt -59.62 177.67 0.2 Allowed 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.358 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.492 ' N ' ' OD1' ' A' ' 103' ' ' ASN . 9.5 p30 -60.05 77.58 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.791 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 101.7 12.36 35.29 Favored Glycine 0 N--CA 1.503 3.112 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.275 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.614 ' O ' ' N ' ' A' ' 102' ' ' LEU . 70.5 p -152.47 152.58 29.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 C-N-CA 118.885 -1.126 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -67.0 173.04 8.93 Favored 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 121.534 1.489 . . . . 0.0 112.141 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.58 ' SG ' HG13 ' A' ' 10' ' ' VAL . 1.8 t -165.2 106.43 0.79 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.833 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.48 138.76 47.25 Favored 'General case' 0 N--CA 1.505 2.309 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.674 HG22 ' N ' ' A' ' 110' ' ' GLY . 1.7 p -68.82 172.08 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.52 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.674 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.442 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.399 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.515 ' H2 ' ' HG3' ' A' ' 5' ' ' PRO . . . . . . . . 0 N--CA 1.481 1.119 0 CA-C-O 120.893 0.377 . . . . 0.0 110.021 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.444 ' C ' ' OG ' ' A' ' 3' ' ' SER . 53.4 p -46.78 -53.9 10.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.319 -0.952 . . . . 0.0 110.661 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.444 ' OG ' ' C ' ' A' ' 2' ' ' SER . 0.3 OUTLIER -165.95 -13.57 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.463 -0.895 . . . . 0.0 110.776 179.983 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.547 ' H ' ' HD3' ' A' ' 5' ' ' PRO . . . 153.31 66.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.428 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.655 ' HG2' HG23 ' A' ' 105' ' ' THR . 5.1 Cg_exo -59.3 -89.45 0.0 OUTLIER 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 121.864 1.709 . . . . 0.0 111.795 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.771 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . -110.96 -159.16 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.854 -0.738 . . . . 0.0 111.814 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.83 39.45 0.02 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 108.061 -2.016 . . . . 0.0 108.061 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.933 ' SG ' HD12 ' A' ' 102' ' ' LEU . 25.2 p -54.0 -178.0 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.707 -0.746 . . . . 0.0 111.823 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.16 138.1 27.91 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.694 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.586 HG12 HG13 ' A' ' 27' ' ' VAL . 1.3 m -128.61 130.14 68.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.574 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.585 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -92.74 169.87 10.15 Favored 'General case' 0 C--N 1.284 -2.278 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.862 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.625 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.1 t-105 -130.62 147.2 52.27 Favored 'General case' 0 C--N 1.309 -1.183 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.986 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.48 75.92 0.39 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.552 HG22 ' OE1' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -69.46 140.01 19.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.797 -179.708 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.538 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 18.1 t-20 -142.5 89.65 2.16 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.049 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.552 ' OE1' HG22 ' A' ' 14' ' ' VAL . 0.3 OUTLIER -94.34 130.57 40.59 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.612 0.967 . . . . 0.0 113.612 -179.74 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.715 ' C ' ' H ' ' A' ' 19' ' ' THR . 9.2 p90 -114.69 75.01 0.9 Allowed 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.471 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER 72.26 -12.87 0.67 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -179.549 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.715 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER 163.71 178.41 0.02 OUTLIER 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 112.766 -2.016 . . . . 0.0 106.477 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.681 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 66.18 96.96 0.03 OUTLIER Glycine 0 C--N 1.285 -2.302 0 C-N-CA 117.482 -2.294 . . . . 0.0 107.536 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.634 ' CZ ' ' OE1' ' A' ' 48' ' ' GLN . 19.7 p90 -106.59 115.83 30.89 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.832 -0.747 . . . . 0.0 112.418 -179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.17 127.08 33.7 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.625 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -104.64 110.87 23.35 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.245 -0.982 . . . . 0.0 113.464 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -95.78 98.58 10.55 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.577 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.558 HG11 ' CE1' ' A' ' 84' ' ' PHE . 38.5 t -96.08 147.01 6.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.585 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.9 m -136.97 101.72 4.65 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.419 -1.264 . . . . 0.0 108.484 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.586 HG13 HG12 ' A' ' 10' ' ' VAL . 1.5 t -72.94 151.97 7.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 C-N-CA 119.669 -0.813 . . . . 0.0 112.364 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.402 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.1 tttt -143.59 104.04 4.16 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.468 179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.661 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.5 t30 -90.61 116.57 28.6 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -120.11 1.5 10.86 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 124.105 0.878 . . . . 0.0 110.147 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' SER . 20.6 p -57.9 -81.62 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.58 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.583 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.54 72.52 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 123.726 0.641 . . . . 0.0 111.592 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.8 152.58 3.75 Favored Pre-proline 0 C--N 1.306 -1.29 0 C-N-CA 119.012 -1.075 . . . . 0.0 111.395 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.37 105.49 1.59 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 121.192 1.261 . . . . 0.0 109.342 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -90.7 92.25 3.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 118.46 -1.296 . . . . 0.0 111.779 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -103.47 67.22 0.9 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.95 148.62 24.01 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.6 -2.2 . . . . 0.0 107.6 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.673 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 41.0 p-90 -165.69 177.44 7.28 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.7 -1.6 . . . . 0.0 112.103 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.412 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.6 OUTLIER -140.72 108.79 5.74 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.625 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.881 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.43 173.7 6.83 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.194 -1.002 . . . . 0.0 108.94 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.495 ' OG1' HG23 ' A' ' 66' ' ' THR . 3.3 m -157.83 152.73 25.36 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 117.745 -1.582 . . . . 0.0 112.913 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' ' N ' ' A' ' 43' ' ' SER . 24.2 p90 -178.69 -142.88 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 113.773 -1.558 . . . . 0.0 108.179 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.574 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 20.2 m -163.24 173.71 13.02 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 117.626 -1.63 . . . . 0.0 112.663 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.71 ' CD1' ' HB1' ' A' ' 95' ' ' ALA . 6.9 m-85 -107.26 101.5 38.92 Favored Pre-proline 0 N--CA 1.486 1.341 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.843 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -55.53 -55.62 2.91 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 120.79 0.993 . . . . 0.0 110.531 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.64 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 8.7 t -69.48 -178.25 1.37 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 118.839 -1.144 . . . . 0.0 109.914 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.64 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -87.27 55.91 4.54 Favored Glycine 0 C--N 1.291 -1.969 0 C-N-CA 118.961 -1.59 . . . . 0.0 110.241 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.845 ' CD ' ' HB2' ' A' ' 95' ' ' ALA . 10.4 mt-30 -90.94 125.34 35.74 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.025 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.462 ' OE1' ' OE1' ' A' ' 60' ' ' GLN . 10.2 mm-40 -115.58 101.8 9.19 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.96 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.55 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.3 p -65.03 161.17 3.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.135 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 43.2 p -142.94 -65.8 0.39 Allowed 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.475 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.552 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -90.81 136.07 33.31 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.093 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.9 153.59 40.3 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.502 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.408 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 44.5 t-105 -154.04 146.18 23.72 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.054 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.408 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.4 OUTLIER 65.88 23.87 11.31 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.776 -179.989 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 58' ' ' VAL . 4.4 p -173.78 113.63 0.2 Allowed 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.17 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -72.64 73.36 1.06 Allowed 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.555 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 56' ' ' SER . 2.0 m -70.13 148.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.719 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.8 p -149.26 107.16 3.69 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.78 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.462 ' OE1' ' OE1' ' A' ' 49' ' ' GLN . 31.1 tt0 -78.59 104.29 9.1 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.594 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.567 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.3 p -82.84 -155.67 0.16 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.409 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.625 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -49.83 88.71 0.01 OUTLIER Glycine 0 N--CA 1.497 2.742 0 C-N-CA 118.967 -1.587 . . . . 0.0 110.098 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.567 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.4 OUTLIER 53.19 2.19 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.549 -0.861 . . . . 0.0 110.49 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.625 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.59 -173.59 2.34 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.315 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.579 HG21 ' CE2' ' A' ' 44' ' ' PHE . 50.0 t -140.82 152.92 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.299 -0.96 . . . . 0.0 112.531 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 41' ' ' THR . 94.5 m -153.94 115.53 4.19 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.308 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.667 HG23 HD21 ' A' ' 40' ' ' LEU . 1.7 t -109.35 145.75 15.69 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.949 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.661 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -131.18 92.91 3.27 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 114.172 -1.376 . . . . 0.0 107.324 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.673 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 4.6 p-10 -74.14 118.43 17.09 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.032 -1.067 . . . . 0.0 112.167 -179.608 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.121 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -43.1 164.68 0.12 Allowed Pre-proline 0 N--CA 1.481 1.111 0 CA-C-N 113.37 -1.741 . . . . 0.0 112.003 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -65.03 -34.78 45.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.066 1.844 . . . . 0.0 112.416 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.667 ' CE3' ' ND2' ' A' ' 73' ' ' ASN . 0.0 OUTLIER -70.92 -54.91 9.69 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.984 -179.892 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.121 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.5 p30 -75.91 -1.16 24.12 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 118.947 -1.101 . . . . 0.0 110.15 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.475 ' CA ' ' ND2' ' A' ' 69' ' ' ASN . . . -113.67 40.08 2.62 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.0 p -105.28 71.41 0.93 Allowed 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.868 -0.733 . . . . 0.0 110.971 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.826 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -127.69 119.8 21.58 Favored Pre-proline 0 CA--C 1.565 1.541 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.483 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.2 Cg_endo -69.85 158.57 56.4 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.594 1.529 . . . . 0.0 114.114 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -22.52 -41.23 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 CA-C-N 114.159 -1.382 . . . . 0.0 114.051 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -117.82 69.31 0.31 Allowed Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.414 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.59 -168.01 17.32 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.354 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.525 ' N ' HG13 ' A' ' 76' ' ' ILE . 16.6 p -139.72 162.56 34.83 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.967 -1.093 . . . . 0.0 113.307 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.635 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -127.51 178.72 5.91 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 113.724 -1.58 . . . . 0.0 107.578 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.483 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 7.0 tt0 -167.66 145.78 4.62 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 116.987 -1.885 . . . . 0.0 113.53 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.558 ' CE1' HG11 ' A' ' 25' ' ' VAL . 16.6 p90 -158.96 -178.91 7.59 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.819 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.21 162.51 36.29 Favored Glycine 0 N--CA 1.495 2.614 0 C-N-CA 117.581 -2.247 . . . . 0.0 112.198 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.6 p90 -155.18 174.19 15.55 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 119.763 -0.775 . . . . 0.0 111.04 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.424 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.6 m-20 -126.65 111.85 14.78 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.053 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.428 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -122.75 154.47 17.01 Favored Glycine 0 N--CA 1.5 2.961 0 C-N-CA 119.983 -1.104 . . . . 0.0 111.966 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.1 p -104.75 145.69 30.01 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.67 ' HD1' ' C ' ' A' ' 90' ' ' HIS . 0.9 OUTLIER -139.26 169.83 17.05 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.638 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.487 ' O ' HG23 ' A' ' 91' ' ' THR . 3.2 t -171.12 55.44 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.514 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -166.22 -71.38 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 118.736 -1.697 . . . . 0.0 112.043 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' THR . . . . . 1.033 HG22 ' H ' ' A' ' 94' ' ' ASN . 84.2 m -145.02 -163.35 1.69 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.57 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 1.033 ' H ' HG22 ' A' ' 93' ' ' THR . 6.4 p30 -78.61 160.09 27.75 Favored 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.908 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.845 ' HB2' ' CD ' ' A' ' 48' ' ' GLN . . . -107.56 -88.98 0.46 Allowed 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.173 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.471 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -23.78 100.0 0.08 OUTLIER Pre-proline 0 N--CA 1.502 2.169 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.971 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.461 ' HD2' ' CE1' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -65.92 -140.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 121.413 1.409 . . . . 0.0 111.189 179.957 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.461 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 76.3 p -112.29 -76.39 0.59 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.571 -0.851 . . . . 0.0 112.857 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.461 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -105.79 99.91 9.49 Favored 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 119.062 -1.055 . . . . 0.0 111.583 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.542 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.8 m-30 -68.73 -142.42 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 115.311 -0.859 . . . . 0.0 108.842 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.7 m -160.8 108.52 1.55 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 116.994 -1.883 . . . . 0.0 113.454 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.933 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.4 OUTLIER -73.2 154.44 40.26 Favored 'General case' 0 C--O 1.206 -1.232 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.651 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.55 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.2 OUTLIER -52.26 81.84 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.624 -1.23 . . . . 0.0 110.793 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.636 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 140.23 -33.95 2.04 Favored Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.989 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.771 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -154.23 163.87 22.65 Favored Pre-proline 0 N--CA 1.505 2.289 0 C-N-CA 118.25 -1.38 . . . . 0.0 113.083 -179.821 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 106' ' ' PRO . . . . . 0.695 ' HD2' HG22 ' A' ' 105' ' ' THR . 1.7 Cg_endo -66.24 118.79 5.8 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 122.654 2.236 . . . . 0.0 111.907 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.525 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.6 t -100.1 123.05 43.89 Favored 'General case' 0 N--CA 1.501 2.108 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.967 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.78 162.22 16.49 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.859 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.984 HG22 ' H ' ' A' ' 110' ' ' GLY . 12.8 p -90.07 -130.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.874 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.984 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.494 2.535 0 CA-C-O 116.323 -2.376 . . . . 0.0 110.308 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 3' ' ' SER . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 120.867 0.365 . . . . 0.0 110.185 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 46.72 14.4 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.863 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.521 ' N ' ' O ' ' A' ' 1' ' ' ALA . 50.6 m -91.6 -69.17 0.75 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.816 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.13 174.46 26.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.377 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.43 ' HG2' ' CG2' ' A' ' 105' ' ' THR . 3.0 Cg_exo -56.05 -79.4 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.083 1.855 . . . . 0.0 111.922 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.637 ' H ' HG21 ' A' ' 105' ' ' THR . . . -99.74 -151.91 0.41 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.092 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.68 39.58 0.02 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 107.422 -2.271 . . . . 0.0 107.422 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.459 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 24.3 p -55.01 -171.1 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.271 -0.964 . . . . 0.0 111.876 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.11 131.8 6.88 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.982 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.507 HG12 HG13 ' A' ' 27' ' ' VAL . 2.6 m -113.79 130.51 67.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 C-N-CA 120.004 -0.679 . . . . 0.0 110.581 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.613 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -97.81 161.03 13.94 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.514 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.895 ' CZ3' ' HB2' ' A' ' 96' ' ' ALA . 22.5 t-105 -112.04 149.41 32.09 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.59 0.71 . . . . 0.0 112.517 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.59 76.98 0.36 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -68.92 146.61 12.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.7 t30 -153.94 97.12 2.04 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.209 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.693 ' NE2' ' CD2' ' A' ' 90' ' ' HIS . 0.5 OUTLIER -88.43 132.08 34.61 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -179.645 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.674 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 44.4 p90 -112.82 -149.4 0.45 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 179.525 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.674 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 81.8 m-20 -65.48 82.31 0.06 Allowed 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.517 -1.673 . . . . 0.0 107.273 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.581 ' O ' ' NE1' ' A' ' 17' ' ' TRP . 0.3 OUTLIER 68.33 133.73 0.03 OUTLIER 'General case' 0 C--O 1.203 -1.366 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.195 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.531 ' HA3' ' CZ2' ' A' ' 17' ' ' TRP . . . 101.75 129.33 6.65 Favored Glycine 0 C--N 1.279 -2.611 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.553 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 32.0 p90 -102.93 133.05 48.68 Favored 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.17 -0.612 . . . . 0.0 112.437 -179.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 22' ' ' THR . 0.8 OUTLIER -99.49 111.91 24.19 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.614 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.492 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -93.75 117.17 29.74 Favored 'General case' 0 C--N 1.292 -1.896 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.727 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.8 102.25 14.03 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.483 HG11 ' HE1' ' A' ' 84' ' ' PHE . 53.2 t -99.71 147.3 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 N-CA-C 113.993 1.109 . . . . 0.0 113.993 -179.555 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.613 ' HB ' HD11 ' A' ' 11' ' ' LEU . 18.5 m -136.71 100.58 4.37 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.948 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.512 HG21 ' CZ2' ' A' ' 38' ' ' TRP . 3.0 t -68.79 146.88 12.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.104 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.637 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.2 tmtt? -138.48 102.91 4.74 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.567 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.693 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -95.58 136.06 36.45 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.516 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -131.64 5.8 4.34 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.544 -1.207 . . . . 0.0 109.523 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' SER . 19.1 p -47.24 -86.58 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.026 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.04 34.51 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.505 -179.951 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.937 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.4 155.71 45.94 Favored Pre-proline 0 N--CA 1.481 1.11 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.886 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.35 96.77 0.49 Allowed 'Trans proline' 0 C--N 1.323 -0.763 0 C-N-CA 121.284 1.322 . . . . 0.0 110.14 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.449 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.3 t -71.08 117.38 14.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.593 -1.243 . . . . 0.0 111.269 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -123.03 75.01 1.25 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.368 -0.833 . . . . 0.0 108.765 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.44 140.19 7.7 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.431 -1.867 . . . . 0.0 108.431 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.706 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 40.8 p-90 -158.79 177.46 11.15 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.303 -1.359 . . . . 0.0 111.626 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -141.08 112.37 7.38 Favored 'General case' 0 C--O 1.202 -1.4 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.715 179.897 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.86 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.41 174.68 5.76 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.934 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.788 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -163.55 157.71 19.89 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 117.325 -1.75 . . . . 0.0 113.153 -179.88 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.512 ' N ' ' CG2' ' A' ' 41' ' ' THR . 31.1 p90 -178.18 -141.43 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 113.368 -1.742 . . . . 0.0 107.997 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.478 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 61.2 m -160.82 146.9 14.87 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 117.876 -1.53 . . . . 0.0 112.187 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.65 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 8.3 m-85 -77.55 119.3 76.88 Favored Pre-proline 0 N--CA 1.482 1.132 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.146 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.544 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 3.7 Cg_endo -63.38 -66.67 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.148 1.232 . . . . 0.0 111.579 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.536 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.4 t -69.44 -122.44 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.536 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -130.96 38.48 1.93 Allowed Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.494 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 3.2 mt-30 -75.24 98.31 3.74 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.517 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.485 ' OE1' HG22 ' A' ' 51' ' ' THR . 1.5 pp0? -98.95 112.42 24.54 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.57 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 58' ' ' VAL . 2.4 p -70.52 148.26 10.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.2 -1.0 . . . . 0.0 111.12 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.619 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 21.8 p -127.6 -63.24 1.04 Allowed 'General case' 0 N--CA 1.491 1.596 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.77 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.619 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -96.94 138.59 34.24 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.794 179.938 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -148.29 157.19 43.34 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.101 -1.039 . . . . 0.0 111.345 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' TRP . . . . . 0.406 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 43.3 t-105 -153.32 146.12 24.36 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.228 -0.989 . . . . 0.0 111.266 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.5 OUTLIER 66.97 22.28 10.1 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.584 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.605 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 13.1 t -175.95 125.8 0.21 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.405 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.1 79.67 9.3 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.608 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 50' ' ' VAL . 1.0 OUTLIER -81.81 152.28 4.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.635 -179.971 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -155.34 131.45 10.16 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.476 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.468 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.6 pt20 -95.12 119.98 34.55 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.647 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.866 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.7 p -86.91 68.93 10.22 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.18 -56.98 4.03 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.404 ' H ' ' H ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -148.91 -20.18 0.3 Allowed 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.404 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.866 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.99 -168.46 2.24 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.942 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.65 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 84.2 t -147.35 155.2 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.757 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.788 HG23 ' OG1' ' A' ' 41' ' ' THR . 70.7 m -161.63 124.29 3.03 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.705 -1.134 . . . . 0.0 108.653 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.605 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.4 t -117.53 146.4 22.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.093 0 C-N-CA 119.548 -0.861 . . . . 0.0 111.857 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -132.16 90.51 2.82 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.706 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 6.8 p-10 -73.53 122.52 22.33 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 118.948 -1.101 . . . . 0.0 112.445 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.772 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.3 155.88 0.18 Allowed Pre-proline 0 N--CA 1.479 0.993 0 CA-C-N 113.592 -1.64 . . . . 0.0 112.186 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.96 -35.28 35.45 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 121.759 1.639 . . . . 0.0 112.297 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.772 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -70.55 -57.38 4.81 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 118.931 -1.108 . . . . 0.0 110.981 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.538 HD21 ' HB2' ' A' ' 69' ' ' ASN . 0.1 OUTLIER -65.85 -21.34 66.46 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.994 -1.082 . . . . 0.0 110.171 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.451 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -96.61 27.87 15.8 Favored Glycine 0 N--CA 1.486 1.967 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.654 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 32.2 m -91.86 60.68 3.95 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.956 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.734 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.49 136.4 19.91 Favored Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.387 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' GLY . 7.2 Cg_endo -69.81 151.42 68.75 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 121.51 1.474 . . . . 0.0 111.181 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.937 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -40.41 -22.32 0.01 OUTLIER 'General case' 0 C--O 1.2 -1.525 0 C-N-CA 119.749 -0.78 . . . . 0.0 112.268 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.71 64.19 0.28 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.31 -162.83 18.68 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 118.11 -1.995 . . . . 0.0 111.485 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.637 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.6 p -139.5 162.41 35.12 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-O 121.867 0.841 . . . . 0.0 112.765 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.734 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -136.84 122.2 19.39 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.592 ' CG ' HG23 ' A' ' 26' ' ' THR . 3.5 mp0 -114.82 164.91 13.43 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.483 ' HE1' HG11 ' A' ' 25' ' ' VAL . 8.3 p90 -163.89 -178.09 5.48 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 112.688 -2.051 . . . . 0.0 108.986 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.24 159.13 32.39 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 117.556 -2.259 . . . . 0.0 111.937 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.3 p90 -154.77 169.2 24.51 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.487 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.416 ' ND2' ' OE1' ' A' ' 52' ' ' GLN . 3.6 m-20 -125.57 112.52 16.28 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.53 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA2' HG23 ' A' ' 51' ' ' THR . . . -121.03 150.23 17.25 Favored Glycine 0 N--CA 1.512 3.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.464 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . 0.427 ' OG ' ' CG ' ' A' ' 49' ' ' GLN . 52.1 p -77.16 155.26 32.42 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 120.121 -0.631 . . . . 0.0 109.715 179.742 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.693 ' CD2' ' NE2' ' A' ' 16' ' ' GLN . 9.6 p80 -147.99 -157.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 118.957 -1.097 . . . . 0.0 111.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.3 p -151.78 -8.46 0.22 Allowed 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.05 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.63 84.7 1.69 Allowed Glycine 0 N--CA 1.494 2.544 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.968 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.944 HG22 ' H ' ' A' ' 94' ' ' ASN . 96.3 m -161.58 -130.86 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.283 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.944 ' H ' HG22 ' A' ' 93' ' ' THR . 32.6 t-20 -87.73 131.34 34.52 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.609 -0.836 . . . . 0.0 111.273 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.454 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -109.46 -155.36 0.56 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.016 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.895 ' HB2' ' CZ3' ' A' ' 12' ' ' TRP . . . -25.26 122.29 0.21 Allowed Pre-proline 0 N--CA 1.502 2.146 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.705 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.8 -142.16 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 121.214 1.276 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.407 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 42.8 p -108.5 -100.57 0.37 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.472 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.27 104.22 16.82 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 118.503 -1.279 . . . . 0.0 112.196 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.3 m-30 -70.37 -141.84 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.363 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.5 m -162.39 109.81 1.32 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 117.022 -1.871 . . . . 0.0 113.869 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.5 mt -53.85 178.14 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.817 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -39.66 -26.41 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.927 -0.709 . . . . 0.0 111.973 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.804 ' O ' HG23 ' A' ' 105' ' ' THR . . . -165.31 41.7 0.29 Allowed Glycine 0 N--CA 1.491 2.307 0 C-N-CA 118.653 -1.737 . . . . 0.0 111.499 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.2 OUTLIER -171.83 147.68 2.01 Favored Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.685 179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.17 156.64 44.03 Favored 'Trans proline' 0 C--O 1.212 -0.813 0 C-N-CA 121.566 1.51 . . . . 0.0 112.554 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.41 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.0 t -147.26 101.65 3.41 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.342 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.01 135.75 57.81 Favored 'General case' 0 N--CA 1.518 2.951 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -179.587 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 1.056 HG22 ' H ' ' A' ' 110' ' ' GLY . 5.3 p -59.93 -163.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 118.795 -1.162 . . . . 0.0 110.926 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 1.056 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 116.35 -2.361 . . . . 0.0 110.386 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.8 t -153.34 69.72 0.83 Allowed 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.849 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.7 p -169.8 155.09 5.64 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.819 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.02 173.27 31.85 Favored Glycine 0 N--CA 1.488 2.164 0 C-N-CA 119.501 -1.333 . . . . 0.0 110.251 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -54.67 -55.24 3.46 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.036 1.824 . . . . 0.0 111.915 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 1.067 ' H ' HG21 ' A' ' 105' ' ' THR . . . -106.21 -159.77 0.72 Allowed 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.946 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.33 38.42 0.05 OUTLIER Glycine 0 N--CA 1.492 2.419 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.446 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 4.3 p -49.21 178.63 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 113.904 -1.148 . . . . 0.0 113.016 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -135.13 106.37 6.74 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.035 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.748 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.1 m -99.45 139.12 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 119.061 -1.056 . . . . 0.0 112.428 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.619 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -109.21 162.65 14.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.848 179.772 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.533 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.2 t-105 -128.05 139.68 52.39 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.318 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -116.22 62.59 0.37 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.334 -2.307 . . . . 0.0 107.334 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 21' ' ' PHE . 14.6 p -69.3 140.84 18.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.485 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.4 t30 -140.06 100.92 4.04 Favored 'General case' 0 N--CA 1.489 1.496 0 CA-C-N 114.616 -1.175 . . . . 0.0 108.762 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.693 ' OE1' ' N ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER -85.17 107.92 17.46 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.105 -1.038 . . . . 0.0 112.967 -179.782 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.693 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 5.0 p90 -106.75 99.84 9.39 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.692 ' C ' HE22 ' A' ' 16' ' ' GLN . 0.1 OUTLIER 78.89 -47.41 0.41 Allowed 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.541 -179.657 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.702 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -170.34 -56.18 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.514 179.894 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.702 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -59.3 163.98 11.3 Favored Glycine 0 C--O 1.198 -2.106 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.684 ' CE1' ' NE2' ' A' ' 48' ' ' GLN . 2.8 p90 -136.28 120.87 18.3 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 119.13 -1.028 . . . . 0.0 112.681 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 15' ' ' ASN . 1.4 t -78.92 174.02 11.95 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 179.443 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.533 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -153.2 125.73 8.18 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 117.04 -1.864 . . . . 0.0 114.053 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -107.8 91.5 3.68 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 179.558 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.626 HG11 ' CE2' ' A' ' 84' ' ' PHE . 40.5 t -96.02 144.3 10.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 113.94 1.089 . . . . 0.0 113.94 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.619 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.4 OUTLIER -126.35 129.72 49.39 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 114.489 -1.232 . . . . 0.0 107.95 179.687 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.823 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 23.7 t -101.2 103.81 15.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 C-N-CA 119.281 -0.968 . . . . 0.0 113.151 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.76 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.6 tmtt? -95.1 106.53 18.54 Favored 'General case' 0 C--N 1.291 -1.951 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.395 179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.531 ' OD1' ' C ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -107.87 140.94 40.22 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.72 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -140.69 19.34 2.34 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 114.214 -1.357 . . . . 0.0 109.028 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.413 ' O ' ' CB ' ' A' ' 32' ' ' SER . 13.1 p -48.08 -88.47 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.176 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 170.41 31.55 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.822 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.998 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -154.47 170.98 7.66 Favored Pre-proline 0 N--CA 1.48 1.07 0 C-N-CA 118.085 -1.446 . . . . 0.0 111.443 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.796 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 9.2 Cg_endo -74.83 97.34 1.06 Allowed 'Trans proline' 0 C--N 1.323 -0.784 0 C-N-CA 121.842 1.695 . . . . 0.0 109.963 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.4 t -75.43 94.31 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 118.249 -1.38 . . . . 0.0 111.591 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.19 50.25 1.37 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 112.1 167.49 17.84 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 107.826 -2.11 . . . . 0.0 107.826 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.756 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 37.8 p-90 -171.17 176.39 3.97 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 117.808 -1.557 . . . . 0.0 111.836 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.1 102.14 4.32 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.887 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -89.63 172.8 8.69 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.699 -1.201 . . . . 0.0 109.409 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 2.0 m -160.73 142.12 12.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.437 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.559 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.6 p90 -171.0 -140.1 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.249 -1.342 . . . . 0.0 108.351 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.562 ' HG ' ' HB1' ' A' ' 64' ' ' ALA . 34.2 m -161.03 168.2 24.94 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 117.419 -1.713 . . . . 0.0 112.782 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.783 ' CE1' ' HB1' ' A' ' 95' ' ' ALA . 2.9 m-85 -101.66 109.41 59.26 Favored Pre-proline 0 N--CA 1.489 1.483 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.31 -63.7 0.12 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.098 1.199 . . . . 0.0 111.367 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 93' ' ' THR . 38.8 t -69.59 -172.7 0.5 Allowed 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.575 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.484 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -84.9 57.9 4.99 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.072 -1.537 . . . . 0.0 109.886 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.684 ' NE2' ' CE1' ' A' ' 21' ' ' PHE . 1.2 mm100 -94.41 108.91 20.81 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 119.213 -0.995 . . . . 0.0 111.014 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.616 ' OE1' ' NE2' ' A' ' 60' ' ' GLN . 30.6 mm-40 -106.57 108.89 20.63 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.913 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.1 p -76.47 157.04 5.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.187 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.505 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 72.6 p -138.47 -68.82 0.44 Allowed 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.531 -0.867 . . . . 0.0 111.1 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLN . . . . . 0.505 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.2 mt-30 -80.59 165.26 22.24 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.03 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.14 153.58 8.24 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 118.717 -1.193 . . . . 0.0 111.923 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 32.3 t-105 -147.32 136.88 22.79 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.354 -0.939 . . . . 0.0 110.899 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.731 ' HA ' HD21 ' A' ' 73' ' ' ASN . 1.7 p 60.23 26.6 16.06 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.196 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.14 117.26 1.65 Allowed 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.0 m -82.11 77.64 8.89 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.977 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.2 m -68.99 154.37 8.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.613 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.9 p -154.07 108.14 3.0 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.908 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.616 ' NE2' ' OE1' ' A' ' 49' ' ' GLN . 3.6 tt0 -88.09 116.01 25.97 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.036 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 4.7 p -94.39 89.38 5.85 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.636 -0.825 . . . . 0.0 110.777 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 71.16 -74.6 0.66 Allowed Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.388 -1.387 . . . . 0.0 109.963 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 -14.69 1.55 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.122 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.562 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.29 -173.91 4.2 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.033 -1.067 . . . . 0.0 110.063 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 44' ' ' PHE . 51.2 t -147.27 160.11 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 118.735 -1.186 . . . . 0.0 113.637 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.3 m -155.53 145.93 21.91 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.899 -1.5 . . . . 0.0 108.563 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.416 HG23 HD21 ' A' ' 40' ' ' LEU . 2.8 t -141.07 119.4 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 118.727 -1.189 . . . . 0.0 112.469 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.83 91.43 4.83 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.97 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.756 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -70.77 122.8 20.53 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.194 -1.003 . . . . 0.0 111.344 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.713 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -43.91 166.65 0.1 Allowed Pre-proline 0 C--N 1.307 -1.276 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.452 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.0 Cg_endo -70.04 -39.98 5.38 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 122.155 1.903 . . . . 0.0 112.392 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' TRP . . . . . 0.605 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -68.56 -55.72 10.68 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.024 -1.07 . . . . 0.0 110.514 -179.875 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.731 HD21 ' HA ' ' A' ' 55' ' ' SER . 21.6 p30 -76.71 11.02 1.84 Allowed 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.18 -1.008 . . . . 0.0 109.624 179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.554 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -139.87 37.56 1.71 Allowed Glycine 0 N--CA 1.484 1.898 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.574 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.1 m -104.08 61.74 0.74 Allowed 'General case' 0 C--N 1.309 -1.162 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.956 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.484 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -109.49 136.68 20.22 Favored Pre-proline 0 N--CA 1.484 1.267 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.368 179.926 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.626 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.9 Cg_endo -71.3 171.16 16.63 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 121.396 1.397 . . . . 0.0 111.068 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.998 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -63.18 17.72 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.563 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.626 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -149.8 61.76 0.42 Allowed Glycine 0 C--N 1.291 -1.954 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.22 -155.12 9.57 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 118.641 -1.742 . . . . 0.0 110.733 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.76 HG22 ' HA ' ' A' ' 28' ' ' LYS . 0.9 OUTLIER -141.73 168.8 18.89 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.244 -0.983 . . . . 0.0 112.603 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.823 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.34 -173.3 3.12 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLN . . . . . 0.641 ' CD ' ' N ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -167.59 144.74 4.4 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 116.792 -1.963 . . . . 0.0 113.649 -179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.641 ' N ' ' CD ' ' A' ' 83' ' ' GLN . 3.9 p90 -164.13 164.73 22.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.604 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.51 178.47 32.96 Favored Glycine 0 N--CA 1.504 3.192 0 C-N-CA 118.068 -2.015 . . . . 0.0 111.855 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 4.4 p90 -164.17 -169.8 1.93 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.687 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -142.93 110.8 5.93 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.64 -0.824 . . . . 0.0 110.741 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.71 164.08 12.7 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.026 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 85.2 p -114.08 136.38 52.99 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.652 ' C ' ' ND1' ' A' ' 90' ' ' HIS . 0.3 OUTLIER -151.03 -175.33 5.1 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 117.538 -1.665 . . . . 0.0 113.514 -179.892 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.53 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 2.3 t -171.17 48.85 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.675 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.44 -129.97 1.98 Allowed Glycine 0 N--CA 1.493 2.459 0 C-N-CA 118.919 -1.61 . . . . 0.0 112.167 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . 0.2 OUTLIER -90.92 -155.65 0.4 Allowed 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -70.72 165.48 22.9 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.84 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.783 ' HB1' ' CE1' ' A' ' 44' ' ' PHE . . . -111.6 -8.38 14.23 Favored 'General case' 0 N--CA 1.486 1.375 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.342 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -106.61 106.44 57.73 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.441 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.522 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.8 Cg_endo -64.25 -95.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 120.834 1.022 . . . . 0.0 112.248 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 109' ' ' VAL . 1.1 p -153.25 -90.41 0.05 OUTLIER 'General case' 0 N--CA 1.497 1.882 0 C-N-CA 118.919 -1.113 . . . . 0.0 112.279 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -96.78 94.51 7.31 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.595 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -66.23 -158.34 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 43.3 m -153.79 118.71 5.03 Favored 'General case' 0 C--N 1.309 -1.179 0 C-N-CA 116.956 -1.898 . . . . 0.0 114.015 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -63.72 176.4 0.91 Allowed 'General case' 0 N--CA 1.48 1.026 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.315 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -36.94 -32.94 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 C-N-CA 120.025 -0.67 . . . . 0.0 112.675 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.856 ' O ' HG23 ' A' ' 105' ' ' THR . . . -155.72 47.03 0.51 Allowed Glycine 0 N--CA 1.499 2.898 0 C-N-CA 118.463 -1.827 . . . . 0.0 111.865 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' THR . . . . . 1.067 HG21 ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER 179.85 160.26 0.83 Allowed Pre-proline 0 C--O 1.192 -1.965 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.97 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.94 179.79 1.69 Allowed 'Trans proline' 0 C--N 1.321 -0.891 0 C-N-CA 122.004 1.802 . . . . 0.0 112.87 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.748 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.5 t -170.13 106.68 0.33 Allowed 'General case' 0 N--CA 1.497 1.898 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.305 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 70.6 p -72.06 149.86 44.47 Favored 'General case' 0 N--CA 1.506 2.358 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 1.095 HG12 ' H ' ' A' ' 110' ' ' GLY . 5.0 t -59.05 -167.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 C-N-CA 118.981 -1.088 . . . . 0.0 110.422 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG12 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.482 0 CA-C-O 116.289 -2.395 . . . . 0.0 110.301 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.969 0.414 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -178.28 43.21 0.09 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.871 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.5 p -60.42 -160.79 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.779 -0.71 . . . . 0.0 110.94 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.64 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -165.3 157.55 15.39 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.192 179.859 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.477 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.0 m -139.63 130.6 32.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.151 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.555 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.79 157.09 16.05 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.718 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.563 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.6 t-105 -114.55 141.44 47.73 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.831 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.14 76.28 0.41 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.2 p -69.23 149.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 . . . . . 0 C--N 1.302 -1.491 0 CA-C-N 113.91 -1.496 . . . . 0.0 107.348 179.839 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.584 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 8.3 p90 . . . . . 0 CA--C 1.487 -1.448 0 CA-C-O 121.583 0.706 . . . . 0.0 111.192 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.504 HG22 ' O ' ' A' ' 22' ' ' THR . 0.4 OUTLIER -97.11 114.34 26.0 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.563 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -93.74 120.62 34.24 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.367 -0.933 . . . . 0.0 113.422 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -99.08 95.83 7.38 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG11 ' CE1' ' A' ' 84' ' ' PHE . 29.8 t -91.81 152.46 3.39 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.555 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.0 OUTLIER -138.88 106.08 5.49 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.184 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.1 t -71.2 149.01 10.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.101 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.514 ' HA ' HG22 ' A' ' 81' ' ' THR . 6.5 tptm -141.03 102.81 4.34 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.12 -0.945 . . . . 0.0 110.186 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.83 HD22 ' N ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -96.76 136.93 36.61 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.948 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.83 ' N ' HD22 ' A' ' 29' ' ' ASN . 9.5 t -141.47 -4.31 1.12 Allowed 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.681 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.1 p -51.97 -81.27 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.118 -1.033 . . . . 0.0 110.339 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.51 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 163.52 73.55 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.373 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.49 149.28 3.67 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.22 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -72.27 97.37 0.85 Allowed 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 121.207 1.271 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.451 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.9 OUTLIER -77.49 100.52 2.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.78 -179.89 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -110.44 58.4 0.61 Allowed 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.06 152.39 21.39 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 107.909 -2.077 . . . . 0.0 107.909 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.644 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 37.3 p-90 -166.35 178.07 6.41 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 117.693 -1.603 . . . . 0.0 112.208 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.34 102.51 4.37 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.133 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.869 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -93.97 175.06 6.86 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.957 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.542 ' HG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -169.92 156.22 6.07 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 117.854 -1.539 . . . . 0.0 112.679 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.498 ' CD2' ' N ' ' A' ' 43' ' ' SER . 20.2 p90 -176.73 -132.81 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 113.565 -1.652 . . . . 0.0 107.8 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.498 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -162.29 148.23 13.0 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 117.726 -1.589 . . . . 0.0 111.951 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.654 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -82.8 119.01 73.62 Favored Pre-proline 0 N--CA 1.486 1.36 0 C-N-CA 118.601 -1.24 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -55.23 -72.42 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 121.083 1.189 . . . . 0.0 111.764 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.6 t -69.58 -134.0 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 110.535 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -118.57 51.86 0.73 Allowed Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.343 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.726 ' C ' HE21 ' A' ' 49' ' ' GLN . 1.6 mp0 -67.96 88.35 0.27 Allowed 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.492 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.859 HE21 ' N ' ' A' ' 49' ' ' GLN . 1.2 mm-40 -76.99 85.75 3.51 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -74.64 144.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.839 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.633 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -143.38 -61.02 0.41 Allowed 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 119.033 -1.067 . . . . 0.0 111.932 -179.838 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.633 ' H ' HG23 ' A' ' 51' ' ' THR . 1.1 mt-30 -75.54 135.26 40.6 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.569 -1.252 . . . . 0.0 110.073 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.431 ' HB2' HG21 ' A' ' 58' ' ' VAL . . . -147.89 156.11 42.33 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 118.785 -1.166 . . . . 0.0 112.146 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 34.2 t-105 -151.91 142.16 22.38 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.6 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 t 62.31 27.43 16.39 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.583 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -171.36 125.34 0.62 Allowed 'General case' 0 C--N 1.303 -1.428 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.317 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -87.28 73.59 9.65 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.035 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.489 HG12 HG13 ' A' ' 67' ' ' VAL . 33.0 m -69.01 153.86 8.66 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 115.044 -0.98 . . . . 0.0 112.484 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.416 HG23 ' C ' ' A' ' 58' ' ' VAL . 44.2 p -155.42 112.4 3.26 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.658 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.475 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 6.8 pt20 -91.02 113.42 25.68 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.489 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 4.7 p -87.68 86.07 7.14 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.774 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 73.71 -71.59 1.34 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -139.28 -15.98 1.08 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.029 -0.668 . . . . 0.0 109.716 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.489 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -87.9 -176.46 5.49 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.048 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.654 HG21 ' CD2' ' A' ' 44' ' ' PHE . 44.8 t -145.54 161.06 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 C-N-CA 118.596 -1.242 . . . . 0.0 113.888 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.611 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 44.9 m -157.52 143.79 17.76 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 113.627 -1.624 . . . . 0.0 108.284 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.556 HG23 HD21 ' A' ' 40' ' ' LEU . 2.2 t -139.66 117.47 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.617 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -99.03 91.87 5.22 Favored 'General case' 0 C--N 1.288 -2.092 0 CA-C-N 114.291 -1.322 . . . . 0.0 108.132 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.644 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.8 p-10 -72.47 121.56 19.8 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.195 -1.002 . . . . 0.0 112.215 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.84 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -40.88 162.07 0.11 Allowed Pre-proline 0 N--CA 1.488 1.475 0 CA-C-N 113.563 -1.653 . . . . 0.0 112.47 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.7 Cg_endo -68.86 -36.36 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 121.869 1.713 . . . . 0.0 111.939 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.719 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.67 -56.3 7.63 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 118.962 -1.095 . . . . 0.0 110.494 -179.895 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.84 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -74.33 2.73 8.64 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 118.818 -1.153 . . . . 0.0 109.492 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.545 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -122.43 37.12 2.94 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -104.71 56.53 0.7 Allowed 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.207 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.681 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -106.86 130.62 22.61 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.741 -0.783 . . . . 0.0 111.195 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 78' ' ' ALA . 8.7 Cg_endo -72.32 154.19 56.2 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 121.606 1.537 . . . . 0.0 113.381 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.51 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -21.84 -49.14 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.67 70.71 0.21 Allowed Glycine 0 N--CA 1.493 2.447 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.417 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -153.5 -165.56 13.71 Favored Glycine 0 C--N 1.285 -2.293 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.069 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.572 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.8 OUTLIER -140.9 164.05 31.29 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 119.271 -0.972 . . . . 0.0 112.528 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.603 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -132.78 -177.35 4.45 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 114.352 -1.294 . . . . 0.0 107.646 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.8 OUTLIER -167.6 143.5 4.06 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 116.875 -1.93 . . . . 0.0 113.54 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.579 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 8.7 p90 -159.22 176.12 12.59 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.664 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.69 170.28 41.12 Favored Glycine 0 N--CA 1.5 2.931 0 C-N-CA 117.897 -2.097 . . . . 0.0 112.137 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.6 p90 -159.32 168.88 25.28 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.703 -0.799 . . . . 0.0 111.022 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.531 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -121.93 114.21 20.68 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.896 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.443 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -126.07 150.29 17.57 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.3 p . . . . . 0 N--CA 1.483 1.204 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.852 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.418 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.492 1.666 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.463 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -66.58 -144.32 0.02 OUTLIER 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 121.454 1.436 . . . . 0.0 111.401 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.82 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.8 OUTLIER -108.45 -101.48 0.37 Allowed 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.002 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.6 106.08 18.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 118.807 -1.157 . . . . 0.0 112.402 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.567 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.3 m-30 -74.99 -148.19 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.397 -0.921 . . . . 0.0 108.714 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.469 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -159.84 114.85 2.36 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 117.145 -1.822 . . . . 0.0 113.457 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.871 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -58.47 -175.84 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.06 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.656 ' ND2' HD22 ' A' ' 102' ' ' LEU . 2.0 p30 -64.89 76.49 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.071 -1.052 . . . . 0.0 111.764 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.49 11.46 33.26 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.57 -1.3 . . . . 0.0 112.374 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.602 ' O ' ' N ' ' A' ' 102' ' ' LEU . 6.5 p -151.92 145.81 18.05 Favored Pre-proline 0 N--CA 1.493 1.709 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.091 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -65.04 170.78 9.87 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.342 1.361 . . . . 0.0 111.713 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.64 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 3.1 t -163.79 106.53 0.96 Allowed 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.491 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.5 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 7.5 p -70.49 130.62 42.37 Favored 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 98' ' ' THR . 0.7 OUTLIER -53.96 175.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.525 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.496 2.649 0 CA-C-O 116.368 -2.351 . . . . 0.0 110.274 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.522 ' N ' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.48 1.048 0 CA-C-O 121.406 0.622 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.43 28.34 0.36 Allowed Glycine 0 N--CA 1.5 2.911 0 N-CA-C 106.939 -2.465 . . . . 0.0 106.939 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -52.83 -174.05 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 113.49 -1.355 . . . . 0.0 113.213 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -137.22 108.16 6.7 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.768 -1.56 . . . . 0.0 109.654 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.836 HG13 ' SG ' ' A' ' 107' ' ' CYS . 4.9 m -100.67 122.73 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.384 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.2 159.62 14.93 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.389 -0.924 . . . . 0.0 109.653 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.562 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.8 t-105 -121.22 139.76 52.94 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.748 -0.781 . . . . 0.0 112.013 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 73.38 0.4 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 107.279 -2.328 . . . . 0.0 107.279 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -72.84 152.27 7.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.574 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.288 0 CA-C-N 113.969 -1.469 . . . . 0.0 108.675 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.527 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.7 p90 . . . . . 0 CA--C 1.506 -0.745 0 CA-C-O 121.185 0.517 . . . . 0.0 112.256 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.574 HG22 ' CB ' ' A' ' 15' ' ' ASN . 8.2 t -73.48 172.86 10.52 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.562 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -159.32 110.23 2.02 Favored 'General case' 0 C--N 1.289 -2.027 0 C-N-CA 117.289 -1.764 . . . . 0.0 112.919 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -93.02 103.92 16.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.618 HG11 ' CE1' ' A' ' 84' ' ' PHE . 24.6 t -99.64 140.43 18.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 119.451 -0.9 . . . . 0.0 113.124 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.569 ' HB ' HD11 ' A' ' 11' ' ' LEU . 3.5 m -131.14 113.11 13.49 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.783 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.699 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -84.7 143.04 12.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.618 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.83 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.2 tptp -124.9 99.92 6.36 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.933 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.658 ' HB3' HD11 ' A' ' 76' ' ' ILE . 0.1 OUTLIER -91.54 106.22 18.32 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.191 -1.004 . . . . 0.0 108.372 179.828 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 t -119.17 -1.11 10.92 Favored 'General case' 0 C--N 1.311 -1.107 0 O-C-N 124.174 0.921 . . . . 0.0 110.142 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.629 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -50.34 -81.85 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.399 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.69 37.49 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.305 -179.886 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.892 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -137.5 146.65 54.39 Favored Pre-proline 0 N--CA 1.485 1.301 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.187 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -70.22 107.4 1.94 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 121.212 1.275 . . . . 0.0 109.882 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -86.63 110.49 20.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.487 -1.285 . . . . 0.0 111.981 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -120.1 65.45 0.82 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.64 146.22 20.56 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 106.885 -2.486 . . . . 0.0 106.885 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 47.9 p-90 -163.51 175.54 10.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 117.419 -1.712 . . . . 0.0 112.095 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.416 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -141.06 112.39 7.4 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.777 179.92 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.44 175.35 5.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.395 179.896 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.484 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -159.35 152.48 22.18 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 117.919 -1.512 . . . . 0.0 112.289 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.533 ' CD2' ' N ' ' A' ' 43' ' ' SER . 23.6 p90 -175.1 -150.91 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.931 -1.486 . . . . 0.0 108.432 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.533 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 14.7 m -158.66 154.39 26.37 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.881 -1.528 . . . . 0.0 111.835 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.518 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.2 m-85 -87.71 116.96 67.82 Favored Pre-proline 0 C--N 1.309 -1.153 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.901 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -56.99 -74.87 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 121.292 1.328 . . . . 0.0 112.619 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.26 -136.11 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.636 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -107.6 63.92 0.27 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.857 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.517 ' O ' ' CD2' ' A' ' 44' ' ' PHE . 21.5 mt-30 -110.97 112.14 23.75 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.802 -0.759 . . . . 0.0 110.667 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.696 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -121.34 118.62 29.93 Favored 'General case' 0 N--CA 1.499 2.007 0 C-N-CA 119.764 -0.774 . . . . 0.0 111.212 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.448 ' H ' HG12 ' A' ' 50' ' ' VAL . 2.0 p -72.79 156.0 6.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.383 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.696 HG22 HE22 ' A' ' 49' ' ' GLN . 80.4 p -132.45 -69.67 0.58 Allowed 'General case' 0 N--CA 1.492 1.669 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.777 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.508 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.8 OUTLIER -88.02 141.88 28.23 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.292 -0.963 . . . . 0.0 109.801 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.99 166.99 29.84 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.859 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.605 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 42.5 t-105 -154.45 157.15 38.01 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.003 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.605 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 51.75 26.79 3.68 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.771 -179.839 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.4 m -172.98 127.58 0.47 Allowed 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.695 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.4 m -90.15 77.19 6.8 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.795 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.499 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.3 m -69.69 151.81 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-N 115.365 -0.834 . . . . 0.0 112.306 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -152.17 104.2 2.94 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.462 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.428 HE22 ' HB2' ' A' ' 49' ' ' GLN . 11.6 tt0 -82.69 120.8 26.04 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.682 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 10.4 p -94.13 75.76 4.05 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.589 -0.844 . . . . 0.0 110.718 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.65 -65.59 2.82 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.041 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.41 -16.01 0.94 Allowed 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.294 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.682 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -91.61 -171.15 2.81 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 119.268 -0.973 . . . . 0.0 110.215 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.518 HG21 ' CE2' ' A' ' 44' ' ' PHE . 72.7 t -147.3 154.55 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 118.744 -1.182 . . . . 0.0 113.262 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.481 ' N ' HG12 ' A' ' 65' ' ' VAL . 17.1 m -155.75 119.82 4.53 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 114.396 -1.275 . . . . 0.0 108.441 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.662 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -114.32 149.38 16.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.938 0 C-N-CA 119.614 -0.835 . . . . 0.0 111.847 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -132.33 93.0 3.18 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.632 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 3.1 p-10 -72.88 122.16 21.18 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.055 -1.058 . . . . 0.0 112.329 -179.582 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.029 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -41.95 161.45 0.15 Allowed Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 113.549 -1.659 . . . . 0.0 112.05 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.0 Cg_endo -65.54 -37.67 28.58 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 121.95 1.767 . . . . 0.0 112.273 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.591 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.46 -55.93 8.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.579 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 1.029 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.8 p30 -74.69 11.83 0.95 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.738 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.568 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -133.44 22.95 3.88 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.747 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.8 m -93.93 57.08 2.39 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.331 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.759 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.52 128.72 24.88 Favored Pre-proline 0 N--CA 1.489 1.495 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.68 179.971 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.599 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.4 Cg_endo -69.8 154.52 67.47 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 121.448 1.432 . . . . 0.0 111.012 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.892 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -42.49 -12.53 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.745 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.08 55.82 0.5 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.98 -165.65 24.74 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 118.511 -1.804 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.83 HG22 ' HA ' ' A' ' 28' ' ' LYS . 5.9 p -137.93 163.17 32.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.183 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.517 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -121.56 -176.95 3.42 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -169.91 144.71 2.81 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 116.906 -1.917 . . . . 0.0 113.246 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.4 p90 -159.31 169.11 24.75 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.045 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -155.99 163.58 31.9 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 118.052 -2.023 . . . . 0.0 112.023 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.5 p90 -161.16 161.52 31.04 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.242 -0.983 . . . . 0.0 112.287 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 25.8 m-20 -112.79 111.79 22.83 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.271 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.25 164.3 12.16 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.948 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.313 -0.986 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.878 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.507 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 111.187 0.069 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.2 Cg_endo -63.13 -121.82 0.0 OUTLIER 'Trans proline' 0 CA--C 1.557 1.658 0 C-N-CA 121.125 1.216 . . . . 0.0 111.935 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.462 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 27.4 p -136.4 -77.43 0.42 Allowed 'General case' 0 N--CA 1.505 2.278 0 C-N-CA 119.246 -0.982 . . . . 0.0 112.608 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -98.72 97.9 9.09 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.842 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 107' ' ' CYS . 45.2 m-85 -66.73 -170.12 0.1 Allowed 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.9 m -146.78 113.99 6.24 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 117.457 -1.697 . . . . 0.0 113.897 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -60.59 -178.19 0.09 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.629 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 102' ' ' LEU . 26.0 m-80 -30.38 -39.85 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -159.98 39.18 0.46 Allowed Glycine 0 N--CA 1.498 2.776 0 C-N-CA 118.583 -1.77 . . . . 0.0 111.598 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.522 HG21 ' N ' ' A' ' 6' ' ' ALA . 9.7 m -162.23 137.61 5.5 Favored Pre-proline 0 N--CA 1.49 1.531 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -50.8 177.57 0.03 OUTLIER 'Trans proline' 0 C--O 1.211 -0.858 0 C-N-CA 121.473 1.448 . . . . 0.0 112.361 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.836 ' SG ' HG13 ' A' ' 10' ' ' VAL . 22.0 t -166.35 98.45 0.6 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.411 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 p -46.68 154.82 0.28 Allowed 'General case' 0 N--CA 1.502 2.129 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.678 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.942 HG22 ' N ' ' A' ' 110' ' ' GLY . 2.8 p -68.92 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 118.787 -1.165 . . . . 0.0 109.4 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.942 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.137 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.435 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.579 ' N ' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 121.358 0.599 . . . . 0.0 112.431 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.23 51.25 0.04 OUTLIER Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -51.56 177.84 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.027 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -133.01 99.84 4.7 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.332 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.741 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -91.87 135.01 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 118.967 -1.093 . . . . 0.0 111.875 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.596 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -112.93 164.83 12.95 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.915 179.824 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.665 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.8 t-105 -125.32 143.95 50.72 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.653 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.83 75.8 0.42 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.592 HG22 ' N ' ' A' ' 15' ' ' ASN . 10.0 p -79.2 158.96 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.602 ' CB ' HG22 ' A' ' 22' ' ' THR . 3.6 t30 . . . . . 0 C--N 1.302 -1.482 0 CA-C-N 113.238 -1.801 . . . . 0.0 107.129 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.612 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.6 p90 . . . . . 0 C--O 1.215 -0.731 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.602 HG22 ' CB ' ' A' ' 15' ' ' ASN . 14.0 t -72.4 173.95 8.05 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.441 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -155.37 120.42 4.85 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 117.251 -1.779 . . . . 0.0 112.908 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -104.0 98.87 8.63 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.561 -1.2 . . . . 0.0 107.904 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.625 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.2 t -96.95 140.8 16.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.306 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.767 HG23 ' HG2' ' A' ' 83' ' ' GLN . 98.7 m -126.39 108.15 10.95 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.278 -0.874 . . . . 0.0 108.809 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.1 t -83.44 101.1 7.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 C-N-CA 119.727 -0.789 . . . . 0.0 111.959 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.772 ' HA ' HG22 ' A' ' 81' ' ' THR . 11.5 tttp -87.82 109.51 19.8 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.512 -1.275 . . . . 0.0 109.992 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.454 ' HB3' HD11 ' A' ' 76' ' ' ILE . 1.4 t-20 -95.56 112.38 24.11 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.504 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -111.68 -7.69 14.24 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.617 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.9 p -72.64 98.84 2.43 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-N 113.779 -1.555 . . . . 0.0 111.314 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.474 ' HA ' ' CB ' ' A' ' 78' ' ' ALA . 69.4 p -27.37 76.43 0.0 OUTLIER 'General case' 0 N--CA 1.512 2.646 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 1.006 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -157.57 137.15 8.45 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.596 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -72.1 100.04 1.06 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.971 1.114 . . . . 0.0 109.463 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -85.03 106.87 15.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.461 -1.296 . . . . 0.0 111.836 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -124.21 80.07 1.8 Allowed 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.55 135.78 3.22 Favored Glycine 0 C--N 1.292 -1.902 0 N-CA-C 106.625 -2.59 . . . . 0.0 106.625 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 43.7 p-90 -159.43 176.68 11.82 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 117.327 -1.749 . . . . 0.0 112.303 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -138.04 113.19 9.26 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.047 179.781 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.888 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.05 172.13 6.99 Favored 'General case' 0 N--CA 1.5 2.026 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.839 -179.968 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.467 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -156.29 146.7 21.59 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 118.017 -1.473 . . . . 0.0 112.605 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.63 ' CD2' ' N ' ' A' ' 43' ' ' SER . 11.7 p90 -172.29 -151.21 0.06 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 114.429 -1.259 . . . . 0.0 108.504 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.63 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.7 m -159.42 158.89 32.96 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.616 -1.633 . . . . 0.0 112.351 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.492 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.8 m-85 -86.28 121.13 72.62 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.88 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -58.75 -67.87 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.084 1.19 . . . . 0.0 112.225 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.483 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 29.8 t -69.54 -112.84 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 118.946 -1.102 . . . . 0.0 111.054 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.483 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -141.98 37.68 1.56 Allowed Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.685 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.47 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 6.7 mt-30 -75.46 115.59 15.28 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.828 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.597 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -106.38 119.04 38.23 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.353 -0.939 . . . . 0.0 111.673 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.464 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.2 p -74.38 157.92 6.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.94 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 20.4 p -132.74 -63.89 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.615 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -88.59 170.51 10.79 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -166.03 151.72 8.85 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 118.521 -1.271 . . . . 0.0 112.194 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.503 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 36.3 t-105 -149.26 150.77 33.1 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.458 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.503 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 1.4 p 46.77 32.11 1.65 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.617 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -173.64 118.08 0.27 Allowed 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.81 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 m -83.33 72.49 10.2 Favored 'General case' 0 C--N 1.279 -2.473 0 C-N-CA 119.161 -1.016 . . . . 0.0 109.377 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.469 HG12 HG13 ' A' ' 67' ' ' VAL . 4.1 m -70.91 166.57 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.832 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.443 ' O ' ' CG2' ' A' ' 59' ' ' THR . 6.1 t -164.68 130.54 2.83 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.557 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.509 HE22 ' HA ' ' A' ' 49' ' ' GLN . 5.0 tt0 -94.67 116.05 28.29 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.477 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 6.2 p -93.92 75.53 4.18 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.304 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.37 -67.38 2.82 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.351 -1.404 . . . . 0.0 109.69 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -143.7 -16.51 0.62 Allowed 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.979 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.566 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.9 -170.81 2.93 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.076 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.521 HG12 ' N ' ' A' ' 66' ' ' THR . 65.2 t -148.39 156.6 8.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 118.826 -1.15 . . . . 0.0 113.038 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.521 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.1 m -154.71 141.2 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.312 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.586 HG23 HD21 ' A' ' 40' ' ' LEU . 2.4 t -134.84 153.51 34.92 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.078 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.426 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -133.39 90.84 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.6 p-10 -72.54 121.07 19.06 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.298 -179.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.835 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -42.68 163.61 0.14 Allowed Pre-proline 0 C--N 1.303 -1.45 0 CA-C-N 113.291 -1.777 . . . . 0.0 111.807 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.2 Cg_endo -66.46 -35.88 28.81 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.901 1.734 . . . . 0.0 112.315 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.39 -54.28 15.2 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.749 -179.891 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.835 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.25 14.17 1.28 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 118.958 -1.097 . . . . 0.0 109.862 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -129.4 18.98 5.43 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.49 77.4 5.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.197 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.862 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -136.64 125.29 15.18 Favored Pre-proline 0 C--O 1.209 -1.063 0 C-N-CA 119.782 -0.767 . . . . 0.0 111.643 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.589 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.8 Cg_endo -71.63 162.86 40.84 Favored 'Trans proline' 0 C--O 1.213 -0.754 0 C-N-CA 120.91 1.073 . . . . 0.0 110.236 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 1.006 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -46.98 -3.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.871 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -120.13 56.77 0.59 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.81 -159.99 15.77 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 117.905 -2.093 . . . . 0.0 111.12 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.772 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.2 p -139.85 155.06 47.43 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.939 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.862 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.1 100.65 5.5 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.767 ' HG2' HG23 ' A' ' 26' ' ' THR . 21.6 mt-30 -91.13 161.21 15.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 114.709 1.374 . . . . 0.0 114.709 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.625 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.1 p90 -166.0 165.17 18.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 113.286 -1.779 . . . . 0.0 109.224 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.98 170.83 37.75 Favored Glycine 0 N--CA 1.504 3.17 0 C-N-CA 117.547 -2.264 . . . . 0.0 112.611 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.2 p90 -156.62 -167.86 2.52 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.345 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.404 ' OD1' ' N ' ' A' ' 87' ' ' ASN . 1.2 m120 -140.53 112.21 7.48 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.821 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -120.14 158.21 15.45 Favored Glycine 0 N--CA 1.505 3.279 0 C-N-CA 119.784 -1.198 . . . . 0.0 111.426 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.486 1.345 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.154 179.926 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.665 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.507 2.418 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.57 -144.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 121.319 1.346 . . . . 0.0 110.965 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 10.5 p -116.78 -63.51 1.44 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.495 -0.882 . . . . 0.0 112.376 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.615 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -107.87 111.09 23.04 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.764 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.4 m-85 -81.16 -163.72 0.65 Allowed 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.618 -0.833 . . . . 0.0 109.545 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -145.44 103.04 3.78 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -52.29 173.92 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.501 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 39' ' ' THR . 8.2 p30 -41.87 -20.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.484 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.83 45.0 0.22 Allowed Glycine 0 N--CA 1.487 2.039 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.171 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.579 HG21 ' N ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -175.01 149.07 1.16 Allowed Pre-proline 0 N--CA 1.494 1.734 0 C-N-CA 119.164 -1.014 . . . . 0.0 111.049 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -63.04 170.35 7.69 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 121.372 1.381 . . . . 0.0 111.956 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.741 ' SG ' HG13 ' A' ' 10' ' ' VAL . 6.5 t -161.88 90.95 0.79 Allowed 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.538 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 m -51.99 165.18 0.22 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.69 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -65.05 -156.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 119.176 -1.01 . . . . 0.0 109.588 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 CA-C-O 116.319 -2.378 . . . . 0.0 110.371 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.895 0 CA-C-O 121.235 0.54 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.18 59.91 0.04 OUTLIER Glycine 0 N--CA 1.49 2.237 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.699 ' SG ' HG13 ' A' ' 10' ' ' VAL . 0.6 OUTLIER -56.32 -161.88 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.278 1.037 . . . . 0.0 112.54 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.674 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 37.0 mt-30 -150.97 89.02 1.5 Allowed 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 113.553 -1.658 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.699 HG13 ' SG ' ' A' ' 8' ' ' CYS . 2.9 m -90.32 128.71 42.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 118.972 -1.091 . . . . 0.0 111.83 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.572 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -102.27 171.27 7.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.149 179.831 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.477 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.5 t-105 -130.39 147.59 52.11 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.768 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.407 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.67 76.4 0.41 Allowed Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.026 -2.03 . . . . 0.0 108.026 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.473 HG23 ' HD2' ' A' ' 21' ' ' PHE . 2.5 p -72.51 142.9 14.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.562 ' CB ' HG22 ' A' ' 22' ' ' THR . 8.4 t-20 . . . . . 0 N--CA 1.493 1.711 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.301 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.62 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.4 p90 . . . . . 0 C--O 1.215 -0.734 0 CA-C-O 121.515 0.674 . . . . 0.0 110.555 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.579 HG23 ' N ' ' A' ' 23' ' ' ALA . 1.0 OUTLIER -71.08 176.56 4.33 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 118.074 -1.451 . . . . 0.0 107.74 179.791 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.579 ' N ' HG23 ' A' ' 22' ' ' THR . . . -148.76 103.08 3.35 Favored 'General case' 0 C--N 1.291 -1.937 0 C-N-CA 118.469 -1.293 . . . . 0.0 111.616 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -94.1 94.35 8.34 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.632 HG11 ' CE2' ' A' ' 84' ' ' PHE . 15.6 t -97.16 137.38 25.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.664 -0.815 . . . . 0.0 113.003 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.572 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -128.36 114.45 16.88 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.864 -1.062 . . . . 0.0 108.406 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.523 HG13 HG12 ' A' ' 10' ' ' VAL . 3.6 t -86.94 128.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 C-N-CA 119.81 -0.756 . . . . 0.0 112.783 -179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.819 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.4 tptt -114.23 100.93 8.73 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.426 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.76 ' HB3' HD11 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -89.87 117.46 28.71 Favored 'General case' 0 C--N 1.282 -2.353 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.452 179.742 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.62 -2.09 8.43 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 124.185 0.928 . . . . 0.0 109.754 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.573 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -49.87 -83.89 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.588 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.545 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.51 72.32 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 123.666 0.604 . . . . 0.0 111.504 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.52 149.9 3.17 Favored Pre-proline 0 C--N 1.304 -1.392 0 C-N-CA 119.148 -1.021 . . . . 0.0 111.016 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -70.45 102.45 1.14 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 121.012 1.142 . . . . 0.0 109.243 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.37 106.56 16.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.48 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -116.94 72.43 0.83 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.11 144.43 13.78 Favored Glycine 0 N--CA 1.484 1.853 0 N-CA-C 107.372 -2.291 . . . . 0.0 107.372 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.602 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 36.9 p-90 -161.05 176.9 10.85 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 117.592 -1.643 . . . . 0.0 112.014 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.895 ' H ' HD21 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.59 103.32 4.66 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.957 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.852 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -91.56 174.2 7.49 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.258 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.605 ' HG1' HG23 ' A' ' 66' ' ' THR . 97.8 m -156.59 146.31 20.87 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.278 -1.369 . . . . 0.0 112.143 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.595 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.1 p90 -172.5 -150.95 0.06 Allowed 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 114.589 -1.187 . . . . 0.0 108.999 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.595 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 20.1 m -156.2 153.42 29.19 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 117.807 -1.557 . . . . 0.0 112.09 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.512 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.1 m-85 -81.03 119.37 75.8 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 118.526 -1.27 . . . . 0.0 109.578 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -55.74 -71.71 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.443 1.429 . . . . 0.0 112.319 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.1 t -69.37 -113.91 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.715 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.02 48.02 0.75 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.436 -1.364 . . . . 0.0 110.334 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.714 ' C ' HE21 ' A' ' 49' ' ' GLN . 20.7 mp0 -71.56 112.86 8.02 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.416 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.714 HE21 ' C ' ' A' ' 48' ' ' GLN . 3.0 mm-40 -93.56 94.94 8.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.0 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.1 p -72.66 151.92 7.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.697 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 43.1 p -143.0 -63.27 0.41 Allowed 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.551 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.98 160.09 30.2 Favored 'General case' 0 C--N 1.301 -1.537 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.164 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -164.22 156.63 17.01 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 118.551 -1.26 . . . . 0.0 112.06 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 23.6 t-105 -155.52 137.04 14.13 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.847 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 62.56 29.14 16.97 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.21 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.43 122.39 0.64 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.613 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.3 m -84.54 69.39 10.58 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.948 -1.101 . . . . 0.0 108.845 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 HG13 ' A' ' 67' ' ' VAL . 3.3 m -69.29 164.39 2.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 114.904 -1.044 . . . . 0.0 112.828 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 1.5 t -168.04 145.54 4.27 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.768 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -98.27 109.72 22.43 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.138 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.543 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 7.7 p -91.2 72.91 6.26 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.67 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 56.38 75.89 0.23 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.2 -1.476 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 74.94 -28.79 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.149 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.543 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.49 -171.65 3.43 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 118.728 -1.189 . . . . 0.0 110.663 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.615 HG12 ' N ' ' A' ' 66' ' ' THR . 55.9 t -148.65 162.34 5.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.471 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.615 ' N ' HG12 ' A' ' 65' ' ' VAL . 6.2 m -157.0 147.63 21.49 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 114.083 -1.417 . . . . 0.0 108.131 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 58' ' ' VAL . 3.1 t -142.95 116.08 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 118.491 -1.284 . . . . 0.0 112.865 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -97.55 89.71 4.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.602 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.3 p-10 -70.27 120.43 15.94 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.075 -1.05 . . . . 0.0 112.063 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.805 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.27 158.33 0.09 OUTLIER Pre-proline 0 N--CA 1.486 1.36 0 CA-C-N 113.745 -1.571 . . . . 0.0 112.611 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.408 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.3 Cg_endo -68.03 -35.49 20.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.897 1.731 . . . . 0.0 112.385 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.805 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -69.86 -56.53 6.84 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.862 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.64 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -74.07 -1.85 21.87 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.823 -1.151 . . . . 0.0 109.696 -179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.634 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -113.17 20.42 19.18 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 8.8 m -90.03 59.73 4.62 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.262 -0.975 . . . . 0.0 111.272 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.782 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.05 122.96 39.09 Favored Pre-proline 0 CA--C 1.566 1.566 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.564 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 78' ' ' ALA . 5.8 Cg_endo -70.25 156.38 62.2 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 121.565 1.51 . . . . 0.0 113.766 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.545 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.47 -46.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.885 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.74 65.88 0.24 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.089 -1.204 . . . . 0.0 110.089 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.427 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.98 -170.31 18.48 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.837 -1.649 . . . . 0.0 110.139 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.819 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.9 p -139.49 158.3 44.36 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.199 -1.001 . . . . 0.0 112.527 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.782 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -125.59 -176.18 3.53 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.429 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 6.3 tt0 -168.12 148.1 4.82 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.019 -1.872 . . . . 0.0 112.92 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.632 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.3 p90 -165.22 168.08 17.41 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.068 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.48 171.95 40.11 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 117.694 -2.193 . . . . 0.0 112.223 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.1 p90 -155.06 -172.75 4.3 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -136.21 112.32 9.71 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.967 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -125.57 153.76 18.34 Favored Glycine 0 N--CA 1.51 3.596 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.024 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.912 179.691 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.477 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.493 1.676 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -62.61 -143.11 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 121.588 1.525 . . . . 0.0 111.771 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.626 ' O ' HG13 ' A' ' 109' ' ' VAL . 19.3 p -127.25 -58.35 1.28 Allowed 'General case' 0 N--CA 1.5 2.036 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.766 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.524 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.25 91.58 3.71 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.443 -0.903 . . . . 0.0 111.996 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.449 ' HD1' ' H ' ' A' ' 100' ' ' PHE . 32.3 m-85 -65.53 -166.81 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.1 m -146.43 107.68 4.22 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 117.552 -1.659 . . . . 0.0 113.884 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.9 mt -58.94 168.19 1.36 Allowed 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.895 HD21 ' H ' ' A' ' 39' ' ' THR . 0.3 OUTLIER -41.24 92.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.053 179.861 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.729 ' O ' HG23 ' A' ' 105' ' ' THR . . . 63.6 45.88 93.59 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 119.495 -1.336 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.729 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.6 OUTLIER -167.13 146.41 4.5 Favored Pre-proline 0 C--O 1.196 -1.743 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.157 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -64.22 166.16 17.67 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.31 1.34 . . . . 0.0 112.241 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -163.68 94.96 0.79 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 17.0 p -65.2 170.26 4.79 Favored 'General case' 0 N--CA 1.511 2.595 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 98' ' ' THR . 17.0 m -60.53 -155.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.562 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 CA-C-O 116.322 -2.377 . . . . 0.0 110.378 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.692 ' HB3' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.725 0.774 . . . . 0.0 113.064 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.99 43.3 0.06 OUTLIER Glycine 0 N--CA 1.497 2.703 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -52.41 -175.81 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 114.496 -0.852 . . . . 0.0 112.774 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.516 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 5.3 pt20 -142.25 126.48 17.53 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.907 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.649 HG12 HG13 ' A' ' 27' ' ' VAL . 3.3 m -115.1 128.41 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.163 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.554 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -97.12 171.93 8.15 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.313 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.893 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.7 t-105 -125.39 147.84 49.01 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.829 -0.748 . . . . 0.0 112.026 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.1 79.66 0.35 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 107.759 -2.137 . . . . 0.0 107.759 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -68.99 146.8 12.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 122.018 0.913 . . . . 0.0 113.112 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 C--N 1.296 -1.718 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.519 179.811 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.647 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.6 p90 . . . . . 0 CA--C 1.497 -1.08 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 22' ' ' THR . 0.7 OUTLIER -101.67 114.32 28.26 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 179.579 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.679 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -91.53 115.83 28.36 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 119.19 -1.004 . . . . 0.0 113.52 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -98.53 96.85 8.26 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.545 HG11 ' CE2' ' A' ' 84' ' ' PHE . 33.5 t -92.64 144.54 9.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.554 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -131.27 103.43 6.46 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.771 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.649 HG13 HG12 ' A' ' 10' ' ' VAL . 2.2 t -74.12 151.57 7.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.731 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.59 ' HB2' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -148.16 111.29 4.88 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.643 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.707 ' HB3' HD11 ' A' ' 76' ' ' ILE . 2.1 t30 -96.85 129.73 44.24 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.962 -1.017 . . . . 0.0 108.397 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -132.06 -6.85 3.48 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 124.087 0.867 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.513 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 2.0 p -51.0 -80.87 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.732 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.0 37.16 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.194 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.556 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.853 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -136.45 147.78 61.33 Favored Pre-proline 0 N--CA 1.488 1.451 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.414 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -72.46 115.95 4.53 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 121.403 1.402 . . . . 0.0 110.406 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 t -98.34 95.83 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.236 -0.985 . . . . 0.0 112.109 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -105.76 63.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 99.99 154.14 27.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.626 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 39.9 p-90 -169.95 177.17 4.44 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.172 -1.811 . . . . 0.0 112.911 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.23 99.19 3.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.017 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.883 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -87.93 172.72 9.38 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 118.576 -1.25 . . . . 0.0 110.051 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.472 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -153.97 145.08 22.82 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 118.642 -1.223 . . . . 0.0 111.633 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.622 ' CD2' ' N ' ' A' ' 43' ' ' SER . 10.6 p90 -172.92 -156.36 0.09 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.407 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.622 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 56.5 m -158.55 157.52 32.2 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 117.53 -1.668 . . . . 0.0 112.075 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' A' ' 65' ' ' VAL . 10.9 m-85 -86.58 122.22 71.89 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 118.712 -1.195 . . . . 0.0 109.443 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.48 -62.1 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.244 1.296 . . . . 0.0 112.196 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.9 p -69.5 -58.81 3.5 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.793 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . 145.65 31.4 0.08 OUTLIER Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.418 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.647 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 49.6 mt-30 -43.69 131.93 5.14 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.394 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.621 ' NE2' HE22 ' A' ' 60' ' ' GLN . 0.1 OUTLIER -94.64 80.49 3.81 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.289 -0.964 . . . . 0.0 111.478 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.1 p -62.78 147.84 11.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.306 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.502 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 61.8 p -140.47 -71.18 0.37 Allowed 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.283 -0.967 . . . . 0.0 111.558 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.52 ' N ' ' NE2' ' A' ' 52' ' ' GLN . 0.0 OUTLIER -69.73 164.36 23.69 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.289 -179.951 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.2 5.51 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 118.645 -1.222 . . . . 0.0 112.056 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.445 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 30.8 t-105 -153.11 143.28 22.35 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.655 -0.818 . . . . 0.0 110.496 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 0.9 OUTLIER 57.71 30.24 18.59 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.663 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.423 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.4 OUTLIER -172.9 119.18 0.34 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.675 -179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 m -82.81 74.37 9.78 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.975 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.404 ' C ' HG23 ' A' ' 59' ' ' THR . 10.3 m -69.41 156.83 6.93 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 CA-C-N 115.017 -0.992 . . . . 0.0 112.78 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.404 HG23 ' C ' ' A' ' 58' ' ' VAL . 58.8 p -155.19 115.65 3.84 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.876 -1.056 . . . . 0.0 109.731 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.621 HE22 ' NE2' ' A' ' 49' ' ' GLN . 5.9 tt0 -89.86 113.44 25.04 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.18 -1.008 . . . . 0.0 110.532 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.413 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.6 p -92.19 80.44 5.04 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.923 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.44 -67.85 2.17 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.443 -1.36 . . . . 0.0 110.127 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 10.3 p -141.94 -17.6 0.75 Allowed 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.223 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -88.93 -172.26 3.62 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.163 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.55 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.0 t -149.93 159.01 5.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 118.709 -1.197 . . . . 0.0 113.639 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.55 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 53.1 m -153.94 149.35 27.18 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.203 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.443 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.8 t -144.63 119.44 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 118.386 -1.326 . . . . 0.0 112.73 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.16 91.08 5.09 Favored 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.046 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.626 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.4 p-10 -71.23 120.95 17.54 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.879 -1.128 . . . . 0.0 111.625 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.723 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -43.14 167.39 0.08 OUTLIER Pre-proline 0 N--CA 1.487 1.377 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.452 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.723 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.8 Cg_endo -70.34 -35.92 10.14 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.23 1.953 . . . . 0.0 112.373 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.683 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.47 -54.29 14.99 Favored 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.869 -179.834 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 4.8 p-10 -79.37 10.79 3.41 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.444 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.536 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -127.42 40.2 1.8 Allowed Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.186 -1.007 . . . . 0.0 110.673 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -109.93 62.82 0.6 Allowed 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.908 -0.717 . . . . 0.0 111.21 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.913 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -116.87 121.4 32.81 Favored Pre-proline 0 N--CA 1.483 1.187 0 C-N-CA 120.058 -0.657 . . . . 0.0 111.243 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.592 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.6 Cg_endo -67.38 156.35 66.55 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 C-N-CA 121.103 1.202 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.853 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -39.36 -18.75 0.01 OUTLIER 'General case' 0 C--O 1.205 -1.271 0 C-N-CA 119.895 -0.722 . . . . 0.0 112.676 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.592 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.24 62.52 0.43 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -163.67 -161.72 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 C-N-CA 118.979 -1.581 . . . . 0.0 110.635 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.59 HG22 ' HB2' ' A' ' 28' ' ' LYS . 7.3 p -143.98 162.94 34.9 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.063 -1.055 . . . . 0.0 112.978 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.707 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -131.31 179.53 5.97 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.106 -1.407 . . . . 0.0 107.733 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.451 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 32.0 tt0 -164.03 144.55 8.36 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 117.226 -1.789 . . . . 0.0 113.187 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.545 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.2 p90 -157.7 170.28 22.74 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.779 -1.101 . . . . 0.0 109.857 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.79 164.8 37.18 Favored Glycine 0 N--CA 1.498 2.798 0 C-N-CA 117.704 -2.189 . . . . 0.0 112.557 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.639 ' C ' ' ND2' ' A' ' 87' ' ' ASN . 1.7 p90 -153.04 -177.77 6.5 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 114.889 -0.656 . . . . 0.0 110.608 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.848 HD22 ' N ' ' A' ' 87' ' ' ASN . 0.1 OUTLIER -138.39 111.4 7.83 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.693 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -109.96 169.38 13.58 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.288 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.484 1.268 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.866 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.893 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.509 2.515 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.504 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.5 Cg_endo -62.7 -101.11 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 120.962 1.108 . . . . 0.0 111.952 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.404 ' O ' ' N ' ' A' ' 109' ' ' VAL . 45.7 p -152.58 -69.2 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 118.829 -1.148 . . . . 0.0 111.946 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -106.54 94.98 5.43 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.56 -0.856 . . . . 0.0 111.255 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.504 ' CZ ' ' HD2' ' A' ' 97' ' ' PRO . 38.6 m-85 -65.03 -162.76 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.057 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -149.93 98.48 2.72 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 117.605 -1.638 . . . . 0.0 113.323 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.586 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.7 mt -52.17 171.59 0.05 OUTLIER 'General case' 0 C--O 1.21 -0.989 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.506 HD22 ' HB2' ' A' ' 38' ' ' TRP . 2.7 p30 -55.54 82.41 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.755 -1.178 . . . . 0.0 110.783 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 87.51 41.85 6.34 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.692 HG21 ' HB3' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -174.44 130.36 0.47 Allowed Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.151 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.63 170.75 3.16 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 121.029 1.153 . . . . 0.0 111.22 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.469 ' SG ' HG13 ' A' ' 10' ' ' VAL . 8.2 t -166.73 101.95 0.57 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.179 -1.008 . . . . 0.0 111.117 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.47 169.48 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.844 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.96 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.8 p -80.25 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.876 -1.13 . . . . 0.0 109.876 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.96 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.402 0 CA-C-O 116.333 -2.371 . . . . 0.0 110.585 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.831 ' HB3' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.32 0.581 . . . . 0.0 111.355 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.15 43.94 0.06 OUTLIER Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.235 -1.946 . . . . 0.0 108.235 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.738 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.58 -168.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.87 -0.665 . . . . 0.0 110.955 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.486 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 1.8 pt20 -159.75 155.96 26.82 Favored 'General case' 0 C--N 1.287 -2.147 0 C-N-CA 118.754 -1.178 . . . . 0.0 110.407 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.595 HG12 HG13 ' A' ' 27' ' ' VAL . 1.1 m -141.35 138.88 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.002 -1.079 . . . . 0.0 111.67 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -100.44 171.61 7.64 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.157 179.95 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -133.94 143.32 48.13 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.834 -0.746 . . . . 0.0 111.961 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.09 71.79 0.41 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.9 p -69.61 140.77 18.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.537 ' CB ' HG22 ' A' ' 22' ' ' THR . 62.9 t30 . . . . . 0 N--CA 1.494 1.758 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.029 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.588 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.5 p90 . . . . . 0 CA--C 1.504 -0.81 0 CA-C-O 121.275 0.56 . . . . 0.0 111.984 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.537 HG22 ' CB ' ' A' ' 15' ' ' ASN . 1.0 OUTLIER -65.13 173.82 2.28 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.487 ' N ' HG23 ' A' ' 22' ' ' THR . . . -152.52 98.25 2.35 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 117.651 -1.62 . . . . 0.0 112.755 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -92.12 97.95 11.24 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.515 HG11 ' CE1' ' A' ' 84' ' ' PHE . 19.4 t -95.55 145.56 8.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 C-N-CA 119.681 -0.807 . . . . 0.0 112.583 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.624 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -134.71 101.75 5.04 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.439 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.595 HG13 HG12 ' A' ' 10' ' ' VAL . 1.9 t -71.06 153.81 8.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.698 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.611 ' HB2' HG22 ' A' ' 81' ' ' THR . 4.3 tttp -148.63 115.35 5.99 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.936 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.702 ' HB3' HD11 ' A' ' 76' ' ' ILE . 1.2 t30 -102.21 119.6 39.07 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.2 t -122.19 1.42 9.71 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 124.169 0.918 . . . . 0.0 109.866 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.53 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -63.02 -79.49 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.951 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.603 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.4 OUTLIER 159.31 78.98 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 123.723 0.639 . . . . 0.0 111.498 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.54 141.24 1.55 Allowed Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.195 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -67.67 100.52 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.712 0 N-CA-C 108.972 -1.203 . . . . 0.0 108.972 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.84 112.29 23.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 118.244 -1.382 . . . . 0.0 111.442 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -124.22 76.76 1.5 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.23 136.76 6.01 Favored Glycine 0 N--CA 1.483 1.8 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.835 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 26.3 p-90 -154.54 -179.81 8.32 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 117.905 -1.518 . . . . 0.0 111.959 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.841 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -140.13 100.48 3.92 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.491 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -91.87 175.51 6.86 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.748 -1.181 . . . . 0.0 109.462 179.932 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.496 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -162.46 149.28 13.3 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 117.629 -1.629 . . . . 0.0 112.731 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.469 ' CD2' ' N ' ' A' ' 43' ' ' SER . 22.2 p90 -173.72 -140.93 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 113.571 -1.65 . . . . 0.0 107.558 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.584 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 31.0 m -163.39 -179.06 6.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.375 -1.73 . . . . 0.0 112.735 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.549 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.1 m-85 -114.64 91.2 24.33 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -55.38 -36.97 94.99 Favored 'Trans proline' 0 CA--C 1.51 -0.72 0 C-N-CA 121.015 1.143 . . . . 0.0 110.065 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.2 p -79.44 165.26 23.25 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 119.322 -0.951 . . . . 0.0 108.973 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.12 48.27 3.31 Favored Glycine 0 C--N 1.29 -2.009 0 C-N-CA 118.663 -1.732 . . . . 0.0 109.968 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.533 ' OE1' ' CE1' ' A' ' 44' ' ' PHE . 3.2 pt20 -109.76 143.46 39.55 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.309 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.48 133.57 34.76 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.496 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.595 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.7 p -72.69 164.48 3.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.584 -0.846 . . . . 0.0 111.728 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.595 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 66.3 p -136.17 -63.24 0.65 Allowed 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.264 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.49 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.6 mt-30 -89.23 164.64 14.87 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.177 -1.009 . . . . 0.0 109.346 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -170.37 153.5 4.4 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.259 -1.376 . . . . 0.0 112.227 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.454 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 33.6 t-105 -156.1 144.84 20.26 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.881 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.454 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.8 OUTLIER 61.82 28.62 17.55 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 119.541 -0.863 . . . . 0.0 109.993 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.594 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.9 OUTLIER -172.58 124.54 0.47 Allowed 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.323 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.5 m -87.99 75.88 8.7 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.43 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.4 m -69.08 152.82 9.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.954 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.403 HG23 ' C ' ' A' ' 58' ' ' VAL . 60.2 p -154.57 113.93 3.71 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.032 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.471 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.9 pt20 -90.51 117.71 29.41 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.924 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.0 p -94.09 85.49 4.71 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.999 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.93 -67.52 2.36 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.391 -1.385 . . . . 0.0 109.966 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -144.82 -12.72 0.56 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.293 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.584 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -93.28 -170.3 2.35 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.119 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.654 HG12 ' N ' ' A' ' 66' ' ' THR . 62.1 t -148.99 162.98 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.795 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.654 ' N ' HG12 ' A' ' 65' ' ' VAL . 10.6 m -156.65 139.87 15.58 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 113.625 -1.625 . . . . 0.0 108.267 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.457 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -132.51 114.88 23.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.368 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -96.63 88.5 4.67 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.835 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.61 119.41 14.72 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.02 -1.072 . . . . 0.0 111.674 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.815 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -41.0 163.83 0.09 OUTLIER Pre-proline 0 N--CA 1.487 1.402 0 CA-C-N 113.741 -1.572 . . . . 0.0 112.417 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.587 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -64.57 -35.29 48.69 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 121.703 1.602 . . . . 0.0 112.195 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.538 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.33 -52.48 22.38 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 118.816 -1.154 . . . . 0.0 111.162 -179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.815 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.08 8.96 4.09 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.883 -1.127 . . . . 0.0 110.224 179.922 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.49 ' CA ' ' OD1' ' A' ' 69' ' ' ASN . . . -124.91 18.3 7.09 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 120.081 -1.057 . . . . 0.0 110.495 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.5 m -86.72 58.44 5.07 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.222 -0.991 . . . . 0.0 111.262 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.921 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.46 114.86 54.77 Favored Pre-proline 0 CA--C 1.564 1.496 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.245 179.934 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.3 Cg_endo -67.57 156.02 67.78 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.395 1.397 . . . . 0.0 113.663 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.45 -45.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 114.273 -1.33 . . . . 0.0 114.156 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.43 69.58 0.28 Allowed Glycine 0 N--CA 1.497 2.712 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.402 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.13 -164.11 11.84 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.62 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.611 HG22 ' HB2' ' A' ' 28' ' ' LYS . 1.2 p -143.38 154.72 44.02 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 118.997 -1.081 . . . . 0.0 112.592 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.768 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -124.34 175.48 7.06 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.624 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -167.22 147.64 5.49 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 116.973 -1.891 . . . . 0.0 113.191 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.594 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 10.9 p90 -157.03 -179.13 7.91 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.609 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.29 161.42 34.82 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 117.471 -2.3 . . . . 0.0 112.705 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.584 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.7 p90 -157.16 175.24 14.32 Favored 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 114.806 -0.697 . . . . 0.0 111.008 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -125.52 115.73 20.67 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.906 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -127.27 158.02 20.96 Favored Glycine 0 N--CA 1.51 3.58 0 C-N-CA 119.38 -1.39 . . . . 0.0 112.638 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.7 p . . . . . 0 N--CA 1.481 1.092 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.789 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.26 0.076 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 3.8 Cg_endo -65.63 -143.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.217 -0.552 0 C-N-CA 121.048 1.166 . . . . 0.0 110.808 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.775 ' O ' HG13 ' A' ' 109' ' ' VAL . 11.1 p -113.45 -92.91 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.6 -0.84 . . . . 0.0 112.112 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -89.1 99.11 12.17 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.625 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.6 m-30 -68.08 -149.41 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.487 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -160.0 112.04 2.03 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 116.712 -1.995 . . . . 0.0 114.521 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.738 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.5 mt -64.77 172.76 2.58 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.841 ' ND2' ' H ' ' A' ' 39' ' ' THR . 69.0 m-80 -35.72 91.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.51 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 55.88 49.42 66.66 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.55 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.831 HG21 ' HB3' ' A' ' 6' ' ' ALA . 21.1 m -163.37 131.6 2.77 Favored Pre-proline 0 C--O 1.189 -2.119 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.92 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -61.06 158.86 32.32 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 121.263 1.309 . . . . 0.0 112.636 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.623 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.1 t -157.62 110.98 2.51 Favored 'General case' 0 N--CA 1.496 1.852 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.221 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -73.45 128.03 34.36 Favored 'General case' 0 N--CA 1.508 2.447 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -179.773 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 98' ' ' THR . 2.5 m -56.53 -177.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.659 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 116.301 -2.388 . . . . 0.0 110.461 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.852 ' N ' ' HG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 121.2 0.524 . . . . 0.0 111.366 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.76 43.25 0.1 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.949 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.3 p -53.55 -178.12 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 121.541 0.686 . . . . 0.0 112.077 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.455 ' NE2' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -138.34 108.44 6.39 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.795 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.886 HG12 HG13 ' A' ' 27' ' ' VAL . 4.6 m -103.39 124.06 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.238 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.576 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.15 165.05 12.6 Favored 'General case' 0 C--N 1.294 -1.84 0 C-N-CA 119.291 -0.964 . . . . 0.0 109.321 179.88 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.594 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.4 t-105 -124.74 143.32 50.84 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.614 -0.835 . . . . 0.0 112.444 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 75.45 0.38 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.76 149.0 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.97 -0.692 . . . . 0.0 112.832 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.482 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.528 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.7 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.0 p90 . . . . . 0 CA--C 1.503 -0.844 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.456 ' CG2' ' N ' ' A' ' 23' ' ' ALA . 0.6 OUTLIER -80.85 163.97 23.01 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 179.407 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.456 ' N ' ' CG2' ' A' ' 22' ' ' THR . . . -145.65 110.11 5.03 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.894 -1.522 . . . . 0.0 112.89 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 31.2 t30 -99.09 101.15 12.41 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.646 HG11 ' CE1' ' A' ' 84' ' ' PHE . 13.4 t -99.5 140.91 17.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 119.645 -0.822 . . . . 0.0 112.341 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.576 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.3 m -133.49 114.83 14.05 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.276 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.886 HG13 HG12 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -85.31 150.38 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.264 -0.975 . . . . 0.0 111.651 -179.849 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.835 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tttt -130.53 85.91 2.33 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.815 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.447 ' HB3' ' CD1' ' A' ' 76' ' ' ILE . 0.8 OUTLIER -68.8 104.94 2.17 Favored 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 118.565 -1.254 . . . . 0.0 109.807 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -105.8 -1.34 24.44 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.335 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.541 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.7 p -81.07 102.56 10.3 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.728 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.711 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 97.5 p -37.23 87.59 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 113.138 0.792 . . . . 0.0 113.138 -179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.541 ' N ' ' O ' ' A' ' 31' ' ' SER . . . -166.06 146.81 5.58 Favored Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.536 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -70.76 100.92 0.99 Allowed 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 121.027 1.152 . . . . 0.0 109.166 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -86.76 108.52 18.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.149 -1.42 . . . . 0.0 111.817 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -122.63 63.32 0.97 Allowed 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.32 142.54 13.47 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 107.42 -2.272 . . . . 0.0 107.42 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.901 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.7 p-90 -159.37 176.1 12.54 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 117.707 -1.597 . . . . 0.0 111.796 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.795 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -140.01 111.93 7.5 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.982 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.843 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.61 178.47 4.62 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.794 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.523 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.26 152.06 16.28 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.245 -1.382 . . . . 0.0 112.413 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' ' N ' ' A' ' 43' ' ' SER . 17.3 p90 -177.12 -150.09 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 113.919 -1.491 . . . . 0.0 108.408 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.549 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 42.7 m -162.16 161.95 28.23 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 118.046 -1.462 . . . . 0.0 112.026 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.613 ' CE2' HG21 ' A' ' 65' ' ' VAL . 16.5 m-85 -91.7 116.25 66.09 Favored Pre-proline 0 N--CA 1.484 1.275 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.005 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.08 -67.82 0.05 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 121.539 1.492 . . . . 0.0 112.938 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 19.7 m -68.74 -132.72 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.515 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -117.33 58.74 0.49 Allowed Glycine 0 N--CA 1.503 3.109 0 C-N-CA 119.631 -1.271 . . . . 0.0 111.715 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.7 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 tt0 -110.48 114.84 28.58 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.961 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.539 HE21 ' HA ' ' A' ' 49' ' ' GLN . 5.2 mm-40 -118.22 136.95 53.34 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 120.131 -0.628 . . . . 0.0 111.291 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 51' ' ' THR . 6.2 p -96.3 156.9 3.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.269 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.587 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -138.56 -59.53 0.62 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 119.598 -0.841 . . . . 0.0 111.059 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.587 ' H ' HG23 ' A' ' 51' ' ' THR . 0.8 OUTLIER -90.32 131.08 36.31 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.499 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.78 160.39 40.82 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.119 -1.032 . . . . 0.0 112.476 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.466 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 39.1 t-105 -155.33 149.46 25.78 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.676 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.466 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.3 t 66.07 20.07 11.2 Favored 'General case' 0 C--N 1.316 -0.877 0 C-N-CA 119.649 -0.82 . . . . 0.0 109.573 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.449 ' HG ' ' HD2' ' A' ' 84' ' ' PHE . 5.5 p -173.25 123.84 0.4 Allowed 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.921 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -80.33 77.88 7.06 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.321 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.447 HG12 HG13 ' A' ' 67' ' ' VAL . 2.2 m -72.6 152.62 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.538 -0.755 . . . . 0.0 112.277 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 40.7 p -150.06 109.15 3.91 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.883 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.522 ' OE1' ' NE2' ' A' ' 49' ' ' GLN . 33.0 tt0 -87.45 114.75 24.35 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.074 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.453 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.3 p -91.41 81.23 5.43 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.864 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.09 -69.74 1.88 Allowed Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.403 -1.379 . . . . 0.0 110.074 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.5 t -139.13 -19.06 0.99 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.858 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -86.65 -173.81 4.68 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.815 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.613 HG21 ' CE2' ' A' ' 44' ' ' PHE . 49.7 t -145.13 160.66 13.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 C-N-CA 118.77 -1.172 . . . . 0.0 113.226 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.571 ' N ' HG12 ' A' ' 65' ' ' VAL . 11.6 m -159.36 129.61 5.72 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.889 -1.505 . . . . 0.0 108.121 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.64 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -125.3 146.89 30.23 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.004 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.849 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -130.47 93.33 3.43 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.901 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.74 117.63 15.75 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.229 -0.988 . . . . 0.0 112.402 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.726 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -42.17 156.91 0.23 Allowed Pre-proline 0 N--CA 1.481 1.088 0 CA-C-N 113.537 -1.665 . . . . 0.0 111.876 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -59.99 -34.91 94.69 Favored 'Trans proline' 0 C--O 1.213 -0.736 0 C-N-CA 121.745 1.63 . . . . 0.0 112.065 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.726 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.92 -53.52 20.53 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.987 179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.715 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -79.67 12.78 2.39 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.496 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -133.6 20.71 4.1 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.516 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.4 m -94.53 60.57 2.62 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.395 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.538 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -113.49 131.81 22.8 Favored Pre-proline 0 N--CA 1.491 1.595 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.472 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.504 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -70.86 151.42 62.77 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.468 1.445 . . . . 0.0 114.19 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.711 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.03 -45.92 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.504 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -106.4 68.31 0.24 Allowed Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.883 -1.151 . . . . 0.0 111.084 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.19 23.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 118.398 -1.858 . . . . 0.0 111.384 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.835 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.2 p -132.39 162.15 31.83 Favored 'General case' 0 N--CA 1.482 1.172 0 CA-C-O 121.74 0.781 . . . . 0.0 112.686 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.03 174.21 9.05 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.439 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 26.6 tt0 -165.96 144.84 5.99 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 116.831 -1.948 . . . . 0.0 113.545 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.646 ' CE1' HG11 ' A' ' 25' ' ' VAL . 18.3 p90 -156.28 178.01 10.79 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.625 -1.171 . . . . 0.0 110.181 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -159.32 169.2 35.42 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 117.761 -2.162 . . . . 0.0 112.107 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 14.4 p90 -166.85 156.89 11.43 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.371 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -108.7 114.79 28.89 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.198 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.6 166.56 12.17 Favored Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.863 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 C--N 1.316 -0.856 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.594 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.493 1.693 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.483 ' HD2' ' CE2' ' A' ' 100' ' ' PHE . 1.9 Cg_endo -64.91 -137.3 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 121.312 1.341 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.489 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 30.9 p -121.09 -59.74 1.7 Allowed 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.309 -0.956 . . . . 0.0 113.027 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.489 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.36 100.06 8.74 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.078 -1.049 . . . . 0.0 112.29 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.502 ' N ' ' O ' ' A' ' 107' ' ' CYS . 19.3 m-85 -72.64 -169.12 0.51 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.5 m -143.5 122.5 12.81 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 117.888 -1.525 . . . . 0.0 112.469 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.949 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -80.81 174.54 11.52 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.538 -0.865 . . . . 0.0 109.243 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.795 ' ND2' ' H ' ' A' ' 39' ' ' THR . 74.7 m-80 -34.61 89.18 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.324 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.073 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 60.45 57.7 17.71 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.466 -1.35 . . . . 0.0 110.744 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.852 ' HG1' ' N ' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -178.24 148.61 0.64 Allowed Pre-proline 0 C--O 1.201 -1.454 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.244 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.41 176.55 3.27 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 121.647 1.565 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.538 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.3 t -173.57 99.06 0.11 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.099 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.455 ' HB ' ' NE2' ' A' ' 9' ' ' GLN . 0.2 OUTLIER -59.97 173.98 0.55 Allowed 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.037 -0.665 . . . . 0.0 112.29 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -71.24 -91.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.592 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.431 ' CA ' ' NE2' ' A' ' 9' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.218 0 CA-C-O 116.364 -2.353 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 121.228 0.537 . . . . 0.0 111.697 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.11 44.98 0.22 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 p -53.27 179.0 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.668 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.52 118.29 12.38 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.096 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.568 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.2 m -108.88 125.97 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.28 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.547 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.53 8.77 Favored 'General case' 0 C--N 1.292 -1.9 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.673 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.71 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 4.8 t-105 -125.44 143.01 51.19 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.769 -0.772 . . . . 0.0 111.785 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.14 72.48 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.62 151.61 9.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.916 0.865 . . . . 0.0 113.266 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.544 ' CB ' HG22 ' A' ' 22' ' ' THR . 0.7 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.005 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.1 p90 . . . . . 0 CA--C 1.493 -1.25 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.544 HG22 ' CB ' ' A' ' 15' ' ' ASN . 6.2 t -70.53 168.92 15.24 Favored 'General case' 0 C--N 1.283 -2.317 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.09 118.74 10.43 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.157 -1.417 . . . . 0.0 112.626 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -104.28 90.93 3.71 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 84' ' ' PHE . 11.5 t -92.73 133.03 35.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.703 -0.799 . . . . 0.0 112.275 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.6 m -119.17 107.2 13.17 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.522 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 82' ' ' ALA . 2.9 t -78.29 144.27 11.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 119.149 -1.021 . . . . 0.0 110.68 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.567 ' HA ' HG22 ' A' ' 81' ' ' THR . 13.4 tptm -135.37 103.05 5.35 Favored 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.859 -0.736 . . . . 0.0 109.576 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.774 HD22 ' N ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -100.33 124.37 45.72 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.088 179.89 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.774 ' N ' HD22 ' A' ' 29' ' ' ASN . 8.6 t -135.78 -2.65 2.36 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.011 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.471 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.3 p -52.19 -80.96 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 119.291 -0.963 . . . . 0.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.08 61.04 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 123.657 0.598 . . . . 0.0 110.803 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 1.027 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -152.72 134.43 8.52 Favored Pre-proline 0 C--N 1.306 -1.283 0 C-N-CA 119.044 -1.063 . . . . 0.0 110.45 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.64 106.7 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 120.922 1.081 . . . . 0.0 110.269 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.552 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.5 t -87.77 67.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 118.639 -1.224 . . . . 0.0 111.809 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -88.16 65.08 7.99 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 101.03 145.6 17.37 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 107.046 -2.421 . . . . 0.0 107.046 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.864 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 49.7 p-90 -162.31 174.61 12.59 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 116.976 -1.89 . . . . 0.0 112.666 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -142.87 99.21 3.42 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.862 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.878 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -87.05 173.34 9.34 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 118.328 -1.349 . . . . 0.0 109.439 179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.477 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -158.12 147.78 19.81 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 117.907 -1.517 . . . . 0.0 112.441 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.594 ' CG ' ' N ' ' A' ' 43' ' ' SER . 10.8 p90 -173.79 -137.29 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.958 -1.474 . . . . 0.0 108.043 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.594 ' N ' ' CG ' ' A' ' 42' ' ' PHE . 41.8 m -161.06 174.33 13.89 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 117.563 -1.655 . . . . 0.0 112.455 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.758 ' CD2' HG21 ' A' ' 65' ' ' VAL . 1.9 m-85 -114.47 95.93 41.54 Favored Pre-proline 0 N--CA 1.496 1.873 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.189 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.451 ' C ' ' H ' ' A' ' 47' ' ' GLY . 5.0 Cg_exo -60.05 -40.9 57.11 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 121.261 1.307 . . . . 0.0 111.676 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.3 t -74.96 15.45 0.4 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.563 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 45' ' ' PRO . . . 55.79 29.38 54.62 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.233 -1.46 . . . . 0.0 110.133 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -61.07 116.47 4.55 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.64 ' CD ' HE22 ' A' ' 60' ' ' GLN . 0.0 OUTLIER -95.5 97.77 10.03 Favored 'General case' 0 N--CA 1.484 1.275 0 C-N-CA 119.359 -0.937 . . . . 0.0 110.621 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 51' ' ' THR . 0.9 OUTLIER -64.47 157.58 4.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.177 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 40.4 p -133.05 -64.45 0.74 Allowed 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.755 -0.778 . . . . 0.0 111.259 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.551 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.9 OUTLIER -90.58 173.98 7.76 Favored 'General case' 0 N--CA 1.494 1.74 0 C-N-CA 118.87 -1.132 . . . . 0.0 110.133 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -173.2 147.46 1.56 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.961 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.474 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 37.2 t-105 -151.2 143.7 24.26 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.713 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.474 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.3 OUTLIER 60.57 27.53 17.21 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.753 -179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.468 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -174.85 122.62 0.24 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.566 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -84.84 77.63 10.05 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 118.987 -1.085 . . . . 0.0 109.462 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.417 ' C ' HG23 ' A' ' 59' ' ' THR . 13.6 m -69.23 152.57 9.34 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.296 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 58' ' ' VAL . 36.9 p -155.24 119.27 4.6 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.074 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.64 HE22 ' CD ' ' A' ' 49' ' ' GLN . 27.9 tt0 -91.53 116.92 29.26 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.906 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.456 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.2 p -90.52 77.35 6.48 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.685 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.36 -68.71 2.06 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.41 -1.376 . . . . 0.0 110.156 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -138.27 -17.16 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.903 -0.719 . . . . 0.0 110.291 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.52 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -91.68 -172.44 3.22 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.988 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.758 HG21 ' CD2' ' A' ' 44' ' ' PHE . 46.1 t -143.83 162.27 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.0 -1.08 . . . . 0.0 113.462 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.612 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 23.5 m -157.79 137.24 11.94 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.573 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.468 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.8 t -131.8 116.33 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 C-N-CA 119.1 -1.04 . . . . 0.0 112.192 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.422 HH11 ' CB ' ' A' ' 68' ' ' ARG . 0.3 OUTLIER -99.53 96.06 7.41 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.269 -1.332 . . . . 0.0 108.74 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.864 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -76.02 120.11 20.89 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.836 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.061 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -40.28 160.62 0.12 Allowed Pre-proline 0 N--CA 1.483 1.192 0 CA-C-N 113.44 -1.709 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -64.89 -38.6 28.83 Favored 'Trans proline' 0 C--O 1.211 -0.844 0 C-N-CA 122.106 1.87 . . . . 0.0 112.229 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.11 -54.69 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.581 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 1.061 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.5 p30 -76.13 5.84 6.23 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.032 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -128.4 50.25 0.9 Allowed Glycine 0 C--O 1.202 -1.901 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.1 m -118.98 61.66 0.8 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 119.78 -0.768 . . . . 0.0 111.303 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.831 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -120.46 109.02 36.97 Favored Pre-proline 0 CA--C 1.56 1.353 0 C-N-CA 119.963 -0.695 . . . . 0.0 111.312 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.633 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.3 Cg_endo -71.65 118.9 5.88 Favored 'Trans proline' 0 C--O 1.207 -1.063 0 C-N-CA 121.182 1.255 . . . . 0.0 111.389 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 1.027 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -7.65 68.07 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.694 1.246 . . . . 0.0 113.257 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.633 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . 170.18 46.1 0.03 OUTLIER Glycine 0 C--N 1.277 -2.722 0 CA-C-N 114.148 -1.387 . . . . 0.0 110.124 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -174.98 -152.92 9.61 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.021 -1.561 . . . . 0.0 110.192 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.567 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.9 p -140.77 173.64 11.29 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.26 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.666 ' O ' HG23 ' A' ' 27' ' ' VAL . . . -148.94 90.79 1.79 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.679 ' HB2' HG23 ' A' ' 26' ' ' THR . 8.5 tt0 -85.04 146.44 27.18 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 25' ' ' VAL . 12.0 p90 -155.03 175.56 13.67 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 113.997 -1.456 . . . . 0.0 108.851 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.7 176.82 41.12 Favored Glycine 0 N--CA 1.498 2.82 0 C-N-CA 117.489 -2.291 . . . . 0.0 112.532 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.489 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 6.8 p90 -163.68 -175.14 3.99 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.949 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -129.77 113.59 14.89 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 119.753 -0.779 . . . . 0.0 110.507 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.495 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.45 152.66 20.3 Favored Glycine 0 N--CA 1.504 3.199 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.481 1.099 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.165 179.79 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.71 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 111.283 0.105 . . . . 0.0 111.283 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.507 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -61.19 -95.72 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.909 1.073 . . . . 0.0 112.465 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 97' ' ' PRO . 6.9 p -155.04 -81.73 0.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.177 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -102.59 94.34 5.6 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.329 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.562 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -67.65 -150.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.209 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 19.4 m -157.12 110.72 2.6 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 117.215 -1.794 . . . . 0.0 113.59 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.575 HD22 HD21 ' A' ' 103' ' ' ASN . 2.5 mt -55.89 177.43 0.06 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.64 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.15 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.544 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -163.63 20.29 0.15 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 118.676 -1.726 . . . . 0.0 111.435 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.605 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 3.5 p -139.6 150.66 64.16 Favored Pre-proline 0 N--CA 1.501 2.087 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.561 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.83 163.82 17.98 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.437 1.425 . . . . 0.0 111.531 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.54 ' SG ' HG13 ' A' ' 10' ' ' VAL . 4.7 t -157.03 98.62 1.76 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.986 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 4.5 p -50.95 161.67 0.35 Allowed 'General case' 0 N--CA 1.498 1.957 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.828 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.946 HG22 ' H ' ' A' ' 110' ' ' GLY . 10.8 p -75.52 -135.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.038 -1.065 . . . . 0.0 109.648 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.946 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.13 0 CA-C-O 116.267 -2.407 . . . . 0.0 110.393 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.49 ' HB1' ' HB3' ' A' ' 31' ' ' SER . . . . . . . . 0 N--CA 1.488 1.453 0 CA-C-O 121.022 0.439 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 177.12 48.33 0.06 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' C ' ' NE2' ' A' ' 9' ' ' GLN . 4.0 p -52.79 178.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.495 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.438 ' NE2' ' C ' ' A' ' 8' ' ' CYS . 0.0 OUTLIER -129.73 124.39 33.39 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.88 179.948 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.558 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.5 m -117.36 125.53 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.532 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.68 168.24 10.28 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.646 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.655 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.4 t-105 -134.31 143.44 47.72 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 119.43 -0.908 . . . . 0.0 112.601 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.66 73.73 0.45 Allowed Glycine 0 N--CA 1.496 2.677 0 N-CA-C 107.3 -2.32 . . . . 0.0 107.3 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.7 OUTLIER -69.93 162.46 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 113.867 1.062 . . . . 0.0 113.867 -179.621 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.466 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.0 t30 . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 113.686 -1.597 . . . . 0.0 108.689 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 37.7 p90 . . . . . 0 CA--C 1.495 -1.171 0 CA-C-O 121.65 0.738 . . . . 0.0 112.62 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.466 HG22 ' HB3' ' A' ' 15' ' ' ASN . 14.8 t -71.81 168.58 17.54 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.655 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -150.18 118.88 6.55 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 117.675 -1.61 . . . . 0.0 112.701 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -100.42 95.82 7.0 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.662 HG11 ' CE2' ' A' ' 84' ' ' PHE . 18.6 t -94.91 141.5 14.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 C-N-CA 119.584 -0.847 . . . . 0.0 112.423 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.541 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.1 m -127.28 120.75 29.36 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.685 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 1.0 OUTLIER -90.55 148.34 4.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.719 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tptp -136.15 103.83 5.46 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.028 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.728 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -95.71 132.56 40.78 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.519 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.462 ' N ' ' ND2' ' A' ' 29' ' ' ASN . 13.7 t -139.48 -3.42 1.51 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 32' ' ' SER . 5.1 p -50.68 -82.15 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.505 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 161.54 69.7 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.478 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.02 154.13 4.99 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 118.518 -1.273 . . . . 0.0 111.499 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -73.18 99.51 1.12 Allowed 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 121.413 1.409 . . . . 0.0 109.598 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.418 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -78.32 81.94 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 118.381 -1.327 . . . . 0.0 111.902 -179.758 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -95.03 54.73 1.72 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 107.38 152.95 18.39 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 107.506 -2.238 . . . . 0.0 107.506 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 41.9 p-90 -163.31 174.09 12.46 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 117.13 -1.828 . . . . 0.0 112.502 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.36 98.16 3.54 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.124 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.867 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -84.9 171.84 11.86 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 118.168 -1.413 . . . . 0.0 109.635 179.945 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.469 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -155.92 142.99 19.08 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 118.673 -1.211 . . . . 0.0 111.63 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.585 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.1 p90 -172.1 -148.92 0.05 Allowed 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.625 -1.171 . . . . 0.0 108.606 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.585 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 65.6 m -159.08 157.71 31.58 Favored 'General case' 0 C--N 1.29 -2.005 0 C-N-CA 117.782 -1.567 . . . . 0.0 111.485 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.564 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.4 m-85 -88.31 114.35 59.15 Favored Pre-proline 0 N--CA 1.491 1.578 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.94 -54.52 4.64 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 N-CA-C 108.654 -1.325 . . . . 0.0 108.654 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.452 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 2.4 t -72.61 163.13 28.55 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 118.777 -1.169 . . . . 0.0 108.063 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.452 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -78.07 59.98 3.89 Favored Glycine 0 C--N 1.277 -2.72 0 C-N-CA 118.338 -1.887 . . . . 0.0 108.72 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.567 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 mt-30 -90.96 176.53 6.57 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.627 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.658 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -162.02 111.92 1.54 Allowed 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.838 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -68.91 157.89 6.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.504 -0.878 . . . . 0.0 111.311 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.658 HG22 HE22 ' A' ' 49' ' ' GLN . 62.2 p -134.71 -66.01 0.61 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.389 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.509 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.1 OUTLIER -83.96 168.98 15.49 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.414 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.33 152.72 7.4 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 118.327 -1.349 . . . . 0.0 112.272 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.43 ' CE2' ' HB2' ' A' ' 55' ' ' SER . 18.4 t-105 -146.72 132.21 18.69 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.626 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.43 ' HB2' ' CE2' ' A' ' 54' ' ' TRP . 2.2 t 58.57 33.18 22.89 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.095 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.5 114.79 0.47 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.376 -0.929 . . . . 0.0 110.672 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.8 m -80.91 74.85 7.88 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 118.87 -1.132 . . . . 0.0 108.929 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.428 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.6 m -69.07 168.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 114.966 -1.016 . . . . 0.0 112.843 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 59' ' ' THR . 10.0 t -170.18 123.57 0.71 Allowed 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.825 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -86.41 102.45 14.06 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.315 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.2 p -91.2 82.83 5.48 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.546 -0.862 . . . . 0.0 111.773 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.554 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 55.69 78.15 0.13 Allowed Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.481 -1.343 . . . . 0.0 110.861 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.2 p 67.59 -23.93 0.12 Allowed 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.825 -0.75 . . . . 0.0 111.487 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.554 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -90.95 -176.07 4.53 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.876 -1.129 . . . . 0.0 110.852 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' A' ' 66' ' ' THR . 33.1 t -149.26 160.11 5.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 118.844 -1.143 . . . . 0.0 113.6 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.572 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.1 m -154.51 154.58 33.36 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.024 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.467 ' HB ' HD22 ' A' ' 40' ' ' LEU . 7.1 t -147.85 117.85 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 118.511 -1.276 . . . . 0.0 112.197 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.24 90.42 5.11 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.441 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.599 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.7 p-10 -70.57 119.01 14.1 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.805 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.811 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.3 158.14 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.482 0 CA-C-N 113.477 -1.692 . . . . 0.0 112.628 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -65.48 -36.74 32.95 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 121.875 1.717 . . . . 0.0 112.072 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.811 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.4 -56.56 7.1 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 118.928 -1.109 . . . . 0.0 110.226 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.65 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -70.22 -3.26 16.15 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.012 179.842 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -123.58 51.3 0.81 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 t -118.2 54.16 0.94 Allowed 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.677 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.69 135.58 20.73 Favored Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.297 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.3 Cg_endo -76.32 156.42 37.2 Favored 'Trans proline' 0 C--O 1.212 -0.793 0 C-N-CA 121.507 1.472 . . . . 0.0 112.306 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.407 ' C ' ' O ' ' A' ' 77' ' ' PRO . . . -28.5 -32.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.5 71.53 0.22 Allowed Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.984 -1.103 . . . . 0.0 110.771 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.442 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -164.54 -164.6 20.18 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 118.739 -1.696 . . . . 0.0 111.07 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 28' ' ' LYS . 11.6 p -139.99 167.78 21.33 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.99 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.437 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.66 -169.05 2.17 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.173 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.505 ' O ' ' NE2' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -169.8 141.82 2.34 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 117.628 -1.629 . . . . 0.0 112.617 -179.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.662 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.5 p90 -163.13 161.73 25.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -157.54 173.18 34.95 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 117.994 -2.051 . . . . 0.0 111.946 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.504 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 7.2 p90 -164.59 -174.63 3.5 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.506 -0.878 . . . . 0.0 111.328 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.497 HD22 ' HB3' ' A' ' 52' ' ' GLN . 70.8 m-80 -130.79 115.71 16.99 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.224 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.41 153.43 20.6 Favored Glycine 0 N--CA 1.511 3.639 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.834 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.64 179.883 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.494 ' HG2' ' CE2' ' A' ' 100' ' ' PHE . 2.3 Cg_endo -64.9 -144.9 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.764 0 C-N-CA 121.548 1.499 . . . . 0.0 111.514 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.622 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.8 p -134.67 -63.37 0.71 Allowed 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 119.696 -0.802 . . . . 0.0 111.873 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.622 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.2 106.98 16.62 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.622 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 12.4 m-85 -80.98 -168.83 1.95 Allowed 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.8 m -144.83 106.24 4.23 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 117.906 -1.517 . . . . 0.0 113.378 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -54.78 174.04 0.08 Allowed 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.236 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.524 HD22 ' HB2' ' A' ' 38' ' ' TRP . 3.1 p30 -57.84 79.95 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.205 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.22 9.02 40.14 Favored Glycine 0 N--CA 1.499 2.877 0 C-N-CA 119.625 -1.274 . . . . 0.0 112.447 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.606 ' O ' ' N ' ' A' ' 102' ' ' LEU . 3.2 p -152.5 153.48 30.63 Favored Pre-proline 0 C--O 1.194 -1.847 0 C-N-CA 118.482 -1.287 . . . . 0.0 111.449 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -66.79 -179.51 1.69 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 121.679 1.586 . . . . 0.0 112.037 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.558 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.4 t -173.2 100.5 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.843 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.31 165.38 4.62 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.791 -0.764 . . . . 0.0 111.879 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.672 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 0.2 OUTLIER -75.11 172.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.012 179.635 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.672 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.178 0 CA-C-O 116.341 -2.366 . . . . 0.0 110.357 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.8 ' HB3' HG21 ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.488 1.448 0 CA-C-O 121.438 0.637 . . . . 0.0 111.848 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.46 55.25 0.06 OUTLIER Glycine 0 N--CA 1.502 3.078 0 N-CA-C 107.384 -2.286 . . . . 0.0 107.384 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -53.88 -165.46 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.503 1.144 . . . . 0.0 113.895 -179.747 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.572 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 13.5 mt-30 -145.03 89.84 1.99 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.455 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.538 ' CG1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 m -87.83 141.3 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.793 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.716 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -116.12 172.8 6.94 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.778 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.896 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 8.8 t-105 -133.14 147.84 52.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.768 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.13 87.85 0.32 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.94 141.03 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.578 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.454 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 55.2 t30 . . . . . 0 C--N 1.303 -1.423 0 CA-C-N 115.105 -0.952 . . . . 0.0 109.327 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.558 ' O ' ' CD2' ' A' ' 21' ' ' PHE . 35.9 p90 . . . . . 0 CA--C 1.49 -1.327 0 CA-C-O 121.355 0.598 . . . . 0.0 112.607 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.555 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.5 OUTLIER -68.95 171.28 8.3 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 179.559 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.555 ' N ' HG23 ' A' ' 22' ' ' THR . . . -151.11 103.34 3.03 Favored 'General case' 0 C--N 1.29 -2.011 0 C-N-CA 117.754 -1.578 . . . . 0.0 112.468 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -91.26 98.88 11.99 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.675 HG11 ' CE2' ' A' ' 84' ' ' PHE . 8.4 t -97.19 139.81 18.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 119.706 -0.797 . . . . 0.0 112.669 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.716 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.2 OUTLIER -125.01 149.47 47.71 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.24 179.796 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.593 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.6 t -123.54 101.65 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.694 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.729 ' HA ' HG22 ' A' ' 81' ' ' THR . 35.3 tptt -87.85 101.95 14.22 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.014 -1.075 . . . . 0.0 110.054 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.722 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -97.16 121.09 38.66 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.274 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -128.51 -1.02 5.57 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.708 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.9 p -47.04 -84.77 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.364 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.473 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 164.75 42.69 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.17 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.817 -179.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.929 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.71 153.17 42.64 Favored Pre-proline 0 N--CA 1.486 1.333 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.337 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -69.6 95.84 0.56 Allowed 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 121.36 1.373 . . . . 0.0 110.006 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.9 t -72.8 96.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.508 -1.277 . . . . 0.0 111.253 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -113.45 82.96 1.76 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.55 139.45 1.92 Allowed Glycine 0 C--N 1.292 -1.89 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.769 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 46.1 p-90 -159.87 176.18 12.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 117.895 -1.522 . . . . 0.0 111.935 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.417 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -142.35 110.03 5.78 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.587 179.925 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.21 173.55 6.74 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.842 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.452 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -154.94 147.72 24.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.01 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.7 p90 -173.26 -144.96 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.451 -1.25 . . . . 0.0 108.904 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.54 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.1 m -159.42 153.3 23.16 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 117.801 -1.56 . . . . 0.0 112.364 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.8 m-85 -84.32 117.56 69.03 Favored Pre-proline 0 N--CA 1.484 1.27 0 C-N-CA 118.825 -1.15 . . . . 0.0 108.23 179.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -57.68 -62.59 0.2 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.628 0.885 . . . . 0.0 110.717 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.444 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 34.9 t -77.91 -174.79 3.7 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.967 -1.093 . . . . 0.0 110.177 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.444 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.81 54.33 4.41 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 118.983 -1.58 . . . . 0.0 109.782 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.552 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 1.9 mt-30 -88.27 139.85 30.08 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 119.106 -1.037 . . . . 0.0 110.79 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.692 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -139.89 112.26 7.75 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.961 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.472 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.43 149.12 11.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.691 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.692 HG22 HE22 ' A' ' 49' ' ' GLN . 26.5 p -126.07 -61.92 1.2 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.898 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.593 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -98.31 125.54 43.47 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.657 -0.817 . . . . 0.0 109.813 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -130.76 160.04 35.51 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 119.445 -0.902 . . . . 0.0 112.388 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.4 ' NE1' ' HB3' ' A' ' 55' ' ' SER . 27.7 t-105 -151.86 143.93 23.87 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.428 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.4 ' HB3' ' NE1' ' A' ' 54' ' ' TRP . 4.7 p 54.74 31.93 16.43 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.686 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.501 ' HB2' ' CG ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -172.89 113.32 0.25 Allowed 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.219 -0.901 . . . . 0.0 109.744 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 m -80.12 77.16 6.85 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.211 -0.995 . . . . 0.0 110.361 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.423 HG12 HG13 ' A' ' 67' ' ' VAL . 3.5 m -71.73 156.03 7.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.401 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.405 HG23 ' C ' ' A' ' 58' ' ' VAL . 64.1 p -155.65 118.18 4.19 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.232 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -81.02 108.24 14.53 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.464 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 p -97.89 94.28 6.81 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.381 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.581 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 47.88 72.58 0.42 Allowed Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.043 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.408 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 68.26 -24.12 0.13 Allowed 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.964 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.581 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -84.93 -172.38 4.15 Favored 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 118.746 -1.182 . . . . 0.0 110.424 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 66' ' ' THR . 75.7 t -142.38 158.68 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.865 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.548 ' N ' HG12 ' A' ' 65' ' ' VAL . 20.3 m -160.0 124.37 3.8 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.384 -1.28 . . . . 0.0 108.649 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.622 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -121.66 148.21 25.23 Favored 'Isoleucine or valine' 0 C--O 1.194 -1.859 0 C-N-CA 119.569 -0.852 . . . . 0.0 111.885 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -130.13 92.91 3.37 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.769 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 13.1 p-10 -71.13 121.02 17.55 Favored 'General case' 0 C--N 1.299 -1.619 0 C-N-CA 119.354 -0.938 . . . . 0.0 111.669 -179.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.824 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -47.71 170.7 0.09 OUTLIER Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.611 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.824 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.7 Cg_endo -68.41 -38.98 10.46 Favored 'Trans proline' 0 C--N 1.322 -0.816 0 C-N-CA 122.163 1.908 . . . . 0.0 112.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.522 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.71 -54.03 15.73 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.063 -1.055 . . . . 0.0 111.335 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.74 HD22 ' HB3' ' A' ' 70' ' ' ALA . 0.9 OUTLIER -75.7 14.73 0.59 Allowed 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.222 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -145.54 34.11 1.51 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 119.284 -1.436 . . . . 0.0 111.319 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.0 m -102.85 58.63 0.78 Allowed 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.584 -0.846 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.523 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -111.98 132.49 21.98 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 119.896 -0.721 . . . . 0.0 111.661 -179.915 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.584 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.9 Cg_endo -69.53 156.26 64.46 Favored 'Trans proline' 0 C--O 1.208 -0.978 0 C-N-CA 121.211 1.274 . . . . 0.0 110.14 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.929 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -41.52 -14.41 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.83 66.85 0.26 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -173.61 -161.51 23.92 Favored Glycine 0 N--CA 1.494 2.534 0 C-N-CA 118.361 -1.876 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.729 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.0 p -139.37 158.17 44.61 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 119.342 -0.943 . . . . 0.0 112.701 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.593 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -124.19 173.94 8.0 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.481 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 9.6 tt0 -169.08 145.79 3.52 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 116.881 -1.928 . . . . 0.0 113.207 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.675 ' CE2' HG11 ' A' ' 25' ' ' VAL . 11.2 p90 -154.98 175.83 13.3 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 114.671 -1.149 . . . . 0.0 109.469 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.18 164.65 37.69 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 116.935 -2.555 . . . . 0.0 112.593 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 3.4 p90 -157.03 -170.23 3.22 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.399 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.454 HD22 ' N ' ' A' ' 87' ' ' ASN . 1.7 m-80 -135.58 114.84 12.42 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.005 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -125.35 150.16 17.25 Favored Glycine 0 N--CA 1.508 3.475 0 C-N-CA 119.408 -1.377 . . . . 0.0 112.342 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 84.9 p . . . . . 0 N--CA 1.476 0.858 0 C-N-CA 120.072 -0.651 . . . . 0.0 109.902 179.788 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.896 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.509 2.485 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.498 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.0 OUTLIER -65.2 -101.4 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 121.14 1.226 . . . . 0.0 112.468 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.52 ' HA ' HG13 ' A' ' 109' ' ' VAL . 81.4 p -150.1 -66.07 0.21 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 118.897 -1.121 . . . . 0.0 112.265 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.479 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -109.93 103.57 12.36 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.594 -0.843 . . . . 0.0 110.662 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 14.4 m-85 -74.57 -169.67 0.89 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.253 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.4 m -136.57 93.61 2.9 Favored 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 118.667 -1.213 . . . . 0.0 112.726 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.636 HD22 ' ND2' ' A' ' 103' ' ' ASN . 1.4 mt -52.53 173.54 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.545 -0.862 . . . . 0.0 108.956 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.636 ' ND2' HD22 ' A' ' 102' ' ' LEU . 1.4 p30 -45.14 90.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.014 -1.074 . . . . 0.0 110.608 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.06 58.22 12.67 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.443 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.8 HG21 ' HB3' ' A' ' 6' ' ' ALA . 0.8 OUTLIER 175.48 139.58 0.2 Allowed Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.869 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.9 167.13 4.52 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 121.551 1.501 . . . . 0.0 112.65 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -164.36 82.33 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.438 HG23 ' H ' ' A' ' 108' ' ' THR . 50.1 p -46.61 167.95 0.02 OUTLIER 'General case' 0 N--CA 1.517 2.88 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.52 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.0 OUTLIER -66.7 -160.08 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.113 -1.035 . . . . 0.0 109.69 179.562 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.099 0 CA-C-O 116.333 -2.37 . . . . 0.0 110.386 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.551 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 121.365 0.602 . . . . 0.0 111.911 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.79 49.35 0.05 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.5 p -53.23 -179.31 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.618 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.536 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 26.6 mt-30 -137.03 113.09 9.73 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.547 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.644 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -108.77 130.82 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.976 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.578 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -103.88 167.38 9.81 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.104 179.94 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.472 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.6 t-105 -130.59 145.45 51.89 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.031 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.18 73.14 0.47 Allowed Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -72.43 153.04 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.564 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.2 t30 . . . . . 0 N--CA 1.485 1.281 0 CA-C-N 114.323 -1.308 . . . . 0.0 108.742 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.592 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 3.1 p90 . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 121.463 0.649 . . . . 0.0 111.629 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.564 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.0 t -75.33 173.84 10.35 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.472 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -158.1 117.01 3.14 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 117.22 -1.792 . . . . 0.0 113.358 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -99.89 101.54 12.69 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.457 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.8 t -99.63 147.05 7.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.58 -0.848 . . . . 0.0 112.802 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.599 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -138.9 110.35 7.0 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.345 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.615 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -83.23 149.81 4.43 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 C-N-CA 119.724 -0.79 . . . . 0.0 112.201 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.536 ' NZ ' ' NE2' ' A' ' 9' ' ' GLN . 2.2 tttm -142.19 106.97 4.87 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.802 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.698 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.3 t30 -93.22 120.17 33.21 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 118.971 -1.092 . . . . 0.0 108.594 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -123.15 -2.77 8.58 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 124.219 0.95 . . . . 0.0 109.818 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.529 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -53.35 -81.4 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.801 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.509 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.52 73.53 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.383 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.26 143.32 1.93 Allowed Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.089 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -68.32 101.88 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.42 109.28 18.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 118.281 -1.367 . . . . 0.0 111.643 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -117.38 73.63 0.89 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.06 143.75 11.75 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.904 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.4 p-90 -162.48 177.31 9.6 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 117.761 -1.576 . . . . 0.0 112.098 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -138.45 112.97 8.86 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.379 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.72 173.29 6.37 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 119.285 -0.966 . . . . 0.0 109.326 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.528 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -167.18 159.2 12.68 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.762 -1.575 . . . . 0.0 112.638 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.528 ' N ' ' CG2' ' A' ' 41' ' ' THR . 23.5 p90 -176.71 -134.49 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.63 -1.623 . . . . 0.0 107.954 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.483 ' OG ' ' C ' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -163.0 139.12 7.11 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.685 -1.606 . . . . 0.0 112.237 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.748 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.7 m-85 -69.28 122.28 84.9 Favored Pre-proline 0 N--CA 1.486 1.344 0 C-N-CA 118.838 -1.145 . . . . 0.0 108.465 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -52.68 -68.76 0.07 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.343 1.362 . . . . 0.0 112.729 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 p -69.42 -68.58 0.4 Allowed 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 119.173 -1.011 . . . . 0.0 111.105 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.13 26.71 0.02 OUTLIER Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.222 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.508 ' N ' ' OE1' ' A' ' 48' ' ' GLN . 1.1 mp0 -43.73 144.6 0.8 Allowed 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.614 -0.834 . . . . 0.0 110.847 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.612 ' CA ' HE21 ' A' ' 49' ' ' GLN . 0.1 OUTLIER -110.54 82.95 1.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.508 -179.944 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.7 p -61.68 147.75 10.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.398 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.498 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 68.5 p -136.77 -71.91 0.44 Allowed 'General case' 0 N--CA 1.497 1.879 0 C-N-CA 119.181 -1.007 . . . . 0.0 112.157 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.498 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -76.6 145.72 38.74 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.935 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -156.19 153.86 29.9 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.733 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.443 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.2 t-105 -152.55 147.98 26.83 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.182 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 71.27 14.3 6.56 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.686 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.587 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 31.3 t -174.1 151.2 1.66 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.396 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -102.66 84.58 2.43 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.699 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -85.43 163.13 2.76 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.963 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.8 t -164.21 132.26 3.47 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.613 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.87 113.27 24.81 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.698 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.894 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.5 p -84.28 68.33 10.14 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.722 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.31 -63.74 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.5 m -142.19 -16.7 0.75 Allowed 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 120.062 -0.655 . . . . 0.0 109.269 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.47 -172.89 3.95 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.252 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.748 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 94.6 t -146.15 153.1 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 118.79 -1.164 . . . . 0.0 112.587 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.451 ' N ' HG12 ' A' ' 65' ' ' VAL . 3.6 m -159.89 135.87 8.64 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 114.909 -1.042 . . . . 0.0 108.976 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.631 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.0 t -129.46 153.36 38.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.943 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.49 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -135.91 89.29 2.47 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.904 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.86 118.53 13.75 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.162 -1.015 . . . . 0.0 112.08 -179.582 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.774 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.07 154.83 0.12 Allowed Pre-proline 0 N--CA 1.484 1.237 0 CA-C-N 113.731 -1.577 . . . . 0.0 112.012 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -64.69 -35.14 48.14 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 121.942 1.762 . . . . 0.0 112.626 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.774 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.59 -57.36 5.28 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.775 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.601 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -69.83 -13.18 62.14 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.106 -1.038 . . . . 0.0 109.911 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.08 22.12 42.46 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.621 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 m -87.53 58.65 5.05 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.002 . . . . 0.0 111.271 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.916 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -108.96 115.39 57.18 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.171 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' GLY . 2.0 Cg_endo -67.96 159.45 52.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 121.317 1.345 . . . . 0.0 113.745 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.509 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -24.08 -38.55 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 114.332 -1.304 . . . . 0.0 114.058 179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.07 68.56 0.33 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -155.35 -168.22 18.14 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 118.857 -1.639 . . . . 0.0 110.284 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.516 ' N ' HG13 ' A' ' 76' ' ' ILE . 22.0 p -141.96 164.37 30.36 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.085 -1.046 . . . . 0.0 112.819 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.578 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.68 -179.95 5.6 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.476 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.599 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -170.24 151.53 3.89 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 116.883 -1.927 . . . . 0.0 113.101 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.457 ' CE1' HG11 ' A' ' 25' ' ' VAL . 5.6 p90 -167.64 171.49 10.16 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.32 160.89 30.5 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.729 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.604 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.4 p90 -150.1 160.42 43.67 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.308 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.4 m-20 -115.62 110.93 19.89 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.428 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -105.6 176.5 22.33 Favored Glycine 0 N--CA 1.501 3.012 0 C-N-CA 119.491 -1.338 . . . . 0.0 111.972 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.482 1.158 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.393 179.968 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.447 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -68.16 -145.02 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 121.244 1.296 . . . . 0.0 111.287 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.879 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.2 p -116.74 -87.91 0.6 Allowed 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 119.667 -0.813 . . . . 0.0 112.259 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.63 107.11 18.67 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.237 -0.985 . . . . 0.0 112.018 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.1 m-30 -78.6 -155.98 0.09 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.63 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.9 m -159.53 122.73 3.63 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 117.043 -1.863 . . . . 0.0 113.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.591 HD22 HD21 ' A' ' 103' ' ' ASN . 3.3 mt -60.65 -178.61 0.1 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.564 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.718 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.09 -41.24 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -155.69 27.7 0.59 Allowed Glycine 0 N--CA 1.495 2.604 0 C-N-CA 118.593 -1.765 . . . . 0.0 111.352 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.551 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 21.3 p -145.07 151.6 49.02 Favored Pre-proline 0 N--CA 1.494 1.752 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.229 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -62.26 174.49 2.59 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 121.628 1.552 . . . . 0.0 112.451 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.644 ' SG ' HG13 ' A' ' 10' ' ' VAL . 3.0 t -168.19 106.38 0.49 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.471 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 41.4 p -72.63 146.08 46.86 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.971 -0.692 . . . . 0.0 112.403 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.879 HG13 ' O ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -59.32 -167.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.257 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 CA-C-O 116.339 -2.367 . . . . 0.0 110.296 179.986 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.855 ' N ' ' HG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-O 121.454 0.645 . . . . 0.0 111.445 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.69 40.04 0.19 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.6 p -50.88 177.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 114.33 -0.935 . . . . 0.0 112.319 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -131.78 121.64 24.51 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.11 -1.404 . . . . 0.0 109.614 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.491 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 m -112.46 127.01 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.603 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.524 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.56 171.38 7.6 Favored 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.055 179.881 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.695 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.2 t-105 -132.25 149.28 52.41 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.706 -0.798 . . . . 0.0 112.042 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.29 83.55 0.32 Allowed Glycine 0 N--CA 1.497 2.726 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.78 144.75 12.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.421 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 54.0 t30 . . . . . 0 N--CA 1.488 1.468 0 CA-C-N 114.165 -1.38 . . . . 0.0 107.619 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.609 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 24.2 p90 . . . . . 0 CA--C 1.505 -0.78 0 CA-C-O 121.308 0.575 . . . . 0.0 111.324 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -83.87 165.37 18.8 Favored 'General case' 0 C--N 1.284 -2.256 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.623 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.691 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -145.56 106.34 4.12 Favored 'General case' 0 C--N 1.29 -2.014 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.899 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -93.35 96.84 10.2 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.567 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.9 t -93.46 147.39 5.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 115.383 -0.826 . . . . 0.0 113.007 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.524 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.3 m -133.36 127.12 32.8 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.5 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -97.73 145.95 8.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.989 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.655 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.2 tptt -126.97 100.56 6.19 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.835 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.69 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -93.7 119.72 33.06 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.561 179.852 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 t -130.53 -0.92 4.4 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.8 p -50.52 -83.01 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.29 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.38 67.78 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.64 -179.943 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.09 157.94 7.37 Favored Pre-proline 0 N--CA 1.482 1.127 0 C-N-CA 118.372 -1.331 . . . . 0.0 111.625 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.65 95.79 0.96 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.588 1.525 . . . . 0.0 109.052 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -74.47 87.54 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 118.47 -1.292 . . . . 0.0 111.744 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -100.06 56.52 0.95 Allowed 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 115.374 -0.83 . . . . 0.0 108.868 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.03 150.28 19.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.908 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 42.0 p-90 -164.14 176.68 9.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 117.652 -1.619 . . . . 0.0 112.059 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.5 OUTLIER -141.28 110.11 6.11 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.545 179.907 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.865 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -99.34 177.0 5.33 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.264 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.505 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.9 150.77 13.69 Favored 'General case' 0 C--N 1.289 -2.024 0 C-N-CA 117.867 -1.533 . . . . 0.0 112.361 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' ' N ' ' A' ' 43' ' ' SER . 14.4 p90 -174.55 -145.99 0.03 OUTLIER 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.753 -1.567 . . . . 0.0 107.952 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.52 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 41.7 m -161.12 154.12 21.15 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 117.804 -1.558 . . . . 0.0 111.758 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.502 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -84.61 116.86 67.1 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.15 -53.89 4.3 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.16 1.24 . . . . 0.0 112.407 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.0 t -74.36 -82.77 0.06 Allowed 'General case' 0 C--N 1.294 -1.842 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.087 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 175.45 25.13 0.03 OUTLIER Glycine 0 N--CA 1.486 2.025 0 C-N-CA 119.289 -1.434 . . . . 0.0 110.193 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.442 ' HG3' ' CE1' ' A' ' 21' ' ' PHE . 0.8 OUTLIER -43.04 121.86 2.26 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.524 179.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.616 ' CA ' HE21 ' A' ' 49' ' ' GLN . 0.0 OUTLIER -93.81 84.78 4.64 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.959 -179.83 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.511 HG12 HE21 ' A' ' 60' ' ' GLN . 0.5 OUTLIER -64.63 148.57 11.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.554 179.786 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.493 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 76.0 p -137.78 -69.23 0.45 Allowed 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.37 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.493 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.5 mt-30 -73.36 161.51 30.38 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 118.842 -1.143 . . . . 0.0 110.024 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.62 142.16 3.05 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.323 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.432 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 38.8 t-105 -146.9 149.09 32.54 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.592 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.432 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 6.3 t 57.11 27.82 14.01 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 119.326 -0.95 . . . . 0.0 109.07 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.588 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -174.66 125.42 0.29 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.135 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -87.57 72.34 9.62 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.596 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 67' ' ' VAL . 2.6 m -71.92 153.18 7.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.33 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.404 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.0 t -153.95 134.94 13.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.944 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.528 HE22 ' NE2' ' A' ' 49' ' ' GLN . 6.9 tt0 -100.51 120.2 39.65 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.285 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.0 p -100.58 80.48 2.21 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.706 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.56 2.53 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.468 -1.349 . . . . 0.0 109.956 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 41.8 t -146.77 -18.23 0.42 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.967 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -87.8 -170.66 3.09 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.155 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 66' ' ' THR . 79.1 t -148.02 160.64 7.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.917 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.8 m -158.65 125.95 4.94 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 114.392 -1.276 . . . . 0.0 108.642 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.589 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.6 t -116.98 146.68 21.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.08 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.674 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -130.18 92.44 3.29 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.908 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.41 118.2 17.1 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.284 -0.966 . . . . 0.0 112.433 -179.709 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.655 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -42.73 165.65 0.1 OUTLIER Pre-proline 0 N--CA 1.487 1.406 0 CA-C-N 113.578 -1.646 . . . . 0.0 112.483 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.619 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 4.9 Cg_endo -68.71 -33.03 22.34 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.058 1.839 . . . . 0.0 112.583 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.614 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.66 -57.7 4.84 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.477 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.655 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.4 p30 -73.26 -4.43 33.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 119.12 -1.032 . . . . 0.0 109.652 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -119.77 50.25 0.83 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.5 t -120.54 57.07 0.97 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 120.029 -0.669 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.543 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.02 134.61 22.13 Favored Pre-proline 0 N--CA 1.486 1.356 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.551 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -71.52 158.71 53.22 Favored 'Trans proline' 0 C--O 1.214 -0.713 0 C-N-CA 121.464 1.443 . . . . 0.0 112.814 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.449 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -31.44 -29.51 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -115.5 72.9 0.25 Allowed Glycine 0 N--CA 1.497 2.706 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.899 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.33 -167.47 27.03 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.793 -1.67 . . . . 0.0 110.809 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.655 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.5 p -138.35 160.01 40.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.088 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -122.56 -176.45 3.38 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.459 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -169.37 142.07 2.6 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 117.068 -1.853 . . . . 0.0 113.361 -179.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.567 ' CE1' HG11 ' A' ' 25' ' ' VAL . 7.5 p90 -159.12 174.14 15.34 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.054 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.0 168.33 39.7 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 117.638 -2.22 . . . . 0.0 112.521 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.9 p90 -152.94 -176.36 5.73 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.944 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.501 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 1.2 m120 -138.09 111.66 8.16 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.774 -0.771 . . . . 0.0 110.783 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -123.42 163.62 16.85 Favored Glycine 0 N--CA 1.507 3.379 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.892 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.6 p . . . . . 0 N--CA 1.481 1.105 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.796 179.74 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.695 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -65.29 -142.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 121.21 1.274 . . . . 0.0 110.772 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.621 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.0 p -116.25 -64.63 1.28 Allowed 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 119.45 -0.9 . . . . 0.0 112.593 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.621 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.03 112.15 23.97 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.288 -0.965 . . . . 0.0 111.333 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 8.9 m-85 -84.32 -164.17 0.91 Allowed 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.035 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.2 m -144.52 117.6 8.89 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 118.421 -1.312 . . . . 0.0 112.009 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.788 HD22 ' ND2' ' A' ' 103' ' ' ASN . 1.3 mt -68.38 -178.67 1.14 Allowed 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.581 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.788 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.5 OUTLIER -27.69 -37.46 0.01 OUTLIER 'General case' 0 N--CA 1.512 2.631 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.82 55.6 0.21 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.199 -1.477 . . . . 0.0 110.274 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.855 ' HG1' ' N ' ' A' ' 6' ' ' ALA . 2.4 t -174.38 145.81 1.04 Allowed Pre-proline 0 C--O 1.196 -1.726 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.774 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -56.3 168.59 1.96 Allowed 'Trans proline' 0 C--N 1.324 -0.758 0 C-N-CA 121.511 1.474 . . . . 0.0 112.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.455 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.8 t -164.84 95.12 0.7 Allowed 'General case' 0 N--CA 1.494 1.74 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.118 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.463 ' OG1' ' N ' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -51.99 168.45 0.09 Allowed 'General case' 0 N--CA 1.501 2.075 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.203 -179.688 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 1.095 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.4 p -67.77 -151.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.442 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.871 0 CA-C-O 116.281 -2.4 . . . . 0.0 110.125 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 122.205 1.002 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.635 ' O ' ' SG ' ' A' ' 8' ' ' CYS . . . -176.55 -79.79 0.05 OUTLIER Glycine 0 C--O 1.189 -2.714 0 N-CA-C 107.023 -2.431 . . . . 0.0 107.023 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.722 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 6.6 p 63.62 176.97 0.16 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.541 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 55.3 mt-30 -151.27 158.98 44.56 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.482 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.53 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.7 m -141.19 126.54 18.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.954 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.579 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.65 8.69 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.023 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.616 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 4.0 t-105 -126.73 144.11 51.04 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 123.895 0.747 . . . . 0.0 112.471 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.31 74.7 0.43 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.538 -2.225 . . . . 0.0 107.538 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 15' ' ' ASN . 7.2 p -69.77 152.52 9.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.472 ' N ' HG22 ' A' ' 14' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.499 0 CA-C-N 113.81 -1.541 . . . . 0.0 107.857 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.563 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 32.5 p90 . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.124 0.488 . . . . 0.0 112.047 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 22' ' ' THR . 0.9 OUTLIER -96.04 106.75 18.97 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.563 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.616 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -90.03 120.62 31.39 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -101.78 96.41 7.05 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 179.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 26' ' ' THR . 33.6 t -90.14 154.46 3.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.836 HG23 ' HB3' ' A' ' 83' ' ' GLN . 1.9 m -142.05 101.19 3.88 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.57 -1.195 . . . . 0.0 109.698 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.431 HG13 HG12 ' A' ' 10' ' ' VAL . 3.4 t -75.06 147.81 8.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.184 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.413 ' HA ' HG22 ' A' ' 81' ' ' THR . 5.8 tttp -136.95 105.43 5.78 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.558 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.81 118.72 29.62 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 118.736 -1.186 . . . . 0.0 108.349 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.0 t -118.21 2.15 11.95 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.185 0.928 . . . . 0.0 110.013 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 32' ' ' SER . 14.9 p -54.09 -84.01 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.646 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.6 OUTLIER 158.77 68.45 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.934 0 O-C-N 123.873 0.733 . . . . 0.0 111.29 -179.953 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.462 ' H ' ' HA ' ' A' ' 78' ' ' ALA . . . -168.16 154.04 6.92 Favored Pre-proline 0 N--CA 1.483 1.192 0 C-N-CA 118.629 -1.228 . . . . 0.0 111.428 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -70.95 93.18 0.63 Allowed 'Trans proline' 0 C--N 1.326 -0.639 0 C-N-CA 121.144 1.23 . . . . 0.0 109.051 179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.456 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -78.33 107.27 10.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.598 -179.852 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -114.41 62.72 0.67 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.22 147.9 20.15 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.894 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 39.6 p-90 -164.45 -179.11 5.8 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.427 -1.309 . . . . 0.0 111.805 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.29 118.29 12.54 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.257 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -112.05 174.81 5.7 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 119.474 -0.891 . . . . 0.0 109.412 179.831 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.503 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -166.05 153.68 10.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.736 -1.586 . . . . 0.0 112.858 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.509 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.9 p90 -176.3 -139.67 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 113.809 -1.541 . . . . 0.0 108.22 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.509 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.6 m -160.15 172.0 18.23 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.798 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.55 ' CD2' HG21 ' A' ' 65' ' ' VAL . 3.0 m-85 -114.14 96.5 42.41 Favored Pre-proline 0 N--CA 1.497 1.881 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.57 -42.95 42.87 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 121.469 1.446 . . . . 0.0 112.209 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.571 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.4 t -69.71 -115.7 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.91 -1.116 . . . . 0.0 110.632 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.571 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -145.85 21.22 1.8 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.498 ' HB2' ' CD1' ' A' ' 44' ' ' PHE . 16.4 mt-30 -61.85 89.96 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.689 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.423 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 2.9 mm100 -88.86 97.18 11.02 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.3 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.583 HG23 ' HB2' ' A' ' 86' ' ' PHE . 1.5 p -68.06 138.25 22.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.651 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 44.0 p -127.19 -65.77 0.93 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.814 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.531 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -81.4 153.34 27.0 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.453 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.412 ' N ' ' HG3' ' A' ' 52' ' ' GLN . . . -162.1 155.05 20.21 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.277 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.4 t-105 -157.71 142.41 16.49 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.796 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.482 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.2 OUTLIER 75.27 14.31 3.02 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.515 179.931 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.574 ' OG ' HG11 ' A' ' 67' ' ' VAL . 1.4 t -174.32 115.43 0.2 Allowed 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.5 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -71.2 85.52 0.76 Allowed 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.898 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 56' ' ' SER . 1.4 m -86.2 167.36 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.821 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.434 ' O ' ' CG2' ' A' ' 59' ' ' THR . 4.0 t -163.55 133.9 4.4 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.21 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.515 ' NE2' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER -94.42 123.99 38.17 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.733 -179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.629 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 34.0 p -110.01 -151.34 0.47 Allowed 'General case' 0 C--O 1.2 -1.519 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.394 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.529 ' C ' ' N ' ' A' ' 64' ' ' ALA . . . -53.33 84.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.657 0 C-N-CA 118.645 -1.74 . . . . 0.0 109.178 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.618 ' N ' ' O ' ' A' ' 61' ' ' SER . 28.4 m 47.68 13.66 0.04 OUTLIER 'General case' 0 C--N 1.31 -1.118 0 C-N-CA 119.606 -0.837 . . . . 0.0 109.686 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.629 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -109.59 -167.55 1.22 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.427 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.55 HG21 ' CD2' ' A' ' 44' ' ' PHE . 99.3 t -148.71 154.55 9.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 118.664 -1.215 . . . . 0.0 112.586 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.508 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.5 m -156.08 139.14 15.46 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.621 179.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.612 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.7 t -132.83 156.4 42.25 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.748 0 C-N-CA 119.05 -1.06 . . . . 0.0 112.442 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.421 ' N ' HG12 ' A' ' 67' ' ' VAL . 6.2 mtm180 -139.85 90.21 2.37 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 113.888 -1.505 . . . . 0.0 106.993 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.894 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.21 121.87 21.92 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.854 -179.554 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.028 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -40.93 158.66 0.17 Allowed Pre-proline 0 N--CA 1.482 1.136 0 CA-C-N 113.618 -1.628 . . . . 0.0 112.049 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.42 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.8 Cg_endo -65.62 -39.14 22.09 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.921 1.747 . . . . 0.0 111.865 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.722 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.54 -55.88 8.91 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.43 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 1.028 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.8 p30 -66.41 -20.8 66.16 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 118.755 -1.178 . . . . 0.0 109.221 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.77 31.77 8.01 Favored Glycine 0 N--CA 1.483 1.802 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 t -92.12 55.77 2.68 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.616 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -104.76 133.9 19.93 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.646 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.46 ' O ' ' N ' ' A' ' 79' ' ' GLY . 11.9 Cg_endo -77.32 163.08 30.49 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 121.628 1.552 . . . . 0.0 114.07 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.29 -39.35 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 114.031 -1.441 . . . . 0.0 113.658 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -123.98 73.37 0.41 Allowed Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.479 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -152.59 -163.18 11.43 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.041 -1.552 . . . . 0.0 110.39 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.563 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.0 OUTLIER -141.8 163.23 33.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.626 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -146.91 99.32 3.17 Favored 'General case' 0 N--CA 1.485 1.278 0 CA-C-N 114.484 -1.235 . . . . 0.0 107.936 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.836 ' HB3' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -94.14 172.7 8.05 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -179.661 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.519 ' CB ' ' HB2' ' A' ' 56' ' ' SER . 34.9 p90 -168.62 -167.93 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 112.633 -2.076 . . . . 0.0 109.482 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 84' ' ' PHE . . . -172.98 158.93 29.14 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 117.483 -2.294 . . . . 0.0 112.555 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.5 p90 -149.69 166.62 28.81 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 114.962 -0.619 . . . . 0.0 110.369 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.0 OUTLIER -123.41 110.26 14.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.89 -0.724 . . . . 0.0 110.724 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.553 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -129.62 167.19 21.57 Favored Glycine 0 N--CA 1.505 3.251 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.711 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p . . . . . 0 N--CA 1.483 1.184 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.133 179.84 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.496 -0.187 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.491 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -59.79 -100.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 120.754 0.969 . . . . 0.0 112.445 -179.898 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.849 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.3 p -150.89 -98.86 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.454 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.71 95.75 9.75 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 118.492 -1.283 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -65.49 -157.33 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.339 -0.945 . . . . 0.0 108.995 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.473 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.58 128.5 5.86 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 116.679 -2.008 . . . . 0.0 113.982 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.8 mt -62.86 -173.27 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.398 179.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.66 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -32.15 -49.17 0.19 Allowed 'General case' 0 N--CA 1.505 2.3 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -147.95 28.46 1.42 Allowed Glycine 0 N--CA 1.494 2.511 0 C-N-CA 118.847 -1.644 . . . . 0.0 111.411 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.579 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.6 OUTLIER -146.15 155.24 50.82 Favored Pre-proline 0 C--O 1.191 -2.026 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.239 -179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -65.97 -178.14 0.97 Allowed 'Trans proline' 0 C--N 1.321 -0.87 0 C-N-CA 121.781 1.654 . . . . 0.0 112.571 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.722 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 9.7 t -174.45 111.76 0.15 Allowed 'General case' 0 N--CA 1.501 2.097 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.907 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.12 132.36 44.94 Favored 'General case' 0 N--CA 1.515 2.814 0 N-CA-C 114.202 1.186 . . . . 0.0 114.202 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 98' ' ' THR . 0.2 OUTLIER -52.33 174.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 C-N-CA 118.824 -1.15 . . . . 0.0 110.54 179.742 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.161 0 CA-C-O 116.371 -2.35 . . . . 0.0 110.479 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.595 ' HB1' ' CB ' ' A' ' 31' ' ' SER . . . . . . . . 0 N--CA 1.485 1.289 0 CA-C-O 120.907 0.385 . . . . 0.0 110.484 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.73 55.23 0.21 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.445 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 2.9 p -51.44 177.39 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.187 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.42 116.36 15.94 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.592 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.662 HG12 HG13 ' A' ' 27' ' ' VAL . 3.5 m -110.51 124.16 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.256 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.11 166.86 11.72 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.582 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.626 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.5 t-105 -134.75 140.05 45.63 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.613 -0.835 . . . . 0.0 111.463 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -122.98 71.22 0.42 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -72.17 147.67 10.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.487 ' HB3' HG22 ' A' ' 22' ' ' THR . 29.7 t30 . . . . . 0 C--N 1.3 -1.562 0 CA-C-N 113.989 -1.459 . . . . 0.0 107.513 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.598 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 20.2 p90 . . . . . 0 N--CA 1.478 0.928 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.487 HG22 ' HB3' ' A' ' 15' ' ' ASN . 2.4 t -72.61 171.87 11.67 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.626 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -156.81 113.54 3.06 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 117.385 -1.726 . . . . 0.0 113.19 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -98.82 101.17 12.48 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.592 HG11 ' CE1' ' A' ' 84' ' ' PHE . 27.2 t -99.43 143.24 13.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.918 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.562 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.8 m -132.54 110.77 10.71 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.93 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.662 HG13 HG12 ' A' ' 10' ' ' VAL . 2.1 t -82.0 150.42 4.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 C-N-CA 119.486 -0.885 . . . . 0.0 112.213 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.419 ' HB2' HG22 ' A' ' 81' ' ' THR . 13.3 tttp -138.91 115.77 10.81 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.067 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.433 ' HB2' ' CD1' ' A' ' 76' ' ' ILE . 1.4 t-20 -98.24 109.71 22.42 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.5 t -121.77 -2.08 9.37 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.147 0.905 . . . . 0.0 109.78 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.595 ' CB ' ' HB1' ' A' ' 6' ' ' ALA . 1.8 p -58.68 -79.46 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.261 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.34 43.21 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.522 -179.857 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.955 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -140.15 145.91 43.87 Favored Pre-proline 0 N--CA 1.487 1.388 0 C-N-CA 118.91 -1.116 . . . . 0.0 111.494 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -72.4 109.26 2.7 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 121.3 1.334 . . . . 0.0 109.596 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -97.5 112.97 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.001 -1.079 . . . . 0.0 112.211 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -122.35 70.01 0.97 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 141.77 12.1 Favored Glycine 0 C--N 1.294 -1.782 0 N-CA-C 106.657 -2.577 . . . . 0.0 106.657 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 31.0 p-90 -158.88 178.86 9.63 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 117.136 -1.825 . . . . 0.0 112.456 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.55 95.76 3.04 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.057 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.893 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -82.22 168.84 17.23 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.223 -1.391 . . . . 0.0 109.469 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.5 m -156.95 149.59 23.45 Favored 'General case' 0 C--N 1.287 -2.152 0 C-N-CA 118.122 -1.431 . . . . 0.0 112.012 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 25.5 p90 -174.03 -149.73 0.04 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.996 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.1 m -158.96 149.62 19.84 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 117.623 -1.631 . . . . 0.0 112.001 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.456 ' CE2' HG21 ' A' ' 65' ' ' VAL . 7.4 m-85 -78.79 123.55 85.26 Favored Pre-proline 0 C--N 1.307 -1.261 0 C-N-CA 118.326 -1.35 . . . . 0.0 107.712 179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -65.72 -63.26 0.07 OUTLIER 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 121.358 1.372 . . . . 0.0 112.226 -179.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 p -69.05 -120.68 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 118.613 -1.235 . . . . 0.0 110.464 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -132.91 42.68 1.35 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -84.92 133.07 34.3 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.762 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.52 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -131.56 117.07 18.24 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.801 179.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.464 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.38 155.06 7.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.974 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.554 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.7 p -128.6 -64.85 0.91 Allowed 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.894 -0.723 . . . . 0.0 110.92 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.554 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -95.28 140.46 30.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.601 -0.839 . . . . 0.0 109.446 179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.73 160.72 40.22 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 118.917 -1.113 . . . . 0.0 112.354 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 35.3 t-105 -153.15 143.07 22.16 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.649 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.3 t 60.97 26.56 16.49 Favored 'General case' 0 C--N 1.313 -0.978 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.466 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.419 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -170.97 124.07 0.63 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.717 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 m -87.01 75.09 9.58 Favored 'General case' 0 C--N 1.281 -2.384 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.354 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.414 ' C ' HG23 ' A' ' 59' ' ' THR . 16.7 m -69.21 151.1 10.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.256 -0.884 . . . . 0.0 112.462 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.414 HG23 ' C ' ' A' ' 58' ' ' VAL . 37.9 p -155.32 115.31 3.74 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -90.74 124.44 35.11 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 119.11 -1.036 . . . . 0.0 110.612 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.96 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.7 p -91.71 75.31 5.77 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.5 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.471 ' C ' ' OG ' ' A' ' 63' ' ' SER . . . 76.18 -42.9 1.69 Allowed Glycine 0 N--CA 1.496 2.661 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.222 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.471 ' OG ' ' C ' ' A' ' 62' ' ' GLY . 0.8 OUTLIER -163.76 -19.01 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.087 -0.645 . . . . 0.0 109.563 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.96 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.33 -169.18 2.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.17 -1.012 . . . . 0.0 109.754 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 66' ' ' THR . 98.3 t -150.33 157.97 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 118.007 -1.477 . . . . 0.0 114.152 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.587 ' N ' HG12 ' A' ' 65' ' ' VAL . 13.4 m -157.86 143.6 17.18 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.67 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.569 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -139.12 114.74 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 C-N-CA 118.834 -1.147 . . . . 0.0 112.144 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -94.14 89.41 5.98 Favored 'General case' 0 C--N 1.281 -2.374 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.095 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.727 HD21 ' CA ' ' A' ' 74' ' ' GLY . 0.9 OUTLIER -71.75 117.28 13.13 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.021 -1.072 . . . . 0.0 111.909 -179.694 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.769 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -37.6 155.75 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.454 0 CA-C-N 113.622 -1.626 . . . . 0.0 112.297 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -62.47 -36.79 63.78 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.998 1.799 . . . . 0.0 112.312 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.754 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.07 -52.45 28.32 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.304 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.769 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -75.56 0.59 16.84 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.686 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.727 ' CA ' HD21 ' A' ' 69' ' ' ASN . . . -118.94 25.41 7.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.6 p -92.73 73.25 4.97 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.75 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.549 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -133.89 126.07 18.58 Favored Pre-proline 0 N--CA 1.483 1.206 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.23 179.928 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.615 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.5 Cg_endo -72.41 167.59 26.57 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 120.953 1.102 . . . . 0.0 110.233 179.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.955 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -52.55 1.71 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.655 0 C-N-CA 119.609 -0.836 . . . . 0.0 112.399 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.615 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -128.8 67.29 0.56 Allowed Glycine 0 N--CA 1.496 2.663 0 C-N-CA 119.597 -1.287 . . . . 0.0 109.945 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 178.73 -162.06 28.92 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 118.831 -1.652 . . . . 0.0 110.376 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.549 ' N ' HG13 ' A' ' 76' ' ' ILE . 15.8 p -142.09 166.32 25.04 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.093 -1.043 . . . . 0.0 113.179 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.473 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -128.56 -177.31 4.13 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 113.896 -1.502 . . . . 0.0 107.113 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.421 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 13.0 tt0 -168.21 148.29 4.78 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 116.85 -1.94 . . . . 0.0 113.494 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.0 p90 -161.86 169.83 20.57 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.312 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.62 161.12 32.47 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 117.981 -2.057 . . . . 0.0 112.174 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.5 p90 -155.37 175.08 14.33 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.46 ' ND2' ' OG1' ' A' ' 22' ' ' THR . 10.5 m120 -124.07 109.42 13.47 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.284 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.81 174.83 15.63 Favored Glycine 0 N--CA 1.497 2.737 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.678 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 N--CA 1.485 1.285 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.705 179.908 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.652 ' HB1' ' HZ ' ' A' ' 100' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 9.2 Cg_endo -68.86 -151.14 0.03 OUTLIER 'Trans proline' 0 C--O 1.216 -0.585 0 C-N-CA 121.408 1.405 . . . . 0.0 111.594 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.633 ' O ' HG13 ' A' ' 109' ' ' VAL . 9.3 p -120.06 -47.82 2.37 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.914 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.433 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.5 91.61 3.72 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.939 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.652 ' HZ ' ' HB1' ' A' ' 96' ' ' ALA . 33.7 m-85 -64.18 -164.03 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.066 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.1 m -146.66 98.9 3.13 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 117.761 -1.576 . . . . 0.0 113.336 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -51.53 165.85 0.15 Allowed 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 119.304 -0.958 . . . . 0.0 108.655 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.522 HD22 HD22 ' A' ' 102' ' ' LEU . 2.0 p30 -43.03 91.15 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.058 -1.057 . . . . 0.0 110.669 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 68.91 55.88 10.18 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.59 -1.291 . . . . 0.0 110.51 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.594 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.9 OUTLIER 175.97 135.57 0.18 Allowed Pre-proline 0 C--O 1.195 -1.797 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.739 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -58.97 166.86 6.27 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 121.568 1.512 . . . . 0.0 112.818 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.511 ' SG ' HG13 ' A' ' 10' ' ' VAL . 9.0 t -165.53 102.36 0.71 Allowed 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.94 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 p -58.68 173.37 0.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.211 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.633 HG13 ' O ' ' A' ' 98' ' ' THR . 16.3 m -64.26 -143.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.66 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.486 2.002 0 CA-C-O 116.32 -2.378 . . . . 0.0 110.227 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 121.213 0.53 . . . . 0.0 110.971 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.44 45.42 0.04 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.917 ' SG ' HD12 ' A' ' 102' ' ' LEU . 4.3 p -50.94 175.12 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 69.0 mt-30 -138.27 118.64 13.73 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.714 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.673 HG12 HG13 ' A' ' 27' ' ' VAL . 3.1 m -109.57 124.47 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.861 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.558 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.72 163.3 12.69 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.966 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.591 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 6.1 t-105 -115.82 143.19 45.75 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.857 -0.737 . . . . 0.0 111.871 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 74.03 0.39 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 21' ' ' PHE . 8.2 p -68.73 141.71 17.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.826 -0.749 . . . . 0.0 112.597 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.307 -1.242 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.006 179.851 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.517 ' CZ ' ' OE1' ' A' ' 48' ' ' GLN . 2.8 p90 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.458 HG22 ' O ' ' A' ' 22' ' ' THR . 0.6 OUTLIER -87.96 118.93 27.84 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 179.577 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.591 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -96.96 110.58 23.08 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 119.239 -0.984 . . . . 0.0 113.517 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -92.77 100.42 12.91 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.599 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.4 t -93.51 145.43 7.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 119.236 -0.985 . . . . 0.0 113.583 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.595 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.7 m -135.52 109.94 8.47 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.239 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.673 HG13 HG12 ' A' ' 10' ' ' VAL . 0.3 OUTLIER -81.02 151.4 4.43 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 C-N-CA 119.501 -0.88 . . . . 0.0 111.816 -179.855 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.648 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.1 OUTLIER -136.92 98.23 3.71 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.535 179.729 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.48 101.22 13.71 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.216 -0.994 . . . . 0.0 108.369 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -114.19 1.85 14.66 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.349 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.1 p -61.7 -79.64 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.61 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.634 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.91 75.24 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.535 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -167.32 152.44 6.98 Favored Pre-proline 0 C--N 1.31 -1.152 0 C-N-CA 118.665 -1.214 . . . . 0.0 111.587 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -72.72 94.64 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.71 0 N-CA-C 108.672 -1.318 . . . . 0.0 108.672 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.23 102.5 5.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 118.31 -1.356 . . . . 0.0 111.698 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -119.92 57.36 0.93 Allowed 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.97 148.76 18.34 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.787 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.7 p-90 -167.08 175.89 7.24 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.637 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.34 109.81 6.59 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.699 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.54 174.94 6.01 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.324 -0.95 . . . . 0.0 109.656 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.479 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -161.65 150.09 15.46 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 117.874 -1.53 . . . . 0.0 112.719 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 43' ' ' SER . 12.9 p90 -175.6 -130.43 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.039 -1.437 . . . . 0.0 108.596 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.498 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 m -167.13 176.9 6.52 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 117.819 -1.553 . . . . 0.0 112.495 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.662 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -117.14 87.81 24.74 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.605 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -59.03 -27.45 85.06 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 121.786 1.657 . . . . 0.0 112.499 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.476 ' OG ' ' CG ' ' A' ' 48' ' ' GLN . 0.9 OUTLIER -69.59 -13.37 62.29 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.731 179.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 78.99 19.78 71.85 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.742 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.517 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 21.7 mt-30 -73.85 177.12 5.76 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.631 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.746 HE22 ' CG2' ' A' ' 51' ' ' THR . 0.0 OUTLIER -141.77 111.26 6.5 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.452 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 50' ' ' VAL . 2.4 p -76.07 155.13 5.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.861 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.746 ' CG2' HE22 ' A' ' 49' ' ' GLN . 64.8 p -138.66 -68.1 0.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.314 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.433 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -82.88 131.01 35.21 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.056 -1.058 . . . . 0.0 110.423 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.44 152.81 41.98 Favored 'General case' 0 N--CA 1.49 1.575 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.65 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 39.5 t-105 -154.73 144.48 21.57 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.004 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 69.0 18.81 8.33 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.071 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.615 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 3.3 m -172.23 111.12 0.26 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.115 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -69.93 79.79 0.47 Allowed 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.484 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.657 HG12 HG13 ' A' ' 67' ' ' VAL . 9.5 m -81.05 155.95 4.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.067 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.6 t -155.43 129.88 9.03 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.21 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -95.68 114.21 25.93 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.518 -0.873 . . . . 0.0 111.043 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.8 p -91.1 78.23 5.92 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.683 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.89 -68.28 2.26 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.095 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -142.08 -15.77 0.78 Allowed 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.188 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.498 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -92.63 -170.81 2.57 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.662 HG21 ' CD2' ' A' ' 44' ' ' PHE . 54.1 t -145.78 160.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 C-N-CA 118.838 -1.145 . . . . 0.0 113.029 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.4 m -161.07 127.36 3.92 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.121 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 58' ' ' VAL . 2.0 t -122.54 147.53 26.65 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.845 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 mtm-85 -129.38 92.73 3.41 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.787 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 8.6 p-10 -72.81 122.05 20.93 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.272 -0.971 . . . . 0.0 112.445 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.766 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -48.25 156.69 0.75 Allowed Pre-proline 0 C--N 1.305 -1.343 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.316 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.98 -36.81 81.08 Favored 'Trans proline' 0 C--N 1.325 -0.706 0 C-N-CA 121.895 1.73 . . . . 0.0 112.628 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.654 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -56.27 7.68 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 118.733 -1.187 . . . . 0.0 110.61 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.766 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -72.33 7.7 1.66 Allowed 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 109.714 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -137.05 33.82 2.27 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 27.9 t -99.94 59.72 1.06 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.846 -0.742 . . . . 0.0 111.298 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.542 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.01 135.86 22.12 Favored Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.808 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.2 Cg_endo -73.44 158.91 47.45 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.631 1.554 . . . . 0.0 114.027 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.634 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.37 -32.73 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 CA-C-N 113.888 -1.505 . . . . 0.0 114.758 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.52 68.82 0.29 Allowed Glycine 0 N--CA 1.503 3.125 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.968 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.15 23.19 Favored Glycine 0 C--N 1.29 -1.992 0 C-N-CA 118.637 -1.744 . . . . 0.0 110.695 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 28' ' ' LYS . 6.3 p -138.08 162.9 32.97 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 119.691 -0.804 . . . . 0.0 112.008 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.36 169.54 14.13 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.595 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.7 OUTLIER -160.45 142.08 12.44 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 117.016 -1.874 . . . . 0.0 113.486 -179.842 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.615 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 13.5 p90 -154.7 177.36 11.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 114.33 -1.305 . . . . 0.0 109.296 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.72 159.69 33.05 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 117.604 -2.236 . . . . 0.0 112.135 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.674 ' C ' HD22 ' A' ' 87' ' ' ASN . 0.9 OUTLIER -145.17 -178.36 6.02 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.798 179.923 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.674 HD22 ' C ' ' A' ' 86' ' ' PHE . 1.0 OUTLIER -133.62 110.53 9.95 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.089 179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -113.91 173.43 14.96 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.899 -1.143 . . . . 0.0 111.278 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.0 p . . . . . 0 N--CA 1.485 1.287 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.828 179.882 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.609 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.453 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.3 Cg_endo -66.3 -142.85 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 121.169 1.246 . . . . 0.0 110.999 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.404 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 42.5 p -111.73 -88.12 0.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.642 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.404 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -97.56 105.54 17.71 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.008 -1.077 . . . . 0.0 112.146 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.564 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -74.9 -146.26 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.528 -0.869 . . . . 0.0 108.995 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.72 98.87 1.96 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 117.369 -1.733 . . . . 0.0 113.775 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.917 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -53.17 172.15 0.06 Allowed 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.812 HD22 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.22 86.83 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.944 -1.102 . . . . 0.0 110.488 179.891 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 76.07 42.86 23.31 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.62 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.612 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -169.92 138.65 1.51 Allowed Pre-proline 0 C--O 1.196 -1.733 0 C-N-CA 119.493 -0.883 . . . . 0.0 110.818 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -64.72 154.8 70.64 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.137 1.225 . . . . 0.0 111.677 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.459 ' SG ' HG13 ' A' ' 10' ' ' VAL . 2.7 t -151.11 104.43 3.13 Favored 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 119.424 -0.91 . . . . 0.0 110.908 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.51 157.37 11.54 Favored 'General case' 0 N--CA 1.5 2.05 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.019 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.896 HG13 ' N ' ' A' ' 110' ' ' GLY . 6.1 p -70.44 -140.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.234 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.896 ' N ' HG13 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.278 0 CA-C-O 116.342 -2.366 . . . . 0.0 110.446 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 121.435 0.636 . . . . 0.0 111.604 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 175.03 41.55 0.05 OUTLIER Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.709 -2.157 . . . . 0.0 107.709 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.664 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.45 -167.94 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.252 -0.974 . . . . 0.0 111.469 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.587 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 2.0 pt20 -159.15 152.67 22.76 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 118.984 -1.086 . . . . 0.0 110.402 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -137.29 133.77 46.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.2 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.56 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.42 164.83 11.57 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.968 179.855 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.609 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.6 t-105 -118.9 142.86 47.37 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.927 -0.709 . . . . 0.0 112.072 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.76 76.58 0.38 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 107.804 -2.119 . . . . 0.0 107.804 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -69.16 150.97 10.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.622 -0.831 . . . . 0.0 113.0 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.418 ' CB ' HG22 ' A' ' 22' ' ' THR . 10.9 t-20 . . . . . 0 C--N 1.305 -1.344 0 CA-C-N 114.321 -1.309 . . . . 0.0 108.534 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.563 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 23.7 p90 . . . . . 0 CA--C 1.494 -1.203 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' CB ' ' A' ' 15' ' ' ASN . 0.6 OUTLIER -81.13 153.25 27.38 Favored 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 105.433 -2.062 . . . . 0.0 105.433 179.447 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -128.79 108.9 10.83 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.378 -1.329 . . . . 0.0 112.657 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -95.74 94.91 7.96 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 84' ' ' PHE . 36.9 t -91.92 154.14 3.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.296 -0.962 . . . . 0.0 112.452 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.56 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.2 m -139.36 104.11 4.89 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.222 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 27' ' ' VAL . 1.5 t -74.8 148.81 7.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 C-N-CA 119.732 -0.787 . . . . 0.0 112.17 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.632 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -136.21 96.09 3.32 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.784 179.693 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.427 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.9 t30 -88.28 106.98 18.58 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.883 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 t -113.45 5.52 16.76 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.835 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.5 ' O ' ' CB ' ' A' ' 32' ' ' SER . 12.6 p -54.17 -84.9 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.894 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.59 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 162.01 65.39 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.752 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB1' ' HD2' ' A' ' 34' ' ' PRO . . . -170.44 160.2 6.17 Favored Pre-proline 0 N--CA 1.486 1.331 0 C-N-CA 118.804 -1.158 . . . . 0.0 111.413 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.44 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 7.1 Cg_endo -71.72 95.07 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.484 1.456 . . . . 0.0 109.571 179.571 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.1 t -75.13 79.79 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 C-N-CA 118.87 -1.132 . . . . 0.0 112.301 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -91.46 57.41 3.31 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.431 -0.908 . . . . 0.0 108.714 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 106.62 157.83 21.5 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.777 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 48.0 p-90 -171.58 178.82 3.03 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 117.752 -1.579 . . . . 0.0 112.382 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.537 ' H ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -141.18 115.63 9.48 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.017 179.779 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.844 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -106.35 176.43 5.17 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.1 179.834 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.624 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.1 m -167.18 152.44 7.43 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 117.5 -1.68 . . . . 0.0 113.009 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.447 ' CD2' ' N ' ' A' ' 43' ' ' SER . 19.4 p90 -176.79 -137.48 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 113.756 -1.566 . . . . 0.0 108.161 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.566 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 6.8 m -165.71 168.55 16.06 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 117.665 -1.614 . . . . 0.0 112.604 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.513 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -102.16 108.12 55.61 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.71 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -55.98 -66.79 0.08 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.051 1.168 . . . . 0.0 111.726 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.478 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 35.2 t -70.28 -171.91 0.52 Allowed 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.526 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.478 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.36 49.07 3.51 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.198 -1.477 . . . . 0.0 109.915 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.18 109.86 19.18 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.445 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.726 ' CD ' ' H ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -113.91 130.4 56.51 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.729 179.978 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 51' ' ' THR . 5.2 p -96.41 159.51 2.98 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.083 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.4 p -133.09 -65.77 0.69 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.707 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.581 ' N ' ' OG1' ' A' ' 51' ' ' THR . 3.5 mt-30 -81.72 166.5 20.03 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.282 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -169.29 148.48 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.976 -1.09 . . . . 0.0 111.454 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.462 ' CD1' ' HB3' ' A' ' 55' ' ' SER . 36.8 t-105 -150.6 141.42 22.81 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.001 -1.079 . . . . 0.0 111.645 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.462 ' HB3' ' CD1' ' A' ' 54' ' ' TRP . 0.9 OUTLIER 63.8 20.92 12.45 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.311 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.642 ' O ' HG13 ' A' ' 58' ' ' VAL . 1.2 m -165.06 109.31 0.89 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.422 -0.911 . . . . 0.0 110.381 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -70.57 78.36 0.58 Allowed 'General case' 0 C--N 1.285 -2.216 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.126 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.642 HG13 ' O ' ' A' ' 56' ' ' SER . 1.0 OUTLIER -81.48 162.34 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.461 -179.899 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.429 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.9 t -160.55 133.92 6.75 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.348 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.94 108.83 18.98 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.734 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.5 p -93.34 75.5 4.54 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.476 -0.889 . . . . 0.0 110.875 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 53.56 74.27 0.32 Allowed Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.357 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 0.3 OUTLIER 76.17 -35.91 0.26 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.491 -179.977 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.566 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -81.67 -171.06 3.13 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.666 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 66' ' ' THR . 77.4 t -149.71 157.62 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 118.725 -1.19 . . . . 0.0 113.05 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.624 HG23 ' OG1' ' A' ' 41' ' ' THR . 35.9 m -156.69 131.9 9.18 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 114.234 -1.348 . . . . 0.0 107.96 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.607 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -126.07 146.98 30.95 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.07 0 C-N-CA 119.326 -0.95 . . . . 0.0 112.225 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -130.46 93.22 3.4 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.777 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -72.7 124.31 25.05 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.373 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.053 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -46.52 162.98 0.24 Allowed Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 113.719 -1.582 . . . . 0.0 111.593 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -67.12 -39.13 14.12 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.897 1.731 . . . . 0.0 111.933 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.698 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.38 -56.06 8.56 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.246 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 1.053 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.0 p30 -70.63 -5.75 31.73 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.024 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -119.62 48.13 0.97 Allowed Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -112.67 74.33 0.86 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.099 -0.641 . . . . 0.0 110.971 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.623 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -130.69 132.28 23.84 Favored Pre-proline 0 CA--C 1.56 1.352 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.94 179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.433 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.4 Cg_endo -71.18 159.24 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 122.023 1.815 . . . . 0.0 114.498 -179.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.59 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -26.24 -40.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.679 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -114.76 68.84 0.26 Allowed Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.77 -1.205 . . . . 0.0 111.038 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.78 -168.83 18.68 Favored Glycine 0 C--N 1.29 -2.023 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.002 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 28' ' ' LYS . 7.6 p -137.1 166.39 23.82 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.818 0.818 . . . . 0.0 112.364 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.556 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -138.38 162.41 34.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.541 ' HG3' HG23 ' A' ' 26' ' ' THR . 1.4 mp0 -139.52 158.2 44.53 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 118.114 -1.434 . . . . 0.0 113.355 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 25' ' ' VAL . 1.6 p90 -171.03 161.86 6.99 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.103 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.57 169.81 37.15 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 117.438 -2.315 . . . . 0.0 112.741 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.1 p90 -150.97 -176.94 5.73 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.347 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.561 HD22 ' C ' ' A' ' 86' ' ' PHE . 0.6 OUTLIER -128.82 104.68 7.76 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.622 179.842 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.34 175.51 15.74 Favored Glycine 0 N--CA 1.498 2.769 0 C-N-CA 120.058 -1.068 . . . . 0.0 111.41 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . 0.516 ' O ' ' NE2' ' A' ' 49' ' ' GLN . 2.7 p . . . . . 0 N--CA 1.483 1.182 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.221 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.609 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 111.295 0.109 . . . . 0.0 111.295 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.6 Cg_endo -65.63 -143.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 121.093 1.195 . . . . 0.0 110.442 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.758 ' O ' HG13 ' A' ' 109' ' ' VAL . 27.0 p -104.39 -101.1 0.31 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.355 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.89 109.6 20.82 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 118.711 -1.196 . . . . 0.0 112.537 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.664 ' CZ ' ' CG1' ' A' ' 109' ' ' VAL . 4.1 m-30 -76.1 -149.76 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.45 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.87 116.27 2.8 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 117.107 -1.837 . . . . 0.0 113.696 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.664 HD12 ' SG ' ' A' ' 8' ' ' CYS . 2.1 mt -58.81 -172.53 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.114 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.537 HD22 ' H ' ' A' ' 39' ' ' THR . 3.5 p30 -65.99 76.53 0.08 Allowed 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.919 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 102.22 10.7 38.5 Favored Glycine 0 N--CA 1.5 2.913 0 C-N-CA 119.521 -1.323 . . . . 0.0 112.374 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 102' ' ' LEU . 62.3 p -150.46 151.14 30.46 Favored Pre-proline 0 N--CA 1.495 1.796 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -66.51 171.53 10.51 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.583 1.522 . . . . 0.0 112.388 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.62 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.8 t -165.85 111.13 0.86 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.088 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 1.1 p -72.58 128.11 34.59 Favored 'General case' 0 N--CA 1.506 2.354 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.758 HG13 ' O ' ' A' ' 98' ' ' THR . 0.9 OUTLIER -54.45 178.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 C-N-CA 118.793 -1.163 . . . . 0.0 110.531 179.796 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.287 0 CA-C-O 116.379 -2.345 . . . . 0.0 110.324 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.418 ' HB3' ' HB ' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.481 1.087 0 CA-C-O 121.256 0.55 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.2 50.45 0.02 OUTLIER Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.722 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.7 p -52.31 178.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.771 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.402 HE21 ' HD3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -137.72 110.67 7.72 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.894 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.58 HG13 ' SG ' ' A' ' 107' ' ' CYS . 3.5 m -101.75 125.79 55.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.2 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.549 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -104.81 133.96 48.75 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.28 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.528 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.4 t-105 -95.17 139.68 31.16 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.911 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.14 73.12 0.44 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.6 OUTLIER -69.73 159.75 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.526 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.3 t30 . . . . . 0 C--N 1.302 -1.461 0 CA-C-N 113.974 -1.466 . . . . 0.0 108.549 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 22.0 p90 . . . . . 0 CA--C 1.495 -1.172 0 CA-C-O 121.906 0.86 . . . . 0.0 113.264 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.5 t -73.26 162.99 28.74 Favored 'General case' 0 C--N 1.283 -2.287 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.33 117.94 10.38 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.048 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.832 HD21 HE21 ' A' ' 83' ' ' GLN . 1.4 t-20 -100.86 99.17 9.63 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.316 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.748 HG11 ' CE2' ' A' ' 84' ' ' PHE . 6.1 t -99.39 136.1 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 119.726 -0.789 . . . . 0.0 112.25 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.549 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.7 m -130.03 108.88 10.42 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.738 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.574 HG13 HG12 ' A' ' 10' ' ' VAL . 1.7 t -78.03 149.87 5.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.903 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.845 ' HA ' HG22 ' A' ' 81' ' ' THR . 3.6 tttt -133.17 96.06 3.67 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.831 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.39 96.75 7.45 Favored 'General case' 0 C--N 1.291 -1.964 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.038 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.5 t -111.65 6.11 19.71 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.334 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.495 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.7 p -71.93 -78.31 0.08 Allowed 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.332 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.62 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 158.27 78.18 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 123.906 0.754 . . . . 0.0 111.498 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -166.17 145.08 4.89 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 118.648 -1.221 . . . . 0.0 111.373 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -68.91 97.34 0.56 Allowed 'Trans proline' 0 N--CA 1.456 -0.719 0 N-CA-C 108.172 -1.511 . . . . 0.0 108.172 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -86.38 100.25 9.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 118.194 -1.402 . . . . 0.0 112.029 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -113.71 55.3 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.85 148.7 14.25 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.916 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 43.3 p-90 -163.55 176.68 9.47 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.964 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -140.54 109.53 6.08 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.805 179.901 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.61 173.22 7.02 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.537 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.474 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.3 m -155.49 148.09 24.08 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.023 -1.471 . . . . 0.0 112.882 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.3 p90 -174.51 -141.54 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 113.999 -1.455 . . . . 0.0 108.417 179.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.5 m -163.17 173.11 13.85 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 117.625 -1.63 . . . . 0.0 112.921 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.561 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 5.3 m-85 -111.12 98.46 39.29 Favored Pre-proline 0 N--CA 1.491 1.575 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.015 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -53.31 -55.15 3.9 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.007 1.138 . . . . 0.0 111.301 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.434 ' C ' ' H ' ' A' ' 48' ' ' GLN . 62.2 p -74.15 -179.83 4.05 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.101 -1.04 . . . . 0.0 109.794 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -77.71 41.79 1.95 Allowed Glycine 0 N--CA 1.484 1.864 0 C-N-CA 118.863 -1.637 . . . . 0.0 109.494 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.434 ' H ' ' C ' ' A' ' 46' ' ' SER . 8.7 mt-30 -78.05 108.53 11.4 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.557 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -116.55 109.85 17.79 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.207 179.91 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.602 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.1 p -68.45 164.54 2.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.089 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.602 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 36.8 p -137.5 -63.92 0.57 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.626 -0.829 . . . . 0.0 110.986 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.523 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -97.59 137.11 37.02 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.709 179.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.52 159.15 42.8 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.726 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.402 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 36.2 t-105 -155.02 141.73 18.96 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.988 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.402 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.0 OUTLIER 67.12 23.84 9.49 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.091 -179.999 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.478 ' HB3' ' CG ' ' A' ' 84' ' ' PHE . 2.1 p -172.8 110.4 0.21 Allowed 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.249 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.4 m -71.46 74.64 0.76 Allowed 'General case' 0 C--N 1.284 -2.239 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.07 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.541 HG12 HG13 ' A' ' 67' ' ' VAL . 13.4 m -69.6 155.05 7.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.953 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 65.5 p -152.6 112.5 3.97 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.196 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -78.57 104.91 9.49 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.001 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.584 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.1 p -85.72 -160.89 0.56 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.948 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.628 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -50.84 88.22 0.01 OUTLIER Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.139 -1.505 . . . . 0.0 109.655 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER 53.22 4.19 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.707 -179.828 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.628 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.51 -169.27 1.6 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.555 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 77.9 t -143.17 154.22 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 C-N-CA 119.119 -1.033 . . . . 0.0 112.691 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.477 ' N ' HG12 ' A' ' 65' ' ' VAL . 15.6 m -158.01 127.83 6.01 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.551 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.594 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -126.35 142.55 42.63 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.958 0 C-N-CA 119.279 -0.968 . . . . 0.0 111.747 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.46 94.33 4.11 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 124.735 1.272 . . . . 0.0 107.938 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.916 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.22 119.78 18.89 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.045 -1.062 . . . . 0.0 111.937 -179.647 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.842 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -46.73 172.43 0.05 OUTLIER Pre-proline 0 N--CA 1.485 1.303 0 CA-C-N 113.751 -1.568 . . . . 0.0 112.308 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.825 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.4 Cg_endo -68.28 -35.8 17.89 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.185 1.924 . . . . 0.0 112.707 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.561 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.9 -52.49 28.88 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 118.743 -1.183 . . . . 0.0 110.529 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.842 HD21 ' N ' ' A' ' 70' ' ' ALA . 1.1 p-10 -80.75 5.07 16.87 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 118.998 -1.081 . . . . 0.0 109.576 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -127.06 26.01 5.12 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -99.09 67.53 1.62 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.733 -0.787 . . . . 0.0 111.487 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.572 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -129.17 127.44 23.25 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 119.858 -0.737 . . . . 0.0 110.615 179.859 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.7 Cg_endo -72.12 156.98 55.01 Favored 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 121.621 1.547 . . . . 0.0 113.846 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.62 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.84 -38.03 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 114.89 1.441 . . . . 0.0 114.89 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -107.0 67.97 0.23 Allowed Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.686 -1.245 . . . . 0.0 111.216 -179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.74 -169.05 25.58 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 118.27 -1.919 . . . . 0.0 111.397 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.845 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.6 p -137.46 163.95 29.87 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.549 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -126.07 177.34 6.42 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.01 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.832 HE21 HD21 ' A' ' 24' ' ' ASN . 30.5 tt0 -168.52 146.66 4.14 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 117.124 -1.83 . . . . 0.0 113.624 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.748 ' CE2' HG11 ' A' ' 25' ' ' VAL . 14.6 p90 -160.1 175.21 13.22 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.037 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.21 166.44 35.21 Favored Glycine 0 N--CA 1.497 2.75 0 C-N-CA 117.902 -2.094 . . . . 0.0 112.166 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.522 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.8 p90 -161.94 156.85 22.94 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.457 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.656 HD22 ' N ' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -104.66 111.41 24.1 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.232 179.889 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.25 163.62 14.66 Favored Glycine 0 N--CA 1.503 3.14 0 C-N-CA 119.737 -1.221 . . . . 0.0 111.33 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 120.42 -0.512 . . . . 0.0 109.996 179.969 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.528 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.506 2.372 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.506 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.7 Cg_endo -62.44 -95.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 120.862 1.041 . . . . 0.0 112.34 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -151.65 -96.77 0.06 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 118.674 -1.211 . . . . 0.0 112.397 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.61 95.07 8.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.844 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.2 m-30 -65.9 -157.46 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.254 -0.979 . . . . 0.0 109.135 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.28 115.0 3.7 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 117.524 -1.67 . . . . 0.0 113.286 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.722 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.3 mt -59.62 177.67 0.2 Allowed 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.358 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.726 HD22 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -60.05 77.58 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.791 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 101.7 12.36 35.29 Favored Glycine 0 N--CA 1.503 3.112 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.275 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.614 ' O ' ' N ' ' A' ' 102' ' ' LEU . 70.5 p -152.47 152.58 29.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 C-N-CA 118.885 -1.126 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -67.0 173.04 8.93 Favored 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 121.534 1.489 . . . . 0.0 112.141 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.58 ' SG ' HG13 ' A' ' 10' ' ' VAL . 1.8 t -165.2 106.43 0.79 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.833 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.48 138.76 47.25 Favored 'General case' 0 N--CA 1.505 2.309 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.674 HG22 ' N ' ' A' ' 110' ' ' GLY . 1.7 p -68.82 172.08 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.52 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.674 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.442 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.399 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.854 ' N ' ' HG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.284 0.564 . . . . 0.0 111.814 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.83 39.45 0.02 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 108.061 -2.016 . . . . 0.0 108.061 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.933 ' SG ' HD12 ' A' ' 102' ' ' LEU . 25.2 p -54.0 -178.0 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.707 -0.746 . . . . 0.0 111.823 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.434 HE21 ' HA ' ' A' ' 8' ' ' CYS . 0.0 OUTLIER -144.16 138.1 27.91 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.694 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.586 HG12 HG13 ' A' ' 27' ' ' VAL . 1.3 m -128.61 130.14 68.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.574 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.585 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -92.74 169.87 10.15 Favored 'General case' 0 C--N 1.284 -2.278 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.862 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.625 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.1 t-105 -130.62 147.2 52.27 Favored 'General case' 0 C--N 1.309 -1.183 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.986 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.48 75.92 0.39 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -69.46 140.01 19.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.797 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 18.1 t-20 . . . . . 0 C--N 1.305 -1.339 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.049 179.814 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.797 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 19.7 p90 . . . . . 0 C--O 1.216 -0.66 0 CA-C-O 121.394 0.616 . . . . 0.0 112.418 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.17 127.08 33.7 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.625 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -104.64 110.87 23.35 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.245 -0.982 . . . . 0.0 113.464 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -95.78 98.58 10.55 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.577 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.558 HG11 ' CE1' ' A' ' 84' ' ' PHE . 38.5 t -96.08 147.01 6.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.585 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.9 m -136.97 101.72 4.65 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.419 -1.264 . . . . 0.0 108.484 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.586 HG13 HG12 ' A' ' 10' ' ' VAL . 1.5 t -72.94 151.97 7.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 C-N-CA 119.669 -0.813 . . . . 0.0 112.364 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.402 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.1 tttt -143.59 104.04 4.16 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.468 179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.661 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.5 t30 -90.61 116.57 28.6 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -120.11 1.5 10.86 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 124.105 0.878 . . . . 0.0 110.147 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' SER . 20.6 p -57.9 -81.62 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.58 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.583 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.54 72.52 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 123.726 0.641 . . . . 0.0 111.592 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.8 152.58 3.75 Favored Pre-proline 0 C--N 1.306 -1.29 0 C-N-CA 119.012 -1.075 . . . . 0.0 111.395 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.37 105.49 1.59 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 121.192 1.261 . . . . 0.0 109.342 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -90.7 92.25 3.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 118.46 -1.296 . . . . 0.0 111.779 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -103.47 67.22 0.9 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.95 148.62 24.01 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.6 -2.2 . . . . 0.0 107.6 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.903 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.0 p-90 -165.69 177.44 7.28 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.7 -1.6 . . . . 0.0 112.103 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.412 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.6 OUTLIER -140.72 108.79 5.74 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.625 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.881 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.43 173.7 6.83 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.194 -1.002 . . . . 0.0 108.94 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.495 ' OG1' HG23 ' A' ' 66' ' ' THR . 3.3 m -157.83 152.73 25.36 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 117.745 -1.582 . . . . 0.0 112.913 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' ' N ' ' A' ' 43' ' ' SER . 24.2 p90 -178.69 -142.88 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 113.773 -1.558 . . . . 0.0 108.179 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.574 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 20.2 m -163.24 173.71 13.02 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 117.626 -1.63 . . . . 0.0 112.663 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.579 ' CE2' HG21 ' A' ' 65' ' ' VAL . 6.9 m-85 -107.26 101.5 38.92 Favored Pre-proline 0 N--CA 1.486 1.341 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.843 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -55.53 -55.62 2.91 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 120.79 0.993 . . . . 0.0 110.531 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.64 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 8.7 t -69.48 -178.25 1.37 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 118.839 -1.144 . . . . 0.0 109.914 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.64 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -87.27 55.91 4.54 Favored Glycine 0 C--N 1.291 -1.969 0 C-N-CA 118.961 -1.59 . . . . 0.0 110.241 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.797 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 3.7 mt-30 -90.94 125.34 35.74 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.025 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.0 OUTLIER -115.58 101.8 9.19 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.96 -179.923 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.55 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.3 p -65.03 161.17 3.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.135 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 43.2 p -142.94 -65.8 0.39 Allowed 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.475 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.552 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -90.81 136.07 33.31 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.093 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.9 153.59 40.3 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.502 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.408 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 44.5 t-105 -154.04 146.18 23.72 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.054 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.408 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.4 OUTLIER 65.88 23.87 11.31 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.776 -179.989 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 58' ' ' VAL . 4.4 p -173.78 113.63 0.2 Allowed 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.17 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -72.64 73.36 1.06 Allowed 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.555 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 56' ' ' SER . 2.0 m -70.13 148.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.719 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.8 p -149.26 107.16 3.69 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.78 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 5.7 tt0 -78.59 104.29 9.1 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.594 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.567 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.3 p -82.84 -155.67 0.16 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.409 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.625 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -49.83 88.71 0.01 OUTLIER Glycine 0 N--CA 1.497 2.742 0 C-N-CA 118.967 -1.587 . . . . 0.0 110.098 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.567 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.4 OUTLIER 53.19 2.19 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.549 -0.861 . . . . 0.0 110.49 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.625 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.59 -173.59 2.34 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.315 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.579 HG21 ' CE2' ' A' ' 44' ' ' PHE . 50.0 t -140.82 152.92 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.299 -0.96 . . . . 0.0 112.531 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 41' ' ' THR . 94.5 m -153.94 115.53 4.19 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.308 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.667 HG23 HD21 ' A' ' 40' ' ' LEU . 1.7 t -109.35 145.75 15.69 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.949 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.661 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -131.18 92.91 3.27 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 114.172 -1.376 . . . . 0.0 107.324 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.903 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.14 118.43 17.09 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.032 -1.067 . . . . 0.0 112.167 -179.608 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.86 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -43.1 164.68 0.12 Allowed Pre-proline 0 N--CA 1.481 1.111 0 CA-C-N 113.37 -1.741 . . . . 0.0 112.003 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -65.03 -34.78 45.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.066 1.844 . . . . 0.0 112.416 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.58 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.92 -54.91 9.69 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.984 -179.892 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.86 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -75.91 -1.16 24.12 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 118.947 -1.101 . . . . 0.0 110.15 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.67 40.08 2.62 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.0 p -105.28 71.41 0.93 Allowed 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.868 -0.733 . . . . 0.0 110.971 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.826 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -127.69 119.8 21.58 Favored Pre-proline 0 CA--C 1.565 1.541 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.483 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.2 Cg_endo -69.85 158.57 56.4 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.594 1.529 . . . . 0.0 114.114 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -22.52 -41.23 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 CA-C-N 114.159 -1.382 . . . . 0.0 114.051 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -117.82 69.31 0.31 Allowed Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.414 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.59 -168.01 17.32 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.354 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.525 ' N ' HG13 ' A' ' 76' ' ' ILE . 16.6 p -139.72 162.56 34.83 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.967 -1.093 . . . . 0.0 113.307 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.635 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -127.51 178.72 5.91 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 113.724 -1.58 . . . . 0.0 107.578 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.483 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 7.0 tt0 -167.66 145.78 4.62 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 116.987 -1.885 . . . . 0.0 113.53 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.558 ' CE1' HG11 ' A' ' 25' ' ' VAL . 16.6 p90 -158.96 -178.91 7.59 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.819 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.21 162.51 36.29 Favored Glycine 0 N--CA 1.495 2.614 0 C-N-CA 117.581 -2.247 . . . . 0.0 112.198 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.6 p90 -155.18 174.19 15.55 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 119.763 -0.775 . . . . 0.0 111.04 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.424 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.6 m-20 -126.65 111.85 14.78 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.053 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.428 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -122.75 154.47 17.01 Favored Glycine 0 N--CA 1.5 2.961 0 C-N-CA 119.983 -1.104 . . . . 0.0 111.966 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.1 p . . . . . 0 N--CA 1.481 1.099 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.773 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.502 2.169 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.461 ' HD2' ' CE1' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -65.92 -140.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 121.413 1.409 . . . . 0.0 111.189 179.957 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.461 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 76.3 p -112.29 -76.39 0.59 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.571 -0.851 . . . . 0.0 112.857 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.461 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -105.79 99.91 9.49 Favored 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 119.062 -1.055 . . . . 0.0 111.583 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.542 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.8 m-30 -68.73 -142.42 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 115.311 -0.859 . . . . 0.0 108.842 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.7 m -160.8 108.52 1.55 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 116.994 -1.883 . . . . 0.0 113.454 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.933 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.4 OUTLIER -73.2 154.44 40.26 Favored 'General case' 0 C--O 1.206 -1.232 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.651 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.55 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.2 OUTLIER -52.26 81.84 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.624 -1.23 . . . . 0.0 110.793 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.636 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 140.23 -33.95 2.04 Favored Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.989 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.854 ' HG1' ' N ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -154.23 163.87 22.65 Favored Pre-proline 0 N--CA 1.505 2.289 0 C-N-CA 118.25 -1.38 . . . . 0.0 113.083 -179.821 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . 0.695 ' HD2' HG22 ' A' ' 105' ' ' THR . 1.7 Cg_endo -66.24 118.79 5.8 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 122.654 2.236 . . . . 0.0 111.907 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.525 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.6 t -100.1 123.05 43.89 Favored 'General case' 0 N--CA 1.501 2.108 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.967 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.78 162.22 16.49 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.859 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.984 HG22 ' H ' ' A' ' 110' ' ' GLY . 12.8 p -90.07 -130.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.874 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.984 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.494 2.535 0 CA-C-O 116.323 -2.376 . . . . 0.0 110.308 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 121.696 0.76 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.68 39.58 0.02 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 107.422 -2.271 . . . . 0.0 107.422 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.459 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 24.3 p -55.01 -171.1 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.271 -0.964 . . . . 0.0 111.876 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.11 131.8 6.88 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.982 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.507 HG12 HG13 ' A' ' 27' ' ' VAL . 2.6 m -113.79 130.51 67.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 C-N-CA 120.004 -0.679 . . . . 0.0 110.581 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.613 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -97.81 161.03 13.94 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.514 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.895 ' CZ3' ' HB2' ' A' ' 96' ' ' ALA . 22.5 t-105 -112.04 149.41 32.09 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.59 0.71 . . . . 0.0 112.517 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.59 76.98 0.36 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -68.92 146.61 12.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.7 t30 . . . . . 0 C--N 1.303 -1.436 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.209 179.824 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.553 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 32.0 p90 . . . . . 0 CA--C 1.507 -0.685 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 22' ' ' THR . 0.8 OUTLIER -99.49 111.91 24.19 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.614 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.492 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -93.75 117.17 29.74 Favored 'General case' 0 C--N 1.292 -1.896 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.727 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.8 102.25 14.03 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.483 HG11 ' HE1' ' A' ' 84' ' ' PHE . 53.2 t -99.71 147.3 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 N-CA-C 113.993 1.109 . . . . 0.0 113.993 -179.555 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.613 ' HB ' HD11 ' A' ' 11' ' ' LEU . 18.5 m -136.71 100.58 4.37 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.948 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.512 HG21 ' CZ2' ' A' ' 38' ' ' TRP . 3.0 t -68.79 146.88 12.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.104 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.637 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.2 tmtt? -138.48 102.91 4.74 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.567 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.693 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -95.58 136.06 36.45 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.516 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -131.64 5.8 4.34 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.544 -1.207 . . . . 0.0 109.523 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' SER . 19.1 p -47.24 -86.58 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.026 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.04 34.51 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.505 -179.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.937 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.4 155.71 45.94 Favored Pre-proline 0 N--CA 1.481 1.11 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.886 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.35 96.77 0.49 Allowed 'Trans proline' 0 C--N 1.323 -0.763 0 C-N-CA 121.284 1.322 . . . . 0.0 110.14 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.449 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.3 t -71.08 117.38 14.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.593 -1.243 . . . . 0.0 111.269 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -123.03 75.01 1.25 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.368 -0.833 . . . . 0.0 108.765 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.44 140.19 7.7 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.431 -1.867 . . . . 0.0 108.431 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.909 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.8 p-90 -158.79 177.46 11.15 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.303 -1.359 . . . . 0.0 111.626 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -141.08 112.37 7.38 Favored 'General case' 0 C--O 1.202 -1.4 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.715 179.897 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.86 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.41 174.68 5.76 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.934 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.788 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -163.55 157.71 19.89 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 117.325 -1.75 . . . . 0.0 113.153 -179.88 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.512 ' N ' ' CG2' ' A' ' 41' ' ' THR . 31.1 p90 -178.18 -141.43 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 113.368 -1.742 . . . . 0.0 107.997 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.478 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 61.2 m -160.82 146.9 14.87 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 117.876 -1.53 . . . . 0.0 112.187 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.65 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 8.3 m-85 -77.55 119.3 76.88 Favored Pre-proline 0 N--CA 1.482 1.132 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.146 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -63.38 -66.67 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.148 1.232 . . . . 0.0 111.579 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.536 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.4 t -69.44 -122.44 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.536 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -130.96 38.48 1.93 Allowed Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.494 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 3.2 mt-30 -75.24 98.31 3.74 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.517 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.8 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -98.95 112.42 24.54 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.57 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 58' ' ' VAL . 2.4 p -70.52 148.26 10.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.2 -1.0 . . . . 0.0 111.12 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.8 HG22 HE22 ' A' ' 49' ' ' GLN . 21.8 p -127.6 -63.24 1.04 Allowed 'General case' 0 N--CA 1.491 1.596 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.77 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.619 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -96.94 138.59 34.24 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.794 179.938 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -148.29 157.19 43.34 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.101 -1.039 . . . . 0.0 111.345 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . 0.406 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 43.3 t-105 -153.32 146.12 24.36 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.228 -0.989 . . . . 0.0 111.266 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.5 OUTLIER 66.97 22.28 10.1 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.584 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.605 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 13.1 t -175.95 125.8 0.21 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.405 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.1 79.67 9.3 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.608 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 50' ' ' VAL . 1.0 OUTLIER -81.81 152.28 4.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.635 -179.971 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -155.34 131.45 10.16 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.476 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.519 HE22 ' HB2' ' A' ' 49' ' ' GLN . 6.8 pt20 -95.12 119.98 34.55 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.647 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.866 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.7 p -86.91 68.93 10.22 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.18 -56.98 4.03 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.404 ' H ' ' H ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -148.91 -20.18 0.3 Allowed 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.404 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.866 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.99 -168.46 2.24 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.942 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.65 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 84.2 t -147.35 155.2 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.757 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.788 HG23 ' OG1' ' A' ' 41' ' ' THR . 70.7 m -161.63 124.29 3.03 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.705 -1.134 . . . . 0.0 108.653 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.605 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.4 t -117.53 146.4 22.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.093 0 C-N-CA 119.548 -0.861 . . . . 0.0 111.857 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -132.16 90.51 2.82 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.909 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.53 122.52 22.33 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 118.948 -1.101 . . . . 0.0 112.445 -179.626 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.772 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.3 155.88 0.18 Allowed Pre-proline 0 N--CA 1.479 0.993 0 CA-C-N 113.592 -1.64 . . . . 0.0 112.186 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.96 -35.28 35.45 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 121.759 1.639 . . . . 0.0 112.297 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.772 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -70.55 -57.38 4.81 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 118.931 -1.108 . . . . 0.0 110.981 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.538 HD21 ' HB2' ' A' ' 69' ' ' ASN . 0.1 OUTLIER -65.85 -21.34 66.46 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.994 -1.082 . . . . 0.0 110.171 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -96.61 27.87 15.8 Favored Glycine 0 N--CA 1.486 1.967 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.654 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 32.2 m -91.86 60.68 3.95 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.956 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.734 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.49 136.4 19.91 Favored Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.387 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' GLY . 7.2 Cg_endo -69.81 151.42 68.75 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 121.51 1.474 . . . . 0.0 111.181 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.937 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -40.41 -22.32 0.01 OUTLIER 'General case' 0 C--O 1.2 -1.525 0 C-N-CA 119.749 -0.78 . . . . 0.0 112.268 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.71 64.19 0.28 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.31 -162.83 18.68 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 118.11 -1.995 . . . . 0.0 111.485 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.637 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.6 p -139.5 162.41 35.12 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-O 121.867 0.841 . . . . 0.0 112.765 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.734 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -136.84 122.2 19.39 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.592 ' CG ' HG23 ' A' ' 26' ' ' THR . 3.5 mp0 -114.82 164.91 13.43 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.483 ' HE1' HG11 ' A' ' 25' ' ' VAL . 8.3 p90 -163.89 -178.09 5.48 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 112.688 -2.051 . . . . 0.0 108.986 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.24 159.13 32.39 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 117.556 -2.259 . . . . 0.0 111.937 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.3 p90 -154.77 169.2 24.51 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.487 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.53 HD22 ' C ' ' A' ' 86' ' ' PHE . 1.4 m120 -125.57 112.52 16.28 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.53 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA2' HG23 ' A' ' 51' ' ' THR . . . -121.03 150.23 17.25 Favored Glycine 0 N--CA 1.512 3.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.464 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . 0.427 ' OG ' ' CG ' ' A' ' 49' ' ' GLN . 52.1 p . . . . . 0 N--CA 1.482 1.14 0 C-N-CA 120.121 -0.631 . . . . 0.0 109.715 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.895 ' HB2' ' CZ3' ' A' ' 12' ' ' TRP . . . . . . . . 0 N--CA 1.502 2.146 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.8 -142.16 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 121.214 1.276 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.407 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 42.8 p -108.5 -100.57 0.37 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.472 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.27 104.22 16.82 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 118.503 -1.279 . . . . 0.0 112.196 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.3 m-30 -70.37 -141.84 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.363 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.5 m -162.39 109.81 1.32 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 117.022 -1.871 . . . . 0.0 113.869 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.5 mt -53.85 178.14 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.817 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -39.66 -26.41 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.927 -0.709 . . . . 0.0 111.973 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.804 ' O ' HG23 ' A' ' 105' ' ' THR . . . -165.31 41.7 0.29 Allowed Glycine 0 N--CA 1.491 2.307 0 C-N-CA 118.653 -1.737 . . . . 0.0 111.499 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.2 OUTLIER -171.83 147.68 2.01 Favored Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.685 179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.17 156.64 44.03 Favored 'Trans proline' 0 C--O 1.212 -0.813 0 C-N-CA 121.566 1.51 . . . . 0.0 112.554 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.41 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.0 t -147.26 101.65 3.41 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.342 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.01 135.75 57.81 Favored 'General case' 0 N--CA 1.518 2.951 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -179.587 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 1.056 HG22 ' H ' ' A' ' 110' ' ' GLY . 5.3 p -59.93 -163.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 118.795 -1.162 . . . . 0.0 110.926 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 1.056 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 116.35 -2.361 . . . . 0.0 110.386 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.719 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.484 0.659 . . . . 0.0 111.946 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.33 38.42 0.05 OUTLIER Glycine 0 N--CA 1.492 2.419 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.446 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 4.3 p -49.21 178.63 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 113.904 -1.148 . . . . 0.0 113.016 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -135.13 106.37 6.74 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.035 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.748 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.1 m -99.45 139.12 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 119.061 -1.056 . . . . 0.0 112.428 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.619 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -109.21 162.65 14.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.848 179.772 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' TRP . . . . . 0.533 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.2 t-105 -128.05 139.68 52.39 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.318 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -116.22 62.59 0.37 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.334 -2.307 . . . . 0.0 107.334 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 21' ' ' PHE . 14.6 p -69.3 140.84 18.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.485 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.4 t30 . . . . . 0 N--CA 1.489 1.496 0 CA-C-N 114.616 -1.175 . . . . 0.0 108.762 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.564 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.8 p90 . . . . . 0 CA--C 1.51 -0.566 0 CA-C-O 121.464 0.649 . . . . 0.0 112.681 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 15' ' ' ASN . 1.4 t -78.92 174.02 11.95 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 179.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.533 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -153.2 125.73 8.18 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 117.04 -1.864 . . . . 0.0 114.053 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -107.8 91.5 3.68 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 179.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.626 HG11 ' CE2' ' A' ' 84' ' ' PHE . 40.5 t -96.02 144.3 10.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 113.94 1.089 . . . . 0.0 113.94 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.619 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.4 OUTLIER -126.35 129.72 49.39 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 114.489 -1.232 . . . . 0.0 107.95 179.687 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.823 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 23.7 t -101.2 103.81 15.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 C-N-CA 119.281 -0.968 . . . . 0.0 113.151 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.76 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.6 tmtt? -95.1 106.53 18.54 Favored 'General case' 0 C--N 1.291 -1.951 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.395 179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.692 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -107.87 140.94 40.22 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.72 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -140.69 19.34 2.34 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 114.214 -1.357 . . . . 0.0 109.028 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.413 ' O ' ' CB ' ' A' ' 32' ' ' SER . 13.1 p -48.08 -88.47 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.176 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 170.41 31.55 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.822 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.998 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -154.47 170.98 7.66 Favored Pre-proline 0 N--CA 1.48 1.07 0 C-N-CA 118.085 -1.446 . . . . 0.0 111.443 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.796 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 9.2 Cg_endo -74.83 97.34 1.06 Allowed 'Trans proline' 0 C--N 1.323 -0.784 0 C-N-CA 121.842 1.695 . . . . 0.0 109.963 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.4 t -75.43 94.31 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 118.249 -1.38 . . . . 0.0 111.591 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.19 50.25 1.37 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 112.1 167.49 17.84 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 107.826 -2.11 . . . . 0.0 107.826 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.756 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 37.8 p-90 -171.17 176.39 3.97 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 117.808 -1.557 . . . . 0.0 111.836 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.1 102.14 4.32 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.887 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -89.63 172.8 8.69 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.699 -1.201 . . . . 0.0 109.409 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 2.0 m -160.73 142.12 12.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.437 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.559 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.6 p90 -171.0 -140.1 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.249 -1.342 . . . . 0.0 108.351 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.562 ' HG ' ' HB1' ' A' ' 64' ' ' ALA . 34.2 m -161.03 168.2 24.94 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 117.419 -1.713 . . . . 0.0 112.782 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.64 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.9 m-85 -101.66 109.41 59.26 Favored Pre-proline 0 N--CA 1.489 1.483 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.31 -63.7 0.12 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.098 1.199 . . . . 0.0 111.367 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.484 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.8 t -69.59 -172.7 0.5 Allowed 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.575 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.484 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -84.9 57.9 4.99 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.072 -1.537 . . . . 0.0 109.886 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.534 ' OE1' ' CE1' ' A' ' 21' ' ' PHE . 11.6 mm-40 -94.41 108.91 20.81 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 119.213 -0.995 . . . . 0.0 111.014 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.9 OUTLIER -106.57 108.89 20.63 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.913 -179.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.1 p -76.47 157.04 5.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.187 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.505 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 72.6 p -138.47 -68.82 0.44 Allowed 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.531 -0.867 . . . . 0.0 111.1 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLN . . . . . 0.505 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.2 mt-30 -80.59 165.26 22.24 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.03 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.14 153.58 8.24 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 118.717 -1.193 . . . . 0.0 111.923 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 32.3 t-105 -147.32 136.88 22.79 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.354 -0.939 . . . . 0.0 110.899 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.7 p 60.23 26.6 16.06 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.196 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.14 117.26 1.65 Allowed 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.0 m -82.11 77.64 8.89 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.977 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.2 m -68.99 154.37 8.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.613 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.9 p -154.07 108.14 3.0 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.908 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 3.6 tt0 -88.09 116.01 25.97 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.036 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 4.7 p -94.39 89.38 5.85 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.636 -0.825 . . . . 0.0 110.777 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 71.16 -74.6 0.66 Allowed Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.388 -1.387 . . . . 0.0 109.963 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 -14.69 1.55 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.122 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.562 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.29 -173.91 4.2 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.033 -1.067 . . . . 0.0 110.063 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 44' ' ' PHE . 51.2 t -147.27 160.11 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 118.735 -1.186 . . . . 0.0 113.637 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.3 m -155.53 145.93 21.91 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.899 -1.5 . . . . 0.0 108.563 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.416 HG23 HD21 ' A' ' 40' ' ' LEU . 2.8 t -141.07 119.4 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 118.727 -1.189 . . . . 0.0 112.469 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.83 91.43 4.83 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.97 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.756 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -70.77 122.8 20.53 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.194 -1.003 . . . . 0.0 111.344 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.863 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -43.91 166.65 0.1 Allowed Pre-proline 0 C--N 1.307 -1.276 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.452 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.0 Cg_endo -70.04 -39.98 5.38 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 122.155 1.903 . . . . 0.0 112.392 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' TRP . . . . . 0.605 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -68.56 -55.72 10.68 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.024 -1.07 . . . . 0.0 110.514 -179.875 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.863 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -76.71 11.02 1.84 Allowed 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.18 -1.008 . . . . 0.0 109.624 179.823 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.557 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -139.87 37.56 1.71 Allowed Glycine 0 N--CA 1.484 1.898 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.574 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.1 m -104.08 61.74 0.74 Allowed 'General case' 0 C--N 1.309 -1.162 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.956 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.484 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -109.49 136.68 20.22 Favored Pre-proline 0 N--CA 1.484 1.267 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.368 179.926 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.626 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.9 Cg_endo -71.3 171.16 16.63 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 121.396 1.397 . . . . 0.0 111.068 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.998 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -63.18 17.72 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.563 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.626 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -149.8 61.76 0.42 Allowed Glycine 0 C--N 1.291 -1.954 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.22 -155.12 9.57 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 118.641 -1.742 . . . . 0.0 110.733 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.76 HG22 ' HA ' ' A' ' 28' ' ' LYS . 0.9 OUTLIER -141.73 168.8 18.89 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.244 -0.983 . . . . 0.0 112.603 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.823 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.34 -173.3 3.12 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . 0.641 ' CD ' ' N ' ' A' ' 84' ' ' PHE . 12.4 tm0? -167.59 144.74 4.4 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 116.792 -1.963 . . . . 0.0 113.649 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.641 ' N ' ' CD ' ' A' ' 83' ' ' GLN . 3.9 p90 -164.13 164.73 22.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.604 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.51 178.47 32.96 Favored Glycine 0 N--CA 1.504 3.192 0 C-N-CA 118.068 -2.015 . . . . 0.0 111.855 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 4.4 p90 -164.17 -169.8 1.93 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.687 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -142.93 110.8 5.93 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.64 -0.824 . . . . 0.0 110.741 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.71 164.08 12.7 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.026 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.48 1.035 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.857 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.839 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.522 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.8 Cg_endo -64.25 -95.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 120.834 1.022 . . . . 0.0 112.248 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 109' ' ' VAL . 1.1 p -153.25 -90.41 0.05 OUTLIER 'General case' 0 N--CA 1.497 1.882 0 C-N-CA 118.919 -1.113 . . . . 0.0 112.279 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -96.78 94.51 7.31 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.595 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -66.23 -158.34 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 43.3 m -153.79 118.71 5.03 Favored 'General case' 0 C--N 1.309 -1.179 0 C-N-CA 116.956 -1.898 . . . . 0.0 114.015 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -63.72 176.4 0.91 Allowed 'General case' 0 N--CA 1.48 1.026 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.315 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 102' ' ' LEU . 0.8 OUTLIER -36.94 -32.94 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 C-N-CA 120.025 -0.67 . . . . 0.0 112.675 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.856 ' O ' HG23 ' A' ' 105' ' ' THR . . . -155.72 47.03 0.51 Allowed Glycine 0 N--CA 1.499 2.898 0 C-N-CA 118.463 -1.827 . . . . 0.0 111.865 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.856 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.0 OUTLIER 179.85 160.26 0.83 Allowed Pre-proline 0 C--O 1.192 -1.965 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.97 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.94 179.79 1.69 Allowed 'Trans proline' 0 C--N 1.321 -0.891 0 C-N-CA 122.004 1.802 . . . . 0.0 112.87 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' CYS . . . . . 0.748 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.5 t -170.13 106.68 0.33 Allowed 'General case' 0 N--CA 1.497 1.898 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.305 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 70.6 p -72.06 149.86 44.47 Favored 'General case' 0 N--CA 1.506 2.358 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 1.095 HG12 ' H ' ' A' ' 110' ' ' GLY . 5.0 t -59.05 -167.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 C-N-CA 118.981 -1.088 . . . . 0.0 110.422 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG12 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.482 0 CA-C-O 116.289 -2.395 . . . . 0.0 110.301 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.106 0 CA-C-O 120.828 0.347 . . . . 0.0 110.098 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 t -89.75 46.07 1.33 Allowed 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.291 -0.964 . . . . 0.0 110.781 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -152.8 -89.13 0.05 Allowed 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.932 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 164.61 69.34 0.02 OUTLIER Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.416 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.1 -154.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.028 1.819 . . . . 0.0 111.577 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.542 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -84.62 -157.5 0.29 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -178.28 43.21 0.09 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.871 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.5 p -60.42 -160.79 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.779 -0.71 . . . . 0.0 110.94 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.64 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -165.3 157.55 15.39 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.192 179.859 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.477 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.0 m -139.63 130.6 32.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.151 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.555 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.79 157.09 16.05 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.718 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.563 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.6 t-105 -114.55 141.44 47.73 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.831 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.14 76.28 0.41 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.2 p -69.23 149.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -152.14 85.47 1.28 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 113.91 -1.496 . . . . 0.0 107.348 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.809 ' NE2' ' N ' ' A' ' 17' ' ' TRP . 0.0 OUTLIER -92.03 121.05 33.23 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 114.993 1.479 . . . . 0.0 114.993 -179.538 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.809 ' N ' ' NE2' ' A' ' 16' ' ' GLN . 19.5 p90 -110.5 128.4 55.6 Favored 'General case' 0 N--CA 1.5 2.051 0 N-CA-C 105.761 -1.94 . . . . 0.0 105.761 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.407 ' C ' ' OE1' ' A' ' 16' ' ' GLN . 0.3 OUTLIER 47.49 -88.51 0.01 OUTLIER 'General case' 0 N--CA 1.509 2.524 0 C-N-CA 118.152 -1.419 . . . . 0.0 107.408 -179.572 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.7 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER -148.83 112.19 4.98 Favored 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 179.405 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.7 ' C ' HE21 ' A' ' 16' ' ' GLN . . . 147.86 87.89 0.07 OUTLIER Glycine 0 C--N 1.274 -2.893 0 N-CA-C 106.276 -2.73 . . . . 0.0 106.276 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.584 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 8.3 p90 -81.49 117.33 21.81 Favored 'General case' 0 CA--C 1.487 -1.448 0 C-N-CA 119.464 -0.895 . . . . 0.0 111.192 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.504 HG22 ' O ' ' A' ' 22' ' ' THR . 0.4 OUTLIER -97.11 114.34 26.0 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.563 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -93.74 120.62 34.24 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.367 -0.933 . . . . 0.0 113.422 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -99.08 95.83 7.38 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG11 ' CE1' ' A' ' 84' ' ' PHE . 29.8 t -91.81 152.46 3.39 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.998 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.555 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.0 OUTLIER -138.88 106.08 5.49 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.184 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.575 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.1 t -71.2 149.01 10.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 C-N-CA 119.693 -0.803 . . . . 0.0 112.101 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.514 ' HA ' HG22 ' A' ' 81' ' ' THR . 6.5 tptm -141.03 102.81 4.34 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.12 -0.945 . . . . 0.0 110.186 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.83 HD22 ' N ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -96.76 136.93 36.61 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.627 -0.829 . . . . 0.0 108.948 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.83 ' N ' HD22 ' A' ' 29' ' ' ASN . 9.5 t -141.47 -4.31 1.12 Allowed 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.681 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.1 p -51.97 -81.27 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.118 -1.033 . . . . 0.0 110.339 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.51 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 163.52 73.55 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.928 -0.709 . . . . 0.0 111.373 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.49 149.28 3.67 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.22 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -72.27 97.37 0.85 Allowed 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 121.207 1.271 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.451 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.9 OUTLIER -77.49 100.52 2.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.78 -179.89 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -110.44 58.4 0.61 Allowed 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.06 152.39 21.39 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 107.909 -2.077 . . . . 0.0 107.909 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.644 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 37.3 p-90 -166.35 178.07 6.41 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 117.693 -1.603 . . . . 0.0 112.208 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.34 102.51 4.37 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.133 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.869 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -93.97 175.06 6.86 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 118.992 -1.083 . . . . 0.0 109.957 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.542 ' HG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -169.92 156.22 6.07 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 117.854 -1.539 . . . . 0.0 112.679 179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.498 ' CD2' ' N ' ' A' ' 43' ' ' SER . 20.2 p90 -176.73 -132.81 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 113.565 -1.652 . . . . 0.0 107.8 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.498 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -162.29 148.23 13.0 Favored 'General case' 0 C--N 1.29 -2.013 0 C-N-CA 117.726 -1.589 . . . . 0.0 111.951 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.654 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -82.8 119.01 73.62 Favored Pre-proline 0 N--CA 1.486 1.36 0 C-N-CA 118.601 -1.24 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.421 ' HB2' HD22 ' A' ' 94' ' ' ASN . 3.3 Cg_exo -55.23 -72.42 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 121.083 1.189 . . . . 0.0 111.764 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.6 t -69.58 -134.0 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 110.535 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -118.57 51.86 0.73 Allowed Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.343 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.726 ' C ' HE21 ' A' ' 49' ' ' GLN . 1.6 mp0 -67.96 88.35 0.27 Allowed 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.492 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.859 HE21 ' N ' ' A' ' 49' ' ' GLN . 1.2 mm-40 -76.99 85.75 3.51 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.425 -0.91 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -74.64 144.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.839 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.633 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -143.38 -61.02 0.41 Allowed 'General case' 0 N--CA 1.492 1.655 0 C-N-CA 119.033 -1.067 . . . . 0.0 111.932 -179.838 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.633 ' H ' HG23 ' A' ' 51' ' ' THR . 1.1 mt-30 -75.54 135.26 40.6 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.569 -1.252 . . . . 0.0 110.073 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.431 ' HB2' HG21 ' A' ' 58' ' ' VAL . . . -147.89 156.11 42.33 Favored 'General case' 0 N--CA 1.49 1.532 0 C-N-CA 118.785 -1.166 . . . . 0.0 112.146 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 34.2 t-105 -151.91 142.16 22.38 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.6 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 t 62.31 27.43 16.39 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.583 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 1.0 OUTLIER -171.36 125.34 0.62 Allowed 'General case' 0 C--N 1.303 -1.428 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.317 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -87.28 73.59 9.65 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.035 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.489 HG12 HG13 ' A' ' 67' ' ' VAL . 33.0 m -69.01 153.86 8.66 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 115.044 -0.98 . . . . 0.0 112.484 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.416 HG23 ' C ' ' A' ' 58' ' ' VAL . 44.2 p -155.42 112.4 3.26 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.658 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.475 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 6.8 pt20 -91.02 113.42 25.68 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.489 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 4.7 p -87.68 86.07 7.14 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.774 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 73.71 -71.59 1.34 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -139.28 -15.98 1.08 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 120.029 -0.668 . . . . 0.0 109.716 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.489 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -87.9 -176.46 5.49 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.048 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.654 HG21 ' CD2' ' A' ' 44' ' ' PHE . 44.8 t -145.54 161.06 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 C-N-CA 118.596 -1.242 . . . . 0.0 113.888 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.611 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 44.9 m -157.52 143.79 17.76 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 113.627 -1.624 . . . . 0.0 108.284 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.556 HG23 HD21 ' A' ' 40' ' ' LEU . 2.2 t -139.66 117.47 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.617 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -99.03 91.87 5.22 Favored 'General case' 0 C--N 1.288 -2.092 0 CA-C-N 114.291 -1.322 . . . . 0.0 108.132 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.644 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.8 p-10 -72.47 121.56 19.8 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.195 -1.002 . . . . 0.0 112.215 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.84 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -40.88 162.07 0.11 Allowed Pre-proline 0 N--CA 1.488 1.475 0 CA-C-N 113.563 -1.653 . . . . 0.0 112.47 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.7 Cg_endo -68.86 -36.36 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 121.869 1.713 . . . . 0.0 111.939 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.719 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.67 -56.3 7.63 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 118.962 -1.095 . . . . 0.0 110.494 -179.895 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.84 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -74.33 2.73 8.64 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 118.818 -1.153 . . . . 0.0 109.492 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.545 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -122.43 37.12 2.94 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -104.71 56.53 0.7 Allowed 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.207 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.681 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -106.86 130.62 22.61 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.741 -0.783 . . . . 0.0 111.195 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.438 ' O ' ' C ' ' A' ' 78' ' ' ALA . 8.7 Cg_endo -72.32 154.19 56.2 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 121.606 1.537 . . . . 0.0 113.381 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.51 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -21.84 -49.14 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.67 70.71 0.21 Allowed Glycine 0 N--CA 1.493 2.447 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.417 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -153.5 -165.56 13.71 Favored Glycine 0 C--N 1.285 -2.293 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.069 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.572 ' N ' HG13 ' A' ' 76' ' ' ILE . 0.8 OUTLIER -140.9 164.05 31.29 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 119.271 -0.972 . . . . 0.0 112.528 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.603 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -132.78 -177.35 4.45 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 114.352 -1.294 . . . . 0.0 107.646 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.8 OUTLIER -167.6 143.5 4.06 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 116.875 -1.93 . . . . 0.0 113.54 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.579 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 8.7 p90 -159.22 176.12 12.59 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.57 -1.196 . . . . 0.0 109.664 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.69 170.28 41.12 Favored Glycine 0 N--CA 1.5 2.931 0 C-N-CA 117.897 -2.097 . . . . 0.0 112.137 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.547 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.6 p90 -159.32 168.88 25.28 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.703 -0.799 . . . . 0.0 111.022 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.531 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -121.93 114.21 20.68 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.896 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.443 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -126.07 150.29 17.57 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.3 p -83.39 136.02 34.48 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.852 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.66 ' NE2' ' CG ' ' A' ' 16' ' ' GLN . 10.2 p80 -114.52 -158.53 0.67 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.882 -0.727 . . . . 0.0 111.76 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -153.69 -2.88 0.2 Allowed 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.789 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.78 67.74 0.86 Allowed Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.742 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.945 HG22 ' H ' ' A' ' 94' ' ' ASN . 10.9 m -162.07 -167.38 1.63 Allowed 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.301 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.945 ' H ' HG22 ' A' ' 93' ' ' THR . 0.0 OUTLIER -61.08 129.16 39.98 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.129 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.54 -55.12 2.51 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.959 -0.696 . . . . 0.0 112.335 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.418 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -101.94 120.72 53.1 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 119.633 -0.827 . . . . 0.0 112.131 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.463 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -66.58 -144.32 0.02 OUTLIER 'Trans proline' 0 CA--C 1.539 0.734 0 C-N-CA 121.454 1.436 . . . . 0.0 111.401 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.82 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.8 OUTLIER -108.45 -101.48 0.37 Allowed 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.002 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.6 106.08 18.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 118.807 -1.157 . . . . 0.0 112.402 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.567 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.3 m-30 -74.99 -148.19 0.02 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.397 -0.921 . . . . 0.0 108.714 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.469 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -159.84 114.85 2.36 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 117.145 -1.822 . . . . 0.0 113.457 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.871 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -58.47 -175.84 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.06 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.656 ' ND2' HD22 ' A' ' 102' ' ' LEU . 2.0 p30 -64.89 76.49 0.05 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.071 -1.052 . . . . 0.0 111.764 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.49 11.46 33.26 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.57 -1.3 . . . . 0.0 112.374 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.602 ' O ' ' N ' ' A' ' 102' ' ' LEU . 6.5 p -151.92 145.81 18.05 Favored Pre-proline 0 N--CA 1.493 1.709 0 C-N-CA 118.781 -1.168 . . . . 0.0 111.091 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -65.04 170.78 9.87 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.342 1.361 . . . . 0.0 111.713 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.64 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 3.1 t -163.79 106.53 0.96 Allowed 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.491 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.5 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 7.5 p -70.49 130.62 42.37 Favored 'General case' 0 N--CA 1.504 2.255 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 98' ' ' THR . 0.7 OUTLIER -53.96 175.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.525 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.496 2.649 0 CA-C-O 116.368 -2.351 . . . . 0.0 110.274 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 120.92 0.39 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.0 p -69.11 148.54 49.84 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.881 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m 59.19 45.0 14.94 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.035 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -87.01 174.67 45.98 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 119.302 -1.428 . . . . 0.0 110.046 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -66.6 159.04 52.75 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 121.898 1.732 . . . . 0.0 111.18 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.675 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -111.51 -123.94 0.28 Allowed 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 115.682 -0.69 . . . . 0.0 112.152 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.43 28.34 0.36 Allowed Glycine 0 N--CA 1.5 2.911 0 N-CA-C 106.939 -2.465 . . . . 0.0 106.939 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -52.83 -174.05 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 113.49 -1.355 . . . . 0.0 113.213 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -137.22 108.16 6.7 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.768 -1.56 . . . . 0.0 109.654 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.836 HG13 ' SG ' ' A' ' 107' ' ' CYS . 4.9 m -100.67 122.73 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.384 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.2 159.62 14.93 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.389 -0.924 . . . . 0.0 109.653 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.562 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.8 t-105 -121.22 139.76 52.94 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.748 -0.781 . . . . 0.0 112.013 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 73.38 0.4 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 107.279 -2.328 . . . . 0.0 107.279 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -72.84 152.27 7.73 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.574 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.0 OUTLIER -158.88 94.46 1.23 Allowed 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 113.969 -1.469 . . . . 0.0 108.675 179.756 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.679 HE21 ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -94.38 157.88 15.82 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-O 121.937 0.875 . . . . 0.0 112.675 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.445 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -124.61 -106.0 0.35 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 113.674 -1.603 . . . . 0.0 109.323 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -66.53 -30.88 71.3 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.121 -1.031 . . . . 0.0 109.688 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.664 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 1.4 t -174.55 -49.48 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.203 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.664 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -58.04 166.27 6.54 Favored Glycine 0 CA--C 1.49 -1.51 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.527 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.7 p90 -137.77 121.28 17.22 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.533 -0.867 . . . . 0.0 112.256 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.574 HG22 ' CB ' ' A' ' 15' ' ' ASN . 8.2 t -73.48 172.86 10.52 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.562 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -159.32 110.23 2.02 Favored 'General case' 0 C--N 1.289 -2.027 0 C-N-CA 117.289 -1.764 . . . . 0.0 112.919 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -93.02 103.92 16.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.618 HG11 ' CE1' ' A' ' 84' ' ' PHE . 24.6 t -99.64 140.43 18.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 119.451 -0.9 . . . . 0.0 113.124 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.569 ' HB ' HD11 ' A' ' 11' ' ' LEU . 3.5 m -131.14 113.11 13.49 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.783 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.699 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -84.7 143.04 12.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.618 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.83 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.2 tptp -124.9 99.92 6.36 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 115.384 -0.826 . . . . 0.0 109.933 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.658 ' HB3' HD11 ' A' ' 76' ' ' ILE . 0.1 OUTLIER -91.54 106.22 18.32 Favored 'General case' 0 C--N 1.288 -2.096 0 C-N-CA 119.191 -1.004 . . . . 0.0 108.372 179.828 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 t -119.17 -1.11 10.92 Favored 'General case' 0 C--N 1.311 -1.107 0 O-C-N 124.174 0.921 . . . . 0.0 110.142 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.629 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -50.34 -81.85 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.399 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.69 37.49 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.305 -179.886 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.892 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -137.5 146.65 54.39 Favored Pre-proline 0 N--CA 1.485 1.301 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.187 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -70.22 107.4 1.94 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 121.212 1.275 . . . . 0.0 109.882 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -86.63 110.49 20.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.487 -1.285 . . . . 0.0 111.981 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -120.1 65.45 0.82 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.64 146.22 20.56 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 106.885 -2.486 . . . . 0.0 106.885 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 47.9 p-90 -163.51 175.54 10.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 117.419 -1.712 . . . . 0.0 112.095 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.416 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -141.06 112.39 7.4 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 114.74 -1.118 . . . . 0.0 110.777 179.92 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.44 175.35 5.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.395 179.896 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.484 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -159.35 152.48 22.18 Favored 'General case' 0 C--N 1.291 -1.967 0 C-N-CA 117.919 -1.512 . . . . 0.0 112.289 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.533 ' CD2' ' N ' ' A' ' 43' ' ' SER . 23.6 p90 -175.1 -150.91 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 113.931 -1.486 . . . . 0.0 108.432 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.533 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 14.7 m -158.66 154.39 26.37 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.881 -1.528 . . . . 0.0 111.835 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.518 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.2 m-85 -87.71 116.96 67.82 Favored Pre-proline 0 C--N 1.309 -1.153 0 C-N-CA 118.937 -1.105 . . . . 0.0 108.901 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -56.99 -74.87 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 121.292 1.328 . . . . 0.0 112.619 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.658 ' CB ' ' H ' ' A' ' 93' ' ' THR . 0.9 OUTLIER -69.26 -136.11 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.636 -179.851 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -107.6 63.92 0.27 Allowed Glycine 0 N--CA 1.505 3.234 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.857 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.517 ' O ' ' CD2' ' A' ' 44' ' ' PHE . 21.5 mt-30 -110.97 112.14 23.75 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.802 -0.759 . . . . 0.0 110.667 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.696 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -121.34 118.62 29.93 Favored 'General case' 0 N--CA 1.499 2.007 0 C-N-CA 119.764 -0.774 . . . . 0.0 111.212 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.448 ' H ' HG12 ' A' ' 50' ' ' VAL . 2.0 p -72.79 156.0 6.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.383 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.696 HG22 HE22 ' A' ' 49' ' ' GLN . 80.4 p -132.45 -69.67 0.58 Allowed 'General case' 0 N--CA 1.492 1.669 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.777 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.508 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.8 OUTLIER -88.02 141.88 28.23 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.292 -0.963 . . . . 0.0 109.801 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.99 166.99 29.84 Favored 'General case' 0 N--CA 1.484 1.248 0 C-N-CA 118.365 -1.334 . . . . 0.0 112.859 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.605 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 42.5 t-105 -154.45 157.15 38.01 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.687 -1.142 . . . . 0.0 110.003 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.605 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 51.75 26.79 3.68 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.771 -179.839 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.579 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 1.4 m -172.98 127.58 0.47 Allowed 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.695 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.4 m -90.15 77.19 6.8 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.795 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.499 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.3 m -69.69 151.81 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 CA-C-N 115.365 -0.834 . . . . 0.0 112.306 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -152.17 104.2 2.94 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.462 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.428 HE22 ' HB2' ' A' ' 49' ' ' GLN . 11.6 tt0 -82.69 120.8 26.04 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.682 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 10.4 p -94.13 75.76 4.05 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.589 -0.844 . . . . 0.0 110.718 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.65 -65.59 2.82 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.041 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.41 -16.01 0.94 Allowed 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.294 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.682 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -91.61 -171.15 2.81 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 119.268 -0.973 . . . . 0.0 110.215 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.518 HG21 ' CE2' ' A' ' 44' ' ' PHE . 72.7 t -147.3 154.55 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 118.744 -1.182 . . . . 0.0 113.262 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.481 ' N ' HG12 ' A' ' 65' ' ' VAL . 17.1 m -155.75 119.82 4.53 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 114.396 -1.275 . . . . 0.0 108.441 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.662 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -114.32 149.38 16.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.938 0 C-N-CA 119.614 -0.835 . . . . 0.0 111.847 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -132.33 93.0 3.18 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.632 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 3.1 p-10 -72.88 122.16 21.18 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.055 -1.058 . . . . 0.0 112.329 -179.582 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.029 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -41.95 161.45 0.15 Allowed Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 113.549 -1.659 . . . . 0.0 112.05 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.0 Cg_endo -65.54 -37.67 28.58 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 121.95 1.767 . . . . 0.0 112.273 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.591 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.46 -55.93 8.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.579 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 1.029 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.8 p30 -74.69 11.83 0.95 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.174 -1.01 . . . . 0.0 109.738 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.568 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -133.44 22.95 3.88 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.747 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.8 m -93.93 57.08 2.39 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.331 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.759 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.52 128.72 24.88 Favored Pre-proline 0 N--CA 1.489 1.495 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.68 179.971 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.599 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.4 Cg_endo -69.8 154.52 67.47 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 121.448 1.432 . . . . 0.0 111.012 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.892 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -42.49 -12.53 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 120.03 -0.668 . . . . 0.0 112.745 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.599 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.08 55.82 0.5 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.98 -165.65 24.74 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 118.511 -1.804 . . . . 0.0 110.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.83 HG22 ' HA ' ' A' ' 28' ' ' LYS . 5.9 p -137.93 163.17 32.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.183 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.517 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -121.56 -176.95 3.42 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 107.232 -1.395 . . . . 0.0 107.232 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -169.91 144.71 2.81 Favored 'General case' 0 C--N 1.296 -1.753 0 C-N-CA 116.906 -1.917 . . . . 0.0 113.246 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.4 p90 -159.31 169.11 24.75 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.045 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -155.99 163.58 31.9 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 118.052 -2.023 . . . . 0.0 112.023 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.5 p90 -161.16 161.52 31.04 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.242 -0.983 . . . . 0.0 112.287 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 25.8 m-20 -112.79 111.79 22.83 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.271 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.25 164.3 12.16 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.948 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.6 p -113.17 143.72 43.9 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.659 ' C ' ' ND1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -154.32 174.63 14.57 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 117.235 -1.786 . . . . 0.0 113.31 -179.901 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.426 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 1.4 t -170.88 8.55 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.446 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.43 -99.94 1.4 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.814 -1.184 . . . . 0.0 111.24 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.931 HG22 ' N ' ' A' ' 94' ' ' ASN . 15.9 m -164.38 -113.06 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.986 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.931 ' N ' HG22 ' A' ' 93' ' ' THR . 60.0 m-20 -30.29 131.52 0.08 Allowed 'General case' 0 N--CA 1.5 2.053 0 CA-C-N 115.316 -0.857 . . . . 0.0 112.449 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -111.73 -121.33 0.28 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.013 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.507 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -53.08 120.15 18.96 Favored Pre-proline 0 N--CA 1.489 1.496 0 C-N-CA 119.742 -0.783 . . . . 0.0 111.187 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.2 Cg_endo -63.13 -121.82 0.0 OUTLIER 'Trans proline' 0 CA--C 1.557 1.658 0 C-N-CA 121.125 1.216 . . . . 0.0 111.935 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.462 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 27.4 p -136.4 -77.43 0.42 Allowed 'General case' 0 N--CA 1.505 2.278 0 C-N-CA 119.246 -0.982 . . . . 0.0 112.608 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -98.72 97.9 9.09 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.842 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 107' ' ' CYS . 45.2 m-85 -66.73 -170.12 0.1 Allowed 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.9 m -146.78 113.99 6.24 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 117.457 -1.697 . . . . 0.0 113.897 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.453 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -60.59 -178.19 0.09 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.629 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.449 ' C ' ' O ' ' A' ' 102' ' ' LEU . 26.0 m-80 -30.38 -39.85 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -159.98 39.18 0.46 Allowed Glycine 0 N--CA 1.498 2.776 0 C-N-CA 118.583 -1.77 . . . . 0.0 111.598 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.675 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 9.7 m -162.23 137.61 5.5 Favored Pre-proline 0 N--CA 1.49 1.531 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -50.8 177.57 0.03 OUTLIER 'Trans proline' 0 C--O 1.211 -0.858 0 C-N-CA 121.473 1.448 . . . . 0.0 112.361 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.836 ' SG ' HG13 ' A' ' 10' ' ' VAL . 22.0 t -166.35 98.45 0.6 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.411 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 p -46.68 154.82 0.28 Allowed 'General case' 0 N--CA 1.502 2.129 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.678 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.942 HG22 ' N ' ' A' ' 110' ' ' GLY . 2.8 p -68.92 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 118.787 -1.165 . . . . 0.0 109.4 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.942 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.137 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.435 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.112 0 CA-C-O 120.787 0.327 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.58 -168.02 1.87 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.787 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -159.71 13.61 0.14 Allowed 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.641 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 175.91 36.45 Favored Glycine 0 N--CA 1.49 2.234 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.326 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.479 ' HG2' HG23 ' A' ' 105' ' ' THR . 6.2 Cg_exo -55.38 -66.84 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.427 2.084 . . . . 0.0 112.757 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 1.021 ' H ' HG21 ' A' ' 105' ' ' THR . . . -106.2 -166.71 1.22 Allowed 'General case' 0 N--CA 1.492 1.668 0 C-N-CA 119.598 -0.841 . . . . 0.0 112.431 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.23 51.25 0.04 OUTLIER Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -51.56 177.84 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.027 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -133.01 99.84 4.7 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.332 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.741 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -91.87 135.01 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 118.967 -1.093 . . . . 0.0 111.875 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.596 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -112.93 164.83 12.95 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.915 179.824 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.665 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.8 t-105 -125.32 143.95 50.72 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.653 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.83 75.8 0.42 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 107.083 -2.407 . . . . 0.0 107.083 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.592 HG22 ' N ' ' A' ' 15' ' ' ASN . 10.0 p -79.2 158.96 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.602 ' CB ' HG22 ' A' ' 22' ' ' THR . 3.6 t30 -152.65 105.14 2.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 113.238 -1.801 . . . . 0.0 107.129 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.835 ' H ' ' NE2' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -113.48 141.86 46.61 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -179.504 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.573 ' CD1' ' O ' ' A' ' 17' ' ' TRP . 34.8 p90 -122.75 95.69 4.73 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 113.175 -1.83 . . . . 0.0 106.49 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.519 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 1.6 t30 79.49 -38.21 0.19 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.764 HG23 ' N ' ' A' ' 20' ' ' GLY . 10.5 t -176.94 -64.0 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.897 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.764 ' N ' HG23 ' A' ' 19' ' ' THR . . . -33.39 97.0 0.01 OUTLIER Glycine 0 N--CA 1.51 3.569 0 N-CA-C 109.058 -1.617 . . . . 0.0 109.058 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.612 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.6 p90 -101.51 109.73 21.6 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 113.34 0.867 . . . . 0.0 113.34 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.602 HG22 ' CB ' ' A' ' 15' ' ' ASN . 14.0 t -72.4 173.95 8.05 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.441 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -155.37 120.42 4.85 Favored 'General case' 0 C--N 1.291 -1.97 0 C-N-CA 117.251 -1.779 . . . . 0.0 112.908 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -104.0 98.87 8.63 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 114.561 -1.2 . . . . 0.0 107.904 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.625 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.2 t -96.95 140.8 16.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.306 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.767 HG23 ' HG2' ' A' ' 83' ' ' GLN . 98.7 m -126.39 108.15 10.95 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.278 -0.874 . . . . 0.0 108.809 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 19.1 t -83.44 101.1 7.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 C-N-CA 119.727 -0.789 . . . . 0.0 111.959 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.772 ' HA ' HG22 ' A' ' 81' ' ' THR . 11.5 tttp -87.82 109.51 19.8 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.512 -1.275 . . . . 0.0 109.992 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.454 ' HB3' HD11 ' A' ' 76' ' ' ILE . 1.4 t-20 -95.56 112.38 24.11 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 119.274 -0.97 . . . . 0.0 109.504 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -111.68 -7.69 14.24 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.617 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.9 p -72.64 98.84 2.43 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-N 113.779 -1.555 . . . . 0.0 111.314 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.474 ' HA ' ' CB ' ' A' ' 78' ' ' ALA . 69.4 p -27.37 76.43 0.0 OUTLIER 'General case' 0 N--CA 1.512 2.646 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 1.006 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -157.57 137.15 8.45 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.596 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -72.1 100.04 1.06 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.971 1.114 . . . . 0.0 109.463 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -85.03 106.87 15.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 118.461 -1.296 . . . . 0.0 111.836 -179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -124.21 80.07 1.8 Allowed 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.55 135.78 3.22 Favored Glycine 0 C--N 1.292 -1.902 0 N-CA-C 106.625 -2.59 . . . . 0.0 106.625 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 43.7 p-90 -159.43 176.68 11.82 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 117.327 -1.749 . . . . 0.0 112.303 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.456 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -138.04 113.19 9.26 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.047 179.781 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.888 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.05 172.13 6.99 Favored 'General case' 0 N--CA 1.5 2.026 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.839 -179.968 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.467 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -156.29 146.7 21.59 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 118.017 -1.473 . . . . 0.0 112.605 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.63 ' CD2' ' N ' ' A' ' 43' ' ' SER . 11.7 p90 -172.29 -151.21 0.06 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 114.429 -1.259 . . . . 0.0 108.504 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.63 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.7 m -159.42 158.89 32.96 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.616 -1.633 . . . . 0.0 112.351 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.492 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.8 m-85 -86.28 121.13 72.62 Favored Pre-proline 0 C--N 1.309 -1.154 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.88 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -58.75 -67.87 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 121.084 1.19 . . . . 0.0 112.225 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.483 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 29.8 t -69.54 -112.84 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 118.946 -1.102 . . . . 0.0 111.054 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.483 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -141.98 37.68 1.56 Allowed Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.685 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.47 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 6.7 mt-30 -75.46 115.59 15.28 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.828 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.597 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -106.38 119.04 38.23 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.353 -0.939 . . . . 0.0 111.673 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.464 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.2 p -74.38 157.92 6.03 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.94 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 20.4 p -132.74 -63.89 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.615 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -88.59 170.51 10.79 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -166.03 151.72 8.85 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 118.521 -1.271 . . . . 0.0 112.194 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.503 ' CD1' ' OG ' ' A' ' 55' ' ' SER . 36.3 t-105 -149.26 150.77 33.1 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.458 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.503 ' OG ' ' CD1' ' A' ' 54' ' ' TRP . 1.4 p 46.77 32.11 1.65 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.617 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -173.64 118.08 0.27 Allowed 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.81 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 m -83.33 72.49 10.2 Favored 'General case' 0 C--N 1.279 -2.473 0 C-N-CA 119.161 -1.016 . . . . 0.0 109.377 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.469 HG12 HG13 ' A' ' 67' ' ' VAL . 4.1 m -70.91 166.57 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.162 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.832 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.443 ' O ' ' CG2' ' A' ' 59' ' ' THR . 6.1 t -164.68 130.54 2.83 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 114.754 -1.112 . . . . 0.0 109.557 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.509 HE22 ' HA ' ' A' ' 49' ' ' GLN . 5.0 tt0 -94.67 116.05 28.29 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 119.313 -0.955 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.477 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 6.2 p -93.92 75.53 4.18 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.304 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.37 -67.38 2.82 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.351 -1.404 . . . . 0.0 109.69 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -143.7 -16.51 0.62 Allowed 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.979 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.566 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.9 -170.81 2.93 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.076 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.521 HG12 ' N ' ' A' ' 66' ' ' THR . 65.2 t -148.39 156.6 8.51 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 118.826 -1.15 . . . . 0.0 113.038 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.521 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.1 m -154.71 141.2 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-N 114.417 -1.265 . . . . 0.0 108.312 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.586 HG23 HD21 ' A' ' 40' ' ' LEU . 2.4 t -134.84 153.51 34.92 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.078 0 C-N-CA 119.034 -1.066 . . . . 0.0 112.426 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -133.39 90.84 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.625 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.6 p-10 -72.54 121.07 19.06 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.298 -179.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.835 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -42.68 163.61 0.14 Allowed Pre-proline 0 C--N 1.303 -1.45 0 CA-C-N 113.291 -1.777 . . . . 0.0 111.807 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.2 Cg_endo -66.46 -35.88 28.81 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.901 1.734 . . . . 0.0 112.315 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.39 -54.28 15.2 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.914 -1.114 . . . . 0.0 110.749 -179.891 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.835 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.25 14.17 1.28 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 118.958 -1.097 . . . . 0.0 109.862 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -129.4 18.98 5.43 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.49 77.4 5.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.197 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.862 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -136.64 125.29 15.18 Favored Pre-proline 0 C--O 1.209 -1.063 0 C-N-CA 119.782 -0.767 . . . . 0.0 111.643 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.589 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.8 Cg_endo -71.63 162.86 40.84 Favored 'Trans proline' 0 C--O 1.213 -0.754 0 C-N-CA 120.91 1.073 . . . . 0.0 110.236 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 1.006 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -46.98 -3.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.844 -0.742 . . . . 0.0 112.871 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -120.13 56.77 0.59 Allowed Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.81 -159.99 15.77 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 117.905 -2.093 . . . . 0.0 111.12 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.772 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.2 p -139.85 155.06 47.43 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 119.22 -0.992 . . . . 0.0 112.939 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.862 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.1 100.65 5.5 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.767 ' HG2' HG23 ' A' ' 26' ' ' THR . 21.6 mt-30 -91.13 161.21 15.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 114.709 1.374 . . . . 0.0 114.709 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.625 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.1 p90 -166.0 165.17 18.16 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 113.286 -1.779 . . . . 0.0 109.224 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.98 170.83 37.75 Favored Glycine 0 N--CA 1.504 3.17 0 C-N-CA 117.547 -2.264 . . . . 0.0 112.611 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.2 p90 -156.62 -167.86 2.52 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.345 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.404 ' OD1' ' N ' ' A' ' 87' ' ' ASN . 1.2 m120 -140.53 112.21 7.48 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.793 -0.763 . . . . 0.0 110.821 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -120.14 158.21 15.45 Favored Glycine 0 N--CA 1.505 3.279 0 C-N-CA 119.784 -1.198 . . . . 0.0 111.426 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.2 p -112.94 151.15 30.88 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.154 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.63 ' ND1' ' N ' ' A' ' 91' ' ' THR . 4.2 p80 -154.45 -144.29 0.14 Allowed 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.779 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.63 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 17.0 p -144.86 -2.38 0.83 Allowed 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.641 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 100.25 93.76 2.12 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.706 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 94' ' ' ASN . 3.2 m -162.74 -145.8 0.1 Allowed 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 119.319 -0.952 . . . . 0.0 111.164 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.611 ' H ' HG22 ' A' ' 93' ' ' THR . 63.4 t-20 -78.7 125.64 29.64 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.98 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.487 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.38 -163.82 0.88 Allowed 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.776 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.665 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -13.78 121.03 0.04 OUTLIER Pre-proline 0 N--CA 1.507 2.418 0 CA-C-N 114.781 -1.1 . . . . 0.0 113.425 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.57 -144.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 121.319 1.346 . . . . 0.0 110.965 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.615 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 10.5 p -116.78 -63.51 1.44 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.495 -0.882 . . . . 0.0 112.376 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.615 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -107.87 111.09 23.04 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.764 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.534 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.4 m-85 -81.16 -163.72 0.65 Allowed 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 119.618 -0.833 . . . . 0.0 109.545 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -145.44 103.04 3.78 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.5 mt -52.29 173.92 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.501 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.456 ' N ' ' O ' ' A' ' 39' ' ' THR . 8.2 p30 -41.87 -20.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.484 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.83 45.0 0.22 Allowed Glycine 0 N--CA 1.487 2.039 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.171 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 1.021 HG21 ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -175.01 149.07 1.16 Allowed Pre-proline 0 N--CA 1.494 1.734 0 C-N-CA 119.164 -1.014 . . . . 0.0 111.049 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -63.04 170.35 7.69 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 121.372 1.381 . . . . 0.0 111.956 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.741 ' SG ' HG13 ' A' ' 10' ' ' VAL . 6.5 t -161.88 90.95 0.79 Allowed 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.538 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 m -51.99 165.18 0.22 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.69 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -65.05 -156.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 119.176 -1.01 . . . . 0.0 109.588 179.703 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 CA-C-O 116.319 -2.378 . . . . 0.0 110.371 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.468 ' OG ' ' N ' ' A' ' 3' ' ' SER . 9.8 p 47.11 -149.9 0.12 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.301 -0.96 . . . . 0.0 110.827 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.468 ' N ' ' OG ' ' A' ' 2' ' ' SER . 64.9 m -145.98 -172.0 3.83 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.752 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.411 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . 51.73 68.66 1.43 Allowed Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.17 -1.49 . . . . 0.0 110.222 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.481 ' CB ' HG22 ' A' ' 105' ' ' THR . 2.9 Cg_endo -63.03 -147.83 0.01 OUTLIER 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 121.892 1.728 . . . . 0.0 111.399 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -92.33 -163.97 1.12 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.647 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 171.18 59.91 0.04 OUTLIER Glycine 0 N--CA 1.49 2.237 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.699 ' SG ' HG13 ' A' ' 10' ' ' VAL . 0.6 OUTLIER -56.32 -161.88 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.278 1.037 . . . . 0.0 112.54 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.674 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 37.0 mt-30 -150.97 89.02 1.5 Allowed 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 113.553 -1.658 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.699 HG13 ' SG ' ' A' ' 8' ' ' CYS . 2.9 m -90.32 128.71 42.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 118.972 -1.091 . . . . 0.0 111.83 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.572 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -102.27 171.27 7.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.149 179.831 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.477 ' CE3' ' CB ' ' A' ' 96' ' ' ALA . 2.5 t-105 -130.39 147.59 52.11 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.768 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.407 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.67 76.4 0.41 Allowed Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.026 -2.03 . . . . 0.0 108.026 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.473 HG23 ' HD2' ' A' ' 21' ' ' PHE . 2.5 p -72.51 142.9 14.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.562 ' CB ' HG22 ' A' ' 22' ' ' THR . 8.4 t-20 -140.53 95.97 2.95 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.578 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -98.46 117.0 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.648 -0.821 . . . . 0.0 112.882 -179.757 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.58 ' C ' ' H ' ' A' ' 19' ' ' THR . 42.0 p90 -98.37 -142.54 0.31 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.844 -1.142 . . . . 0.0 108.177 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.7 ' H ' ' ND2' ' A' ' 18' ' ' ASN . 0.3 OUTLIER -47.82 -16.79 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.083 -1.447 . . . . 0.0 108.2 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.647 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.3 OUTLIER 170.42 -179.88 0.05 OUTLIER 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.126 -1.852 . . . . 0.0 107.054 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.647 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 69.4 111.44 0.03 OUTLIER Glycine 0 C--N 1.274 -2.905 0 C-N-CA 117.901 -2.095 . . . . 0.0 109.634 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.62 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 14.4 p90 -102.86 115.63 30.97 Favored 'General case' 0 C--N 1.298 -1.673 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.555 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.579 HG23 ' N ' ' A' ' 23' ' ' ALA . 1.0 OUTLIER -71.08 176.56 4.33 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 118.074 -1.451 . . . . 0.0 107.74 179.791 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.579 ' N ' HG23 ' A' ' 22' ' ' THR . . . -148.76 103.08 3.35 Favored 'General case' 0 C--N 1.291 -1.937 0 C-N-CA 118.469 -1.293 . . . . 0.0 111.616 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -94.1 94.35 8.34 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.632 HG11 ' CE2' ' A' ' 84' ' ' PHE . 15.6 t -97.16 137.38 25.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.664 -0.815 . . . . 0.0 113.003 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.572 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -128.36 114.45 16.88 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.864 -1.062 . . . . 0.0 108.406 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.523 HG13 HG12 ' A' ' 10' ' ' VAL . 3.6 t -86.94 128.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 C-N-CA 119.81 -0.756 . . . . 0.0 112.783 -179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.819 ' HA ' HG22 ' A' ' 81' ' ' THR . 1.4 tptt -114.23 100.93 8.73 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.426 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.76 ' HB3' HD11 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -89.87 117.46 28.71 Favored 'General case' 0 C--N 1.282 -2.353 0 C-N-CA 119.082 -1.047 . . . . 0.0 108.452 179.742 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.62 -2.09 8.43 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 124.185 0.928 . . . . 0.0 109.754 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.573 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -49.87 -83.89 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.588 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.545 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.51 72.32 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 123.666 0.604 . . . . 0.0 111.504 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.52 149.9 3.17 Favored Pre-proline 0 C--N 1.304 -1.392 0 C-N-CA 119.148 -1.021 . . . . 0.0 111.016 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -70.45 102.45 1.14 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 121.012 1.142 . . . . 0.0 109.243 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -87.37 106.56 16.27 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.48 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -116.94 72.43 0.83 Allowed 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.11 144.43 13.78 Favored Glycine 0 N--CA 1.484 1.853 0 N-CA-C 107.372 -2.291 . . . . 0.0 107.372 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.602 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 36.9 p-90 -161.05 176.9 10.85 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 117.592 -1.643 . . . . 0.0 112.014 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.895 ' H ' HD21 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.59 103.32 4.66 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.957 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.852 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -91.56 174.2 7.49 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.258 179.938 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.605 ' HG1' HG23 ' A' ' 66' ' ' THR . 97.8 m -156.59 146.31 20.87 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.278 -1.369 . . . . 0.0 112.143 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.595 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.1 p90 -172.5 -150.95 0.06 Allowed 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 114.589 -1.187 . . . . 0.0 108.999 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.595 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 20.1 m -156.2 153.42 29.19 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 117.807 -1.557 . . . . 0.0 112.09 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.512 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.1 m-85 -81.03 119.37 75.8 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 118.526 -1.27 . . . . 0.0 109.578 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.475 ' HB2' HD22 ' A' ' 94' ' ' ASN . 5.6 Cg_exo -55.74 -71.71 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.443 1.429 . . . . 0.0 112.319 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.412 ' N ' HD22 ' A' ' 94' ' ' ASN . 32.1 t -69.37 -113.91 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.715 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.02 48.02 0.75 Allowed Glycine 0 N--CA 1.489 2.187 0 C-N-CA 119.436 -1.364 . . . . 0.0 110.334 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.714 ' C ' HE21 ' A' ' 49' ' ' GLN . 20.7 mp0 -71.56 112.86 8.02 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.416 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.714 HE21 ' C ' ' A' ' 48' ' ' GLN . 3.0 mm-40 -93.56 94.94 8.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.0 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.1 p -72.66 151.92 7.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.697 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 43.1 p -143.0 -63.27 0.41 Allowed 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.551 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.98 160.09 30.2 Favored 'General case' 0 C--N 1.301 -1.537 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.164 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -164.22 156.63 17.01 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 118.551 -1.26 . . . . 0.0 112.06 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 23.6 t-105 -155.52 137.04 14.13 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.847 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 62.56 29.14 16.97 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.21 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.43 122.39 0.64 Allowed 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.613 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.3 m -84.54 69.39 10.58 Favored 'General case' 0 C--N 1.281 -2.407 0 C-N-CA 118.948 -1.101 . . . . 0.0 108.845 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 HG13 ' A' ' 67' ' ' VAL . 3.3 m -69.29 164.39 2.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 114.904 -1.044 . . . . 0.0 112.828 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 1.5 t -168.04 145.54 4.27 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.768 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -98.27 109.72 22.43 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.138 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.543 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 7.7 p -91.2 72.91 6.26 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.67 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 56.38 75.89 0.23 Allowed Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.2 -1.476 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 74.94 -28.79 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 119.802 -0.759 . . . . 0.0 111.149 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.543 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.49 -171.65 3.43 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 118.728 -1.189 . . . . 0.0 110.663 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.615 HG12 ' N ' ' A' ' 66' ' ' THR . 55.9 t -148.65 162.34 5.5 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.471 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.615 ' N ' HG12 ' A' ' 65' ' ' VAL . 6.2 m -157.0 147.63 21.49 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 114.083 -1.417 . . . . 0.0 108.131 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 58' ' ' VAL . 3.1 t -142.95 116.08 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 118.491 -1.284 . . . . 0.0 112.865 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -97.55 89.71 4.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.602 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.3 p-10 -70.27 120.43 15.94 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.075 -1.05 . . . . 0.0 112.063 -179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.805 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.27 158.33 0.09 OUTLIER Pre-proline 0 N--CA 1.486 1.36 0 CA-C-N 113.745 -1.571 . . . . 0.0 112.611 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.408 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 5.3 Cg_endo -68.03 -35.49 20.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.897 1.731 . . . . 0.0 112.385 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.805 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -69.86 -56.53 6.84 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.862 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.64 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -74.07 -1.85 21.87 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 118.823 -1.151 . . . . 0.0 109.696 -179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.634 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -113.17 20.42 19.18 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 8.8 m -90.03 59.73 4.62 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.262 -0.975 . . . . 0.0 111.272 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.782 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.05 122.96 39.09 Favored Pre-proline 0 CA--C 1.566 1.566 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.564 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 78' ' ' ALA . 5.8 Cg_endo -70.25 156.38 62.2 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 121.565 1.51 . . . . 0.0 113.766 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.545 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.47 -46.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.885 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -109.74 65.88 0.24 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.089 -1.204 . . . . 0.0 110.089 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.427 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.98 -170.31 18.48 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.837 -1.649 . . . . 0.0 110.139 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.819 HG22 ' HA ' ' A' ' 28' ' ' LYS . 1.9 p -139.49 158.3 44.36 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.199 -1.001 . . . . 0.0 112.527 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.782 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -125.59 -176.18 3.53 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.429 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 6.3 tt0 -168.12 148.1 4.82 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 117.019 -1.872 . . . . 0.0 112.92 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.632 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.3 p90 -165.22 168.08 17.41 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.068 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.48 171.95 40.11 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 117.694 -2.193 . . . . 0.0 112.223 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.1 p90 -155.06 -172.75 4.3 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -136.21 112.32 9.71 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.967 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -125.57 153.76 18.34 Favored Glycine 0 N--CA 1.51 3.596 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.024 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p -78.78 156.52 28.77 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.912 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.593 ' NE2' ' N ' ' A' ' 20' ' ' GLY . 11.9 p80 -140.57 -161.54 1.22 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.556 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 90' ' ' HIS . 0.8 OUTLIER -159.03 -4.33 0.08 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.574 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 104.91 65.2 0.67 Allowed Glycine 0 N--CA 1.497 2.751 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.674 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.406 HG22 ' H ' ' A' ' 94' ' ' ASN . 4.0 m -162.67 170.75 17.94 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.922 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.475 HD22 ' HB2' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -42.81 125.61 3.48 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.841 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -108.23 -50.97 2.96 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.141 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.477 ' CB ' ' CE3' ' A' ' 12' ' ' TRP . . . -110.06 125.63 30.69 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.897 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -62.61 -143.11 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 121.588 1.525 . . . . 0.0 111.771 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.626 ' O ' HG13 ' A' ' 109' ' ' VAL . 19.3 p -127.25 -58.35 1.28 Allowed 'General case' 0 N--CA 1.5 2.036 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.766 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.524 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.25 91.58 3.71 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.443 -0.903 . . . . 0.0 111.996 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.449 ' HD1' ' H ' ' A' ' 100' ' ' PHE . 32.3 m-85 -65.53 -166.81 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.1 m -146.43 107.68 4.22 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 117.552 -1.659 . . . . 0.0 113.884 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.9 mt -58.94 168.19 1.36 Allowed 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.895 HD21 ' H ' ' A' ' 39' ' ' THR . 0.3 OUTLIER -41.24 92.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.053 179.861 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.729 ' O ' HG23 ' A' ' 105' ' ' THR . . . 63.6 45.88 93.59 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 119.495 -1.336 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.729 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.6 OUTLIER -167.13 146.41 4.5 Favored Pre-proline 0 C--O 1.196 -1.743 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.157 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -64.22 166.16 17.67 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.31 1.34 . . . . 0.0 112.241 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -163.68 94.96 0.79 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 17.0 p -65.2 170.26 4.79 Favored 'General case' 0 N--CA 1.511 2.595 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 98' ' ' THR . 17.0 m -60.53 -155.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.562 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 CA-C-O 116.322 -2.377 . . . . 0.0 110.378 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.91 0.386 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.445 ' H ' ' H ' ' A' ' 3' ' ' SER . 0.3 OUTLIER 171.13 2.42 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.49 -0.884 . . . . 0.0 110.57 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.445 ' H ' ' H ' ' A' ' 2' ' ' SER . 6.3 p -151.51 157.93 42.94 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.601 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.57 ' N ' ' HD2' ' A' ' 5' ' ' PRO . . . 138.33 -55.65 0.67 Allowed Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.402 -1.38 . . . . 0.0 111.399 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 4' ' ' GLY . 9.2 Cg_exo -54.0 -77.31 0.02 OUTLIER 'Trans proline' 0 C--N 1.317 -1.104 0 C-N-CA 121.795 1.663 . . . . 0.0 112.735 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.848 ' H ' ' CG2' ' A' ' 105' ' ' THR . . . -102.12 -171.84 2.04 Favored 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 119.633 -0.827 . . . . 0.0 113.064 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.99 43.3 0.06 OUTLIER Glycine 0 N--CA 1.497 2.703 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -52.41 -175.81 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 114.496 -0.852 . . . . 0.0 112.774 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.516 ' OE1' ' NZ ' ' A' ' 28' ' ' LYS . 5.3 pt20 -142.25 126.48 17.53 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.907 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.649 HG12 HG13 ' A' ' 27' ' ' VAL . 3.3 m -115.1 128.41 72.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.163 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.554 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -97.12 171.93 8.15 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.313 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.893 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 2.7 t-105 -125.39 147.84 49.01 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.829 -0.748 . . . . 0.0 112.026 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.1 79.66 0.35 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 107.759 -2.137 . . . . 0.0 107.759 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -68.99 146.8 12.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 122.018 0.913 . . . . 0.0 113.112 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -154.85 89.7 1.25 Allowed 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 113.839 -1.528 . . . . 0.0 107.519 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.904 ' H ' ' NE2' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -116.1 150.84 36.71 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -179.602 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.526 ' CD1' ' O ' ' A' ' 17' ' ' TRP . 17.4 p90 -115.81 92.72 3.99 Favored 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 112.998 -1.91 . . . . 0.0 107.771 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.493 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 78.9 -30.63 0.15 Allowed 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.095 -179.849 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.755 HG22 ' H ' ' A' ' 20' ' ' GLY . 0.5 OUTLIER -175.84 -65.83 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 119.051 -1.06 . . . . 0.0 111.587 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.755 ' H ' HG22 ' A' ' 19' ' ' THR . . . -46.52 110.31 0.5 Allowed Glycine 0 C--O 1.201 -1.963 0 N-CA-C 108.382 -1.887 . . . . 0.0 108.382 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.647 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.6 p90 -103.9 137.26 42.14 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 -179.465 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 22' ' ' THR . 0.7 OUTLIER -101.67 114.32 28.26 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 179.579 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.679 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -91.53 115.83 28.36 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 119.19 -1.004 . . . . 0.0 113.52 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -98.53 96.85 8.26 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 179.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.545 HG11 ' CE2' ' A' ' 84' ' ' PHE . 33.5 t -92.64 144.54 9.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.554 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.5 m -131.27 103.43 6.46 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.771 179.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.649 HG13 HG12 ' A' ' 10' ' ' VAL . 2.2 t -74.12 151.57 7.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.731 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.59 ' HB2' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -148.16 111.29 4.88 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.643 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.707 ' HB3' HD11 ' A' ' 76' ' ' ILE . 2.1 t30 -96.85 129.73 44.24 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.962 -1.017 . . . . 0.0 108.397 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -132.06 -6.85 3.48 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 124.087 0.867 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.513 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 2.0 p -51.0 -80.87 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.732 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.48 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.0 37.16 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.194 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.556 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.853 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -136.45 147.78 61.33 Favored Pre-proline 0 N--CA 1.488 1.451 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.414 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -72.46 115.95 4.53 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 121.403 1.402 . . . . 0.0 110.406 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 t -98.34 95.83 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.236 -0.985 . . . . 0.0 112.109 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -105.76 63.95 0.68 Allowed 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 99.99 154.14 27.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.626 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 39.9 p-90 -169.95 177.17 4.44 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.172 -1.811 . . . . 0.0 112.911 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.23 99.19 3.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.017 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.883 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -87.93 172.72 9.38 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 118.576 -1.25 . . . . 0.0 110.051 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.472 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -153.97 145.08 22.82 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 118.642 -1.223 . . . . 0.0 111.633 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.622 ' CD2' ' N ' ' A' ' 43' ' ' SER . 10.6 p90 -172.92 -156.36 0.09 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.407 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.622 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 56.5 m -158.55 157.52 32.2 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 117.53 -1.668 . . . . 0.0 112.075 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' A' ' 65' ' ' VAL . 10.9 m-85 -86.58 122.22 71.89 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 118.712 -1.195 . . . . 0.0 109.443 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.465 ' HB2' ' ND2' ' A' ' 94' ' ' ASN . 4.9 Cg_exo -57.48 -62.1 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.244 1.296 . . . . 0.0 112.196 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.9 p -69.5 -58.81 3.5 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.793 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . 145.65 31.4 0.08 OUTLIER Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.418 -1.372 . . . . 0.0 110.418 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.647 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 49.6 mt-30 -43.69 131.93 5.14 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.394 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.621 ' NE2' HE22 ' A' ' 60' ' ' GLN . 0.1 OUTLIER -94.64 80.49 3.81 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.289 -0.964 . . . . 0.0 111.478 179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 2.1 p -62.78 147.84 11.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 119.224 -0.991 . . . . 0.0 110.306 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.502 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 61.8 p -140.47 -71.18 0.37 Allowed 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.283 -0.967 . . . . 0.0 111.558 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.52 ' N ' ' NE2' ' A' ' 52' ' ' GLN . 0.0 OUTLIER -69.73 164.36 23.69 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.289 -179.951 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.2 5.51 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 118.645 -1.222 . . . . 0.0 112.056 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.445 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 30.8 t-105 -153.11 143.28 22.35 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.655 -0.818 . . . . 0.0 110.496 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 0.9 OUTLIER 57.71 30.24 18.59 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.663 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.423 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.4 OUTLIER -172.9 119.18 0.34 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.675 -179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.2 m -82.81 74.37 9.78 Favored 'General case' 0 C--N 1.281 -2.37 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.975 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.404 ' C ' HG23 ' A' ' 59' ' ' THR . 10.3 m -69.41 156.83 6.93 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 CA-C-N 115.017 -0.992 . . . . 0.0 112.78 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.404 HG23 ' C ' ' A' ' 58' ' ' VAL . 58.8 p -155.19 115.65 3.84 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.876 -1.056 . . . . 0.0 109.731 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.621 HE22 ' NE2' ' A' ' 49' ' ' GLN . 5.9 tt0 -89.86 113.44 25.04 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.18 -1.008 . . . . 0.0 110.532 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.413 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.6 p -92.19 80.44 5.04 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.923 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.44 -67.85 2.17 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.443 -1.36 . . . . 0.0 110.127 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 10.3 p -141.94 -17.6 0.75 Allowed 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.223 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -88.93 -172.26 3.62 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.163 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.55 ' CG1' ' N ' ' A' ' 66' ' ' THR . 51.0 t -149.93 159.01 5.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 118.709 -1.197 . . . . 0.0 113.639 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.55 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 53.1 m -153.94 149.35 27.18 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 114.153 -1.385 . . . . 0.0 108.203 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.443 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.8 t -144.63 119.44 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 118.386 -1.326 . . . . 0.0 112.73 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.16 91.08 5.09 Favored 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.046 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.626 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 2.4 p-10 -71.23 120.95 17.54 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.879 -1.128 . . . . 0.0 111.625 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.723 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -43.14 167.39 0.08 OUTLIER Pre-proline 0 N--CA 1.487 1.377 0 CA-C-N 113.627 -1.624 . . . . 0.0 112.452 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.723 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.8 Cg_endo -70.34 -35.92 10.14 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.23 1.953 . . . . 0.0 112.373 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.683 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.47 -54.29 14.99 Favored 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.869 -179.834 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 4.8 p-10 -79.37 10.79 3.41 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.444 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.536 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -127.42 40.2 1.8 Allowed Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.186 -1.007 . . . . 0.0 110.673 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.2 t -109.93 62.82 0.6 Allowed 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.908 -0.717 . . . . 0.0 111.21 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.913 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -116.87 121.4 32.81 Favored Pre-proline 0 N--CA 1.483 1.187 0 C-N-CA 120.058 -0.657 . . . . 0.0 111.243 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.592 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.6 Cg_endo -67.38 156.35 66.55 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 C-N-CA 121.103 1.202 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.853 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -39.36 -18.75 0.01 OUTLIER 'General case' 0 C--O 1.205 -1.271 0 C-N-CA 119.895 -0.722 . . . . 0.0 112.676 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.592 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.24 62.52 0.43 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -163.67 -161.72 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 C-N-CA 118.979 -1.581 . . . . 0.0 110.635 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.59 HG22 ' HB2' ' A' ' 28' ' ' LYS . 7.3 p -143.98 162.94 34.9 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.063 -1.055 . . . . 0.0 112.978 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.707 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -131.31 179.53 5.97 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.106 -1.407 . . . . 0.0 107.733 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.451 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 32.0 tt0 -164.03 144.55 8.36 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 117.226 -1.789 . . . . 0.0 113.187 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.545 ' CE2' HG11 ' A' ' 25' ' ' VAL . 3.2 p90 -157.7 170.28 22.74 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.779 -1.101 . . . . 0.0 109.857 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.79 164.8 37.18 Favored Glycine 0 N--CA 1.498 2.798 0 C-N-CA 117.704 -2.189 . . . . 0.0 112.557 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.639 ' C ' ' ND2' ' A' ' 87' ' ' ASN . 1.7 p90 -153.04 -177.77 6.5 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 114.889 -0.656 . . . . 0.0 110.608 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.848 HD22 ' N ' ' A' ' 87' ' ' ASN . 0.1 OUTLIER -138.39 111.4 7.83 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.536 -0.866 . . . . 0.0 110.693 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -109.96 169.38 13.58 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.288 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.5 p -110.29 135.83 50.43 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' A' ' 91' ' ' THR . 0.8 OUTLIER -146.02 -169.85 3.34 Favored 'General case' 0 N--CA 1.502 2.171 0 C-N-CA 117.664 -1.614 . . . . 0.0 112.603 -179.919 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.581 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -135.55 2.74 2.98 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.285 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.465 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 99.43 106.87 2.75 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 119.677 -1.249 . . . . 0.0 110.482 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.465 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.2 OUTLIER -164.16 -84.63 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 118.991 -1.084 . . . . 0.0 111.43 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.542 ' OD1' ' N ' ' A' ' 94' ' ' ASN . 1.3 p-10 -173.87 124.99 0.36 Allowed 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.491 -0.884 . . . . 0.0 110.852 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.474 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -110.79 -134.91 0.35 Allowed 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.177 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.893 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -9.53 106.36 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.515 0 CA-C-N 114.537 -1.21 . . . . 0.0 113.567 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.504 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.5 Cg_endo -62.7 -101.11 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 120.962 1.108 . . . . 0.0 111.952 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.404 ' O ' ' N ' ' A' ' 109' ' ' VAL . 45.7 p -152.58 -69.2 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 118.829 -1.148 . . . . 0.0 111.946 -179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -106.54 94.98 5.43 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.56 -0.856 . . . . 0.0 111.255 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.504 ' CZ ' ' HD2' ' A' ' 97' ' ' PRO . 38.6 m-85 -65.03 -162.76 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.057 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 m -149.93 98.48 2.72 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 117.605 -1.638 . . . . 0.0 113.323 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.586 ' O ' ' N ' ' A' ' 104' ' ' GLY . 1.7 mt -52.17 171.59 0.05 OUTLIER 'General case' 0 C--O 1.21 -0.989 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.506 HD22 ' HB2' ' A' ' 38' ' ' TRP . 2.7 p30 -55.54 82.41 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.755 -1.178 . . . . 0.0 110.783 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.586 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 87.51 41.85 6.34 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.848 ' CG2' ' H ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -174.44 130.36 0.47 Allowed Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.151 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.63 170.75 3.16 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 121.029 1.153 . . . . 0.0 111.22 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.469 ' SG ' HG13 ' A' ' 10' ' ' VAL . 8.2 t -166.73 101.95 0.57 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.179 -1.008 . . . . 0.0 111.117 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -50.47 169.48 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.991 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.844 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.96 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.8 p -80.25 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.876 -1.13 . . . . 0.0 109.876 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.96 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.402 0 CA-C-O 116.333 -2.371 . . . . 0.0 110.585 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.133 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.9 p -109.79 124.27 50.99 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.961 -0.695 . . . . 0.0 110.765 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.3 164.48 37.35 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.825 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.466 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . -146.24 64.83 0.44 Allowed Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.38 -1.39 . . . . 0.0 110.476 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.466 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 3.2 Cg_exo -58.82 -77.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 121.989 1.792 . . . . 0.0 111.695 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.831 ' HB3' HG21 ' A' ' 105' ' ' THR . . . -110.15 -152.39 0.49 Allowed 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.355 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.15 43.94 0.06 OUTLIER Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.235 -1.946 . . . . 0.0 108.235 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.738 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.58 -168.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.87 -0.665 . . . . 0.0 110.955 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.486 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 1.8 pt20 -159.75 155.96 26.82 Favored 'General case' 0 C--N 1.287 -2.147 0 C-N-CA 118.754 -1.178 . . . . 0.0 110.407 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.595 HG12 HG13 ' A' ' 27' ' ' VAL . 1.1 m -141.35 138.88 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.002 -1.079 . . . . 0.0 111.67 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.569 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -100.44 171.61 7.64 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.157 179.95 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -133.94 143.32 48.13 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.834 -0.746 . . . . 0.0 111.961 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.09 71.79 0.41 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.9 p -69.61 140.77 18.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.571 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 62.9 t30 -136.61 86.2 2.2 Favored 'General case' 0 N--CA 1.494 1.758 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.029 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.602 ' CG ' ' NE2' ' A' ' 90' ' ' HIS . 0.0 OUTLIER -88.53 130.18 35.29 Favored 'General case' 0 N--CA 1.498 1.927 0 N-CA-C 113.458 0.911 . . . . 0.0 113.458 -179.682 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.777 ' C ' ' H ' ' A' ' 19' ' ' THR . 21.6 p90 -121.78 82.55 1.96 Allowed 'General case' 0 N--CA 1.495 1.818 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.468 ' O ' ' CB ' ' A' ' 19' ' ' THR . 0.5 OUTLIER 67.39 -15.16 0.18 Allowed 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.059 -1.056 . . . . 0.0 108.492 -179.587 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.777 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.8 OUTLIER 163.27 171.13 0.02 OUTLIER 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 113.424 -1.717 . . . . 0.0 107.015 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.613 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 68.18 101.75 0.03 OUTLIER Glycine 0 C--N 1.283 -2.366 0 C-N-CA 117.717 -2.183 . . . . 0.0 107.698 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.588 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.5 p90 -111.55 113.6 26.12 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.864 -0.734 . . . . 0.0 111.984 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.537 HG22 ' CB ' ' A' ' 15' ' ' ASN . 1.0 OUTLIER -65.13 173.82 2.28 Favored 'General case' 0 C--N 1.288 -2.101 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.487 ' N ' HG23 ' A' ' 22' ' ' THR . . . -152.52 98.25 2.35 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 117.651 -1.62 . . . . 0.0 112.755 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -92.12 97.95 11.24 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.515 HG11 ' CE1' ' A' ' 84' ' ' PHE . 19.4 t -95.55 145.56 8.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 C-N-CA 119.681 -0.807 . . . . 0.0 112.583 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.624 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -134.71 101.75 5.04 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.439 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.595 HG13 HG12 ' A' ' 10' ' ' VAL . 1.9 t -71.06 153.81 8.17 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 C-N-CA 119.583 -0.847 . . . . 0.0 111.698 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.611 ' HB2' HG22 ' A' ' 81' ' ' THR . 4.3 tttp -148.63 115.35 5.99 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.936 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.702 ' HB3' HD11 ' A' ' 76' ' ' ILE . 1.2 t30 -102.21 119.6 39.07 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.2 t -122.19 1.42 9.71 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 124.169 0.918 . . . . 0.0 109.866 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.53 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.5 p -63.02 -79.49 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.951 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.603 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.4 OUTLIER 159.31 78.98 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 123.723 0.639 . . . . 0.0 111.498 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.54 141.24 1.55 Allowed Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.195 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -67.67 100.52 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.712 0 N-CA-C 108.972 -1.203 . . . . 0.0 108.972 179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.84 112.29 23.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 C-N-CA 118.244 -1.382 . . . . 0.0 111.442 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -124.22 76.76 1.5 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.23 136.76 6.01 Favored Glycine 0 N--CA 1.483 1.8 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.835 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 26.3 p-90 -154.54 -179.81 8.32 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 117.905 -1.518 . . . . 0.0 111.959 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.841 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -140.13 100.48 3.92 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.491 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.87 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -91.87 175.51 6.86 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.748 -1.181 . . . . 0.0 109.462 179.932 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.496 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.1 m -162.46 149.28 13.3 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 117.629 -1.629 . . . . 0.0 112.731 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.469 ' CD2' ' N ' ' A' ' 43' ' ' SER . 22.2 p90 -173.72 -140.93 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 113.571 -1.65 . . . . 0.0 107.558 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.584 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 31.0 m -163.39 -179.06 6.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.375 -1.73 . . . . 0.0 112.735 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.549 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.1 m-85 -114.64 91.2 24.33 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.174 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -55.38 -36.97 94.99 Favored 'Trans proline' 0 CA--C 1.51 -0.72 0 C-N-CA 121.015 1.143 . . . . 0.0 110.065 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.439 ' CB ' ' HB ' ' A' ' 93' ' ' THR . 22.2 p -79.44 165.26 23.25 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 119.322 -0.951 . . . . 0.0 108.973 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -79.12 48.27 3.31 Favored Glycine 0 C--N 1.29 -2.009 0 C-N-CA 118.663 -1.732 . . . . 0.0 109.968 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.688 HE22 ' CB ' ' A' ' 95' ' ' ALA . 3.2 pt20 -109.76 143.46 39.55 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.309 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.48 133.57 34.76 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.496 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.595 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.7 p -72.69 164.48 3.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.584 -0.846 . . . . 0.0 111.728 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.595 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 66.3 p -136.17 -63.24 0.65 Allowed 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.264 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.49 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.6 mt-30 -89.23 164.64 14.87 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.177 -1.009 . . . . 0.0 109.346 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -170.37 153.5 4.4 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.259 -1.376 . . . . 0.0 112.227 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.454 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 33.6 t-105 -156.1 144.84 20.26 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.881 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.454 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.8 OUTLIER 61.82 28.62 17.55 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 119.541 -0.863 . . . . 0.0 109.993 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.594 ' OG ' ' CB ' ' A' ' 84' ' ' PHE . 0.9 OUTLIER -172.58 124.54 0.47 Allowed 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.323 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.5 m -87.99 75.88 8.7 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.43 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.4 m -69.08 152.82 9.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.954 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.403 HG23 ' C ' ' A' ' 58' ' ' VAL . 60.2 p -154.57 113.93 3.71 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.032 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.471 ' CG ' ' O ' ' A' ' 60' ' ' GLN . 7.9 pt20 -90.51 117.71 29.41 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.924 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.0 p -94.09 85.49 4.71 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.569 -0.852 . . . . 0.0 110.999 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.93 -67.52 2.36 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.391 -1.385 . . . . 0.0 109.966 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -144.82 -12.72 0.56 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.293 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.584 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -93.28 -170.3 2.35 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.119 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.654 HG12 ' N ' ' A' ' 66' ' ' THR . 62.1 t -148.99 162.98 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.795 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.654 ' N ' HG12 ' A' ' 65' ' ' VAL . 10.6 m -156.65 139.87 15.58 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-N 113.625 -1.625 . . . . 0.0 108.267 179.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.457 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -132.51 114.88 23.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.368 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -96.63 88.5 4.67 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.835 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.61 119.41 14.72 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.02 -1.072 . . . . 0.0 111.674 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.815 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -41.0 163.83 0.09 OUTLIER Pre-proline 0 N--CA 1.487 1.402 0 CA-C-N 113.741 -1.572 . . . . 0.0 112.417 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.587 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -64.57 -35.29 48.69 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 121.703 1.602 . . . . 0.0 112.195 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.538 ' CE2' ' CB ' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.33 -52.48 22.38 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 118.816 -1.154 . . . . 0.0 111.162 -179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.815 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.4 OUTLIER -78.08 8.96 4.09 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.883 -1.127 . . . . 0.0 110.224 179.922 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.49 ' CA ' ' OD1' ' A' ' 69' ' ' ASN . . . -124.91 18.3 7.09 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 120.081 -1.057 . . . . 0.0 110.495 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.5 m -86.72 58.44 5.07 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.222 -0.991 . . . . 0.0 111.262 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.921 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.46 114.86 54.77 Favored Pre-proline 0 CA--C 1.564 1.496 0 C-N-CA 119.974 -0.69 . . . . 0.0 110.245 179.934 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' GLY . 1.3 Cg_endo -67.57 156.02 67.78 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.395 1.397 . . . . 0.0 113.663 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.45 -45.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 114.273 -1.33 . . . . 0.0 114.156 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.43 69.58 0.28 Allowed Glycine 0 N--CA 1.497 2.712 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.402 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -151.13 -164.11 11.84 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.62 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.611 HG22 ' HB2' ' A' ' 28' ' ' LYS . 1.2 p -143.38 154.72 44.02 Favored 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 118.997 -1.081 . . . . 0.0 112.592 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.768 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -124.34 175.48 7.06 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.624 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -167.22 147.64 5.49 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 116.973 -1.891 . . . . 0.0 113.191 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.594 ' CB ' ' OG ' ' A' ' 56' ' ' SER . 10.9 p90 -157.03 -179.13 7.91 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.609 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.29 161.42 34.82 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 117.471 -2.3 . . . . 0.0 112.705 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.584 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.7 p90 -157.16 175.24 14.32 Favored 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 114.806 -0.697 . . . . 0.0 111.008 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -125.52 115.73 20.67 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.906 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -127.27 158.02 20.96 Favored Glycine 0 N--CA 1.51 3.58 0 C-N-CA 119.38 -1.39 . . . . 0.0 112.638 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.7 p -107.42 152.93 23.53 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.745 ' HD1' ' N ' ' A' ' 91' ' ' THR . 4.6 p80 -142.62 -153.45 0.46 Allowed 'General case' 0 N--CA 1.495 1.792 0 C-N-CA 119.127 -1.029 . . . . 0.0 111.9 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.745 ' N ' ' HD1' ' A' ' 90' ' ' HIS . 1.3 p -145.52 -9.52 0.56 Allowed 'General case' 0 N--CA 1.482 1.151 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.501 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 105.63 81.15 1.42 Allowed Glycine 0 N--CA 1.499 2.863 0 C-N-CA 119.889 -1.148 . . . . 0.0 110.88 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.632 HG22 ' H ' ' A' ' 94' ' ' ASN . 2.1 m -163.12 -174.64 3.93 Favored 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.855 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.632 ' H ' HG22 ' A' ' 93' ' ' THR . 0.0 OUTLIER -61.24 101.52 0.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.208 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.688 ' CB ' HE22 ' A' ' 48' ' ' GLN . . . -88.33 -118.57 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.441 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -39.24 115.92 1.0 Allowed Pre-proline 0 N--CA 1.486 1.33 0 C-N-CA 120.024 -0.671 . . . . 0.0 111.141 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 3.8 Cg_endo -65.63 -143.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.217 -0.552 0 C-N-CA 121.048 1.166 . . . . 0.0 110.808 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.775 ' O ' HG13 ' A' ' 109' ' ' VAL . 11.1 p -113.45 -92.91 0.48 Allowed 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.6 -0.84 . . . . 0.0 112.112 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -89.1 99.11 12.17 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.625 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 6.6 m-30 -68.08 -149.41 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.487 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -160.0 112.04 2.03 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 116.712 -1.995 . . . . 0.0 114.521 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.738 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.5 mt -64.77 172.76 2.58 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.841 ' ND2' ' H ' ' A' ' 39' ' ' THR . 69.0 m-80 -35.72 91.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.51 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 55.88 49.42 66.66 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.55 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.831 HG21 ' HB3' ' A' ' 6' ' ' ALA . 21.1 m -163.37 131.6 2.77 Favored Pre-proline 0 C--O 1.189 -2.119 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.92 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -61.06 158.86 32.32 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 121.263 1.309 . . . . 0.0 112.636 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.623 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.1 t -157.62 110.98 2.51 Favored 'General case' 0 N--CA 1.496 1.852 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.221 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -73.45 128.03 34.36 Favored 'General case' 0 N--CA 1.508 2.447 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 -179.773 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 98' ' ' THR . 2.5 m -56.53 -177.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.659 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.491 2.31 0 CA-C-O 116.301 -2.388 . . . . 0.0 110.461 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.167 0 CA-C-O 120.887 0.375 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -152.62 -10.61 0.17 Allowed 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.446 -0.901 . . . . 0.0 110.667 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -176.1 -162.11 0.09 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.484 -0.887 . . . . 0.0 110.873 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.406 ' N ' ' HD3' ' A' ' 5' ' ' PRO . . . -156.63 69.84 0.27 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.406 ' HD3' ' N ' ' A' ' 4' ' ' GLY . 1.1 Cg_endo -66.85 -173.87 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.966 1.777 . . . . 0.0 111.303 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.776 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -104.36 -161.96 0.86 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.953 -0.699 . . . . 0.0 111.366 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.76 43.25 0.1 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.949 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.3 p -53.55 -178.12 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 121.541 0.686 . . . . 0.0 112.077 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.455 ' NE2' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -138.34 108.44 6.39 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.795 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.886 HG12 HG13 ' A' ' 27' ' ' VAL . 4.6 m -103.39 124.06 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.238 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.576 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.15 165.05 12.6 Favored 'General case' 0 C--N 1.294 -1.84 0 C-N-CA 119.291 -0.964 . . . . 0.0 109.321 179.88 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.594 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.4 t-105 -124.74 143.32 50.84 Favored 'General case' 0 N--CA 1.487 1.396 0 C-N-CA 119.614 -0.835 . . . . 0.0 112.444 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 75.45 0.38 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.438 HG22 HE22 ' A' ' 16' ' ' GLN . 0.3 OUTLIER -69.76 149.0 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.97 -0.692 . . . . 0.0 112.832 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -152.99 91.39 1.53 Allowed 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.528 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.637 HE21 ' N ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -75.76 132.34 40.4 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.397 -179.961 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.49 ' CZ3' ' N ' ' A' ' 22' ' ' THR . 5.5 p90 -106.54 -35.71 6.98 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 119.47 -0.892 . . . . 0.0 110.872 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.432 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 17.5 t-20 -157.7 -20.08 0.08 Allowed 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 122.041 0.924 . . . . 0.0 108.793 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.706 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -178.09 -55.2 0.01 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.281 179.957 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.706 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -65.77 176.23 15.97 Favored Glycine 0 C--N 1.292 -1.887 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.7 ' CZ ' ' CD ' ' A' ' 48' ' ' GLN . 10.0 p90 -149.11 140.72 23.46 Favored 'General case' 0 C--N 1.283 -2.292 0 C-N-CA 118.498 -1.281 . . . . 0.0 112.984 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.49 ' N ' ' CZ3' ' A' ' 17' ' ' TRP . 0.6 OUTLIER -80.85 163.97 23.01 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 179.407 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.456 ' N ' ' CG2' ' A' ' 22' ' ' THR . . . -145.65 110.11 5.03 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 117.894 -1.522 . . . . 0.0 112.89 -179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 31.2 t30 -99.09 101.15 12.41 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.646 HG11 ' CE1' ' A' ' 84' ' ' PHE . 13.4 t -99.5 140.91 17.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 119.645 -0.822 . . . . 0.0 112.341 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.576 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.3 m -133.49 114.83 14.05 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.276 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.886 HG13 HG12 ' A' ' 10' ' ' VAL . 0.2 OUTLIER -85.31 150.38 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 C-N-CA 119.264 -0.975 . . . . 0.0 111.651 -179.849 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.835 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tttt -130.53 85.91 2.33 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.815 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.447 ' HB3' ' CD1' ' A' ' 76' ' ' ILE . 0.8 OUTLIER -68.8 104.94 2.17 Favored 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 118.565 -1.254 . . . . 0.0 109.807 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.4 t -105.8 -1.34 24.44 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.335 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.541 ' O ' ' N ' ' A' ' 33' ' ' ALA . 2.7 p -81.07 102.56 10.3 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.728 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.711 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 97.5 p -37.23 87.59 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 113.138 0.792 . . . . 0.0 113.138 -179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.541 ' N ' ' O ' ' A' ' 31' ' ' SER . . . -166.06 146.81 5.58 Favored Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 119.117 -1.033 . . . . 0.0 111.536 179.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -70.76 100.92 0.99 Allowed 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 121.027 1.152 . . . . 0.0 109.166 179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -86.76 108.52 18.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.149 -1.42 . . . . 0.0 111.817 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -122.63 63.32 0.97 Allowed 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.32 142.54 13.47 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 107.42 -2.272 . . . . 0.0 107.42 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.901 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.7 p-90 -159.37 176.1 12.54 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 117.707 -1.597 . . . . 0.0 111.796 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.795 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -140.01 111.93 7.5 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.982 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.843 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -101.61 178.47 4.62 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.794 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.523 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.26 152.06 16.28 Favored 'General case' 0 C--N 1.298 -1.632 0 C-N-CA 118.245 -1.382 . . . . 0.0 112.413 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' ' N ' ' A' ' 43' ' ' SER . 17.3 p90 -177.12 -150.09 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 113.919 -1.491 . . . . 0.0 108.408 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.549 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 42.7 m -162.16 161.95 28.23 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 118.046 -1.462 . . . . 0.0 112.026 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.613 ' CE2' HG21 ' A' ' 65' ' ' VAL . 16.5 m-85 -91.7 116.25 66.09 Favored Pre-proline 0 N--CA 1.484 1.275 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.005 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.08 -67.82 0.05 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 121.539 1.492 . . . . 0.0 112.938 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.52 ' HB3' ' H ' ' A' ' 93' ' ' THR . 19.7 m -68.74 -132.72 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 118.863 -1.135 . . . . 0.0 111.515 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -117.33 58.74 0.49 Allowed Glycine 0 N--CA 1.503 3.109 0 C-N-CA 119.631 -1.271 . . . . 0.0 111.715 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.7 ' CD ' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 tt0 -110.48 114.84 28.58 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.961 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.539 HE21 ' HA ' ' A' ' 49' ' ' GLN . 5.2 mm-40 -118.22 136.95 53.34 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 120.131 -0.628 . . . . 0.0 111.291 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 51' ' ' THR . 6.2 p -96.3 156.9 3.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.269 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.587 HG23 ' H ' ' A' ' 52' ' ' GLN . 0.1 OUTLIER -138.56 -59.53 0.62 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 119.598 -0.841 . . . . 0.0 111.059 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.587 ' H ' HG23 ' A' ' 51' ' ' THR . 0.8 OUTLIER -90.32 131.08 36.31 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.499 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.78 160.39 40.82 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.119 -1.032 . . . . 0.0 112.476 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.466 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 39.1 t-105 -155.33 149.46 25.78 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.676 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.466 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.3 t 66.07 20.07 11.2 Favored 'General case' 0 C--N 1.316 -0.877 0 C-N-CA 119.649 -0.82 . . . . 0.0 109.573 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.449 ' HG ' ' HD2' ' A' ' 84' ' ' PHE . 5.5 p -173.25 123.84 0.4 Allowed 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.921 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -80.33 77.88 7.06 Favored 'General case' 0 C--N 1.28 -2.431 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.321 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.447 HG12 HG13 ' A' ' 67' ' ' VAL . 2.2 m -72.6 152.62 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.538 -0.755 . . . . 0.0 112.277 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 40.7 p -150.06 109.15 3.91 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.883 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.522 ' OE1' ' NE2' ' A' ' 49' ' ' GLN . 33.0 tt0 -87.45 114.75 24.35 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.074 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.453 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.3 p -91.41 81.23 5.43 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.864 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.09 -69.74 1.88 Allowed Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.403 -1.379 . . . . 0.0 110.074 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.5 t -139.13 -19.06 0.99 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.858 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -86.65 -173.81 4.68 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.815 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.613 HG21 ' CE2' ' A' ' 44' ' ' PHE . 49.7 t -145.13 160.66 13.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 C-N-CA 118.77 -1.172 . . . . 0.0 113.226 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.571 ' N ' HG12 ' A' ' 65' ' ' VAL . 11.6 m -159.36 129.61 5.72 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.889 -1.505 . . . . 0.0 108.121 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.64 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -125.3 146.89 30.23 Favored 'Isoleucine or valine' 0 C--O 1.191 -2.004 0 C-N-CA 119.277 -0.969 . . . . 0.0 111.849 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -130.47 93.33 3.43 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.901 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.74 117.63 15.75 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.229 -0.988 . . . . 0.0 112.402 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.726 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -42.17 156.91 0.23 Allowed Pre-proline 0 N--CA 1.481 1.088 0 CA-C-N 113.537 -1.665 . . . . 0.0 111.876 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -59.99 -34.91 94.69 Favored 'Trans proline' 0 C--O 1.213 -0.736 0 C-N-CA 121.745 1.63 . . . . 0.0 112.065 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.726 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.92 -53.52 20.53 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.987 179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.715 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -79.67 12.78 2.39 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.496 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' A' ' 72' ' ' TRP . . . -133.6 20.71 4.1 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.516 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.4 m -94.53 60.57 2.62 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.395 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.538 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -113.49 131.81 22.8 Favored Pre-proline 0 N--CA 1.491 1.595 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.472 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.504 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -70.86 151.42 62.77 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 121.468 1.445 . . . . 0.0 114.19 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.711 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -18.03 -45.92 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.504 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -106.4 68.31 0.24 Allowed Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.883 -1.151 . . . . 0.0 111.084 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.19 23.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 118.398 -1.858 . . . . 0.0 111.384 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.835 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.2 p -132.39 162.15 31.83 Favored 'General case' 0 N--CA 1.482 1.172 0 CA-C-O 121.74 0.781 . . . . 0.0 112.686 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -127.03 174.21 9.05 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.439 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 26.6 tt0 -165.96 144.84 5.99 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 116.831 -1.948 . . . . 0.0 113.545 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.646 ' CE1' HG11 ' A' ' 25' ' ' VAL . 18.3 p90 -156.28 178.01 10.79 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.625 -1.171 . . . . 0.0 110.181 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -159.32 169.2 35.42 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 117.761 -2.162 . . . . 0.0 112.107 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 14.4 p90 -166.85 156.89 11.43 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.371 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -108.7 114.79 28.89 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.198 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.6 166.56 12.17 Favored Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.837 -1.173 . . . . 0.0 111.863 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 p -115.29 139.54 49.88 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.68 ' C ' ' ND1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -150.61 175.28 12.07 Favored 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 117.332 -1.747 . . . . 0.0 113.423 -179.872 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.402 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 1.7 t -170.8 13.46 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 114.356 -1.293 . . . . 0.0 109.208 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.76 -93.69 1.67 Allowed Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.743 -1.218 . . . . 0.0 111.352 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.94 HG22 ' H ' ' A' ' 94' ' ' ASN . 47.7 m -161.15 -122.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 118.955 -1.098 . . . . 0.0 112.17 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.94 ' H ' HG22 ' A' ' 93' ' ' THR . 10.7 p-10 -69.53 137.9 52.86 Favored 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.81 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.466 ' CB ' ' CD ' ' A' ' 48' ' ' GLN . . . -110.97 -98.28 0.41 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.726 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.594 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -32.75 108.63 0.3 Allowed Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.109 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.483 ' HD2' ' CE2' ' A' ' 100' ' ' PHE . 1.9 Cg_endo -64.91 -137.3 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 121.312 1.341 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.489 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 30.9 p -121.09 -59.74 1.7 Allowed 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.309 -0.956 . . . . 0.0 113.027 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.489 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.36 100.06 8.74 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.078 -1.049 . . . . 0.0 112.29 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.502 ' N ' ' O ' ' A' ' 107' ' ' CYS . 19.3 m-85 -72.64 -169.12 0.51 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.5 m -143.5 122.5 12.81 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 117.888 -1.525 . . . . 0.0 112.469 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.949 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.1 mt -80.81 174.54 11.52 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.538 -0.865 . . . . 0.0 109.243 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.795 ' ND2' ' H ' ' A' ' 39' ' ' THR . 74.7 m-80 -34.61 89.18 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.324 0 C-N-CA 119.837 -0.745 . . . . 0.0 112.073 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 60.45 57.7 17.71 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.466 -1.35 . . . . 0.0 110.744 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.776 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -178.24 148.61 0.64 Allowed Pre-proline 0 C--O 1.201 -1.454 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.244 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.41 176.55 3.27 Favored 'Trans proline' 0 CA--C 1.539 0.727 0 C-N-CA 121.647 1.565 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.538 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.3 t -173.57 99.06 0.11 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.099 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.455 ' HB ' ' NE2' ' A' ' 9' ' ' GLN . 0.2 OUTLIER -59.97 173.98 0.55 Allowed 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 120.037 -0.665 . . . . 0.0 112.29 -179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 10' ' ' VAL . 0.0 OUTLIER -71.24 -91.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 C-N-CA 118.972 -1.091 . . . . 0.0 109.592 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.431 ' CA ' ' NE2' ' A' ' 9' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.218 0 CA-C-O 116.364 -2.353 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.142 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.52 -60.95 1.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.658 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.5 t -76.42 -173.74 2.61 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.89 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -99.45 -178.11 31.28 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.468 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HG2' HG22 ' A' ' 105' ' ' THR . 12.0 Cg_exo -54.08 -61.58 0.41 Allowed 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.238 1.959 . . . . 0.0 112.182 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . -95.74 -173.97 3.01 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.697 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.11 44.98 0.22 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 p -53.27 179.0 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.668 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.52 118.29 12.38 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.096 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.568 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.2 m -108.88 125.97 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.28 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.547 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.53 8.77 Favored 'General case' 0 C--N 1.292 -1.9 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.673 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.71 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 4.8 t-105 -125.44 143.01 51.19 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.769 -0.772 . . . . 0.0 111.785 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.14 72.48 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.62 151.61 9.7 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.916 0.865 . . . . 0.0 113.266 -179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.544 ' CB ' HG22 ' A' ' 22' ' ' THR . 0.7 OUTLIER -162.1 101.42 1.11 Allowed 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 114.036 -1.438 . . . . 0.0 108.005 179.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.821 HE21 ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -129.87 166.0 20.87 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 122.556 1.169 . . . . 0.0 113.773 -179.761 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.639 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 32.9 p90 -126.22 -126.67 0.24 Allowed 'General case' 0 C--N 1.287 -2.137 0 CA-C-N 112.646 -2.07 . . . . 0.0 108.85 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.639 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 43.3 m-80 -77.26 72.78 3.83 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 19' ' ' THR . 0.3 OUTLIER 70.42 117.73 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.694 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' ' CZ2' ' A' ' 17' ' ' TRP . . . 125.88 96.34 1.03 Allowed Glycine 0 C--N 1.284 -2.346 0 N-CA-C 105.672 -2.971 . . . . 0.0 105.672 -179.593 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 27.1 p90 -113.46 119.56 38.02 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 -179.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.544 HG22 ' CB ' ' A' ' 15' ' ' ASN . 6.2 t -70.53 168.92 15.24 Favored 'General case' 0 C--N 1.283 -2.317 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.09 118.74 10.43 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.157 -1.417 . . . . 0.0 112.626 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -104.28 90.93 3.71 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 84' ' ' PHE . 11.5 t -92.73 133.03 35.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.703 -0.799 . . . . 0.0 112.275 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.6 m -119.17 107.2 13.17 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.522 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 82' ' ' ALA . 2.9 t -78.29 144.27 11.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 119.149 -1.021 . . . . 0.0 110.68 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.567 ' HA ' HG22 ' A' ' 81' ' ' THR . 13.4 tptm -135.37 103.05 5.35 Favored 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.859 -0.736 . . . . 0.0 109.576 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.774 HD22 ' N ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -100.33 124.37 45.72 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.088 179.89 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.774 ' N ' HD22 ' A' ' 29' ' ' ASN . 8.6 t -135.78 -2.65 2.36 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.011 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.471 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.3 p -52.19 -80.96 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 119.291 -0.963 . . . . 0.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.471 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.08 61.04 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 123.657 0.598 . . . . 0.0 110.803 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 1.027 ' H ' ' HB2' ' A' ' 78' ' ' ALA . . . -152.72 134.43 8.52 Favored Pre-proline 0 C--N 1.306 -1.283 0 C-N-CA 119.044 -1.063 . . . . 0.0 110.45 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.64 106.7 0.33 Allowed 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 120.922 1.081 . . . . 0.0 110.269 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.552 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.5 t -87.77 67.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 118.639 -1.224 . . . . 0.0 111.809 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -88.16 65.08 7.99 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 101.03 145.6 17.37 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 107.046 -2.421 . . . . 0.0 107.046 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.864 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 49.7 p-90 -162.31 174.61 12.59 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 116.976 -1.89 . . . . 0.0 112.666 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -142.87 99.21 3.42 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.862 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.878 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -87.05 173.34 9.34 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 118.328 -1.349 . . . . 0.0 109.439 179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.477 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -158.12 147.78 19.81 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 117.907 -1.517 . . . . 0.0 112.441 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.594 ' CG ' ' N ' ' A' ' 43' ' ' SER . 10.8 p90 -173.79 -137.29 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.958 -1.474 . . . . 0.0 108.043 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.594 ' N ' ' CG ' ' A' ' 42' ' ' PHE . 41.8 m -161.06 174.33 13.89 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 117.563 -1.655 . . . . 0.0 112.455 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.758 ' CD2' HG21 ' A' ' 65' ' ' VAL . 1.9 m-85 -114.47 95.93 41.54 Favored Pre-proline 0 N--CA 1.496 1.873 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.189 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.478 ' HB2' ' ND2' ' A' ' 94' ' ' ASN . 5.0 Cg_exo -60.05 -40.9 57.11 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 121.261 1.307 . . . . 0.0 111.676 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.3 t -74.96 15.45 0.4 Allowed 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.563 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 45' ' ' PRO . . . 55.79 29.38 54.62 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.233 -1.46 . . . . 0.0 110.133 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.692 ' NE2' ' HB1' ' A' ' 95' ' ' ALA . 7.3 mt-30 -61.07 116.47 4.55 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.64 ' CD ' HE22 ' A' ' 60' ' ' GLN . 0.0 OUTLIER -95.5 97.77 10.03 Favored 'General case' 0 N--CA 1.484 1.275 0 C-N-CA 119.359 -0.937 . . . . 0.0 110.621 -179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 51' ' ' THR . 0.9 OUTLIER -64.47 157.58 4.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.177 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 40.4 p -133.05 -64.45 0.74 Allowed 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.755 -0.778 . . . . 0.0 111.259 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.551 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.9 OUTLIER -90.58 173.98 7.76 Favored 'General case' 0 N--CA 1.494 1.74 0 C-N-CA 118.87 -1.132 . . . . 0.0 110.133 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -173.2 147.46 1.56 Allowed 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 118.734 -1.186 . . . . 0.0 111.961 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.474 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 37.2 t-105 -151.2 143.7 24.26 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.713 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.474 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.3 OUTLIER 60.57 27.53 17.21 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.753 -179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.468 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -174.85 122.62 0.24 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.566 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -84.84 77.63 10.05 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 118.987 -1.085 . . . . 0.0 109.462 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.417 ' C ' HG23 ' A' ' 59' ' ' THR . 13.6 m -69.23 152.57 9.34 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.296 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 58' ' ' VAL . 36.9 p -155.24 119.27 4.6 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.074 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.64 HE22 ' CD ' ' A' ' 49' ' ' GLN . 27.9 tt0 -91.53 116.92 29.26 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.906 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.456 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.2 p -90.52 77.35 6.48 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.685 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.36 -68.71 2.06 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 119.41 -1.376 . . . . 0.0 110.156 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 12.4 t -138.27 -17.16 1.19 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 119.903 -0.719 . . . . 0.0 110.291 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.52 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -91.68 -172.44 3.22 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.216 -0.993 . . . . 0.0 109.988 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.758 HG21 ' CD2' ' A' ' 44' ' ' PHE . 46.1 t -143.83 162.27 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.0 -1.08 . . . . 0.0 113.462 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.612 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 23.5 m -157.79 137.24 11.94 Favored 'General case' 0 C--N 1.304 -1.413 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.573 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.468 ' CG1' ' HB2' ' A' ' 56' ' ' SER . 2.8 t -131.8 116.33 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 C-N-CA 119.1 -1.04 . . . . 0.0 112.192 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.422 HH11 ' CB ' ' A' ' 68' ' ' ARG . 0.3 OUTLIER -99.53 96.06 7.41 Favored 'General case' 0 C--N 1.29 -2.002 0 CA-C-N 114.269 -1.332 . . . . 0.0 108.74 179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.864 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -76.02 120.11 20.89 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.836 -179.767 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.061 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -40.28 160.62 0.12 Allowed Pre-proline 0 N--CA 1.483 1.192 0 CA-C-N 113.44 -1.709 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -64.89 -38.6 28.83 Favored 'Trans proline' 0 C--O 1.211 -0.844 0 C-N-CA 122.106 1.87 . . . . 0.0 112.229 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.706 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.11 -54.69 13.64 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.581 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 1.061 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.5 p30 -76.13 5.84 6.23 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 119.171 -1.011 . . . . 0.0 109.032 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -128.4 50.25 0.9 Allowed Glycine 0 C--O 1.202 -1.901 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.1 m -118.98 61.66 0.8 Allowed 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 119.78 -0.768 . . . . 0.0 111.303 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.831 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -120.46 109.02 36.97 Favored Pre-proline 0 CA--C 1.56 1.353 0 C-N-CA 119.963 -0.695 . . . . 0.0 111.312 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.633 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.3 Cg_endo -71.65 118.9 5.88 Favored 'Trans proline' 0 C--O 1.207 -1.063 0 C-N-CA 121.182 1.255 . . . . 0.0 111.389 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 1.027 ' HB2' ' H ' ' A' ' 33' ' ' ALA . . . -7.65 68.07 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.694 1.246 . . . . 0.0 113.257 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.633 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . 170.18 46.1 0.03 OUTLIER Glycine 0 C--N 1.277 -2.722 0 CA-C-N 114.148 -1.387 . . . . 0.0 110.124 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -174.98 -152.92 9.61 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.021 -1.561 . . . . 0.0 110.192 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.567 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.9 p -140.77 173.64 11.29 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.26 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.666 ' O ' HG23 ' A' ' 27' ' ' VAL . . . -148.94 90.79 1.79 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.679 ' HB2' HG23 ' A' ' 26' ' ' THR . 8.5 tt0 -85.04 146.44 27.18 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 113.897 1.073 . . . . 0.0 113.897 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 25' ' ' VAL . 12.0 p90 -155.03 175.56 13.67 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 113.997 -1.456 . . . . 0.0 108.851 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.7 176.82 41.12 Favored Glycine 0 N--CA 1.498 2.82 0 C-N-CA 117.489 -2.291 . . . . 0.0 112.532 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.489 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 6.8 p90 -163.68 -175.14 3.99 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.949 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -129.77 113.59 14.89 Favored 'General case' 0 N--CA 1.496 1.852 0 C-N-CA 119.753 -0.779 . . . . 0.0 110.507 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.495 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.45 152.66 20.3 Favored Glycine 0 N--CA 1.504 3.199 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 p -94.23 135.52 35.53 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.165 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.427 ' NE2' ' HA ' ' A' ' 19' ' ' THR . 17.2 p80 -97.87 -166.17 1.35 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.303 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 36.4 p -145.78 -5.31 0.63 Allowed 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.081 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.66 73.12 1.14 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.574 -1.298 . . . . 0.0 110.594 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.837 HG22 ' ND2' ' A' ' 94' ' ' ASN . 88.7 m -161.17 -118.89 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.202 -0.999 . . . . 0.0 111.518 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.837 ' ND2' HG22 ' A' ' 93' ' ' THR . 0.0 OUTLIER -129.9 121.1 25.98 Favored 'General case' 0 N--CA 1.497 1.875 0 C-N-CA 120.104 -0.639 . . . . 0.0 111.259 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.692 ' HB1' ' NE2' ' A' ' 48' ' ' GLN . . . -92.08 -113.56 0.09 Allowed 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.732 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.71 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -40.78 110.45 0.7 Allowed Pre-proline 0 N--CA 1.488 1.467 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.283 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.507 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -61.19 -95.72 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.909 1.073 . . . . 0.0 112.465 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 97' ' ' PRO . 6.9 p -155.04 -81.73 0.08 Allowed 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.177 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -102.59 94.34 5.6 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.329 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.562 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -67.65 -150.65 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.209 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 19.4 m -157.12 110.72 2.6 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 117.215 -1.794 . . . . 0.0 113.59 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.575 HD22 HD21 ' A' ' 103' ' ' ASN . 2.5 mt -55.89 177.43 0.06 Allowed 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.64 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.15 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.544 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -163.63 20.29 0.15 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 118.676 -1.726 . . . . 0.0 111.435 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.605 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 3.5 p -139.6 150.66 64.16 Favored Pre-proline 0 N--CA 1.501 2.087 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.561 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.83 163.82 17.98 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.437 1.425 . . . . 0.0 111.531 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.54 ' SG ' HG13 ' A' ' 10' ' ' VAL . 4.7 t -157.03 98.62 1.76 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.986 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 4.5 p -50.95 161.67 0.35 Allowed 'General case' 0 N--CA 1.498 1.957 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.828 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.946 HG22 ' H ' ' A' ' 110' ' ' GLY . 10.8 p -75.52 -135.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 119.038 -1.065 . . . . 0.0 109.648 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.946 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.13 0 CA-C-O 116.267 -2.407 . . . . 0.0 110.393 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.95 0.405 . . . . 0.0 110.07 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.478 ' C ' ' OG ' ' A' ' 3' ' ' SER . 0.4 OUTLIER 166.43 -86.23 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.668 179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.478 ' OG ' ' C ' ' A' ' 2' ' ' SER . 1.2 p 42.57 79.4 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.87 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 88.12 179.72 47.03 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.469 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -61.58 -81.25 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.167 1.912 . . . . 0.0 111.559 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.627 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -107.91 -162.88 0.85 Allowed 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.07 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 177.12 48.33 0.06 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' C ' ' NE2' ' A' ' 9' ' ' GLN . 4.0 p -52.79 178.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.495 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.438 ' NE2' ' C ' ' A' ' 8' ' ' CYS . 0.0 OUTLIER -129.73 124.39 33.39 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.88 179.948 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.558 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.5 m -117.36 125.53 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.532 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.68 168.24 10.28 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.646 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.655 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.4 t-105 -134.31 143.44 47.72 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 119.43 -0.908 . . . . 0.0 112.601 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.66 73.73 0.45 Allowed Glycine 0 N--CA 1.496 2.677 0 N-CA-C 107.3 -2.32 . . . . 0.0 107.3 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.7 OUTLIER -69.93 162.46 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 113.867 1.062 . . . . 0.0 113.867 -179.621 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.466 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.0 t30 -170.13 101.32 0.28 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 113.686 -1.597 . . . . 0.0 108.689 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.853 HE21 ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -121.47 164.56 16.97 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.97 -179.813 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.55 ' NE1' ' O ' ' A' ' 19' ' ' THR . 19.8 p90 -122.84 -137.07 0.3 Allowed 'General case' 0 N--CA 1.506 2.367 0 CA-C-N 113.593 -1.64 . . . . 0.0 110.532 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.435 ' H ' ' HB2' ' A' ' 17' ' ' TRP . 15.7 t-20 -46.02 -33.22 3.25 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 118.735 -1.186 . . . . 0.0 108.806 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.55 ' O ' ' NE1' ' A' ' 17' ' ' TRP . 0.4 OUTLIER 178.16 135.0 0.08 Allowed 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.368 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.423 ' H ' ' CD2' ' A' ' 90' ' ' HIS . . . 114.88 104.06 2.51 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 106.821 -2.512 . . . . 0.0 106.821 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 37.7 p90 -107.7 116.34 31.78 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 121.65 0.738 . . . . 0.0 112.62 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.466 HG22 ' HB3' ' A' ' 15' ' ' ASN . 14.8 t -71.81 168.58 17.54 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.655 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -150.18 118.88 6.55 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 117.675 -1.61 . . . . 0.0 112.701 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -100.42 95.82 7.0 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.662 HG11 ' CE2' ' A' ' 84' ' ' PHE . 18.6 t -94.91 141.5 14.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 C-N-CA 119.584 -0.847 . . . . 0.0 112.423 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.541 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.1 m -127.28 120.75 29.36 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.685 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 1.0 OUTLIER -90.55 148.34 4.63 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.719 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.9 tptp -136.15 103.83 5.46 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.028 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.728 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -95.71 132.56 40.78 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.519 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.462 ' N ' ' ND2' ' A' ' 29' ' ' ASN . 13.7 t -139.48 -3.42 1.51 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 32' ' ' SER . 5.1 p -50.68 -82.15 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.505 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 161.54 69.7 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.478 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.02 154.13 4.99 Favored Pre-proline 0 C--N 1.312 -1.026 0 C-N-CA 118.518 -1.273 . . . . 0.0 111.499 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -73.18 99.51 1.12 Allowed 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 121.413 1.409 . . . . 0.0 109.598 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.418 HG12 ' HD1' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -78.32 81.94 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 118.381 -1.327 . . . . 0.0 111.902 -179.758 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -95.03 54.73 1.72 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 107.38 152.95 18.39 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 107.506 -2.238 . . . . 0.0 107.506 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 41.9 p-90 -163.31 174.09 12.46 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 117.13 -1.828 . . . . 0.0 112.502 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.36 98.16 3.54 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.124 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.867 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -84.9 171.84 11.86 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 118.168 -1.413 . . . . 0.0 109.635 179.945 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.469 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 18.7 m -155.92 142.99 19.08 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 118.673 -1.211 . . . . 0.0 111.63 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.585 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.1 p90 -172.1 -148.92 0.05 Allowed 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 114.625 -1.171 . . . . 0.0 108.606 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.585 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 65.6 m -159.08 157.71 31.58 Favored 'General case' 0 C--N 1.29 -2.005 0 C-N-CA 117.782 -1.567 . . . . 0.0 111.485 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.564 ' CE2' HG21 ' A' ' 65' ' ' VAL . 4.4 m-85 -88.31 114.35 59.15 Favored Pre-proline 0 N--CA 1.491 1.578 0 C-N-CA 119.155 -1.018 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.567 ' HG2' ' ND2' ' A' ' 94' ' ' ASN . 8.0 Cg_exo -53.94 -54.52 4.64 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 N-CA-C 108.654 -1.325 . . . . 0.0 108.654 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.608 ' HA ' ' H ' ' A' ' 93' ' ' THR . 2.4 t -72.61 163.13 28.55 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 118.777 -1.169 . . . . 0.0 108.063 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.582 ' H ' ' HA3' ' A' ' 92' ' ' GLY . . . -78.07 59.98 3.89 Favored Glycine 0 C--N 1.277 -2.72 0 C-N-CA 118.338 -1.887 . . . . 0.0 108.72 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.567 ' NE2' ' CZ ' ' A' ' 21' ' ' PHE . 1.5 mt-30 -90.96 176.53 6.57 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.627 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.658 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -162.02 111.92 1.54 Allowed 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.838 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.6 p -68.91 157.89 6.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 119.504 -0.878 . . . . 0.0 111.311 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.658 HG22 HE22 ' A' ' 49' ' ' GLN . 62.2 p -134.71 -66.01 0.61 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.389 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.509 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.1 OUTLIER -83.96 168.98 15.49 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 118.87 -1.132 . . . . 0.0 109.414 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.33 152.72 7.4 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 118.327 -1.349 . . . . 0.0 112.272 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.43 ' CE2' ' HB2' ' A' ' 55' ' ' SER . 18.4 t-105 -146.72 132.21 18.69 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.626 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.43 ' HB2' ' CE2' ' A' ' 54' ' ' TRP . 2.2 t 58.57 33.18 22.89 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.095 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.5 114.79 0.47 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.376 -0.929 . . . . 0.0 110.672 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.8 m -80.91 74.85 7.88 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 118.87 -1.132 . . . . 0.0 108.929 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.428 ' H ' HG13 ' A' ' 58' ' ' VAL . 2.6 m -69.07 168.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 CA-C-N 114.966 -1.016 . . . . 0.0 112.843 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 59' ' ' THR . 10.0 t -170.18 123.57 0.71 Allowed 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.825 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -86.41 102.45 14.06 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.315 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.2 p -91.2 82.83 5.48 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.546 -0.862 . . . . 0.0 111.773 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.554 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 55.69 78.15 0.13 Allowed Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.481 -1.343 . . . . 0.0 110.861 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.2 p 67.59 -23.93 0.12 Allowed 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.825 -0.75 . . . . 0.0 111.487 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.554 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -90.95 -176.07 4.53 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.876 -1.129 . . . . 0.0 110.852 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' A' ' 66' ' ' THR . 33.1 t -149.26 160.11 5.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 118.844 -1.143 . . . . 0.0 113.6 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.572 ' N ' ' CG1' ' A' ' 65' ' ' VAL . 1.1 m -154.51 154.58 33.36 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 114.169 -1.378 . . . . 0.0 108.024 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.467 ' HB ' HD22 ' A' ' 40' ' ' LEU . 7.1 t -147.85 117.85 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 118.511 -1.276 . . . . 0.0 112.197 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.24 90.42 5.11 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.441 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.599 ' CG ' ' CE2' ' A' ' 38' ' ' TRP . 1.7 p-10 -70.57 119.01 14.1 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.805 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.811 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.3 158.14 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.482 0 CA-C-N 113.477 -1.692 . . . . 0.0 112.628 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -65.48 -36.74 32.95 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 121.875 1.717 . . . . 0.0 112.072 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.811 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -69.4 -56.56 7.1 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 118.928 -1.109 . . . . 0.0 110.226 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.65 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -70.22 -3.26 16.15 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.012 179.842 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -123.58 51.3 0.81 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.3 t -118.2 54.16 0.94 Allowed 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.677 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -110.69 135.58 20.73 Favored Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.297 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.557 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.3 Cg_endo -76.32 156.42 37.2 Favored 'Trans proline' 0 C--O 1.212 -0.793 0 C-N-CA 121.507 1.472 . . . . 0.0 112.306 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.407 ' C ' ' O ' ' A' ' 77' ' ' PRO . . . -28.5 -32.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.5 71.53 0.22 Allowed Glycine 0 N--CA 1.497 2.7 0 C-N-CA 119.984 -1.103 . . . . 0.0 110.771 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.442 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -164.54 -164.6 20.18 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 118.739 -1.696 . . . . 0.0 111.07 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 28' ' ' LYS . 11.6 p -139.99 167.78 21.33 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.99 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.437 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.66 -169.05 2.17 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.173 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.505 ' O ' ' NE2' ' A' ' 83' ' ' GLN . 0.0 OUTLIER -169.8 141.82 2.34 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 117.628 -1.629 . . . . 0.0 112.617 -179.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.662 ' CE2' HG11 ' A' ' 25' ' ' VAL . 2.5 p90 -163.13 161.73 25.29 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -157.54 173.18 34.95 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 117.994 -2.051 . . . . 0.0 111.946 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.504 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 7.2 p90 -164.59 -174.63 3.5 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.506 -0.878 . . . . 0.0 111.328 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.497 HD22 ' HB3' ' A' ' 52' ' ' GLN . 70.8 m-80 -130.79 115.71 16.99 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.224 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.529 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -132.41 153.43 20.6 Favored Glycine 0 N--CA 1.511 3.639 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.834 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 9.0 p -84.63 144.22 28.74 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.64 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.582 ' O ' HG23 ' A' ' 91' ' ' THR . 18.9 p80 -111.94 119.66 39.29 Favored 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.334 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.582 HG23 ' O ' ' A' ' 90' ' ' HIS . 1.8 p -161.29 83.53 0.63 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.464 -0.895 . . . . 0.0 110.906 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.582 ' HA3' ' H ' ' A' ' 47' ' ' GLY . . . 175.72 -100.59 0.15 Allowed Glycine 0 N--CA 1.491 2.331 0 C-N-CA 118.199 -1.953 . . . . 0.0 112.411 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.608 ' H ' ' HA ' ' A' ' 46' ' ' SER . 19.6 m -153.53 112.85 3.79 Favored 'General case' 0 N--CA 1.491 1.625 0 C-N-CA 119.617 -0.833 . . . . 0.0 111.777 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.766 HD22 ' N ' ' A' ' 95' ' ' ALA . 0.0 OUTLIER 60.78 122.32 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.259 0 C-N-CA 120.178 -0.609 . . . . 0.0 110.408 -179.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.766 ' N ' HD22 ' A' ' 94' ' ' ASN . . . -94.58 -50.64 5.1 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 114.406 1.262 . . . . 0.0 114.406 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -94.15 118.55 67.16 Favored Pre-proline 0 N--CA 1.492 1.672 0 C-N-CA 118.936 -1.105 . . . . 0.0 113.489 -179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.494 ' HG2' ' CE2' ' A' ' 100' ' ' PHE . 2.3 Cg_endo -64.9 -144.9 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.764 0 C-N-CA 121.548 1.499 . . . . 0.0 111.514 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.622 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.8 p -134.67 -63.37 0.71 Allowed 'General case' 0 N--CA 1.496 1.859 0 C-N-CA 119.696 -0.802 . . . . 0.0 111.873 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.622 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.2 106.98 16.62 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.622 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.533 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 12.4 m-85 -80.98 -168.83 1.95 Allowed 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.8 m -144.83 106.24 4.23 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 117.906 -1.517 . . . . 0.0 113.378 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -54.78 174.04 0.08 Allowed 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.236 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.524 HD22 ' HB2' ' A' ' 38' ' ' TRP . 3.1 p30 -57.84 79.95 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.205 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 103.22 9.02 40.14 Favored Glycine 0 N--CA 1.499 2.877 0 C-N-CA 119.625 -1.274 . . . . 0.0 112.447 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.627 ' HB ' ' H ' ' A' ' 6' ' ' ALA . 3.2 p -152.5 153.48 30.63 Favored Pre-proline 0 C--O 1.194 -1.847 0 C-N-CA 118.482 -1.287 . . . . 0.0 111.449 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -66.79 -179.51 1.69 Allowed 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 121.679 1.586 . . . . 0.0 112.037 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.558 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.4 t -173.2 100.5 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.843 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.31 165.38 4.62 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 119.791 -0.764 . . . . 0.0 111.879 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.672 ' CG2' ' N ' ' A' ' 110' ' ' GLY . 0.2 OUTLIER -75.11 172.02 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.012 179.635 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.672 ' N ' ' CG2' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.178 0 CA-C-O 116.341 -2.366 . . . . 0.0 110.357 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.1 m -83.47 107.78 16.18 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.849 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.2 p -152.22 166.13 32.7 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.633 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.72 74.59 0.24 Allowed Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.101 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -66.83 -179.12 1.52 Allowed 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 121.819 1.679 . . . . 0.0 111.378 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.8 ' HB3' HG21 ' A' ' 105' ' ' THR . . . -110.9 -162.88 0.82 Allowed 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.848 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.46 55.25 0.06 OUTLIER Glycine 0 N--CA 1.502 3.078 0 N-CA-C 107.384 -2.286 . . . . 0.0 107.384 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -53.88 -165.46 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.503 1.144 . . . . 0.0 113.895 -179.747 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.572 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 13.5 mt-30 -145.03 89.84 1.99 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.455 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.538 ' CG1' ' SG ' ' A' ' 8' ' ' CYS . 1.1 m -87.83 141.3 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.793 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.716 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -116.12 172.8 6.94 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.778 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.896 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 8.8 t-105 -133.14 147.84 52.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.768 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.13 87.85 0.32 Allowed Glycine 0 N--CA 1.496 2.651 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.94 141.03 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.578 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 55.2 t30 -150.37 71.11 1.04 Allowed 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.105 -0.952 . . . . 0.0 109.327 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.819 ' H ' ' NE2' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -92.17 147.38 22.98 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.18 -1.008 . . . . 0.0 113.707 -179.748 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.765 ' C ' ' H ' ' A' ' 19' ' ' THR . 1.2 p90 -116.46 92.31 3.84 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 113.26 -1.791 . . . . 0.0 109.711 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.507 ' O ' ' CB ' ' A' ' 19' ' ' THR . 1.0 OUTLIER 63.79 -13.06 0.09 Allowed 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 118.805 -1.158 . . . . 0.0 108.884 -179.746 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.765 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.8 OUTLIER 163.74 163.63 0.02 OUTLIER 'General case' 0 C--N 1.287 -2.114 0 CA-C-N 114.079 -1.419 . . . . 0.0 108.167 -179.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.514 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 73.53 89.6 0.16 Allowed Glycine 0 C--N 1.284 -2.353 0 N-CA-C 106.568 -2.613 . . . . 0.0 106.568 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.558 ' O ' ' CD2' ' A' ' 21' ' ' PHE . 35.9 p90 -95.38 117.31 30.11 Favored 'General case' 0 CA--C 1.49 -1.327 0 C-N-CA 119.791 -0.764 . . . . 0.0 112.607 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.555 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.5 OUTLIER -68.95 171.28 8.3 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 179.559 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.555 ' N ' HG23 ' A' ' 22' ' ' THR . . . -151.11 103.34 3.03 Favored 'General case' 0 C--N 1.29 -2.011 0 C-N-CA 117.754 -1.578 . . . . 0.0 112.468 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -91.26 98.88 11.99 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.675 HG11 ' CE2' ' A' ' 84' ' ' PHE . 8.4 t -97.19 139.81 18.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 119.706 -0.797 . . . . 0.0 112.669 -179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.716 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.2 OUTLIER -125.01 149.47 47.71 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.24 179.796 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.593 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 2.6 t -123.54 101.65 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.694 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.729 ' HA ' HG22 ' A' ' 81' ' ' THR . 35.3 tptt -87.85 101.95 14.22 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.014 -1.075 . . . . 0.0 110.054 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.722 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -97.16 121.09 38.66 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.274 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -128.51 -1.02 5.57 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.708 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.9 p -47.04 -84.77 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.364 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.473 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 164.75 42.69 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.17 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.817 -179.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.929 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.71 153.17 42.64 Favored Pre-proline 0 N--CA 1.486 1.333 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.337 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -69.6 95.84 0.56 Allowed 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 121.36 1.373 . . . . 0.0 110.006 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.9 t -72.8 96.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.508 -1.277 . . . . 0.0 111.253 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -113.45 82.96 1.76 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.55 139.45 1.92 Allowed Glycine 0 C--N 1.292 -1.89 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.769 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 46.1 p-90 -159.87 176.18 12.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 117.895 -1.522 . . . . 0.0 111.935 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.417 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -142.35 110.03 5.78 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.587 179.925 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.21 173.55 6.74 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.842 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.452 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -154.94 147.72 24.43 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.01 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.7 p90 -173.26 -144.96 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.451 -1.25 . . . . 0.0 108.904 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.54 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.1 m -159.42 153.3 23.16 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 117.801 -1.56 . . . . 0.0 112.364 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.533 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.8 m-85 -84.32 117.56 69.03 Favored Pre-proline 0 N--CA 1.484 1.27 0 C-N-CA 118.825 -1.15 . . . . 0.0 108.23 179.762 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -57.68 -62.59 0.2 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.628 0.885 . . . . 0.0 110.717 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.496 ' OG ' ' N ' ' A' ' 93' ' ' THR . 34.9 t -77.91 -174.79 3.7 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.967 -1.093 . . . . 0.0 110.177 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.444 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.81 54.33 4.41 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 118.983 -1.58 . . . . 0.0 109.782 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.615 ' OE1' ' HB2' ' A' ' 95' ' ' ALA . 1.9 mt-30 -88.27 139.85 30.08 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 119.106 -1.037 . . . . 0.0 110.79 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.692 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -139.89 112.26 7.75 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.961 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.472 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.43 149.12 11.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.691 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.692 HG22 HE22 ' A' ' 49' ' ' GLN . 26.5 p -126.07 -61.92 1.2 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.898 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.593 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -98.31 125.54 43.47 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.657 -0.817 . . . . 0.0 109.813 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -130.76 160.04 35.51 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 119.445 -0.902 . . . . 0.0 112.388 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.4 ' NE1' ' HB3' ' A' ' 55' ' ' SER . 27.7 t-105 -151.86 143.93 23.87 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.428 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.4 ' HB3' ' NE1' ' A' ' 54' ' ' TRP . 4.7 p 54.74 31.93 16.43 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.686 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.501 ' HB2' ' CG ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -172.89 113.32 0.25 Allowed 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.219 -0.901 . . . . 0.0 109.744 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 m -80.12 77.16 6.85 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.211 -0.995 . . . . 0.0 110.361 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.423 HG12 HG13 ' A' ' 67' ' ' VAL . 3.5 m -71.73 156.03 7.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.401 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.405 HG23 ' C ' ' A' ' 58' ' ' VAL . 64.1 p -155.65 118.18 4.19 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.232 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -81.02 108.24 14.53 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.184 -1.006 . . . . 0.0 110.464 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 p -97.89 94.28 6.81 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.381 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.581 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . 47.88 72.58 0.42 Allowed Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.043 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.408 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 1.0 OUTLIER 68.26 -24.12 0.13 Allowed 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.964 -179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.581 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -84.93 -172.38 4.15 Favored 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 118.746 -1.182 . . . . 0.0 110.424 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 66' ' ' THR . 75.7 t -142.38 158.68 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.865 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.548 ' N ' HG12 ' A' ' 65' ' ' VAL . 20.3 m -160.0 124.37 3.8 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.384 -1.28 . . . . 0.0 108.649 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.622 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -121.66 148.21 25.23 Favored 'Isoleucine or valine' 0 C--O 1.194 -1.859 0 C-N-CA 119.569 -0.852 . . . . 0.0 111.885 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -130.13 92.91 3.37 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.769 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 13.1 p-10 -71.13 121.02 17.55 Favored 'General case' 0 C--N 1.299 -1.619 0 C-N-CA 119.354 -0.938 . . . . 0.0 111.669 -179.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.824 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -47.71 170.7 0.09 OUTLIER Pre-proline 0 C--N 1.308 -1.202 0 CA-C-N 114.374 -1.285 . . . . 0.0 111.611 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.824 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.7 Cg_endo -68.41 -38.98 10.46 Favored 'Trans proline' 0 C--N 1.322 -0.816 0 C-N-CA 122.163 1.908 . . . . 0.0 112.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.522 ' CD1' ' N ' ' A' ' 72' ' ' TRP . 0.0 OUTLIER -69.71 -54.03 15.73 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.063 -1.055 . . . . 0.0 111.335 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.74 HD22 ' HB3' ' A' ' 70' ' ' ALA . 0.9 OUTLIER -75.7 14.73 0.59 Allowed 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.222 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -145.54 34.11 1.51 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 119.284 -1.436 . . . . 0.0 111.319 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.0 m -102.85 58.63 0.78 Allowed 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.584 -0.846 . . . . 0.0 110.6 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.523 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -111.98 132.49 21.98 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 119.896 -0.721 . . . . 0.0 111.661 -179.915 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.584 ' O ' ' N ' ' A' ' 79' ' ' GLY . 3.9 Cg_endo -69.53 156.26 64.46 Favored 'Trans proline' 0 C--O 1.208 -0.978 0 C-N-CA 121.211 1.274 . . . . 0.0 110.14 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.929 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -41.52 -14.41 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -113.83 66.85 0.26 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -173.61 -161.51 23.92 Favored Glycine 0 N--CA 1.494 2.534 0 C-N-CA 118.361 -1.876 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.729 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.0 p -139.37 158.17 44.61 Favored 'General case' 0 N--CA 1.482 1.171 0 C-N-CA 119.342 -0.943 . . . . 0.0 112.701 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.593 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -124.19 173.94 8.0 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.481 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 9.6 tt0 -169.08 145.79 3.52 Favored 'General case' 0 C--N 1.298 -1.647 0 C-N-CA 116.881 -1.928 . . . . 0.0 113.207 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.675 ' CE2' HG11 ' A' ' 25' ' ' VAL . 11.2 p90 -154.98 175.83 13.3 Favored 'General case' 0 C--N 1.302 -1.47 0 CA-C-N 114.671 -1.149 . . . . 0.0 109.469 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.18 164.65 37.69 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 116.935 -2.555 . . . . 0.0 112.593 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 3.4 p90 -157.03 -170.23 3.22 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.399 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.454 HD22 ' N ' ' A' ' 87' ' ' ASN . 1.7 m-80 -135.58 114.84 12.42 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.005 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -125.35 150.16 17.25 Favored Glycine 0 N--CA 1.508 3.475 0 C-N-CA 119.408 -1.377 . . . . 0.0 112.342 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 84.9 p -86.28 152.2 22.96 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 120.072 -0.651 . . . . 0.0 109.902 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.548 ' NE2' ' HA ' ' A' ' 19' ' ' THR . 24.7 p80 -137.27 156.51 48.18 Favored 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.516 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.594 ' O ' HG23 ' A' ' 91' ' ' THR . 15.3 t -171.13 36.95 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.591 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -156.75 -115.57 0.48 Allowed Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.919 -1.61 . . . . 0.0 111.629 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.496 ' N ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -86.75 -153.63 0.21 Allowed 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 120.163 -0.615 . . . . 0.0 112.017 -179.763 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.841 ' H ' ' ND2' ' A' ' 94' ' ' ASN . 0.0 OUTLIER -88.45 -179.41 6.08 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.744 -0.782 . . . . 0.0 111.374 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.615 ' HB2' ' OE1' ' A' ' 48' ' ' GLN . . . -110.88 -132.14 0.32 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-N 115.523 -0.762 . . . . 0.0 112.006 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.896 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -8.73 108.31 0.04 OUTLIER Pre-proline 0 N--CA 1.509 2.485 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.417 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.498 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.0 OUTLIER -65.2 -101.4 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 121.14 1.226 . . . . 0.0 112.468 -179.997 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.52 ' HA ' HG13 ' A' ' 109' ' ' VAL . 81.4 p -150.1 -66.07 0.21 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 118.897 -1.121 . . . . 0.0 112.265 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.479 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -109.93 103.57 12.36 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.594 -0.843 . . . . 0.0 110.662 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 14.4 m-85 -74.57 -169.67 0.89 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.253 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.4 m -136.57 93.61 2.9 Favored 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 118.667 -1.213 . . . . 0.0 112.726 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.636 HD22 ' ND2' ' A' ' 103' ' ' ASN . 1.4 mt -52.53 173.54 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.545 -0.862 . . . . 0.0 108.956 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.636 ' ND2' HD22 ' A' ' 102' ' ' LEU . 1.4 p30 -45.14 90.92 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.014 -1.074 . . . . 0.0 110.608 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 63.06 58.22 12.67 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.443 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.8 HG21 ' HB3' ' A' ' 6' ' ' ALA . 0.8 OUTLIER 175.48 139.58 0.2 Allowed Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.869 -180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.9 167.13 4.52 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 121.551 1.501 . . . . 0.0 112.65 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -164.36 82.33 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.438 HG23 ' H ' ' A' ' 108' ' ' THR . 50.1 p -46.61 167.95 0.02 OUTLIER 'General case' 0 N--CA 1.517 2.88 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.52 HG13 ' HA ' ' A' ' 98' ' ' THR . 0.0 OUTLIER -66.7 -160.08 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.113 -1.035 . . . . 0.0 109.69 179.562 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.099 0 CA-C-O 116.333 -2.37 . . . . 0.0 110.386 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.133 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 50.0 -142.1 0.66 Allowed 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.922 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 p -124.1 86.36 2.56 Favored 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.74 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.33 74.34 0.29 Allowed Glycine 0 N--CA 1.49 2.234 0 C-N-CA 119.388 -1.386 . . . . 0.0 110.402 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.19 -156.57 0.02 OUTLIER 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 121.661 1.574 . . . . 0.0 111.444 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.618 ' H ' ' HB ' ' A' ' 105' ' ' THR . . . -90.29 -154.57 0.34 Allowed 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.911 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.79 49.35 0.05 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.5 p -53.23 -179.31 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.618 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.536 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 26.6 mt-30 -137.03 113.09 9.73 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.547 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.644 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.0 m -108.77 130.82 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.976 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.578 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -103.88 167.38 9.81 Favored 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.104 179.94 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.472 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.6 t-105 -130.59 145.45 51.89 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.031 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.18 73.14 0.47 Allowed Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -72.43 153.04 7.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.564 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.2 t30 -157.23 92.87 1.28 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 114.323 -1.308 . . . . 0.0 108.742 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.683 HE21 ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -97.64 158.35 15.55 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 121.764 0.792 . . . . 0.0 112.336 -179.757 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.444 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.9 OUTLIER -123.26 -107.88 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.136 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -67.44 -27.06 66.73 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.468 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.697 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -174.96 -55.2 0.01 OUTLIER 'General case' 0 C--O 1.203 -1.368 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.274 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.697 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -50.33 158.23 1.82 Allowed Glycine 0 CA--C 1.484 -1.852 0 C-N-CA 119.355 -1.402 . . . . 0.0 109.632 -179.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.592 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 3.1 p90 -134.52 117.25 16.0 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.629 -179.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.564 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.0 t -75.33 173.84 10.35 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.472 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -158.1 117.01 3.14 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 117.22 -1.792 . . . . 0.0 113.358 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -99.89 101.54 12.69 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.457 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.8 t -99.63 147.05 7.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.58 -0.848 . . . . 0.0 112.802 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.599 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.5 m -138.9 110.35 7.0 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.345 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.615 HG13 HG12 ' A' ' 10' ' ' VAL . 1.8 t -83.23 149.81 4.43 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 C-N-CA 119.724 -0.79 . . . . 0.0 112.201 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.536 ' NZ ' ' NE2' ' A' ' 9' ' ' GLN . 2.2 tttm -142.19 106.97 4.87 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.802 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.698 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.3 t30 -93.22 120.17 33.21 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 118.971 -1.092 . . . . 0.0 108.594 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -123.15 -2.77 8.58 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 124.219 0.95 . . . . 0.0 109.818 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.529 ' OG ' ' ND2' ' A' ' 29' ' ' ASN . 1.4 p -53.35 -81.4 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 119.716 -0.793 . . . . 0.0 110.801 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.509 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.52 73.53 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.383 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.26 143.32 1.93 Allowed Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.089 179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -68.32 101.88 0.77 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 108.847 -1.251 . . . . 0.0 108.847 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -86.42 109.28 18.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 118.281 -1.367 . . . . 0.0 111.643 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -117.38 73.63 0.89 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.06 143.75 11.75 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.904 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.4 p-90 -162.48 177.31 9.6 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 117.761 -1.576 . . . . 0.0 112.098 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -138.45 112.97 8.86 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.379 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.72 173.29 6.37 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 119.285 -0.966 . . . . 0.0 109.326 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.528 ' CG2' ' N ' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -167.18 159.2 12.68 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.762 -1.575 . . . . 0.0 112.638 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.528 ' N ' ' CG2' ' A' ' 41' ' ' THR . 23.5 p90 -176.71 -134.49 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.63 -1.623 . . . . 0.0 107.954 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.483 ' OG ' ' C ' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -163.0 139.12 7.11 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.685 -1.606 . . . . 0.0 112.237 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.748 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 6.7 m-85 -69.28 122.28 84.9 Favored Pre-proline 0 N--CA 1.486 1.344 0 C-N-CA 118.838 -1.145 . . . . 0.0 108.465 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -52.68 -68.76 0.07 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.343 1.362 . . . . 0.0 112.729 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.455 ' HB3' ' CG2' ' A' ' 93' ' ' THR . 2.5 p -69.42 -68.58 0.4 Allowed 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 119.173 -1.011 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.13 26.71 0.02 OUTLIER Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.222 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.637 ' CD ' ' HB2' ' A' ' 95' ' ' ALA . 1.1 mp0 -43.73 144.6 0.8 Allowed 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.614 -0.834 . . . . 0.0 110.847 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.612 ' CA ' HE21 ' A' ' 49' ' ' GLN . 0.1 OUTLIER -110.54 82.95 1.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.508 -179.944 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.7 p -61.68 147.75 10.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.398 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.498 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 68.5 p -136.77 -71.91 0.44 Allowed 'General case' 0 N--CA 1.497 1.879 0 C-N-CA 119.181 -1.007 . . . . 0.0 112.157 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.498 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -76.6 145.72 38.74 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.935 -179.889 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -156.19 153.86 29.9 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.733 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.443 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.2 t-105 -152.55 147.98 26.83 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.182 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.1 OUTLIER 71.27 14.3 6.56 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.686 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.587 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 31.3 t -174.1 151.2 1.66 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.396 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -102.66 84.58 2.43 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.699 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -85.43 163.13 2.76 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.963 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.428 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.8 t -164.21 132.26 3.47 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.613 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.87 113.27 24.81 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.698 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.894 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.5 p -84.28 68.33 10.14 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.722 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 77.31 -63.74 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 58.5 m -142.19 -16.7 0.75 Allowed 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 120.062 -0.655 . . . . 0.0 109.269 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -88.47 -172.89 3.95 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.252 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.748 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 94.6 t -146.15 153.1 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 118.79 -1.164 . . . . 0.0 112.587 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.451 ' N ' HG12 ' A' ' 65' ' ' VAL . 3.6 m -159.89 135.87 8.64 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 114.909 -1.042 . . . . 0.0 108.976 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.631 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.0 t -129.46 153.36 38.63 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.943 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.49 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.8 mtm180 -135.91 89.29 2.47 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.904 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -70.86 118.53 13.75 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.162 -1.015 . . . . 0.0 112.08 -179.582 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.774 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -38.07 154.83 0.12 Allowed Pre-proline 0 N--CA 1.484 1.237 0 CA-C-N 113.731 -1.577 . . . . 0.0 112.012 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -64.69 -35.14 48.14 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 121.942 1.762 . . . . 0.0 112.626 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.774 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -69.59 -57.36 5.28 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 118.839 -1.145 . . . . 0.0 110.775 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.601 ' C ' ' ND2' ' A' ' 73' ' ' ASN . 0.1 OUTLIER -69.83 -13.18 62.14 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.106 -1.038 . . . . 0.0 109.911 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.08 22.12 42.46 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.621 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 m -87.53 58.65 5.05 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.196 -1.002 . . . . 0.0 111.271 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.916 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -108.96 115.39 57.18 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.171 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' GLY . 2.0 Cg_endo -67.96 159.45 52.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 121.317 1.345 . . . . 0.0 113.745 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.509 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -24.08 -38.55 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 114.332 -1.304 . . . . 0.0 114.058 179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -118.07 68.56 0.33 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -155.35 -168.22 18.14 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 118.857 -1.639 . . . . 0.0 110.284 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.516 ' N ' HG13 ' A' ' 76' ' ' ILE . 22.0 p -141.96 164.37 30.36 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.085 -1.046 . . . . 0.0 112.819 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.578 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -130.68 -179.95 5.6 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.476 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.599 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -170.24 151.53 3.89 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 116.883 -1.927 . . . . 0.0 113.101 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.457 ' CE1' HG11 ' A' ' 25' ' ' VAL . 5.6 p90 -167.64 171.49 10.16 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.32 160.89 30.5 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.729 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.604 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.4 p90 -150.1 160.42 43.67 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.308 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.462 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.4 m-20 -115.62 110.93 19.89 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.428 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -105.6 176.5 22.33 Favored Glycine 0 N--CA 1.501 3.012 0 C-N-CA 119.491 -1.338 . . . . 0.0 111.972 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -127.29 134.47 50.03 Favored 'General case' 0 N--CA 1.482 1.158 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.393 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.743 ' ND1' ' N ' ' A' ' 92' ' ' GLY . 1.7 p80 -150.18 -159.7 1.07 Allowed 'General case' 0 N--CA 1.502 2.145 0 C-N-CA 117.754 -1.579 . . . . 0.0 112.627 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.612 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -127.62 -2.96 6.05 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.115 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.743 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 111.81 90.09 1.92 Allowed Glycine 0 N--CA 1.504 3.226 0 C-N-CA 119.882 -1.152 . . . . 0.0 110.905 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.475 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.6 OUTLIER -165.85 167.47 16.79 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.514 -0.875 . . . . 0.0 110.961 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -70.13 115.63 9.56 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.662 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.637 ' HB2' ' CD ' ' A' ' 48' ' ' GLN . . . -111.28 -3.63 15.26 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.998 -0.681 . . . . 0.0 112.177 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -110.1 107.11 58.68 Favored Pre-proline 0 N--CA 1.492 1.637 0 C-N-CA 119.556 -0.857 . . . . 0.0 111.901 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.447 ' HG2' ' CE1' ' A' ' 100' ' ' PHE . 1.2 Cg_endo -68.16 -145.02 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.675 0 C-N-CA 121.244 1.296 . . . . 0.0 111.287 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.879 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.2 p -116.74 -87.91 0.6 Allowed 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 119.667 -0.813 . . . . 0.0 112.259 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.63 107.11 18.67 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 119.237 -0.985 . . . . 0.0 112.018 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 2.1 m-30 -78.6 -155.98 0.09 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.63 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.9 m -159.53 122.73 3.63 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 117.043 -1.863 . . . . 0.0 113.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.591 HD22 HD21 ' A' ' 103' ' ' ASN . 3.3 mt -60.65 -178.61 0.1 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.564 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.718 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -32.09 -41.24 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -155.69 27.7 0.59 Allowed Glycine 0 N--CA 1.495 2.604 0 C-N-CA 118.593 -1.765 . . . . 0.0 111.352 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.618 ' HB ' ' H ' ' A' ' 6' ' ' ALA . 21.3 p -145.07 151.6 49.02 Favored Pre-proline 0 N--CA 1.494 1.752 0 C-N-CA 119.342 -0.943 . . . . 0.0 110.229 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -62.26 174.49 2.59 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 121.628 1.552 . . . . 0.0 112.451 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.644 ' SG ' HG13 ' A' ' 10' ' ' VAL . 3.0 t -168.19 106.38 0.49 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.471 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 41.4 p -72.63 146.08 46.86 Favored 'General case' 0 N--CA 1.5 2.071 0 C-N-CA 119.971 -0.692 . . . . 0.0 112.403 -179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.879 HG13 ' O ' ' A' ' 98' ' ' THR . 0.1 OUTLIER -59.32 -167.85 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.257 179.803 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 CA-C-O 116.339 -2.367 . . . . 0.0 110.296 179.986 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.162 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.511 ' OG ' ' N ' ' A' ' 3' ' ' SER . 13.5 p 44.98 -142.6 0.22 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.813 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.511 ' N ' ' OG ' ' A' ' 2' ' ' SER . 2.5 m 53.35 77.84 0.16 Allowed 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.381 -0.928 . . . . 0.0 111.005 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.98 -172.97 0.47 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.372 -1.394 . . . . 0.0 110.078 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -67.28 173.98 7.81 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 121.799 1.666 . . . . 0.0 110.819 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.631 ' H ' ' CB ' ' A' ' 105' ' ' THR . . . -110.43 -162.49 0.8 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.445 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -170.69 40.04 0.19 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.6 p -50.88 177.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 114.33 -0.935 . . . . 0.0 112.319 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -131.78 121.64 24.51 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.11 -1.404 . . . . 0.0 109.614 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.491 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 m -112.46 127.01 69.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.155 -1.018 . . . . 0.0 111.603 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.524 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.56 171.38 7.6 Favored 'General case' 0 C--N 1.292 -1.908 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.055 179.881 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.695 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 3.2 t-105 -132.25 149.28 52.41 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.706 -0.798 . . . . 0.0 112.042 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' TRP . . . -130.29 83.55 0.32 Allowed Glycine 0 N--CA 1.497 2.726 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.78 144.75 12.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.421 ' HB3' ' CG2' ' A' ' 22' ' ' THR . 54.0 t30 -148.67 100.72 3.14 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 114.165 -1.38 . . . . 0.0 107.619 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.685 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -102.49 149.61 24.22 Favored 'General case' 0 N--CA 1.494 1.774 0 N-CA-C 114.969 1.47 . . . . 0.0 114.969 -179.568 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.652 ' O ' ' N ' ' A' ' 19' ' ' THR . 30.0 p90 -142.54 117.05 9.69 Favored 'General case' 0 C--N 1.293 -1.876 0 CA-C-N 113.217 -1.81 . . . . 0.0 106.245 179.463 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 52.05 -89.46 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 118.214 -1.394 . . . . 0.0 107.341 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.4 OUTLIER -144.84 106.17 4.22 Favored 'General case' 0 C--N 1.281 -2.411 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 179.505 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.4 ' N ' ' NE2' ' A' ' 90' ' ' HIS . . . 156.22 101.36 0.18 Allowed Glycine 0 C--N 1.272 -2.98 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.685 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 24.2 p90 -95.05 118.17 31.41 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.324 -179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -83.87 165.37 18.8 Favored 'General case' 0 C--N 1.284 -2.256 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.623 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.691 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -145.56 106.34 4.12 Favored 'General case' 0 C--N 1.29 -2.014 0 C-N-CA 118.242 -1.383 . . . . 0.0 111.899 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -93.35 96.84 10.2 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.567 HG11 ' CE1' ' A' ' 84' ' ' PHE . 17.9 t -93.46 147.39 5.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 115.383 -0.826 . . . . 0.0 113.007 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.524 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.3 m -133.36 127.12 32.8 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.5 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -97.73 145.95 8.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.989 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.655 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.2 tptt -126.97 100.56 6.19 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.835 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.69 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -93.7 119.72 33.06 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.561 179.852 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.1 t -130.53 -0.92 4.4 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.541 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 32' ' ' SER . 4.8 p -50.52 -83.01 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.29 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.38 67.78 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.64 -179.943 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -169.09 157.94 7.37 Favored Pre-proline 0 N--CA 1.482 1.127 0 C-N-CA 118.372 -1.331 . . . . 0.0 111.625 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -74.65 95.79 0.96 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.588 1.525 . . . . 0.0 109.052 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -74.47 87.54 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 118.47 -1.292 . . . . 0.0 111.744 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -100.06 56.52 0.95 Allowed 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 115.374 -0.83 . . . . 0.0 108.868 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 105.03 150.28 19.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.908 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 42.0 p-90 -164.14 176.68 9.04 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 117.652 -1.619 . . . . 0.0 112.059 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.5 OUTLIER -141.28 110.11 6.11 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.545 179.907 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.865 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -99.34 177.0 5.33 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.264 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.505 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -162.9 150.77 13.69 Favored 'General case' 0 C--N 1.289 -2.024 0 C-N-CA 117.867 -1.533 . . . . 0.0 112.361 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' ' N ' ' A' ' 43' ' ' SER . 14.4 p90 -174.55 -145.99 0.03 OUTLIER 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.753 -1.567 . . . . 0.0 107.952 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.52 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 41.7 m -161.12 154.12 21.15 Favored 'General case' 0 C--N 1.287 -2.119 0 C-N-CA 117.804 -1.558 . . . . 0.0 111.758 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.502 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -84.61 116.86 67.1 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -57.15 -53.89 4.3 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.16 1.24 . . . . 0.0 112.407 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.531 ' OG ' HG21 ' A' ' 93' ' ' THR . 14.0 t -74.36 -82.77 0.06 Allowed 'General case' 0 C--N 1.294 -1.842 0 C-N-CA 118.958 -1.097 . . . . 0.0 111.087 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 175.45 25.13 0.03 OUTLIER Glycine 0 N--CA 1.486 2.025 0 C-N-CA 119.289 -1.434 . . . . 0.0 110.193 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.442 ' HG3' ' CE1' ' A' ' 21' ' ' PHE . 0.8 OUTLIER -43.04 121.86 2.26 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 119.545 -0.862 . . . . 0.0 110.524 179.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.616 ' CA ' HE21 ' A' ' 49' ' ' GLN . 0.0 OUTLIER -93.81 84.78 4.64 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.129 -1.028 . . . . 0.0 110.959 -179.83 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.511 HG12 HE21 ' A' ' 60' ' ' GLN . 0.5 OUTLIER -64.63 148.57 11.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.554 179.786 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.493 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 76.0 p -137.78 -69.23 0.45 Allowed 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.37 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.493 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.5 mt-30 -73.36 161.51 30.38 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 118.842 -1.143 . . . . 0.0 110.024 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -168.62 142.16 3.05 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.323 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.432 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 38.8 t-105 -146.9 149.09 32.54 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.592 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.432 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 6.3 t 57.11 27.82 14.01 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 119.326 -0.95 . . . . 0.0 109.07 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.588 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 1.0 OUTLIER -174.66 125.42 0.29 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.135 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -87.57 72.34 9.62 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.596 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.484 HG12 HG13 ' A' ' 67' ' ' VAL . 2.6 m -71.92 153.18 7.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.33 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.404 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.0 t -153.95 134.94 13.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.944 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.528 HE22 ' NE2' ' A' ' 49' ' ' GLN . 6.9 tt0 -100.51 120.2 39.65 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.285 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.0 p -100.58 80.48 2.21 Favored 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 119.844 -0.742 . . . . 0.0 110.706 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.56 2.53 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.468 -1.349 . . . . 0.0 109.956 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 41.8 t -146.77 -18.23 0.42 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.967 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.52 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -87.8 -170.66 3.09 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.063 -1.055 . . . . 0.0 110.155 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.592 HG12 ' N ' ' A' ' 66' ' ' THR . 79.1 t -148.02 160.64 7.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 C-N-CA 118.707 -1.197 . . . . 0.0 112.917 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 2.8 m -158.65 125.95 4.94 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 114.392 -1.276 . . . . 0.0 108.642 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.589 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.6 t -116.98 146.68 21.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.08 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.674 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -130.18 92.44 3.29 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.908 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.41 118.2 17.1 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.284 -0.966 . . . . 0.0 112.433 -179.709 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.655 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -42.73 165.65 0.1 OUTLIER Pre-proline 0 N--CA 1.487 1.406 0 CA-C-N 113.578 -1.646 . . . . 0.0 112.483 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.619 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 4.9 Cg_endo -68.71 -33.03 22.34 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.058 1.839 . . . . 0.0 112.583 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.614 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.66 -57.7 4.84 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.477 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.655 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.4 p30 -73.26 -4.43 33.08 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 119.12 -1.032 . . . . 0.0 109.652 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -119.77 50.25 0.83 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.5 t -120.54 57.07 0.97 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 120.029 -0.669 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.543 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.02 134.61 22.13 Favored Pre-proline 0 N--CA 1.486 1.356 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.551 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 79' ' ' GLY . 6.7 Cg_endo -71.52 158.71 53.22 Favored 'Trans proline' 0 C--O 1.214 -0.713 0 C-N-CA 121.464 1.443 . . . . 0.0 112.814 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.449 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -31.44 -29.51 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -115.5 72.9 0.25 Allowed Glycine 0 N--CA 1.497 2.706 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.899 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.33 -167.47 27.03 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.793 -1.67 . . . . 0.0 110.809 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.655 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.5 p -138.35 160.01 40.6 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.088 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -122.56 -176.45 3.38 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.459 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 0.3 OUTLIER -169.37 142.07 2.6 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 117.068 -1.853 . . . . 0.0 113.361 -179.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.567 ' CE1' HG11 ' A' ' 25' ' ' VAL . 7.5 p90 -159.12 174.14 15.34 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.054 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.0 168.33 39.7 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 117.638 -2.22 . . . . 0.0 112.521 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.9 p90 -152.94 -176.36 5.73 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.944 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.501 ' ND2' ' C ' ' A' ' 86' ' ' PHE . 1.2 m120 -138.09 111.66 8.16 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.774 -0.771 . . . . 0.0 110.783 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.504 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -123.42 163.62 16.85 Favored Glycine 0 N--CA 1.507 3.379 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.892 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.6 p -94.87 132.1 40.05 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.796 179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.732 ' O ' HG23 ' A' ' 91' ' ' THR . 6.7 p80 -100.22 -161.55 0.88 Allowed 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.686 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.732 HG23 ' O ' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -166.27 0.92 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.436 179.933 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.451 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 98.71 75.34 1.2 Allowed Glycine 0 N--CA 1.496 2.634 0 C-N-CA 119.673 -1.251 . . . . 0.0 110.309 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.648 HG22 ' H ' ' A' ' 94' ' ' ASN . 1.7 m -163.91 -159.29 0.49 Allowed 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 119.354 -0.939 . . . . 0.0 111.063 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.648 ' H ' HG22 ' A' ' 93' ' ' THR . 0.0 OUTLIER -101.57 127.25 48.36 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.853 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.28 -108.12 0.35 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.935 -0.706 . . . . 0.0 111.585 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.695 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -38.72 109.23 0.5 Allowed Pre-proline 0 N--CA 1.488 1.445 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.961 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.5 Cg_endo -65.29 -142.41 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.739 0 C-N-CA 121.21 1.274 . . . . 0.0 110.772 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.621 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 7.0 p -116.25 -64.63 1.28 Allowed 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 119.45 -0.9 . . . . 0.0 112.593 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.621 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -110.03 112.15 23.97 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.288 -0.965 . . . . 0.0 111.333 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.525 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 8.9 m-85 -84.32 -164.17 0.91 Allowed 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.035 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.2 m -144.52 117.6 8.89 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 118.421 -1.312 . . . . 0.0 112.009 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.788 HD22 ' ND2' ' A' ' 103' ' ' ASN . 1.3 mt -68.38 -178.67 1.14 Allowed 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 119.086 -1.045 . . . . 0.0 108.581 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.788 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.5 OUTLIER -27.69 -37.46 0.01 OUTLIER 'General case' 0 N--CA 1.512 2.631 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . -168.82 55.6 0.21 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.199 -1.477 . . . . 0.0 110.274 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.631 ' CB ' ' H ' ' A' ' 6' ' ' ALA . 2.4 t -174.38 145.81 1.04 Allowed Pre-proline 0 C--O 1.196 -1.726 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.774 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -56.3 168.59 1.96 Allowed 'Trans proline' 0 C--N 1.324 -0.758 0 C-N-CA 121.511 1.474 . . . . 0.0 112.837 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.455 ' SG ' HG13 ' A' ' 10' ' ' VAL . 10.8 t -164.84 95.12 0.7 Allowed 'General case' 0 N--CA 1.494 1.74 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.118 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.463 ' OG1' ' N ' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -51.99 168.45 0.09 Allowed 'General case' 0 N--CA 1.501 2.075 0 C-N-CA 119.795 -0.762 . . . . 0.0 112.203 -179.688 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 1.095 HG22 ' H ' ' A' ' 110' ' ' GLY . 9.4 p -67.77 -151.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.442 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.871 0 CA-C-O 116.281 -2.4 . . . . 0.0 110.125 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.191 0 CA-C-O 120.874 0.369 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.97 19.91 3.88 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.791 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 t -78.54 -69.23 0.58 Allowed 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.41 -0.916 . . . . 0.0 111.103 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.66 72.13 0.02 OUTLIER Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.438 -1.363 . . . . 0.0 110.209 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.484 ' HB2' HG21 ' A' ' 105' ' ' THR . 4.9 Cg_exo -57.28 -80.81 0.01 OUTLIER 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 121.841 1.694 . . . . 0.0 112.206 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.836 ' H ' HG21 ' A' ' 105' ' ' THR . . . -105.32 -160.78 0.77 Allowed 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 122.205 1.002 . . . . 0.0 112.396 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.635 ' O ' ' SG ' ' A' ' 8' ' ' CYS . . . -176.55 -79.79 0.05 OUTLIER Glycine 0 C--O 1.189 -2.714 0 N-CA-C 107.023 -2.431 . . . . 0.0 107.023 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.722 ' C ' ' SG ' ' A' ' 107' ' ' CYS . 6.6 p 63.62 176.97 0.16 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.541 ' N ' ' SG ' ' A' ' 107' ' ' CYS . 55.3 mt-30 -151.27 158.98 44.56 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.482 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.53 ' O ' HG23 ' A' ' 10' ' ' VAL . 2.7 m -141.19 126.54 18.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.954 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.579 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.44 170.65 8.69 Favored 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.023 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.616 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 4.0 t-105 -126.73 144.11 51.04 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 123.895 0.747 . . . . 0.0 112.471 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.31 74.7 0.43 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 107.538 -2.225 . . . . 0.0 107.538 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 15' ' ' ASN . 7.2 p -69.77 152.52 9.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.472 ' N ' HG22 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -149.21 100.06 3.0 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 113.81 -1.541 . . . . 0.0 107.857 179.87 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.742 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -96.83 145.56 25.74 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 114.681 1.364 . . . . 0.0 114.681 -179.593 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.545 ' O ' ' N ' ' A' ' 19' ' ' THR . 16.6 p90 -129.58 -147.51 0.34 Allowed 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 105.777 -1.935 . . . . 0.0 105.777 179.439 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.477 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 74.4 m-20 -67.31 76.73 0.15 Allowed 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 117.717 -1.593 . . . . 0.0 106.783 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.545 ' N ' ' O ' ' A' ' 17' ' ' TRP . 0.5 OUTLIER 65.56 114.07 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.606 ' H ' ' CD2' ' A' ' 90' ' ' HIS . . . 135.62 105.32 0.8 Allowed Glycine 0 C--N 1.275 -2.838 0 N-CA-C 107.089 -2.404 . . . . 0.0 107.089 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.742 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 32.5 p90 -96.56 124.52 40.58 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.654 -0.818 . . . . 0.0 112.047 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.513 HG22 ' O ' ' A' ' 22' ' ' THR . 0.9 OUTLIER -96.04 106.75 18.97 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.563 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.616 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -90.03 120.62 31.39 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -101.78 96.41 7.05 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 179.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 26' ' ' THR . 33.6 t -90.14 154.46 3.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.836 HG23 ' HB3' ' A' ' 83' ' ' GLN . 1.9 m -142.05 101.19 3.88 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.57 -1.195 . . . . 0.0 109.698 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.431 HG13 HG12 ' A' ' 10' ' ' VAL . 3.4 t -75.06 147.81 8.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.184 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.413 ' HA ' HG22 ' A' ' 81' ' ' THR . 5.8 tttp -136.95 105.43 5.78 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.558 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.81 118.72 29.62 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 118.736 -1.186 . . . . 0.0 108.349 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.0 t -118.21 2.15 11.95 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.185 0.928 . . . . 0.0 110.013 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 32' ' ' SER . 14.9 p -54.09 -84.01 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.548 -0.861 . . . . 0.0 110.566 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.646 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.6 OUTLIER 158.77 68.45 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.934 0 O-C-N 123.873 0.733 . . . . 0.0 111.29 -179.953 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.462 ' H ' ' HA ' ' A' ' 78' ' ' ALA . . . -168.16 154.04 6.92 Favored Pre-proline 0 N--CA 1.483 1.192 0 C-N-CA 118.629 -1.228 . . . . 0.0 111.428 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -70.95 93.18 0.63 Allowed 'Trans proline' 0 C--N 1.326 -0.639 0 C-N-CA 121.144 1.23 . . . . 0.0 109.051 179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.456 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -78.33 107.27 10.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.598 -179.852 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -114.41 62.72 0.67 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.22 147.9 20.15 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.894 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 39.6 p-90 -164.45 -179.11 5.8 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.427 -1.309 . . . . 0.0 111.805 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.516 ' O ' ' N ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.29 118.29 12.54 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.257 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.871 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -112.05 174.81 5.7 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 119.474 -0.891 . . . . 0.0 109.412 179.831 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.503 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.0 OUTLIER -166.05 153.68 10.28 Favored 'General case' 0 C--N 1.299 -1.606 0 C-N-CA 117.736 -1.586 . . . . 0.0 112.858 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.509 ' CD2' ' N ' ' A' ' 43' ' ' SER . 13.9 p90 -176.3 -139.67 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 113.809 -1.541 . . . . 0.0 108.22 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.509 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 67.6 m -160.15 172.0 18.23 Favored 'General case' 0 N--CA 1.491 1.61 0 C-N-CA 117.585 -1.646 . . . . 0.0 112.798 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.55 ' CD2' HG21 ' A' ' 65' ' ' VAL . 3.0 m-85 -114.14 96.5 42.41 Favored Pre-proline 0 N--CA 1.497 1.881 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.617 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 4.4 Cg_exo -59.57 -42.95 42.87 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 121.469 1.446 . . . . 0.0 112.209 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.571 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 26.4 t -69.71 -115.7 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.91 -1.116 . . . . 0.0 110.632 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.571 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -145.85 21.22 1.8 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.613 ' NE2' ' HB1' ' A' ' 95' ' ' ALA . 16.4 mt-30 -61.85 89.96 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.689 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.423 ' HA ' ' NE2' ' A' ' 49' ' ' GLN . 2.9 mm100 -88.86 97.18 11.02 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.3 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.583 HG23 ' HB2' ' A' ' 86' ' ' PHE . 1.5 p -68.06 138.25 22.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.651 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 44.0 p -127.19 -65.77 0.93 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.814 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.531 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -81.4 153.34 27.0 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.453 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.412 ' N ' ' HG3' ' A' ' 52' ' ' GLN . . . -162.1 155.05 20.21 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 118.283 -1.367 . . . . 0.0 112.277 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' SER . 39.4 t-105 -157.71 142.41 16.49 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.796 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.482 ' CB ' ' O ' ' A' ' 54' ' ' TRP . 0.2 OUTLIER 75.27 14.31 3.02 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.515 179.931 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.574 ' OG ' HG11 ' A' ' 67' ' ' VAL . 1.4 t -174.32 115.43 0.2 Allowed 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.5 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -71.2 85.52 0.76 Allowed 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.898 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 56' ' ' SER . 1.4 m -86.2 167.36 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.821 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.434 ' O ' ' CG2' ' A' ' 59' ' ' THR . 4.0 t -163.55 133.9 4.4 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.42 -0.809 . . . . 0.0 110.21 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.515 ' NE2' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER -94.42 123.99 38.17 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.733 -179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.629 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 34.0 p -110.01 -151.34 0.47 Allowed 'General case' 0 C--O 1.2 -1.519 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.394 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.529 ' C ' ' N ' ' A' ' 64' ' ' ALA . . . -53.33 84.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.657 0 C-N-CA 118.645 -1.74 . . . . 0.0 109.178 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.618 ' N ' ' O ' ' A' ' 61' ' ' SER . 28.4 m 47.68 13.66 0.04 OUTLIER 'General case' 0 C--N 1.31 -1.118 0 C-N-CA 119.606 -0.837 . . . . 0.0 109.686 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.629 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -109.59 -167.55 1.22 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.427 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.55 HG21 ' CD2' ' A' ' 44' ' ' PHE . 99.3 t -148.71 154.55 9.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 118.664 -1.215 . . . . 0.0 112.586 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.508 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.5 m -156.08 139.14 15.46 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.621 179.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.612 ' HB ' HD22 ' A' ' 40' ' ' LEU . 2.7 t -132.83 156.4 42.25 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.748 0 C-N-CA 119.05 -1.06 . . . . 0.0 112.442 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.421 ' N ' HG12 ' A' ' 67' ' ' VAL . 6.2 mtm180 -139.85 90.21 2.37 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 113.888 -1.505 . . . . 0.0 106.993 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.894 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.21 121.87 21.92 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.854 -179.554 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.028 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -40.93 158.66 0.17 Allowed Pre-proline 0 N--CA 1.482 1.136 0 CA-C-N 113.618 -1.628 . . . . 0.0 112.049 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.42 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 2.8 Cg_endo -65.62 -39.14 22.09 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.921 1.747 . . . . 0.0 111.865 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.722 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.54 -55.88 8.91 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 119.121 -1.031 . . . . 0.0 110.43 -179.887 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 1.028 HD22 ' HB3' ' A' ' 70' ' ' ALA . 1.8 p30 -66.41 -20.8 66.16 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 118.755 -1.178 . . . . 0.0 109.221 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.77 31.77 8.01 Favored Glycine 0 N--CA 1.483 1.802 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 5.1 t -92.12 55.77 2.68 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.616 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -104.76 133.9 19.93 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 119.785 -0.766 . . . . 0.0 110.646 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.46 ' O ' ' N ' ' A' ' 79' ' ' GLY . 11.9 Cg_endo -77.32 163.08 30.49 Favored 'Trans proline' 0 C--O 1.214 -0.695 0 C-N-CA 121.628 1.552 . . . . 0.0 114.07 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.29 -39.35 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 CA-C-N 114.031 -1.441 . . . . 0.0 113.658 179.771 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -123.98 73.37 0.41 Allowed Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.479 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -152.59 -163.18 11.43 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.041 -1.552 . . . . 0.0 110.39 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.563 ' N ' HG13 ' A' ' 76' ' ' ILE . 1.0 OUTLIER -141.8 163.23 33.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.626 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -146.91 99.32 3.17 Favored 'General case' 0 N--CA 1.485 1.278 0 CA-C-N 114.484 -1.235 . . . . 0.0 107.936 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.836 ' HB3' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -94.14 172.7 8.05 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -179.661 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.519 ' CB ' ' HB2' ' A' ' 56' ' ' SER . 34.9 p90 -168.62 -167.93 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 112.633 -2.076 . . . . 0.0 109.482 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 84' ' ' PHE . . . -172.98 158.93 29.14 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 117.483 -2.294 . . . . 0.0 112.555 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.5 p90 -149.69 166.62 28.81 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-N 114.962 -0.619 . . . . 0.0 110.369 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.0 OUTLIER -123.41 110.26 14.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.89 -0.724 . . . . 0.0 110.724 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.553 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -129.62 167.19 21.57 Favored Glycine 0 N--CA 1.505 3.251 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.711 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p -89.96 141.58 28.52 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.133 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.606 ' CD2' ' H ' ' A' ' 20' ' ' GLY . 13.1 p80 -112.66 -160.92 0.73 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 120.009 -0.676 . . . . 0.0 111.436 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.497 HG22 ' C ' ' A' ' 90' ' ' HIS . 0.2 OUTLIER -162.77 -7.65 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.219 179.928 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.469 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 86.55 76.26 1.25 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.723 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.469 ' OG1' ' C ' ' A' ' 92' ' ' GLY . 0.4 OUTLIER -164.87 -175.45 3.77 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.05 179.966 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.617 ' ND2' ' CB ' ' A' ' 45' ' ' PRO . 9.9 t30 -51.84 101.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.112 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.613 ' HB1' ' NE2' ' A' ' 48' ' ' GLN . . . -90.68 -119.24 0.07 Allowed 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.858 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -42.85 113.77 1.39 Allowed Pre-proline 0 C--N 1.307 -1.263 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.496 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.491 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -59.79 -100.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 120.754 0.969 . . . . 0.0 112.445 -179.898 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.849 ' O ' HG13 ' A' ' 109' ' ' VAL . 1.3 p -150.89 -98.86 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.454 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -92.71 95.75 9.75 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 118.492 -1.283 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -65.49 -157.33 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.339 -0.945 . . . . 0.0 108.995 179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.473 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.58 128.5 5.86 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 116.679 -2.008 . . . . 0.0 113.982 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 105' ' ' THR . 2.8 mt -62.86 -173.27 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.398 179.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.66 ' H ' ' ND2' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -32.15 -49.17 0.19 Allowed 'General case' 0 N--CA 1.505 2.3 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -147.95 28.46 1.42 Allowed Glycine 0 N--CA 1.494 2.511 0 C-N-CA 118.847 -1.644 . . . . 0.0 111.411 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.836 HG21 ' H ' ' A' ' 6' ' ' ALA . 0.6 OUTLIER -146.15 155.24 50.82 Favored Pre-proline 0 C--O 1.191 -2.026 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.239 -179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -65.97 -178.14 0.97 Allowed 'Trans proline' 0 C--N 1.321 -0.87 0 C-N-CA 121.781 1.654 . . . . 0.0 112.571 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.722 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 9.7 t -174.45 111.76 0.15 Allowed 'General case' 0 N--CA 1.501 2.097 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.907 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.12 132.36 44.94 Favored 'General case' 0 N--CA 1.515 2.814 0 N-CA-C 114.202 1.186 . . . . 0.0 114.202 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 98' ' ' THR . 0.2 OUTLIER -52.33 174.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 C-N-CA 118.824 -1.15 . . . . 0.0 110.54 179.742 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.161 0 CA-C-O 116.371 -2.35 . . . . 0.0 110.479 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.169 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.9 t -108.3 -72.71 0.71 Allowed 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.8 m 45.41 -122.66 1.04 Allowed 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.64 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.08 156.28 26.8 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 119.106 -1.521 . . . . 0.0 110.502 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -64.46 176.92 2.41 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.755 1.637 . . . . 0.0 111.366 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.595 ' HB1' ' CB ' ' A' ' 31' ' ' SER . . . -98.33 -160.03 0.78 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.484 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.73 55.23 0.21 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.445 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 2.9 p -51.44 177.39 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.187 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.42 116.36 15.94 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.592 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.662 HG12 HG13 ' A' ' 27' ' ' VAL . 3.5 m -110.51 124.16 67.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.256 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -95.11 166.86 11.72 Favored 'General case' 0 C--N 1.29 -1.989 0 C-N-CA 119.154 -1.018 . . . . 0.0 109.582 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.626 ' NE1' ' HB1' ' A' ' 23' ' ' ALA . 1.5 t-105 -134.75 140.05 45.63 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.613 -0.835 . . . . 0.0 111.463 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -122.98 71.22 0.42 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 107.664 -2.174 . . . . 0.0 107.664 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -72.17 147.67 10.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.487 ' HB3' HG22 ' A' ' 22' ' ' THR . 29.7 t30 -150.1 92.55 1.9 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 113.989 -1.459 . . . . 0.0 107.513 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.868 ' H ' ' NE2' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -114.61 145.48 41.93 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 -179.583 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.541 ' CZ2' ' O ' ' A' ' 20' ' ' GLY . 2.3 p90 -104.47 -109.58 0.27 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-N 113.55 -1.659 . . . . 0.0 108.09 179.677 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -62.98 -29.9 71.17 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.044 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.711 HG23 ' N ' ' A' ' 20' ' ' GLY . 9.4 t -176.16 -53.52 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.148 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.711 ' N ' HG23 ' A' ' 19' ' ' THR . . . -38.4 108.22 0.07 OUTLIER Glycine 0 N--CA 1.493 2.461 0 N-CA-C 107.903 -2.079 . . . . 0.0 107.903 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.598 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 20.2 p90 -112.97 113.65 25.79 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 119.598 -0.841 . . . . 0.0 112.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.487 HG22 ' HB3' ' A' ' 15' ' ' ASN . 2.4 t -72.61 171.87 11.67 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.626 ' HB1' ' NE1' ' A' ' 12' ' ' TRP . . . -156.81 113.54 3.06 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 117.385 -1.726 . . . . 0.0 113.19 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 6.1 t30 -98.82 101.17 12.48 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.592 HG11 ' CE1' ' A' ' 84' ' ' PHE . 27.2 t -99.43 143.24 13.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 C-N-CA 119.55 -0.86 . . . . 0.0 112.918 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.562 ' HB ' HD11 ' A' ' 11' ' ' LEU . 1.8 m -132.54 110.77 10.71 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.93 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.662 HG13 HG12 ' A' ' 10' ' ' VAL . 2.1 t -82.0 150.42 4.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 C-N-CA 119.486 -0.885 . . . . 0.0 112.213 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.419 ' HB2' HG22 ' A' ' 81' ' ' THR . 13.3 tttp -138.91 115.77 10.81 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.067 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.433 ' HB2' ' CD1' ' A' ' 76' ' ' ILE . 1.4 t-20 -98.24 109.71 22.42 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.5 t -121.77 -2.08 9.37 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 124.147 0.905 . . . . 0.0 109.78 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.595 ' CB ' ' HB1' ' A' ' 6' ' ' ALA . 1.8 p -58.68 -79.46 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.261 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 162.34 43.21 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.522 -179.857 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.955 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -140.15 145.91 43.87 Favored Pre-proline 0 N--CA 1.487 1.388 0 C-N-CA 118.91 -1.116 . . . . 0.0 111.494 179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -72.4 109.26 2.7 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 121.3 1.334 . . . . 0.0 109.596 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -97.5 112.97 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 C-N-CA 119.001 -1.079 . . . . 0.0 112.211 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -122.35 70.01 0.97 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 141.77 12.1 Favored Glycine 0 C--N 1.294 -1.782 0 N-CA-C 106.657 -2.577 . . . . 0.0 106.657 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CE2' ' CG ' ' A' ' 69' ' ' ASN . 31.0 p-90 -158.88 178.86 9.63 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 117.136 -1.825 . . . . 0.0 112.456 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.55 95.76 3.04 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.057 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.893 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -82.22 168.84 17.23 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 118.223 -1.391 . . . . 0.0 109.469 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.5 m -156.95 149.59 23.45 Favored 'General case' 0 C--N 1.287 -2.152 0 C-N-CA 118.122 -1.431 . . . . 0.0 112.012 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 25.5 p90 -174.03 -149.73 0.04 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 113.808 -1.542 . . . . 0.0 107.996 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 34.1 m -158.96 149.62 19.84 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 117.623 -1.631 . . . . 0.0 112.001 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.456 ' CE2' HG21 ' A' ' 65' ' ' VAL . 7.4 m-85 -78.79 123.55 85.26 Favored Pre-proline 0 C--N 1.307 -1.261 0 C-N-CA 118.326 -1.35 . . . . 0.0 107.712 179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.639 ' CG ' HD22 ' A' ' 94' ' ' ASN . 11.5 Cg_endo -65.72 -63.26 0.07 OUTLIER 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 121.358 1.372 . . . . 0.0 112.226 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.461 ' HB3' ' H ' ' A' ' 94' ' ' ASN . 62.0 p -69.05 -120.68 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.192 0 C-N-CA 118.613 -1.235 . . . . 0.0 110.464 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -132.91 42.68 1.35 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.511 HE22 ' HA ' ' A' ' 95' ' ' ALA . 9.1 mt-30 -84.92 133.07 34.3 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.762 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.52 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -131.56 117.07 18.24 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.801 179.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.464 ' H ' HG12 ' A' ' 50' ' ' VAL . 1.6 p -69.38 155.06 7.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.974 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.554 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.7 p -128.6 -64.85 0.91 Allowed 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.894 -0.723 . . . . 0.0 110.92 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.554 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.6 OUTLIER -95.28 140.46 30.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.601 -0.839 . . . . 0.0 109.446 179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.73 160.72 40.22 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 118.917 -1.113 . . . . 0.0 112.354 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 35.3 t-105 -153.15 143.07 22.16 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.649 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.3 t 60.97 26.56 16.49 Favored 'General case' 0 C--N 1.313 -0.978 0 C-N-CA 119.534 -0.866 . . . . 0.0 109.466 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.419 ' HB2' ' CG1' ' A' ' 67' ' ' VAL . 0.2 OUTLIER -170.97 124.07 0.63 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.717 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.9 m -87.01 75.09 9.58 Favored 'General case' 0 C--N 1.281 -2.384 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.354 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.414 ' C ' HG23 ' A' ' 59' ' ' THR . 16.7 m -69.21 151.1 10.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.256 -0.884 . . . . 0.0 112.462 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.414 HG23 ' C ' ' A' ' 58' ' ' VAL . 37.9 p -155.32 115.31 3.74 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.109 -0.951 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -90.74 124.44 35.11 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 119.11 -1.036 . . . . 0.0 110.612 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.96 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 5.7 p -91.71 75.31 5.77 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.5 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.471 ' C ' ' OG ' ' A' ' 63' ' ' SER . . . 76.18 -42.9 1.69 Allowed Glycine 0 N--CA 1.496 2.661 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.222 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.471 ' OG ' ' C ' ' A' ' 62' ' ' GLY . 0.8 OUTLIER -163.76 -19.01 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.087 -0.645 . . . . 0.0 109.563 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.96 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.33 -169.18 2.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.17 -1.012 . . . . 0.0 109.754 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.587 HG12 ' N ' ' A' ' 66' ' ' THR . 98.3 t -150.33 157.97 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 118.007 -1.477 . . . . 0.0 114.152 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.587 ' N ' HG12 ' A' ' 65' ' ' VAL . 13.4 m -157.86 143.6 17.18 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 113.925 -1.489 . . . . 0.0 108.67 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.569 ' HB ' HD22 ' A' ' 40' ' ' LEU . 3.2 t -139.12 114.74 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 C-N-CA 118.834 -1.147 . . . . 0.0 112.144 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -94.14 89.41 5.98 Favored 'General case' 0 C--N 1.281 -2.374 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.095 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.727 HD21 ' CA ' ' A' ' 74' ' ' GLY . 0.9 OUTLIER -71.75 117.28 13.13 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.021 -1.072 . . . . 0.0 111.909 -179.694 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.769 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -37.6 155.75 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.454 0 CA-C-N 113.622 -1.626 . . . . 0.0 112.297 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -62.47 -36.79 63.78 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.998 1.799 . . . . 0.0 112.312 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.754 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.07 -52.45 28.32 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 118.765 -1.174 . . . . 0.0 110.304 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.769 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -75.56 0.59 16.84 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.004 -1.078 . . . . 0.0 109.686 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.727 ' CA ' HD21 ' A' ' 69' ' ' ASN . . . -118.94 25.41 7.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.6 p -92.73 73.25 4.97 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 119.42 -0.912 . . . . 0.0 111.75 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.549 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -133.89 126.07 18.58 Favored Pre-proline 0 N--CA 1.483 1.206 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.23 179.928 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.615 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.5 Cg_endo -72.41 167.59 26.57 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 120.953 1.102 . . . . 0.0 110.233 179.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.955 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -52.55 1.71 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.655 0 C-N-CA 119.609 -0.836 . . . . 0.0 112.399 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.615 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -128.8 67.29 0.56 Allowed Glycine 0 N--CA 1.496 2.663 0 C-N-CA 119.597 -1.287 . . . . 0.0 109.945 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 178.73 -162.06 28.92 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 118.831 -1.652 . . . . 0.0 110.376 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.549 ' N ' HG13 ' A' ' 76' ' ' ILE . 15.8 p -142.09 166.32 25.04 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.093 -1.043 . . . . 0.0 113.179 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.473 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -128.56 -177.31 4.13 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 113.896 -1.502 . . . . 0.0 107.113 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.421 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 13.0 tt0 -168.21 148.29 4.78 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 116.85 -1.94 . . . . 0.0 113.494 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CE1' HG11 ' A' ' 25' ' ' VAL . 4.0 p90 -161.86 169.83 20.57 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.312 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.62 161.12 32.47 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 117.981 -2.057 . . . . 0.0 112.174 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.5 p90 -155.37 175.08 14.33 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.46 ' ND2' ' OG1' ' A' ' 22' ' ' THR . 10.5 m120 -124.07 109.42 13.47 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.284 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -114.81 174.83 15.63 Favored Glycine 0 N--CA 1.497 2.737 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.678 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . 0.412 ' HA ' ' HA2' ' A' ' 20' ' ' GLY . 29.2 p -136.22 160.56 38.32 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.705 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 91' ' ' THR . 10.1 p80 -158.8 -137.01 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 117.516 -1.674 . . . . 0.0 112.928 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.624 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 3.2 p -146.05 -6.91 0.56 Allowed 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.43 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.465 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 96.38 91.71 1.82 Allowed Glycine 0 N--CA 1.495 2.568 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.94 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.802 HG22 ' H ' ' A' ' 94' ' ' ASN . 99.4 m -162.99 -124.17 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 119.479 -0.889 . . . . 0.0 111.122 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.802 ' H ' HG22 ' A' ' 93' ' ' THR . 1.3 t30 -81.64 119.93 24.43 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 119.776 -0.77 . . . . 0.0 111.078 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.511 ' HA ' HE22 ' A' ' 48' ' ' GLN . . . -91.82 -178.39 5.02 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.222 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.652 ' HB1' ' HZ ' ' A' ' 100' ' ' PHE . . . -34.03 147.26 0.11 Allowed Pre-proline 0 N--CA 1.491 1.58 0 CA-C-N 115.135 -0.939 . . . . 0.0 112.196 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 9.2 Cg_endo -68.86 -151.14 0.03 OUTLIER 'Trans proline' 0 C--O 1.216 -0.585 0 C-N-CA 121.408 1.405 . . . . 0.0 111.594 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.633 ' O ' HG13 ' A' ' 109' ' ' VAL . 9.3 p -120.06 -47.82 2.37 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 119.821 -0.752 . . . . 0.0 111.914 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.433 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -111.5 91.61 3.72 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.939 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.652 ' HZ ' ' HB1' ' A' ' 96' ' ' ALA . 33.7 m-85 -64.18 -164.03 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.36 -0.936 . . . . 0.0 109.066 179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.1 m -146.66 98.9 3.13 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 117.761 -1.576 . . . . 0.0 113.336 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' A' ' 105' ' ' THR . 1.9 mt -51.53 165.85 0.15 Allowed 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 119.304 -0.958 . . . . 0.0 108.655 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.522 HD22 HD22 ' A' ' 102' ' ' LEU . 2.0 p30 -43.03 91.15 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.058 -1.057 . . . . 0.0 110.669 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 68.91 55.88 10.18 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.59 -1.291 . . . . 0.0 110.51 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.594 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.9 OUTLIER 175.97 135.57 0.18 Allowed Pre-proline 0 C--O 1.195 -1.797 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.739 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -58.97 166.86 6.27 Favored 'Trans proline' 0 CA--C 1.54 0.806 0 C-N-CA 121.568 1.512 . . . . 0.0 112.818 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.511 ' SG ' HG13 ' A' ' 10' ' ' VAL . 9.0 t -165.53 102.36 0.71 Allowed 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.94 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 p -58.68 173.37 0.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.211 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.633 HG13 ' O ' ' A' ' 98' ' ' THR . 16.3 m -64.26 -143.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.66 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.486 2.002 0 CA-C-O 116.32 -2.378 . . . . 0.0 110.227 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.79 121.84 11.41 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.7 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.07 -40.25 95.18 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.046 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.24 -150.78 20.78 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.164 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.44 ' HB2' ' CG2' ' A' ' 105' ' ' THR . 3.3 Cg_exo -60.71 -79.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.322 -0.822 0 C-N-CA 121.375 1.383 . . . . 0.0 111.252 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.601 ' H ' HG22 ' A' ' 105' ' ' THR . . . -109.23 -156.33 0.58 Allowed 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.937 -0.705 . . . . 0.0 110.971 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.44 45.42 0.04 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.917 ' SG ' HD12 ' A' ' 102' ' ' LEU . 4.3 p -50.94 175.12 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 69.0 mt-30 -138.27 118.64 13.73 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.714 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.673 HG12 HG13 ' A' ' 27' ' ' VAL . 3.1 m -109.57 124.47 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.861 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.558 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -98.72 163.3 12.69 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.966 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.591 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 6.1 t-105 -115.82 143.19 45.75 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.857 -0.737 . . . . 0.0 111.871 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 74.03 0.39 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.798 ' CG2' HE22 ' A' ' 16' ' ' GLN . 8.2 p -68.73 141.71 17.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 C-N-CA 119.826 -0.749 . . . . 0.0 112.597 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -145.19 80.24 1.6 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.006 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.798 HE22 ' CG2' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -64.94 130.21 42.58 Favored 'General case' 0 N--CA 1.496 1.855 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.85 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.564 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 19.0 p90 -103.86 -43.65 5.26 Favored 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.344 -0.942 . . . . 0.0 110.137 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.564 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 46.5 t-20 -148.35 -19.71 0.33 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.713 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -177.16 -56.66 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.734 0 CA-C-N 114.034 -1.439 . . . . 0.0 108.006 179.919 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.713 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -63.31 168.47 20.82 Favored Glycine 0 C--N 1.295 -1.711 0 N-CA-C 107.748 -2.141 . . . . 0.0 107.748 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.625 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 2.8 p90 -138.45 133.18 32.44 Favored 'General case' 0 C--N 1.29 -1.986 0 C-N-CA 119.149 -1.02 . . . . 0.0 112.598 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.458 HG22 ' O ' ' A' ' 22' ' ' THR . 0.6 OUTLIER -87.96 118.93 27.84 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 179.577 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.591 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -96.96 110.58 23.08 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 119.239 -0.984 . . . . 0.0 113.517 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -92.77 100.42 12.91 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.599 HG11 ' CE2' ' A' ' 84' ' ' PHE . 23.4 t -93.51 145.43 7.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 119.236 -0.985 . . . . 0.0 113.583 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.595 HG23 ' HB2' ' A' ' 83' ' ' GLN . 1.7 m -135.52 109.94 8.47 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.239 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.673 HG13 HG12 ' A' ' 10' ' ' VAL . 0.3 OUTLIER -81.02 151.4 4.43 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 C-N-CA 119.501 -0.88 . . . . 0.0 111.816 -179.855 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.648 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.1 OUTLIER -136.92 98.23 3.71 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.535 179.729 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.48 101.22 13.71 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.216 -0.994 . . . . 0.0 108.369 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -114.19 1.85 14.66 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.349 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 32' ' ' SER . 3.1 p -61.7 -79.64 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.61 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.634 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 160.91 75.24 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 120.064 -0.654 . . . . 0.0 111.535 -179.935 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -167.32 152.44 6.98 Favored Pre-proline 0 C--N 1.31 -1.152 0 C-N-CA 118.665 -1.214 . . . . 0.0 111.587 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -72.72 94.64 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.71 0 N-CA-C 108.672 -1.318 . . . . 0.0 108.672 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.23 102.5 5.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 118.31 -1.356 . . . . 0.0 111.698 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -119.92 57.36 0.93 Allowed 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.97 148.76 18.34 Favored Glycine 0 N--CA 1.486 1.982 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.787 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 43.7 p-90 -167.08 175.89 7.24 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.39 -1.324 . . . . 0.0 111.637 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -139.34 109.81 6.59 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.699 179.969 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -99.54 174.94 6.01 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.324 -0.95 . . . . 0.0 109.656 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.479 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.2 m -161.65 150.09 15.46 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 117.874 -1.53 . . . . 0.0 112.719 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 43' ' ' SER . 12.9 p90 -175.6 -130.43 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.039 -1.437 . . . . 0.0 108.596 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.498 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 3.5 m -167.13 176.9 6.52 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 117.819 -1.553 . . . . 0.0 112.495 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.662 ' CD2' HG21 ' A' ' 65' ' ' VAL . 2.2 m-85 -117.14 87.81 24.74 Favored Pre-proline 0 N--CA 1.492 1.665 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.605 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -59.03 -27.45 85.06 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 121.786 1.657 . . . . 0.0 112.499 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.535 ' N ' ' O ' ' A' ' 94' ' ' ASN . 0.9 OUTLIER -69.59 -13.37 62.29 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.731 179.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 78.99 19.78 71.85 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.742 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.517 ' OE1' ' CZ ' ' A' ' 21' ' ' PHE . 21.7 mt-30 -73.85 177.12 5.76 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.631 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.746 HE22 ' CG2' ' A' ' 51' ' ' THR . 0.0 OUTLIER -141.77 111.26 6.5 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.452 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 50' ' ' VAL . 2.4 p -76.07 155.13 5.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.861 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.746 ' CG2' HE22 ' A' ' 49' ' ' GLN . 64.8 p -138.66 -68.1 0.45 Allowed 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.489 -0.884 . . . . 0.0 111.314 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.433 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.1 mt-30 -82.88 131.01 35.21 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.056 -1.058 . . . . 0.0 110.423 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -143.44 152.81 41.98 Favored 'General case' 0 N--CA 1.49 1.575 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.65 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 39.5 t-105 -154.73 144.48 21.57 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.004 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 69.0 18.81 8.33 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.071 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.615 ' OG ' ' CG ' ' A' ' 84' ' ' PHE . 3.3 m -172.23 111.12 0.26 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.115 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.2 m -69.93 79.79 0.47 Allowed 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.484 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.657 HG12 HG13 ' A' ' 67' ' ' VAL . 9.5 m -81.05 155.95 4.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.067 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.446 ' O ' ' CG2' ' A' ' 59' ' ' THR . 1.6 t -155.43 129.88 9.03 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.21 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -95.68 114.21 25.93 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.518 -0.873 . . . . 0.0 111.043 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.8 p -91.1 78.23 5.92 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.683 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.89 -68.28 2.26 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.095 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -142.08 -15.77 0.78 Allowed 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.188 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.498 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -92.63 -170.81 2.57 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.662 HG21 ' CD2' ' A' ' 44' ' ' PHE . 54.1 t -145.78 160.83 11.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 C-N-CA 118.838 -1.145 . . . . 0.0 113.029 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.4 m -161.07 127.36 3.92 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.121 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 58' ' ' VAL . 2.0 t -122.54 147.53 26.65 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.088 0 C-N-CA 119.341 -0.944 . . . . 0.0 111.845 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 mtm-85 -129.38 92.73 3.41 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.787 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 8.6 p-10 -72.81 122.05 20.93 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.272 -0.971 . . . . 0.0 112.445 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.766 ' HB3' ' OD1' ' A' ' 73' ' ' ASN . . . -48.25 156.69 0.75 Allowed Pre-proline 0 C--N 1.305 -1.343 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.316 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.98 -36.81 81.08 Favored 'Trans proline' 0 C--N 1.325 -0.706 0 C-N-CA 121.895 1.73 . . . . 0.0 112.628 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.654 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -69.71 -56.27 7.68 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 118.733 -1.187 . . . . 0.0 110.61 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.766 ' OD1' ' HB3' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -72.33 7.7 1.66 Allowed 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 118.997 -1.081 . . . . 0.0 109.714 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -137.05 33.82 2.27 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 27.9 t -99.94 59.72 1.06 Allowed 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.846 -0.742 . . . . 0.0 111.298 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.542 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -114.01 135.86 22.12 Favored Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.808 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' GLY . 10.2 Cg_endo -73.44 158.91 47.45 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 121.631 1.554 . . . . 0.0 114.027 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.634 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -27.37 -32.73 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 CA-C-N 113.888 -1.505 . . . . 0.0 114.758 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -116.52 68.82 0.29 Allowed Glycine 0 N--CA 1.503 3.125 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.968 -179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.15 23.19 Favored Glycine 0 C--N 1.29 -1.992 0 C-N-CA 118.637 -1.744 . . . . 0.0 110.695 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.648 HG22 ' HA ' ' A' ' 28' ' ' LYS . 6.3 p -138.08 162.9 32.97 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 119.691 -0.804 . . . . 0.0 112.008 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -128.36 169.54 14.13 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.595 ' HB2' HG23 ' A' ' 26' ' ' THR . 0.7 OUTLIER -160.45 142.08 12.44 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 117.016 -1.874 . . . . 0.0 113.486 -179.842 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.615 ' CG ' ' OG ' ' A' ' 56' ' ' SER . 13.5 p90 -154.7 177.36 11.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 114.33 -1.305 . . . . 0.0 109.296 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.72 159.69 33.05 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 117.604 -2.236 . . . . 0.0 112.135 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.674 ' C ' HD22 ' A' ' 87' ' ' ASN . 0.9 OUTLIER -145.17 -178.36 6.02 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.798 179.923 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.674 HD22 ' C ' ' A' ' 86' ' ' PHE . 1.0 OUTLIER -133.62 110.53 9.95 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.089 179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -113.91 173.43 14.96 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.899 -1.143 . . . . 0.0 111.278 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.0 p -115.51 140.04 49.51 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 120.4 -0.52 . . . . 0.0 109.828 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.648 ' C ' ' ND1' ' A' ' 90' ' ' HIS . 0.1 OUTLIER -150.29 -175.8 5.22 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 118.241 -1.384 . . . . 0.0 112.28 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.561 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 26.1 p -123.68 -3.21 8.28 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.304 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.533 ' N ' ' ND1' ' A' ' 90' ' ' HIS . . . 106.17 95.69 2.41 Favored Glycine 0 N--CA 1.499 2.836 0 C-N-CA 119.889 -1.148 . . . . 0.0 110.836 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.474 HG22 ' H ' ' A' ' 94' ' ' ASN . 2.0 m -163.78 175.93 10.02 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.076 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -71.21 112.73 7.59 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.895 -179.961 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -106.94 -99.47 0.35 Allowed 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.53 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.417 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -34.89 102.55 0.23 Allowed Pre-proline 0 N--CA 1.491 1.609 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.876 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.453 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.3 Cg_endo -66.3 -142.85 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 121.169 1.246 . . . . 0.0 110.999 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.404 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 42.5 p -111.73 -88.12 0.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.642 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.404 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -97.56 105.54 17.71 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.008 -1.077 . . . . 0.0 112.146 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.564 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.0 m-30 -74.9 -146.26 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.528 -0.869 . . . . 0.0 108.995 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.72 98.87 1.96 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 117.369 -1.733 . . . . 0.0 113.775 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.917 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -53.17 172.15 0.06 Allowed 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.812 HD22 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.22 86.83 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 118.944 -1.102 . . . . 0.0 110.488 179.891 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 76.07 42.86 23.31 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.62 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.612 ' O ' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -169.92 138.65 1.51 Allowed Pre-proline 0 C--O 1.196 -1.733 0 C-N-CA 119.493 -0.883 . . . . 0.0 110.818 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -64.72 154.8 70.64 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 121.137 1.225 . . . . 0.0 111.677 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.459 ' SG ' HG13 ' A' ' 10' ' ' VAL . 2.7 t -151.11 104.43 3.13 Favored 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 119.424 -0.91 . . . . 0.0 110.908 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.51 157.37 11.54 Favored 'General case' 0 N--CA 1.5 2.05 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.019 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.896 HG13 ' N ' ' A' ' 110' ' ' GLY . 6.1 p -70.44 -140.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.234 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.896 ' N ' HG13 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.278 0 CA-C-O 116.342 -2.366 . . . . 0.0 110.446 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.166 0 CA-C-O 120.834 0.349 . . . . 0.0 110.082 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.2 m -153.82 -70.89 0.14 Allowed 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.822 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -175.2 -42.47 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.859 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.7 -178.51 21.7 Favored Glycine 0 N--CA 1.492 2.411 0 C-N-CA 119.455 -1.355 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -55.05 -80.87 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.042 1.828 . . . . 0.0 111.857 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.37 -169.0 1.38 Allowed 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.946 -0.702 . . . . 0.0 111.604 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 175.03 41.55 0.05 OUTLIER Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.709 -2.157 . . . . 0.0 107.709 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.664 ' SG ' HD12 ' A' ' 102' ' ' LEU . 26.7 p -56.45 -167.94 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 114.252 -0.974 . . . . 0.0 111.469 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.587 ' NE2' ' NZ ' ' A' ' 28' ' ' LYS . 2.0 pt20 -159.15 152.67 22.76 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 118.984 -1.086 . . . . 0.0 110.402 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' A' ' 110' ' ' GLY . 1.1 m -137.29 133.77 46.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.2 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.56 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -101.42 164.83 11.57 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.968 179.855 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.609 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.6 t-105 -118.9 142.86 47.37 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.927 -0.709 . . . . 0.0 112.072 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.76 76.58 0.38 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 107.804 -2.119 . . . . 0.0 107.804 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -69.16 150.97 10.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 119.622 -0.831 . . . . 0.0 113.0 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.418 ' CB ' HG22 ' A' ' 22' ' ' THR . 10.9 t-20 -158.23 69.45 0.51 Allowed 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 114.321 -1.309 . . . . 0.0 108.534 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.891 ' H ' ' NE2' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -104.55 148.38 26.57 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.972 -179.719 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.634 ' C ' ' H ' ' A' ' 19' ' ' THR . 8.0 p90 -102.97 -136.11 0.33 Allowed 'General case' 0 N--CA 1.493 1.699 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.39 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -50.68 -13.88 0.16 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.679 179.745 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.696 ' CG2' ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER 168.6 -179.59 0.03 OUTLIER 'General case' 0 C--N 1.282 -2.342 0 CA-C-N 112.97 -1.923 . . . . 0.0 107.309 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.696 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 74.39 97.0 0.1 Allowed Glycine 0 C--N 1.279 -2.638 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.563 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 23.7 p90 -108.85 123.6 49.31 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' CB ' ' A' ' 15' ' ' ASN . 0.6 OUTLIER -81.13 153.25 27.38 Favored 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 105.433 -2.062 . . . . 0.0 105.433 179.447 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -128.79 108.9 10.83 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.378 -1.329 . . . . 0.0 112.657 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -95.74 94.91 7.96 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 84' ' ' PHE . 36.9 t -91.92 154.14 3.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.296 -0.962 . . . . 0.0 112.452 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.56 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.2 m -139.36 104.11 4.89 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.222 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 27' ' ' VAL . 1.5 t -74.8 148.81 7.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 C-N-CA 119.732 -0.787 . . . . 0.0 112.17 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.632 ' HA ' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -136.21 96.09 3.32 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.784 179.693 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.427 ' ND2' ' OG ' ' A' ' 31' ' ' SER . 1.9 t30 -88.28 106.98 18.58 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.883 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.6 t -113.45 5.52 16.76 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.835 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.5 ' O ' ' CB ' ' A' ' 32' ' ' SER . 12.6 p -54.17 -84.9 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.894 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.59 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 162.01 65.39 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.752 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB1' ' HD2' ' A' ' 34' ' ' PRO . . . -170.44 160.2 6.17 Favored Pre-proline 0 N--CA 1.486 1.331 0 C-N-CA 118.804 -1.158 . . . . 0.0 111.413 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.44 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 7.1 Cg_endo -71.72 95.07 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.484 1.456 . . . . 0.0 109.571 179.571 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.1 t -75.13 79.79 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 C-N-CA 118.87 -1.132 . . . . 0.0 112.301 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -91.46 57.41 3.31 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.431 -0.908 . . . . 0.0 108.714 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 106.62 157.83 21.5 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.777 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 48.0 p-90 -171.58 178.82 3.03 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 117.752 -1.579 . . . . 0.0 112.382 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.537 ' H ' HD22 ' A' ' 103' ' ' ASN . 0.2 OUTLIER -141.18 115.63 9.48 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.017 179.779 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.844 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -106.35 176.43 5.17 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.1 179.834 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.624 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.1 m -167.18 152.44 7.43 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 117.5 -1.68 . . . . 0.0 113.009 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.447 ' CD2' ' N ' ' A' ' 43' ' ' SER . 19.4 p90 -176.79 -137.48 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 113.756 -1.566 . . . . 0.0 108.161 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.566 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 6.8 m -165.71 168.55 16.06 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 117.665 -1.614 . . . . 0.0 112.604 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.513 ' CE2' HG21 ' A' ' 65' ' ' VAL . 8.4 m-85 -102.16 108.12 55.61 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.71 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.513 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 2.9 Cg_exo -55.98 -66.79 0.08 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.051 1.168 . . . . 0.0 111.726 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.478 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 35.2 t -70.28 -171.91 0.52 Allowed 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.526 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.478 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -79.36 49.07 3.51 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.198 -1.477 . . . . 0.0 109.915 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -86.18 109.86 19.18 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.445 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.726 ' CD ' ' H ' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -113.91 130.4 56.51 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.729 179.978 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 51' ' ' THR . 5.2 p -96.41 159.51 2.98 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.083 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 30.4 p -133.09 -65.77 0.69 Allowed 'General case' 0 N--CA 1.496 1.854 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.707 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.581 ' N ' ' OG1' ' A' ' 51' ' ' THR . 3.5 mt-30 -81.72 166.5 20.03 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.282 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -169.29 148.48 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 118.976 -1.09 . . . . 0.0 111.454 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.462 ' CD1' ' HB3' ' A' ' 55' ' ' SER . 36.8 t-105 -150.6 141.42 22.81 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.001 -1.079 . . . . 0.0 111.645 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.462 ' HB3' ' CD1' ' A' ' 54' ' ' TRP . 0.9 OUTLIER 63.8 20.92 12.45 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.311 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.642 ' O ' HG13 ' A' ' 58' ' ' VAL . 1.2 m -165.06 109.31 0.89 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.422 -0.911 . . . . 0.0 110.381 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.7 m -70.57 78.36 0.58 Allowed 'General case' 0 C--N 1.285 -2.216 0 C-N-CA 119.351 -0.94 . . . . 0.0 110.126 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.642 HG13 ' O ' ' A' ' 56' ' ' SER . 1.0 OUTLIER -81.48 162.34 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.259 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.461 -179.899 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.429 ' O ' ' CG2' ' A' ' 59' ' ' THR . 3.9 t -160.55 133.92 6.75 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.348 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.94 108.83 18.98 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.734 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.5 p -93.34 75.5 4.54 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.476 -0.889 . . . . 0.0 110.875 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 63' ' ' SER . . . 53.56 74.27 0.32 Allowed Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.357 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 62' ' ' GLY . 0.3 OUTLIER 76.17 -35.91 0.26 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.491 -179.977 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.566 ' CB ' ' OG ' ' A' ' 43' ' ' SER . . . -81.67 -171.06 3.13 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 118.954 -1.098 . . . . 0.0 110.666 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.537 HG12 ' N ' ' A' ' 66' ' ' THR . 77.4 t -149.71 157.62 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 118.725 -1.19 . . . . 0.0 113.05 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.624 HG23 ' OG1' ' A' ' 41' ' ' THR . 35.9 m -156.69 131.9 9.18 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 114.234 -1.348 . . . . 0.0 107.96 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.607 HG23 HD21 ' A' ' 40' ' ' LEU . 2.0 t -126.07 146.98 30.95 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.07 0 C-N-CA 119.326 -0.95 . . . . 0.0 112.225 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -130.46 93.22 3.4 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.777 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -72.7 124.31 25.05 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.373 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.053 ' HB3' HD22 ' A' ' 73' ' ' ASN . . . -46.52 162.98 0.24 Allowed Pre-proline 0 C--N 1.308 -1.198 0 CA-C-N 113.719 -1.582 . . . . 0.0 111.593 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 3.2 Cg_endo -67.12 -39.13 14.12 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.897 1.731 . . . . 0.0 111.933 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.698 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -69.38 -56.06 8.56 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.246 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 1.053 HD22 ' HB3' ' A' ' 70' ' ' ALA . 2.0 p30 -70.63 -5.75 31.73 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 118.792 -1.163 . . . . 0.0 109.024 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.553 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . -119.62 48.13 0.97 Allowed Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -112.67 74.33 0.86 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.099 -0.641 . . . . 0.0 110.971 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.623 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -130.69 132.28 23.84 Favored Pre-proline 0 CA--C 1.56 1.352 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.94 179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.433 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.4 Cg_endo -71.18 159.24 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 122.023 1.815 . . . . 0.0 114.498 -179.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.59 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -26.24 -40.18 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.679 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -114.76 68.84 0.26 Allowed Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.77 -1.205 . . . . 0.0 111.038 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.78 -168.83 18.68 Favored Glycine 0 C--N 1.29 -2.023 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.002 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.632 HG22 ' HA ' ' A' ' 28' ' ' LYS . 7.6 p -137.1 166.39 23.82 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.818 0.818 . . . . 0.0 112.364 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.556 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -138.38 162.41 34.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.541 ' HG3' HG23 ' A' ' 26' ' ' THR . 1.4 mp0 -139.52 158.2 44.53 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 118.114 -1.434 . . . . 0.0 113.355 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 25' ' ' VAL . 1.6 p90 -171.03 161.86 6.99 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.146 -1.388 . . . . 0.0 110.103 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.57 169.81 37.15 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 117.438 -2.315 . . . . 0.0 112.741 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 1.1 p90 -150.97 -176.94 5.73 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.347 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.561 HD22 ' C ' ' A' ' 86' ' ' PHE . 0.6 OUTLIER -128.82 104.68 7.76 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.622 179.842 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.34 175.51 15.74 Favored Glycine 0 N--CA 1.498 2.769 0 C-N-CA 120.058 -1.068 . . . . 0.0 111.41 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . 0.516 ' O ' ' NE2' ' A' ' 49' ' ' GLN . 2.7 p -126.26 156.77 39.79 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.221 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.731 ' HE2' ' HG3' ' A' ' 16' ' ' GLN . 4.7 p80 -153.79 -150.73 0.34 Allowed 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.485 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.545 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 55.6 p -147.89 -2.6 0.54 Allowed 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' C ' ' OG1' ' A' ' 93' ' ' THR . . . 99.04 83.83 1.75 Allowed Glycine 0 N--CA 1.497 2.732 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.888 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.568 HG22 ' H ' ' A' ' 94' ' ' ASN . 2.0 m -163.87 -149.37 0.13 Allowed 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.527 -0.869 . . . . 0.0 110.869 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.568 ' H ' HG22 ' A' ' 93' ' ' THR . 40.3 t30 -73.16 120.91 19.43 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.896 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -110.3 -115.11 0.31 Allowed 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.994 -0.682 . . . . 0.0 111.96 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.609 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -50.19 118.07 8.64 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.295 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.443 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 2.6 Cg_endo -65.63 -143.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 121.093 1.195 . . . . 0.0 110.442 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.758 ' O ' HG13 ' A' ' 109' ' ' VAL . 27.0 p -104.39 -101.1 0.31 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.355 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.89 109.6 20.82 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 118.711 -1.196 . . . . 0.0 112.537 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.664 ' CZ ' ' CG1' ' A' ' 109' ' ' VAL . 4.1 m-30 -76.1 -149.76 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.45 ' OG ' ' C ' ' A' ' 100' ' ' PHE . 0.7 OUTLIER -158.87 116.27 2.8 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 117.107 -1.837 . . . . 0.0 113.696 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.664 HD12 ' SG ' ' A' ' 8' ' ' CYS . 2.1 mt -58.81 -172.53 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.114 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.537 HD22 ' H ' ' A' ' 39' ' ' THR . 3.5 p30 -65.99 76.53 0.08 Allowed 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.919 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 102.22 10.7 38.5 Favored Glycine 0 N--CA 1.5 2.913 0 C-N-CA 119.521 -1.323 . . . . 0.0 112.374 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.593 ' O ' ' N ' ' A' ' 102' ' ' LEU . 62.3 p -150.46 151.14 30.46 Favored Pre-proline 0 N--CA 1.495 1.796 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -66.51 171.53 10.51 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.583 1.522 . . . . 0.0 112.388 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.62 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.8 t -165.85 111.13 0.86 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.088 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 9' ' ' GLN . 1.1 p -72.58 128.11 34.59 Favored 'General case' 0 N--CA 1.506 2.354 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.758 HG13 ' O ' ' A' ' 98' ' ' THR . 0.9 OUTLIER -54.45 178.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 C-N-CA 118.793 -1.163 . . . . 0.0 110.531 179.796 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 10' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.287 0 CA-C-O 116.379 -2.345 . . . . 0.0 110.324 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 CA-C-O 120.853 0.359 . . . . 0.0 110.058 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.4 t 44.42 -105.69 0.09 Allowed 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.786 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 t 174.36 105.65 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.316 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.768 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.67 104.05 1.86 Allowed Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.414 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -62.23 -152.26 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 121.45 1.434 . . . . 0.0 111.606 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.418 ' HB3' ' HB ' ' A' ' 105' ' ' THR . . . -66.35 -145.5 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.994 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.2 50.45 0.02 OUTLIER Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.722 ' SG ' HD12 ' A' ' 102' ' ' LEU . 2.7 p -52.31 178.38 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.771 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.402 HE21 ' HD3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -137.72 110.67 7.72 Favored 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.894 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.58 HG13 ' SG ' ' A' ' 107' ' ' CYS . 3.5 m -101.75 125.79 55.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 C-N-CA 119.419 -0.912 . . . . 0.0 110.2 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.549 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -104.81 133.96 48.75 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.28 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.528 ' CE3' ' HB2' ' A' ' 96' ' ' ALA . 1.4 t-105 -95.17 139.68 31.16 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.296 -0.962 . . . . 0.0 111.911 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.14 73.12 0.44 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 21' ' ' PHE . 0.6 OUTLIER -69.73 159.75 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.262 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.526 ' CB ' HG22 ' A' ' 22' ' ' THR . 1.3 t30 -170.05 97.43 0.28 Allowed 'General case' 0 C--N 1.302 -1.461 0 CA-C-N 113.974 -1.466 . . . . 0.0 108.549 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.891 HE21 ' H ' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -124.86 165.77 17.46 Favored 'General case' 0 N--CA 1.496 1.865 0 CA-C-O 122.391 1.091 . . . . 0.0 113.58 -179.693 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.48 ' O ' ' CB ' ' A' ' 18' ' ' ASN . 7.0 p90 -124.32 75.34 1.38 Allowed 'General case' 0 C--N 1.29 -2.004 0 CA-C-N 112.875 -1.966 . . . . 0.0 108.938 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.505 ' N ' ' ND2' ' A' ' 18' ' ' ASN . 0.4 OUTLIER 78.19 -56.51 0.48 Allowed 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 m -149.42 121.83 8.47 Favored 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.716 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.41 ' O ' ' CE2' ' A' ' 17' ' ' TRP . . . 113.53 90.41 1.83 Allowed Glycine 0 C--N 1.284 -2.312 0 N-CA-C 105.719 -2.952 . . . . 0.0 105.719 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 22.0 p90 -109.47 118.37 36.44 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-O 121.906 0.86 . . . . 0.0 113.264 -179.64 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 15' ' ' ASN . 7.5 t -73.26 162.99 28.74 Favored 'General case' 0 C--N 1.283 -2.287 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.33 117.94 10.38 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.048 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.832 HD21 HE21 ' A' ' 83' ' ' GLN . 1.4 t-20 -100.86 99.17 9.63 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.316 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.748 HG11 ' CE2' ' A' ' 84' ' ' PHE . 6.1 t -99.39 136.1 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 119.726 -0.789 . . . . 0.0 112.25 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.549 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.7 m -130.03 108.88 10.42 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.738 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.574 HG13 HG12 ' A' ' 10' ' ' VAL . 1.7 t -78.03 149.87 5.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.903 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.845 ' HA ' HG22 ' A' ' 81' ' ' THR . 3.6 tttt -133.17 96.06 3.67 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.831 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.39 96.75 7.45 Favored 'General case' 0 C--N 1.291 -1.964 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.038 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.5 t -111.65 6.11 19.71 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.334 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.495 ' O ' ' CB ' ' A' ' 32' ' ' SER . 1.7 p -71.93 -78.31 0.08 Allowed 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.332 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.62 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 158.27 78.18 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 O-C-N 123.906 0.754 . . . . 0.0 111.498 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -166.17 145.08 4.89 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 118.648 -1.221 . . . . 0.0 111.373 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -68.91 97.34 0.56 Allowed 'Trans proline' 0 N--CA 1.456 -0.719 0 N-CA-C 108.172 -1.511 . . . . 0.0 108.172 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 35' ' ' VAL . 0.6 OUTLIER -86.38 100.25 9.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 C-N-CA 118.194 -1.402 . . . . 0.0 112.029 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -113.71 55.3 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.85 148.7 14.25 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.916 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 43.3 p-90 -163.55 176.68 9.47 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.964 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 67' ' ' VAL . 0.3 OUTLIER -140.54 109.53 6.08 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.805 179.901 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.868 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.61 173.22 7.02 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.537 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.474 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 1.3 m -155.49 148.09 24.08 Favored 'General case' 0 C--N 1.302 -1.483 0 C-N-CA 118.023 -1.471 . . . . 0.0 112.882 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.569 ' CD2' ' N ' ' A' ' 43' ' ' SER . 16.3 p90 -174.51 -141.54 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 113.999 -1.455 . . . . 0.0 108.417 179.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.569 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 19.5 m -163.17 173.11 13.85 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 117.625 -1.63 . . . . 0.0 112.921 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.561 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 5.3 m-85 -111.12 98.46 39.29 Favored Pre-proline 0 N--CA 1.491 1.575 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.015 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -53.31 -55.15 3.9 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.007 1.138 . . . . 0.0 111.301 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.56 ' N ' HD22 ' A' ' 94' ' ' ASN . 62.2 p -74.15 -179.83 4.05 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.101 -1.04 . . . . 0.0 109.794 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -77.71 41.79 1.95 Allowed Glycine 0 N--CA 1.484 1.864 0 C-N-CA 118.863 -1.637 . . . . 0.0 109.494 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.69 ' NE2' ' HB2' ' A' ' 95' ' ' ALA . 8.7 mt-30 -78.05 108.53 11.4 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.557 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -116.55 109.85 17.79 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.207 179.91 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.602 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.1 p -68.45 164.54 2.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.089 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.602 ' N ' ' CG2' ' A' ' 50' ' ' VAL . 36.8 p -137.5 -63.92 0.57 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.626 -0.829 . . . . 0.0 110.986 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.523 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -97.59 137.11 37.02 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.709 179.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.52 159.15 42.8 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.726 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.402 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 36.2 t-105 -155.02 141.73 18.96 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.988 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.402 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 1.0 OUTLIER 67.12 23.84 9.49 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.091 -179.999 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.478 ' HB3' ' CG ' ' A' ' 84' ' ' PHE . 2.1 p -172.8 110.4 0.21 Allowed 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.249 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.4 m -71.46 74.64 0.76 Allowed 'General case' 0 C--N 1.284 -2.239 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.07 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.541 HG12 HG13 ' A' ' 67' ' ' VAL . 13.4 m -69.6 155.05 7.9 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.953 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 65.5 p -152.6 112.5 3.97 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.196 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -78.57 104.91 9.49 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.001 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.584 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.1 p -85.72 -160.89 0.56 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.948 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.628 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -50.84 88.22 0.01 OUTLIER Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.139 -1.505 . . . . 0.0 109.655 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.1 OUTLIER 53.22 4.19 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.707 -179.828 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.628 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.51 -169.27 1.6 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.555 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.561 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 77.9 t -143.17 154.22 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 C-N-CA 119.119 -1.033 . . . . 0.0 112.691 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.477 ' N ' HG12 ' A' ' 65' ' ' VAL . 15.6 m -158.01 127.83 6.01 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.551 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.594 HG23 HD21 ' A' ' 40' ' ' LEU . 1.9 t -126.35 142.55 42.63 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.958 0 C-N-CA 119.279 -0.968 . . . . 0.0 111.747 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.46 94.33 4.11 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 124.735 1.272 . . . . 0.0 107.938 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.916 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.22 119.78 18.89 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.045 -1.062 . . . . 0.0 111.937 -179.647 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.842 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -46.73 172.43 0.05 OUTLIER Pre-proline 0 N--CA 1.485 1.303 0 CA-C-N 113.751 -1.568 . . . . 0.0 112.308 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.825 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.4 Cg_endo -68.28 -35.8 17.89 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.185 1.924 . . . . 0.0 112.707 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.561 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -68.9 -52.49 28.88 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 118.743 -1.183 . . . . 0.0 110.529 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.842 HD21 ' N ' ' A' ' 70' ' ' ALA . 1.1 p-10 -80.75 5.07 16.87 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 118.998 -1.081 . . . . 0.0 109.576 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -127.06 26.01 5.12 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -99.09 67.53 1.62 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.733 -0.787 . . . . 0.0 111.487 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.572 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -129.17 127.44 23.25 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 119.858 -0.737 . . . . 0.0 110.615 179.859 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 79' ' ' GLY . 8.7 Cg_endo -72.12 156.98 55.01 Favored 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 121.621 1.547 . . . . 0.0 113.846 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.62 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -23.84 -38.03 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 114.89 1.441 . . . . 0.0 114.89 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -107.0 67.97 0.23 Allowed Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.686 -1.245 . . . . 0.0 111.216 -179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.74 -169.05 25.58 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 118.27 -1.919 . . . . 0.0 111.397 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.845 HG22 ' HA ' ' A' ' 28' ' ' LYS . 2.6 p -137.46 163.95 29.87 Favored 'General case' 0 C--N 1.311 -1.078 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.549 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -126.07 177.34 6.42 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.01 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.832 HE21 HD21 ' A' ' 24' ' ' ASN . 30.5 tt0 -168.52 146.66 4.14 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 117.124 -1.83 . . . . 0.0 113.624 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.748 ' CE2' HG11 ' A' ' 25' ' ' VAL . 14.6 p90 -160.1 175.21 13.22 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.037 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.21 166.44 35.21 Favored Glycine 0 N--CA 1.497 2.75 0 C-N-CA 117.902 -2.094 . . . . 0.0 112.166 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.522 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 5.8 p90 -161.94 156.85 22.94 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.457 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.656 HD22 ' N ' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -104.66 111.41 24.1 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.232 179.889 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -121.25 163.62 14.66 Favored Glycine 0 N--CA 1.503 3.14 0 C-N-CA 119.737 -1.221 . . . . 0.0 111.33 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.2 p -112.97 148.87 34.14 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 120.42 -0.512 . . . . 0.0 109.996 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.708 ' HE2' ' HG3' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -142.67 -168.97 2.89 Favored 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 119.096 -1.042 . . . . 0.0 111.938 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.542 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 30.0 p -134.76 -8.88 2.41 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.23 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.46 94.73 1.41 Allowed Glycine 0 N--CA 1.496 2.692 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.863 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.852 HG22 ' OD1' ' A' ' 94' ' ' ASN . 56.0 m -160.9 -50.73 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.259 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.852 ' OD1' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER 172.46 110.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 C-N-CA 119.496 -0.882 . . . . 0.0 110.863 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.69 ' HB2' ' NE2' ' A' ' 48' ' ' GLN . . . -98.51 -133.93 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.683 -0.807 . . . . 0.0 111.998 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.528 ' HB2' ' CE3' ' A' ' 12' ' ' TRP . . . -21.45 109.55 0.12 Allowed Pre-proline 0 N--CA 1.506 2.372 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.4 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.506 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.7 Cg_endo -62.44 -95.18 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 120.862 1.041 . . . . 0.0 112.34 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -151.65 -96.77 0.06 Allowed 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 118.674 -1.211 . . . . 0.0 112.397 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.61 95.07 8.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.844 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.2 m-30 -65.9 -157.46 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.254 -0.979 . . . . 0.0 109.135 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.6 m -155.28 115.0 3.7 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 117.524 -1.67 . . . . 0.0 113.286 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.722 HD12 ' SG ' ' A' ' 8' ' ' CYS . 1.3 mt -59.62 177.67 0.2 Allowed 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.358 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.726 HD22 ' N ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -60.05 77.58 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.791 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 101.7 12.36 35.29 Favored Glycine 0 N--CA 1.503 3.112 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.275 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.614 ' O ' ' N ' ' A' ' 102' ' ' LEU . 70.5 p -152.47 152.58 29.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 C-N-CA 118.885 -1.126 . . . . 0.0 110.895 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -67.0 173.04 8.93 Favored 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 121.534 1.489 . . . . 0.0 112.141 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.58 ' SG ' HG13 ' A' ' 10' ' ' VAL . 1.8 t -165.2 106.43 0.79 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.833 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.48 138.76 47.25 Favored 'General case' 0 N--CA 1.505 2.309 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.674 HG22 ' N ' ' A' ' 110' ' ' GLY . 1.7 p -68.82 172.08 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 119.229 -0.988 . . . . 0.0 110.52 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.674 ' N ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.442 0 CA-C-O 116.366 -2.352 . . . . 0.0 110.399 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.515 ' H2 ' ' HG3' ' A' ' 5' ' ' PRO . . . . . . . . 0 N--CA 1.481 1.119 0 CA-C-O 120.893 0.377 . . . . 0.0 110.021 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.444 ' C ' ' OG ' ' A' ' 3' ' ' SER . 53.4 p -46.78 -53.9 10.92 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.319 -0.952 . . . . 0.0 110.661 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.444 ' OG ' ' C ' ' A' ' 2' ' ' SER . 0.3 OUTLIER -165.95 -13.57 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.463 -0.895 . . . . 0.0 110.776 179.983 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.547 ' H ' ' HD3' ' A' ' 5' ' ' PRO . . . 153.31 66.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.428 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.655 ' HG2' HG23 ' A' ' 105' ' ' THR . 5.1 Cg_exo -59.3 -89.45 0.0 OUTLIER 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 121.864 1.709 . . . . 0.0 111.795 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.771 ' HB3' ' OG1' ' A' ' 105' ' ' THR . . . -110.96 -159.16 0.67 Allowed 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.854 -0.738 . . . . 0.0 111.814 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.83 39.45 0.02 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 108.061 -2.016 . . . . 0.0 108.061 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.933 ' SG ' HD12 ' A' ' 102' ' ' LEU . 25.2 p -54.0 -178.0 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 114.707 -0.746 . . . . 0.0 111.823 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.434 HE21 ' HA ' ' A' ' 8' ' ' CYS . 0.0 OUTLIER -144.16 138.1 27.91 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.694 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.586 HG12 HG13 ' A' ' 27' ' ' VAL . 1.3 m -128.61 130.14 68.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.574 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.585 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -92.74 169.87 10.15 Favored 'General case' 0 C--N 1.284 -2.278 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.862 179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.625 ' CE2' ' HB1' ' A' ' 23' ' ' ALA . 2.1 t-105 -130.62 147.2 52.27 Favored 'General case' 0 C--N 1.309 -1.183 0 C-N-CA 119.772 -0.771 . . . . 0.0 111.986 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.48 75.92 0.39 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 1.011 HG22 HE22 ' A' ' 16' ' ' GLN . 0.4 OUTLIER -69.46 140.01 19.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.797 -179.708 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.538 ' O ' ' CZ3' ' A' ' 17' ' ' TRP . 18.1 t-20 -142.5 89.65 2.16 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.049 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 1.011 HE22 HG22 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -94.34 130.57 40.59 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 113.612 0.967 . . . . 0.0 113.612 -179.74 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.715 ' C ' ' H ' ' A' ' 19' ' ' THR . 9.2 p90 -114.69 75.01 0.9 Allowed 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 179.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.471 ' CB ' ' O ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER 72.26 -12.87 0.67 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -179.549 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.715 ' H ' ' C ' ' A' ' 17' ' ' TRP . 0.7 OUTLIER 163.71 178.41 0.02 OUTLIER 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 112.766 -2.016 . . . . 0.0 106.477 -179.763 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.681 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . 66.18 96.96 0.03 OUTLIER Glycine 0 C--N 1.285 -2.302 0 C-N-CA 117.482 -2.294 . . . . 0.0 107.536 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.797 ' CZ ' ' NE2' ' A' ' 48' ' ' GLN . 19.7 p90 -106.59 115.83 30.89 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.832 -0.747 . . . . 0.0 112.418 -179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.17 127.08 33.7 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.625 ' HB1' ' CE2' ' A' ' 12' ' ' TRP . . . -104.64 110.87 23.35 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.245 -0.982 . . . . 0.0 113.464 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -95.78 98.58 10.55 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.577 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.558 HG11 ' CE1' ' A' ' 84' ' ' PHE . 38.5 t -96.08 147.01 6.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.585 ' HB ' HD11 ' A' ' 11' ' ' LEU . 2.9 m -136.97 101.72 4.65 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 114.419 -1.264 . . . . 0.0 108.484 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.586 HG13 HG12 ' A' ' 10' ' ' VAL . 1.5 t -72.94 151.97 7.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 C-N-CA 119.669 -0.813 . . . . 0.0 112.364 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.402 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.1 tttt -143.59 104.04 4.16 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.468 179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.661 ' HB3' HD11 ' A' ' 76' ' ' ILE . 3.5 t30 -90.61 116.57 28.6 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -120.11 1.5 10.86 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 124.105 0.878 . . . . 0.0 110.147 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' SER . 20.6 p -57.9 -81.62 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.58 -179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.583 ' HA ' ' HB1' ' A' ' 78' ' ' ALA . 0.5 OUTLIER 159.54 72.52 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 123.726 0.641 . . . . 0.0 111.592 -179.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -170.8 152.58 3.75 Favored Pre-proline 0 C--N 1.306 -1.29 0 C-N-CA 119.012 -1.075 . . . . 0.0 111.395 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -70.37 105.49 1.59 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 121.192 1.261 . . . . 0.0 109.342 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -90.7 92.25 3.89 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 118.46 -1.296 . . . . 0.0 111.779 -179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -103.47 67.22 0.9 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.95 148.62 24.01 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.6 -2.2 . . . . 0.0 107.6 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.903 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 41.0 p-90 -165.69 177.44 7.28 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 117.7 -1.6 . . . . 0.0 112.103 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.412 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.6 OUTLIER -140.72 108.79 5.74 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.625 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.881 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -98.43 173.7 6.83 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.194 -1.002 . . . . 0.0 108.94 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.495 ' OG1' HG23 ' A' ' 66' ' ' THR . 3.3 m -157.83 152.73 25.36 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 117.745 -1.582 . . . . 0.0 112.913 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' ' N ' ' A' ' 43' ' ' SER . 24.2 p90 -178.69 -142.88 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 113.773 -1.558 . . . . 0.0 108.179 179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.574 ' OG ' ' CB ' ' A' ' 64' ' ' ALA . 20.2 m -163.24 173.71 13.02 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 117.626 -1.63 . . . . 0.0 112.663 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.71 ' CD1' ' HB1' ' A' ' 95' ' ' ALA . 6.9 m-85 -107.26 101.5 38.92 Favored Pre-proline 0 N--CA 1.486 1.341 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.843 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -55.53 -55.62 2.91 Favored 'Trans proline' 0 N--CA 1.456 -0.73 0 C-N-CA 120.79 0.993 . . . . 0.0 110.531 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.64 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 8.7 t -69.48 -178.25 1.37 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 118.839 -1.144 . . . . 0.0 109.914 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.64 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -87.27 55.91 4.54 Favored Glycine 0 C--N 1.291 -1.969 0 C-N-CA 118.961 -1.59 . . . . 0.0 110.241 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.845 ' CD ' ' HB2' ' A' ' 95' ' ' ALA . 3.7 mt-30 -90.94 125.34 35.74 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.025 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.0 OUTLIER -115.58 101.8 9.19 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.96 -179.923 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.55 ' CG2' ' N ' ' A' ' 51' ' ' THR . 1.3 p -65.03 161.17 3.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 C-N-CA 119.197 -1.001 . . . . 0.0 111.135 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 43.2 p -142.94 -65.8 0.39 Allowed 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.475 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.552 ' N ' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -90.81 136.07 33.31 Favored 'General case' 0 C--N 1.302 -1.493 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.093 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.9 153.59 40.3 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.193 -1.003 . . . . 0.0 111.502 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.408 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 44.5 t-105 -154.04 146.18 23.72 Favored 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 119.328 -0.949 . . . . 0.0 111.054 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.408 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.4 OUTLIER 65.88 23.87 11.31 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.776 -179.989 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 58' ' ' VAL . 4.4 p -173.78 113.63 0.2 Allowed 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.17 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -72.64 73.36 1.06 Allowed 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.555 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 56' ' ' SER . 2.0 m -70.13 148.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.637 -0.825 . . . . 0.0 111.719 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.8 p -149.26 107.16 3.69 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.78 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.769 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 5.7 tt0 -78.59 104.29 9.1 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.594 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.567 ' O ' ' N ' ' A' ' 63' ' ' SER . 3.3 p -82.84 -155.67 0.16 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.405 -0.918 . . . . 0.0 109.409 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.625 ' C ' ' H ' ' A' ' 64' ' ' ALA . . . -49.83 88.71 0.01 OUTLIER Glycine 0 N--CA 1.497 2.742 0 C-N-CA 118.967 -1.587 . . . . 0.0 110.098 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.567 ' N ' ' O ' ' A' ' 61' ' ' SER . 0.4 OUTLIER 53.19 2.19 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.549 -0.861 . . . . 0.0 110.49 -179.92 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.625 ' H ' ' C ' ' A' ' 62' ' ' GLY . . . -104.59 -173.59 2.34 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.315 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.579 HG21 ' CE2' ' A' ' 44' ' ' PHE . 50.0 t -140.82 152.92 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 C-N-CA 119.299 -0.96 . . . . 0.0 112.531 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 41' ' ' THR . 94.5 m -153.94 115.53 4.19 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.308 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.667 HG23 HD21 ' A' ' 40' ' ' LEU . 1.7 t -109.35 145.75 15.69 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.949 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.661 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -131.18 92.91 3.27 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 114.172 -1.376 . . . . 0.0 107.324 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.903 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -74.14 118.43 17.09 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 119.032 -1.067 . . . . 0.0 112.167 -179.608 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.86 ' N ' HD21 ' A' ' 73' ' ' ASN . . . -43.1 164.68 0.12 Allowed Pre-proline 0 N--CA 1.481 1.111 0 CA-C-N 113.37 -1.741 . . . . 0.0 112.003 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 1.2 Cg_endo -65.03 -34.78 45.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.066 1.844 . . . . 0.0 112.416 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.58 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.0 OUTLIER -70.92 -54.91 9.69 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.984 -179.892 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.86 HD21 ' N ' ' A' ' 70' ' ' ALA . 0.6 OUTLIER -75.91 -1.16 24.12 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 118.947 -1.101 . . . . 0.0 110.15 179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.67 40.08 2.62 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.0 p -105.28 71.41 0.93 Allowed 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.868 -0.733 . . . . 0.0 110.971 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.826 ' O ' HD13 ' A' ' 76' ' ' ILE . 0.0 OUTLIER -127.69 119.8 21.58 Favored Pre-proline 0 CA--C 1.565 1.541 0 C-N-CA 120.051 -0.66 . . . . 0.0 110.483 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 79' ' ' GLY . 5.2 Cg_endo -69.85 158.57 56.4 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 121.594 1.529 . . . . 0.0 114.114 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB1' ' HA ' ' A' ' 32' ' ' SER . . . -22.52 -41.23 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 CA-C-N 114.159 -1.382 . . . . 0.0 114.051 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -117.82 69.31 0.31 Allowed Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.414 ' C ' HG13 ' A' ' 76' ' ' ILE . . . -154.59 -168.01 17.32 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.354 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.525 ' N ' HG13 ' A' ' 76' ' ' ILE . 16.6 p -139.72 162.56 34.83 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.967 -1.093 . . . . 0.0 113.307 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.635 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -127.51 178.72 5.91 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 113.724 -1.58 . . . . 0.0 107.578 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.483 ' HG2' ' N ' ' A' ' 84' ' ' PHE . 7.0 tt0 -167.66 145.78 4.62 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 116.987 -1.885 . . . . 0.0 113.53 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.558 ' CE1' HG11 ' A' ' 25' ' ' VAL . 16.6 p90 -158.96 -178.91 7.59 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.819 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.21 162.51 36.29 Favored Glycine 0 N--CA 1.495 2.614 0 C-N-CA 117.581 -2.247 . . . . 0.0 112.198 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.6 p90 -155.18 174.19 15.55 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 119.763 -0.775 . . . . 0.0 111.04 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.424 ' N ' ' OD1' ' A' ' 87' ' ' ASN . 1.6 m-20 -126.65 111.85 14.78 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.053 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.428 ' O ' ' CD1' ' A' ' 21' ' ' PHE . . . -122.75 154.47 17.01 Favored Glycine 0 N--CA 1.5 2.961 0 C-N-CA 119.983 -1.104 . . . . 0.0 111.966 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 95.1 p -104.75 145.69 30.01 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.67 ' HD1' ' C ' ' A' ' 90' ' ' HIS . 0.9 OUTLIER -139.26 169.83 17.05 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.638 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.487 ' O ' HG23 ' A' ' 91' ' ' THR . 3.2 t -171.12 55.44 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.514 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -166.22 -71.38 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 118.736 -1.697 . . . . 0.0 112.043 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 1.033 HG22 ' H ' ' A' ' 94' ' ' ASN . 84.2 m -145.02 -163.35 1.69 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.57 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 1.033 ' H ' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER -78.61 160.09 27.75 Favored 'General case' 0 N--CA 1.497 1.92 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.908 -179.908 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.845 ' HB2' ' CD ' ' A' ' 48' ' ' GLN . . . -107.56 -88.98 0.46 Allowed 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.173 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.471 ' C ' ' O ' ' A' ' 95' ' ' ALA . . . -23.78 100.0 0.08 OUTLIER Pre-proline 0 N--CA 1.502 2.169 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.971 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.461 ' HD2' ' CE1' ' A' ' 100' ' ' PHE . 0.9 OUTLIER -65.92 -140.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.541 0.873 0 C-N-CA 121.413 1.409 . . . . 0.0 111.189 179.957 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.461 ' OG1' ' N ' ' A' ' 99' ' ' ALA . 76.3 p -112.29 -76.39 0.59 Allowed 'General case' 0 N--CA 1.5 2.062 0 C-N-CA 119.571 -0.851 . . . . 0.0 112.857 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.461 ' N ' ' OG1' ' A' ' 98' ' ' THR . . . -105.79 99.91 9.49 Favored 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 119.062 -1.055 . . . . 0.0 111.583 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.542 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.8 m-30 -68.73 -142.42 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 115.311 -0.859 . . . . 0.0 108.842 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.7 m -160.8 108.52 1.55 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 116.994 -1.883 . . . . 0.0 113.454 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.933 HD12 ' SG ' ' A' ' 8' ' ' CYS . 0.4 OUTLIER -73.2 154.44 40.26 Favored 'General case' 0 C--O 1.206 -1.232 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.651 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.55 ' ND2' HD22 ' A' ' 102' ' ' LEU . 0.2 OUTLIER -52.26 81.84 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.624 -1.23 . . . . 0.0 110.793 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.636 ' N ' ' O ' ' A' ' 102' ' ' LEU . . . 140.23 -33.95 2.04 Favored Glycine 0 N--CA 1.491 2.361 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.989 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.771 ' OG1' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -154.23 163.87 22.65 Favored Pre-proline 0 N--CA 1.505 2.289 0 C-N-CA 118.25 -1.38 . . . . 0.0 113.083 -179.821 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . 0.695 ' HD2' HG22 ' A' ' 105' ' ' THR . 1.7 Cg_endo -66.24 118.79 5.8 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 122.654 2.236 . . . . 0.0 111.907 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.525 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 5.6 t -100.1 123.05 43.89 Favored 'General case' 0 N--CA 1.501 2.108 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.967 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.78 162.22 16.49 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.859 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.984 HG22 ' H ' ' A' ' 110' ' ' GLY . 12.8 p -90.07 -130.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.874 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.984 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.494 2.535 0 CA-C-O 116.323 -2.376 . . . . 0.0 110.308 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 3' ' ' SER . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 120.867 0.365 . . . . 0.0 110.185 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 46.72 14.4 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.863 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.521 ' N ' ' O ' ' A' ' 1' ' ' ALA . 50.6 m -91.6 -69.17 0.75 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.347 -0.941 . . . . 0.0 110.816 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.13 174.46 26.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.377 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.43 ' HG2' ' CG2' ' A' ' 105' ' ' THR . 3.0 Cg_exo -56.05 -79.4 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.083 1.855 . . . . 0.0 111.922 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.637 ' H ' HG21 ' A' ' 105' ' ' THR . . . -99.74 -151.91 0.41 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.784 -0.766 . . . . 0.0 112.092 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.68 39.58 0.02 OUTLIER Glycine 0 N--CA 1.487 2.059 0 N-CA-C 107.422 -2.271 . . . . 0.0 107.422 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.459 ' SG ' ' CD1' ' A' ' 102' ' ' LEU . 24.3 p -55.01 -171.1 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 114.271 -0.964 . . . . 0.0 111.876 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.11 131.8 6.88 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.852 -1.139 . . . . 0.0 110.982 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.507 HG12 HG13 ' A' ' 27' ' ' VAL . 2.6 m -113.79 130.51 67.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 C-N-CA 120.004 -0.679 . . . . 0.0 110.581 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.613 HD11 ' HB ' ' A' ' 26' ' ' THR . 0.2 OUTLIER -97.81 161.03 13.94 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.514 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.895 ' CZ3' ' HB2' ' A' ' 96' ' ' ALA . 22.5 t-105 -112.04 149.41 32.09 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.59 0.71 . . . . 0.0 112.517 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.59 76.98 0.36 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 107.846 -2.101 . . . . 0.0 107.846 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -68.92 146.61 12.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 113.598 0.962 . . . . 0.0 113.598 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.7 t30 -153.94 97.12 2.04 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.209 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.694 ' NE2' ' CB ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -88.43 132.08 34.61 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -179.645 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.674 ' CD1' ' N ' ' A' ' 18' ' ' ASN . 44.4 p90 -112.82 -149.4 0.45 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 179.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.674 ' N ' ' CD1' ' A' ' 17' ' ' TRP . 81.8 m-20 -65.48 82.31 0.06 Allowed 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 117.517 -1.673 . . . . 0.0 107.273 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.581 ' O ' ' NE1' ' A' ' 17' ' ' TRP . 0.3 OUTLIER 68.33 133.73 0.03 OUTLIER 'General case' 0 C--O 1.203 -1.366 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.195 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.531 ' HA3' ' CZ2' ' A' ' 17' ' ' TRP . . . 101.75 129.33 6.65 Favored Glycine 0 C--N 1.279 -2.611 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.694 ' CB ' ' NE2' ' A' ' 16' ' ' GLN . 32.0 p90 -102.93 133.05 48.68 Favored 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.17 -0.612 . . . . 0.0 112.437 -179.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 22' ' ' THR . 0.8 OUTLIER -99.49 111.91 24.19 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.614 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.492 ' HB3' ' CZ ' ' A' ' 86' ' ' PHE . . . -93.75 117.17 29.74 Favored 'General case' 0 C--N 1.292 -1.896 0 C-N-CA 119.02 -1.072 . . . . 0.0 113.727 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.8 102.25 14.03 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.483 HG11 ' HE1' ' A' ' 84' ' ' PHE . 53.2 t -99.71 147.3 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 N-CA-C 113.993 1.109 . . . . 0.0 113.993 -179.555 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.613 ' HB ' HD11 ' A' ' 11' ' ' LEU . 18.5 m -136.71 100.58 4.37 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.948 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.512 HG21 ' CZ2' ' A' ' 38' ' ' TRP . 3.0 t -68.79 146.88 12.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.104 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.637 ' HA ' HG22 ' A' ' 81' ' ' THR . 9.2 tmtt? -138.48 102.91 4.74 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.567 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.693 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -95.58 136.06 36.45 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.516 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -131.64 5.8 4.34 Favored 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.544 -1.207 . . . . 0.0 109.523 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 32' ' ' SER . 19.1 p -47.24 -86.58 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.026 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 163.04 34.51 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 120.002 -0.679 . . . . 0.0 111.505 -179.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.937 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -147.4 155.71 45.94 Favored Pre-proline 0 N--CA 1.481 1.11 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.886 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -68.35 96.77 0.49 Allowed 'Trans proline' 0 C--N 1.323 -0.763 0 C-N-CA 121.284 1.322 . . . . 0.0 110.14 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.449 ' H ' HG23 ' A' ' 35' ' ' VAL . 1.3 t -71.08 117.38 14.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.593 -1.243 . . . . 0.0 111.269 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -123.03 75.01 1.25 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.368 -0.833 . . . . 0.0 108.765 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.44 140.19 7.7 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.431 -1.867 . . . . 0.0 108.431 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.909 ' H ' ' ND2' ' A' ' 69' ' ' ASN . 40.8 p-90 -158.79 177.46 11.15 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.303 -1.359 . . . . 0.0 111.626 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.447 ' N ' ' HE3' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -141.08 112.37 7.38 Favored 'General case' 0 C--O 1.202 -1.4 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.715 179.897 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.86 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -103.41 174.68 5.76 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.934 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.788 ' OG1' HG23 ' A' ' 66' ' ' THR . 1.0 OUTLIER -163.55 157.71 19.89 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 117.325 -1.75 . . . . 0.0 113.153 -179.88 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.512 ' N ' ' CG2' ' A' ' 41' ' ' THR . 31.1 p90 -178.18 -141.43 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.3 0 CA-C-N 113.368 -1.742 . . . . 0.0 107.997 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.478 ' N ' ' CD2' ' A' ' 42' ' ' PHE . 61.2 m -160.82 146.9 14.87 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 117.876 -1.53 . . . . 0.0 112.187 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.65 ' CD2' ' CG2' ' A' ' 65' ' ' VAL . 8.3 m-85 -77.55 119.3 76.88 Favored Pre-proline 0 N--CA 1.482 1.132 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.146 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.544 ' CB ' ' ND2' ' A' ' 94' ' ' ASN . 3.7 Cg_endo -63.38 -66.67 0.05 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 121.148 1.232 . . . . 0.0 111.579 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.536 ' OG ' ' N ' ' A' ' 47' ' ' GLY . 38.4 t -69.44 -122.44 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.829 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.536 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -130.96 38.48 1.93 Allowed Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.494 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . 3.2 mt-30 -75.24 98.31 3.74 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.517 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.8 HE22 HG22 ' A' ' 51' ' ' THR . 0.0 OUTLIER -98.95 112.42 24.54 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.57 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 58' ' ' VAL . 2.4 p -70.52 148.26 10.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.2 -1.0 . . . . 0.0 111.12 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.8 HG22 HE22 ' A' ' 49' ' ' GLN . 21.8 p -127.6 -63.24 1.04 Allowed 'General case' 0 N--CA 1.491 1.596 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.77 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.619 ' N ' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -96.94 138.59 34.24 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.794 179.938 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -148.29 157.19 43.34 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.101 -1.039 . . . . 0.0 111.345 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . 0.406 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 43.3 t-105 -153.32 146.12 24.36 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.228 -0.989 . . . . 0.0 111.266 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 54' ' ' TRP . 0.5 OUTLIER 66.97 22.28 10.1 Favored 'General case' 0 C--N 1.317 -0.816 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.584 -179.983 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.605 ' OG ' ' CG1' ' A' ' 67' ' ' VAL . 13.1 t -175.95 125.8 0.21 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.405 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -83.1 79.67 9.3 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.608 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.67 HG21 HG21 ' A' ' 50' ' ' VAL . 1.0 OUTLIER -81.81 152.28 4.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.635 -179.971 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -155.34 131.45 10.16 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.476 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.519 HE22 ' HB2' ' A' ' 49' ' ' GLN . 6.8 pt20 -95.12 119.98 34.55 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.647 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.866 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 3.7 p -86.91 68.93 10.22 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.84 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.18 -56.98 4.03 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.404 ' H ' ' H ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -148.91 -20.18 0.3 Allowed 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.404 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.866 ' HB3' ' OG ' ' A' ' 61' ' ' SER . . . -85.99 -168.46 2.24 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.463 -0.895 . . . . 0.0 109.942 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.65 ' CG2' ' CD2' ' A' ' 44' ' ' PHE . 84.2 t -147.35 155.2 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.757 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.788 HG23 ' OG1' ' A' ' 41' ' ' THR . 70.7 m -161.63 124.29 3.03 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.705 -1.134 . . . . 0.0 108.653 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.605 ' CG1' ' OG ' ' A' ' 56' ' ' SER . 2.4 t -117.53 146.4 22.06 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.093 0 C-N-CA 119.548 -0.861 . . . . 0.0 111.857 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -132.16 90.51 2.82 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.909 ' ND2' ' H ' ' A' ' 38' ' ' TRP . 0.0 OUTLIER -73.53 122.52 22.33 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 118.948 -1.101 . . . . 0.0 112.445 -179.626 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.772 ' HB1' ' NE1' ' A' ' 72' ' ' TRP . . . -40.3 155.88 0.18 Allowed Pre-proline 0 N--CA 1.479 0.993 0 CA-C-N 113.592 -1.64 . . . . 0.0 112.186 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -65.96 -35.28 35.45 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 121.759 1.639 . . . . 0.0 112.297 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.772 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -70.55 -57.38 4.81 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 118.931 -1.108 . . . . 0.0 110.981 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.538 HD21 ' HB2' ' A' ' 69' ' ' ASN . 0.1 OUTLIER -65.85 -21.34 66.46 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 118.994 -1.082 . . . . 0.0 110.171 179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -96.61 27.87 15.8 Favored Glycine 0 N--CA 1.486 1.967 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.654 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 32.2 m -91.86 60.68 3.95 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.956 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.734 HG21 ' HB2' ' A' ' 82' ' ' ALA . 0.0 OUTLIER -108.49 136.4 19.91 Favored Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 119.909 -0.716 . . . . 0.0 111.387 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' GLY . 7.2 Cg_endo -69.81 151.42 68.75 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 121.51 1.474 . . . . 0.0 111.181 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.937 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -40.41 -22.32 0.01 OUTLIER 'General case' 0 C--O 1.2 -1.525 0 C-N-CA 119.749 -0.78 . . . . 0.0 112.268 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' PRO . . . -112.71 64.19 0.28 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -166.31 -162.83 18.68 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 118.11 -1.995 . . . . 0.0 111.485 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.637 HG22 ' HA ' ' A' ' 28' ' ' LYS . 3.6 p -139.5 162.41 35.12 Favored 'General case' 0 N--CA 1.48 1.069 0 CA-C-O 121.867 0.841 . . . . 0.0 112.765 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.734 ' HB2' HG21 ' A' ' 76' ' ' ILE . . . -136.84 122.2 19.39 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.592 ' CG ' HG23 ' A' ' 26' ' ' THR . 3.5 mp0 -114.82 164.91 13.43 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.483 ' HE1' HG11 ' A' ' 25' ' ' VAL . 8.3 p90 -163.89 -178.09 5.48 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 112.688 -2.051 . . . . 0.0 108.986 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -167.24 159.13 32.39 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 117.556 -2.259 . . . . 0.0 111.937 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 2.3 p90 -154.77 169.2 24.51 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.487 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.53 HD22 ' C ' ' A' ' 86' ' ' PHE . 1.4 m120 -125.57 112.52 16.28 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.53 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA2' HG23 ' A' ' 51' ' ' THR . . . -121.03 150.23 17.25 Favored Glycine 0 N--CA 1.512 3.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.464 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . 0.427 ' OG ' ' CG ' ' A' ' 49' ' ' GLN . 52.1 p -77.16 155.26 32.42 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 120.121 -0.631 . . . . 0.0 109.715 179.742 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.551 ' CD2' ' OE1' ' A' ' 16' ' ' GLN . 9.6 p80 -147.99 -157.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 118.957 -1.097 . . . . 0.0 111.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.3 p -151.78 -8.46 0.22 Allowed 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.05 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.63 84.7 1.69 Allowed Glycine 0 N--CA 1.494 2.544 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.968 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.944 HG22 ' H ' ' A' ' 94' ' ' ASN . 96.3 m -161.58 -130.86 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.283 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.944 ' H ' HG22 ' A' ' 93' ' ' THR . 32.6 t-20 -87.73 131.34 34.52 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.609 -0.836 . . . . 0.0 111.273 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.454 ' O ' ' C ' ' A' ' 96' ' ' ALA . . . -109.46 -155.36 0.56 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.016 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.895 ' HB2' ' CZ3' ' A' ' 12' ' ' TRP . . . -25.26 122.29 0.21 Allowed Pre-proline 0 N--CA 1.502 2.146 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.705 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HB2' ' H ' ' A' ' 98' ' ' THR . 1.3 Cg_endo -64.8 -142.16 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.944 0 C-N-CA 121.214 1.276 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.407 ' H ' ' HB2' ' A' ' 97' ' ' PRO . 42.8 p -108.5 -100.57 0.37 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.472 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -90.27 104.22 16.82 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 118.503 -1.279 . . . . 0.0 112.196 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.3 m-30 -70.37 -141.84 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.363 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.5 m -162.39 109.81 1.32 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 117.022 -1.871 . . . . 0.0 113.869 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.5 mt -53.85 178.14 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.26 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.817 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -39.66 -26.41 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.927 -0.709 . . . . 0.0 111.973 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.804 ' O ' HG23 ' A' ' 105' ' ' THR . . . -165.31 41.7 0.29 Allowed Glycine 0 N--CA 1.491 2.307 0 C-N-CA 118.653 -1.737 . . . . 0.0 111.499 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 104' ' ' GLY . 0.2 OUTLIER -171.83 147.68 2.01 Favored Pre-proline 0 N--CA 1.493 1.704 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.685 179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.17 156.64 44.03 Favored 'Trans proline' 0 C--O 1.212 -0.813 0 C-N-CA 121.566 1.51 . . . . 0.0 112.554 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.41 ' SG ' ' C ' ' A' ' 8' ' ' CYS . 4.0 t -147.26 101.65 3.41 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.342 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.01 135.75 57.81 Favored 'General case' 0 N--CA 1.518 2.951 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -179.587 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 1.056 HG22 ' H ' ' A' ' 110' ' ' GLY . 5.3 p -59.93 -163.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 118.795 -1.162 . . . . 0.0 110.926 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 1.056 ' H ' HG22 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 116.35 -2.361 . . . . 0.0 110.386 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.8 t -153.34 69.72 0.83 Allowed 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.849 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.7 p -169.8 155.09 5.64 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.819 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.02 173.27 31.85 Favored Glycine 0 N--CA 1.488 2.164 0 C-N-CA 119.501 -1.333 . . . . 0.0 110.251 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -54.67 -55.24 3.46 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.036 1.824 . . . . 0.0 111.915 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 1.067 ' H ' HG21 ' A' ' 105' ' ' THR . . . -106.21 -159.77 0.72 Allowed 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.946 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.33 38.42 0.05 OUTLIER Glycine 0 N--CA 1.492 2.419 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.446 ' SG ' ' HG ' ' A' ' 102' ' ' LEU . 4.3 p -49.21 178.63 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 113.904 -1.148 . . . . 0.0 113.016 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -135.13 106.37 6.74 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.035 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.748 HG13 ' SG ' ' A' ' 107' ' ' CYS . 2.1 m -99.45 139.12 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 119.061 -1.056 . . . . 0.0 112.428 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.619 HD21 ' HB ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -109.21 162.65 14.09 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.848 179.772 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.533 ' HE1' ' CB ' ' A' ' 23' ' ' ALA . 1.2 t-105 -128.05 139.68 52.39 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.318 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -116.22 62.59 0.37 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.334 -2.307 . . . . 0.0 107.334 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 21' ' ' PHE . 14.6 p -69.3 140.84 18.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.485 ' HB3' HG22 ' A' ' 22' ' ' THR . 2.4 t30 -140.06 100.92 4.04 Favored 'General case' 0 N--CA 1.489 1.496 0 CA-C-N 114.616 -1.175 . . . . 0.0 108.762 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.843 ' NE2' ' N ' ' A' ' 17' ' ' TRP . 0.0 OUTLIER -85.17 107.92 17.46 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.105 -1.038 . . . . 0.0 112.967 -179.782 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.843 ' N ' ' NE2' ' A' ' 16' ' ' GLN . 5.0 p90 -106.75 99.84 9.39 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.828 HD22 ' N ' ' A' ' 18' ' ' ASN . 0.0 OUTLIER 78.89 -47.41 0.41 Allowed 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.541 -179.657 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.784 ' N ' HE22 ' A' ' 16' ' ' GLN . 0.7 OUTLIER -170.34 -56.18 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.514 179.894 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.702 ' N ' ' CG2' ' A' ' 19' ' ' THR . . . -59.3 163.98 11.3 Favored Glycine 0 C--O 1.198 -2.106 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.564 ' CG ' ' O ' ' A' ' 21' ' ' PHE . 2.8 p90 -136.28 120.87 18.3 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 119.13 -1.028 . . . . 0.0 112.681 -179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.485 HG22 ' HB3' ' A' ' 15' ' ' ASN . 1.4 t -78.92 174.02 11.95 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 105.651 -1.981 . . . . 0.0 105.651 179.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.533 ' CB ' ' HE1' ' A' ' 12' ' ' TRP . . . -153.2 125.73 8.18 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 117.04 -1.864 . . . . 0.0 114.053 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -107.8 91.5 3.68 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 179.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.626 HG11 ' CE2' ' A' ' 84' ' ' PHE . 40.5 t -96.02 144.3 10.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 113.94 1.089 . . . . 0.0 113.94 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.619 ' HB ' HD21 ' A' ' 11' ' ' LEU . 0.4 OUTLIER -126.35 129.72 49.39 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 114.489 -1.232 . . . . 0.0 107.95 179.687 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.823 ' HB ' ' HB3' ' A' ' 82' ' ' ALA . 23.7 t -101.2 103.81 15.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 C-N-CA 119.281 -0.968 . . . . 0.0 113.151 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.76 ' HA ' HG22 ' A' ' 81' ' ' THR . 12.6 tmtt? -95.1 106.53 18.54 Favored 'General case' 0 C--N 1.291 -1.951 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.395 179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.692 ' C ' ' ND2' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -107.87 140.94 40.22 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.72 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -140.69 19.34 2.34 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 114.214 -1.357 . . . . 0.0 109.028 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.413 ' O ' ' CB ' ' A' ' 32' ' ' SER . 13.1 p -48.08 -88.47 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.176 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 31' ' ' SER . 0.5 OUTLIER 170.41 31.55 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.822 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.998 ' N ' ' HB2' ' A' ' 78' ' ' ALA . . . -154.47 170.98 7.66 Favored Pre-proline 0 N--CA 1.48 1.07 0 C-N-CA 118.085 -1.446 . . . . 0.0 111.443 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.796 ' HD2' ' HB1' ' A' ' 33' ' ' ALA . 9.2 Cg_endo -74.83 97.34 1.06 Allowed 'Trans proline' 0 C--N 1.323 -0.784 0 C-N-CA 121.842 1.695 . . . . 0.0 109.963 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.4 t -75.43 94.31 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 118.249 -1.38 . . . . 0.0 111.591 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.19 50.25 1.37 Allowed 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' GLY . . . 112.1 167.49 17.84 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 107.826 -2.11 . . . . 0.0 107.826 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.756 ' NE1' ' ND2' ' A' ' 69' ' ' ASN . 37.8 p-90 -171.17 176.39 3.97 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 117.808 -1.557 . . . . 0.0 111.836 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.1 102.14 4.32 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.887 ' O ' HD23 ' A' ' 40' ' ' LEU . 0.2 OUTLIER -89.63 172.8 8.69 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 118.699 -1.201 . . . . 0.0 109.409 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.463 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 2.0 m -160.73 142.12 12.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 117.945 -1.502 . . . . 0.0 112.437 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.559 ' CD2' ' N ' ' A' ' 43' ' ' SER . 15.6 p90 -171.0 -140.1 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.249 -1.342 . . . . 0.0 108.351 179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.562 ' HG ' ' HB1' ' A' ' 64' ' ' ALA . 34.2 m -161.03 168.2 24.94 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 117.419 -1.713 . . . . 0.0 112.782 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.783 ' CE1' ' HB1' ' A' ' 95' ' ' ALA . 2.9 m-85 -101.66 109.41 59.26 Favored Pre-proline 0 N--CA 1.489 1.483 0 CA-C-N 115.101 -0.954 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.31 -63.7 0.12 Allowed 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 121.098 1.199 . . . . 0.0 111.367 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.624 ' OG ' ' N ' ' A' ' 93' ' ' THR . 38.8 t -69.59 -172.7 0.5 Allowed 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.575 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.484 ' N ' ' OG ' ' A' ' 46' ' ' SER . . . -84.9 57.9 4.99 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.072 -1.537 . . . . 0.0 109.886 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.812 HE22 ' CD2' ' A' ' 90' ' ' HIS . 11.6 mm-40 -94.41 108.91 20.81 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 119.213 -0.995 . . . . 0.0 111.014 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 60' ' ' GLN . 0.9 OUTLIER -106.57 108.89 20.63 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.913 -179.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' A' ' 51' ' ' THR . 2.1 p -76.47 157.04 5.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.187 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.505 ' OG1' ' N ' ' A' ' 52' ' ' GLN . 72.6 p -138.47 -68.82 0.44 Allowed 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.531 -0.867 . . . . 0.0 111.1 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLN . . . . . 0.505 ' N ' ' OG1' ' A' ' 51' ' ' THR . 2.2 mt-30 -80.59 165.26 22.24 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.03 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -167.14 153.58 8.24 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 118.717 -1.193 . . . . 0.0 111.923 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' TRP . . . . . . . . . . . . . 32.3 t-105 -147.32 136.88 22.79 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 119.354 -0.939 . . . . 0.0 110.899 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.7 p 60.23 26.6 16.06 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.196 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.14 117.26 1.65 Allowed 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.0 m -82.11 77.64 8.89 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 118.828 -1.149 . . . . 0.0 108.977 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.2 m -68.99 154.37 8.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.613 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.9 p -154.07 108.14 3.0 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.939 -1.028 . . . . 0.0 109.908 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.76 ' NE2' ' NE2' ' A' ' 49' ' ' GLN . 3.6 tt0 -88.09 116.01 25.97 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.036 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 4.7 p -94.39 89.38 5.85 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.636 -0.825 . . . . 0.0 110.777 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 71.16 -74.6 0.66 Allowed Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.388 -1.387 . . . . 0.0 109.963 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 -14.69 1.55 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.122 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.562 ' HB1' ' HG ' ' A' ' 43' ' ' SER . . . -89.29 -173.91 4.2 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.033 -1.067 . . . . 0.0 110.063 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 44' ' ' PHE . 51.2 t -147.27 160.11 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 C-N-CA 118.735 -1.186 . . . . 0.0 113.637 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 65' ' ' VAL . 1.3 m -155.53 145.93 21.91 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 113.899 -1.5 . . . . 0.0 108.563 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.416 HG23 HD21 ' A' ' 40' ' ' LEU . 2.8 t -141.07 119.4 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 118.727 -1.189 . . . . 0.0 112.469 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.83 91.43 4.83 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.97 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.756 ' ND2' ' NE1' ' A' ' 38' ' ' TRP . 10.4 p-10 -70.77 122.8 20.53 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.194 -1.003 . . . . 0.0 111.344 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.863 ' HB3' ' ND2' ' A' ' 73' ' ' ASN . . . -43.91 166.65 0.1 Allowed Pre-proline 0 C--N 1.307 -1.276 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.452 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 6.0 Cg_endo -70.04 -39.98 5.38 Favored 'Trans proline' 0 C--O 1.211 -0.845 0 C-N-CA 122.155 1.903 . . . . 0.0 112.392 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' TRP . . . . . 0.605 ' NE1' ' HB1' ' A' ' 70' ' ' ALA . 0.3 OUTLIER -68.56 -55.72 10.68 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.024 -1.07 . . . . 0.0 110.514 -179.875 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.863 ' ND2' ' HB3' ' A' ' 70' ' ' ALA . 0.1 OUTLIER -76.71 11.02 1.84 Allowed 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.18 -1.008 . . . . 0.0 109.624 179.823 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.557 ' N ' HD22 ' A' ' 73' ' ' ASN . . . -139.87 37.56 1.71 Allowed Glycine 0 N--CA 1.484 1.898 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.574 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.1 m -104.08 61.74 0.74 Allowed 'General case' 0 C--N 1.309 -1.162 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.956 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.484 HG13 ' N ' ' A' ' 81' ' ' THR . 0.0 OUTLIER -109.49 136.68 20.22 Favored Pre-proline 0 N--CA 1.484 1.267 0 C-N-CA 119.744 -0.783 . . . . 0.0 110.368 179.926 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.626 ' C ' ' H ' ' A' ' 79' ' ' GLY . 6.9 Cg_endo -71.3 171.16 16.63 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 121.396 1.397 . . . . 0.0 111.068 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.998 ' HB2' ' N ' ' A' ' 33' ' ' ALA . . . -63.18 17.72 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.563 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.626 ' H ' ' C ' ' A' ' 77' ' ' PRO . . . -149.8 61.76 0.42 Allowed Glycine 0 C--N 1.291 -1.954 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.22 -155.12 9.57 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 118.641 -1.742 . . . . 0.0 110.733 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.76 HG22 ' HA ' ' A' ' 28' ' ' LYS . 0.9 OUTLIER -141.73 168.8 18.89 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.244 -0.983 . . . . 0.0 112.603 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.823 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -132.34 -173.3 3.12 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . 0.641 ' CD ' ' N ' ' A' ' 84' ' ' PHE . 12.4 tm0? -167.59 144.74 4.4 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 116.792 -1.963 . . . . 0.0 113.649 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.641 ' N ' ' CD ' ' A' ' 83' ' ' GLN . 3.9 p90 -164.13 164.73 22.68 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.604 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -156.51 178.47 32.96 Favored Glycine 0 N--CA 1.504 3.192 0 C-N-CA 118.068 -2.015 . . . . 0.0 111.855 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 86' ' ' PHE . 4.4 p90 -164.17 -169.8 1.93 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.687 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 9.6 m-80 -142.93 110.8 5.93 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.64 -0.824 . . . . 0.0 110.741 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -117.71 164.08 12.7 Favored Glycine 0 N--CA 1.497 2.721 0 C-N-CA 119.925 -1.131 . . . . 0.0 112.026 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 85.2 p -114.08 136.38 52.99 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.812 ' CD2' HE22 ' A' ' 48' ' ' GLN . 0.3 OUTLIER -151.03 -175.33 5.1 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 117.538 -1.665 . . . . 0.0 113.514 -179.892 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.53 ' N ' ' ND1' ' A' ' 90' ' ' HIS . 2.3 t -171.17 48.85 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.675 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.44 -129.97 1.98 Allowed Glycine 0 N--CA 1.493 2.459 0 C-N-CA 118.919 -1.61 . . . . 0.0 112.167 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.624 ' N ' ' OG ' ' A' ' 46' ' ' SER . 0.2 OUTLIER -90.92 -155.65 0.4 Allowed 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.416 ' ND2' ' H ' ' A' ' 94' ' ' ASN . 0.2 OUTLIER -70.72 165.48 22.9 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.84 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.783 ' HB1' ' CE1' ' A' ' 44' ' ' PHE . . . -111.6 -8.38 14.23 Favored 'General case' 0 N--CA 1.486 1.375 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.342 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -106.61 106.44 57.73 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.647 -0.821 . . . . 0.0 112.441 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.522 ' HD2' ' CZ ' ' A' ' 100' ' ' PHE . 1.8 Cg_endo -64.25 -95.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 120.834 1.022 . . . . 0.0 112.248 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.461 ' O ' HG23 ' A' ' 109' ' ' VAL . 1.1 p -153.25 -90.41 0.05 OUTLIER 'General case' 0 N--CA 1.497 1.882 0 C-N-CA 118.919 -1.113 . . . . 0.0 112.279 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -96.78 94.51 7.31 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.595 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 100' ' ' PHE . 4.6 m-30 -66.23 -158.34 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 43.3 m -153.79 118.71 5.03 Favored 'General case' 0 C--N 1.309 -1.179 0 C-N-CA 116.956 -1.898 . . . . 0.0 114.015 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.544 ' N ' ' O ' ' A' ' 105' ' ' THR . 3.2 mt -63.72 176.4 0.91 Allowed 'General case' 0 N--CA 1.48 1.026 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.315 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 102' ' ' LEU . 0.8 OUTLIER -36.94 -32.94 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 C-N-CA 120.025 -0.67 . . . . 0.0 112.675 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.856 ' O ' HG23 ' A' ' 105' ' ' THR . . . -155.72 47.03 0.51 Allowed Glycine 0 N--CA 1.499 2.898 0 C-N-CA 118.463 -1.827 . . . . 0.0 111.865 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 1.067 HG21 ' H ' ' A' ' 6' ' ' ALA . 0.0 OUTLIER 179.85 160.26 0.83 Allowed Pre-proline 0 C--O 1.192 -1.965 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.97 179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -65.94 179.79 1.69 Allowed 'Trans proline' 0 C--N 1.321 -0.891 0 C-N-CA 122.004 1.802 . . . . 0.0 112.87 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.748 ' SG ' HG13 ' A' ' 10' ' ' VAL . 5.5 t -170.13 106.68 0.33 Allowed 'General case' 0 N--CA 1.497 1.898 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.305 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 70.6 p -72.06 149.86 44.47 Favored 'General case' 0 N--CA 1.506 2.358 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 1.095 HG12 ' H ' ' A' ' 110' ' ' GLY . 5.0 t -59.05 -167.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 C-N-CA 118.981 -1.088 . . . . 0.0 110.422 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 1.095 ' H ' HG12 ' A' ' 109' ' ' VAL . . . . . . . . 0 N--CA 1.493 2.482 0 CA-C-O 116.289 -2.395 . . . . 0.0 110.301 -179.978 . . . . . . . . 1 1 . 1 stop_ save_